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Methods for the estimation of the National Institute for
Health and Care Excellence cost-effectiveness threshold
Karl Claxton,1,2 Steve Martin,2 Marta Soares,1 Nigel Rice,1,2
Eldon Spackman,1 Sebastian Hinde,1 Nancy Devlin,3
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1Centre for Health Economics, University of York, York, UK
2Department of Economics and Related Studies, University of York, York, UK
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4Imperial College Business School and Centre for Health Policy, Imperial College London,
London, UK
*Corresponding author
Background: Cost-effectiveness analysis involves the comparison of the incremental cost-effectiveness ratio
of a new technology, which is more costly than existing alternatives, with the cost-effectiveness threshold.
This indicates whether or not the health expected to be gained from its use exceeds the health expected to
be lost elsewhere as other health-care activities are displaced. The threshold therefore represents the
additional cost that has to be imposed on the system to forgo 1 quality-adjusted life-year (QALY) of health
through displacement. There are no empirical estimates of the cost-effectiveness threshold used by the
National Institute for Health and Care Excellence.
Objectives: (1) To provide a conceptual framework to define the cost-effectiveness threshold and to
provide the basis for its empirical estimation. (2) Using programme budgeting data for the English NHS,
to estimate the relationship between changes in overall NHS expenditure and changes in mortality.
(3) To extend this mortality measure of the health effects of a change in expenditure to life-years and to
QALYs by estimating the quality-of-life (QoL) associated with effects on years of life and the additional
direct impact on QoL itself. (4) To present the best estimate of the cost-effectiveness threshold for
policy purposes.
Methods: Earlier econometric analysis estimated the relationship between differences in primary care trust
(PCT) spending, across programme budget categories (PBCs), and associated disease-specific mortality.
This research is extended in several ways including estimating the impact of marginal increases or
decreases in overall NHS expenditure on spending in each of the 23 PBCs. Further stages of work link the
econometrics to broader health effects in terms of QALYs.
Results: The most relevant ‘central’ threshold is estimated to be £12,936 per QALY (2008 expenditure,
2008–10 mortality). Uncertainty analysis indicates that the probability that the threshold is < £20,000 per
QALY is 0.89 and the probability that it is < £30,000 per QALY is 0.97. Additional ‘structural’ uncertainty
suggests, on balance, that the central or best estimate is, if anything, likely to be an overestimate.
The health effects of changes in expenditure are greater when PCTs are under more financial pressure and
are more likely to be disinvesting than investing. This indicates that the central estimate of the threshold is
likely to be an overestimate for all technologies which impose net costs on the NHS and the appropriate
threshold to apply should be lower for technologies which have a greater impact on NHS costs.
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Limitations: The central estimate is based on identifying a preferred analysis at each stage based on
the analysis that made the best use of available information, whether or not the assumptions required
appeared more reasonable than the other alternatives available, and which provided a more complete
picture of the likely health effects of a change in expenditure. However, the limitation of currently available
data means that there is substantial uncertainty associated with the estimate of the overall threshold.
Conclusions: The methods go some way to providing an empirical estimate of the scale of opportunity
costs the NHS faces when considering whether or not the health benefits associated with new
technologies are greater than the health that is likely to be lost elsewhere in the NHS. Priorities for future
research include estimating the threshold for subsequent waves of expenditure and outcome data, for
example by utilising expenditure and outcomes available at the level of Clinical Commissioning Groups as
well as additional data collected on QoL and updated estimates of incidence (by age and gender) and
duration of disease. Nonetheless, the study also starts to make the other NHS patients, who ultimately
bear the opportunity costs of such decisions, less abstract and more ‘known’ in social decisions.
Funding: The National Institute for Health Research-Medical Research Council Methodology
Research Programme.
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Scientific summary
Introduction
The National Institute for Health and Care Excellence’s (NICE) comparison of the incremental
cost-effectiveness ratio of a new technology, which is more costly than existing alternatives, with
the cost-effectiveness threshold is important in assessing whether or not the health expected to be gained
from its use exceeds the health expected to be forgone elsewhere as other NHS activities are displaced
(i.e. whether or not the new technology is cost-effective).
When NICE issues positive guidance for a new intervention which imposes additional costs on the NHS,
the resources required to deliver it must be found by disinvesting from other interventions and services
elsewhere. This displacement will inevitably result in health decrements for other types of individuals.
Thus, the threshold represents the additional cost that has to be imposed on the system to forgo 1
quality-adjusted life-year (QALY) of health through displacement.
Currently NICE uses a threshold range of £20,000–30,000 QALY gained, and this has remained the case in
the NICE methods guidance since 2004. There have been a number of calls for further research on the
value of the threshold.
This report details a 2-year project, funded by the National Institute for Health Research (NIHR) and
Medical Research Council (MRC) Methodology Research Programme, to develop methods to estimate the
NICE cost-effectiveness threshold.
The NICE remit implies a series of characteristics for any empirical research on the threshold:
l Reflect the expected health effects [in terms of length and quality-of-life (QoL)] of NICE guidance
through the displacement decisions taken across the NHS rather than what specific services are
(or could have been) displaced.
l Facilitate regular updates, based on routinely available data, to reflect NHS changes such as real overall
expenditure and productivity. This would encourage accountability through scrutiny by stakeholders
and provide predictability for technology manufacturers’ investment decisions.
l The nature of service displacement and the magnitude of the health forgone will depend on the scale
of the budget impact which should, ideally, be reflected in the value of the threshold.
l Methods should recognise the inevitable uncertainty relating to the evidence currently available for the
threshold and reflect its implications for policy.
Study methods
The aim was to develop methods to estimate the NICE cost-effectiveness threshold making use of routinely
available data. Objectives were:
i. informed by relevant literature, to provide a conceptual framework to define the threshold and the
basis of its estimation
ii. using programme budgeting (PB) data for the English NHS, to estimate the relationship between
changes in overall NHS expenditure and changes in mortality
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iii. to extend the measure of benefit in the threshold to QALYs by estimating the QoL associated with
additional years of life and the direct impact of health services on QoL
iv. to present the best estimate of the cost-effectiveness threshold for policy purposes.
Earlier econometric analysis estimated the relationship between differences in primary care trust (PCT)
spending and associated disease-specific mortality. Expenditure came from PB data which allocates the
entire volume of health-care expenditure to broad programme budget categories (PBCs) according to
primary diagnosis.
This research extended this in several ways including estimating the impact of marginal increases or
decreases in overall NHS expenditure on spending in each of the 23 PBCs. These were linked to changes in
mortality outcomes by PBC across 11 PBCs.
The results of the econometric analysis were translated into broader effects in terms of QALYs. The first
stage linked estimated effects on mortality to life-years taking into account the ‘counterfactual’ deaths that
would have occurred if the population in a given PBC faced the same mortality risks as the general
population. The second stage accounted for the health (QALY) effects of changes in mortality due to
changes in expenditure reflecting how QoL differs by age and gender. The third stage incorporated those
effects on health not directly associated with mortality and life-year effects (i.e. the ‘pure’ QoL effects) to
estimate an overall cost per QALY threshold. The approach uses the estimates of mortality and life-year
effects as ‘surrogate outcomes’ for a more complete measure of the health effects of a change in
expenditure. This appears more plausible than assuming no effects of NHS expenditure on QoL outcomes.
The estimated proportional effect on the mortality and life-year burden of disease is applied to measures
of QALY burden. Applying a proportionate effect to measures of QALY burden of disease is equivalent
to assuming that any estimated effects on life-years are lived at QoL that reflects a proportionate
improvement to the QoL with disease. It also allows QoL effects of changes in expenditure to be included,
also based on proportionate improvement in the QoL with disease. In those PBCs where mortality effects
could not be estimated, the proportional effect of changes in expenditure on QALY burden of disease is
assumed to be the same as the overall proportional effect on the life-year burden of disease across those
PBCs where mortality effects could be estimated.
The methods planned for the study included a consideration of local data, collected routinely by PCTs,
on the types of intervention in which local decision-makers were investing and disinvesting. The aim was
to inform the link between the effects of expenditure changes on mortality and impacts on broader health
in terms of QALYs. These data may have indicated the types of interventions and services, within a given
PBC, on which investment and disinvestment were taking place. Using targeted literature reviews,
estimates of QoL for those activities may have been identified. However, it was established that there were
limited data available at a local level to facilitate this type of analysis, so other data sources were used for
this purpose.
Central or ‘best’ estimate of the threshold
The most relevant threshold is estimated using the latest available data (2008 expenditure, 2008–10
mortality). The central or ‘best’ threshold is estimated to be £12,936 per QALY.
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Which programme budget categories have the greatest
influence on the overall threshold?
Although the 11 PBCs where a mortality effect of changes in expenditure could be estimated only account
for 50% of the change in overall expenditure, they account for 78% of the overall health effects. The
other 12 PBCs, where mortality effects could not be estimated, account for an equal part of a change in
overall expenditure (50%) but only 22% of the overall health effects (i.e. the cost per QALY estimates
associated with a change in expenditure in these PBCs are, in general, much higher).
Insofar as investment and disinvestment opportunities in these PBCs might have been more valuable
(offered greater improvement in QoL) than suggested by the implied PBC thresholds, the overall QALY
effects will tend to be underestimated and the overall cost per QALY threshold will be overestimated.
The overall threshold of £12,936 may be conservative (i.e. could be overestimated) with respect to health
effects in PBC5 (mental health disorders), which accounts for a large proportion of the change in overall
expenditure (18%) and contributes most to the overall health effects (12%) compared with other PBCs.
The cost per QALY associated with this PBC is based on an extrapolation rather than observations of the
direct impact of changes in expenditure on QoL. Available evidence suggests that the investment and
disinvestment opportunities in mental health may have been more valuable than its implied cost per QALY.
How uncertain are the estimates and what are the implications?
Simulation methods were used to reflect the combined uncertainty in the various estimates from the
econometric analysis. This indicated that the probability that the overall threshold is < £20,000 per QALY is
0.89 and the probability that it is < £30,000 per QALY is 0.97.
As the consequences of overestimating the threshold are more serious than underestimating it in terms
of population health, a policy threshold will be lower than the mean of the cost per QALY threshold
(i.e. lower than £12,936) to compensate for the more serious consequences of overestimating the
‘true’ value.
There were other (‘structural’) sources of uncertainty associated with the estimated threshold, specifically
relating to the choice of econometric models and identification of causal effects. Although all the models
passed the relevant tests of validity, there remained some uncertainty about the validity of the instruments.
This structural uncertainty constituted a greater part of the overall uncertainty associated with the mortality
effects of changes in expenditure, but the central estimate of the cost per QALY threshold was robust to
this uncertainty.
The method of analysis used to link the effects of changes in expenditure on mortality to a fuller measure
of health expressed in QALYs was also subject to uncertainty. A preferred analysis (or scenario) was
identified as making the best use of available information, with assumptions appearing more reasonable
than the available alternatives and providing a more complete picture of the likely health effects of a
change in expenditure.
A critical issue is whether, on balance, the central or best estimate is likely to be an underestimate or
overestimate of the cost per QALY threshold. Although other assumptions and judgements are possible
that retain some level of plausibility, they do not necessarily favour a higher threshold. Indeed, when
considered together, they suggest that, on balance, the central or best estimate of £12,936 is, if anything,
likely to be an overestimate.
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There are some reasons why the central estimate of the QALY threshold might be underestimated. First, in
calculating life-year effects it is assumed that those deaths averted by a change in expenditure returns the
individuals to the mortality risk of the general population (matched for age and gender). There are a
number of other reasons why the central estimate might be overestimated. For example, the health effects
of a change in expenditure are restricted to the population at risk during 1 year. This also means that the
health effects of changes in expenditure which reduce incidence (prevention of disease) will not be
captured either. A more formal and longer lag structure in the estimation of outcome elasticities would be
likely to capture more health effects of a change in expenditure.
The effect of other assumptions that have been necessary are more ambiguous, although some evidence
suggests their net effect may be conservative with respect to health effects of changes in expenditure.
The impact of investment, disinvestment and non-marginal effects
The central estimate of the cost per QALY threshold is based on estimates of the health effects of changes
in expenditure across all 152 PCTs, some of which will be making investments (where expenditure is
increasing) and others making disinvestments (where expenditure is reduced or growing more slowly).
The threshold is, however, likely to differ across these different types of PCT. It would be expected that,
other things being equal, more expenditure would increase health but at a diminishing rate. Therefore,
the amount of health displaced by disinvestment would be expected to be greater, and the associated
threshold lower than the central estimate. Conversely, the health gained from investment would be
expected to be lower, and the associated threshold higher.
This was examined by re-estimating the outcome and expenditure effects separately for those PCTs where
their actual budget is under the target allocation from the Department of Health resource allocation
formula (i.e. those under greater financial pressure and more likely to be disinvesting than investing), and
those that are over target (under less financial pressure and more likely to be investing than disinvesting).
The results confirm these expectations. The health effects of changes in expenditure are greater when
PCTs are under more financial pressure and are more likely to be disinvesting than investing. The analysis
suggests that budget impact not only displaces more valuable activities within each PBC, but that overall
expenditure tends to be reallocated to PBCs which can generate more health. Although further research
might enable a quantitative assessment of how the relevant threshold should be adjusted for the scale of
budget impacts, the qualitative assessment seems clear: the central estimate of the threshold is likely to be
an overestimate for all technologies which impose net costs on the NHS (almost all technologies appraised
by NICE); and the appropriate threshold to apply should be lower for technologies which have a greater
impact on NHS costs.
How does the threshold change with overall expenditure?
The same methods were used to consider how the cost per QALY threshold is likely to have changed from
2007 to 2008 as overall expenditure has increased. This provides some insights into how the threshold
might be expected to change over time as, for example, overall expenditure and NHS productivity changes.
This has implications for a judgement about the appropriate frequency of periodic reassessment of the cost
per QALY threshold. Other things being equal, the threshold would be expected to increase following a
rise in overall expenditure, although this will depend on whether or not there is discretion over how
additional resources can be spent. However, insofar as the productivity of those activities that are valuable
to the NHS also improves through innovation, the threshold will tend to fall. So, the net impact of these
two countervailing effects on the threshold cannot be determined a priori.
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Differences in the estimated thresholds between 2007 and 2008 were assessed. Although overall
expenditure increased by 6% between 2007 and 2008, which represented real growth of 2% in 2007
prices, the overall threshold for all 23 PBCs fell by 5% in nominal terms and by 8% in real terms.
The reasons are complex but reflect changes in productivity, which differ across PBCs, but also a general
reallocation of a change in overall expenditure towards those PBCs that appear more valuable in 2008.
Given the uncertainty in estimation, subtle differences between 2007 and 2008 should not be
overinterpreted. This analysis does suggest, however, that the overall threshold will not necessary increase
with growth in the real or even nominal NHS budget. This suggests that the threshold is more likely to
fall at a time when real budget growth is flat or falling and PCTs find themselves under increasing
financial pressure.
What type of health is forgone by approval of a new technology?
The methods of analysis can identify not only how many QALYs are likely to be forgone across the NHS as
a consequence of approving a technology which imposes additional costs on the NHS, but also where
those QALYs are likely to be forgone and how they are made up (i.e. the additional deaths, life-years lost
and the QoL impacts on those with disease).
As an example, based on the 2008 central estimate of the cost per QALY threshold (£12,936),
the approval of ranibizumab (Lucentis®, Roche) for the treatment of diabetic macular oedema
(prior to the Patient Access Scheme agreement) would have imposed additional annual costs of up to
£80M on the NHS each year and been likely to displace 6184 QALYs elsewhere in the NHS. This forgone
health is likely to be made up of 411 additional deaths and 1864 life-years forgone, most of which are
likely to occur in circulatory, respiratory, gastrointestinal and cancer PBCs. However, much of the total
health effect of these additional costs (4987 QALYs) is associated with QoL forgone during disease which
is most likely to occur in respiratory, neurological, circulatory and mental health PBCs.
Conclusions and implications for practice
The research presented here goes some way to providing an empirically-based and explicit quantification
of the scale of opportunity costs the NHS faces when considering whether or not the health benefits
associated with new technologies are expected to be greater than the health that is likely to be forgone
elsewhere in the NHS. As such, it provides a basis for determining the appropriate threshold for NICE
decisions as well as those made centrally by the NHS and Department of Health more generally.
The methods presented can be used as a framework for further empirical work as additional and more
appropriate data emerge in the NHS. They also offer a basis for threshold estimation in other health-care
systems with budget constraints or limits on increasing expenditure.
The study also starts to make the other NHS patients, who ultimately bear the opportunity costs of such
decisions, less abstract and more ‘known’ in social decisions. As who happens to be known or unknown is
only a matter of perspective, time and ignorance, ethical and coherent social decisions require that both
should be treated in the same way. These methods contribute to removing some of the ‘ignorance’ and
making the unknown more real.
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Research recommendations
There is a need to update estimates of the threshold with more recent and future waves of expenditure
and mortality data.
If other aspects of social value are applied to health benefits of a new technology they must also be
attached to the type of health that is likely to be forgone due to additional NHS costs. The methods
developed here can be extended to allow weights to be also attached to the type of health that is forgone
and estimate the wider social benefits that are likely to be lost when the NHS must accommodate the
additional costs of new drugs.
We have demonstrated that these methods of analysis can be applied to QoL data collected as part of
patient-reported outcome measures (PROMs). This type of analysis could be applied to these data
in key PBCs as PROMs are rolled out providing some evidence about the QoL effects of changes in
PBC expenditure.
A key PBC is mental health. Currently outcomes data that could be linked to measures of QoL are
routinely collected in primary care. In principle, the same methods of analysis can be applied to these
data once they are made available providing some evidence about the QoL effects of changes in mental
health expenditure.
Improved and more recent estimates of incidence (by age and gender) and duration of disease will
soon be available from the recently published updated World Health Organization Global Burden of
Disease study. These data could be used when the threshold is re-estimated for later waves of expenditure
data. Alternatively, estimates could be based on Clinical Practice Research Datalink data.
Estimating a more complex lag structure based on the evolving panel data would provide valuable
evidence about the duration of the health effects of changes in expenditure. The recent release of census
data for 2011 may allow a panel model to be estimated allowing better control for unobserved
heterogeneity across PCTs as well as exploiting variation in outcomes, expenditure and other covariates
over time. The formation of Clinical Commissioning Groups (CCGs) in 2013 will make the time series
problematic for waves of expenditure after 2012 unless it is possible to match CCG and PCT boundaries.
If PBC expenditure and outcome data are available at CCG level (as well as covariates and suitable
instruments), it might become possible to estimate outcome and expenditure equations simultaneously
across PBCs. This would enable more of the likely health effects of changes in expenditure to be reflected
in the analysis.
Funding
Funding for this study was provided by the NIHR-MRC Methodology Research Programme.
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Chapter 1 Introduction
Policy context
A comparison of the incremental cost-effectiveness ratio (ICER) of a new technology with a
cost-effectiveness threshold is not the only consideration when the National Institute for Health and
Care Excellence (NICE) and its advisory committees issues guidance. However, it is an important one as it
allows an assessment of whether or not the health expected to be gained from the use of a technology
exceeds the health expected to be forgone elsewhere as other NHS activities are displaced. For this reason
a comparison of the ICER of a technology to a threshold range is a critical part of the reference case in
the NICE Guide to the Methods of Technology Appraisal3 and is often taken to be the starting point for
deliberations about other considerations including judgements of social value. Therefore, the value of the
threshold is critical to the assessment of whether or not technologies can be regarded as cost-effective.
This is also true for other NHS resource allocation decisions which potentially impose additional costs on
local NHS commissioners.
Estimating the cost-effectiveness threshold
A key part of NICE’s remit is to make decisions which are consistent with the efficient use of NHS
resources. In the context of the NHS budget constraint, a consideration of efficiency has to reflect the
implications of imposing additional costs on the system which will displace existing services thus leading to
health decrements for patients other than those benefiting from the new technology being appraised.
The cost-effectiveness threshold is an estimate of health forgone as other NHS activities are displaced to
accommodate the additional costs of new technologies. A national decision-making body such as NICE
needs an estimate of what is likely to be forgone across the NHS as we currently find it.1 Of course,
this will change as circumstances and the NHS change; tending to rise with increases in budget and
health-care costs but tending to fall with increases in the productivity of health technologies and the
efficiency of the NHS in general (including better local commissioning decisions).2 A body such as NICE
cannot and does not necessarily need to know what specific services and treatments will be displaced in
particular localities or who will actually forgo health.
What is required, therefore, is an accountable and empirically-based assessment of the health that is likely
to be forgone on average across the NHS. Currently NICE uses a threshold range of £20,000–30,000 per
quality-adjusted life-year (QALY) gained, where additional considerations are required towards the upper
bound.3 The empirical basis of this range of values is very limited and there have been calls for further
research in this area.4 Explicit scientific methods are required which will provide accountability so that
estimates can be scrutinised by a range of stakeholders. As estimates of the threshold will need to be
periodically revised, methods which make best use of routinely available NHS data are needed. As well
as accountability, this will provide more predictability in likely changes to the threshold for the investment
decisions of technology manufacturers.
Aims and objectives
The aim of this research is to develop and to demonstrate methods to estimate the cost-effectiveness
threshold for the NHS which makes best use of routinely available data. Methods are required which can
capture the impact of a change in expenditure on length and quality-of-life (QoL), indicate how estimates
of the threshold have changed over time, reflect uncertainty in any estimates and assess its implications,
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and indicate the impact of increases or decreases in spending. The project also aims to discuss options for
developing data sources in the UK to estimate the threshold more precisely over time.
The research has four main objectives:
i. informed by relevant literature, to provide a conceptual framework to define the threshold and the
basis of its estimation
ii. using programme budgeting (PB) data for the English NHS, to estimate the cost per years of life gained
(YLG) on average across the NHS, for marginal changes in budget
iii. to extend the measure of the health effects of changes in expenditure by estimating the QoL associated
with additional years of life and the direct impact of health services on QoL
iv. to synthesise this work to bring evidence on life-years and QALYs together, to present the best estimate
of the cost-effectiveness threshold given existing data, to show the implications of the uncertainty in
the current evidence and to provide recommendations for future data collection and analysis.
Report structure
The main report is set out as a series of chapters, most of which are linked to more detailed analysis in
separate appendices. Chapter 2 provides a policy context for the research and a conceptual framework for
the subsequent empirical work. Chapter 3 outlines a simple theoretical model and associated econometric
analysis of PB data to estimate the link between changes in overall NHS expenditure and mortality.
Chapter 4 considers a range of analyses to extend the measure of health effect from mortality to YLGs
and to QALYs. Chapter 5 draws out the main conclusions and insights from the research.
INTRODUCTION
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Chapter 2 Policy context and conceptual
framework
Introduction
The purpose of this chapter is to provide the foundation for the empirical chapters that follow. It addresses
a series of questions regarding the nature of the cost-effectiveness threshold that NICE use to guide its
decisions, and the principles of how it should be estimated.
The chapter is informed by the results of a systematic literature search relating to these questions. Details
of the methods and results of that search, together with a summary of the papers identified, are provided
in Appendix 1. In brief, the search uses a ‘pearl growing’ method to identify relevant papers. This identifies
a number of initial key articles (‘pearls’) on the basis of expert advice, and ‘grows’ these pearls in a series
of steps: extraction of citations and references from the initial pearls; identification of further pearls from
cited and referenced papers; repetition of citation and reference searches; and manual search of
references. This process is repeated until no further papers of relevance are identified. On this basis,
76 relevant papers were identified and are referred to, when relevant, in this chapter.
This chapter is organised as follows. The next section considers, at a conceptual level, what the
cost-effectiveness threshold to inform NHS decisions, such as those made by NICE’s advisory committees,
should represent. Estimating the threshold considers alternative routes to generating an empirical estimate
of such a threshold. The final section provides a brief overview of the methods used in the study.
What should the National Institute for Health and Care
Excellence threshold represent?
The threshold as a measure of opportunity cost
The National Institute for Health and Care Excellence uses cost-effectiveness analysis (CEA) to inform the
decisions underlying most types of guidance that it publishes. The use of CEA is most prominent in
appraisals relating to new medicines,3 but is also a key input into diagnostics appraisals as well as clinical
guidelines and public health guidance.3,5 For those interventions and programmes which impose additional
costs on the NHS budget, their ICERs indicate the incremental cost per additional QALY achieved relative
to appropriate comparators. Although the ICER is one of a number of evidential inputs into NICE
committees’ decisions, is has been shown to be the most important, at least for technology appraisals.6
Interpreting whether or not a given ICER is acceptable requires the use of a cost-effectiveness threshold.
Given that NICE has no influence on the level of the NHS budget, its decisions need to consider that
budget as a fixed constraint.1 Therefore, the threshold should reflect the opportunity costs, in terms
of health forgone, resulting from the imposition of additional costs on the NHS. When NICE issues
positive guidance for a new intervention which imposes additional costs on the system, the resources
required to deliver it must be found by disinvesting from other interventions and services elsewhere.7
This displacement of existing services will result in health decrements for other types of individual.8
Thus, the threshold represents the additional cost that has to be imposed on the system to forgo 1 QALY’s
worth of health through displacement.
Resource allocation decisions based on comparing an ICER with a cost-effectiveness threshold uses
some simplifying assumptions, including those of constant returns to scale and perfect divisibility of
programmes.9 Some have suggested that this makes these methods unreliable,10 although it has also been
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argued that they provide useful approximations to guide decisions.11 This report takes NICE’s use of these
methods as a starting point, and does not review the literature relating to this debate in any depth.
As Figure 1 illustrates, CEA effectively becomes an analysis of net health benefits (NHBs): does the health
gain from the new intervention outweigh the health decrements associated with the displacement of
existing services necessary to fund it? Figure 1 shows the incremental costs and QALYs associated with a
new intervention relative to a comparator (the latter being shown at the origin). The new intervention
generates 2 additional QALYs per patient and, at price P1, imposes an additional £20,000 per patient; the
ICER is, therefore, £10,000 per QALY gained. At a threshold of £20,000 per QALY, the additional cost of
£20,000 per patient translates into a decrement of 1 QALY (the distance between the y-axis and the
threshold). This is because the threshold indicates the additional cost that needs to be imposed on the NHS
budget in order to displace services that result in 1 QALY being forgone. Therefore, at that price, there
is a net health gain of 1 QALY per patient (2 gained from the new intervention and 1 forgone through
displacement). At a price of P2, the additional cost per patient of the new intervention is £40,000 and the
net health gain is 0: the 2 additional QALYs from the new intervention are the same as the QALYs forgone
through displacement. At the highest price of P3, the adoption of the new intervention would actually
result in a net health decrement of 1 QALY as it generates fewer QALYs (2) than are forgone (3).
The use of the threshold to facilitate this NHB analysis can be expressed as in Equation 1:
NHB = Δh −
ΔCh
k
(1)
where Δh is the change in health generated by the new intervention, ΔCh is the additional health-care cost
imposed on the NHS, and k is the cost-effectiveness threshold. The net health gain from adopting the new
intervention is therefore the health gained, Δh, minus the health forgone, ΔChk .
Understanding the NICE cost-effectiveness threshold as representing opportunity costs in terms of health is
explicit in NICE documentation (e.g. the Guide to the Methods for Technology Appraisal3). It is also clear in
reports published by the Department of Health, such as the consultation report on value-based pricing.4,12,13
£20,000
per QALY
Price = P2 £40,000
Cost-effectiveness
threshold
£20,000 per QALY
QALYs gained
Cost
£30,000
per QALY
Price = P3  £60,000
3
Price = P1 £20,000
2
£10,000
per QALY
1
NHB
1 QALY
NHB
−1 QALY
FIGURE 1 Graph showing illustration of the NICE threshold as a basis for assessing NHB. Reproduced from
Value based pricing for NHS drugs: an opportunity not to be missed?, Claxton K, et al., vol. 336, pp. 251–4, 2008
with permission from BMJ Publishing Group Ltd.
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This conceptualisation of the principles of the NICE threshold is also described in the broader literature.1,2
Formally, the threshold can be seen as the shadow price of the budget constraint.1,2,8,14–16 Although this
project focused on the use and estimation of a cost-effectiveness threshold for NICE decisions, the methods
and estimates relate to any resource allocation decision within the NHS where the opportunity
cost could fall anywhere in the system. Hence it could apply, for example, to Department of Health targets
or to NHS England directives, as well as NICE guidance.
The threshold as the consumption value of health
Another view of what the threshold used in CEA should represent exists in the literature; however,
in general terms this is based on the rate at which individuals are willing to forgo other forms of
consumption to achieve health improvement [sometimes referred to as ‘willingness to pay’ (WTP)].17–36
Although this consumption value of health can provide information on the value of health improvement
and may guide decisions such as the level of the overall NHS budget, it does not inform decisions
regarding how to allocate a fixed budget within the health-care system.
The reason for this is that the consumption value of health applies equally to health gained as well as to
health forgone. This is shown in Equation 2 where the consumption value of health, v, is added to the
definition of NHB in Equation 1. This simply involves valuing both health gained and health forgone by the
same consumption value of a unit of health, v. Therefore, the use of the consumption value is irrelevant: a
treatment considered cost-effective in Equation 1 (i.e. to have a positive NHB) will inevitably be considered
cost-effective in Equation 2, and an intervention with negative NHB (i.e. not cost-effective) will remain as
such in Equation 2.a Therefore, the magnitude of the threshold, k, is not a value judgment but an empirical
question which can, in principle, be estimated.
NHB = v.Δh −
v
k
ΔCh (2)
Estimating the threshold
The National Institute for Health and Care Excellence’s threshold range
The National Institute for Health and Care Excellence has been reluctant to specify a single cost-effectiveness
threshold used in its decision-making.6 It has also consistently emphasised that factors other than CEA are
taken into consideration by the various advisory committees.3,5,6,38–40 Therefore, it has preferred to indicate
the range within which its threshold value lies (i.e. £20,000–30,000 per QALY gained).3,5 Alongside this,
it has provided an indication of the role other factors play in determining which point of threshold range is
relevant. The latest guide3 suggests that an ICER < £20,000 is likely to lead to recommendation unless
the evidence is considered highly uncertain; an ICER between £20,000 and £30,000 will lead to
recommendation if the committee is also happy with the levels of uncertainty in the evidence and/or the
QALY does not capture all aspects of benefit; and an ICER > £30,000 would be recommended only if
issues related to levels of evidential uncertainty and a failure to capture all benefits in the QALY are
particularly compelling.
In 2009, NICE issued further supplementary guidance relating to the appraisal of interventions for
patients with short life expectancy (LE), although this can be considered to relate more to the measure
of benefit than factors to be considered outside of cost-effectiveness.41 In 2012 NICE issued a draft
update of its methods guide which added that, if a new technology has an ICER > £20,000 per QALY, the
committee’s deliberations would also consider ‘aspects that relate to non-health objectives of the NHS’
(e.g. wider social considerations and/or costs that fall outside the NHS budget).42
DOI: 10.3310/hta19140 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 14
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Claxton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
5
Although NICE has carefully argued the case for why its decisions are not driven entirely by a comparison
of the ICER with its threshold range, it has not provided any empirical evidence for why the threshold
range takes the value it does. Indeed it has been widely argued than an empirical basis for these values
should be generated.4,43–47 For example, the House of Commons Health Select Committee in 2008 argued:
The affordability of NICE guidance and the threshold it uses to decide whether a treatment is
cost-effective is of serious concern. The threshold is not based on empirical research and is not directly
related to the budget, it seems to be higher than the threshold used by [primary care trusts] PCTs for
treatments not assessed by NICE. Some witnesses, including patient organisations and pharmaceutical
companies, thought that NICE should be more generous in the cost per QALY threshold it uses, and
should approve more products. On the other hand, some PCTs struggle to implement NICE guidance
at the current threshold and other witnesses argued that a lower threshold should be used. We
recommend that the threshold used by NICE in its full assessments be reviewed; further research
comparing thresholds used by PCTs and those used by NICE should be undertaken . . .
p. 64
The basis for empirical work
Although there is acceptance of the need for empirical work on the NICE cost-effectiveness threshold,
a set of issues exists regarding the starting point for such analysis. One aspect of this is the view that the
nature of the services that are displaced in response to additional costs being imposed by NICE guidance,
and hence the magnitude of the health forgone for other patients, will depend on the productivity of the
NHS and its overall (inflation-adjusted) budget, both of which have increased since NICE initially defined
its threshold range.48,49 In principle an increase in the (real) NHS budget would allow it to introduce
interventions which were previously not cost-effective which might be expected to increase the threshold
if these interventions were the marginal ones displaced in response to the budget impacts of NICE
recommendations. However, any increase in the NHS budget may be allocated to non-discretionary
expenditure. This would include, for example, expenditure relating to national initiatives such as
new contracts for consultants and activities to meet waiting list targets as well as, of course, the
implementation of NICE guidance. The non-discretionary nature of such expenditure means that these
types of activities cannot easily be disinvested from given a need to release resources to fund NICE
guidance. Therefore, if an increase in the NHS budget is largely devoted to these types of non-discretionary
expenditure, there will be a limited impact on the threshold.
Gains in productivity may come through doing worthwhile activities more cost-effectively, including for
those marginal interventions displaced by NICE recommendations, suggesting a reduction in the threshold.
Alternatively, productivity gains might come through discontinuing activities which are not worth doing
(i.e. that produce no health improvement), freeing resources for additional cost-effective interventions
which may be the marginal services displaced by NICE guidance – this can have the result of increasing
the threshold.
The net effect of these changes on the threshold could not be determined a priori and would depend on
how any additional (real) budgets were allocated and how the gains in productivity where achieved. This
does emphasise the fact that the threshold may change over time in response to these and other broader
developments, and this would have to be considered as part of any regular updating of the empirical
analysis of the threshold.
A second issue to be considered relates to how decisions are taken locally about any displacement
following NICE guidance. The principles of CEA suggest that such displacement should relate to
interventions which are the least cost-effective of those currently covered by the budget.14 The basis for
how local commissioners and providers make their disinvestment decisions is not clear, however, and there
have been calls for greater transparency and guidance in this area.48 It would be entirely unrealistic to
assume that displacement only takes place in those existing services which are the least cost-effective.
The reality is that numerous criteria are likely to be used by commissioners in implementing disinvestment,
POLICY CONTEXT AND CONCEPTUAL FRAMEWORK
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and that significant variation will exist between local decision-makers.8 Such criteria might include, for
example, equity concerns about a particular disadvantaged group locally or capacity constraints regarding
particular services. Therefore NICE needs to know what is likely to happen on average across the NHS
given the reality of local decisions. If local decision-making changes over time – for example, if local
commissioners become more focussed on displacing services which are the least cost-effective, in terms of
population health – this may affect the estimate of the threshold.
Studying displacement locally
A reasonable conclusion from a consideration of these issues is, therefore, that local decisions about
disinvestment are likely to be an important determinant of the NICE threshold.50–55 Appleby et al.56
sought to assess whether or not it was possible to study local decisions about service investment and
disinvestment to infer the cost-effectiveness thresholds being used (implicitly) locally and to draw
conclusions about the appropriate level of the NICE threshold. They identified six PCTs and undertook
structured interviews with each of the directors of public health. They also administrated questionnaires to
an opportunistic sample of finance directors from NHS trusts. On this basis they developed a list of new
services as well as those that had been deferred or discontinued. An attempt was made to estimate the
implicit local ICER relating to these decisions by using any cost-effectiveness evidence used to inform
the decisions together with relevant evidence on cost-effectiveness from the published literature.
The study found it quite straightforward to identify specific services that had been introduced,
discontinued or deferred, but concluded that these decisions were typically based on clinical and other
non-economic factors. A number of ‘decisions at the margin’ were identified but none of these were
based on CEA. Instead, the basis for changes in services was a ‘business case’, or overall cost impact.
It was possible to impute cost-effectiveness for most of the services affected, but the study concluded that,
even with a larger sample of commissioners and providers, it would be very difficult to estimate an
implied cost-effectiveness threshold locally. This would be because, first, most PCT decisions were service
reconfigurations including demand management and waiting list initiatives. By their nature, teasing out
the incremental cost and health effects, potentially across numerous types of patients, would be an
enormous challenge. Second, there would be difficulty in identifying all local decisions as many options
for investment, deferment or discontinuation are rejected before they are made more explicit in
documentation. A third problem would be the finding that a range of criteria is used to make local
decisions, with relatively little concern for cost-effectiveness, making a local threshold estimated in this
way hard to interpret. A final challenge would be that it would be very difficult to establish a causal link
between a change in local NHS budget and specific local investment and disinvestment decisions.
The Appleby et al.56 study highlights the problems that exist in deriving a cost-effectiveness threshold
from a bespoke study of specific local resource allocation decisions.
What evidence is needed?
Given the challenges of studying local decisions as a means of establishing the NICE threshold, and
keeping in mind NICE’s remit, it is possible to suggest a series of important characteristics that estimation
methods should have from the perspective of principle and practice:
l They should reflect the effect of NICE guidance on the average of the displacement decisions taken
across the NHS, with less consideration on which types of patients and interventions are affected and
why the decisions are taken. NICE cannot be expected to reflect what is likely to be marked variation
between local commissioners and providers in how they react to an effective reduction in their budget
as a result of positive guidance. Given NICE’s remit, it is the expected health effects (in terms of length
and QoL) of the average displacement within the current NHS (given existing budgets, productivity and
the quality of local decisions) that is relevant to the estimate of the threshold.
l The methods used should not be a ‘once and for all’ effort but should facilitate regular updates to
reflect changes in the broader NHS context such as changes in the overall real budget and productivity.
This requires the use of data sources that are currently routinely available, are expected to become so
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in the future or could be made available at reasonable cost. It may be possible to glean some idea of
how the threshold may change in the future by studying how it has changed in the past, which would
require routine data sources to extend back over a period of time. Periodic updating using explicit
scientific methods would encourage accountability through scrutiny of estimates by relevant
stakeholders. It would also provide more predictability in likely changes to the threshold for the
investment decisions of technology manufacturers.
l The nature of the displacement of existing services (and hence the magnitude of the health forgone)
will depend on the scale of the budget impact coming through NICE guidance. Therefore, the methods
used to estimate the threshold should ideally be able to reflect this budget impact.
l The methods should recognise the inevitable uncertainty relating to the evidence currently available
for threshold estimation and translate this into an expression of the uncertainty in the estimate
of the threshold. As well as providing information with which NICE can determine the appropriate
implications for its choice of a threshold value, this consideration of uncertainty can help to prioritise
further research or the collection of routine data.
An introduction to study methods
The current study has sought to develop methods consistent with these desired characteristics. This section
provides a summary of the methods used. Further details are provided in each of the later chapters relating
to the various components of work, and in the associated appendices. The general approach taken is to
use routinely available data to look at the relationship between overall NHS expenditure and patients’
health outcomes. By exploiting differences between PCTs in expenditure and outcomes, it is possible to
infer the costs of generating health improvement from NHS services at the margin. In principle, this is what
is needed as the basis of the NICE cost-effectiveness threshold as it provides an indication of the health
forgone through the services displaced by the additional budget effect of the Institute’s guidance.
Past work
The study was able to build on some key existing research relating to the relationship between NHS
expenditure and mortality.57–59 Since 2003 data on expenditure on health care across 23 programme
budget categories (PBCs) of care have been available for each PCT in the NHS in England. These PB data
seek to allocate, to broad areas of illness according to the primary diagnosis [using International
Classification of Diseases, Tenth Edition (ICD-10) codes], all items of NHS expenditure, including
expenditure on inpatient care, outpatient care, community care, primary care, and pharmaceuticals
and devices.
For the purposes of this study, the merit of these data is that they open up the possibility of examining the
relationship between differences in local spending and associated disease-specific mortality outcomes
routinely available from the National Centre for Health Outcomes Development. In each programme, the
elasticity of outcome with respect to changes in expenditure was estimated controlling for differences
between PCTs in need. Changes in mortality were then transformed into YLG using assumptions regarding
LE without the change in expenditure. This provides estimates of the marginal cost per YLG on average
across the NHS by PBC.
This work focused largely on spending and outcomes in two of the largest programmes: circulatory
disease and cancer,60 but has also informed the link across other programme categories.58,61 Estimates
of the cost per YLG for 2006/7 were £15,387 for cancer, £9974 for circulation problems, £5425 for
respiratory problems, £21,538 for gastrointestinal problems and £26,428 for diabetes. These estimates
were based on a straightforward, though carefully constructed, theoretical model of health production
which informs the specification and estimation of a set of equations. These dealt with the challenge of
there being alternative plausible directions of causation (e.g. between expenditure and health outcomes
within a programme). This problem of endogeneity was addressed by identifying and testing suitable
instrumental variables (IVs). In doing so, they accounted for variation in the clinical needs of the local
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population relevant to each programme together with broader local environmental factors relevant to the
costs of care and outcomes.
This earlier work provides a strong foundation for the current study through its consideration of the
average marginal elasticity of outcome with respect to programme expenditure. However, to estimate
the threshold suitable for NICE decision-making, a number of further elements of research are necessary,
and these are described below.
Further econometric analysis
This further econometric research is covered in Chapter 3, with full details in Appendix 2. The earlier work
estimated the cost per YLG for the major programme areas. The NICE threshold needs to relate to the
whole NHS and will, therefore, depend on all the programmes of care where disinvestment takes place.
Given that each programme of care has been estimated separately, it is not clear how expenditure on
particular programmes changes with the overall budget. For example, does disinvestment tend to fall on
respiratory care or diabetes following a budget impact from NICE guidance? Therefore, the current study
has further developed the econometric analysis to reflect the need for PCTs to operate within a fixed
overall budget. This provides an estimate of the ‘budget elasticity of expenditure’ in each PBC, and
facilities estimates of the impact of marginal increases (or decreases) in overall PCT budgets on spending
in each PBC.
As well as indicating budgetary influences on programme spending, these elasticities have then been
linked to changes in mortality outcomes by programme. These changes are used to estimate years of life
lost (YLL) taking account of the fact that some of the observed deaths would have occurred anyway
(had the same population not been at risk in the particular PBC); that is, taking account of unobserved
counterfactual deaths. This takes into account how such budgetary changes (such as those imposed by
NICE guidance) translate through local decisions into changes in expenditure on programmes of care and
then to health outcomes.
Changes in budgets are in practice incremental rather than marginal, and it may be the case that the
outcome elasticities of programme expenditure in times of budgetary increase (when new initiatives are
introduced) are not the same as in times of budgetary decrease (when the focus is on disinvestment).
The possible effects of non-marginal changes have therefore been explored. The project has also sought
to explore how both expenditure and outcome elasticities, and hence the threshold, vary over time,
and this has been assessed by generating relevant estimates for three sets of data.
A development from earlier work has been to relate expenditure in period t to mortality in periods t, t + 1
and t + 2. Although the data used are largely cross-sectional, mortality data are linked so as to follow
expenditures. Given the inevitable uncertainty relating to assumptions in the analysis, extensive sensitivity
analysis is undertaken to consider the implications for the estimates.
Moving from life-years to quality-adjusted life-years gained
A key element of the research has been to take the results of the econometric work linking NHS spending
and mortality, and to translate this into effects on life-years and QALYs. The methods planned for the
study included a consideration of local data, collected routinely by PCTs, on the types of interventions in
which local decision-makers were investing and disinvesting. The aim was to inform the link between the
effects of expenditure changes on mortality and impacts on broader health in terms of QALYs. These data
may have indicated the types of interventions and services, within a given PBC, on which investment and
disinvestment were taking place. Using targeted literature reviews, estimates of QoL for those activities
may have been identified. However, it was established that there were limited data available at a local level
to facilitate this type of analysis, so other data sources were used for this purpose (see Addendum 2:
the role of data on local NHS decisions in Appendix 3).
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It has therefore been necessary to consider alternative data and approaches. This is tackled using
three sequential steps:
i. translate the estimated effects on mortality from the econometrics work into life-years by exploring
the limitations of the mortality data available at PCT level and the published YLL figures used in the
econometric analysis, and by considering how to improve the estimates using additional data
and analysis
ii. consider how estimates of life-year effects can be adjusted for the QoL in which they are lived, taking
account of the gender and the age at which life-years are gained or lost as well as the QoL implications
of particular diseases
iii. explore ways to take account of those effects on health not directly associated with mortality and
life-year affects (i.e. the ‘pure’ QoL effects) to estimate an overall cost per QALY threshold.
This aspect of the analysis is described in Chapter 4 with further details provided in Appendix 3.
The central or ‘best’ estimate is based on two assumptions relating to the health effects associated with
expenditure, one conservative and the other more optimistic. The first assumption is that the health effects
of changes in 1 year of expenditure are restricted to 1 year. This is implicit in the estimates of outcome
elasticities estimated in the econometric analysis. This is likely to underestimate effects on mortality as
expenditure that reduces mortality risk for an individual in 1 year may well also reduce their risk over
subsequent years, and expenditure may also prevent disease in future patient populations. Therefore, total
health effects will be underestimated and the cost per life-year or QALY threshold will be overestimated.
Although undoubtedly conservative, it may be offset to some extent by the more optimistic assumption.
It is assumed that any death averted by expenditure in 1 year will return the individual to the mortality risk
of the general population, that is the years of life gained (YLG) associated with each death averted are
based on what would have been their LE taking account of their of age and gender (using life tables for
the general population).
The extreme upper and lower bounds for cost per life-year and cost per QALY thresholds are based on
making both of these assumptions either optimistic (providing the lower bound for the threshold) or
conservative (an upper bound for the threshold). The lower bound is based on assuming that health effects
are not restricted to 1 year but apply to the remaining disease duration for the population at risk during
the expenditure year. The upper bound is based on the combination of assuming that health effects are
restricted to 1 year and that any death averted is only averted for the minimum duration consistent with
the mortality data used to estimate the outcome. It is very important to note that the lower and upper
bounds are very much extreme values with limited plausibility.
Conclusions
A cost-effectiveness threshold is needed to inform decisions by NICE, the NHS more generally or the
Department of Health which reflects the fact that opportunity costs fall on services and population health
at a local level. Given that it is (and will continue to be) unfeasible to know precisely which services are
displaced across all localities within the NHS, the threshold should reflect the average implications on
health of actual local decisions about marginal changes in local service caused by changes in expenditure.
The absence of an empirical estimate of the threshold which reflects these principles lies behind the
project. Using data routinely collected in the NHS or available data that could be routinely updated, the
study is organised into two major parts. The first updates earlier analysis to estimate the relationship
between NHS expenditure and mortality, and the second seeks to translate these mortality effects into the
more general measure of health – the QALY.
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Chapter 3 The link between NHS spending,
mortality and the cost of a life-year
Introduction
This section presents an overview of the econometric work undertaken to estimate the link between NHS
spending and mortality and how this is used to calculate the cost of a life-year. As well as providing the
analytical foundations for estimates of cost per QALY threshold presented in Chapters 4 and 5, this work
contributes to the ongoing debate about the extent to which additional health-care expenditure yields
improved patient health outcomes.
The work presented in this report takes advantage of the availability of two new data sets to examine the
relationship between NHS expenditure and mortality rates for various disease categories. One data set
contains mortality rates for various disease categories at the level of geographically defined local health
authorities, PCTs. The other data set presents NHS expenditure by PCT on 23 broad programmes of
care (these programmes are listed in Table 1). This data set embraces most items of publicly funded
expenditure, including inpatient, outpatient and community care, and pharmaceutical prescriptions. NHS
revenue derives almost entirely from national taxation, and access to the system is generally free to the
patient. The system is organised geographically, with responsibility for the local administration of the NHS
devolved to PCTs.a PCTs are allocated fixed annual budgets by the Department of Health, within which
they are expected to manage the health care in the locality.
We employ a model that assumes that each PCT receives an annual financial lump sum budget and
allocates its resources across the 23 programmes of care to maximize the health benefits associated with
that expenditure. Estimation of this model using the expenditure and mortality data facilitates two related
studies: first, a study of how changes in the NHS budget impact on expenditure in each care programme;
and second, a study of the link between expenditure in a programme and the health outcomes achieved,
notably in the form of disease-specific mortality rates. The latter also permits the calculation of the cost of
an additional life-year for individual programmes of expenditure.
The work presented here draws heavily on previous studies using these data57,59,60,62,63 and innovates in
four major ways: (1) we relate expenditure in time period t to outcomes in periods t, t + 1, and t + 2
combined;b (2) we present plausible outcome models for a large number of budgeting categories – previous
studies have tended to focus on the four largest care programmes; (3) we present estimates of the cost of a
life-year for the enlarged number of programmes and, importantly, with the aid of assumptions about the
productivity of programmes without a meaningful mortality-based outcome indicator, we extend our
individual programme estimates to incorporate expenditure across all programmes of care; and (4) although
the models we present appear well specified according to appropriate statistical tests, we subject our
results to a substantial sensitivity analysis.
The next section presents a brief review of the relevant literature on which the study builds. This is
followed by a summary overview of our approach to estimating the cost per life-year across the various
programmes of care and the results obtained using PB data provided by the Department of Health.
Further details of all aspects of the modelling approach, description of the data, the results we derive and
calculation of costs per life-year are set out in Appendix 2. This section is intended to be supported by the
information contained within Appendix 2.
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TABLE 1 National (all PCT) expenditure per head (£) and growth in expenditure (%) by PBC group, 2003/4–2008/9
PBC
Spend
(£)
per
head
Spend
(£)
per
head
Spend
(£)
per
head
Spend
(£)
per
head
Spend
(£)
per
head
Spend
(£)
per
head
Growth
(%)
Growth
(%)
Growth
(%)
Growth
(%)
Growth
(%)
Share of
total
spend
(%)
Share of
total
spend
(%)
2003/4 2004/5 2005/6 2006/7 2007/8 2008/9 2004/5 2005/6 2006/7 2007/8 2008/9 2004/5 2008/9
1 Infectious diseases 17.95 20.22 23.61 20.88 22.08 23.46 13 17 –12 6 6 1.7 1.5
2 Cancers and
tumours
64.95 75.54 83.24 81.67 90.21 94.55 16 10 –2 10 5 6.3 6.2
3 Blood disorders 14.08 17.00 17.48 16.58 19.44 19.50 21 3 –5 17 0 1.4 1.3
4 Endocrine,
nutritional
28.96 31.86 37.26 36.70 39.39 43.38 10 17 –1 7 10 2.7 2.8
5 Mental health 133.31 146.83 158.95 166.53 180.90 191.21 10 8 5 9 6 12.2 12.5
6 Learning disability 37.93 43.37 46.54 48.36 54.20 56.11 14 7 4 12 4 3.6 3.7
7 Neurological 29.83 35.09 41.06 55.27 62.43 67.64 18 17 35 13 8 2.9 4.4
8 Vision problems 24.61 27.65 28.24 26.97 30.69 32.95 12 2 –4 14 7 2.3 2.2
9 Hearing problems 5.73 6.32 6.27 6.21 8.07 8.16 10 –1 –1 30 1 0.5 0.5
10 Circulatory disease 110.12 122.37 124.28 122.06 124.77 129.94 11 2 –2 2 4 10.2 8.5
11 Respiratory system 54.60 62.71 69.56 65.07 67.68 77.97 15 11 –6 4 15 5.2 5.1
12 Dental problems 10.78 13.55 24.91 51.93 59.45 62.44 26 84 108 14 5 1.1 4.1
13 Gastrointestinal
system
63.56 73.22 81.30 73.30 75.05 77.89 15 11 –10 2 4 6.1 5.1
14 Skin problems 20.98 24.90 26.84 28.31 30.41 32.34 19 8 5 7 6 2.1 2.1
15 Musculoskeletal
system
61.36 71.72 74.74 66.75 75.91 79.68 17 4 –11 14 5 6.0 5.2
16 Trauma and injuries 62.31 72.13 76.41 57.29 57.56 63.54 16 6 –25 0 10 6.0 4.2
17 Genitourinary
system
55.32 62.38 67.38 68.98 67.83 73.78 13 8 2 –2 9 5.2 4.8
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PBC
Spend
(£)
per
head
Spend
(£)
per
head
Spend
(£)
per
head
Spend
(£)
per
head
Spend
(£)
per
head
Spend
(£)
per
head
Growth
(%)
Growth
(%)
Growth
(%)
Growth
(%)
Growth
(%)
Share of
total
spend
(%)
Share of
total
spend
(%)
2003/4 2004/5 2005/6 2006/7 2007/8 2008/9 2004/5 2005/6 2006/7 2007/8 2008/9 2004/5 2008/9
18 Maternity 52.28 55.04 60.42 57.64 57.09 60.44 5 10 –5 –1 6 4.6 3.9
19 Neonate conditions 11.72 13.93 13.42 13.17 15.15 17.23 19 –4 –2 15 14 1.2 1.1
20 Poisoning 9.68 12.32 14.25 14.59 15.84 18.31 27 16 2 9 16 1.0 1.2
21 Healthy individuals 20.29 22.77 26.18 26.85 31.44 35.74 12 15 3 17 14 1.9 2.3
22 Social care needs 24.81 30.93 33.59 30.29 35.29 36.58 25 9 –10 17 4 2.6 2.4
23 Other (includes
GMS/PMS)
136.94 157.75 171.82 209.70 232.02 227.71 15 9 22 11 –2 13.2 14.9
1–23 All PBCs 1052.12 1199.60 1307.76 1345.10 1452.91 1530.59 14 9 3 8 5
GMS, general medical services; PMS, primary medical services.
The population figures for 2003/4, 2004/5 and 2005/6 are identical (the total for England is 49,175,998).
The corresponding figure for 2006/7 is 50,476,231, for 2007/8 it is 50,695,989 and for 2008/9 it is 51,220,531.
The spend per head figures are calculated by summing expenditure across all PCTs and dividing by the national population.
All figures are at current prices.
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Previous studies
One of the most fundamental yet unresolved issues in health policy is the extent to which additional
health-care expenditure yields patient benefits, in the form of improved health outcomes. The work of
health technology agencies such as NICE has greatly improved our understanding at the micro level of the
costs and benefits of individual technologies. However, there remains a dearth of reliable evidence at
the macro level on the benefits of increased health system expenditure.
The empirical problems of estimating the link between spending and health outcomes are manifest.
If one relies on a time series of health outcome data for an individual health system it is difficult to
disentangle the impact of expenditure from a wide range of other temporal influences on health, such as
technological advances, epidemiological changes, and variations in broader economic circumstances.
Similar methodological difficulties arise if one attempts a cross-sectional comparison of different health
systems. In particular, when seeking to draw inferences from international comparisons, researchers might
have failed to adjust for all the potential external influences on health outcomes and this might account in
part for their findings. For example, in an early cross-sectional study of 18 developed countries, Cochrane
et al.64 use regression analysis to examine the statistical relationship between mortality rates on the
one hand and per capita gross national product (GNP) and per capita consumption of inputs such as
health-care provision on the other. They found that the indicators of health-care provision were generally
not associated with outcomes in the form of mortality rates. Thereafter, the failure to identify strong and
consistent relationships between health-care expenditure and health outcomes (after controlling for other
factors) has become a consistent theme in the literature, whereas, in contrast, socioeconomic factors are
often found to be good determinants of health outcomes.65–67
There is furthermore the possibility that indicators of health system inputs, such as expenditure,
are endogenous, in the sense that they have to some extent been influenced by the levels of health
outcome achieved. In addition, the difficulty of satisfactorily estimating the impact of health system
inputs on outcomes is compounded by the great heterogeneity of health care, the multiple influences
on outcomes, and the rather general nature of the outcome mortality measure traditionally used.
Consequently, the failure to detect a significant positive relationship between expenditure and health
outcome might reflect the difficulties associated with any such study rather than the absence of such a
relationship. For example, Gravelle and Backhouse68 examine some of the methodological difficulties
associated with empirical investigation of the determinants of mortality rates. These include simultaneous
equation bias and the associated endogeneity problem (that the level of health-care input might reflect
the level of health outcome achieved in the past), and that a lag may occur between expenditure and
outcomes (studies typically assume that expenditure has an immediate effect on mortality).
To avoid the difficulties imposed by data heterogeneity inherent in international analyses, the study by
Cremieux et al.69 examines the relationship between expenditure and outcomes across 10 Canadian
provinces over the 15-year period 1978–92. They find that lower health-care spending is associated with a
significant increase in infant mortality and a decrease in LE. Although challenging the received empirical
wisdom, one difficulty with the Cremieux et al.69 study is that the estimated regression equation consists of
a mixture of potentially endogenous variables (such as the number of physicians, health spending, alcohol
and tobacco consumption, expenditure on meat and fat) and exogenous variables (such as income and
population density). The authors’ chosen estimation technique (generalised least squared; GLS) does not
allow for this endogeneity and consequently the coefficients on the endogenous variables may be biased.68
Similarly, Nixon and Ulmann’s study,70 which uses three health outcome measures and various explanatory
variables (such as per capita health expenditure) for 15 European Union (EU) countries over the period
1980–95, does not allow for the possibility that some of the explanatory variables may be endogenous.
More recently, studies have started to address the endogeneity issue.71,72 Bokhari et al.71 estimate a
cross-section model for 127 countries using data for 2000. They employ two health outcome indicators
(the under-5 mortality rate and the maternal mortality rate). Bokhari et al.71 allow for the endogeneity of
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health expenditure via the use of IV techniques, and they estimate the elasticity of these indicators
with respect to total government health expenditure conditional on the level of education and basic
infrastructure (such as road transport and sanitation). They find that health expenditure has a statistically
significant negative impact on both under-five mortality and maternal mortality. The authors do note,
however, that their focus on child and maternal mortality implicitly assumes that these outcome indicators
are in some way representative of outcomes across all activities financed by government health-care
expenditure. Data permitting, it would be preferable to relate health-care expenditure on under-fives to
under-five mortality, and expenditure on maternal care to maternal mortality.
In this study we relate expenditure in a specific disease area to mortality associated with those diseases.
We also address the endogeneity issue through the use of IVs and, unlike previous studies; we examine
the sensitivity of our results to questions of instrument validity. Moreover, although previous empirical
work has been loosely based on the notion of a health production function, it has rarely been informed
by an explicit theoretical model. This is understandable, as the processes giving rise to the observed
health outcome are likely to be very complex, and any theoretical model might become rather unwieldy.
However, this absence of atheoretical model has sometimes led to atheoretical search for measures of
health inputs demonstrating a statistically ‘significant’ association with health outcomes. In contrast, in this
study we inform our empirical modelling with a theoretical framework. We believe that this may lead to a
more convincing and better specified model of health outcomes than that used in many previous studies,
and this model is outlined in the next section.
Modelling framework
In the literature on the relationship between health expenditure and health outcomes, the statistical model
estimated often contains a mixture of exogenous variables (such as income and population density) and
endogenous variables (such as health spending, the number of doctors, and spending on cigarettes
and alcohol). In such circumstances, the application of ordinary least squares will lead to biased coefficients
on the endogenous variables. To avoid this problem, Gravelle and Backhouse68 recommend that analysts
model, even if only informally, the decision-making process which generates the observed data set.
To avoid the problem of simultaneous equation bias we have constructed a very basic model of the
budgeting and outcomes data generation processes. In places, the model makes some heroic assumptions
(which we hope to relax in future work) but the framework reveals some of the more salient features of
the data generation processes.
We assume – quite realistically – that each PCT, i, receives an annual financial lump sum allocation, yi,
from the Department of Health and that total within year expenditure for each PCT cannot exceed this
amount. We also assume – less realistically – that this lump sum is allocated across the J programmes of
care (J= 23) by a single decision-maker (although we know that in practice the programme budget data
will in part reflect the myriad of individual clinical decisions that health-care professionals take every day
and that these are decisions over which PCTs exercise little control).
We assume that each PCT adheres to a social welfare function, W(.), that incorporates the health outcome
(h) across all 23 programmes of care so that for each PCT:
W = W (h1, h2, . . . , h J). (3)
Health outcomes might be measured in a variety of ways, but the most obvious is to consider some
measure of improvement in LE, possibly adjusted for QoL, in the form of a QALY.
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We assume that, for each PCT and for each programme of care, there is a ‘health production function’
that indicates the link between local spending on programme j (xj) and health outcomes in the same
programme (hj). Two such production functions are illustrated in Figure 2. We assume that increased
expenditure yields improvements in health outcomes, as expressed, for example, in local mortality rates,
but at a diminishing rate. Clearly the shape of the curve might depend on the health needs of the local
population (such as epidemiological conditions) and other local circumstances, such as socioeconomic
conditions and local service input prices. Note that in Figure 2 the cost of securing a given level of health
outcome is – for whatever reason – higher in PCTa than PCTb.
In algebraic form, each PCT seeks to maximise total welfare across all J programmes of care (J= 23) subject
to the health production function for each programme of care of the form:
h j = f j(x j, n j, z j), (4)
where nj is the need for health care in programme j, xj is PCT expenditure on programme j, and zj
represents environmental variables affecting the production of health outcomes in programme j [which
might include private (non-PCT) health-care expenditure in the disease area]. Each PCT’s problem is to
select an expenditure level for each programme ((xj )), so as to maximise the utility function in Equation 3
subject to the health production functions in Equation 4 and the budget constraint that total expenditure
on all programmes should not exceed PCT income (y).
Algebraically, the budget constraint is:
x1 + x2 + . . . + x23 ≤ y (5)
Solving this maximisation problem yields the result that the optimal level of PCT expenditure in each
category, (xj ), is a function of the need for health care in each category (n1, n2, . . ., n23), environmental
variables affecting the production of health outcomes in each category, (z1, z2, . . ., z23) and PCT income (y).
Thus:
x1 = x1(n1, n2 . . . , n23, z1, z2. . . , z23, y)
x2 = x2(n1, n2 . . . , n23, z1, z2. . . , z23, y)
x23= x23(n1, n2 . . . , n23, z1, z2. . . , z23, y)
(6)
PCTb
PCTa
Xj
hj
Local spending on programme j(xj)
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FIGURE 2 The health production function for programme j in two PCTs.
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These results imply that each PCT will allocate expenditure across the 23 programmes of care so that the
marginal utility of the last pound spent in each programme of care is the same. Of course, this does not
mean that each programme receives the same amount of cash; financial allocations will depend on both
the relationship between utility and outcomes, and on the relationship between outcomes and expenditure
for each programme of care. If we assume that one extra unit of health outcome improves managerial
utility by the same amount irrespective of the programme of care, then the decision-maker simply allocates
expenditure across all programmes to maximise total health outcomes. This is achieved by ensuring that
the marginal health outcome benefit (measured perhaps in QALYs) is the same for the last pound spent
across all programmes of care.
Thus, for each programme of care, there exists an expenditure equation (see Equation 6) explaining the
expenditure choice of PCTs and a health outcome equation (see Equation 4) which models the associated
health outcomes achieved. As presented, our basic model is static in the sense that the health production
function (see Equation 4) assumes that all health benefits occur contemporaneously with expenditure.
We acknowledge that for some programmes of care benefits might occur ≥ 1 year after expenditure has
occurred. This is particularly likely to be the case for those programmes aimed at encouraging healthy
lifestyles, where some benefits may occur decades after the actual programme expenditure. For other
programmes, such as maternity/reproductive conditions and neonate conditions, benefits may be largely
contemporaneous with expenditure. However, although our data are largely cross-sectional in nature,
we are able to link mortality data in such a way that this follows expenditures. Accordingly, for our
empirical modelling we estimate models using expenditure for period t with mortality data for periods
t, t + 1, and t + 2 combined. Appendix 2 presents a number of sensitivity checks on these assumptions
including models where mortality data precedes expenditure datac and shows that these results are fairly
consistent with the results presented here.
Data
Programme budgeting in England
Prior to October 2006, there were 303 PCTs in England with an average population of about
160,000 people. In October 2006 the 303 PCTs became 152 PCTs. Some PCT boundaries remained
unchanged while other PCTs were merged with one or more neighbours to form a new, larger, PCT. In a
few cases the geographic area covered by an existing PCT was split between two or more new PCTs.
These 152 PCTs have an average population of about 330,000 people. PCTs are allocated fixed annual
budgets within which they are expected to meet expenditure on most aspects of health care, including
inpatient, outpatient and community care, primary care and pharmaceutical prescriptions.
Programme budgeting data collection was initiated by the Department of Health in April 2003 when each
PCT was required to prepare expenditure data disaggregated according to 23 programmes of health care.
These programmes are defined by reference to ICD-10 codes at the four digit level, and most PBCs
reflect ICD-10 chapter headings (e.g. cancer and tumours, circulation problems, renal problems, neonates,
problems associated with the skin, problems associated with vision, problems associated with hearing,
etc.). In some cases the 23 categories are broken down into further subareas to achieve a closer match
with the various National Service Frameworks (NSFs); for example, the large mental health category is
broken down into ‘substance abuse’, ‘dementia’, and ‘other’.
Programme budgeting seeks to allocate all types of PCT expenditure to the various PBCs, including
secondary care, community care and prescribing. However, the system acknowledges that a medical model
of care may not always be appropriate, and two specific non-clinical groups – ‘healthy individuals’ and
‘social care needs’ – have been created. These are intended to capture the costs of disease-prevention
programmes and the costs of services that support individuals with social rather than health-care needs.
In addition, in some cases it is not possible to assign activity by medical condition, preventative activity, or
social care need and, in these cases, expenditure is assigned to a residual category (PBC 23) entitled
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‘other’. The most important element of this residual programme is expenditure on general practitioner (GP)
services (PBC 23a). In principle it should be possible to allocate each GP consultation to a particular care
programme. However, at the moment the available data information systems do not permit such an
allocation and so all primary care expenditure is allocated to this residual programme. The use of this
residual category ensures that all expenditure is assigned to a programme of care.73
The aim of the programme budget classifications is to identify the entire volume of health-care resources
assigned to broad areas of illness according to the primary diagnosis associated with an intervention. It
serves a number of purposes, most notably to assist in the local planning of health care. However, for this
study its crucial merit is that it opens up the possibility of examining the statistical relationship between
local programme spending and the associated disease-specific outcome. Various forms of data collection
and analysis are required to map PCT expenditure on acute, community and other services to the 23 PBCs.
From the PCT perspective, however, the construction of each PCT’s return largely involves collating
information provided by other bodies and drawing on other information already in the PCT’s own annual
accounts. Details of how expenditure is assigned to programmes of care can be found in Appendix 2,
The collection of programme budgeting data.
Table 1 shows the expenditure per head and the growth in this expenditure for each PBC for
2003/4–2008/9.d Year-on-year comparisons of expenditure in each group are complicated by the fact
that the algorithms used to allocate activity to PBCs are regularly revised.e However, by 2008/9 total PCT
expenditure per person had increased to £1531 (up 28% from 2004/5). The residual ‘other’ category
(PBC 23) still accounted for the largest share of expenditure (14.9%) with per capita expenditure of almost
£228, of which £145 was accounted for by primary care expenditure. Mental health (PBC 5) accounted
for just over 12% of expenditure, but the expenditure share recorded by circulation problems (PBC 10) had
fallen from 10.2% to 8.5%. Other categories recording a fall in budget share of more than a half of
1 percentage point included: the gastrointestinal system (down from 6.1% to 5.1%), the musculoskeletal
system (down from 6.0% to 5.2%), trauma and injuries (down from 6.0% to 4.2%), and maternity
(down from 4.6% to 3.9%). Categories recording an increase in budget share of more than a half of
1 percentage point included neurological problems (up from 2.9% to 4.4%) and dental problems
(up from 1.1% to 4.1%).
Some of these changes will partly reflect revisions to the algorithms used to allocate expenditure to
particular PBCs. For example in 2006/7 expenditure per person on musculoskeletal problems fell by
11% and expenditure on trauma and injuries fell by 25%. In the same year, expenditure on neurological
problems increased by 35%. This suggests that some types of activity, which were previously allocated to
musculoskeletal problems and/or trauma and injuries, were reallocated to neurological problems.
Similarly, up to and including 2006/7 expenditure that was not directly attributable to a particular
programme category was apportioned using admitted patient care percentages.f In other words, if x% of
total admitted patient care expenditure was allocated to PBC 1, then x% of all expenditure that was not
directly attributable to a particular programme category was also allocated to PBC 1. With effect from
2007/8, however, NHS organisations were asked to select an appropriate basis for the apportionment of
this non-programme-specific expenditure and that, where no reasonable basis existed, such expenditure
was to be allocated to the ‘other – miscellaneous’ (PBC 23X) category. These two changes to the
algorithm used to allocate expenditure to particular PBCs illustrate that year-on-year comparisons of
expenditure need to be interpreted with care.
Expenditure per head on any given programme varies from one PCT to another and Table 2 presents some
statistics that indicate the degree of variation in expenditure levels across PCTs by PBC. Columns 3–6 of
Table 2 present descriptive statistics for PCT expenditure per person. These reveal that, for example, PCT
per capita expenditure in the cancer programme averaged £96.30 across all PCTs, with the minimum
spend being £62.90 and the maximum being £155.70.
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TABLE 2 Primary care trust expenditure per head by PBC, 2008/9: (a) unadjusted; (b) adjusted for local costs; and (c) adjusted for local costs and local need
PBC
Spend per head (unadjusted) (£) Spend per head (cost adjusted) (£) Spend per head (cost and need adjusted) (£)
Mean SD Min. Max. Mean SD Min. Max. Mean SD Min. Max.
1 Infectious diseases 26.5 24.6 8.6 151.8 25.7 21.7 8.6 136.7 25.0 21.4 9.5 139.5
2 Cancers and tumours 96.3 16.9 62.9 155.7 96.7 19.7 59.1 163.1 94.2 15.3 55.2 154.0
3 Blood disorders 20.3 7.0 7.7 49.4 20.2 6.5 8.0 49.1 19.7 6.0 8.2 44.2
4 Endocrine, nutritional 44.6 8.8 28.9 74.8 44.7 9.5 27.4 77.0 43.3 6.1 29.9 61.5
5 Mental health 201.4 60.0 118.9 474.1 200.3 54.0 122.8 422.8 194.0 41.9 132.3 362.0
6 Learning disability 56.8 18.8 7.7 125.9 57.0 19.4 6.8 123.6 55.7 18.8 6.7 136.6
7 Neurological 68.5 13.8 41.1 133.8 68.8 15.6 38.4 137.5 66.9 12.1 41.5 125.2
8 Vision problems 33.2 6.7 16.7 57.7 33.4 7.5 14.8 59.2 32.5 6.1 15.6 48.3
9 Hearing problems 8.6 3.7 0.9 24.0 8.7 3.9 0.9 25.5 8.3 3.3 0.8 22.0
10 Circulatory disease 131.6 26.7 88.0 317.3 132.2 30.5 78.2 327.6 128.5 24.4 75.7 326.9
11 Respiratory system 80.5 17.4 48.0 141.2 80.9 19.8 42.7 145.3 78.1 12.4 48.2 126.0
12 Dental problems 64.8 13.4 28.0 111.9 64.9 14.1 24.9 115.8 63.0 10.7 28.1 97.1
13 Gastrointestinal system 80.0 14.5 46.7 119.6 80.4 16.8 41.5 124.6 78.0 11.3 41.6 114.4
14 Skin problems 33.1 8.0 18.1 66.4 33.3 8.6 16.5 69.1 32.2 6.3 16.0 57.7
15 Musculoskeletal system 79.9 17.6 43.3 127.3 80.4 19.9 39.6 132.5 78.2 16.6 41.0 116.4
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TABLE 2 Primary care trust expenditure per head by PBC, 2008/9: (a) unadjusted; (b) adjusted for local costs; and (c) adjusted for local costs and local need (continued )
PBC
Spend per head (unadjusted) (£) Spend per head (cost adjusted) (£) Spend per head (cost and need adjusted) (£)
Mean SD Min. Max. Mean SD Min. Max. Mean SD Min. Max.
16 Trauma and injuries 63.2 16.7 12.5 139.3 63.4 17.4 11.5 125.0 61.8 15.6 10.4 103.6
17 Genitourinary system 75.7 13.7 49.9 112.3 75.6 13.6 48.4 108.9 73.7 10.1 50.6 105.5
18 Maternity 63.3 16.7 24.6 124.4 63.1 15.8 21.9 117.9 61.4 12.8 24.4 96.5
19 Neonate conditions 18.4 7.3 6.4 46.4 18.2 6.8 6.6 43.7 17.8 6.6 5.8 47.8
20 Poisoning 18.6 4.2 10.8 31.2 18.7 4.7 9.6 32.3 18.2 3.9 10.1 33.1
21 Healthy individuals 38.4 18.1 9.7 125.0 38.4 17.8 8.9 115.6 36.7 14.5 9.4 104.5
22 Social care needs 40.8 56.6 0.1 415.2 41.2 59.2 0.1 432.9 39.7 55.0 0.0 411.5
23 Other (includes GMS/PMS) 230.8 44.5 138.2 396.1 230.2 42.4 140.7 356.5 226.8 45.8 134.1 346.0
All All PBCs 1575.6 196.7 1225.7 2079.9 1576.3 217.3 1183.0 2173.1 1534.0 86.2 1390.1 1987.0
GMS, general medical services; max., maximum; min., minimum; PMS, primary medical services; SD, standard deviation.
Note
The above statistics relate to 152 PCTs and the mean expenditure figures will differ slightly from the national ones in Table 1 because the statistics across PCTs are not weighted for the size
of each PCT’s population.
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Some PCTs will be spending more than other PCTs simply because they face higher input costs.
Columns 7–10 in Table 2 present descriptive statistics for PCT per capita expenditure that has been
adjusted for the unavoidable geographical variation in costs (input prices) faced by PCTs.g However,
if anything, this adjustment appears to increase the variation in expenditure across PCTs; for example,
the range of per capita expenditure on cancer increases from between £62.90 and £155.70 (unadjusted)
to between £59.10 and £163.10 (adjusted for local health-care input prices).
Another cause of the variation in expenditure levels is the fact that the need for health care varies from
one PCT to another. For example, areas with a relatively large proportion of elderly residents, or PCTs
operating in relatively deprived locations, can be expected to experience relatively high levels of spending.
The Department of Health has a well-developed methodology for estimating the relative health-care needs,
which it uses as the basis for allocating health-care funds to PCTs.75
Columns 11–14 in Table 2 present descriptive statistics for PCT per capita expenditure that has been
adjusted for both the unavoidable geographical variation in costs and the local need for health care faced
by PCTs.h For virtually every PBC, this adjustment reduces the variation in expenditure across PCTs; for
example, the standard deviation of PCT per capita expenditure falls from £19.70 to £15.30 for the cancer
programme. Although this adjustment reduces the variation in expenditure levels across PCTs, this decline
is quite modest and there are still substantial differences in expenditure even after allowing for differences
in local cost and need. For example, expenditure per head in the circulation problems category varies
between £78 and £328 using cost-adjusted expenditure data, but falls between £76 and £327 using
cost- and need-adjusted population data.
The variation in expenditure across PCTs has led some commentators to question the reliability of the
PB data. The National Audit Office (NAO)77 undertook a survey of trusts, PCTs and Strategic Health
Authorities (SHAs) to assess the quality of the data. They concluded that although the processes for
collecting the budgeting data were well defined in most areas, there remained scope for improvements to
the robustness of some of the data (e.g. non-admitted patient care). Appleby et al.78 also considered the
issue of data reliability in variations in spending on cancer services and noted some large year-on-year
changes. However, the authors point out that it is difficult to define what might be either an implausible
level of expenditure or an implausibly large change in expenditure. This is complicated by the fact that
the Department of Health makes regular improvements to the way in which activity is matched to
programme categories.
As with most data sets, there are likely to be recording and other errors associated with the PB data.
However, although we note that the allocation of PB data might not be perfect there is no systematic
evidence of this. Accordingly, for each disease category, we observe that PCT expenditure per person
varies considerably and this variation – holding constant input prices and the need for health care – offers
the opportunity to examine whether or not PCTs that spend more on health care achieve a better outcome
and, if so, at what cost. Empirical estimates of the strength of this relationship for several programmes of
care are presented in this report.
Health outcome data
Most studies of the relationship between expenditure and outcome have used some measure of mortality
as an indicator of the latter. We also employ mortality as an outcome measure. First, it is a relevant
(albeit not comprehensive) measure of the outcome of health-care expenditure; and second, it is available
for more disease areas than any other outcome measure at PCT level.
Although mortality is available (by PCT) for several disease areas, it is not available for just over a half of all
programmes not least because it is simply not relevant for these programmes (e.g. for learning disabilities,
vision problems, hearing problems, dental problems and skin problems). Moreover, even where a mortality
measure is available, the ICD-10 coverage of the mortality data often falls short of the coverage of the
expenditure data. For some programmes, therefore, we have combined the published mortality rates for
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two or more disease areas in an attempt to match the ICD-10 coverage of the mortality data with that of
the expenditure data.
Table 37 (see Appendix 2) shows how we have attempted to marry the mortality data (column C) and the
expenditure data (column A). ICD-10 coverage of the component mortality rates for some PBCs falls short
of the expenditure data and the extent of this shortfall is illustrated by the ratio reported in the final
column of Table 3. For example, the cancers and tumours programme covers all expenditure associated
with ICD-10 codes C00–C97 and D00–D49 but the PCT-based mortality data only relates to ICD-10 codes
C00–C97. At the national (all England) level, figures are available which show that, in 2008, there were
62,072 deaths of those aged < 75 years from codes C00–C97 and that there were 63,076 deaths from
codes C00–C97 and D00–D49 combined. In other words, the PCT-level mortality data reflect 98.4% of all
deaths associated with the expenditure codes. We adjust our cost of life (year) estimates for this mismatch.
We acknowledge that mortality is a more relevant outcome indicator for some programmes (e.g. for
circulatory problems) than for others (e.g. for epilepsy) and, for this reason, we would expect better results
in some programmes than others. We also acknowledge that this focus on mortality ignores the impact of
expenditure aimed at chronic care and at palliative care. Nevertheless, our focus on mortality is purely
practical: it is both a widely available measure and clearly a relevant outcome indicator.i
The mortality data provide us with a number of possible outcome indicators including the < 75 years of
age standardised mortality rate (SMR) and the (< 75 years) standardised years of life lost rate (SYLLR).
The SMR gives equal weight to all deaths irrespective of the age at which they occur but the SYLLR gives
greater weight to deaths that occur at earlier ages. For our purposes we focus on a measure of the
avoidable YLL.j This is calculated by summing over ages 1–74 years the number of deaths at each age
multiplied by the number of years of life remaining up to age 75 years. The crude YLL rate is simply the
number of YLL divided by the resident population aged < 75 years. Like conventional mortality rates,
the crude YLL rate can be age standardised to eliminate the effects of differences in population age
structures between areas, and this (age) standardised YLL rate is the health outcome variable generally
employed in this study.79
Other variables
We employ an IV estimation technique to our empirical models of the outcome and expenditure equations
as described in the next section. This is due to (i) own programme expenditure is likely to be endogenous
in the outcome equation and (ii) other programme need is likely to be endogenous in the own programme
expenditure equation. Endogeneity of programme expenditure results from expenditure levels being
responsive to levels of outcomes and/or unobserved need rendering expenditure correlated with the
residuals in an ordinary least squared (OLS) regression of outcomes on expenditure. Due to limitations
in the data available, need in the expenditure equation in the ‘other’ programmes is proxied by death rates
(minus that due to the programme under investigation). This will be influenced by expenditure decisions,
including expenditure in other programmes and is treated as endogenous in the expenditure model.
Instrumental variable estimation basically involves replacing the endogenous variable in the equation of
interest with its predicted value from an OLS regression which regresses the endogenous variable on
a set of IVs. These instruments should be good predictors of the endogenous variable (i.e. they should
be relevant and strong predictors) but should be appropriately excluded from the equation of interest
(i.e. they should be valid instruments).
We have a number of potential instruments available, mostly derived from the 2001 Population Census.80
In our earlier studies we found that a small subset of these instruments proved sufficient to generate
plausible results. These included the proportion of the population providing unpaid care; the proportion
of households that are one pensioner households; index of multiple deprivation; and proportion of the
population in the white ethnic group.
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TABLE 3 Descriptive statistics for the instrumental and other variables74
Description Observations Mean SD Min. Max.
Proportion of residents born outside the EU 151 0.0794 0.0876 0.0088 0.3817
Proportion of population in white ethnic group 151 0.8927 0.1299 0.3942 0.9926
Proportion of population of working age (16–74 years)
with LLT
151 0.1182 0.0250 0.0709 0.1798
Proportion of population providing unpaid care 151 0.0990 0.0118 0.0662 0.1221
Proportion of population providing unpaid care
(< 20 hours per week)
151 0.0667 0.0079 0.0461 0.0817
Proportion of population providing unpaid care
(20–49 hours per week)
151 0.0113 0.0025 0.0065 0.0195
Proportion of population providing unpaid care
(> 50 hours per week)
151 0.0210 0.0051 0.0093 0.0353
Proportion of population aged 16–74 years with
no qualifications
151 0.2960 0.0642 0.1301 0.4555
Proportion of population aged 16–74 tears that are
full-time students
151 0.0720 0.0270 0.0425 0.1626
Proportion of households without a car 151 0.2932 0.1046 0.1325 0.5761
Proportion of owner occupied households 151 0.6692 0.1128 0.2891 0.8205
Proportion of households in rented social (LA/HA) housing 151 0.2071 0.0918 0.0817 0.5356
Proportion of households in rented private housing 151 0.0924 0.0449 0.0349 0.2961
Proportion of lone pensioner households 151 0.1434 0.0184 0.0979 0.1942
Proportion of one parent households 151 0.0684 0.0180 0.0401 0.1207
Proportion of population aged 16–74 years that are
permanently sick
151 0.0574 0.0213 0.0242 0.1215
Proportion of population aged 16–74 years that are
long-term unemployed
151 0.0113 0.0052 0.0036 0.0287
Proportion of population aged 16–74 years in
employment that are in agriculture
151 0.0117 0.0119 0.0016 0.0668
Proportion of those aged 16–74 years that are in
professional occupations
151 0.2672 0.0688 0.1470 0.4958
IMD2007 151 23.8098 9.1168 8.0857 48.2627
Need index (incorporates CARAN formula) 151 1.0253 0.1334 0.7311 1.3479
MFF index for HCHS and prescribing 151 1.0021 0.0559 0.9410 1.1243
Diabetes prevalence rate 2007/8 (%, over 17 years) 151 5.4872 0.7982 3.2200 8.5100
Epilepsy prevalence rate 2007/8 (%, over 18 years) 151 0.7884 0.1489 0.4100 1.0900
HIV need index 151 1.1848 1.4984 0.1648 8.3332
Chronic kidney disease 2007/8 (%, over 18 years) 151 4.1687 1.2711 1.3500 8.4100
Maternity need index 151 1.0345 0.2106 0.6845 1.8129
Raw (unadjusted) population 2007/8 151 335,735 196,501 90,142 1,264,298
CARAN, Combining Age-Related and Additional Needs; HA, housing association; HIV, human immunodeficiency virus;
IMD2007, Index of Multiple Deprivation 2007 data set; LA, local association; LLT, limited long-term illness; max., maximum;
min., minimum; SD, standard deviation.
Note
These statistics are unweighted across PCTs and reflect the values for these variables as available for the regression analysis
of PB expenditure data for 2007/8 and for 2008/9.
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We also had available a further set of potential instruments and, where our more limited set of instruments
failed to generate plausible results, we extended our instrument search to include this wider set of variables.
This extended set of instruments is shown in Table 3.k
Our instruments reflect factors, such as socioeconomic deprivation and the availability of informal care in
the community, which might indirectly impact on mortality rates and/or health-care expenditure levels.
As we shall see, although our instruments ‘pass’ the appropriate statistical tests, some commentators claim
that such tests may have ‘low power’ to detect the presence of invalid instruments. Consequently, in
Appendix 2, The sensitivity of the outcome elasticity to the validity of the instrument exclusion restrictions
we examine how sensitive our results are to the presence of invalid instruments.
Table 3 reports descriptive statistics for the socioeconomic and needs variables used in the study (these
statistics are for the variables in absolute form). For example, on average, lone pensioner households
comprise 14% of all households, the ‘white ethnic’ group accounts for 89% of the population and
10% of the population provide unpaid care.
In addition to the IVs, Table 3 also reports descriptive statistics for the Department of Health’s ‘need for
health care’ index,l its need for human immunodeficiency virus (HIV) services index, and its need for maternity
services index. The latter two indices are used to either supplement or replace the all service measure of need
when estimating our models. The ‘need for health care’ index averages about 1 but varies substantially, with
some PCTs having a needs index more than 25% below the national average and others facing a need for
health care more than 30% above the national average. Table 3 also reports descriptive statistics for some
disease prevalence rates (e.g. for diabetes and for epilepsy) and, again, these are used to either supplement
or replace the all service measure of need when estimating our models. Finally, the MFF index shows that
input prices in the most expensive PCT are almost 20% above those in the least expensive PCT.
Approach to model estimation
The theoretical framework suggests the specification and estimation of a system of equations, with an
expenditure and health outcome equation for each of the 23 programmes of care. However, this approach
makes infeasible data demands, requiring variables to identify expenditure, need, environmental factors
and health outcomes in each of the 23 programmes of care. Moreover, mortality rates are available
for less than half of the 23 programmes. Rather than estimate a system of equations, we proceed on a
programme-by-programme basis, estimating health outcome and expenditure equations for those
programmes for which mortality data are available.
In line with the theoretical framework presented above, we specify the following expenditure (see
Equation 7) and health outcome (see Equation 8) models for each of the 23 programmes of care.
Accordingly, for the j-th programme of care we have:
x i ¼ αþ βni þ γmi þ θy i þ εi, i ¼ 1, : : . , 152 (7)
hi ¼ ρþ δni þ πx i þ εi, i ¼ 1, : : : , 152, (8)
where xi is expenditure; ni is the own programme need for care; mi is the need for care in other
programmes; yi is the total budget and hi is the health gain in PCT i.
Ideally we should employ a programme-specific indicator of the level of need for each care
programme (nij) but these are not readily available. When estimating both the outcome and expenditure
models we therefore proxy the own programme health-care need using the ‘needs’ component of the
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Department of Health’s resource allocation formula.m This needs element is specifically designed to adjust
PCT allocations for local health-care needs and accordingly, ceteris paribus, we would expect a positive
relationship between expenditure and need for each programme of care. We would also expect a
positive relationship between need and adverse health outcomes.n
The expenditure model includes both the own programme health-care need (which is proxied using the
‘needs’ component of the Department of Health’s resource allocation formula) and the need for health
care in all other programmes. In the absence of programme-specific measures of need, we use the
‘all-cause mortality rate excluding the mortality rate in the programme of interest’, mi, as the proxy for
need in other programmes of care.
All variables have been log-transformed so that parameter estimates can be interpreted as elasticities.
In other words, a regression coefficient of 0.5 implies that a 1% increase in the regressor is associated with
a 0.5% increase in the dependent variable.
Instrumental variable estimation
Other programme need, mi, in the expenditure Equation 7 and expenditure, xi, in the outcome Equation 8
are both likely to be endogenous rendering OLS both biased and inconsistent. Endogeneity of programme
expenditure results from expenditure levels being responsive to levels of outcomes and/or unobserved
need. Other programme need in the expenditure equation is proxied by death rates which is influenced by
expenditure decisions and hence is treated as endogenous. To deal with this endogeneity we employ IVs
estimation and implement two-stage least squares (2SLS). Unlike OLS, IV is a consistent estimator in the
presence of an endogenous regressor and, although in finite samples the IV estimator will be biased, with the
bias (providing certain assumptions are met) being less than that associated with OLS.
For the health outcome equation, IV estimation can be viewed as finding variables (instruments) that are
good predictors of programme expenditure but which are appropriately excluded from the outcome
equation of interest (that is, from Equation 8) because they are not predictive of outcome. The assumption
is that these instruments impact on health outcome through their impact on expenditure only, and that
they do not have a direct effect on the outcome.o
Similarly, for the expenditure equation, IV estimation can be viewed as finding variables (instruments)
that are good predictors of the proxy for other programme need (mi) but which do not belong in the
expenditure equation of interest (that is, Equation 7). The assumption is that these predictors impact on
own programme expenditure only through their impact on other programme need and that they do not
have a direct effect on own programme expenditure.
The outcome and expenditure equations for any given programme may contain different IVs because these
instruments are trying to predict different variables (own programme expenditure and other programme
mortality respectively). In addition, the instrument set for, say, the expenditure equation may vary
across programmes because the other programme need variable will reflect need in a different basket
of programmes for each expenditure equation.
We have a number of potential instruments available, mostly derived from the 2001 Population Census.80
In previous studies, we have often found that a small subset (four) of these instruments often proved
sufficient to generate plausible results. However, if plausible results were not obtainable with some
combination of these four instruments, we employed an extended instrument set. Further details of the
identification of suitable instruments for each model can be found in Appendix 2, Re-estimation of poorly
performing models with an extended instrument set.
The available instruments reflect factors, such as socioeconomic deprivation and the availability of informal
care in the community, which might indirectly impact on mortality rates and/or health-care expenditure
levels. The set of instruments associated with each estimated equation was selected on both technical and
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pragmatic grounds. From a pragmatic point of view, we require a parsimonious set of instruments that
satisfy the necessary technical criteria. These are, first, that they have face validity, that is, that they are
plausible determinants of the endogenous variable being instrumented, and second, that the instruments
are both relevant and valid. The relevance of an instrument set refers to its ability to predict the
endogenous variable of concern, whereas validity refers to the requirement that instruments should be
uncorrelated with the error term in the equation of interest.
Should the instrument set be strong, relevant and valid, 2SLS will produce consistent estimates of
the parameters of the reduced form models. We subject the instrument sets to tests for validity using the
Sargan–Hansen test of over identifying restrictions. The joint null hypothesis is that the instruments are
valid instruments (i.e. they are uncorrelated with the error term), and that the instruments are correctly
excluded from the outcome equation of interest. A rejection of the null hypothesis casts doubt on the
validity of the instruments. We test for instrument relevance using Shea’s81 partial R2 measure; this reflects
the correlation between the excluded instruments and the endogenous regressor. However, even where
valid and relevant, a non-zero but small correlation between the set of instruments and the endogenous
regressors can lead to the problem of weak instruments, again rendering IV estimation biased.
We test for the presence of weak instruments using the procedures set out in Stock and Yogo82 and
the Kleibergen–Paap Lagrange multiplier (LM) statistic. A general test of model specification is provided
through the use of Ramsey’s83 reset test for OLS and an adapted version of the test for IVs.84
Finally, we check that the presumed endogenous variable is in fact endogenous using the test proposed by
Durbin.85 If the null hypothesis of exogeneity cannot be rejected, then we revert to using OLS. Although,
in general, our instruments ‘pass’ the appropriate statistical tests, some commentators claim that such tests
may have ‘low power’ to, and hence may fail, to reject the validity of the instruments when this is false in
small samples. Consequently, in Appendix 2, The sensitivity of the outcome elasticity to the validity of
the instrument exclusion restrictions we examine how sensitive our results are to the relaxation of the
assumption that the instruments are valid.
Further details of our approach to IV estimation are set out in Appendix 2.
Results
The work presented here builds on previous studies of the link between expenditure and health outcomes.
Martin et al.60 reported outcome elasticities for two programmes (cancer and circulatory disease) using
expenditure data for 2004/5 and pooled mortality data for 2002, 2003 and 2004.p This work was extended
in a subsequent study63 to include several other programmes and updated expenditure data (2005/6).
However, the authors struggled to obtain sensible outcome models for some programmes of care. Attempts
to improve model estimates by considering alternating measures of the population need for health careq
and an extended set of potential IVs are presented in Appendix 2, Analysis of programme budgeting
expenditure for 2005/6 and mortality data for 2002/3/4. This work forms the basis for the set of key results
from the empirical modelling of health-care expenditures and outcomes using more contemporaneous data
presented in the following sections. Details of all results presented are set out in Appendix 2.
2006/7 expenditure data and mortality data for 2006/7/8
This section presents results that relate expenditure in 2006 to mortality in the same year and in the
2 following years (i.e. in 2006, 2007 and 2008). Throughout our measure of the need for health care is
derived from the Department of Health’s resource allocation model based on the CARAN needs formula.74
This represents a more up-to-date needs adjustment than the AREA based model76 that has been applied
in previous studies,60,63 and is directly applicable to the 152 PCTs in existence in the 2006/7 expenditure
year. Expenditure data has been adjusted for differences in input prices using the MFFs for HCHS and
prescribing.r The outcome and expenditure results for the big four programmes are shown in Table 4 with
the relevant outcome and expenditure elasticities highlighted.
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TABLE 4 Outcome and expenditure models for the big four programmes using spend data for 2006/7 (two MFFs) and mortality data for 2006/7/8
Equation variable
(1) PBC 2,
cancer
(2) PBC 2,
cancer
(3) PBC 10,
circulation
(4) PBC 10,
circulation
(5) PBC 11,
respiratory
(6) PBC 11,
respiratory
(7) PBC 13,
gastrointestinal
(8) PBC 13,
gastrointestinal
Outcome model Spend model Outcome model Spend model Outcome model Spend model Outcome model Spend model
Own programme spend
per head
–0.342*** –1.434*** –2.029*** –1.536***
[0.099] [0.218] [0.636] [0.468]
Need (CARAN per head) 0.995*** 1.626*** 2.860*** 2.306*** 2.696*** 1.449*** 4.160*** 2.040***
[0.106] [0.343] [0.252] [0.372] [1.044] [0.331] [0.577] [0.378]
Need (CARAN per head
squared)
1.163*** 2.451
[0.348] [1.561]
SYLLR (all deaths
excluding cancer)
–0.855***
[0.191]
PCT budget per head 0.465 0.540* 0.679*** 0.446*
[0.300] [0.299] [0.251] [0.263]
SYLLR (all deaths
excluding circulatory)
–1.666***
[0.295]
Permanently sick 0.759**
[0.367]
SYLLR (all deaths
excluding respiratory)
–0.672**
[0.305]
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TABLE 4 Outcome and expenditure models for the big four programmes using spend data for 2006/7 (two MFFs) and mortality data for 2006/7/8 (continued )
Equation variable
(1) PBC 2,
cancer
(2) PBC 2,
cancer
(3) PBC 10,
circulation
(4) PBC 10,
circulation
(5) PBC 11,
respiratory
(6) PBC 11,
respiratory
(7) PBC 13,
gastrointestinal
(8) PBC 13,
gastrointestinal
Outcome model Spend model Outcome model Spend model Outcome model Spend model Outcome model Spend model
SYLLR (all deaths excluding
gastrointestinal)
–1.206***
[0.314]
Constant 6.501*** 5.913*** 11.413*** 10.696*** 13.756*** 3.346 9.719*** 8.370***
[0.436] [2.815] [1.046] [2.379] [3.279] [2.075] [2.009] [2.299]
Endogeneity test statistic 13.695 19.421 42.548 24.461 17.687 8.439 16.373 15.211
Endogeneity p-value 0.000215 1.05e-05 6.90e-11 7.58e-07 2.60e-05 0.00367 5.20e-05 9.61e-05
Hansen–Sargan test statistic 0.685 0.021 0.949 1.262 1.462 0.302 2.761 0.0164
Hansen–Sargan p-value 0.408 0.084 0.814 0.261 0.227 0.583 0.0966 0.0898
Shea’s partial R2 0.164 0.445 0.300 0.296 0.0785 0.327 0.140 0.356
Kleibergen–Paap LM
test statistic
17.85 41.88 32.37 32.02 10.02 34.98 14.86 35.72
Kleibergen–Paap p-value 0.000133 8.04e-10 1.61e-06 1.11e-07 0.00666 2.54e-08 0.000592 1.75e-08
Kleibergen–Paap F-statistic 13.28 56.69 17.14 31.84 7.022 20.94 11.63 22.40
Pesaran–Taylor reset statistic 0.00537 0.18 0.136 0.00349 0.0120 1.497 1.669 0.007
Pesaran–Taylor p-value 0.942 0.668 0.712 0.953 0.913 0.221 0.196 0.935
Note
Robust standard errors in brackets.
* p< 0.1; ** p< 0.05; *** p< 0.01.
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In all four outcome models expenditure has a significant negative effect on mortality and the all service
measure of need has a significant positive effect. The squared value of the measure of need is also positive
and significant in the cancer outcome equation. In the respiratory outcome model, there is an additional
indicator of need – the proportion of the population that are permanently sick – and this is both positive
and statistically significant. The diagnostic statistics suggest that, in all four cases, own programme
expenditure is endogenous and that the instruments are valid. They also suggest that the instruments are
relevant. There is no evidence that the instruments are weak in three of the four outcome results.
The Pesaran–Taylor test suggests that there is no evidence of model misspecification.
However, the Kleibergen–Paap F-statistic for the respiratory disease outcome model is 7.022 and this is less
than the ‘critical’ target of 10.0. This indicates that the instruments may be weak and not good predictors
of the programme expenditure. However, if we re-estimate this model having dropped the least significant
instrument, the coefficient on own programme expenditure becomes −2.622 and is significant at the
1% level. Moreover, there is now no evidence of weak instruments (the Kleibergen–Paap F-statistic
is 11.025) and it is this coefficient that we use for the respiratory outcome model in the cost of a life-year
calculations below.
In three of the four expenditure models both the need and budget variables have a positive and significant
effect on own programme expenditure. In addition, the proxy for need in other programmes is negative
and significant in all four cases. The diagnostic statistics suggest that, for all four expenditure models,
expenditure is endogenous and the instruments are valid. They also suggest that the instruments are
relevant and there is no evidence that the instruments are weak. The Pesaran–Taylor test suggests that
there is no evidence of model misspecification.
Cost of a life-year
The outcome and expenditure elasticities presented in Table 4 can be used to calculate the cost of a
life-year in each programme. These calculations – for both the big four programmes as well as for the
other six programmes with mortality based outcome indicators – are shown in Table 5. The cost of a life
(year) estimates presented in Table 5 assume a 1% increase in each PCT’s budget and are calculated as:
the cost of an additional life in a particular programme
= the change in expenditure in that programme/the change in mortality in that programme
= (annual spend × expenditure elasticity)/(annual mortality × outcome elasticity × expenditure elasticity)
and
the cost of an additional life-year in a particular programme
= the change in expenditure in that programme/the change in life-years lost in that programme
= (annual spend× expenditure elasticity)/(annual life-years lost× outcome elasticity× expenditure elasticity).
To illustrate this calculation let us calculate the cost of a life-year for, say, the cancer programme.
The annual spend on cancer in 2006/7 is £4122M and the expenditure elasticity for the programme is
0.465 so that the change in expenditure associated with a 1% increase in each PCT’s budget is £19.1673M
(= 1% × £4122M × 0.465). The total number of life-years lost to cancer for 2006/7/8 totals 2,207,021
life-years and so the average annual loss is 735,674 life-years. The outcome elasticity for the cancer
programme is 0.342 and the expenditure elasticity is 0.465 so the reduction in the number of life-years lost
associated with a 1% increase in each PCT’s budget is 1170 (= 1% × 735,674 life-years × 0.342 × 0.465).
The cost of an additional life-year is therefore £19.1673M (the change in expenditure in the programme)
divided by 1170 (the reduction in the number of life-years lost), and this equals £16,383.
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TABLE 5 Cost of life-year estimates by PBC for PCT expenditure in 2006/7, 2007/8 and 2008/9
PBC
Expenditure 2006/7, outcome 2006/7/8 Expenditure 2007/8, outcome 2007/8/9 Expenditure 2008/9, outcome 2008/9/10
Spend
(£M)
2006/7
Total
life-years
lost,
< 75 years,
2006/7/8
Cost per
YLG (£)
Cost per YLG
adjusted
for YLL
coverage (£)
Spend
(£M)
2007/8
Total
life-years
lost,
< 75 years,
2007/8/9
Cost per
YLG (£)
Cost per YLG
adjusted
for YLL
coverage (£)
Spend
(£M)
2008/9
Total
life-years
lost,
< 75 years,
2008/9/10
Cost per
YLG (£)
Cost per YLG
adjusted
for YLL
coverage (£)
Cancer 4122 2,207,021 16,383 16,121 4573 2,189,685 17,165 16,891 4843 2,170,660 21,802 21,454
Circulatory
problems
6161 1,361,634 9466 9390 6325 1,313,223 11,315 11,224 6655 1,285,026 11,779 11,685
Respiratory
problems
3285 324,223 11,593 8961 3431 315,457 14,798 11,439 3994 311,034 21,307 16,470
Gastrointestinal
problems
3700 345,908 20,892 11,929 3805 343,355 25,034 14,295 3989 341,884 25,662 14,653
Big four
programmes
summary
17,268 4,238,786 12,333 10,604 18,134 4,161,720 16,345 13,830 19,481 4,108,604 16,688 14,650
Infectious
diseases
1053 106,552 630,798 630,798 1119 106,092 57,742 57,742 1201 100,078 71,432 71,432
Endocrine
problems
1852 57,672 114,416 72,539 1997 55,492 190,745 120,932 2222 54,779 104,008 65,941
Neurological
problems
2790 66,137 1,129,960 153,675 3165 64,873 431,749 58,718 3466 64,222 388,267 52,804
Genitourinary
problems
3482 10,030 20,421,090 3,512,427 3439 8,529 652,096 112,160 3779 8004 877,038 150,851
Trauma and
injuries
2892 30,000 N/A N/A 2918 21,273 1,115,197 195,159 3255 6881 N/A N/A
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PBC
Expenditure 2006/7, outcome 2006/7/8 Expenditure 2007/8, outcome 2007/8/9 Expenditure 2008/9, outcome 2008/9/10
Spend
(£M)
2006/7
Total
life-years
lost,
< 75 years,
2006/7/8
Cost per
YLG (£)
Cost per YLG
adjusted
for YLL
coverage (£)
Spend
(£M)
2007/8
Total
life-years
lost,
< 75 years,
2007/8/9
Cost per
YLG (£)
Cost per YLG
adjusted
for YLL
coverage (£)
Spend
(£M)
2008/9
Total
life-years
lost,
< 75 years,
2008/9/10
Cost per
YLG (£)
Cost per YLG
adjusted
for YLL
coverage (£)
Maternity and
neonates
3574 492,600 45,158 30,662 3662 489,170 204,168 138,630 3978 479,905 198,939 135,080
Other
six programmes
summary
15,643 762,991 258,046 146,108 16,300 745,429 274,309 99,428 17,901 713,869 254,794 112,674
All 10 programmes
summary
32,911 5,001,777 £23,780 19,965 34,434 4,907,149 38,110 28,983 37,382 4,822,473 38,328 30,883
Other
13 programmes
summary
34,985 39,223 41,016
All 23 programmes 67,896 87,494 73,457 73,657 108,829 82,765 78,398 105,460 84,974
N/A, not applicable.
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An integral part of the calculation of the cost of a life-year is the annual mortality (life-years lost) figure
associated with a particular programme. Ideally, the ICD-10 coverage of the expenditure data should
coincide with that of the mortality data. However, as shown in Table 37 of Appendix 2, the ICD-10
coverage of the mortality data typically falls short of that for the expenditure data. Unless we adjust the
annual mortality figure so that its ICD-10 coverage approximates that of the expenditure data, our cost of
life (year) estimates will be too large because they will underestimate the mortality gain.
Table 5 reports cost of a life-year estimates both with and without this adjustment for ICD-10 coverage.
Having incorporated this adjustment, the results show that the cost of a life-year for the big four PBCs is
estimated as £10,604 and, for all 10 programmes with a mortality outcome measure, the estimate is
£19,965. For all programmes, assuming a zero gain for the 13 PBCs without an outcome indicator, the
corresponding estimate is £73,457.
If we assume that PBC 23 (largely primary care) generates a zero health gain (because the gains from
primary care are already reflected in the mortality rates for disease-specific programmes) and that the gain
attributable to the remaining 12 programmes is, on average, the same as that attributable to those with a
mortality outcome measure, then the cost of a life-year across all programmes is £22,565.s
Non-primary care trust Department of Health funded expenditure
Primary care trust expenditure accounts for a large proportion of Department of Health expenditure
but PCTs do not account for the Department’s entire budget. In 2006/7 the Department of Health’s
gross expenditure totalled £83.5B. Charges raised £3.4B so net expenditure totalled £80.1B. Of this net
expenditure, PCTs accounted for £67.3B (that is, 84%) and various other bodies accounted for the
remaining £12.8B. A breakdown of this gross and net expenditure by major body is shown in Table 70
of Appendix 2. The Department of Health has allocated net non-PCT expenditure across the 23 PBCs.
Of the additional £12B of net expenditure, £11.2B (93%) has been allocated to PBC 23. This largely
reflects (a) the allocation of almost all SHA expenditure to either PBC 23B (‘other: SHAs including
workforce development committees’) or PBC 23X (‘other: miscellaneous’); and (b) the allocation of
almost two-thirds of Department of Health expenditure to PBC 23X (‘other: miscellaneous’). The remaining
£0.8B of additional net expenditure is spread across all PBCs according to various allocation rules and
although this approach avoids allocating expenditure to the ‘other: miscellaneous’ category, this allocation
of expenditure does not necessarily reflect actual expenditure.
The cost of a life (year) estimates presented above are based on the impact of a 1% exogenous change in
total net PCT spend. All of our outcome and expenditure models have been estimated using net PCT
expenditure, and all of our elasticities relate to this expenditure. Implicitly we assume that any budgetary
shock only affects PCT funding and that it leaves non-PCT funding unchanged. Suppose instead we
assume a 1% exogenous change in the Departmental budget. We have no information on how this
Departmental budgetary shock is likely to be split between PCT and non-PCTs budgets. One might assume
that the non-PCT budget is as responsive to a Departmental budgetary shock as is the PCT budget. If this
was the case then it would add 17.7% to our cost of a life-year estimate for 2006/7. However, in the
absence of any information about the responsiveness of the non-PCT budget, it is difficult to come to any
firm conclusion about the impact of non-PCT expenditure on our cost of a life-year estimates.
2007/8 expenditure data and mortality data for 2007/8/9
Outcome and expenditure models were estimated using updated data for expenditure (from 2006/7 to
2007/8) and updated mortality data (from 2006/7/8 to 2007/8/9). Appendix 2, Analysis of programme
budgeting expenditure for 2007/8 and mortality data for 2007/8/9 presents detailed discussion of the
findings including tables of results.
Outcome models
As before, we model outcome as a function of own programme expenditure and a measure of health-care
need, where the latter is proxied by the measure of need as employed by the Department of Health for
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resource allocation purposes.t There are, however, a few exceptions. For the respiratory programme we
further included the square of the measure of need to improve model fit. In some other PBCs we found
that the all service measure of need performed poorly and we replaced or supplemented this measure with
either a more programme-specific measure (e.g. the epilepsy prevalence rate for neurological mortality)
or with a better performing proxy for need (e.g. the percentage of residents born outside the EU for
maternity/neonate mortality). These amendments improved model specification.
u
Full results for all
programmes are presented in Appendix 2, Table 81; below is a summary of the findings.
Two sets of models were estimated for three of the big four programmes (cancer, respiratory problems and
gastrointestinal problems). One of the two models used two instruments and so we report the instrument
validity test statistic. In all three cases we failed to reject the null hypothesis of instrument validity. However,
there is some evidence of weak instruments (at least in the respiratory and gastrointestinal programmes)
and if we dropped one instrument and re-estimated the model, evidence of instrument weakness
disappeared. The removal of one instrument has little impact on the coefficient on expenditure and it
is this coefficient that we use below in our cost of a life-year calculations reported in Table 5.
For the big four programmes the need variable has a positive and significant effect on mortality,
and expenditure has the anticipated negative effect. The diagnostic statistics reveal that, in all four PBCs,
own programme expenditure is endogenous and that the instruments are valid. They also suggest that the
instruments are relevant and there is no evidence that they are weak in the models with one excluded
instrument. The Pesaran–Taylor test reveals no evidence of model misspecification.
The outcome results for the other programmes are similar to but more diverse than those for the big four
programmes. This is to be anticipated because mortality is a much rarer outcome in these programmes
than it is in the big four programmes. Own programme expenditure is not endogenous in four of these
programmes, but we retain the IV estimator for three of these four because this yields more plausible
results than the OLS estimator (the results are more plausible in the sense that the signs on the coefficients
are more in line with our prior expectations).
v
Expenditure has the anticipated negative effect on mortality in the endocrine problems programme but
this is not statistically significant. The all service measure of need is not relevant for this PBC; instead,
we find that the diabetes prevalence rate is positively associated with mortality, as is a measure of
deprivation (the IMD2007).
Mortality from epilepsy is negatively and significantly associated with expenditure in the neurological
programme. Both the all service need for health care and the epilepsy prevalence rate are positively and
significantly associated with mortality in this programme.
Expenditure has a negative and statistically significant effect on mortality (from renal problems) in the
genitourinary problems programme. The prevalence of lone parent households is positively associated
with mortality.
Expenditure has the anticipated negative effect on mortality in the infectious disease programme and this
is statistically significant. The all service measure of need is not relevant for this PBC; instead, we find
that a measure of need associated with HIV is positively associated with mortality, as is a measure of
deprivation (the IMD2007).
Expenditure has the anticipated negative effect on mortality in the maternity and neonates programme but
the estimated coefficient is not statistically significant. In this PBC the generic all service measure of need
has been replaced with two other indicators of deprivation – the proportion of residents born outside the
EU and the proportion of those aged 16–74 years without any qualifications – both of these are positively
associated with mortality.
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Finally, expenditure and need have the anticipated effects on mortality in the trauma and injuries
programme. In addition, the proportion of households without access to a car is negatively associated with
mortality from fractures (perhaps access to a car facilitates involvement in serious road traffic accidents),
and the proportion of residents that are students is positively associated with mortality from fractures.
The relevant statistical test suggests that expenditure is endogenous in 6 of the 10 programmes but we
have retained the IV estimates for three of the other four programmes because they provide plausible
results. The Hansen–Sargen test suggests that the selected instruments are valid, and the Kleibergen–Paap
LM statistic suggests that they are relevant (i.e. correlated with the endogenous regressor). With the
possible exception of the trauma and injuries programme, the Kleibergen–Paap F-statistic suggests that we
do not have a problem with weak instruments.w Finally, the Pesaran–Taylor reset test statistics and the
Ramsey reset F-statistics reveal no evidence of misspecification.
Expenditure models
The majority of the expenditure models contain the three variables: the PCT budget, a proxy for the
own programme need for health care, and a proxy for the need for health care in other programmes.
The budget term is positive in all 11 models and it is statistically significant in 8 of these 11 models.
The usual proxy for the own programme need for health care (i.e. the all service measure of need) is
present in six of the models and it is significant in five of them. Its presence is supplemented with the
addition of its squared value to improve model fit in the respiratory problems programme. In some
programmes (e.g. the endocrine, metabolic and nutritional, and neurological),
x
we have replaced and/or
supplemented the all service measure of need with a more programme specific measure (e.g. the diabetes
prevalence rate and the epilepsy prevalence rate) and these measures of need have the anticipated positive
impact on expenditure.
In addition, in a couple of other programmes we have used alternative proxies for the own programme
need (e.g. with the use of the Department of Health’s measure of maternity need in the maternity/neonates
expenditure equation). Full results for all programmes are presented in Appendix 2, Table 82; below is a
summary of the findings.
For 8 of the 11 programmes we have used the all-cause mortality rate less own programme mortality rate
as the proxy for the need for health care in other programmes, and the coefficient on this term is negative
in seven programmes and statistically significant in six of the seven. In three programmes – maternity/
neonates, GMS/PMS and trauma and injuries – we have used the all-cause mortality rate as the proxy for
the need for health care in other programmes due to difficulties associated with the measurement of the
own programme mortality rate. The coefficient on this term is not significant in any of the three models.
The relevant statistical test suggests that expenditure is endogenous in 6 of the 11 programmes but we
have retained the IV estimates for two other programmes (GMS/PMS and trauma and injuries) because the
IV estimator provides more plausible results. In the other three programmes we report OLS results.
The Hansen–Sargen test suggests that the selected instruments are valid, and the Kleibergen–Paap
LM statistic suggests that they are relevant (i.e. correlated with the endogenous regressor).
The Kleibergen–Paap F-statistic suggests that we do not have a problem with weak instruments.
Finally, the Pesaran–Taylor reset test statistics and the Ramsey reset F-statistics reveal no evidence of
model misspecification.
Calculation of the cost of a life and life-year
Expenditure and outcome elasticities for preferred models are used to calculate the cost of a life-year,
both for individual programmes and for all programmes collectively. The relevant figures are summarised in
Table 5.y The cost per YLG is £13,830 for the big four programmes and £28,983 for all 10 programmes
THE LINK BETWEEN NHS SPENDING, MORTALITY AND THE COST OF A LIFE-YEAR
NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
with a mortality-based outcome indicator. These represent 30% and 45% increases on the respective costs
for the previous year (i.e. using expenditure data for 2006/7 and mortality data for 2006/7/8).
If we assume that the other 13 programmes (all without a mortality-based outcome indicator) offer no
health gain, then the cost per life-year across all PCT expenditure is £82,765. This is up from £73,457
using data for the previous year (an increase of 13%).
In addition, if we assume that PBC 23 generates a zero health gain and that the gain attributable to the
remaining 12 programmes is, on average, the same as that attributable to those with a mortality outcome
measure, then the cost of a life-year across all programmes is £31,846 (it was £22,565 using data for the
previous year).
The next section presents outcome and expenditure models using programme budget data for 2008/9 and
mortality data for 2008/9/10, and it explores the reasons for the increase in the cost of an additional
life-year identified in this section.
2008/9 expenditure data and mortality data for 2008/9/10
Outcome and expenditure models were estimated using updated data for expenditure (from 2007/8 to
2008/9) and updated mortality data (from 2007/8/9 to 2008/9/10). Detailed results for the outcome model
and expenditure model are shown in Appendix 2, Tables 85 and 86 respectively. First-stage regressions for
these IV models can be found in Tables 99 and 100 in the Annex to Appendix 2.
Outcome models
The majority of the outcome models contain the two variables: own programme expenditure and a
measure of the need for health care (the measure of need as employed by the Department of Health for
resource allocation purposes
z
). For the respiratory disease programme we have added the square of the
need measure to improve the model fit. In other PBCs (e.g. for the endocrine, metabolic and nutritional),
we found that the all service measure of need performed poorly and we have replaced it with a more
programme specific measure (e.g. the diabetes prevalence rate) or with a better performing proxy for need
(e.g. the percentage of residents born outside the EU for maternity/neonate mortality).aa
The relevant statistical test suggests that expenditure is endogenous in 6 of the 10 programmes but we
have retained the IV estimates for the other four because they provide plausible results. The Hansen–Sargen
test suggests that the selected instruments are valid, and the Kleibergen–Paap LM statistic suggests that
they are relevant (i.e. correlated with the endogenous regressor). The Kleibergen–Paap F-statistic suggests
that we do not have a problem with weak instruments. Finally, the Pesaran–Taylor reset test statistics reveal
no evidence of misspecification.
In all of the big four programmes the need for health-care variable has a positive and significant effect on
mortality, and expenditure has the anticipated negative effect. As we have noted before, the outcome
results for the other programmes are similar to, but more diverse than, those for the big four programmes.
This is to be anticipated because mortality is a much rarer outcome in these programmes than it is in the
big four programmes.
Expenditure has the anticipated negative effect on mortality in the endocrine problems programme and
this is statistically significant. The all service measure of need is not relevant for this PBC; instead, we find
that the diabetes prevalence rate is positively associated with mortality, as is a measure of deprivation
(the IMD2007).
Expenditure has a negative but statistically insignificant impact on mortality from epilepsy in the
neurological programme, and the all service indicator of the need for health care is positively and
significantly associated with mortality in this programme.
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Expenditure also has a negative but not statistically significant effect on mortality (from renal problems) in
the genitourinary problems programme. The prevalence of lone parent households is positively associated
with mortality.
Expenditure has the anticipated negative effect on mortality in the infectious disease programme and this
is statistically significant. The all service measure of need is not relevant for this PBC; instead, we find
that a measure of need associated with HIV is positively associated with mortality, as is a measure of
deprivation (the IMD2007).
Expenditure has the anticipated negative effect on mortality in the maternity and neonates programme.
In this PBC the coefficient on the generic all service measure of need is positive but not significant. It has
been supplemented with two other indicators of deprivation – the proportion of residents born outside the
EU and the proportion of those aged 16–74 years without any qualifications – and both of these are
positively associated with mortality.
Finally, we were unable to develop a plausible outcome model for the trauma and injuries programme.
Expenditure models
The majority of expenditure models contain the three variables: the PCT budget, a proxy for the own
programme need for health care, and a proxy for the need for health care in other programmes.
The budget term is positive and statistically significant in 10 of the 11 models.
The usual proxy for the own programme need for health care (i.e. the all service measure of need) is
positive and significant in 5 of the 11 results. In a couple of programmes (respiratory disease and
endocrine problems) we have added the squared value of need to improve the model fit and in both
cases this term is positive and significant. In some programmes (e.g. the endocrine PBC and the
neurological PBC), we have replaced and/or supplemented the all service measure of need with a more
programme-specific measure (e.g. the diabetes and the epilepsy prevalence rates) and these usually
have a positive and significant impact on expenditure. In addition, in a couple of programmes we have
used alternative proxies for own programme need (e.g. with the use of the Department of Health’s
measure of maternity need in the maternity/neonates expenditure equation and the use of HIV need in
the infectious diseases programme).ab
For 8 of the 11 programmes we have used the all-cause mortality rate less the own programme mortality rate
as the proxy for the need for health care in other programmes, and the coefficient on this term is negative in
seven programmes and statistically significant in six of the seven. In three programmes – maternity/neonates,
GMS/PMS and trauma and injuries – we have used the all-cause mortality rate as the proxy for the need for
health care in other programmes due to difficulties associated with the measurement of the own programme
mortality rate. The coefficient on this term is negative but not significant in these three models.
The relevant statistical test suggests that expenditure is endogenous in 5 of the 11 programmes but we
have retained the IV estimates for two further programmes (endocrine problems and maternity/neonates)
because the IV estimator provides more plausible results than the OLS estimator. In the other four
programmes we report OLS results.
The Hansen–Sargen test suggests that the selected instruments are valid, and the Kleibergen–Paap LM
statistic suggests that they are relevant (i.e. correlated with the endogenous regressor). The Kleibergen–Paap
F-statistic suggests that we do not have a problem with weak instruments. Finally, the Pesaran–Taylor reset
test statistics and the Ramsey reset F-statistics reveal no evidence of model misspecification.
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Calculation of the cost of a life and life-year
Expenditure and outcome elasticities for our preferred models are used to calculate the cost of a life-year,
both for individual programmes and for all programmes collectively. This results in the cost per YLG having
increased slightly compared with using the previous expenditure and mortality data set (i.e. for 2007 and
2007/8/9 respectively): increasing from £13,830 to £14,650 for the big four programmes and from
£28,983 to £30,883 for all 10 programmes with a mortality-based outcome indicator. If we assume that
the other 13 programmes offer no health gain, then the cost per life-year across all PCT expenditure has
increased from £82,765 in 2007/8 to £84,974 in 2008/9.
In addition, if we assume that PBC 23 generates a zero health gain and that the gain attributable to the
remaining 12 programmes is, on average, the same as that attributable to those with a mortality outcome
measure, then the cost of a life-year across all programmes in 2008/9 is £33,333. This is a 5% increase on
the figure (£31,846) for the previous year.
Comparing the cost of life-year estimates associated with different data sets
Table 6 presents expenditure and outcome elasticities for the five combinations of expenditure and
outcome data that have been used to estimate our model. It also reports the corresponding unadjusted
cost of life-year estimates (i.e. estimates that are unadjusted for the mismatch in the ICD-10 coverage of
the expenditure and mortality data). It is clear from this Table 6 (see row 13) that the (unadjusted) cost
of a life-year for the 10 programmes with a mortality-based outcome indicator fluctuated around £22,000
for the first three sets of estimations (see columns M–O). However, using the two most recent sets of
expenditure data (i.e. for 2007/8 and then for 2008/9), the figures in the table suggest that this cost has
increased to about £38,000.
What are the proximate causes of this increase? Recall that the cost of a life-year is calculated as:
The change in expenditure associated with a 1% budget increase
The change in the number of life-years lost associated with this increase
For 2006/7 (using mortality data for 2006/7/8) and for the 10 programmes with a mortality-based outcome
indicator, the change in expenditure associated with a 1% budget increase is £184.53M and the change
in the number of life-years lost associated with this increase is 7760 (see Appendix 2, Table 67 for the
calculation of these figures). Thus the cost of a life-year is £23,780 (= £184.53M/7760).
For 2007/8 (using mortality data for 2007/8/9) and for the 10 programmes with a mortality-based outcome
indicator, the change in expenditure associated with a 1% budget increase is £257.94M and the change
in the number of life-years lost associated with this increase is 6768 (see Appendix 2, Table 83 for the
calculation of these figures). Thus the cost of a life-year is £38,110 (= £257.94M/6768).
It is clear that the 60% increase in the cost of a life-year between 2006/7 and 2007/8 is largely attributable
to (a) the 40% increase in the additional expenditure (up from £184.53M to £257.94M) directed towards
these 10 programmes following a 1% budget increase; and (b) the 12% decline in the number of life-years
saved by this increase in expenditure (down from 7760 to 6768 life-years).
The rise in the share of the budget increase directed towards these programmes can be attributed to the
increase in the implied expenditure elasticity associated with these 10 programmes (up from 0.561 to
0.749). The decrease in the number of years of life saved appears to be due to (a) an overall reduction in
the (absolute) size of the outcome elasticities; and (b) a shift in the additional expenditure towards those
programmes with a relatively high cost of a life-year. For example, the cost of a life-year for the ‘small six’
programmes is much larger than for the ‘big four PBCs’. However, in 2007/8 the spend elasticity for the
small six increases from 0.561 to 0.961 (71%) whereas the expenditure elasticity for the big four rises
from 0.528 to 0.559 (6%). A similar pattern – of additional expenditure shifting away from the low
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TABLE 6 Expenditure and outcome elasticities for five combinations of expenditure and outcome data, and
corresponding (unadjusted) cost of life-year estimates
A B C D E F G H I
PBC Spend elasticities Outcome elasticities
Using
spend for
2005 and
mortality
for
2002/3/4
Using
spend for
2006 and
mortality
for
2004/5/6
Using
spend for
2006 and
mortality
for
2006/7/8
Using
spend for
2007 and
mortality
for
2007/8/9
Using
spend for
2008 and
mortality
for
2008/9/10
Using
spend for
2005 and
mortality
for
2002/3/4
Using
spend for
2006 and
mortality
for
2004/5/6
1 Cancer 0.968 0.548 0.465 0.890 0.525 −0.394 −0.337
2 Circulatory
problems
0.682 0.701 0.540 0.293 0.648 −1.370 −1.447
3 Respiratory
problems
0.849 0.718 0.679 0.536 0.652 −1.574 −3.507
4 Gastrointestinal
problems
0.772 0.667 0.446 0.622 0.456 −2.018 −2.137
5 All big four PBCs 0.801 0.660 0.528 0.559 0.579 −0.941 −1.083
6 Infectious diseases 0.742 0.731 0.792 1.436 1.545 −0.152 −0.030
7 Endocrine
problems
0.425 0.966 0.953 0.264 0.484 −0.244 −0.812
8 Neurological
problems
1.111 0.648 0.616 1.035 0.98 −0.182 −0.098
9 Genitourinary
problems
1.041 0.837 0.912 1.004 0.697 −0.034 −0.073
10 Trauma and
injuries
0.627 0.617 0.358 1.686 1.344 −1.332 −0.527
11 Maternity and
neonates
0.388 0.601 0.224 0.514 0.975 −0.237 −0.035
12 All small six PBCs 0.780 0.717 0.596 0.961 0.962 −0.262 −0.122
13 All 10 PBCs with
mortality
0.792 0.687 0.561 0.749 0.762 −0.844 −0.940
14 All 23 PBCs
assuming zero
gain in PBCs
without mortality
indicator
15 GMS/PMS 0.926 0.759 0.739 0.563 0.494 N/A N/A
16 All 23 PBCs
assuming zero
gain in PBC 23
but average gain
in other PBCs
without a
mortality indicator
N/A, not applicable.
The spend and outcome elasticities reported for groups of programmes are the implied elasticites calculated from the totals
for the relevant individual programmes [i.e. group spend elasticity= (PBC spend× PBC spend elasticity)/PBC spend, and
group outcome elasticity= (PBC mortality× PBC outcome elasticity)/PBC mortality]. For the purpose of the calculation of the
group outcome elasticity, we have used the YLL as the mortality indicator. The implied group elasticities cannot be used to
calculate directly the cost of a life (year) for a group of PBCs. Instead, the latter should be calculated by summing across the
change in spend and the change in mortality for the individual PBCs within the group. For further details see, for example,
Table 67 in Appendix 2.
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J K L M N O P Q
Cost of an additional life-year (£) (unadjusted for YLL coverage)
Using
spend for
2006 and
mortality
for
2006/7/8
Using
spend for
2007 and
mortality
for
2007/8/9
Using
spend for
2008 and
mortality
for
2008/9/10
Using
spend for
2005 and
mortality
for
2002/3/4
Using
spend for
2006 and
mortality
for
2004/5/6
Using
spend for
2006 and
mortality
for
2006/7/8
Using
spend for
2007 and
mortality
for
2007/8/9
Using
spend for
2008 and
mortality
for
2008/9/10
−0.342 −0.365 −0.307 13,741 16,518 16,383 17,165 21,802
−1.434 −1.277 −1.319 8328 8725 9466 11,315 11,779
−2.622 −2.205 −1.808 20,601 8747 11,593 14,798 21,307
−1.536 −1.328 −1.364 18,303 15,795 20,892 25,034 25,662
−0.965 −0.872 −0.825 12,855 10,783 12,333 16,345 16,688
−0.047 −0.548 −0.504 215,054 1,036,377 630,798 57,742 71,432
−0.842 −0.566 −1.170 371,601 112,882 114,416 190,745 104,008
−0.112 −0.339 −0.417 503,201 1,241,253 1,129,960 431,749 388,267
−0.051 −1.855 −1.615 29,144,918 12,384,965 20,421,090 652,096 877,038
0 −0.369 0 282,132 548,767 N/A 1,115,197 N/A
−0.482 −0.110 −0.125 17,490 631,700 45,158 204,168 198,939
−0.392 −0.254 −0.300 295,074 449,706 258,046 274,309 254,794
−0.877 −0.778 −0.747 21,256 20,893 23,780 38,110 38,328
56,799 62,718 87,494 108,829 105,460
N/A N/A N/A N/A N/A N/A N/A N/A
24,200 23,697 26,876 41,875 41,369
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cost PBCs – can be seen within the big four programmes. However, it is not clear why such rather
dramatic changes should have taken place.
If we correct the cost of life-year estimates adjusting for the mismatch in the ICD-10 coverage of the
expenditure and mortality data, these reveal similar increases in the cost of a life-year between 2006/7 on
the one hand and 2007/8 and 2008/9 on the other. The cost of a life-year increased from £19,965 in
2006/7 to £28,983 in 2007/8 for the 10 programmes with mortality rate, an increase of 45%; and it
increased from £22,565 to £31,846 for all programmes if we assume a zero health gain in PBC 23 and the
same gain in the other 12 programmes as in the 10 with a mortality rate (an increase of 41%).
A potential reason for this apparent step change in the cost of a life-year is the adjustment that was made
to the methodology for the collection of the 2007/8 PB data. In previous years expenditure that was not
directly attributable to a particular programme category was apportioned using admitted patient care
percentages.ac In other words, if x% of total admitted patient care expenditure was allocated to PBC 1,
then x% of all expenditure that was not directly attributable to a particular programme category was
also allocated to PBC 1. With effect from 2007/8, however, NHS organisations were asked to select an
appropriate basis for the apportionment of this non-programme-specific expenditure and that, where
no reasonable basis existed, such expenditure was to be allocated to the ‘other – miscellaneous’
(PBC 23X) category.
The Department of Health estimates that this allocation rule change increased the amount of expenditure
attributed to PBC 23X by £700M. It will also, of course, have reduced expenditure across other programmes
by the same amount in total. However, not all programmes will have been equally affected; PBCs that are
more heavily inpatient based would have ‘lost’ expenditure whereas others, such as learning disabilities,
social care and mental health, will have ‘lost’ considerably less. In addition, not all PCTs will have been equally
affected because each will have employed different apportionment rules for the non-programme-specific
expenditure (Bryn Shorney, Department of Health, 2012, personal communication).
Although this allocation rule change has considerably increased the estimated cost of a life-year, we
believe that this rule change has led to a more accurate allocation of expenditure across PBCs, and that
the more recent estimates of the cost of a life-year (for 2007/8 and 2008/9) are more accurate than those
for the earlier years (for 2005/6 and 2006/7).
Adjusting the cost of a life-year estimates to constant prices
The estimates of the cost of a life-year presented above are all at current prices. To put them on a constant
price basis, we need an index of pay and price inflation for the labour and goods/services purchased by the
NHS. Curtis87 reports a pay and prices index for HCHS and this implies an inflation rate of 3.7% in 2006/7,
2.9% in 2007/8 and 3.9% in 2008/9.ad If we assume that similar inflation rates also apply to the purchase
of pharmaceuticals and the provision of primary care (items that are excluded from the HCHS index),
then we can use these figures to put the estimates of the cost of a life-year on a constant price basis.
For example, if we assume that PBC 23 generates a zero health gain and that the gain attributable to the
12 programmes without a mortality indicator is, on average, the same as that attributable to those with a
mortality outcome measure, then the cost of a life-year across all programmes in 2008/9 is £33,333
at current (2008/9) prices. The cost for 2007/8 is £31,846 at current (2007/8) prices or £33,088 at
constant (2008/9) prices, and the figure for 2006/7 is £22,565 at current (2006/7) prices or £24,125
at constant (2008/9) prices. The conversion of the costs from a current to constant price basis has relatively
little impact because the inflation rate over the relevant period is quite small.
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Summary and concluding remarks
The findings presented in this report build on four previous studies. These studies and the results presented
here draw on the availability of two new data sets to obtain empirical estimates of the relationship
between mortality and expenditure across all English local health authorities.
In this research we have extended the previous studies in several ways. First, we have derived plausible
outcome and expenditure models for a larger number of programmes (10) than previous studies.
Second, we relate expenditure in time period t to mortality in that period (t) and in the next two periods
(t + 1 and t + 2). In other words, we assume that the health benefits associated with expenditure occur
either in the same period as the expenditure or in the next two periods. This is an improvement on past
practice where data constraints forced researchers to relate expenditure to the current and two previous
periods.ae When we re-estimated our models using expenditure data for 2006/7 and mortality data for
2006/7/8, we found that the cost of a life-year across the 10 programmes with a mortality-based outcome
indicator is £23,780 (up from £20,893 when expenditure data for 2006/7 is combined with mortality data
for 2004/5/6; an increase of 14%).
Third, we have noted the mismatch in the ICD-10 coverage of the expenditure and mortality data. If we
adjust the calculation of the cost of a life-year for 2006/7 for this mismatch then the cost of a life-year
across the 10 programmes with a mortality-based outcome indicator declines from £23,780 to £19,965
(a decrease of 16%).
Fourth, previous estimates of the cost of a life-year have been for individual programmes of care. In this
report we have presented estimates of the cost of a life-year for an enlarged number of programmes and,
with the aid of assumptions about the productivity (health gain) of programmes without a meaningful
mortality-based outcome indicator, we have extended our individual programme estimates to incorporate
expenditure across all programmes of care. Thus for 2006/7, the cost of a life-year for those PBCs with a
mortality-based outcome indicator is £19,965. If we assume (a) that the health gains associated with
PBC23, which includes primary care and workforce training expenditure, are reflected in the mortality rates
for disease-specific programmes and (b) that the average health gain across the other programmes without
a mortality-based outcome indicator is the same as that for those PBCs with a mortality-based outcome
indicator, then the cost of life-year across all programmes is £22,565.
Fifth, we have extended our cost of life-year estimates beyond 2006/7. Re-estimation of our model using
budgeting expenditure for 2007/8 generates an all programme cost of a life-year estimate of £31,846, and
re-estimation of our model using budgeting expenditure for 2008/9 generates a similar cost of a life-year
estimate (£33,333). Together, the last two estimates suggest that there has been step change in the cost
of a life-year, and that this appears to have occurred between 2006/7 and 2007/8. The cost of a life-year
estimates are very similar up to and including 2006/7, and they are very similar for 2007/8 and 2008/9.
However, there is a substantial difference between the figures for 2004/5, 2005/6 and 2006/7 on the one
hand (at about £22,000), and for 2007/8 and 2008/9 on the other (at about £33,000). The reason for this
step change is not obvious but it might be due to changes in the algorithm used by the Department of
Health to allocate non-admitted patient care activity to budget categories. Although this allocation rule
change has considerably increased the estimated cost of a life-year, we believe that this rule change has
led to a more accurate allocation of expenditure across PBCs, and that the more recent estimates of the
cost of a life-year (for 2007/8 and 2008/9) are more accurate than those for the earlier years (for 2005/6
and 2006/7). A summary of the estimates of the cost of a life-year adjusted for the mismatch between
ICD-10 chapters for expenditure and mortality are provided in Table 7.
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Virtually all of the cost of a life-year estimates presented in this report are calculated at current prices.
However, it is possible to put them on a constant price basis using the HCHS pay and prices index.87
For 2006/7, 2007/8 and 2008/9 this index recorded an annual rate of inflation of about 3.5% and so the
impact of this constant price adjustment is fairly minimal. For example, if we assume that PBC 23
generates a zero health gain and that the gain attributable to the 12 programmes without a mortality
indicator is, on average, the same as that attributable to those with a mortality outcome measure, then the
cost of a life-year across all programmes at constant 2008/9 prices is £33,333 for 2008/9, £33,088 for
2007/8, and £24,125 for 2006/7.
Finally, although previous results and our current models ‘pass’ the appropriate statistical tests and, in
particular, the Hansen–Sargen test for valid instruments, we are aware that this test might be unable
to detect the presence of invalid instruments in some circumstances and that the validity of IVs is often
open to question. Responding to this, several studies88,89 have suggested that researchers using IV
techniques should subject the estimated coefficient on the endogenous variable to a sensitivity analysis.
We undertake a comprehensive sensitivity analysis for the outcome equation for each of the big four
models. This sensitivity analysis reveals that uncertainty associated with instrument validity has little effect
on our estimate of the cost of a life-year but it does increase the degree of uncertainty associated with
this estimate.
We recognise that this study has a number of limitations. The estimates of the cost of an additional
life-year for programmes with a mortality-based outcome indicator are unadjusted for the QoL during the
additional year. Accordingly, the quoted costs will be an underestimate of the QALY cost of a life-year to
the extent that additional life-years are not in perfect health. In previous studies we have noted that a
rudimentary adjustment for this issue using Health Outcomes Data Repository (HODaR) data increased the
cost of a life-year by about 50–60%.60,63
TABLE 7 Adjusted cost of life-year estimates for various combinations of programmes
A B C D E
PBC Cost per life-year (£) (adjusted
for ICD-10 coverage of spend
and mortality data)
2006/7 2007/8 2008/9
1 Cancer 16,121 16,891 21,454
2 Circulatory disease 9390 11,224 11,685
3 Respiratory problems 8961 11,439 16,470
4 Gastrointestinal problems 11,929 14,295 14,653
5 All big four programmes 10,604 13,830 14,650
6 Other six programmes with a mortality rate 146,108 99,428 112,674
7 All 10 PBCs with a mortality rate 19,965 28,983 30,883
(a) If we assume a zero health gain in those PBCs without a mortality rate . . .
8 All 23 programmes 73,457 82,765 84,974
. . . or (b) if we assume a zero gain in PBC 23 and that the average gain
from the
the 10 PBCs with a mortality rate is applied to the remaining programmes
9 All 23 programmes 22,565 31,846 33,333
Note that the figures for 2006/7 relate to the use of mortality for 2006/7/8 combined.
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At the same time, however, the estimated costs will exaggerate the cost of an additional QALY for those
programmes with a mortality-based outcome indicator because they ignore any health benefits that
are not associated with a reduction in mortality. In other words, expenditure that improves the QoL
(e.g. cancer palliative care) but which does not extend the length of life is implicitly given a zero health
gain value.
In addition, the expenditure data relate to expenditure on all patients whereas the mortality data are based
on a LE of 75 years. Thus implicitly our calculations attribute a zero health gain to all expenditure on those
aged over 75 years. To illustrate the magnitude of the potential health gain ignored by this restriction,
note that in a recent study of costs associated with all inpatient and outpatient activity (excluding mental
health), those aged over 75 years accounted for 25% of all costs in 2007/8.86
The results presented in this study are all from the estimation of the relationship between expenditure
and mortality using data for a single time period. With the availability of several years of data for both
expenditure and mortality, we wanted to estimate a panel data model because a panel can offer
advantages over a one period model (e.g. it is better able to handle any unobserved heterogeneity across
PCTs). However, most of the instruments employed here are based on the 2001 Census80 and, thus, time
invariant, rendering them of little use in panel data modelling.
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Chapter 4 Translating mortality effects into
life-years and quality-adjusted life-years
Introduction
This chapter presents an overview of how the results of the econometric work undertaken to estimate the
link between NHS spending and mortality, which was summarised in the previous chapter and detailed in
Appendix 2, can be translated into effects on life-years and QALYs.
In this chapter we present three sequential steps of analysis which lead to estimates of the overall cost per
QALY threshold for the NHS:
i. In From mortality to life-years we reconsider how the estimated effects on mortality from the
econometrics work conducted in Chapter 3 might better translate in to life-years by exploring
the limitations of mortality data available at PCT level and the published YLL figures presented.
We explore how these estimates might be improved using additional data and analysis.
ii. In Adjusting life-years for quality-of-life we consider how these estimates of life-year effects might be
adjusted for the QoL in which they are lived, taking account of the gender and the age at which
life-years are gained or lost as well as the disutility associated with particular diseases.
iii. In Including quality-of-life effects during disease we explore ways to also take account of those effects
on health not directly associated with mortality and life-year affects (i.e. the ‘pure’ QoL effects) to
estimate an overall cost per QALY threshold.
This sequence of analysis is set out and explained based on the analysis of 2006 expenditure and mortality
data from 2006 to 2008. In Chapter 5, Re-estimating the cost per quality-adjusted life-year threshold using
more recent data we present estimates for 2008 expenditure and 2008–10 mortality data using the same
methods and discuss the uncertainties associated with these estimates. As in the previous chapter much of
the detail of data and analysis that supports this overview is presented in an appendix (see Appendix 3).
At the end of each section we present a summary which includes a central ‘best’ estimate as well as
extreme lower and upper bounds for the cost per life-year and cost per QALY threshold.
The core assumptions which underpin these three values are common across the above mentioned
sections. The central or ‘best’ estimate is based on two assumptions: one conservative and the other more
optimistic with respect to the health effects associated with expenditure. The first is that the health effects
of changes in 1 year of expenditure are restricted to 1 year. This is implicit in the estimates of outcome
elasticities presented in the previous chapter.a This is likely to underestimate effects on mortality as
expenditure that reduces mortality risk for an individual in 1 year may well also reduce their risk over
subsequent years; possibly over the whole of their remaining disease duration. Expenditure may also
prevent disease in future patient populations. Therefore, total health effects will be underestimated and
the cost per life-year or QALY threshold will be overestimated. Although undoubtedly conservative, it may
be offset to some extent by the more optimistic assumption used to translate mortality effects into
life-years. Any death averted by expenditure in 1 year is assumed to return the individual to the mortality
risk of the general population, i.e. the YLG associated with each death averted are based on what would
have been their LE taking account of their of age and gender (using life tables for the general population).
The extreme upper and lower bounds for cost per life-year and cost per QALY thresholds are based on
making both assumptions either optimistic (providing the lower bound for the threshold) or both
conservative (an upper bound for the threshold). The lower bound is based on assuming that health effects
are not restricted to 1 year but apply to the remaining disease duration for the population at risk during
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the expenditure year (although this still does not account for the effects of expenditure on preventing
disease). The upper bound is based on the combination of assuming that health effects are restricted to
1 year and that any death averted is only averted for the minimum duration consistent with the mortality
data used to estimate the outcome elasticities in Chapter 3 (see Summary of cost per life-year estimates
for a more detailed discussion). It is very important to note that the lower and upper bounds represent
extreme values rather than alternative but plausible views that could reasonably be taken. We discuss
this in more detail in Chapter 5, Future research and improving estimates and explain why establishing
narrower bounds, which might retain some plausibility, has not been possible given the data available and
therefore the analysis that has been feasible.
From mortality to life-years
In this section we summarise our examination of a number of issues associated with available PCT-based
mortality data and the associated published estimates of YLL. We then examine how, given the limited
information available about the population at risk in each PBC, we might take proper account of the fact
that some of the observed deaths would have occurred anyway (had the same population not been at risk
in the particular PBC) when estimating YLL (i.e. taking account of unobserved counterfactual deaths).
This allows us to estimate the YLL that better reflects the effect of expenditure on the mortality observed
in each PBC, and infer the excess deaths associated with each PBC. Finally we present cost per death
averted and cost per life-year which accounts for the issues raised in this section.
Mortality and years of life lost coverage
The mortality data that is available at PCT level does not offer full coverage of all deaths across all the
ICD-10 codes that make up each PBC (see Table 37 in Appendix 2 for how three-digit ICD-10 codes are
mapped to PBCs). However, national (English) data are available that covers all deaths associated with all
the ICD-10 codes that make up each PBC. Therefore, it is possible to adjust the incomplete reporting of
mortality at PCT level (see Chapter 3, Previous studies) before applying the estimated outcome elasticities
to calculate the deaths averted due to expenditure.b Applying published estimates of YLL per death to all
the deaths averted provides the estimate of the cost per life-year reported in Chapter 3.
The published estimates of YLL (National Health Service Information Centre; NHS IC) used in Chapter 3
only include deaths below the age of 75 years (but exclude deaths below age 1 year) and are based on
the difference between age 75 years and the age of each death below 75 years. These estimates have the
same limited coverage as PCT-level mortality data so are not available for all the ICD-10 codes that make
up each PBC. Therefore, applying the available estimates of YLL per death to the estimated number of
deaths averted requires an assumption that the YLL per death is similar for those groups of ICD-10 codes
covered and not covered by the published YLL figures.
This can be examined by using national Office for National Statistics (ONS) data to calculate YLL in the
same way as NHS IC, but with full coverage of all the ICD-10 codes that make up each PBC.c Although
ONS data provides complete coverage and reports gender, age at death is only reported in 5-year ranges
(these data are not available at PCT level so could not be used when estimating outcome elasticities in
Chapter 3). Therefore, using ONS data to estimate YLL requires taking the mid-point of each range as the
age of death, i.e. assuming reported deaths are equally likely over the range in which they are reported.
For this reason it is not possible to precisely recover the published YLL figures using ONS data for those
ICD groupings that can be precisely matched to the NHS IC coverage. However, the differences are small
(see Appendix 3, Table 102), suggesting that taking the mid-point of each range as the age of death may
be a reasonable approximation.
The differences between estimates of YLL based on ONS and NHS IC data are, however, much more
significant and are reported in Table 8. These reflect differences in the distribution of ages at death
between those groups of ICD-10 codes covered and not covered in the NHS IC figures. For example,
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NHS IC figures available at PCT level for PBC 7 (neurological problems) have low coverage of all deaths in
this PBC [0.14 in column (1)]. The deaths that are reported in NHS IC are associated with epilepsy and the
YLL [22,046 in column (2)] reflects the generally younger age at death in this group. When adjusted for full
coverage [22,046/0.14= 162,100 in column (3)] the estimated YLL is much greater than the YLL based
directly on all deaths by age group reported in ONS. This difference in YLL reflects the fact that the deaths
in PBC 7 which are not covered by NHS IC figures tend to be in older age groups so generate fewer YLL.
Using ONS data also allows deaths under the age of 1 year to be appropriately assigned to PBCs via the
ICD-10 code in which they occurred (NHS IC YLL figures exclude deaths under 1 year), rather than
assigning them all to PBC 18 + 19 as in the previous chapter.d This explains the large reduction in YLL for
PBC 18 + 19 (maternity and neonates) as much of the mortality is reassigned to ICD-10 codes which
contribute to other PBCs. As most of the deaths that are reassigned are allocated to PBC 1 (infectious
diseases) the YLL for this PBC increases despite complete reporting of deaths at PCT level and full coverage
by NHS IC figures (see also Table 104 in Appendix 3).
Life expectancy and years of life lost
As noted above, the NHS IC estimates of YLL only include deaths below age 75 years and are based on
the difference between age 75 years and the age of each death below 75 years. Implicitly this treats
75 years as the appropriate normal LE for males and females for the population at risk in each PBC.
However, with the exception of maternity and neonates most deaths in PBCs occur above the age of
75 years and LEs are significantly > 75 years. For example, based on 2006–8 data, LE for the general
population is 80.7 years for males and 84.4 years for females (considering age distribution) and even LE
at birth is > 75 years (77.74 years for males and 81.88 years for females).90
Based on ONS data YLL can be recalculated using gender-specific LE for the general population.e When
increasing LE two effects occur, both of which tend to increase estimates of YLL. First, more deaths
are included in the YLL calculation (those that occur between age 75 years and LE) and second, each
death previously counted below 75 years will generate 5.7 or 9.4 more YLL for males and females
respectively. The effect on the number of deaths and the YLL for each PBC of using the LE of the general
population is reported in Table 9 [see columns (1), (2) and (3)].
TABLE 8 Estimates of YLL for NHS IC and ONS
PBC
(1) Coverage
of mortality
data relative
to spend data
(2) YLL
< 75 years
(NHS IC)
(3) YLL
< 75 years,
adjusted
(NHS IC)
(4) YLL
< 75 years,
no adjustment
needed (ONS)
(5) Difference
from adjusted
NHS IC to
ONS (%)
1 Infectious
diseases
1.00 35,517 35,517 40,928 15
2 Cancer 0.98 735,674 747,636 758,804 1
4 Endocrine
problems
0.63 19,224 30,322 41,548 37
7 Neurological
problems
0.14 22,046 162,100 93,755 −42
10 Circulatory 0.99 453,878 457,538 481,246 5
11 Respiratory 0.77 108,074 139,812 147,465 6
13 Gastrointestinal 0.57 115,303 201,931 177,532 −12
17 Genitourinary 0.17 3343 19,438 17,380 −11
18+ 19 Maternity and
neonates
0.68 164,200 241,826 15,409 −94
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The number of deaths counted below LE increases for every PBC except for maternity and neonates
because, as expected, all deaths are below age 75 years in PBC 18 + 19. However, YLL increases for all
PBCs reflecting the additional years otherwise expected to be lived to an older LE. Of course including
more of the deaths observed in each PBC and the greater YLL associated with them will generate more
deaths averted and more YLGs when applying the same proportionate effects from the outcome
elasticities estimated in Chapter 3. Therefore, the cost per death averted and cost per life-year threshold
are lower using these figures than those reported in Chapter 3 (see Table 13 and Table 107 in Appendix 3
for a summary of the effects on the thresholds). However, there are good reasons why YLL figures
calculated as the difference between age of death and LE are likely to be overestimated. This is dealt with
in the next section (see Years of life lost and accounting for counterfactual deaths). In Inferring excess
deaths we take account of the fact that some of the deaths observed in a PBC would have occurred
anyway in a similar ‘normal’ population (i.e. the counterfactual population not at risk through membership
of the PBC) so not all observed deaths are ‘excess’ and generate YLL.
Years of life lost and accounting for counterfactual deaths
The estimates of YLL based on ONS data overcome many of the limitations of the published NHS IC
figures. However, the YLLs reported in Tables 8 and 9, are calculated in the same way as the
NHS IC figures, by taking the difference between a fixed LE and the age at death of deaths observed
below that LE. This will tend to overestimate the YLL for two reasons: (1) it does not account for the fact
that not all deaths observed below LE are ‘excess’ deaths in the sense that some deaths would have
occurred (at the same age) in a similar population not at risk in the PBC; and (2) some of the deaths
observed above LE may be ‘excess’ deaths that would not otherwise have occurred at that age. The overall
effect on YLL, and the cost per life-year, will depend on the number of deaths above and below LE that
are excess. Therefore, estimates of YLL are required which take account of the ‘counterfactual’ deaths that
would have occurred even if the population in the PBC was not at risk through membership of the ICD-10
codes that make it up, but faced the same mortality risks as the general population, accounting for the
age and gender distribution of the PBC population.
Ideally, with reliable information about the size of the population at risk in each PBC and its age and
gender distribution it would be possible to estimate the number of deaths that would be expected to
occur had this population not been at risk, based on mortality data for the general population.
The difference between deaths observed across all ages and the deaths expected to have occurred in
TABLE 9 The difference in YLL by LE
PBC
(1) Deaths
< 75 years
(ONS)
(2) Deaths
< LE (ONS)
(3) Difference
in deaths due
to increased
LE (%)
(4) YLL
< 75 years
(ONS)
(5) YLL
< LE (ONS)
(6) Difference
in YLL due to
increased
LE (%)
1 Infectious
diseases
2050 3710 81 40,928 62,051 52
2 Cancer 62,944 95,212 51 758,804 1,345,013 77
4 Endocrine 2367 4000 69 41,548 65,015 56
7 Neurological 5095 8975 76 93,755 145,526 55
10 Circulatory 41,487 82,098 98 481,246 916,170 90
11 Respiratory 14,000 30,500 118 147,465 310,326 110
13 Gastrointestinal 10,611 15,827 49 177,532 273,303 54
17 Genitourinary 1588 4197 164 17,380 39,098 125
18+ 19 Maternity and
neonates
226 226 0 15,409 17,167 11
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this matched ‘normal’ population would provide the number of ‘excess’ deaths by age and gender.f
The YLL associated with each of these excess deaths is the LE conditional on gender and on surviving
to the age at which the excess death occurred. The total YLL for the at risk population is simply the sum of
these YLLs over all excess deaths, which could occur at any age. This YLL is equivalent to the area between
the survival curve for the population at risk in a PBC and the counterfactual survival curve for the same
population but not at risk from membership of the PBC. The difficultly is that routinely available data do
not provide any information about the size of the population at risk or its age and gender distribution.
All that is routinely available are observed deaths (by age and gender). Therefore, it is not possible to
directly estimate excess deaths or compare survival curves.
Even if the size of the at risk population is unknown we can still use information that might be available about
its age and gender distribution (or make reasonable assumptions) to estimate a matched ‘normal’ LE using life
tables for the general population (such a LE summarises the area under the counterfactual survival curve).
Unfortunately, it is not possible to also calculate the LE for the population at risk in the PBC (or represent the
survival curve) without information about the size of the at risk population (if it was possible the difference
between these life expectancies would approximate the YLL per patient at risk in a PBC).
Fortunately, we can still recover a consistent estimate of YLL using observed deaths and a LE that
represents the normal LE of a matched population that is not at risk. This requires all observed deaths,
both those that occur below and those that occur above this LE to be taken into account. Those deaths
occurring below LE generate YLL – compared with the average of a matched population not at risk.
However, we must also account for those deaths that occur at ages above LE. These deaths generate YLGs
compared with the average of a matched population not at risk. Therefore, the appropriate estimate is a
net YLL (i.e. YLL – YLG). In effect, by subtracting YLG from YLL we take account of the fact that not all
deaths below LE are excess deaths but some deaths above LE are (see Appendix 3 for more formal
explanation of the equivalence of these ways of calculating YLL).g
Using the life expectancy of the general population
Routinely available data provides the age and gender of observed deaths but no information about the
age and gender distribution of the at risk population itself. Using observed age and gender at death as an
indication of the distribution of the at risk population will significantly overestimate the LE of a normal
matched population insofar as a disease may be chronic (not all PBC mortality occurs on entry into the at
risk population), and that PBC-related mortality risk may increase with age (see Appendix 3, Table 114).h
In the absence of additional external information the net YLL could be based on the LE of the general
population, reflecting its current age and gender distribution. These are reported in Table 10 and illustrate
the impact of accounting for counterfactual deaths in the way described above. The YLL reported in
column (5) of Table 10 are calculated the same way and are the same as the figures previously reported
[column (5) of Table 9]. That is, they do not account for deaths that would have otherwise occurred below
LE or the very many deaths that occur above LE. With the exception of PBC 18 + 19 many deaths occur
above the LE of the general population [see column (4) in Table 10] in all PBCs. As a consequence there
are YLG associated with all other PBCs [see Table 10, column (6)] so the net YLL in column (7) are lower
than YLL based on the same LE. Therefore, failure to account for counterfactual deaths would lead to an
overestimate of the YLL associated with a PBC and the effects of expenditure on YLL. Consequently, the
cost per life-year threshold would be underestimated (see Table 13).
However, these figures are only correct insofar as the distribution of age and gender in each PBC is similar
to the general population. For example, if the at risk population tends to be younger the correct LE for the
PBC will be lower and the net YLL will also tend to be lower. Similarly, if the at risk population tends to be
older than the general population the correct LE will be higher and net YLL will also tend to be higher.i
This explains the apparent net gain in YLL (negative net YLL) for PBC 17 (genitourinary) where most deaths
occur at ages greater than the LE of the general population so that YLG exceeds YLL. As we are able to
show later (see Table 11) this is because the age distribution in this PBC tends to be older than the general
DOI: 10.3310/hta19140 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 14
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Claxton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49
TABLE 10 Net YLL using LE of the general population
PBC
(1) LE of
males
(years)
(2) LE of
females
(years)
Average 2006–8
(3)
Deaths< LE
(4)
Deaths> LE (5) YLL (6) YLG (7) Net YLL
1 Infectious
diseases
80.7 84.4 3710 3248 62,052 18,796 43,256
2 Cancer 80.7 84.4 95,213 35,597 1,345,038 175,350 1,169,689
4 Endocrine 80.7 84.4 4000 2764 65,016 15,864 49,152
7 Neurological 80.7 84.4 8975 6378 145,529 34,621 110,908
10 Circulatory 80.7 84.4 82,099 77,752 916,192 444,694 471,498
11 Respiratory 80.7 84.4 30,500 34,945 310,334 215,829 94,505
13 Gastrointestinal 80.7 84.4 15,827 8320 273,308 45,295 228,012
17 Genitourinary 80.7 84.4 4198 6427 39,099 40,530 –1431
18+ 19 Maternity and
neonates
80.7 84.4 226 0 17,167 0 17,167
TABLE 11 Average age and LE for PBCs based on GBD
PBC Sex
(1) Average age
of general
population (years)
(2) LE of general
population (years)
(3) Average age
in PBC (years)
(GBD)
(4) LE of at risk
population
(years) (GBD)
1 Infectious
diseases
M 38.5 80.7 28.6 79.6
F 40.8 84.4 30.2 83.6
2 Cancer M 38.5 80.7 61.3 83.0
F 40.8 84.4 52.3 84.7
4 Endocrine M 38.5 80.7 44.2 81.0
F 40.8 84.4 50.8 84.7
7 Neurological M 38.5 80.7 24.8 79.6
F 40.8 84.4 23.5 83.3
10 Circulatory M 38.5 80.7 55.4 83.0
F 40.8 84.4 57.9 86.5
11 Respiratory M 38.5 80.7 32.1 80.3
F 40.8 84.4 33.7 84.0
13 Gastrointestinal M 38.5 80.7 35.8 80.6
F 40.8 84.4 41.9 84.5
17 Genitourinary M 38.5 80.7 63.2 83.5
F 40.8 84.4 47.3 85.6
18 + 19 Maternity and
neonates
M 38.5 80.7 3.0 78.7
F 40.8 84.4 24.1 83.1
F, female; GBD, Global Burden of Disease; M, male.
TRANSLATING MORTALITY EFFECTS INTO LIFE-YEARS AND QUALITY-ADJUSTED LIFE-YEARS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
50
population, that is the LE for a matched normal population should be higher with fewer deaths above and
more below this LE.
Using additional information about age and gender distribution
It is evident that estimates of YLL require some account to be taken of counterfactual deaths. In the absence
of routinely available information this requires examination of alternative sources of information which might
provide a basis for more credible assumptions about the age and gender distribution of the PBC population
than either, the distribution of observed deaths or the general population.j The World Health Organization
(WHO) Global Burden of Disease (GBD) study, updated in 2008 using 2004 data (see Addendum 1: data
sources in Appendix 3 for more details),k provides a range of summary health indicators for the UK, which
are, in part, based on estimates of the incidence of sequelae associated with different types of disease by age
and gender.l Therefore, the type of information used by WHO in the GBD study to generate summary
estimates for the UK can also be used to improve the assumptions required about the age and gender
distribution of the PBC populations. Importantly, at this stage, we do not need to rely on estimates of the
absolute size of the at risk population, but only the relative ‘share’ by age and gender.
The Global Burden of Disease study classifies diseases by U-codes, which are groups of three digit ICD-10
codes (see Addendum 1: data sources in Appendix 3 for details of how U-codes map to ICD-10 codes).m
As we know which ICD-10 codes contribute to each PBC we can map information from U-codes to PBCs
via the ICD-10 codes that contribute to each. The resulting average age and LE for each PBC is reported in
columns (3) and (4) of Table 11 using the information available from GBD in combination with life tables
for the general population.
These summary estimates suggest that some of the PBC populations may on average be older than the
general population (e.g. cancer, circulatory and genitourinary) or younger (e.g. maternity and neonates,
infectious diseases and neurological). However, when trying to interpret these summaries it should be
noted that the average age reported in Table 11 is the average over the ages at which sequelae occur
within the ICD-10 codes contributing to the PBC. Therefore, a similar average age can reflect very different
age distributions. Some reflect a markedly bimodal distribution (e.g. respiratory, where there is high
incidence at very young and older ages), or very different age distributions across the type of diseases that
contribute to the PBC. For example PBC 7 (neurological) includes dementia which accounts for the vast
majority of the PBC population older than 70 years. However, a greater proportion of the population is in
much younger age groups with other conditions, especially migraine (see Appendix 3, Addendum 1: data
sources). When interpreting these summary estimates it should also be noted that the reported life
expectancies are not the life expectancies at the average ages reported in column (3), but the average over
the life expectancies for each age group within the contributing ICD-10 codes weighted by the age
distribution of sequelae from GBD U-codes.
The implications for net YLL of using these PBC-specific estimates of ‘normal’ LE are reported in Table 12.
As expected, the net YLL for those PBC with a LE greater than the general population are higher than those
reported in column (5) in Table 10 (e.g. PBC 10 circulatory and PBC 17 genitourinary, which now has
positive net YLL). Similarly, those PBCs with a LE less than the general population have lower net YLL than
reported in column (5) in Table 10 (e.g. PBC 1 infectious diseases and PBC 18 + 19 maternity and neonates,
where the effect of a lower LE is more modest as there are no deaths above either of the estimates of LE).
The impact on the cost per life-year threshold of the issues discussed in the Introduction, From mortality to
life-years and Adjusting life-years for quality-of-life are summarised in Table 13 (see Table 116 in Appendix 3
for detailed breakdown of changes in spend and YLLs across PBCs).
Using ONS data to calculate YLL in the same way as the published NHS IC figures, but overcoming some
of the issues associated with the reporting of mortality at PCT level and the coverage of published
estimates of YLL (see Mortality and years of life lost coverage), generates similar estimates of a cost per
life-year threshold [see Table 13, column (1)] to those reported in Chapter 3. Calculating YLL in the same
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way, but based on the LE of the general population significantly overestimates YLL for the reasons set out
in Life expectancy and years of life lost so underestimates the cost per life-year threshold [see Table 13,
column (2)]. Taking account of counterfactual deaths by calculating net YLL based on the LE of the general
population [see Table 13, column (3)] provides similar estimates to those reported in Chapter 3. Assuming
that PBC populations have the same age and gender distribution as the general population when the,
albeit limited, information that is available suggests otherwise, seems inappropriate. Therefore, our
preferred central estimate of the cost per life-year threshold is reported in Table 13, column (4). These are
lower than those based on the general population, reflecting the impact on net YLL of evidence that
the population at risk in some key PBCs (especially PBCs 2 and 10) tend to be older than the general
population. In Summary of cost per life-year estimates we consider extreme upper and lower bounds that
might be placed on this central estimate.
Inferring excess deaths
We have been able to establish a measure of net YLL, which takes account of deaths that would have
occurred anyway below a normal LE for the PBC population (i.e. not all deaths observed in a PBC are
excess), and that some deaths observed above this LE would not otherwise have occurred at that age
TABLE 12 Net YLL using LE for each PBC
PBC
(1) LE of
males
(years)
(2) LE of
females
(years)
Average 2006–8
(7)
Net YLL
(3)
Death< LE
(4)
Death> LE (5) YLL (6) YLG
1 Infectious
diseases
79.6 83.6 3498 3460 58,686 21,724 36,962
2 Cancer 83.0 84.7 101,203 29,607 1,473,733 126,549 1,347,184
4 Endocrine 81.0 84.7 4068 2696 66,283 15,058 51,225
7 Neurological 79.6 83.3 8370 6983 135,686 41,770 93,917
10 Circulatory 83.0 86.5 96,694 63,157 1,102,020 278,251 823,768
11 Respiratory 80.3 84.0 29,549 35,897 298,343 230,313 68,030
13 Gastrointestinal 80.6 84.5 15,824 8323 273,117 45,414 227,703
17 Genitourinary 83.5 85.6 4969 5655 47,229 29,101 18,127
18+ 19 Maternity and
neonates
78.7 83.1 226 0 16,801 0 16,801
TABLE 13 Summary of cost per life-year threshold
PBC grouping
Using cut-off in estimating YLL
(ONS) (£) Using net YLL estimates (£)
(1) Cut-off
of 75 years
(2) Cut-off of LE of the
general population
(3) Using LE of the
general population
(4) Using LE of the PBC
population (GBD)
All big four programmes 10,398 5487 10,421 8080
11 PBCs (with mortality) 20,031 10,660 19,928 15,628
All 23 PBCs (zero health effects
for remaining 12 PBCs)
73,697 39,218 73,317 57,497
All 23 PBCs (non-zero health
effects for remaining 12 PBCs,
except GMS)a
22,639 12,048 22,523 17,663
a In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal.
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(i.e. some of these deaths are excess). As explained in Years of life lost and accounting for counterfactual
deaths, net YLL calculated in this way is equivalent to first establishing the number of excess deaths
at each age, then calculating YLL for each excess death (based on the LE conditional on the age at which
each excess death occurred) and then summing these YLL across all excess deaths (i.e. across all ages).
In other words, the estimates of net YLL imply a number of excess deaths required to generate them in
each PBC. Therefore, it is possible to solve for the total number of excess deaths based on the net YLL
and the average YLL per observed death.n The net YLL divided by the average YLL per death provides the
number of excess deaths required, which on average will generate the estimated net YLL.o
The implied excess deaths associated with net YLL based on the LE of the PBCs [see Table 12, column (7)]
are reported in Table 14. With the exception of PBC 18 + 19, excess deaths are some proportion of total
observed deaths in each PBC. The proportion of excess deaths differs by PBC reflecting the distribution of
deaths relative to the LE of the PBC.p For example, in those PBCs where a large proportion of deaths occur
below LE [see Table 12, columns (3) and (4)], excess deaths tend to be a greater proportion of the total
deaths (e.g. PBC 2, 13 and 10). Where most deaths occur above LE, excess deaths as a proportion of the
total deaths tend to be lower (e.g. PBC 1, 11 and 17).
Estimates of net YLL and changes in life-years due to expenditure (see Tables 12 and 13) have already
accounted for the fact that not all deaths are excess and don’t generate YLL. Nevertheless, solving for the
number of implied excess deaths associated with these net YLL estimates allows a comparison of the cost
per excess and observed PBC death avoided and an examination of the interpretation that can be placed on
the life-years expected to be gained from an excess or observed death averted. As only deaths observed
in the PBC can be used to estimate the effects of expenditure (excess deaths are not directly observed as
they rely on an unobserved counterfactual population and would occur outside the PBC), the outcome
elasticities can be interpreted as the proportionate change in observed PBC mortality due to a proportionate
change in PBC expenditure. Equally, however, they can also be interpreted as the proportionate effect on
excess death due to a proportionate change in expenditure so can be applied to either total observed or
total excess deaths.q
The cost per excess death and the cost per PBC death averted are reported in Table 15 (see Table 119 in
Appendix 3 for a detailed breakdown of changes in spend and excess or PBC deaths across PBCs). The cost
per PBC death averted is, of course, significantly lower than the cost per excess death as excess deaths are
only a proportion of total deaths (see Table 14). Also the cost per PBC death averted is substantially lower
than those reported in Chapter 3 (see Tables 68 and 69 in Appendix 2), as these estimates do not restrict
the effects of expenditure to PBC deaths under the age of 75 years.r The cost per PBC or excess death
TABLE 14 Excess deaths implied by net YLL
PBC (1) Net YLL
(2) YLL per
observed death
(3) Excess
deaths
(4) Total
deaths
(5) % excess
deaths
1 Infectious
diseases
36,962 13.4 2797 6958 40
2 Cancer 1,347,184 14.1 95,715 130,810 73
4 Endocrine 51,225 13.7 3769 6764 56
7 Neurological 93,917 13.7 6909 15,353 45
10 Circulatory 823,768 10.5 79,218 159,851 50
11 Respiratory 68,030 9.2 7386 65,445 11
13 Gastrointestinal 227,703 15.2 15,199 24,147 63
17 Genitourinary 18,127 8.3 2172 10,625 20
18 + 19 Maternity and
neonates
16,801 73.9 226 226 100
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averted (or life saved) should not be over interpreted as they are of little direct policy interest because lives
are never saved (death is only delayed), and the significance of a death averted depends critically on how
long it is averted for (the YLGs, see Table 13) and the QoL in which additional years are lived (see Adjusting
life-years for quality-of-life).
However, establishing the number of excess and PBC deaths averted which are associated with net YLL is
useful because it enables an assessment of the number of YLGs associated with each death averted. On
average, across all 11 PBCs, each excess death averted is associated with 11.4 YLGs. These are reported for
each PBC in Table 121 in Appendix 3, and range from 74.3 years per excess death for PBC 18 + 19
maternity and neonates to 8.3 years for PBC 17 genitourinary. However, clinicians or the evaluative
literature cannot distinguish whether or not an observed death is excess. What can be observed is whether
or not groups of similar patients with and without access to a treatment survive and for how long.
Therefore, it is the life-years associated with each observed death that provide a context that can be
interpreted based on experience and evidence of how effective those interventions that could be invested
or disinvested intend to be. The average life-years expected to be gained associated with each observed
PBC death averted takes account of the fact that some deaths that are avoided in the PBC are not delayed
for very long but quickly occurs elsewhere and do not generate YLGs (i.e. they were not excess deaths).
These are also reported for each PBC in Table 121 in Appendix 3 and range from 74.3 years per observed
death for PBC 18 + 19 maternity and neonatest to 1.0 year for PBC 11 respiratory problems (i.e. the YLL per
PBC death are much lower for those PBCs where a small proportion of observed deaths are excess).
Each PBC death averted is associated with 4.1 YLGs on average across all 11 PBCs.
Summary of cost per life-year estimates
The sequence of analysis set out above has enabled an examination of the impact of the limitations
associated with the incomplete reporting of mortality data at PCT level and incomplete coverage of
published YLL estimates. We have also been able to consider effects above the age of 75 years while
taking account of that fact that many deaths would have occurred anyway, despite the limited information
available about the population at risk within a PBC. The GBD study does provide some information about
the age and gender distribution of the population at risk in a PBC so offers some improvement over the
other assumptions that would otherwise be required (i.e. that the distribution of age and gender is the
same as the general population or follows the distribution of observed deaths). For this reason the cost per
life-year threshold in column (4) of Table 13 and repeated in lines (1)–(4) in Table 16 are regarded as the
central or best estimates given the evidence available and the credibility of alternative assumptions that
could be made. As explained in the Introduction of this chapter, these are based on the conservative
assumption that any health effects of changes in expenditure are restricted to 1 year, which, to some
extent, may be offset by the more optimistic assumption any death averted returns the individual to the
mortality risk faced by the general population, matched for age and gender.
TABLE 15 Summary of the cost per death averted threshold
PBC grouping
(1) Cost per excess death
averted (£)
(2) Cost per PBC death
averted (£)
All big four programmes 91,129 32,864
11 PBCs (with mortality) 177,692 64,774
All 23 PBCs (zero health effects for remaining 12 PBCs) 653,748 238,310
All 23 PBCs (non-zero health effects for remaining 12 PBCs,
except GMS)a
200,829 73,208
a In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal.
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It does not seem credible to imagine that NHS expenditure has no health effects in the 12 PBCs which do
not have sufficient mortality reported at PCT level to estimate outcome elasticities – what is implied by the
estimate reported in Table 16, line (3). Therefore, it is the estimates reported in Table 16, lines (2) and (4) that
are of policy interest. The estimate of £15,628 per life-year [see Table 16, line (2)] is restricted to the effects
of changes in expenditure in the 11 PBCs where outcome elasticities can be estimated. The threshold of
£17,663 per life-year uses the estimated health effects of expenditure in these PBC as a surrogate for health
effects in the others, that is assuming that the effects that can be observed will be similar to those that
cannot. However, no health effects are assigned to PBC 23 (GMS) on the basis that any health effects of this
expenditure would be recorded in the other PBCs.u
The extreme upper and lower bounds for the cost per life-year thresholds in Table 16 are based on
making the necessary assumptions about duration of health effects and how long a death might be
averted optimistic (providing the lower bound for the threshold) or conservative (an upper bound for the
threshold). The lower bound [see Table 16, lines (5)–(8)] is based on assuming that health effects are not
restricted to 1 year but apply to the whole of the remaining disease duration of the population at risk
in PBCs during the expenditure year.v Although this combines optimistic assumptions, it is possible, indeed
likely, that at least some expenditure may have effects on the health outcomes of future patients who are
not currently part of the population at risk in a PBC (e.g. investments or disinvestment in prevention will
TABLE 16 Summary of the cost per life-year threshold with upper and lower bounds
PBC grouping Cost per life-year threshold
Best estimate
Effect of expenditure on mortality 1 year
YLL per PBC death averted ∼ 4.1a
(1) All big four programmes £8080
(2) 11 PBCs (with mortality) £15,628
(3) All 23 PBCs (zero health effects for remaining 12 PBCs) £57,497
(4) All 23 PBCs (non-zero health effects for remaining 12 PBCs, except GMS)b £17,663
Lower bound
Effect of expenditure on mortality Remainder of disease
YLL per PBC death averted ∼ 4.1a
(5) All big four programmes £3846
(6) 11 PBCs (with mortality) £6106
(7) All 23 PBCs (zero health effects for remaining 12 PBCs) £22,463
(8) All 23 PBCs (non-zero health effects for remaining 12 PBCs, except GMS)b £6901
Upper bound
Effect of expenditure on mortality 1 year
YLL per PBC death averted 2
(9) All big four programmes £16,432
(10) 11 PBCs (with mortality) £32,387
(11) All 23 PBCs (zero health effects for remaining 12 PBCs) £119,155
(12) All 23 PBCs (non-zero health effects for remaining 12 PBCs, except GMS)b £36,604
a See Tables 114, 115 and 118 in Appendix 3.
b In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal.
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have an impact on populations that are incident to PBCs in the future). Such effects are not captured in
any of the estimates presented in this chapter so all are conservative with respect to this type of health
effect of changes in expenditure.
The upper bound [see Table 16, lines (9)–(12)] is based on the combination of assuming that health effects
are restricted to 1 year for the population currently at risk and that any death averted is only averted for
the minimum duration consistent with the mortality data. The econometrics work used the average of
3 years of mortality (2006–8), so the estimated outcome elasticities are based on differences in mortality
that remain after averaging over 3 years. Therefore, the estimated effects are based on differences in
observed PBC deaths that must have been sustained, on average, for more than a minimum of 2 years.w
Adjusting life-years for quality-of-life
The central or best estimates of the cost per life-year threshold, which were presented in Table 16,
lines (2) and (4), take no account of the health-related QoL in which years of life, expected to be gained or
lost through changes in expenditure, are likely to be lived. Even if attention is restricted to the direct health
consequences of changes in mortality, estimates of the cost per life-year will tend to overestimate the effects
of changes in expenditure (i.e. underestimate the threshold) compared with a more complete measure
of health that accounts for the quality in which the years of life are expected to be lived. In this section we
examine the ways in which the life-years reported in From mortality to life-years can be adjusted for quality,
taking account of information that is available about (i) how QoL differs by age and gender (see Quality of life
based on the general population); and (ii) how the quality-of-life-years associated with mortality changes
might be affected by the types of diseases that make up each PBC (see Adjusting age-related quality-of-life for
disease decrements). Throughout, we continue to take account of counterfactual deaths in the way described
in Years of life lost and accounting for counterfactual deaths by making the adjustment for quality to the
life-years associated with every observed death before calculating a quality-adjusted net YLL. The implications
for a cost per QALY threshold that only accounts for the health effects of mortality changes are presented in
Summary of the cost per quality-adjusted life-year threshold based only on mortality effects. In Including
quality-of-life effects during disease we explore the ways in which the likely direct effects of expenditure on
QoL (other than through mortality) might also be taken into account.
Quality of life based on the general population
The most commonly used metric of health-related QoL in the UK is European Quality of Life-5 Dimensions
(EQ-5D),91 which is specified in the NICE reference case for methods of technology appraisal.3 This metric
has five dimensions of quality each with three possible levels. Each of these 243 possible health states is
valued relative to a score of one, which represents full or best imaginable health (the best score across
all five dimensions), and a score of zero, which represents death, based on a representative sample of
the UK population.92 Therefore, insofar as the years of life expected to be gained (or lost) through changes
in expenditure would be lived in this state of full health, the cost per life-year thresholds reported in
Table 16 would also be the cost per QALY thresholds, albeit ones that only account for the health effects
of mortality changes. However, unsurprisingly, there is good evidence that, on average, the general
population is not in this state of full health. Therefore, the QoL score associated with the health states
experienced by the general population are less than 1, decline with age and differ by gender. These QoL
‘norms’ for the general population by age and gender are illustrated in Figure 3 based on an analysis of
data from the Health Survey for England (HSE).x
These QoL norms can be applied to the YLL associated with all observed deaths in each PBC, taking
account of gender and age at death. The results are reported in columns (4)–(6) of Table 17. There are
two effects of adjusting life-years for quality: (i) as QoL norms are always < 1 the adjusted YLL and YLG
are always lower than the unadjusted values in columns (1) and (2) (previously reported in Table 12);
and (ii) deaths above LE are necessarily at older ages with poorer QoL norms than those below, so the
difference between adjusted and unadjusted values is greater for YLG than YLL. The overall effect of
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quality adjustment on net YLL is the balance of these two effects. The overall effect of quality adjustment
is to reduce the net YLL [compare Table 17, columns (3) and (6)].y
The quality adjusted net YLL figures in Table 17, column (6) suggests that the health effects of mortality
are lower than when relying only on unadjusted life-years in From mortality to life-years. Therefore
the health effects of changes in expenditure on this more complete measure of health are lower. The
implications of these adjustments on a cost per QALY threshold that only accounts for the direct health
effects of mortality are reported in Table 18. As expected the cost per QALY threshold based on
adjusting the YLGs or lost [see Table 18, column (2)] is higher than a threshold based on unadjusted
life-years [see Table 18, column (1) and previously reported in Table 16].
Adjusting age-related quality-of-life for disease decrements
Adjusting life-years for age- and gender-related QoL norms assumes that any YLG through a change in
expenditure would be lived in a similar QoL to the general population. It is possible, however, that patients
benefiting from reduced mortality may, nevertheless, continue to be affected by the type of diseases that
make up each PBC and experience the QoL associated with the original disease.
The HODaR93 provides over 30,000 observations of EQ-5D measures of QoL by ICD-10 code and the age
and gender of the patients in the sample (see Appendix 3, Addendum 1: data sources). Although this is a
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FIGURE 3 Quality of life for the general population by age and gender. Pooled QoL estimates provided by personal
communication with Dr Anju Keetharuth, University of Sheffield, 2013.
TABLE 17 Net YLL adjusted for the QoL ‘norms’
PBC
Unadjusted life-years QALYs
(1) YLL (2) YLG (3) Net YLL (4) YLL (5) YLG (6) Net YLL
1 Infectious diseases 58,686 21,724 36,962 47,481 14,618 32,864
2 Cancer 1,473,733 126,549 1,347,184 1,143,445 84,036 1,059,409
4 Endocrine 66,283 15,058 51,225 52,856 9973 42,883
7 Neurological 135,686 41,770 93,917 109,349 28,262 81,087
10 Circulatory 1,102,020 278,251 823,768 848,046 183,330 664,717
11 Respiratory 298,343 230,313 68,030 231,578 154,743 76,835
13 Gastrointestinal 273,117 45,414 227,703 216,256 30,277 185,979
17 Genitourinary 47,229 29,101 18,127 35,929 18,947 16,982
18+ 19 Maternity and neonates 16,801 0 16,801 14,568 0 14,568
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rich UK data set, there were a limited number of observations for some of the less common ICD-10 codes.
For this reason HODaR was supplemented with information from the Medical Expenditure Panel Survey
(MEPS)94 which also provides EQ-5D by ICD-10 and reports the average age of respondents (see Appendix 3,
Addendum 1: data sources). These data provided a means of estimating the QoL associated with each
ICD-10 code at the average age of respondents in the pooled sample.
z
The QoL associated with each PBC
can be expressed as an average of the QoL associated with its component ICD-10 codes.aa The QoL effects
of being in each PBC can then be expressed as a disease-related decrement compared with the population
norms at the same age (see Table 129 in Appendix 3). This is illustrated for PBC 1 (infectious disease)
in Figure 4, where the weighted average of QoL scores across the component ICD-10 codes was 0.667,
at an average age average age of 54 years for male respondents. As the QoL norms for males age
54 years is 0.859 this suggests a decrement associated with membership of PBC 1 of 0.192, which can
then be applied to QoL norms by age.ab
Quality-of-life norms adjusted for disease-related decrements can be applied to the YLL associated with
observed deaths in each PBC, taking account of gender and age at death in the same way as in Quality of
life based on the general population.ac The results are reported in columns (4)–(6) of Table 19. The overall
effect of quality adjustment that also applies a disease-related decrement is to reduce the net YLL to a
greater extent than adjustment with population norms alone [compare column (6) in Table 19 with
column (6) in Table 17].
It should be noted that combining QoL adjustments for both population norms and disease-related
decrements assumes that any YLGs due to a reduction in mortality will be lived in the diseased state
until LE (i.e. that all diseases are not just chronic but disease duration is lifelong). Inevitably this
assumption means that the health effects of changes in mortality will be reduced. Consequently,
the cost per QALY threshold reported in Table 20, column (2) will be higher than adjusting YLGs for
population norms in Table 18.
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FIGURE 4 Quality of life for males in PBC 1 (infectious disease) and the general population by age.
TABLE 18 Summary of cost per QALY threshold based on population norms and mortality effects
PBC grouping (1) Cost per life-year threshold (£) (2) Cost per QALY threshold (population norms) (£)
All big four programmes 8080 9631
11 PBCs (with mortality) 15,628 18,622
All 23 PBCsa 17,663 21,047
a In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal, except GMS.
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Summary of the cost per quality-adjusted life-year threshold based only on
mortality effects
The analysis to this point is summarised in Table 21. The three estimates of a cost per QALY threshold are
based on assuming that each YLG is either lived in full health [see Table 21, column (1), equal to the cost
per life-year estimates in Table 16]; lived in a QoL that reflects age and gender norms of the general
population [see Table 21, column (2)]; or lived in a QoL that reflects the original disease state
[see Table 21, column (3)].
Assuming that YLGs are lived in full health is not credible and should be regarded as an underestimate of
the threshold, given what is known about QoL norms for the general population (see Figure 3). Equally,
assuming that all YLGs are lived in the QoL of the original disease state does not seem credible either and
is likely to overestimate the threshold as it assumes that all disease is not only chronic but lifelong and all
life-years would be lived in the diseased state until death.ad Although adjusting YLGs for the QoL of the
general population, taking account of age and gender [see Table 21, column (2)], is likely to underestimate
a cost per QALY threshold based only on mortality effects, it probably represents the ‘best’ of the three
alternative estimates available at this stage of the analysis (see Using estimates of the QALY burden of
disease for how analysis based on measures of QALY burden allows this assumption to be relaxed).ae
The lower and upper bounds are based on combining optimistic and pessimistic assumptions about the
duration of health effects and how long a death might be averted as described in Summary of cost per
life-year estimates.
TABLE 19 Net YLL adjusted for disease- and age-related QoL
PBC
Unadjusted life-years QALYs
(1) YLL (2) YLG (3) Net YLL (4) YLL (5) YLG (6) Net YLL
1 Infectious diseases 58,686 21,724 36,962 37,055 10,793 26,262
2 Cancer 1,473,733 126,549 1,347,184 955,690 67,930 887,760
4 Endocrine 66,283 15,058 51,225 43,394 7844 35,550
7 Neurological 135,686 41,770 93,917 68,893 15,842 53,050
10 Circulatory 1,102,020 278,251 823,768 656,145 135,241 520,905
11 Respiratory 298,343 230,313 68,030 169,269 106,505 62,764
13 Gastrointestinal 273,117 45,414 227,703 163,593 21,677 141,916
17 Genitourinary 47,229 29,101 18,127 29,749 15,152 14,598
18+ 19 Maternity and neonates 16,801 0 16,801 13,662 0 13,662
TABLE 20 Summary of cost per QALY threshold based on disease-related decrements
PBC grouping (1) Cost per life-year threshold (£)
(2) Cost per QALY threshold
(disease-related decrements) (£)
All big four programmes 8080 12,109
11 PBCs (with mortality) 15,628 23,395
All 23 PBCsa 17,663 26,441
a In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal, except GMS.
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However, it should be noted that these cost per QALY thresholds only account for the direct health effects
of changes in mortality due to changes in expenditure. Insofar as much, or at least some, of NHS activity
and expenditure is intended to improve QoL, not just mortality, then these estimates will underestimate
total health effects and overestimate a cost per QALY threshold based on a more complete measure of
possible health effects. In Including quality-of-life effects during disease we explore the ways in which the
likely effects of expenditure on QoL (other than through mortality) might also be taken into account.
Including quality-of-life effects during disease
The cost per QALY thresholds presented in Adjusting life-years for quality-of-life only account for the
health (QALY) effects of changes in mortality due to changes in expenditure. It does not seem credible to
suppose that all NHS activity and expenditure only influences mortality with no effect on the QoL while
alive and experiencing a disease. Insofar as changes in NHS expenditure will also affect QoL as well as
mortality then total health effects will be underestimated and the thresholds presented in Table 21 will
overestimate the cost per QALY threshold. In this section we explore ways to also take account of those
effects on health not directly associated with mortality and life-year effects (i.e. the ‘pure’ QoL effects)
to estimate an overall cost per QALY threshold.
TABLE 21 Summary of QALY threshold estimates based only on mortality effects
PBC grouping (1) QoL score= 1 (2) QoL norm (3) QoL diseased
Best estimate
Effect of expenditure on mortality 1 year 1 year 1 year
YLL per PBC death averted ∼ 4.1a ∼ 4.1a ∼ 4.1a
QALYs per death averted ∼ 4.1 ∼ 3.5 ∼ 2.8
(1) All big four programmes £8080 £9631 £12,109
(2) 11 PBCs (with mortality) £15,628 £18,622 £23,395
(3) All 23 PBCsb £17,663 £21,047 £26,441
Lower bound
Effect of expenditure on mortality Remainder of disease Remainder of disease Remainder of disease
YLL per PBC death averted ∼ 4.1a ∼ 4.1a ∼ 4.1a
QALYs per death averted ∼ 4.1 ∼ 3.5 ∼ 2.8
(4) All big four programmes £3846 £4252 £5319
(5) 11 PBCs (with mortality) £6106 £6852 £8568
(6) All 23 PBCsb £6901 £7744 £9683
Upper bound
Effect of expenditure on mortality 1 year 1 year 1 year
YLL per PBC death averted 2 2 2
QALYs per death averted 2 ∼ 1.9 ∼ 1.5
(7) All big four programmes £16,432 £17,456 £21,747
(8) 11 PBCs (with mortality) £32,387 £34,492 £42,967
(9) All 23 PBCsb £36,604 £38,983 £48,561
a See Tables 114, 115 and 118 in Appendix 3.
b In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal, except GMS.
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The routine reporting of QoL outcomes is increasingly available at PCT level (see Addendum 1: data
sources in Appendix 3 for a description of these data). In principle, the variation in such measures of
outcome across PCTs could be used to estimate outcome elasticities for QoL rather than mortality effects
using similar econometric methods to those described in Chapter 3 (see Application of method to other
non-mortality-based outcome indicators in Appendix 2 for the results of an exploratory econometric
analysis of these data). However, the currently limited coverage of routine reporting of these outcomes
means that it is not feasible to estimate QoL effects across all the PBCs using these data. In Chapter 5,
Future research and improving estimates of the threshold we discuss how these data might be used to
improve estimates of the threshold as the coverage and routine reporting of QoL outcomes improves, and
how the analysis presented in Chapter 5, Which programme budget categories matter most?, might help
prioritise reporting in particular areas (i.e. those PBCs and ICD-10 codes that have the greatest influence
on estimates of the threshold).
Here we explore how estimates of effects of expenditure that can be observed (i.e. on mortality) can be
used to infer the likely effects on what cannot be directly observed (QoL), rather than making extreme
assumptions that are not credible (e.g. assuming that changes in expenditure will have no effects on
QoL outcomes).
In Using ratios of quality-adjusted life-years to years of life lost we use three alternative estimates of the
ratio of QALYs to life-years lost due to different types of disease as a means of inferring the change in
QALYs that is likely to be associated with the estimated change in YLL (i.e. applying the total QALYs lost
associated with each YLL with disease). This is consistent with regarding the estimates of the mortality
and life-year effects as a surrogate for a more complete measure of the health effects of a change
in expenditure.
However, these ratios of QALYs lost to life-years lost due to disease in those PBCs where outcome
elasticities could not be estimated cannot inform estimates of the threshold (there are no estimated
life-year effects with which to apply the ratios). Nonetheless, the sources of information on which ratios
are based also provides much of the information required to calculate the QALY burden of disease in
these areas, which can be used to inform estimates of the threshold. Therefore, in Using estimates of the
quality-adjusted life-years burden of disease we use estimates of the QALY burden of disease, infer a
proportionate effect on burden from the estimated effects on life-years, and then apply this proportionate
effect to the measures of QALY burden for all the other PBCs. In this way we can use all the information
available about the mortality and QoL effects of the different types of disease that make up each PBC,
including those where mortality-based outcome elasticities are not available.
Using ratios of quality-adjusted life-years to years of life lost
The ratio of the total QALYs to YLL due to a disease indicates the number of QALYs associated with each
YLL. Therefore, any change in YLL is likely to generate a number of QALYs indicated by the ratio – if it is
reasonable to interpret the estimated effects on mortality and life-years as a surrogate for a more complete
measure of total health effects. For example, a disease with a ratio > 1 suggests that each YLL across the
at risk population is associated with more than 1 QALY (i.e. where there are significant QoL effects while
experiencing the disease).af Therefore, a change in expenditure that leads to 1 YLG in this type of disease
may be expected to generate > 1 QALY and a greater QALY effect than the same life-year effects in a
disease where this ratio is < 1 (i.e. where most of the effect of disease is on mortality rather than QoL).
Therefore, information which allows these ratios to be estimated for the diseases that make up each PBC
provides a means of accounting for the likely effect on QoL other than through effects on mortality.
To understand the differences between the three ratios presented below it is useful to regard the total QALY
lost to YLL ratio (R) for a particular disease as the sum of two ratios: (i) the QALYs lost due to premature death
to YLL ratio (Rdeath);
ag and (ii) the QALYs lost during disease (while alive) to YLL ratio (Ralive) (see Using ratios of
quality-adjusted life-year to years of life lost in Appendix 3 for more detailed explanation).
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Disability-adjusted life-year to years of life lost ratios
The WHO GBD study provides UK-specific estimates of the years of life lived with disability (YLD) and
the YLL due to different types of disease (classified by U-codes that can be mapped to ICD-10,
see From mortality to life-years and Addendum 1: data sources in Appendix 3). The GBD study uses
disability-adjusted life-years (DALYs) as a measure of the burden of disease. This DALY measure has two
components: (i) the YLD, which incorporates weights (between 0 and 1) to reflect the scale of disability
experienced each year and the number of YLDs over the durations of disease; and (ii) the YLL. The total
DALY associated with a disease is simply YLL + YLD. Therefore, the DALY to YLL ratio is (YLL + YLD)/
YLL or equivalently YLL/YLL + YLD/YLL. As the first term (YLL/YLL= Rdeath) must equal 1 and the second
(Ralive= YLD/YLL) must be ≥ 0, a ratio based on DALYs must necessarily be bounded below by 1. This is
illustrated in Table 22 for four different types of diseases (classified by U-codes) which reflect diseases
where mortality is the major component (e.g. U016) and where the impact of disease on the QoL while
alive is the major component (e.g. U141).
Adjusting disability-adjusted life-years for quality-of-life norms
The use of DALY ratios bounded below by 1 essentially assumes that YLL would have otherwise been lived
in a state of full health. As was discussed in Quality of life based on the general population this is not
credible given information available about the QoL in the general population (see Figure 3). It would lead
to over estimating the QALYs associated with mortality and life-year effects and underestimating the cost
per QALY threshold. Therefore, it is important to adjust these DALY ratios for the QoL norms by age and
gender in the same way as described in Quality of life based on the general population. The effect of this
adjustmentah is illustrated in Table 23. Now those types of disease where mortality rather than QoL with
the disease is the major component can have ratios < 1. Indeed, the first term of these ratios (Rdeath) is
consistent with, and is implied by, the analysis in Quality of life based on the general population where the
ratio of quality-adjusted net YLL to unadjusted net YLL represents this ratio on average for each PBC.
TABLE 22 Examples of DALY to YLL ratios
U-code DALY ratios (Rdeath+Ralive)
U037 (other infectious diseases) 1.23 (1 + 0.23)
U016 (tetanus) 1.00 (1 + 0)a
U061 (mouth and oropharynx cancers) 1.05 (1 + 0.05)
U141 (spina bifida) 2.34 (1 + 1.34)b
a Given the short disease duration, it is only mortality effects that contribute to the ratio.
b QoL effects during disease contribute significantly to estimates of the ratio.
TABLE 23 Examples of modified DALY to YLL ratios
U-code Modified DALY ratios (Rdeath+Ralive)
U037 (other infectious diseases) 1.01 (0.78 + 0.23)
U016 (tetanus) 0.78 (0.78 + 0)
U061 (mouth and oropharynx cancers) 0.83 (0.78 + 0.05)
U141 (spina bifida) 2.18 (0.85 + 1.34)
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Using quality-of-life estimates (based on Health Outcomes Data Repository
and Medical Expenditure Panel Survey data)
The disability weights used in the DALY measure are not based on the same description of health states
as the EQ-5D measure, nor are the weights based on a representative sample of the UK population
responding to choice-based elicitation questions. EQ-5D-based QoL decrements (adjustments to
age-related QoL norms) associated with different types of disease can be estimated from HODaR and
MEPS data (previously described in Adjusting age-related quality-of-life for disease decrements).ai These
disease-related QoL decrements be can be calculated for each U-code (based on the contributing ICD-10
codes) so can be used to replace the DALY disability weights in Ralive reported in Tables 22 and 23.
aj
This final adjustment is illustrated in Table 24 and turns, what were originally, DALY ratios into EQ-5D
QALY ratios.ak For these reasons we regard the QALY to YLL ratios rather than DALY or modified DALY
ratios as the preferred basis of estimating a cost per QALY threshold that provides a more complete
picture of the likely health effects of changes in expenditure.
Allocating effects at programme budget category level to International
Classification of Diseases codes
Tables 22–24 illustrate how QALY ratios can be calculated for and differ by U-code.al Unsurprisingly, these
ratios differ across the type of diseases that make up each PBC (see Table 147 in Appendix 3). When using
this information to estimate a cost per QALY threshold the mortality and life-year effects observed at PBC
level must be allocated in some way to the component ICD-10 codes before ratios are applied to life-year
effects and the resulting QALY effects are summed across all the contributing ICD-10 codes.am For this
reason it is important to consider how other information might inform the different ways in which the
effects observed at PBC level might be generated by the distribution of impacts at ICD-10 level (i.e. where
investment or disinvestment is likely to occur within the PBC and, therefore, which ICD-10 codes are likely
to contribute most to overall health effects).
An important and complementary element to the econometric analysis of routinely reported information
at PBC level was to investigate whether or not other information, commonly available at a local level
within the NHS, might provide a useful indication of where, within a PBC, investment or disinvestment is
more likely across the NHS. The details of this investigation are reported in Addendum 2: the role of data
on local NHS decisions in Appendix 3. The review of local data sources suggested that there are very
few routinely collected data on investment and disinvestment by local NHS organisations beyond the
high-level aggregate data on spending by PBC which are used in the econometric analysis. Although more
disaggregated data on spending decisions about specific services relevant to particular ICD-10 codes could
in principle be acquired through additional primary research (surveys or freedom of information requests),
this would be costly and with a risk that information acquired in this way may not be complete, consistent
or representative.
In the absence of useful information at a local level it is possible to assume that a change in PBC
expenditure will be allocated equally (on a per-patient basis) across the component ICD-10 codes (i.e. any
investment or disinvestment is equally likely across the population at risk within the PBC). Hospital Episode
Statistics (HES) (see Addendum 1: data sources in Appendix 3) provides information about the costs
associated with each ICD-10 code by PCT so it is possible to establish which ICD-10 codes contribute most
TABLE 24 Examples of QALY to YLL ratios (HODaR and MEPS)
U-code QALY ratios (HODaR and MEPS) (Rdeath+Ralive)
U037 (other infectious diseases) 1.37 (0.78 + 0.60)
U016 (tetanus) 0.78 (0.78 + 0)
U061 (mouth and oropharynx cancers) 0.80 (0.78 + 0.02)
U141 (spina bifida) 1.88 (0.85 + 1.03)
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to the variability in HES costs within a PBC across PCTs. Those that contribute most to this variance might
be expected to be more likely to have been subject to differential investment or disinvestment
across PCTs.an
There are differences in relative weight assigned to ICD-10 code based on the size of the population or its
contribution to variance in HES costs. If investment or disinvestment within a PBC tends to focus on ICD-10
codes representing areas of marginal value, the health effects of a change in PBC expenditure may be
overestimated and a cost per QALY threshold underestimated when allocating effects equally across the
population at risk within each PBC. However, weighting ICD-10 codes based on HES data is likely to favour
those ICD-10 codes which represent more severe disease requiring more hospital care. This may over
represent ICD-10 codes with lower QALY to YLL ratios if mortality effects tend to be a major component
of these types of disease and may be conservative with respect to the health effects of changes
in expenditure.
The implications for a cost per QALY threshold that uses the estimated mortality and life-year effects as a
surrogate for a more complete measure of the likely health effects (i.e. that includes QoL as well as QALY
effects) is summarised in Table 25. These results use the contribution to variance in HES costs to ‘weight’
the different ICD-10 codes within a PBC (when allocating the life-year effects), before applying the QALY
ratios associated with each ICD-10 code (see Table 143 in Appendix 3).
The QALY to YLL ratio implied by this analysis for all 11 PBCs with outcome elasticities is 1.52, which
suggests that every (unadjusted) life-year is associated with 1.52 QALYs on average across these PBCs.
However, this implied QALY ratio differs across these PBCs, ranging from 0.79 in PBC 2 to 15.05 in
PBC 18 + 19 (see Table 145 in Appendix 3). As all the analysis in this section seeks to use the estimated
mortality and life-year effects as a surrogate for a more complete measure of likely health effects, it is the
cost per QALY threshold for all 23 PBCs that is most relevant. As expected, this threshold (£11,638) is
lower than a cost per QALY threshold based only the QoL adjusted YLL effects (£21,047 in Table 21 that
assumes no effects of NHS expenditure on QoL itself). This difference gives some indication of the relative
importance of QALY effects due to avoidance of premature death and the QALY effects of avoiding
disability during disease.
Table 26 reports how the estimated QALY effects for each PBC can be decomposed into that part
associated with life-year effects and that part associated with ‘pure’ QoL effects. These results appear
credible for the first 11 PBCs, where those for which mortality is the major concern have a much greater
share of total QALY effects associated with avoidance of premature death (e.g. PBC 2 and PBC 10)
compared with those where QoL is the major concern (e.g. PBC 7).ao
The ratios of QALYs to YLL due to disease in those PBCs where outcome elasticities could not be estimated
cannot be used to inform estimates of the threshold because there are no estimated life-year effects with
which to apply the ratios. Therefore, as in previous sections, the estimated effect of expenditure on health
for the 11 PBCs with outcome elasticities is applied to the estimated changes in PBC expenditure for the
TABLE 25 Summary of the QALY threshold using QALY to YLL ratios
PBC grouping (1) DALY ratios (£) (2) Modified DALY ratios (£)
(3) QALY ratios
(HODaR and MEPS) (£)
All big four programmes 5402 6419 5990
11 PBCs (with mortality) 9958 11,718 10,297
All 23 PBCs 11,254 13,244 11,638a
a Preferred analysis.
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other 12 PBCs (excluding GMS for the reasons given in From mortality to life-years), i.e. assuming that the
health effects that can be observed from a change in expenditure will be similar to those that cannot.
However, the use of QALY ratios also implies that the share of total health effects between QALY effects
and that part associated with ‘pure’ QoL effects are also similar to those PBC with estimated outcome
elasticities. Summing the different types of health effects across these 11 PBCs suggests that 50% is due
to avoidance of premature death and 50% is due to avoidance of disability. This is clearly not credible
when applied to the other PBCs. For example, to mental health, vision and hearing are likely to have a
much greater share of total health effects associated with QoL effects and very little associated with
premature mortality.
The problem is that using QALY to YLL ratios means that much of the information that is available
about the other 12 PBCs cannot be used to inform the estimates of the cost per QALY threshold.
Fortunately, the sources of information on which ratios are based also provide much of the information
required to calculate the QALY burden of disease in these areas. Using estimates of the quality-adjusted
TABLE 26 Decomposing estimated QALY effects by PBC
PBC
QALY change
(total)
QALY change
(death)
% QALY gained
Due to avoidance of
premature death
Due to avoidance of
disability while alive
2 Cancer 1699 1641 97 3
10 Circulatory 6713 4856 72 28
11 Respiratory 3215 923 29 71
13 Gastrointestinal 3605 1193 33 67
1 Infectious diseases 27 11 40 60
4 Endocrine 2036 323 16 84
7 Neurological 342 52 15 85
17 Genitourinary 12 6 52 48
16 Trauma and injuries 0 0 N/A N/A
18+ 19 Maternity and neonates 273 15 6 94
3 Disorders of blood 1087 547 50 50
5 Mental health 19,828 9979 50 50
6 Learning disability 2990 1505 50 50
8 Problems of vision 2348 1181 50 50
9 Problems of
hearing
621 313 50 50
12 Dental problems 2282 1148 50 50
14 Skin 1021 514 50 50
15 Musculoskeletal 1469 739 50 50
20 Poisoning and
adverse events
426 215 50 50
21 Healthy individuals 1781 896 50 50
22 Social care needs 6566 3304 50 50
23 Other 0 0 N/A N/A
N/A, not applicable.
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life-year burden of disease explores how measures of burden can be used to estimate a cost per QALY
threshold that captures the likely effects of a change in expenditure on all aspects of health while using all
the information that is available about all the PBCs.
Using estimates of the quality-adjusted life-year burden of disease
In this section we use estimates of the QALY burden of disease to infer QALY effects in those PBCs where
the mortality effects of changes in expenditure can be observed and then extrapolate the estimated
proportionate effects to those PBCs where the health effects of changes in expenditure cannot be
observed. The estimated proportionate effect of change in expenditure on the life-year burden of disease
in the 11 PBCs where mortality-based outcome elasticities could be estimated are applied to measures of
QALY burden in each of these PBCs (i.e. effects on the mortality burden of disease are used as a surrogate
for effects on QALY burden). The proportionate effect on burden of disease due to the change in
expenditure across these PBCs can then be applied to measures of QALY burden in the other 11 PBCs
where mortality effects could not be estimated (i.e. the observed effects of changes in expenditure on
burden of disease is extrapolated to the other PBCs where health effects cannot be observed). In this way
we can use all the information available about the mortality and QoL effects of the different types of
disease that make up each PBC, particularly those where mortality-based outcome elasticities are not
available. Applying a proportionate effect to measures of QALY burden of disease is equivalent to
assuming that any effects on life-years are lived at a QoL that reflects a proportionate improvement to the
QoL with disease.ap It also allows QoL effects of changes in expenditure to be included; also based on
proportionate improvement in the QoL with disease.
Previously in Chapter 3 and From mortality to life-years, Adjusting life-years for quality-of-life and Using
ratios of quality-adjusted life-years to years of life lost, expenditure elasticities were not estimated for the
other 11 PBCs where outcome elasticities could not be estimated because the same health effect of
changes in expenditure was assumed (i.e. it did not matter how changes in expenditure was allocated
between them). However, in this section it does matter how the remaining change in expenditure is
allocated between the other 11 PBCs as they have different QALY burdens so different implied health
effects of expenditure. Therefore, expenditure elasticities are estimated for all 23 PBCs (see column 2 of
Table 108 in Appendix 3). However, it is not possible to estimate expenditure equations for all 23 PBCs
simultaneously (see Chapter 5, Future research and improving estimates of the threshold), so the
23 independently-estimated expenditure elasticities do not account for all of the change in overall spend
(i.e. the sum of changes in PBC expenditure based on the estimated PBC expenditure elasticities accounts
for a < 1% change in total spend). This remaining change in total spend is allocated between all 23 PBCs
reflecting their relative share of changes in expenditure based on their estimated expenditure elasticities
[see column (4) of Table 108 in Appendix 3].aq
The total QALY burden of disease for the population with disease in a particular year includes
(i) the quality-adjusted YLL due to all the disease-related mortality that could occur in this population
over their remaining duration of disease; and (ii) the reduction in QoL while alive also for their remaining
disease duration. However, applying the estimated proportionate effects on mortality and life-years to
such a measure of total burden would provide an estimate of the effects of a change in expenditure, not
just in 1 year, but in all the remaining years of disease for the population at risk in that year. Recall from
From mortality to life-years that we have adopted the conservative assumption that changes in expenditure
will only have health effects in 1 year for the population with disease in that year. Therefore it is not a
measure of total burden that is required, but a measure of the QALY burden of disease during 1 year for
the population with disease (prevalent and incident) in that year. The estimated outcome elasticities can
then be appropriately applied to this measure of burden.ar
The information from GBD used to derive QALY ratios in Using ratios of quality-adjusted life-years to years
of life lost includes information about the YLL and duration of disease for those incident to a U-code
[i.e. the measure of QALY burden from the information included in the ratios is a measure of the total
burden of the disease, but only for the population that is incident (rather than the total population with
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disease) in 1 year]. Assuming that incidence is stable over the disease duration, this is also equivalent to
the QALY burden of disease during 1 year for the population with disease (i.e. those that are incident and
prevalent) in that year.as
However, in moving from ratios to absolute measures of burden it becomes more important to examine
and then adjust for any inconsistency between information about YLL and size of the incident population
from GBD (which is available by U-codes and can be mapped to ICD-10 codes), and the information about
net YLL and observed deaths for each PBC based on ONS data as described in Inferring excess deaths
(see Table 146 in Appendix 3).a
t
The implications for the cost per QALY threshold of using information about the QALY burden of disease
for all PBCs rather than QALY ratios for those where an outcome elasticity can be estimated are reported
in Table 27. The QALY effects of a change in PBC expenditure are a weighted average of the QALY effects
within each of the ICD-10 codes that contribute to the PBC. The figures reported in Table 27, column (2)
are based on weighing the effects at ICD-10 level by the proportion of the total PBC population
within each contributing ICD-10 code, rather than the contribution to variance in HES costs.a
u
The cost per QALY threshold for the 11 PBCs with outcome elasticities is lower using a measure of
QALY burden (£5128) rather than the QALY ratios (£10,297) described in Mortality and years of life lost.
This is in part because GBD calculates YLL in the same way as published NHS IC figures and so will tend to
overestimate a net YLL which accounts for counterfactual deaths (see Years of life lost and accounting for
counterfactual deaths). This will make little difference to the first term in the QALY ratio (Rdeath) used
in Mortality and years of life lost coverage as an overestimate of YLL affects both denominator and
numerator of the ratio. However, the second term (Ralive) is likely to be underestimated. Therefore the ratios
used in Using ratios of quality-adjusted life-years to years of life lost will tend to underestimate the QALY
effects of expenditure and overestimate the cost per QALY threshold (see Table 27). We are able to adjust
the GBD-based measure of QALY burden for this overestimation of net YLL in calculating the QALY
threshold reported in Table 27, column (2).av
As the purpose of this section is to use the estimated mortality and life-year effects as a surrogate for a
more complete measure of likely health effects, it is the cost per QALY threshold for all 23 PBCs that is of
most relevance. The cost per QALY threshold for all 23 PBCs is based on applying the proportionate effects
on the QALY burden of disease, based on the observed effects of changes in expenditure on mortality in
the 11 PBCs with outcome elasticities,aw to the QALY burden of disease in the other PBCs. This generates
a higher cost per QALY threshold (£10,187) than the one based only on the 11 PBCs with outcome
elasticities (£5128). The reason is that the QALY burden of disease in the other PBCs is, in general, lower
than the QALY burden of disease across those PBCs where outcome elasticities can be estimated
(see Table 147 in Appendix 3). Therefore, applying the same proportionate effects to a lower QALY
burden generates a smaller health effect of a change in expenditure.a
x
TABLE 27 Summary of the cost per QALY threshold
PBC grouping
Cost per QALY gained (£)a
(1) QALY ratios (HODaR and MEPS) (2) QALY burden (HODaR and MEPS)
All big four programmes 5990 3036
11 PBCs (with mortality) 10,297 5128
All 23 PBCs 11,638 10,187a
a Preferred analysis.
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In essence the difference between the estimates in Table 27 is that in column (1) the absolute effect on
health associated with an absolute change in expenditure is extrapolated to the other PBCs, whereas in
column (2) it is the relative effect on health of an absolute change in expenditure that is extrapolated. As
we know that QALY burden differs between (and within) PBCs and especially between the groups of PBCs
with and without estimated outcome elasticities (see Table 147 in Appendix 3),ay it is the values based on
QALY burden in column (2) that are regarded as most credible and represent our central or best estimate.
A detailed breakdown of changes in expenditure and changes in QALYs across all PBCs is provided in
Table 150 in Appendix 3, both when the analysis is based on QALY ratios and when it is based on QALY
burden of disease. A comparison of these values suggests that QALY effects for the other PBCs are
generally lower and therefore the cost per QALY for each of these PBCs are, in general, higher when based
on a proportionate effect on QALY burden. Of course, we have not directly observed QoL effects in these
PBCs but inferred them from the proportionate effects that we can observe. Insofar as investment and
disinvestment opportunities in these PBCs might have been more valuable (offered greater improvement
in QoL)a
z
than suggested by the implied PBC thresholds, then overall QALY effects will tend to be
underestimated and the cost per QALY threshold overestimated. For the reasons discussed in previous
sections, we regard all the costs per QALY threshold reported in column (2) of Table 27 as on balance
conservative with respect to overall health effects of a change in expenditure. However, the estimate of
£10,187 may be conservative with respect to health effects (i.e. overestimated), as it is based on an
extrapolation of the proportionate effects to measures of burden on these PBCs, rather than observations
of the direct impact of changes in expenditure on QoL in these types of disease. This is especially important
in PBC 5 (mental health disorders), which accounts for a large proportion of the change in overall
expenditure (22%) and where a review of the evidence suggests that the investment and disinvestment
opportunities in this PBC may have been more valuable than the implied PBC cost per QALY of £13,876
(see Table 155, Appendix 3 and Addendum 3: characterisation of the investment and disinvestment decisions
in mental health – depression and schizophrenia).az The lower cost per QALY threshold for the 11 PBCs with
outcome elasticities (£5128) might be regarded as more secure in this respect but they only account for a
proportion (38%) of any change in overall expenditure (see Table 155 in Appendix 3).
Table 28 reports how the estimated QALY effects based on measures of QALY burden for each PBC can be
decomposed into that part associated with life-year effects adjusted for quality and that part associated with
‘pure’ QoL effects. These results are similar to those reported in Table 26 which were based on QALY ratios
for the 11 PBCs with an estimated outcome elasticity. Those PBCs for which mortality is the major concern
have a much greater share of total QALY effects associated with avoidance of premature death (e.g. PBC 2
and PBC 10) compared with those where QoL is the major concern (e.g. PBC 7). The differences tend to
favour QALYs gained though avoidance of disability, which reflects the underestimation of the effects on
‘pure’ QoL when using QALY ratios based on estimates of YLL from GBD (see the discussion above).aaa
The QALY to YLL ratios that are implied by this analysis are reported in Appendix 3, Table 152. As expected
the implied QALY ratio across all 11 PBCs with outcome elasticities is higher (3.05aab) than reported in Using
ratios of quality-adjusted life-years to years of life lost because the previous bias against QoL effects by using
QALY ratios based on unadjusted GBD information has been removed.
In Using ratios of quality-adjusted life-years to years of life lost the ratios of QALYs to YLL due to disease
in those PBCs where outcome elasticities could not be estimated could not be used to inform estimates
of the threshold or indicate how any total health effects in these other PBCs are likely to be ‘shared’
between life-year effects adjusted for quality and that part associated with ‘pure’ QoL effects (see Table 26).
By applying the observed proportionate effects of changes in expenditure to measures of QALY burden
of disease in these other PBCs, the likely share of any effects on QALYs between avoidance of premature
mortality and avoidance of disability more closely reflect the nature of these types of diseases (see Table 28).
As expected, a much greater proportion of QALY effects are associated with QoL during the disease
compared with the 11 PBCs where mortality-based outcome elasticities could be estimated. The share
of effects in particular PBCs are also much more credible. For example, in PBC 5 (mental health disorders)
the overwhelming share of QALY effects are associated with QoL itself and for others, such as PBC 12
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(dental problems), PBC 9 (problems of hearing) and PBC 8 (problems of vision); almost all effects are
associated with QoL rather than mortality and life-years. For this, and the other reasons discussed above,
the analysis based on measures of QALY burden are regarded as the best estimate of a cost per QALY ratio
that reflects a more complete picture of the likely health effects of changes in overall expenditure.
Summary of the cost per quality-adjusted life-year threshold
The results of the three sequential steps of analysis described in this chapter are summarised in Table 29.
In From mortality to life-years we explored ways in which the estimated effects on mortality from the
econometrics work in Chapter 3 might be better translated in to life-year effects by overcoming some of
the limitations of mortality data available at PCT level and taking account of counterfactual deaths. The results
of this analysis were reported in Table 28 and are repeated in column (1) of Table 29.aac In Adjusting life-years
for quality-of-life we considered how the estimated life-year effects might be adjusted for the QoL in which
they are likely to be lived, taking account of the gender and the age at which life-years are gained or lost
(see Table 21). The results of this analysis are repeated in column (2) of Table 29. Finally in Including
TABLE 28 Decomposing estimated QALY effects by PBC
PBC
(1) QALY change
(total)
(2) QALY change
(death)
% QALY gained
(3) For premature
death
(4) For disability
while alive
2 Cancer 2121 1968 93 7
10 Circulatory 8347 5727 69 31
11 Respiratory 28,072 1072 4 96
13 Gastrointestinal 3922 1446 37 63
1 Infectious diseases 74 13 18 82
4 Endocrine 6905 380 5 95
7 Neurological 1361 60 4 96
17 Genitourinary 34 8 22 78
16 Trauma and injuries 0 0 N/A N/A
18+ 19 Maternity and neonates 14 10 69 31
3 Disorders of blood 1215 62 5 95
5 Mental health 10,878 949 9 91
6 Learning disability 207 41 20 80
8 Problems of vision 561 22 4 96
9 Problems of hearing 1168 9 1 99
12 Dental problems 578 1 0 100
14 Skin 103 38 37 63
15 Musculoskeletal 1005 50 5 95
20 Poisoning and
adverse events
42 7 16 84
21 Healthy individuals 40 6 16 84
22 Social care needs 0 0 N/A N/A
23 Other 0 0 N/A N/A
N/A, not applicable.
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TABLE 29 Summary of cost per QALY threshold estimates
PBC grouping
(1) From mortality to
life-years analysis
(2) Adjusting life-years for
quality-of-life analysis
(3) Including quality-of-life
effects during disease analysis
QoL associated
with life extension
1 Norm
QoL during disease 0 0 Based on burden
Best estimate
Effect of
expenditure
on mortality
1 year 1 year 1 year
YLL per death
averted
∼ 4.1 ∼ 4.1 ∼ 4.1
QALYs per death
averted
∼ 4.1 ∼ 3.5 ∼ 14.9
(1) All big
four programmes
£8080 £9631 £3036
(2) 11 PBCs
(with mortality)
£15,628 £18,622 £5128
(3) All 23 PBCs £17,663 £21,047 £10,187
Lower bound
Effect of
expenditure
on mortality
Remainder of disease duration Remainder of disease duration Remainder of disease duration
YLL per death
averted
∼ 4.1 ∼ 4.1 ∼ 4.1
QALYs per death
averted
∼ 4.1 ∼ 3.5 ∼ 14.9
(4) All big
four programmes
£3846 £4252 £674
(5) 11 PBCs
(with mortality)
£6106 £6852 £860
(6) All 23 PBCs £6901 £7744 £1843
Upper bound
Effect of
expenditure
on mortality
1 year 1 year 1 year
YLL per death
averted
2 2 2
QALYs per death
averted
∼ 2 ∼ 1.9 ∼ 7.2
(7) All big
four programmes
£16,432 £17,456 £6292
(8) 11 PBCs
(with mortality)
£32,387 £34,492 £10,626
(9) All 23 PBCs £36,604 £38,983 £21,111
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quality-of-life effects during disease we explored ways to also take account of the likely effects of changes in
expenditure on QoL during disease as well as the effects associated with mortality and life-years [see Table 29,
column (3)]. These estimates provide our central estimate of a cost per QALY threshold, because they make
best use of available information while the assumptions required, which on balance are likely to be
conservative with respect to health effects, appear more reasonable than the other alternatives available.aad
The estimate of £5128 per QALY [see Table 29, line (2)] is restricted to the effects of changes in expenditure
in the 11 PBCs where outcome elasticities can be estimated. Although this might be regarded as more
secure, these PBCs only account for a proportion of a change in overall expenditure [approximately 38%,
see column (6) in Table 108 in Appendix 3]. The threshold of £10,187 uses the estimated proportionate
effects of expenditure on the QALY burden of disease in these PBCs as a surrogate for proportionate effects
in the others (i.e. assuming that the effects that can be observed will be similar to those that cannot).
As discussed in Using estimates of the quality-adjusted life-years burden of disease there are reasons to
suspect that this may underestimate health effects in these PBCs which have most influence on the overall
threshold. As in previous sections, no health effects are assigned to PBC 23 (GMS) on the basis that any
health effects of this expenditure would be recorded in the other PBCs.aae Therefore, the best or central
estimate of cost per QALY threshold is £10,187 [see Table 29, column (3), line (3)]. However, this estimate
reflects changes in undiscounted QALYs associated with changes in expenditure. Although all the health
effects of a change in expenditure are restricted to 1 year (so no discounting is necessary) some of the
QALY effects of a change in mortality in that year will occur in future years, so in principle should be
discounted. However, discounting these life-year effects, even at the higher rate of 3.5% recommended
by NICE, only increases the cost per QALY threshold to £10,333 (see Table 154 in Appendix 3 for
discounted values).
As in previous sections of this chapter, the upper and lower bounds for the cost per QALY thresholds in
Table 29, column (3) are based on making the necessary assumptions about duration of health effects
and how long a death might be averted optimistic (providing the lower bound for the threshold) or
conservative (providing an upper bound for the threshold). The lower bound [see Table 29, lines (4)–(6)] is
based on assuming that health effects are not restricted to 1 year but apply to the whole of the remaining
disease duration of the population at risk in PBCs during 1 year. Although this combines optimistic
assumptions, it is possible that at least some part of a change in expenditure may prevent disease so will
have an impact on populations that are incident to PBCs in the future. Such effects are not captured in any
of the estimates presented in this chapter so all are conservative with respect to this type of health effects
of expenditure. The upper bound [see Table 29, lines (7)–(9)] is based on the combination of assuming that
health effects are restricted to 1 year for the population currently at risk and that any death averted is only
averted for 2 years (see Summary of cost per life-year estimates).
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Chapter 5 Implications for a policy threshold
Introduction
The three sequential steps of analysis, which provide a cost per life-year threshold (see Chapter 4, From
mortality to life-years) through a cost per life-year adjusted for quality (see Chapter 4, Adjusting life-years
for quality-of-life) to a cost per QALY threshold (see Chapter 4, Including quality-of-life effects during
disease), have been explained in Chapter 4 using the analysis of 2006 expenditure and mortality data from
2006 to 2008 (see Instrumental variable estimation in Chapter 3 and Model estimation using 2006/7
expenditure data and mortality data for 2006/7/8: CARAN need and two market forces factors in
Appendix 2) to illustrate the implications for the threshold estimates. At each step we explored the
different ways that routinely available data could be used and how additional information could improve
our estimates. In doing so we identified a preferred analysis at each stage based on which made the best
use of available information, whether or not the necessary assumptions appeared more reasonable than
the alternatives available, and which provided a more complete picture of the likely health effects of a
change in expenditure. Although other assumptions and judgements are possible that retain some level of
plausibility, they do not necessarily favour a higher threshold. Indeed, when considered together, they
suggest that on balance the central or best estimate presented in Chapter 4 and in Table 30 is, if anything,
likely to be an overestimate (see How uncertain are the estimates and what are the implications? for a
more detailed discussion and summary). In Future research and improving estimates of the threshold we
discuss how some of these remaining uncertainties might be resolved through access to additional and
better data and the type of analysis that would then be possible.
Re-estimating the cost per quality-adjusted life-year threshold
using more recent data
The same methods of analysis can be applied to the econometric analysis of the 2008 expenditure and
2008 to 2010 mortality data (see 2008/9 expenditure data and mortality for 2008/9/10 in Chapter 3 and
The correlation between the outcome and expenditure elasticities in Appendix 2). The differences between
the 2006 analysis reported in Chapter 4 and the analysis of expenditure in 2008 reported below are the
(i) total PBC expenditure; (ii) estimated expenditure elasticities; (iii) estimated outcome elasticities;
(iv) observed PBC deaths by age and gender; and (v) LE by age and gender. The other information about
QoL norms (see Chapter 4, Quality of life based on the general population), disease-related decrements
in QoL (see Chapter 4, Adjusting age-related quality-of-life for disease decrements) and the information
from GBD about incidence and duration of disease remain unchanged between 2006 and 2008
(we discuss how these estimates might be improved through access to more recent and better data
in Future research and improving estimates of the threshold).
It should be noted that important improvements were made to the classification and collection of PBC
expenditure data that took place after the 2006 data were collected. Therefore, the differences in
threshold estimates between 2006 and 2008 partly reflect this (see Comparing the cost of life-year
estimates associated with different data sets in Chapter 3 and Comparing the cost of life-year estimates
associated with different data sets in Appendix 2) so should not be overinterpreted. The results of
the analysis of 2007 and 2008 expenditure are comparable in this respect, providing insights into how the
threshold might change over time and with changes in the overall budget. The implications of this analysis
on the need for periodic reassessment are discussed in How does the threshold change with overall
expenditure? For the purposes of this methodological research the 2008 expenditure and 2008–10
mortality data were the latest to be analysed. As it is the analysis of the most recent data that is of most
policy relevance, our discussion throughout this section is based on analysis of 2008 expenditure, although
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TABLE 30 Summary of cost per QALY threshold estimates (expenditure in 2008)
PBC grouping
(1) From mortality to
life-years analysis
(2) Adjusting life-years
for quality-of-life analysis
(3) Including quality-of-life
effects during disease analysis
QoL associated with
life extension
1 Norm
QoL during disease 0 0 Based on burden
Best estimate
Effect of expenditure
on mortality
1 year 1 year 1 year
YLL per death averted ∼ 4.5 ∼ 4.5 ∼ 4.5
QALYs per death averted ∼ 4.5 ∼ 3.8 ∼ 15.0
(1) All big
four programmes
£10,220 £12,338 £4872
(2) 11 PBCs
(with mortality)
£23,360 £28,045 £8308
(3) All 23 PBCs £25,214 £30,270 £12,936
Lower bound
Effect of expenditure
on mortality
Remainder of disease
duration
Remainder of disease
duration
Remainder of disease
duration
YLL per death averted ∼ 4.5 ∼ 4.5 ∼ 4.5
QALYs per death averted ∼ 4.5 ∼ 3.8 ∼ 15.0
(4) All big
four programmes
£5083 £5811 £1194
(5) 11 PBCs
(with mortality)
£8579 £9861 £1175
(6) All 23 PBCs £9260 £10,644 £2018
Upper bound
Effect of expenditure
on mortality
1 year 1 year 1 year
YLL per death averted 2 2 2
QALYs per death averted ∼ 2 ∼ 1.4 ∼ 6.6
(7) All big
four programmes
£23,346 £26,138 £11,040
(8) 11 PBCs
(with mortality)
£52,936 £59,151 £18,827
(9) All 23 PBCs £57,136 £63,844 £29,314
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the same sensitivity analysis (see Which programme budget categories matter most?) and analysis of
uncertainty (see How uncertain are the estimates and what are the implications?) is available for 2006 and
2007 expenditure (see How uncertain are the estimates? in Appendix 3).
It is unnecessary to repeat all the analysis presented in Chapter 4, From mortality to life-years, Adjusting
life-years for quality-of-life and Including quality-of-life effects during disease (the details of each stage of
the analysis of 2008 data can be found in Appendix 3). Instead the results of the three sequential steps
of analysis are summarised in Table 30. They include (i) the cost per life-year [see Table 30, column (1)],a
based on the methods of analysis outlined in Chapter 4, From mortality to life-years; (ii) the cost per
life-year adjusted for QoL [see Table 30, column (2)],b based on the methods of analysis outlined in
Chapter 4, Adjusting life-years for quality-of-life; and (iii) the cost per QALY [see Table 30, column (3)],
based on the methods of analysis outlined in Chapter 4, Using estimates of the quality-adjusted life-year
burden of disease. These estimates, in Table 30, column (3), take account of the likely effects of changes
in expenditure on QoL during disease as well as the effects associated with mortality and life-years; making
best use of available information, while the assumptions required appear more reasonable than the other
alternatives available. For this reason these estimates remain our central or best estimates for all the waves
of expenditure and mortality data.
The estimate of £8308 per QALY [see Table 30, column (3), line (2)] is restricted to the effects of changes
in expenditure in the 11 PBCs where outcome elasticities can be estimated. However, these PBCs only
account for a proportion of the change in overall expenditure (approximately 50%, Table 31). As was
explained in Chapter 4, Using estimates of the quality-adjusted life-year burden of disease and Summary of
the cost per quality-adjusted life-year threshold, the QALY threshold of £12,936 [see Table 30, column (3),
line (3)] uses the estimated proportionate effects of expenditure on the QALY burden of disease in the
11 PBCs as a surrogate for proportionate effects in the others (i.e. assuming that the effects that can be
observed will be similar to those that cannot), and represents our central or best estimate. As in previous
sections, no health effects are assigned to PBC 23 or 22 (GMS and social care) on the basis that any
health effects of this expenditure would be recorded in the other PBCs.c Although this estimate of
£12,936 reflects changes in undiscounted QALYs associated with changes in expenditure, discounting
the QALY effects only increases the cost per QALY threshold to £13,141.d
The upper and lower bounds for the cost per QALY thresholds in column (3) in Table 30 are based on
making the necessary assumptions about duration of health effects of expenditure and how long a death
might be averted optimistic (providing the lower bound for the threshold) or conservative (providing an
upper bound for the threshold). The lower bound [see Table 30, lines (4)–(6)] is based on assuming that
the health effects of expenditure are not restricted to 1 year but apply to the whole of the remaining
disease duration of the population at risk in PBCs during 1 year. Although this combines optimistic
assumptions, it is possible that at least some part of a change in expenditure may prevent disease so will
have an impact on populations that are incident to PBCs in the future. Such effects are not captured in any
of the estimates presented in this report so all estimates are conservative in this respect (the possibility of
a longer and more complex lag structure for the effects of expenditure are discussed in Future research
and improving estimates of the threshold). The upper bound [see Table 30, lines (7)–(9)] is based on the
combination of assuming that health effects are restricted to 1 year for the population currently at risk and
that any death averted is only averted for 2 years (see Chapter 4, Summary of cost per life-year estimates).
The estimated QALY effects associated with each PBC can be decomposed into that part due to life-year
effects adjusted for quality and that part associated with effects on QoL during disease. The proportionate
share of these different aspects of the total health effects are the same as reported in Table 28; where
those PBCs for which mortality is the major concern have a much greater share of total QALY effects
associated with avoidance of premature death (e.g. PBC 2 and PBC 10) than those where QoL
is the major concern (e.g. PBC 7).
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Which programme budget categories matter most?
Which PBCs have the greatest influence on the overall threshold depends, to a large extent, on how a
change in overall expenditure is allocated to the different PBCs [see column (1) in Table 31],e i.e. those that
account for a greater share of the change in expenditure will tend to have the greater influence. However,
it also depends on the proportionate effect of a change in PBC expenditure on the QALY burden
associated with the PBCf and the scale of the QALY burden (for the population at risk) associated with the
type of diseases that make up each PBC.g These determine the cost per QALY associated with each PBC
TABLE 31 Impact of each PBC on the overall cost per QALY threshold (2008)
PBC
(1) % Share of change
in overall expenditure
(2) % Share of total
health effects (QALY)
(3) Elasticity of
the thresholda
(4) PBC cost
per QALY (£)
2 Cancer 4.47 3.41 0.34 16,997
10 Circulatory 7.59 13.95 1.40 7038
11 Respiratory 4.58 29.67 2.97 1998
13 Gastrointestinal 3.20 5.68 0.57 7293
1 Infectious
diseases
3.27 2.03 0.20 20,829
4 Endocrine 1.89 7.84 0.78 3124
7 Neurological 5.98 14.11 1.41 5480
17 Genitourinary 4.64 1.37 0.14 43,813
16 Trauma and
injuries
7.70 0 0 N/A
18+ 19 Maternity and
neonates
6.83 0.03 < 0.01 2,969,208
3 Disorders of
blood
2.06 2.82 0.28 9419
5 Mental health 17.86 12.32 1.23 18,744
6 Learning
disability
1.04 0.09 0.01 149,883
8 Problems of
vision
1.94 0.55 0.05 45,788
9 Problems of
hearing
0.87 1.81 0.18 6239
12 Dental problems 2.89 0.88 0.09 42,472
14 Skin 1.97 0.25 0.03 101,042
15 Musculoskeletal 3.63 3.00 0.30 15,628
20 Poisoning and
adverse events
0.93 0.11 0.01 113,546
21 Healthy
individuals
3.53 0.09 0.01 526,771
22 Social care
needs
3.00 0 0 N/A
23 Other 10.14 0 0 N/A
N/A, not applicable.
a The proportionate change in the overall cost per QALY threshold due to a 10% increase or decrease in the health effects
associated with the PBC. These elasticities are correct up to a 50% change in health effects.
IMPLICATIONS FOR A POLICY THRESHOLD
NIHR Journals Library www.journalslibrary.nihr.ac.uk
76
[see Table 31, column (4) and Table 180 in Appendix 3]. The share, attributable to each PBC, of the total
health effects of a change in overall expenditure [see column (2) of Table 31] is the combined effect of
all of these. The proportionate impact on the overall cost per QALY threshold of a 10% change in PBC
health effects in Table 31, column (3) gives an indication of how sensitive the overall threshold is to the
estimate of health effects associated with each PBC. It starts to suggest where further efforts to
improve estimates of the overall threshold might be most usefully directed.
Although the 11 PBCs where outcome elasticities could be estimated only account for 50% of the change
in overall expenditure, they account for 78% of the overall health effects. Within this group some PBCs
contribute more than others. For example, PBC 11 (respiratory) accounts for a greater share of total health
effects and has a higher elasticity (2.97%) than PBC 10 (circulatory) even though the latter accounts for a
greater part of a change in overall expenditure. The reason is that the cost per QALY associated with
changes in expenditure in PBC 11 is lower than PBC 10 and much lower than the overall threshold
(so generates more health effects for the same, or even smaller, change in expenditure).h The elasticities in
Table 31, column (3), are instructive, for example the elasticity for PBC 11 suggests that even if the health
effects of a change in expenditure in this PBC were overestimated by 30% the overall threshold would
increase by 8.90% to £14,089. All other PBCs have much less influence in this respect. Nonetheless,
PBC 10 is important compared with others as it does contribute a large share of total health effects and
has one of the highest elasticities (1.40%).i Also PBC 7 (neurological), although accounting for a smaller
share of a change in overall expenditure, does contribute a large share of total health effects with an
elasticity of 1.41% and a relatively low cost per QALY associated with changes in PBC expenditure.j
The other 11 PBCs, where outcome elasticities could not be estimated (excluding PBC 23, GMS) account
for a large part of a change in overall expenditure (40%) but only 22% of the overall health effects
(i.e. the cost per QALYs associated with a change in expenditure in these PBCs is, in general, higher).
Of course, we have not directly observed QoL effects in these PBCs but inferred them from the
proportionate effects that we can observe. Insofar as investment and disinvestment opportunities in these
PBCs might have been more valuable (i.e. offered greater improvement in QoL) than suggested by the
implied PBC thresholds in Table 31, column (4), the overall QALY effects will tend to be underestimated
and the overall cost per QALY threshold will be overestimated.
Programme budget category 5 (mental health disorders) accounts for a large proportion of the change in
overall expenditure (18%), contributes most to the overall health effects (12%) and has the highest
elasticity (1.23%) compared with these other PBCs. The cost per QALY associated with this PBC (£18,744)
is based on an extrapolation of estimated proportionate effects to a population-based measure of QALY
burden in this PBC, rather than observations of the direct impact of changes in expenditure on QoL in the
types of diseases that make up the PBC. Evidence that is available suggests that the investment and
disinvestment opportunities in this PBC may have been more valuable than this implied cost per QALY.
A review of the evidence of the cost-effectiveness of the investment and disinvestment opportunities that
have been available in mental health during this period is reported in Appendix 3, Addendum 3:
characterisation of the investment and disinvestment decisions in mental health – depression and
schizophrenia. A search for evidence about interventions in those ICD-10 codes that contribute most to the
PBC (based on prevalence or the contribution to the variance in PBC costs), suggests that pharmacological,
psychological and social interventions for depression are all more cost-effective (in general much
< £10,000 per QALY) than the overall threshold, and significantly more valuable than the implied QALY
threshold for this PBC. Based on the contribution that each ICD-10 code makes to variance in HES costs
across PCTs, it is schizophrenia that contributes most.k Although interventions that may have been invested
or disinvested in in schizophrenia are, in general, less cost-effective (in general < £24,000 per QALY) than
those available for depression, they do not appear any less valuable than the implied cost per QALY of this
PBC in Table 31.l
It is very important not to misinterpret the cost per QALY associated with each PBC in column (4) of
Table 31. These are not cost-effectiveness thresholds. That is, they do not represent the QALYs likely to be
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forgone due to costs imposed (e.g. by the approval of a new and more costly technology by NICE) in a
particular PBC because NHS expenditure is not devolved and constrained to PBC specific budgets. Rather,
the overall expenditure is constrained through government decisions about public expenditure, but within
the NHS resources (at the margin at least) can be reallocated in anything other than the very short run
across different activities and disease areas. For example, the additional net NHS costs of approving a new
but more costly technology in PBC 10 (circulatory) will not be restricted to the circulatory PBC [7.6% will,
see column (1) in Table 31], but are likely to be reallocated in the same way as an equivalent reduction in
overall expenditure [i.e. the shares of a change in overall expenditure in Table 31, column (1)].m Therefore,
the relevant cost per QALY threshold for a technology in the circulatory PBC is not £7038 but the overall
threshold of £12,936.
The primary purpose of Table 31 is to identify which PBCs have greatest influence on the estimate of the
overall threshold and examine whether the implied values for the other PBCs are likely to lead to under- or
overestimation. There are differences in the implied cost per QALY ratio between PBCs, including some with
very high implied cost per QALY (e.g. PBCs 18 + 19, 20 and 21 reflecting small estimated health effects in
the denominator), although they have limited influence on the overall estimate of the threshold. These
differences in the implied cost per QALY across PBCs should not be overinterpreted. For example, these
differences could be interpreted as evidence of a misallocation of resources (e.g. reallocating expenditure
from PBCs with higher to lower cost per QALY would improve health) if the purpose of the NHS and PCTs is
to maximise unweighted QALYs. However, rather than a misallocation, these differences (between the first
11 PBCs) might indicate that the actual QoL effects of expenditure are proportionally greater (lower) than
mortality effects in those with a higher (lower) cost per QALY, or that the health effects in these PBCs are
more socially valuable with a greater implicit weight attached to QALYs gained or lost in these areas
(e.g. maternity and neonates). The higher cost per QALY for the remaining PBCs may reflect that the actual
QoL effects of changes in expenditure may be more than proportional to QALY burden (e.g. evidence from
mental health PBC suggests that investment and disinvestment opportunities may have been more valuable
than the implied PBC cost per QALY of £18,744). Additionally, it was not possible to estimate the health
effects of changes in PBC expenditure simultaneously across PBCs. Consequently, the effects of changes in
expenditure in one PBC may be recorded in ICD-10 codes relevant to other PBCs, so it is possible that PBCs
with a higher implied cost per QALY may be contributing health effects to other (recipient) PBCs.n
Whether or not these differences are regarded as evidence of a misallocation, however, is unimportant
for an estimate of a cost per QALY threshold that reflects the health effects of how changes in overall
expenditure are currently expected to be allocated. Whether or not PCTs do or should maximise QALYs
has no influence on the current estimate of the threshold, given that NICE currently uses an unweighted
QALY threshold.o In addition, insofar as local objectives do change or national policy does reallocate
expenditure, the impact of these and other changes that will take place over time will be reflected in
estimates of the threshold in subsequent periods once these changes have taken place (see How does the
threshold change with overall expenditure?).
How uncertain are the estimates and what are the implications?
There are a number of sources of uncertainty which contribute to an assessment of how uncertain a
central or best estimate of the cost per QALY threshold might be. There are three reasons why uncertainty
in the estimate of the threshold might be of policy interest: (i) the uncertainty in the parameters that
determine the threshold might influence the mean or expected value of the threshold if they have a
non-linear relationship to the threshold or when they have a multilinear relationship but are correlated
with each other; (ii) the consequences of over- or underestimating the threshold differ so the uncertainty
may have an influence on the extent to which a policy threshold (a single value that can be compared to
the ICER of a new technology) should differ from the mean or expected value of the central or best
estimate; and (iii) in conjunction with other methods of analysisp,95 it can indicate the potential value of
gathering more information to improve these estimates in the future. Of course, hypothesis testing and the
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traditional rules of inference associated with it, such as statistical significance, p-values and confidence
intervals, have no relevance when making unavoidable decisions about policy relevant quantities based on
information currently available and the best use thereof.96
An assessment of parameter uncertainty
Two sets of parameters are critical to the threshold, the expenditure elasticities estimated for each of the
23 PBCs, and the outcome elasticities estimated for 11 of these. These parameters are estimated with
uncertainty, indicated by the standard errors on the relevant coefficients in the econometric analysis
outlined in Chapter 3 and detailed in Appendix 2. As these statistical models estimate coefficients using
normality on the relevant scale, normal distributions can be assigned to each of these estimated
coefficients, each with a mean and standard deviation based on the results of the econometric analysis.q
These distributions, represent the uncertainty in the mean estimate of each of the parameters and can be
propagated through the various calculations required to estimate an overall cost per QALY threshold
(i.e. through the sequence of analysis detailed in Chapter 4, From mortality to life-years, Adjusting life-years
for quality-of-life and Including quality-of-life effects during disease) using Monte Carlo simulation which
randomly samples from the assigned distributions. The results of each random sample represent one
possible realisation of the overall threshold, given the uncertainty in estimates of the mean parameter values
that determine it. By repeatedly sampling, a distribution of potential values that the overall threshold might
take can be revealed. The results of this simulation are illustrated in Figure 5 which shows the cumulative
probability density function for a cost per QALY threshold based only on the 11 PBCs with estimated
outcome elasticities and for all 23 PBCs. It represents the probability (on the y-axis) that the threshold lies
below a particular value.
It has already been noted that restricting attention only to changes in expenditure in those 11 PBCs where an
outcome elasticity can be estimated results in a much lower estimate of the threshold than considering all
changes in expenditure across all PBCs This lower estimate of £8308 per QALY is much less uncertain but these
PBCs only account for 50% of a change in overall expenditure, so it is the higher estimate, for all 23 PBCs, that
is of most relevance for policy (see Re-estimating the cost per quality-adjusted life-year threshold using more
recent data and Chapter 4, Summary of the cost per quality-adjusted life-year threshold). The fact that this
estimate is more uncertain simply reflects the quality and quantity of data currently available. As useful analysis
should endeavour to faithfully characterise uncertainty in policy relevant quantities, rather than select those
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FIGURE 5 Cumulative probability density function for the cost per QALY threshold.
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quantities or questions for which precise estimates are possible, it is the more uncertain estimate for all 23 PBCs
that should be of primary interest. The values that are used to generate Figure 5 are available in Table 183 in
Appendix 3. They indicate that the probability that the overall threshold is < £20,000 per QALY is 0.89 and the
probability that it is < £30,000 is 0.97.
The implications of uncertainty
Integrating this parameter uncertainty into the estimates of the overall threshold does not change the
mean or expected value of the cost per QALY threshold.r This is to be expected as the expenditure and
outcome elasticities have a multilinear relationship to the overall threshold and the analysis sampled
independently from the distributions assigned to estimated coefficients. We did investigate the potential
correlation between the expenditure and outcome elasticities by repeatedly re-estimating both based on
randomly sampling with replacement the 152 PCTs – creating bootstrapped data sets where the original
PCTs could appear more than once or not at all in the re-sampled data. This analysis indicated a small
positive correlation between outcome and expenditure elasticities in four PBCs using 2006 expenditure
data (see Analysis of programme budgeting expenditure for 2007/8 and mortality data for 2007/8/9 in
Appendix 2). Such levels of correlation will tend to have a modest but positive influence on the mean value
of the cost per QALY threshold.s
Uncertainty in the estimate of the overall threshold means that a policy threshold set at its mean or
expected value may be inappropriate. Insofar as the consequences (to the NHS) of under- or overestimation
are symmetrical, then the expected or mean value would be the appropriate policy threshold irrespective
of the scale of uncertainty. However, the consequences of overestimating the threshold are more serious
than underestimating it. This is illustrated in Figure 6 which is similar to Figure 1 presented in Chapter 2.
Figure 6 shows the impact on NHB if the central estimate of £20,000 is in fact an overestimate and the
threshold should be £10,000 per QALY. In these circumstances the technology should not have been
approved at price P2. This overestimation leads to a loss of NHB of 2 QALYs as a consequence.
Alternatively, the central estimate of £20,000 may be an underestimate and the threshold should be
£30,000 per QALY. In these circumstances the technology could just as easily have been rejected or
approved based on the central estimate and price P2. However, if the threshold is £30,000 per QALY
rather than £20,000 it should be approved. If it was rejected, this underestimation leads to a loss of
£20,000
per QALY
Price = P2  £40,000
Central estimate of the 
threshold £20,000 per QALY
Health gained
Cost
Price = P3  £60,000
32
Price = P1  £20,000
1
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FIGURE 6 Consequences of over- and underestimating the overall threshold.
IMPLICATIONS FOR A POLICY THRESHOLD
NIHR Journals Library www.journalslibrary.nihr.ac.uk
80
NHB of two-thirds of a QALY as a consequence (i.e. less than the loss associated with the same scale
of overestimation). If the scale of under- or overestimation of the central estimate is equally likely
(the distribution of possible values of the threshold is symmetrical) then using the mean or expected value
as a policy threshold (one that can be compared with the ICER of a new technology) will lead to a loss of
net benefit.t A policy threshold that represents the maximum the NHS can afford to pay for QALY gains
offered by a technology will be lower than the mean of the cost per QALY threshold (i.e. < £12,936) to
compensate for the more serious consequences of overestimating the ‘true’ value.u Importantly, this
remains the case even if effects are expressed in terms of their equivalent consumption value (net monetary
benefit based on WTP) rather than a measure of NHB.
v
How much lower a policy threshold should be set below the mean or expected value depends on three
considerations: (i) the scale of uncertainty in the estimate of the threshold (greater uncertainty implies a
lower policy threshold); (ii) the scale of the incremental costs relative to incremental health benefits offered
by the technology (policy threshold should only be equal to mean estimate if there are no additional NHS
costs associated with the technology); and (iii) the skewness of the distribution of cost per QALY threshold
(a negative skew tends to offset these effects – see Figure 52 in Appendix 3). The overall scale of the impact
on a policy threshold will be specific to the additional NHS costs associated with a technology as well as the
other sources of uncertainty, discussed below, and possible correlations between expenditure and outcome
elasticities, discussed above. We have not quantitatively integrated all these considerations into an analysis
of an appropriate policy threshold, although this may be possible in future research.
Structural uncertainty
The uncertainty associated with the parameters estimated in the econometric models is only one, and
not necessarily the most important, source of uncertainty associated with the cost per QALY threshold.
The parameter uncertainty presented above is conditional on the econometric model being ‘correct’.
In particular, that the instruments used to identify the causal effect on health of changes in expenditure
are valid. Although all the models passed the relevant tests of validity, there remains some uncertainty
about the validity of the instruments used, i.e. there remains structural or model uncertainty (see Chapter 3
for an overview).97 For this reason we undertook an analysis of how sensitive estimates of outcome
elasticities might be to instrumental validity (see The identification of values to be imposed on the
coefficients on the excluded instruments in Appendix 2). We were also able to specify a distribution for
the measure of instrumental validity used in this sensitivity analysis, i.e. how ‘likely’ each value might be
(see Obtaining the outcome elasticities associated with sampled coefficients on the excluded instruments
in Appendix 2). Therefore, there are two ‘levels’ of uncertainty: (i) the parameter uncertainty (uncertainty in
estimated coefficients given a particular ‘level’ of instrumental validity); and (ii) the structural uncertainty
in the level of instrumental validity. Both sources of uncertainty were integrated by randomly sampling the
distribution of measures of instrumental validity and then, conditional on this sampled value, re-estimating
outcome equations and sampling the estimated coefficients. This analysis in Obtaining the outcome
elasticities associated with sampled coefficients on the excluded instruments of Appendix 2 shows that
model or structural uncertainty constitutes a greater part of the overall uncertainty associated with the
outcome elasticities, so fully integrating this source of uncertainty is likely to have a significant impact on
the extent to which a policy threshold should be lower than the mean or expected value of the cost per
QALY threshold. Importantly, this additional structural uncertainty has little effect on the point estimates of
the outcome elasticities, i.e. the central estimate of the cost per QALY threshold is robust to uncertainty in
instrumental validity in the econometric models.
w
Other sources of uncertainty
Of course the parameter and structural uncertainty associated with the econometrics work outlined in
Chapter 3 is itself only one source of uncertainty associated with the estimated cost per QALY threshold.
Each of the steps of analysis in Chapter 4, From mortality to life-years, Adjusting life-years for quality-of-life
and Including quality-of-life effects during disease explored the different ways routinely available data could
be used and how additional information could improve the estimates. We identified a preferred analysis
(or scenario) at each stage based on which made the best use of available information, whether or not the
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assumptions required appeared more reasonable than the other alternatives available, and which provided a
more complete picture of the likely health effects of a change in expenditure. Insofar as the preferred
analysis is the only plausible scenario, there would be no other sources of uncertainty. However, other
assumptions and judgements are possible, which although they may be judged less credible might,
nonetheless, have some probability of being the most credible (given the evidence currently available).
Therefore, there will be uncertainty between these alternative ‘scenarios’ as well as within each (the
parameter and model uncertainty described above).95 Although in principle this can be integrated into
the analysis even in the absence of data to test alternative views,98 we do not do so here as assigning
probabilities to alternative scenarios would be somewhat speculative and inevitably disputed. Instead we
offer a summary of the qualitative considerations. Of course any increase in the uncertainty associated with
the central estimate of the cost per QALY will impact on the extent to which a policy threshold should be
lower than the mean. However, a critical issue is whether or not consideration of other ‘scenarios’ might
change this central estimate (e.g. if scenarios that lead to a lower estimate are judged more credible than
those that lead to higher ones). In other words the question is whether on balance the central or best
estimate of £12,936 in Table 30 is likely to be an under- or overestimate of the cost per QALY threshold.
Most of the considerations have been discussed in detail throughout Chapter 4 so are only briefly
summarised here. The key assumptions made in Chapter 4 that underpin the central estimate of the cost
per QALY threshold reported in Table 30 are briefly summarised in Table 32, including a brief indication
why such an assumption was required, the likely qualitative effect that each is likely to have on estimates
for the health effects of changes in expenditure and where these are introduced in Chapter 4.
On the one hand, there are some reasons why the health effects might be overestimated and the central
estimate of the QALY threshold underestimated (e.g. see assumptions 1–4 in Table 32). Calculating the
life-years lost that account for deaths that would have otherwise occurred as described in Chapter 4, Years
of life lost and accounting for counterfactual deaths and Inferring excess deaths is equivalent to assuming
that those deaths averted by a change in expenditure returns the individuals to the mortality risk of the
general population (matched for age and gender). Although this appears more credible than the alternative
assumptions that could be made (e.g. restricting life-year effects of changes in mortality to the period of
observed variation in mortality outcomes), it is likely to be optimistic with respect to the life-year effects of
changes in mortality, tending to underestimate the cost per QALY threshold.
On the other hand there are a number of reasons why the central estimate might be overestimated
(e.g. see assumptions 5 and 6 in Table 32). The health effects of a change in expenditure are restricted to
the population at risk during 1 year. This is undoubtedly pessimistic in three respects: (i) it means that effects
on QoL during disease only occur for 1 year (the effect of investment that might have long-term effects on
QoL, e.g. hip replacement are excluded); (ii) mortality effects are also restricted to 1 year, so the full effect of
investments that reduce mortality for patients throughout their disease duration, not just in the first year, will
not be captured; and (iii) changes in expenditure that reduce incidence in the at risk population in the future
(i.e. prevention of disease) will not be captured either. A more formal and longer lag structure in the
estimation of outcome elasticities would be likely to capture more health effects of a change in expenditure.
The effect of other assumptions that have been necessary are more ambiguous although some evidence
suggests their net effect may be conservative with respect to health effects of changes in expenditure
(e.g. see assumptions 7–9 in Table 32). The observed effects of a change in expenditure on mortality and
life-years in the 11 PBCs where outcome elasticities could be estimated was used as a surrogate for health
effects in the other 12 PBCs (excluding GMS), i.e. the estimated effects of a change in expenditure that
could be observed were used to inform those effects that currently, at least, cannot. This approach is not
necessarily optimistic with respect to overall health effects. In fact, there are reasons to believe it may
underestimate them (overestimate the threshold). As discussed previously in Chapter 4, Summary of the
cost per quality-adjusted life-year threshold and Re-estimating the cost per quality-adjusted life-year
threshold using more recent data, if this means of extrapolating from observed to unobserved effects is
rejected then threshold estimates could be based only on the health effects of changes in expenditure in
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TABLE 32 Summary of assumptions and their likely impact on the central estimate of £12,936 per QALY
Assumption Justification Likely impact on estimates Reference
1. Deaths averted by a change in expenditure
returns an individual to the mortality risk
of the general population (matched for
age and gender)
No data to directly estimate the effects on
survival. Appears more credible than
restricting life-year effects of changes in
mortality to the period of observed variation
in mortality outcomes
Overestimate health effects Chapter 4, Introduction and Summary of
cost per life-year estimates
Chapter 4, notes b and w, and Chapter 5,
note ak
2. Expenditure and outcome elasticities
are uncorrelated
Expenditure and outcome equations were
estimated separately
If the small but positive correlation between
outcome and expenditure elasticises found
in four PBCs was applied to all PBCs it is
likely to have a modest but positive impact
on the expected value of the threshold
How does the threshold change with overall
expenditure?
Chapter 5, note u
3. Mortality effects of changes in expenditure
(reported at PCT level) can be applied to
all mortality recorded in a PBC
Assuming no health effects of expenditure in
areas of disease where mortality is not
recorded at PCT level or in over 75-years age
groups appears arbitrary and less plausible
than basing estimates of effects that cannot
be observed on what can
Although including persons aged over
75 years mortality may overestimate the
effects on observed PBC deaths (if mortality
in older ages groups is less sensitive to
changes in expenditure) it has a much
more limited impact on life-year effects
(i.e. including mortality above LE reduces
net YLL)
Chapter 4, Mortality and years of life lost
coverage, Life expectancy and years of life
lost, Years of life lost and accounting for
counterfactual deaths and Inferring excess
deaths
Chapter 4, notes b, q and s
4. The PBC QALY effects are a weighted
average of effects within each of the
ICD-10 codes that contribute to the PBC
based on the proportion of the total
PBC population within each contributing
ICD-10 code
PBC costs are not available at ICD-10 level
across PCTs. Although costs from HES data
are available at ICD-10 level they are only a
small component of total PBC costs and
contribute very little to the variability in PBC
costs across PCTs, especially when
considering PBCs where mortality effects
could not be estimated
There is no information about how changes
in PBC expenditure are allocated to
particular ICD-10 codes so the effect is
unclear. However, it may overestimate
health effects if investment within a PBC is
focused on ICD-10 codes where expenditure
has greater health effects and disinvestment
focuses on ICD-10 codes with less
health effects
Chapter 4, Using ratios of quality-adjusted
life-years to years of life lost and Using
estimates of the quality-adjusted life-year
burden of disease
Chapter 4, notes an and au, and Chapter 5,
note ai
5. Health effects of changes in expenditure
are restricted to the population at risk
during 1 year
It was not possible to estimate a longer and
more complex lag structure. Assuming that
estimated health effects could be applied to
the whole remaining duration of disease for
the population at risk appears less plausible
Underestimate health effects Chapter 4, Introduction, Summary of cost
per life-year estimates, Summary of the cost
per quality-adjusted life-year threshold and
Future research and improving estimates of
the threshold
Chapter 4, note a, and Chapter 5, notes aj
and ao
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TABLE 32 Summary of assumptions and their likely impact on the central estimate of £12,936 per QALY (continued )
Assumption Justification Likely impact on estimates Reference
6. Health effects restricted to the PBC in
which expenditure changes. No health
effects associated with changes in GMS
expenditure (or PBC 22, social care)
It was not possible to estimate outcome
equations for PBCs simultaneously so
estimated outcome elasticities do not
account for health effects due to changes
in expenditure in other PBCs
Likely to underestimate health effects
because effects of changes in expenditure in
‘contributory’ PBCs will not be reflected
in estimates of health effects in other
(recipient) PBCs unless they happen to be
correlated with changes in expenditure in
these PBCs
Chapter 4, Years of life lost and accounting
for counterfactual deaths and Summary of
cost per life-year estimates, Which
programme budget categories matter
most? and Future research and improving
estimates of the threshold
Chapter 4, notes c, m and u, Chapter 5,
notes b, e, p, an and ar
7. Same proportional effect on QALY
burden of disease as the estimated
proportional effect on the life-year
burden of disease
Estimates of effects on mortality and
life-years are used as a surrogate for effects
on QoL. Appears more plausible than
assuming no effects of NHS expenditure
on QoL outcomes
May underestimate the QoL effects of
changes in expenditure in these PBCs if
effects are more than proportional to
mortality and life-year effects or
overestimate them if they are less
than proportional
Chapter 4, Summary of the cost per
quality-adjusted life-year threshold based
only on mortality effects and Using
estimates of the quality-adjusted life-year
burden of disease
Chapter 4, note ad
8. Life-year effects are lived at a QoL that
reflects a proportionate improvement to
the QoL with disease
Consistent with using estimated mortality
and life-year effects as a surrogate for a
more complete measure of health outcome
(QALYs). Appears more plausible than
assigning QoL norms or a QoL with disease
to life-year effects
This assumption is more conservative
than assigning QoL norms to life-years
(assuming that all disease is acute), but less
conservative than assigning QoL with
disease (assuming that all life-years would
be lived in the diseased state until death)
Chapter 4, Summary of the cost per
quality-adjusted life-year threshold based
only on mortality effects and Using
estimates of the quality-adjusted life-year
burden of disease
Chapter 4, notes ad and ap
9. Proportional effect on QALY burden of
disease in PBCs where mortality effects
could not be estimated is assumed to be
the same as the overall proportional
effect on the life-year burden of disease
across those PBCs where mortality effects
could be estimated
Consistent with using estimated mortality
and life-year effects as a surrogate for health
effects (QALYs) where mortality effects
cannot be directly estimated. Appears more
plausible than assuming no health effects of
NHS expenditure in these PBCs
May underestimate the QALY effects of
changes in expenditure in these PBCs if
effects are more than proportional to QALY
burden of disease. Other evidence suggests
that the effect of this assumption may be to
underestimate health effects in key PBCs
(mental health)
Chapter 4, Using estimates of the
quality-adjusted life-year burden of disease,
Summary of the cost per quality-adjusted
life-year threshold and Which programme
budget categories matter most?
Chapter 4, notes aw and ax, Chapter 5,
notes g, al, am
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4
those PBCs where outcome elasticities can be estimated. This generates a much lower cost per QALY
threshold (£8308) even if that portion of GMS expenditure was allocated to these 11 PBCs (see Chapter 4,
Summary of cost per life-year estimates). Alternatively, taking account of the large proportion of the
change in expenditure allocated to the other 11 PBCs but assuming that there are no health effects of
expenditure in all these other PBCs is not plausible. The evidence that is available about the value of
investment and disinvestment opportunities in the most important of these other PBCs (PBC 5 mental
health disorders), suggests that the health effects of changes in expenditure in this PBC might be
underestimated and the central estimate of the threshold overestimated (see Which programme budget
categories matter most? and Addendum 3: characterisation of the investment and disinvestment decisions
in mental health – depression and schizophrenia in Appendix 3).
In addition, we have also shown that the uncertainty associated with our central estimate (from all sources)
means that an appropriate policy threshold is likely to be below its mean or expected value. Finally, in
Impact of investment, disinvestment and non-marginal effects we explore how the threshold is likely to
differ when considering opportunities to make investments (i.e. an increase in overall expenditure, or cost
saving accruing to the NHS), and when disinvestment is required (a reduction in overall expenditure or costs
imposed on the NHS). This analysis shows that a cost per QALY threshold relevant to technologies which
impose costs on the NHS is likely to be less than our central estimate of £12,936. Therefore, although other
assumptions and judgements are possible that retain some level of plausibility, they do not all favour a
higher threshold. Indeed, when considered together, they suggest that on balance the central or best
estimate of £12,936 presented in Table 30 is, if anything, likely to be an overestimate. In Future research
and improving estimates of the threshold we discuss how some of these remaining uncertainties might be
resolved through access to additional and better data and the type of analysis that would then be possible.
Impact of investment, disinvestment and non-marginal effects
The central estimate of the cost per QALY threshold in Table 30 is based on estimates of the health
effects of changes in expenditure across all 152 PCTs, some of which will be making investments
(where expenditure is increasing) and others making disinvestments (where expenditure is reduced or
growing more slowly). The cost per QALY threshold, however, is likely to differ across these different
types of PCTs. This is illustrated in Figure 7 where the total observed variation in expenditure includes the
Health
H1
− E
B1
1/k1
1/k1−
+ E
k1
− E 0 + E
Threshold
k1+
k1−
1/k1+
Variation in expenditure
1/k1
FIGURE 7 Investment, disinvestment and budget impact. –ΔE, disinvestment; +ΔE, investment; B1, current budget;
H1, current level of health; k1, cost per QALY threshold; k1–, QALY threshold associated with disinvestment;
k1+, QALY threshold associated with investment.
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impact of disinvestment (–ΔE) (e.g. where costs are imposed on the NHS by the approval of a more costly
technology) and investment (ΔE) (e.g. where cost savings are accruing to the NHS). The central estimate
of the cost per QALY threshold is the health effect of a change in expenditure across this variation in
expenditure (k1).
x One would expect that, other things being equal, more expenditure (expanding the
budget from B1) would increase health but at a diminishing rate. Therefore, the amount of health
displaced by disinvestment, or a reduction in expenditure, would be expected to be greater, i.e. the
threshold associated with –ΔE (k1–) will be lower than the central estimate, k1. Equally, the health gained
from investments, or an increase in expenditure, would be expected to be lower, that is the threshold
associated with +ΔE (k1+) will be higher than k1.
We have been able to examine this by re-estimating the outcome and expenditure elasticities separately for
those PCTs where their actual budget is under the target allocation from the Department of Health resource
allocation formula (i.e. those under greater financial pressure and more likely to be disinvesting than
investing), and those that are over target (under less financial pressure and more likely to be investing than
disinvesting). The detail of this analysis (based on 2006 expenditure and restricted to the ‘big four′ PBCs) are
reported in Comparing outcome models for ‘high’ spending and ‘low’ spending primary care trusts in
Appendix 2. The results confirm what would be expected given Figure 7 and the discussion above – the
outcome elasticities are smaller (in absolute terms) for all four PBCs in the group of PCTs above their
target allocation and larger for all four PBCs below their target allocation. Therefore, the health effects of
changes in expenditure are greater in all these PBCs when PCTs are under more financial pressure and are
more likely to be disinvesting then investing. The cost per life-year estimates for these PBCs are reported in
Appendix 2: £10,604 for all PCTs combined (k1); £8441 for those PCTs under their target allocation
(i.e. k1– associated with –ΔE); and £14,083 for PCTs over their target allocation (i.e. k1+ associated with +ΔE).
Although these cost per life-year estimates are not based on the same calculations as Chapter 4, From
mortality to life-years, they do start to indicate the scale of the effect on a threshold that is most relevant for
new technologies that impose net costs on the NHS.
Expenditure elasticities for these PBCs also differ between these groups of PCTs – they are higher for those
under their target allocation. These PBCs together consistently offer the greatest value in terms of cost
per death averted, life-year or QALY (see Tables 30 and 31). This suggests that budget impact not only
displaces more valuable activities within each PBC (outcome elasticities are larger), but that overall
expenditure tends to be reallocated to more valuable PBCs. The effect of this reallocation on the overall
threshold is not captured in the cost per life-year estimates reported above, which are restricted to these
four PBCs. Therefore, extending this type of analysis to all PBCs in future research is likely to show that the
effect on the cost per QALY threshold of both the sign and scale of changes in overall expenditure will be
greater. Subsequent work might enable a quantitative assessment of how the relevant threshold should be
adjusted for the scale of the budget impact of technologies appraised by NICE.
Although further work is needed to fully specify the quantitative effect of the scale of the non-marginal
impact of new technologies on an appropriate threshold, the qualitative impact seems clear. First, the
central estimate of the threshold is likely to be an overestimate for all technologies which impose net costs
on the NHS (almost all technologies appraised by NICE have positive incremental NHS costs).12,99,100 Second,
the appropriate threshold to apply should be lower for technologies which have a greater impact on
NHS costs.
How does the threshold change with overall expenditure?
The same methods of analysis can be applied to the econometric analysis of the 2007 expenditure and
2007–9 mortality data (see Analysis of programme budgeting expenditure for 2007/8 and mortality data
for 2007/8/9 in Appendix 2). This provides an opportunity to consider how the cost per QALY threshold is
likely to have changed from 2007 to 2008 as overall expenditure has increased. This can provide some
insights into how the threshold might be expected to change over time, for example, overall expenditure
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changes and productivity in the NHS might be expected to rise with innovation in health technologies,
clinical practice and service delivery. This has implications for a judgement about the appropriate frequency
of periodic reassessment of the cost per QALY threshold.
It is not necessarily the case that the threshold will rise with overall expenditure or even with NHS prices.
This is illustrated in Figure 8 where the threshold at budget B1 is represented by k1. If overall expenditure
increases to B2 then, other things being equal, the threshold would also be expected to increase (i.e. k1
now overestimates the health effects of a change in expenditure at B2).y Increasing overall expenditure
from B1 to B2 is equivalent to eliminating the same amount of waste in Figure 8, i.e. by reallocating
resources devoted to activities unproductive to health. Again, other things being equal, the threshold
would be expected to increase (k1 now overestimates the health effects of a change in expenditure at B1)
once the waste has been eliminated. However, insofar as the productivity of those activities that are
valuable to the NHS also improve through innovation in health technologies, clinical practice and service
delivery, the threshold will tend to fall. Figure 8 illustrates a situation where the effects of eliminating
waste (NHS stopping doing things it should not be doing) and, at the same time, improving productivity
(NHS getting better at doing things it should do) means that the overall threshold is unchanged.
In making an assessment of whether or not the threshold is likely to increase with the NHS budget it is
also necessary to consider whether or not there is discretion over how additional resources can be spent.
For example, if any growth in the overall budget is spent on national initiatives or other activities that
cannot easily be disinvested, then the additional costs of technologies approved by NICE must be
accommodated by displacing other activities elsewhere. Therefore, it is growth in expenditure on more
‘discretionary’ parts of NHS expenditure and changes in the productivity and input prices of those health
care activities which are more likely to be displaced, which are most relevant.
Over recent years much of the real budget growth in the NHS has been devoted to national initiatives
that are not easily displaced (e.g. new contracts for GPs and consultants, national waiting time targets,
information technology initiatives, etc.).101 It also includes technology appraisal guidance issued by NICE
itself, which has a funding mandate. Therefore, any real growth in what remains may have been more
modest, so it is more likely to have been offset by any growth in the productivity of displaceable activities
(e.g. drugs, devices, procedures and other services). Similarly, although there has been a general rise in
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FIGURE 8 Impact of changes in budget and productivity. B1, current budget; B2, increased budget; H1, current
level of health; k1, cost per QALY threshold.
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input prices for the NHS, much of this inflation has been driven by staff as well as capital and overhead
costs, some of which cannot be easily displaced. What are more relevant are the prices of inputs which
could be displaced, an important element of which is drug prices. Although branded drug prices have
tended to rise, at the same time there has been generic entry on patent expiry with dramatic reductions in
prices for important classes of drugs.102 Therefore, it is not self-evident that the threshold has grown over
recent years, despite real increases in the NHS budget.
The central estimates of the cost per QALY threshold for 2007 and 2008 expenditure years are reported
in Table 33. In comparing these estimates of the QALY threshold it should be noted that important
improvements were made to the classification and collection of PBC expenditure data that took place after
the 2006 data were collected. Therefore, the differences in threshold estimates for 2006 and 2007 partly
reflect this (see Comparing the cost of life-year estimates associated with different data sets in Chapter 3
and Comparing the cost of life-year estimates associated with different data sets in Appendix 2) so should
not be overinterpreted. The results of the analysis of 2007 and 2008 expenditure are comparable in
this respect.
Although overall expenditure increased by 6% between 2007 and 2008 which represented real growth
of 2% in 2007 prices,z the overall threshold for all 23 PBCs fell by 5% in nominal terms and by 8% in
real terms.
The reasons are complex but reflect changes in productivity, which differs across PBCs (changes in outcome
elasticities), but also a general reallocation of a change in overall expenditure (changes in expenditure elasticities)
towards those PBCs that appear more valuable in 2008.aa Given the sources of uncertainty described above,
subtle differences between 2007 and 2008 should not be overinterpreted. However, this analysis does suggest
that the overall threshold will not necessarily increase with growth in the real or even nominal NHS budget. In
conjunction with the results of the analysis described in How uncertain are the estimates and what are the
implications? it does suggest that the threshold is more likely to fall at a time when real budget growth is flat or
falling and PCTs find themselves under increasing financial pressure.
Within the NICE technology appraisal process, the future incremental costs of a technology are expressed
in real terms (at current prices) prior to discounting. Therefore, the estimates that are relevant to NICE
decisions are: (i) the nominal threshold in the current year;ab and (ii) some assessment of the real growth in
the threshold over the time horizon where incremental NHS costs are incurred. If there is an expectation of
real growth (or fall) in the threshold over time then one way to incorporate this is through a higher (lower)
discount rate applied to future cost.103 Indeed, an expectation of changes in the real threshold over time
also suggests something about the social rate of time preference for health, as revealed by budget
allocations decisions.104 However, incorporating an expected growth or decline in the threshold over time
by adjusting discount rates is likely to be problematic once it is recognised that the expected incremental
costs imposed by a technology are rarely uniform over time.
TABLE 33 Growth in the cost per QALY threshold (2007–8)
PBC grouping
(1) Cost per QALY
threshold (2007) (£)
(2) Cost per QALY
threshold (2008) (£)
(3) Nominal
growth (%)
(4) Cost per QALY
threshold (2008),
2007 NHS prices (£)
(5) Real
growth (%)
All big four
programmes
4549 4872 7 4689 3
11 PBCs
(with mortality)
8513 8308 –2 7996 –6
All 23 PBCs 13,554 12,936 –5 12,450 –8
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This discussion and the results reported in Table 33 suggest that there is little empirical support for an
assumption that there will have been growth in the nominal threshold between 2008 and 2012.a
b
Growth
in the nominal or real threshold seems much less likely in the future with the prospect of reduced budget
growth, increased pressures to improve productivity and downward pressure on input prices. As how the
nominal or real threshold is likely to change over time cannot be assumed to follow prices or overall
expenditure nor empirical estimates or theoretical predictions of a growth in the private consumption value
of health (WTP), it becomes especially important to be able to regularly update estimates of the cost per
QALY threshold based on routinely available data (see Future research and improving estimates of
the threshold).
What type of health is forgone by approval of a new technology?
The methods of analysis described in Chapters 3 and 4 and discussed in this chapter can identify, not only
how many QALYs are likely to be forgone across the NHS as a consequence of approving a technology
which imposes incremental costs on the NHS, it can also indicate where those QALYs are likely to be
forgone and how they are made up, i.e. the additional deaths, life-years lost (unadjusted and adjusted for
QoL) and the QoL impacts on those with disease.
For example, in 2011, NICE considered whether ranibizumab (Lucentis®, Roche) for the treatment of
diabetic macular oedema should be approved for widespread use in the NHS (TA237).105 Initially this
technology was rejected by NICE on the grounds that, at its current price, it would be unlikely to be
cost-effective. In 2012, however, a rapid review of TA237 approved ranibizumab if use was restricted to
the most cost-effective subgroup (those with central retinal thickness ≥ 400 micrometres) and after a
Patient Access Scheme (PAS) for this subgroup of patients was offered (details of the PAS which provides
a discount to the NHS is commercial in confidence).106
The appraisal and guidance documents105–109,ac provide the information required to estimate the additional
NHS costs of treating this subgroup of patients each year (see Appendix 3, Addendum 4: what type of
health is forgone by the approval of a new technology? for details of this example). Up to 44,000 NHS
patients would be eligible for treatment with ranibizumab each year based on its licensed indication.107
However, the subgroup of patients where ranibizumab was ultimately approved is likely to be 23,000 each
year. This suggests that the approval of ranibizumab in this subgroup at the original appraisal price set in
2011 (i.e. without a PAS) would impose just over £80M of additional NHS costs for treating the eligible
population each year.
Based on the 2008 central estimate of the cost per QALY threshold (£12,936 in Table 30) the approval
of ranibizumab without a PAS would have been likely to displace 6184 QALYs elsewhere in the NHS.
However, the analysis which underpins the threshold estimate can also be used to identify where the
additional NHS cost of £80M are likely to impact and where and what type of health effects are likely to
be forgone. This is illustrated in Table 34. For example, the estimated expenditure elasticities and total PBC
expenditure indicates how these costs will tend to affect spending in each of the 23 PBCs [see Table 34,
column (1)]. The estimated outcome elasticities allow this change in spending in each PBC to be translated
into a change in deaths and life-year effects for the 11 PBCs where mortality effects could be estimated
[see Table 34, columns (2) and (3)]. Applying the estimated proportional effect on the mortality burden of
disease to measures of QALY (including the other PBCs) provides an estimate of the total QALY effect of
the change in spend in each PBC [see Table 34, column (4)].ad The comparison of life-year and total QALY
effects allows the distinction to be made between QALY effects due the life-year effects of additional
deaths and QALY effects due only to QoL [see Table 34, columns (5) and (6)].
The results reported in Table 34 suggests that approval is likely to result in 411 additional deaths
[most of which are likely to occur in PBCs circulatory, respiratory and cancer see Table 34, column (2)],
and 1864 life-years forgone [most of which are likely to occur in PBCs circulatory, cancer and
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TABLE 34 Heath forgone across PBCs due to the approval of ranibizumab (£80M budget impact)
PBC
(1) Change in
spend (£M)
(2) Additional
deaths
(3) Life-years
forgone
QALYs forgone
(4) Total
QALYs
forgone
(5) Due to
premature
death
(6) QoL
effects
2 Cancer 3.58 30 300 211 195 16
10 Circulatory
problems
6.07 182 928 863 590 273
11 Respiratory
problems
3.67 107 129 1,835 80 1754
13 Gastrointestinal 2.56 21 197 351 129 222
All big four programmes 16 340 1554 3259 995 2265
1 Infectious
diseases
2.61 6 43 125 29 97
4 Endocrine problems 1.51 5 40 485 26 459
7 Neurological
problems
4.78 10 52 873 34 838
17 Genitourinary
problems
3.71 18 26 85 17 68
16 Trauma and injuries 6.16 0 0 0 0 0
18+ 19 Maternity and
neonates
5.46 0 3 2 1 1
11 PBCs 40 389 1717 4828 1101 3727
3 Disorders of blood 1.65 3 13 175 9 166
5 Mental health
disorders
14.29 23 103 762 67 696
6 Learning disability 0.83 0 2 6 1 4
8 Problems of vision 1.55 0 2 34 1 33
9 Problems of
hearing
0.70 0 1 112 1 111
12 Dental problems 2.31 0 0 54 0 54
14 Skin 1.57 2 9 16 6 10
15 Musculoskeletal
system
2.90 3 14 186 9 176
20 Poisoning and
adverse events
0.74 0 2 7 1 5
21 Healthy individuals 2.83 0 1 5 1 5
22 Social care needs 2.40 0 0 0 0 0
23 Other 8.11 0 0 0 0 0
All 23 PBCs 80 411 1864 6184 1197 4987
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gastrointestinal – see Table 34, column (3)].ae However, the impact of approval of this technology on
QALYs forgone due to premature death [see Table 34, column (5)] only accounts for a proportion of the
total QALY effects [see Table 34, column (4)]. Most (4987) are associated with QoL forgone during disease
[see Table 34, column (6)]. These QoL impacts are most likely to occur in PBCs respiratory, neurological
and mental health. The PBC level effects in Table 34 can also be examined at ICD-10 code level, although
recognising the caveats discussed in Chapter 4, Adjusting life-years for quality of life and Including
quality-of-life effects during disease.af For example, in the respiratory PBC it appears to be chronic lower
respiratory diseases (J40–J47) where most additional deaths, life-years and QoL are forgone. In the mental
health PBC the additional deaths appear to be associated with disorders due to psychoactive substance use
(F10–F19) and mood (affective) disorders (F30–F39) (see Addendum 4: what type of health is forgone by
the approval of a new technology? in Appendix 3). However, it should be recognised that these effects,
which are based on the central estimate in Table 30, are likely to underestimate the health forgone given
the discussion in How uncertain are the estimates and what are the implications? and especially in Impact
of investment, disinvestment and non-marginal effects.
The impact of a reduction in the price of this technology, through either value-based pricing or the PAS that
was offered during the rapid review,106 can also be examined in the same way. The PAS was commercial in
confidence but we will consider a scenario where a 30% reduction in NHS costs was applied for this
subgroup of patients. Such a discount would be expected to save 1855 QALYs including 126 deaths
averted, 559 life-years (359 when adjusted for quality) and QoL effects during disease equivalent to 1496
QALYs, when compared with approval of the technology at the original price (see Addendum 4: what type
of health is forgone by the approval of a new technology? in Appendix 3 for more details on this
scenario analysis).
In many respects this starts to make ‘real’ the previously abstract notion that additional NHS costs are the
health and opportunities of other unknown NHS patients. The methods of analysis presented in this report
go some way to providing an empirically based and explicit quantification of the scale of opportunity costs
the NHS faces when considering whether or not the health benefits associated with new technologies are
expected to offset the health that is likely to be forgone elsewhere in the NHS. It also starts to make the
other NHS patients, who ultimately bear the opportunity costs of such decisions, less abstract and more
‘known’ in social decisions. As who happens to be known or unknown is only a matter of perspective,
time and ignorance,110 ethical and coherent social decisions require that both should be treated in the
same way. The methods of analysis discussed in this chapter have contributed to removing some of the
‘ignorance’ and making the unknown more real.
Future research and improving estimates of the threshold
There are a number of ways in which this research could be usefully extended based on existing data and
the information currently available, most of which have been discussed in previous sections of this chapter.
Here we consider the scale of the evaluation problem in this context, examining what, in principle, would
be required to resolve some of the key uncertainties discussed in How uncertain are the estimates and
what are the implications?, before a more detailed examination of how additional routine data and greater
access to existing data or data that are likely to become available, might improve estimates of the cost per
QALY threshold in the future.
Two important questions remain when attempting to translate the estimated proportionate effects on
mortality due to a change in expenditure into a more complete measure of the health effects (see Chapter 4,
Introduction and How uncertain are the estimates and what are the implications?). These are (i) whether the
health effects of a change in expenditure in 1 year should be restricted to 1 year or extend over a longer
period; and (ii) the extent to which any death averted by expenditure in 1 year returns an individual to
the mortality risk of the general population matched for age and gender. The central or ‘best’ estimates
presented in Chapters 4 and 5 are based on combining the conservative assumption that the health effects of
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changes in 1 year of expenditure are restricted to 1 year,ag with the more optimistic assumption that any
death averted by expenditure in 1 year returns the individual to the mortality risk of the general population.a
h
The combination of assumptions that underpin the central estimates appear to be on balance conservative
(see Table 32 and discussion in How uncertain are the estimates and what are the implications?) and are
certainly more credible than the implausibly pessimistic or optimistic assumptions that underpin the upper
and lower bounds for the threshold that are also reported in Chapters 4 and 5. Key questions remain,
however. Why can routine data not resolve some of these remaining uncertainties? What would be required
to found a central estimate of the cost per life-year or cost per QALY threshold only on econometric estimates
rather than, in part at least, resting on judgements about the credibility of these alternative assumptions?ai
A brief reiteration of the scale of this evaluation problem and the approaches to estimation that might be
taken illustrates the quite profound difficulties and, therefore, the unavoidable need for explicit and
accountable judgement and assumptions.aj
A longer and more complex lag structure
Of course, a longer and more complex lag structure exploiting the PBC panel data set (i.e. both
cross-section and time series observations) that is becoming available over time, could in principle at least,
identify the effect of a change in expenditure taking place in year t on health in years t, t+ 1 , . . . , t+ n.
However, the health effects in subsequent years would need to be isolated from the effects of change in
expenditure also occurring in subsequent years (which would also have both immediate and lagged health
effects). The health effects of changes in expenditure in year t would need to be isolated from the lagged
effects of changes in expenditure in previous years. Depending on the length of time series data available
it may be possible to specify and estimate a richer empirical model to account for the lagged health effects
of past expenditure and of lagged expenditure effects of past health outcomes.ak
Although this is not a problem in principle it does pose difficulties as there are very real limits to the
current time series because (i) there are a limited number of observations in the cross-section (152 PCTs);
(ii) the definition (and boundaries) of PCTs has changed and has recently changed again with the
formation of CCGs; (iii) there are a limited number of years of observation in the time series (especially if
lags are long); and (iv) as noted in Chapters 3 and 5, the quality of PBC reporting has changed over time
(recall that estimates from 2006 and 2007 PBC expenditure were not as comparable as 2007 and 2008).
Nonetheless, as the panel data evolves over time there will be more opportunities to explore whether
judgements about the duration of effects on mortality can be informed using the type of analysis
presented in the report. Insofar as there are later lagged health effects this will tend to reduce the estimate
of the cost per death averted, cost per life-year and cost per QALY threshold.al
In many respects the problem of duration of mortality effects is a relatively straightforward one compared
with the second issue of how changes in mortality (whether immediate or lagged) translate into life-years.
In principle, estimating the effect of change in expenditure on life-years is really estimating the effect of
changes in expenditure on the survival curves of the population at risk through membership of ICD-10
codes that contribute to each PBC. Even if the issue of lags is set aside, and attention is restricted to
mortality effects in the expenditure year, translating these effects into life-years would require observations
on the entire survival curve of the at risk population. This poses two profound difficulties: (i) we would
need detailed information about the members of the at risk population (patient identifiers); and
(ii) sufficient time to follow up the entire cohort from expenditure change to death (also accounting for
other changes that are likely to take place during that time). Even if these data were available and such
heroic estimation was possible, any estimate would be so historic that it would be of limited policy
relevance. This is not a problem unique to this research but remains a problem for all estimates of the
YLL due to disease. It may be possible to use external, non-routine, historic data sources where patient
identifiers are available to inform a judgement about whether or not changes in mortality in critical ICD-10
codes (e.g. respiratory) tend to return patients to mortality risks similar to those of the general population.
If historic evidence suggests that they remain at higher mortality risk it might indicate the likely scale of
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overestimation if life-year effects are based on the mortality risk of the general population. However, this
would not be without major problems of distinguishing causality from selection effects.
The evolving panel data do have another advantage that could be exploited in the future. Currently it is
only cross-sectional variation (i.e. between PCTs) that contributes to the estimates of outcome elasticities.
This means that changes in expenditure that all PCTs tend to make together, that might have very large
health effects (they all tend to invest in obviously valuable activities at the same time) or limited health
effects (they all disinvest in some activities that are not valuable at the same time), may not be fully
reflected in the current estimates.am However, using variation in expenditure and outcome in both
cross-section and time series could more confidently pick up the full effects of simultaneous investment
and disinvestment. The likely net effect on the overall threshold is unclear and will depend on whether
PCTs tend to be more co-ordinated when investing in valuable activities (tending to reduce the threshold)
or when disinvesting in ineffective ones (tending to increase the threshold).an
Simultaneous estimation across programme budget categories
Although expenditure equations are estimated for all 23 PBCs and outcome equations for the 11 PBCs
where there are sufficient mortality data, these are estimated separately; each accounting for other
PBC expenditure and other PBC need (see Chapter 3, Modelling framework). The correlations between
expenditure and outcome elasticities within each PBC were also estimated by repeatedly resampling the
data set and re-estimating expenditure and outcome elasticities (see Appendix 2, The correlation between
the outcome and expenditure elasticities). Although the estimate of the overall threshold accounts for
changes in expenditure across all 23 PBCs with health effects estimated in 11 and inferred in the others,
it is possible that changes in expenditure in one PBC may have health effects in others. Although total
deaths across all 23 PBCs are accounted for, unless the possible ‘external’ mortality effects in other PBCs
happen to be associated with variation in expenditure in those PBCs then these health effects will not be
reflected in the estimated outcome elasticities. This seems likely to underestimate the total health effects of
changes in expenditure unless positive health effects are thought to be offset by expenditure in one PBC
damaging health outcome in others (e.g. adverse events associated with treatment or other iatrogenic
effects).ao To account properly for these possible effects would require estimating the interaction of
changes in expenditure in each PBC on all the others while still accounting for possible endogeneity.
Unfortunately, with only 152 observations in the cross-section (PCTs), this type of simultaneous estimation
is currently not feasible.
Throughout Chapters 3–5 we have not imputed health effects for PBC 23 (GMS) or procedural ICD-10
codes on the grounds that the health effects of this type of expenditure will appear in ICD-10 codes that
contribute to other PBCs. However, the health effects of this type of expenditure (PBCs 22 and 23) will
only be reflected in the estimated outcome elasticities insofar as the variation in outcomes reported in
other PBCs, due to variation in GMS expenditure, happens to be associated with variation in expenditure
in those other PBCs. Therefore our approach to GMS (and social care, PBC 22) expenditure is likely to be
conservative with respect to overall health effects; tending to overestimate the cost per life-year and cost
per QALY threshold.
Exogenous shocks and quasi-experiments
One response to these difficulties would be to look for exogenous budgetary shocks to the whole
health-care system and then estimate the health effects of the shock at a macro level. In principle this is
very attractive as it would avoid all the difficulties of endogeneity and identifying valid instruments,
exploring sensitivity and structural uncertainty. If a complete measure of health outcome was available
at a health system level it would also avoid much of the complexity of working at a PBC and ultimately at
ICD-10 code level.
Unfortunately, there are a number of difficulties. Although the NHS budget is set each year through an
essentially political process (so each year’s change in budget might be regarded as an exogenous shock),
insofar as public expenditure decisions are to some extent influenced by public sector performance,
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then these apparent ‘shocks’ are endogenous in a very similar way to PCT expenditure decisions about
particular PBCs, but just at a higher level of aggregation. However, even if some arbitrary exogenous
change to overall expenditure could be identified there are other serious difficulties. There is no
comprehensive measure of outcome relevant to all NHS activities currently reported. This has two
implications: (i) the mortality data that are available are only relevant to approximately 36% of a change
in overall expenditure (see Which programme budget categories matter most?); and (ii) how mortality
translates into life-years and QALYs depends critically on where those effects occur (the ICD-10 codes
that contribute to each PBC). In addition, there are very good reasons why one would expect covariates
(especially measures on need) and instruments to differ between different programmes of care. For all
these reasons this research has focused on using routinely available data at its lowest level of aggregation.
By doing so we not only provide an estimate of a threshold based on a more complete measure of health
effects, we are also able to indicate what type of health is affected and where they are most likely to
occur. This provides a means to update estimates of the threshold should other aspects of social value be
applied to measures of health or other aspects of social value be included in the future (e.g. consumption
and other public expenditure effects). For example, any ‘weights’ that might be assigned to different types
of QALY gains or consumption and other public expenditure effects associated with health effects and
the patient characteristics associated with ICD-10 codes (e.g. QALY burden, YLL or other patient
characteristics, such as age and gender) can be included in the current framework and a threshold
re-estimated for ‘weighted’ QALYs or, give an estimate of the consumption value of a QALY, a threshold
benefit–cost ratio that includes consumption as well as health effects.
Evolving programme budget category data
Each year offers another wave of PBC expenditure data which means that a potentially useful panel data set
is developing. This offers some useful opportunities that have been described above. However, with only
152 PCTs in the cross-section, there is a limit to how much of the remaining uncertainty might be resolved.
The utility of this evolving panel will also be limited by the formation of CCGs rather than PCTs as an
important locus of expenditure decisions. Changes in PCT boundaries and the formation of CCGs will make
the time series problematic unless CCGs can be mapped to previous PCT boundaries. However, updating
expenditure and outcome elasticities based on variation in expenditure and outcomes across CCGs would
be possible (it would provide more observations in the cross-section) so long as PBC expenditure and
mortality outcomes are reported at CCG level.
Of course it would also be useful to be able to observe PBC expenditure at a lower level of aggregation
(ideally at ICD-10 code) as this would avoid the assumption necessary to allocate PBC level effects to
ICD-10 codes based on either estimates of the size of the at risk population or the crude (unadjusted for
covariates) contribution to variance in PBC expenditure. As the only expenditure data that are available by
ICD-10 code (and therefore PBC) for each PCT are HES-based estimates of cost, the relevance of measures
of contribution to variance in PBC expenditure depends on what proportion of PBC costs are accounted
for by HES. However, HES costs are only a small component of total PBC expenditure and contribute very
little to the variability in PBC expenditure across PCTs especially when considering PBCs where mortality
effects could not be estimated (see Chapter 4, Including quality-of-life effects during disease and Chapter 4,
notes an and au). Greater disaggregation within PBCs would be particularly useful as the examination of
information routinely collected by PCTs was not particularly helpful in identifying what investment and
disinvestments within a PBC explain the variation in expenditure across PCTs (see Addendum 2: the role of
data on local NHS decisions in Appendix 3).
Extending measures of health outcome
Currently the only routinely collected health outcome data that can be matched to expenditure by PBC at
PCT level is mortality. For this reason outcome equations could only be estimated for 11 of the 23 PBCs.
As discussed in Chapter 4, Adjusting life-years for quality-of-life and Including quality-of-life effects during
disease, this represents only one aspect of health outcome and is not particularly relevant to many disease
categories and much of the care that the NHS offers, when the primary purpose is to improve health
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experience and QoL rather than to extend survival. Therefore, the estimated proportionate effects of
expenditure on the QALY burden of disease in these 11 PBCs were used as a surrogate for proportionate
effects in the others, i.e. assuming that the proportionate effects that can be observed will be similar to
those that cannot (see Re-estimating the cost per quality-adjusted life-year threshold using more
recent data).
Of course, with access to a more complete measure of health outcome, which is routinely reported
at PCT level and that can also be associated with PBC expenditure, it would be possible to use the same
econometric methods to estimate the health effects of a change in expenditure across all PBCs, rather than
imputing them in those PBCs where mortality is not the most relevant measure of health outcome.
The English NHS PROMs programme was introduced in 2009 and routinely collects self-reported health status
of patients receiving surgery for four elective procedures: knee replacement, hip replacement, groin hernia
repair and varicose vein surgery. The data that are collected include both condition-specific questions
(the Oxford Hip Score, Oxford Knee Score and the Aberdeen Varicose Vein score; no condition-specific
instrument is available for hernia) as well as the generic instrument, the EQ-5D (both the EQ-5D profile, and
the patient’s global assessment of their health, the European Quality of Life-visual analogue scale (EQ-VAS).
Patient-level data from the PROMs programme are freely available and can be linked to the HES database
which provides a potential link to PBCs. Standardised reports on the PROMs data, including the average
(case-mix adjusted) performance of providers, are regularly published by the NHS IC, currently on a quarterly
basis. Although currently offering very limited coverage for our purposes, there are plans to extend the
PROMs programme in the future, with work under way or being planned around the potential use of PROMs
in a wide range of long-term conditions, primary care, in cancer survivorship, cardiovascular services,
musculoskeletal and cosmetic surgery.
In Appendix 2, Application of method to other non-mortality-based outcome indicators we demonstrate
how the econometric methods set out in Chapter 3 can be extended to these other non-mortality-based
outcome measures. EQ-5D utility scores (pre and post an operative procedure) from the PROMs
programme are used to generate a non-mortality-based outcome measure, which we use to estimate our
outcome model. Although the Department of Health does not report the number of patients undergoing
an eligible operation by commissioner (PCT) it was possible to use the HES data set to obtain this
information. Routine reporting of procedure or intervention by commissioner in the PROMs data set would
seem a simple but important and valuable extension, especially as data are extended to primary care
where HES cannot be used to substitute for this omission.
With data for both the average health gain per operation and the number of operations, we were able to
estimate ‘the health gain per head of population’ for hip and knee replacements as defined above. This
estimated outcome elasticity can then be used as an outcome measure for changes in expenditure in the
‘problems of the musculoskeletal system’ programme (i.e. PBC 15).ap However, translating the short-term
impact of an intervention on QoL, which can be estimated from PROMs data, into an estimate of the
longer-term effects on QoL remains problematic.
Table 72 in Appendix 2 reports the estimated outcome equation for PBC 15 (musculoskeletal system) using
the PROMs-based outcome measure. The result is intuitively plausible; an increase in expenditure improves
health outcomes but, for a given spend, more need reduces the gain. The diagnostic statistics suggest that
expenditure is endogenous and that the instruments are valid. They also suggest that the instruments are
relevant and there is no evidence that the instruments are weak. Therefore, it is feasible to extend our
modelling approach beyond those programmes with mortality outcomes should PROMs be extended more
widely. Insofar as PROMs can contribute to a more secure estimate of the overall cost per QALY threshold
in the future, the sensitivity analysis discussed in Which programme budget categories matter most? starts
to indicate where this type of information might be most useful.
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Musculoskeletal is an important PBC, accounting for over 5% of a change on overall expenditure and
almost 5% of the change in health outcomes. However, of those PBCs without mortality outcomes,
it is PBC 5 (mental health) that is most critical (see Table 31 in Which programme budget categories
matter most?).
Measures of anxiety and depression are already routinely collected before, during and at the end of
interventions as part of Improving Access to Psychological Therapies (IAPT), which is an NHS programme
rolling out services across England offering interventions approved by NICE for the treatment of depression
and anxiety disorders. By March 2011 IAPT services were offered in 142 of 151 PCTs. A requirement of
the programme is to complete the Patient Health Questionnaire-9 (a measure of depression)110 and
Generalised Anxiety Disorder Assessment-7 (a measure of anxiety).111 Both of these disease-specific
measures can be linked to Short Form questionnaire-20 items and further work could, in principle, link
these scores to EQ-5D. This is a rich, valuable and evolving data set which potentially provides much of the
information required to extend the econometric modelling to the mental health PBC. The experience with
PROMs data suggests that this would be feasible, and the analysis in Which programme budget categories
matter most? indicates that this could make a significant contribution to strengthening the assessment
of the overall threshold. It would also contribute to an assessment of the cost-effectiveness of this
programme both nationally and by PCT, which would be of value in its own right. Unfortunately, despite
the collection of these data for every patient encounter for a number of years, unlike PROMs, these data
have not yet been made publicly available.aq Of course, the services offered by the IAPT programme do not
account for all the variation in expenditure in the mental health PBC. Nevertheless, access to data that
have been and continues to be collected by practitioners and NHS patients, could provide estimates of
changes in mental health outcomes due to changes in some types of mental health expenditure, which
would be a significant advance.ar
Incidence and duration of disease
Chapter 4, From mortality to life-years sets out the series of steps required to translate mortality effects
into life-years while taking account of competing risks or counterfactual deaths. This analysis used ONS
data on deaths by age and gender in the ICD-10 codes that contribute to each PBC, as well as LEs by age
and gender for the general population. Some information was also required about the age and gender
distribution of the population at risk in the ICD-10 codes that contribute to each PBC (see Tables 11 and
12). In Chapter 4, Years of life lost and accounting for counterfactual deaths this was based on age and
gender distribution of estimates of incidence from the WHO GBD study. The same information was also
used in Chapter 4, Quality of life based on the general population to adjust life-years for the QoL norms of
the general population by age and gender. In Chapter 4, Using estimates of the quality-adjusted life-year
burden of disease the measures of QALY burden of disease also used information about the duration as
well as incidence of disease from the same GBD study. These estimates, published in 2008, were based on
2004 UK data and proved to be the best available source of this type of information given the resources
available for this research. However, the GBD study has recently been updated with the findings first
publicly presented in December 2012.113 The methodology of the new study as well as sources of
information used have been much improved and any subsequent research on the threshold could integrate
these new and improved estimates.
However, the GBD study is not the only potential source of information about estimates of incidence
of disease by age and gender and disease duration across all the ICD-10 codes that contribute to the
23 PBCs. For example, the Clinical Practice Research Datalink (CPRD) [previously named General Practice
Research Database (GPRD)] contains over 3 million active patient records drawn from approximately
400 primary care practices in the UK. CPRD is jointly funded by the NHS National Institute for Health
Research (NIHR) and the Medicines and Healthcare products Regulatory Agency. The database has clinical
and prescription data and can provide information to support pharmacovigilance (indication, utilisation,
and risk/benefit profiles of drugs) and formal pharmacoepidemiological studies, including information on
demographics, medical symptoms, therapy (medicines, vaccines, devices) and treatment outcomes.
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Although this research was not funded to purchase access to CPRD data, we were able to examine a sample
which comprised 22,313,086 rows/patient–ICD-10 events (three digit) representing 4,229,910 patients with
data on diagnosis of diseases observed between 1 January 2006 and 24 June 2011 (see Addendum 1: data
sources in Appendix 3). Although CPRD data could, in principle, provide the type of information required,
the difficulties faced and the interpretation of the sample of data in the form available to us meant that it
was not directly useful. The particular problems faced included: (i) read rather than ICD-10 codes reported in
the data set, although mapping is and was possible; (ii) being able to identify when an episode of disease
ended; (iii) estimating duration of disease from the sample of data when observations were censored by the
limited years of data available to us; and (iv) confidently identifying incident patients in diseases of longer
duration despite 2 years of washout prior to extracting the sample. CPRD is quite clearly a rich and valuable
data set. However, our experience suggests that, to make best use of these data, specialist knowledge and
experience of these data is really needed as well as access to a much larger sample than we were able to
acquire with the limited resources available. Therefore, although CPRD could well help to improve estimates
of incidence by age, gender and duration of disease, it would require additional well-resourced research
including excess to specialist expertise and experience with this particular data set.
Recommendations for research
The priorities for further research that may be feasible based on data which are, or will become,
available can be summarised as follows:
1. Any growth in the nominal or real threshold cannot be assumed (see Impact of investment,
disinvestment and non-marginal effects and How does the threshold change with overall expenditure?),
so it will be important to update estimates of the threshold with more recent and future waves of
expenditure and mortality data.
2. If other aspects of social value are applied to health benefits of a new technology they must also be attached
to the type of health that is likely to be forgone due to additional NHS costs. The methods developed in this
research can be extended to allow the same weights to be also attached to the type of health that is forgone
and estimate the wider social benefits that are likely to be lost when the NHS must accommodate the
additional costs of new drugs.
3. We have demonstrated that these methods of analysis can be applied to QoL data collected as part of
PROMs. This type of analysis could be applied to these data in key PBCs as PROMs is rolled out
providing some evidence about the QoL effects of changes in PBC expenditure.
4. A key PBC is mental health. Currently, outcomes data that could be linked to measures of QoL are
routinely collected in primary care. In principle, the same methods of analysis can be applied to these
data once they are made available providing some evidence about the QoL effects of changes in mental
health expenditure.
5. Improved and more recent estimates of incidence (by age and gender) and duration of disease will
soon be available from the recently published updated GBD study. These data could be used when the
threshold is re-estimated for later waves of expenditure data. Alternatively, estimates could be based
on CPRD data. However, our experience suggests that utilising CPRD data would need research that is
well resourced with access to specialist expertise and experience with this particular data set.
6. Estimating a more complex lag structure based on the evolving panel data would provide valuable
evidence about the duration of the health effects of changes in expenditure. The recent release of
census data for 2011 may allow a panel model to be estimated allowing better control for unobserved
heterogeneity across PCTs as well as exploiting variation in outcomes, expenditure and other covariates
over time. There are, however, significant challenges including the formation of CCGs in 2013, which
will make the time series problematic for waves of expenditure and outcomes after 2012.
7. If PBC expenditure and outcome data are available at CCG level (as well as covariates and suitable
instruments), it might become possible to estimate outcome and expenditure equations simultaneously
across PBCs. This would enable more of the likely health effects of changes in expenditure to be
reflected in the analysis.
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Conclusions and implications for practice
The methods of analysis presented here go some way to providing an empirically-based and explicit
quantification of the scale of opportunity costs the NHS faces when considering whether or not the health
benefits associated with new technologies are expected to offset the health that is likely to be forgone
elsewhere in the NHS. As such, it provides a basis for determining the appropriate threshold for NICE
decisions as well as those made centrally by the NHS and Department of Health more generally.
Since 2004, NICE has used a threshold range of £20,000–30,000 per QALY. It has been widely recognised
for many years that this range is not based on evidence. The central estimate of the cost per QALY
threshold (£12,936 per QALY based on 2008 expenditure) suggests that the upper bound to this range is
almost certainly too high and the lower bound is also likely to be an overestimate (see Re-estimating
the cost per quality-adjusted life-year threshold using more recent data). For example, the analysis of the
uncertainty associated with the estimated expenditure and outcome elasticities indicates that the chance
the threshold is < £20,000 per QALY is 89% and the chance that it is < £30,000 is 97% (see How
uncertain are the estimates and what are the implications?).
The central estimate is based on identifying a preferred analysis at each stage based on the analysis that
made the best use of available information, whether or not the assumptions required appeared more
reasonable than the other alternatives available, and which provided a more complete picture of the likely
health effects of a change in expenditure. Although other assumptions and judgements are possible that
retain some level of plausibility, they do not all favour a higher threshold. Indeed, when considered
together, they suggest that on balance the central estimate of £12,936 is, if anything, likely to be an
overestimate (see How uncertain are the estimates and what are the implications?).
Although there is substantial uncertainty associated with the estimate of the overall threshold (including
parameter, structural and other sources of uncertainty), a policy threshold set at its mean or expected value
may be inappropriate because the consequences for the NHS of overestimating the threshold are more
serious than underestimating it (see How uncertain are the estimates and what are the implications?). In
principle, a policy threshold (a single value that can be compared to an ICER) should be set below its mean
value to take account of the non-linear relationship between the threshold and the additional NHB offered
by a technology.
The analysis of PCTs that are under more or less financial pressure (above or below their target resource
allocation) starts to indicate the quantitative effect of the scale of the non-marginal impact of new
technologies on an appropriate threshold (see Impact of investment, disinvestment and non-marginal
effects). It suggests that the central estimate of the threshold is likely to be an overestimate for all
technologies which impose net costs on the NHS (almost all technologies appraised by NICE have positive
incremental NHS costs), and that the threshold might be lower for technologies which have a greater
impact on NHS costs.
The research found no evidence that the threshold had increased with real growth in the NHS budget or
with NHS prices (2007–8) (see How does the threshold change with overall expenditure?). There is little
empirical support for an assumption that there will have been growth in the nominal threshold between
2008 and 2012. As how the nominal or real threshold is likely to change over time cannot be assumed to
follow prices or overall expenditure, nor empirical estimates or theoretical predictions of a growth in the
private consumption value of health (WTP), it becomes especially important to be able to regularly update
estimates of the cost per QALY threshold based on routinely available data (see Future research and
improving estimates of the threshold).
IMPLICATIONS FOR A POLICY THRESHOLD
NIHR Journals Library www.journalslibrary.nihr.ac.uk
98
The methods of analysis can not only identify how many QALYs are likely to be forgone across the NHS as
a consequence of approving a technology which imposes incremental costs on the NHS, they can also
indicate where those QALYs are likely to be forgone and how they are made up, that is the additional
deaths, life-years lost (unadjusted and adjusted for QoL) and the QoL impacts on those with disease (see
What type of health is forgone by approval of a new technology?). In doing so the study starts to make
the other NHS patients, who ultimately bear the opportunity costs of such decisions, less abstract and
more ‘known’ in social decisions. As who happens to be known or unknown is only a matter of
perspective, time and ignorance, ethical and coherent social decisions require that both should be treated
in the same way. These methods contribute to removing some of the ‘ignorance’ and making the
unknown more real.
These methods also allow other aspects of health outcome to be incorporated in the estimate of the
threshold. This has implications should a system of value-based pricing for new prescription pharmaceuticals
be introduced, which may include some additional weight for health benefits in diseases which impose a
large health burden and/or where there are wider social benefits for patients, their carers and the wider
economy. The methods developed in this research will allow the same weights to be also attached to the
type of health that is lost and estimate the wider social benefits that are likely to be lost when the NHS must
accommodate the additional costs of new drugs.
The methods of analysis can be used as a framework for further empirical work as additional and more
appropriate data emerge in the NHS (see Future research and improving estimates of the threshold).
They also offer a basis for threshold estimation in other health-care systems which face constraints on the
growth of health-care expenditure and use CEA to inform resource allocation decisions.
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Notes
Chapter 2
a. This is the case as long as all incremental costs are health-care system costs or, as currently,
the perspective adopted by NICE is commonly restricted to the health-care system. If a broader
perspective was to be adopted and, insofar as there are some incremental costs (or benefits) of
adopting a technology that fall on private consumption, then v does become relevant to
decision-making because it represents the value of these consumption effects in terms of health.
In these circumstances it would be inappropriate either to compare an ICER which included
consumption effects to k (because consumption costs do not displace health in the NHS), or to
compare it to v (because some of the costs do not displace private consumption but displace health
at rate k). The ratio of k/v represents the value of NHS resources relative to private consumption.
Observing k< v would suggest a positive shadow price on NHS resources and public expenditure
more generally (i.e. it would indicate that a public sector £ is scarce relative to a private £).
See Claxton et al.37 for a more extended treatment of perspective, the implications for decision
rules and the centrality of an estimate of the threshold, k.
Chapter 3
a. Strictly speaking, these local health authorities are primary care organisations (PCOs), but the vast
majority of these are ‘trusts’ and we retain this terminology throughout.
b. Owing to data limitations the cited studies were only able to relate expenditure in period t to
mortality in periods t, t – 1, and t – 2 combined. Such studies assumed that PCTs had reached some
sort of equilibrium in the expenditure choices they make and the outcomes they secure.
c. Owing to data availability constraints previous studies had to relate expenditure in period t to
mortality data in periods t, t – 1, and t – 2 combined. Implicitly this assumes that data represent a
quasi-long-run equilibrium position, and that relative expenditure levels and health outcomes within
each PCT have been reasonably stable over a period of time.
d. Comparable data for each programme budget subcategory is shown in Table 91 in Appendix 2.
e. These revisions are documented in Appendix 2, Programme budgeting expenditure, 2003/4–2008/9.
f. Expenditure on, for example, community care, accident and emergency (A&E), ambulance services
and outpatients can be difficult to attribute a particular PBC. Critical care, rehabilitation and
specialised commissioning across care settings will also be difficult to attribute to a
particular programme.
g. This cost adjustment reflects the fact that health economy input prices vary considerably across the
country and, for some inputs, are up to 40% higher in London and the south east of England than
elsewhere. We have used a weighted average of the three market forces factor (MFF) indices for
Hospital and Community Health Service (HCHS), for prescribing, and for general medical services
(GMS)/primary medical services (PMS) to adjust the raw expenditure figures in table 2 for local
input prices.74
h. This needs adjustment incorporates the AREA resource allocation formula for HCHS.76
i. The approach adopted here is extendable in principle to other non-mortality-based outcome indicators.
We illustrate such an application in Appendix 2, Application of method to other non-mortality-based
indicators where we use European Quality of Life-5 Dimensions (EQ-5D) utility scores pre and post an
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operative procedure from the patient-reported outcome measures (PROMs) programme to generate a
non-mortality-based outcome indicator, and we use this indicator to estimate our outcome model.
j. One exception to this is the mortality rate for the trauma and injuries programme where initially only
SMRs were available.
k. Details of the construction of all instruments are shown in Table 92 of Appendix 2.
l. This incorporates the Combining Age-Related and Additional Needs (CARAN) formula for HCHS and
reflects need across all health-care services.
m. However, we do experiment replacing and supplementing this all service measure of need with more
programme-specific measures where these are available (e.g. the diabetes and epilepsy
prevalence rates).
n. Although need is a function of mortality/morbidity in the resource allocation formula, the
relationship is not sufficiently strong enough for us to be concerned about the endogeneity of the
need in any individual care programme.
o. Instrumental variable estimation of say, Equation 8, involves a first-stage regression of the
endogenous expenditure variable, x, on the instrument, z, and the set of exogenous regressors in
Equation 8, n. Predictions,bx, from this model can then be included in a second-stage regression of
Equation 8 as a replacement for the endogenous regressor, x.
p. Note that the mortality data precedes expenditure in these models. This was due to data limitations
at the time of the study.
q. Initial modelling work employed the Department of Health’s resource allocation model of the need
for health care based on the AREA report.76 Subsequent refinements and updates to this model
employed the implementation of the CARAN model74 and the initial findings of a person-based
resource allocation (PBRA) study.86
The use of these alternative models for the need for health care was explored.
r. An exception to this is expenditure on GMS/PMS (PBC 23a) which is adjusted using the
GMS/PMS MFF.
s. Refer to Appendix 2, Table 69.
t. Using the CARAN model.74
u. In addition to respiratory and neurological programmes the other programmes where the all service
measure of need was replaced are: endocrine: Index of Multiple Deprivation 2007 data set
(IMD2007) and diabetes prevalence rate; genitourinary: lone parent households; infectious diseases:
IMD2007 and HIV need per head and its square; maternity and neonates: proportion born outside
EU and proportion of population with no qualification aged 16–74 years. For trauma and injuries,
the all service measure of need was supplemented with the proportion of households without a car
and proportion of full-time students.
v. The four programmes are endocrine, infectious diseases, maternity/neonates and trauma/injuries.
w. The Kleibergen–Paap F-statistic is very close to the target value of 10 for both the genitourinary and
infectious diseases outcome models.
x. These are endocrine: all service measure of need and diabetes prevalence rate; neurological: epilepsy
prevalence; GMS/PMS: proportion of lone pensioner households; trauma/injuries: proportion of
population working in agriculture.
y. Full details of these calculations can be found in Appendix 2, Tables 83 and 84.
z. The CARAN measure of service need.
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aa. The amendments are respiratory diseases: all service need and all service need squared; endocrine:
IMD2007 and diabetes prevalence rate; genitourinary: lone parent households; infectious diseases:
IMD2007 and HIV need per head and its square; maternity and neonates: all service need and
proportion born outside EU and proportion of population with no qualifications aged 16–74 years.
ab. These are infectious diseases: HIV need and its square; endocrine: all service measure of need, its square
and diabetes prevalence rate; genitourinary: all service measure of need and proportion of residence
born outside EU; maternity/neonates: maternity measure of need; GMS/PMS: all service measure of
need, proportion of residents reporting permanent sickness (aged 16–74 years), proportion of lone
pensioner households and proportion in professional occupations; trauma/injuries: proportion of
population working in agriculture.
ac. Expenditure on, for example, community care, A&E, ambulance services and outpatients can be
difficult to attribute to a particular PBC. Critical care, rehabilitation and specialised commissioning
across care settings will also be difficult to attribute to a particular programme.
ad. With the index for 1987/8 set equal to 100, then 2005/6= 240.9, 2006/7= 249.8, 2007/8= 257.0
and 2008/9= 267.0.87
ae. Such studies assumed that PCTs had reached some sort of equilibrium in the expenditure choices
they make and the outcomes they secure.
Chapter 4
a. Although 3 years of mortality data are used in the analysis of each year of expenditure, these are
averaged to an annual value prior to estimating outcome elasticities. Therefore, the estimated
outcome elasticities represent the proportionate effect on mortality in 1 year due to a proportionate
change in expenditure.
b. This does assume that the proportionate effects on mortality due to changes in expenditure are
similar for mortality that is, and is not, recorded at PCT level. This seems more reasonable than
assuming no effect of expenditure on mortality that happens not to be recorded at PCT level.
c. The estimated outcome elasticity for PBC 16 (trauma and injuries) was zero for 2006 and could not
be estimated for 2008 expenditure. Therefore, this PBC does not contribute any changes in health
outcomes, although the changes in this expenditure are included in subsequent estimates of cost
per life-year and QALY thresholds. However, there was a very limited coverage of mortality data
recorded at PCT level and the expenditure data for this PBC. In addition, the mortality data that was
available (ICD-10 codes S72, S02, S06 and T90) was less likely to be associated with changes in
expenditure in this PBC and more likely to be associated with changes in expenditure in others.
Consequently, the health effects of changes in expenditure in PBC 16 may be underestimated.
d. The YLL available from NHS IC represented all deaths from maternity and all deaths under 28 days
across PBCs. The coverage factor [0.68 in column (1) of Table 8] adjusts this YLL to represent
maternity and all deaths < 1 year across PBCs. The calculation is described in Appendix 2, Table 37.
e. This is the LE that reflects the age distribution of the general population, i.e. the average of the sum of
the LEs conditional on age, over the current age distribution. It will always be higher than LE at birth.
f. These ‘counterfactual’ deaths will occur in the other PBCs insofar as all deaths are recorded in an
ICD-10 code. Therefore, we take account of the unavoidable fact that everyone must die of
something at some time. For example, even if all observed cancer mortality was avoidable and could
in principle be eliminated with sufficient expenditure, lives would not be ‘saved’ but deaths delayed
and reallocated to other causes. Note that the outcome elasticities are based on PBC mortality that
is sensitive to changes in expenditure (i.e. is avoidable) at the margin so no assumptions about how
much of the PBC mortality is avoidable is required.
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g. Simply taking the difference between a fixed LE and the age at death of deaths that occur below LE
and ignoring those death that occur above LE, would only provide the correct figure if it is reasonable
to assume that no deaths would have otherwise occurred prior to LE (so all ‘normal’ deaths must
occur at LE) and that there are no deaths (survivors) beyond LE in the at risk population, i.e. all deaths
below LE are excess deaths and there are no excess deaths above LE.
h. If risk increases over the disease duration more deaths would be observed in groups that have been
prevalent for some time (i.e. are older) than those that are incident. Also if PBC-related mortality is
higher for older age groups they will be overrepresented in observed deaths compared with a
matched normal population. For both reasons LE, YLL and cost per life-year would be overestimated
using age at death as a proxy for the age distribution of the at risk population.
i. A higher (lower) LE will mean that there are more (less) deaths below LE, each generating more
(fewer) YLL and fewer (more) deaths above LE each generating fewer (more) YLG.
j. Although this research was not funded to purchase access to General Practice Research Database
(GPRD) data we were able to examine a sample of it which comprised 22,313,086 rows/
patient-ICD-10 events (3 digit) representing 4,229,910 patients with data on new diagnosis of
diseases observed between 1 January 2006 and 24 June 2011 (see Addendum 1: Data sources in
Appendix 3). Although GPRD data could, in principle, provide this type of information the difficulties
of reliability, face validity and interpretation of the sample data in the form available to us meant
that it was not directly useful. We discuss the potential value of other sources of information,
including GPRD in Chapter 5.
k. We are aware that the 2000–2 WHO GBD study and the update which was published in 2008 using
2004 data has itself recently been updated. However, the report and tools were not publically
available at the time this research was conducted. We discuss the potential of future sources of
information in Chapter 5.
l. The WHO, through the National Burden of Disease toolkit, reports UK-specific information about the
incidence and duration of sequelae associated with different types of disease by age and gender.
As it is possible that a patient may experience more than one of the types of sequelae reported in
GBD we use the gender and age distribution of the sequelae with the highest prevalence (evaluated
as incidence x duration) to evaluate the age and gender distribution within each disease, i.e. the
minimum estimate of prevalence consistent with these figures (see Years of life lost and accounting
for counterfactual deaths and Addendum 1: Data sources in Appendix 3).
m. Throughout the analysis in Chapter 4 mortality, life-years and QALY were not assigned to procedural
ICD-10 codes (Appendix 3, Years of life lost and accounting for counterfactual deaths) as these are
likely to be evident in other ICD-10 codes related to the procedure. This means that no health effects
are associated with PBC 22 social care (which only includes procedural ICD-10 codes), although
changes in expenditure on PBC 22 are included. This is likely to overestimate the threshold because
any health effects associated with PBC 22 will not be reflected in the estimated outcome elasticities
of other PBCs unless the effects happen to be correlated with changes in expenditure in those
other PBCs.
n. The average of the sum of the YLLs for every observed death where the YLL for each observed death
is the difference between age at death and LE conditional on age of death.
o. In the absence of information about the age distribution of excess deaths this assumes that the
average YLL associated with observed and excess deaths are similar. Insofar as excess deaths are
thought likely to generate more YLL than observed deaths the number of excess deaths will tend to
be overestimated. This would tend to underestimate the cost per excess death averted. However, the
cost per life-year estimates remain unchanged and do not require such an assumption.
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p. The impact of the age distribution of deaths and the age distribution of the at risk population
(summarised as LE) on the calculation of excess deaths is not always obvious as both will affect the
numerator (net YLL) as well as the denominator (average YLL per death) in this calculation.
q. Observed PBC mortality that is sensitive to changes in expenditure can be regarded as ‘avoidable’
and it is only this mortality that contributes to the estimates of outcome elasticities (not all observed
mortality is necessarily avoidable and sensitive to expenditure – such mortality will not contribute to
the estimates). Not all observed mortality is excess when compared with the counterfactual population
but this is unrelated to the question of how sensitive it is to expenditure, i.e. observed mortality will be
just as sensitive to expenditure whether or not it is regarded as excess. Therefore, the estimated
outcome elasticities can be applied to either observed PBC deaths or excess PBC deaths.
r. Recall from Chapter 3 and Appendix 2 that the measure of mortality that is available at PCT level and
used to estimate the outcome elasticities is restricted to deaths under 75 years, as are the published
estimates of YLL associated with them (see Life expectancy and years of life lost). However, to restrict
effects only to those under 75 years would imply that there is no excess mortality above 75 years or
equivalently that there are no health effects of PBC expenditure above 75 years. Rather than assume
no affects of NHS activity in older populations we apply the effects that can be observed to the whole
PBC but account for deaths that would otherwise have occurred in our estimate of net YLL in Years of
life lost and accounting for counterfactual deaths. In many respects whether or not PBC deaths at
older ages are as sensitive to changes in expenditure is not critical as any observed deaths that might
be averted at older ages are less likely to generate YLGs because they are more likely to have occurred
anyway in that year (i.e. are excess so generate zero YLGs anyway). Therefore, they will have very
limited impact on cost per life-year or subsequently on cost per QALY (estimates in Adjusting life-years
for quality-of-life and Including quality-of-life effects during disease). For this, and the reasons given in
the text, it is the cost per life-year rather than cost per death averted, whether excess or observed,
that is of primary interest.
s. What portion of observed deaths are regarded as excess depend on how time is discretised. The data
available reports deaths in annual intervals so in this context ‘quickly’ means within 1 year. If deaths
were reported in narrower time intervals then a greater proportion of observed deaths would be
regarded as excess and in the limit with continuous time all observed deaths would be excess. Of
course, the average YLL associated with them would be smaller and is approximated by the net YLL
reported in Table 12 per observed death (the effects of approximation is likely to be small but
unavoidable as it is due to deaths being reported in annual intervals).
t. This is the same as life-years associated with excess deaths, as all observed deaths in this PBC
are excess.
u. It would be inappropriate to assign all the change in GMS expenditure to the estimate of cost per
life-year based only on the 11 PBCs with outcome elasticities because it would imply that GMS only
contributes to these PBCs. Restricting attention to the 11 PBCs with outcome elasticities but
allocating part of the change in GMS expenditure to them based on their proportional share of
changes in overall expenditure would yield the same cost per life-year as reported in Table 16, line
(4). It should be noted that including changes in GMS expenditure but not assigning health effects to
this PBC is likely to overestimate the threshold because any health effects associated with GMS will
not be reflected in the estimated outcome elasticities of other PBCs unless the effects happen to be
correlated with changes in expenditure in those PBCs.
v. Estimates of the duration of disease for each U-code are available from the GBD study (see Table 122
and Addendum 1: data sources in Appendix 3). This information is also used in Including quality-of-life
effects during disease.
w. Variation in mortality in the first year of data will only contribute to these estimates if differences are
sustained for a minimum of 3 years. Similarly, variation in mortality in the second (third) year will only
contribute if it is sustained for a minimum of 2 (1) years. If differences in mortality are similar each
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year (contribute equally to the estimates) then estimated effects must have been sustained on
average for a minimum of 2 years. As some of the variation in mortality in the first year that is not
sustained to the third year will nevertheless be sustained for 1 or 2 years, 2 life-years per death
averted represents somewhat less than the minimum, consistent with restricting YLGs to the
observed mortality data. Of course, this is the minimum difference in observed rather than
unobserved counterfactual excess deaths. Nonetheless, it can be interpreted as an upper bound
given the data available and therefore the analysis that has been feasible.
x. See Addendum 1: data sources in Appendix 3 for a description of HSE data and Appendix 3, Quality
of life based on the general population for the analysis of QoL norms illustrated in Figure 3.
y. The only exception is PBC 11 (respiratory) which has a large proportion of deaths occurring above
the LE of the PBC population (see Table 12).
z. ICD-10 estimates of the QoL score and age were pooled across data sets by considering the number
of patients from each data set contributing to estimates, i.e. a weighted average.
aa. The average QoL scores across the ICD-10 codes which contribute to each PBC and the average age
and gender of respondents were used to calculate a PBC disease-related decrement based on QoL
norms from the general population. This ‘PBC decrement’ could then be applied to each observed
death and the age at which each life-year was gained or lost. In Including quality-of-life effects
during disease information about the relative share of different types of disease (U-codes) within a
PBC and the information about which ICD-10 codes are more likely to contribute to the effects of
changes in PBC expenditure are explored.
ab. In principle it would be possible to estimate disease-related disutility by age rather than assume a
fixed decrement. HODaR does provide age for each reported QoL score but MEPS only provides
average age of respondents in published summaries. However, even with access to ‘raw’ scores
and the age and gender of each, it is very unlikely that there would be sufficient data to estimate
age-related decrements in each of the component ICD-10 codes. It would, however, be possible to
assume a proportionate rather than fixed decrement by age. As the average age of respondents in
the pooled HODaR and MEPS sample tends to be older than the age distribution of the PBC
populations (see Tables 113 and 129 in Appendix 3) this would tend to increase the quality-adjusted
net YLL and reduce the cost per QALY threshold compared with the fixed decrement applied here.
ac. The QoL score was applied to each observed death considering the age at which each life-year was
gained or lost (from ONS) using the ‘PBC decrements’ from HODaR and MEPS.
ad. The information that is available about disease duration suggests that many types of disease that
comprise the PBCs are not chronic and certainly not lifelong (see Table 122 in Appendix 3).
In Including quality-of-life effects during disease we take account of QoL experienced while alive in
the diseased state.
ae. In Using estimates of the quality-adjusted life-year burden of disease, measures of QALY burden are
used as the basis of estimating the health effects of changes in expenditure. This analysis applies
the estimated proportionate effect of changes in expenditure on life-year burden of disease to
measures of the total QALY burden. This is equivalent to assigning a proportional adjustment to the
QoL with disease to YLGs.
af. Insofar as YLL would not have been lived in full health (see Adjusting life-years for quality-of-life),
the QoL effects during disease must offset the less than full QoL of the YLL to generate a ratio > 1.
Therefore, ratios < 1 are possible even when disease has measurable QoL effects for those
experiencing it.
ag. The analysis in Adjusting life-years for quality-of-life already implies an Rdeath ratio at PBC level.
ah. Reflecting the QoL norms for the general population in Figure 3 and the distribution of ages and
gender within each U-code (see Addendum 1: data sources in Appendix 3).
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ai. As QoL effects of different disease states are expressed as age-related decrements (see Figure 4) we
do not require the HODaR and MEPS samples to necessarily be representative of the age distribution
of the population at risk in the groups of ICD-10 codes that make up each U-code.
aj. The average QoL scores across the ICD-10 codes which contribute to each U-code (see Addendum 1:
data sources in Appendix 3 for how ICD-10 codes map to U-codes) and the average age and gender
of respondents from HODaR and MEPS were used to calculate a disease decrement for each U-code,
based on QoL norms from the general population. These U-code disease decrements can then be
applied to the age and gender distribution of each U-code, based on information from GBD about
the prevalence and age distribution of each – using information about the incidence of sequelae
associated with them (as described in Years of life lost and accounting for counterfactual deaths) and
information about the durations of disease (see Appendix 3, Table 122).
ak. For example, the evidence about QoL from HODaR and MEPS suggests that the impact of U037 on
QoL is greater than indicated by DALY disability weights. The QoL effects of U141, although still
very significant, are lower than indicated by DALY disability weights.
al. Information about the size, and age and gender distribution is only available at U-code level.
Therefore U-code ratios are applied to all the ICD-10 codes that contribute to a particular U-code.
Note that, unlike ICD-10 codes, U-codes do not map directly to PBCs so some ICD-10 codes in
different PBCs may belong to the same U-code and therefore have the same U-code ratio. Some
ICD-10 codes are not included in the U-code classification of disease. Most of these are procedural
codes where we do not assign life-year and QALY effects anyway (any health effects would be
evident in other ICD-10 codes), so it was not necessary to impute ratios for them (84 out of 1562).
Of the others, most were associated with PBC 16 with a zero outcome elasticity so did not require
imputation either (186 out of 1562). Imputation based on the median ratio across the ICD-10 codes
within the PBC was required for the remaining (482 out of 1562). Eighty-eight of these cannot be
mapped into U-codes. The remaining 394 were associated with U-codes where the ratio was
undefined because the denominator (YLL) was zero. In both these cases, values were imputed based
on the median ratio across the ICD-10 codes within the PBC. As the distribution of ratios within
a PBC tend to be highly positively skewed, imputation based on the median is likely to be
conservative with respect to health effects and especially in the latter case where mortality effects
appear to be a much less important aspect of the disease.
am. It is important to note that it would be inappropriate to calculate an average of the ratios within a
PBC and then apply this ‘average ratio’ to life-year effects at PBC level, rather than calculate QALY
effects at ICD-10 level by applying the relevant ratio. The results, however, can be presented as an
implied PBC ratio (i.e. a ratio of averages) (see Table 145 in Appendix 3).
an. Unfortunately, total PBC costs are not available at ICD-10 level across PCTs so could not be used for
this purpose. Costs from HES data are only a component of total PBC costs (41% of total PBC costs
for the 11 PBCs where mortality effects can be estimated) and contribute less to the variability in
PBC costs across PCTs (HES contribute only 23% of the variability for the 11 PBCs where mortality
effect can be estimated).
ao. It should be noted that the implied QALY ratio of 1.52 for the 11 PBCs with outcome elasticities is a
ratio of QALYs to unadjusted YLL. The proportion of total QALY effects due to premature deaths for
the same PBCs (50% in Table 26) also implies a ratio – equal to 2. However, this is a ratio of total
QALY effects to quality-adjusted YLL. The difference between these two ratios is the denominator
(i.e. quality-adjusted YLL are lower than unadjusted YLL).
ap. In Adjusting life-years for quality-of-life each YLG could be assumed to be lived in full health,
i.e. lived in a QoL that reflects age and gender norms of the general population or lived in a QoL
that reflects the original disease state. Applying an estimated proportionate effect on the life-year
burden of disease to measures of QALY burden of disease implies a proportionate improvement in
the QoL with disease applied to any life-year effects. Therefore, basing estimates on measures of
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QALY burden provides a more conservative estimate of the QALY effects of changes in mortality than
the best estimate reported in Adjusting life-years for quality-of-life, which was based on QoL norms.
aq. Previously in Chapter 3 and in From mortality to life-years, Adjusting life-years for quality-of-life and
Using ratios of quality-adjusted life-years to years of life lost, expenditure elasticities were only
estimated for PBC 23 and the 11 PBCs where outcome elasticities could be estimated, with the
remaining change in total spend assigned to the other 11 PBCs. As a consequence, proportionally
more of the share of a change in total spend was allocated to these other PBCs in previous sections
[see column (3) of Table 108 in Appendix 3].
ar. Of course it would be possible to solve for a lower outcome elasticity that could be applied to
total burden which would return the required estimate of total QALY effects restricted to 1 year
(see From mortality to life-years in Appendix 3).
as. As long as estimates of the QoL decrement of disease from HODaR and MEPS are representative of
average effects across those earlier (incident) and later (prevalent) in their disease duration, an
assumption of constant QoL decrement with respect to disease duration is not required.
at. There are a number of reasons for potential inconsistencies: (i) GBD is based on earlier years of
mortality data; (ii) the imprecision of mapping from U-codes to PBC via ICD-10 codes; and (iii) the
YLL reported in GBD are calculated in the same way as published NHS IC estimates (see Life
expectancy and years of life lost and Years of life lost and accounting for counterfactual deaths)
and will tend to overestimate the net YLL (see Table 146 in Appendix 3). The YLL by U-code,
reported in GBD, that are mapped to ICD-10 codes are adjusted by these proportionate differences
to ensure that the YLL associated with all contributing ICD-10 codes are consistent with (do not
overestimate) the net YLL for the PBC as a whole. However, due to the earlier years of data and
imprecision in mapping from U-codes to ICD-10 codes there might also be some inconsistency in
estimates of the total incidence of disease for a PBC. Insofar as disease-related mortality risk is
stable, the same number of deaths should be observed in GBD and ONS data for the same at risk
population. The PBC deaths recorded in GBD and those observed in ONS data (see Table 146 in
Appendix 3) are similar but nonetheless the proportionate difference is used to adjust the scale of
QoL burden while alive based on GBD information (equivalent to adjusting estimates of incidence).
Notable exceptions are PBC 1 and PBC 18 + 19 where the discrepancies are due to imperfect
mapping from U-codes to PBC via ICD-10 codes.
au. HES costs are a much smaller proportion of total PBC expenditure for the 11 PBCs where mortality
effects could not be estimated (HES costs account for < 15% of total PBC expenditure) and account
for very little of the variability in PBC costs across PCTs (the contribution that variance in HES costs
makes to variance in PBC expenditure in this group of PBCs is < 8%). Therefore allocating PBC level
effects to ICD-10 codes based on contribution to variance in HES costs is less appropriate when
information about QALY burden in this group of PBCs is used to inform the estimate of the
overall threshold.
av. See note au and Table 154 in Appendix 3.
aw. Note that this is the ratio of total change in health to total change in expenditure across these
PBCs (rather than an average ratio), and the contribution that each of these PBCs make to these
total effects on health and expenditure depends on the estimated expenditure as well as
outcome elasticities.
ax. Applying the absolute health effect of expenditure from the 11 PBCs with outcome elasticities
implies different (higher) proportionate effects in the other PBCs.
ay. The QALY burdens per incident patient are reported in this Table 147 for each PBC, including the
median and range across the contributing ICD-10 codes. However, these values should not be over
interpreted as the ‘average’ QALY burden for the PBC depends on how PBC effects are allocated to
ICD-10 codes and the ‘average’ burden for groups of PBCs depends on how a change in overall
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expenditure is shared between them (i.e. the expenditure elasticities estimated for each PBC in
Chapter 3 and Appendix 2).
az. See Addendum 3: characterisation of the investment and disinvestment decisions in mental
health – depression and schizophrenia in Appendix 3 for an examination of the value of investment
and disinvestments that may have been available in PBC 5 (mental health disorders), which
accounts for much of the change in overall expenditure.
aaa. The exception is PBC 18 + 19. The reason is that there are significant adjustments made based on
differences in observed and recorded mortality (to adjust for differences in classification when
mapping from U-codes to PBCs via ICD-10 codes) as well as differences in YLL due to the GBD
method of calculation (see Table 146 in Appendix 3).
aab. The implied QALY ratios across these 11 PBCs range from 0.70 in PBC 2 (cancer) to 14.86 in
PBC 7 (neurological).
aac. The cost per life-year threshold in Table 16 can be interpreted as cost per QALY thresholds
conditional on the assumption that all life-years are lived in full health and the QoL with disease is
zero (equivalent to death).
aad. Note that the proportionate differences between the estimates in Table 29, column (3) and
columns (1) and (2) are greater in lines (1) and (2), reflecting the additional health effects from
considering the likely impact of changes in expenditure on QoL during disease. These differences
are less marked in line (3) because the effects in those PBCs where an outcome elasticity can be
estimated are extrapolated to the other PBCs using proportionate effect on QALY burden and
measures of QALY burden in these other PBCs (see the discussion in Using estimates of the
quality-adjusted life-year burden of disease for more details).
aae. It would be inappropriate to assign all the change in GMS expenditure to the estimate of cost per
QALY based only on the 11 PBCs with outcome elasticities because it would imply that GMS only
contributes to these PBCs. Restricting attention to the 11 PBCs with outcome elasticities but
allocating part of the change in GMS expenditure to them based on their proportional share of
changes in overall expenditure would yield a slightly higher cost per QALY than reported in Table 29,
line (2). It should be noted that including changes in GMS expenditure but not assigning health
effects to this PBC is likely to overestimate the threshold because any health effects associated with
GMS (or PBC 22, see notes m and u) will not be reflected in the estimated outcome elasticities of
other PBCs unless the effects happen to be correlated with changes in expenditure in those PBCs.
Chapter 5
a. The cost per life-year threshold in Table 30, column (1) can be interpreted as cost per QALY
threshold conditional on the assumption that all YLGs or lost are lived in full health but the QoL
with disease is zero (equivalent to death).
b. The cost per life-year adjusted for QoL in Table 30, column (2) can be interpreted as cost per QALY
threshold conditional on the assumption that the QoL with disease is zero (equivalent to death);
effectively ignoring any effects on those who survive with disease.
c. It would be inappropriate to assign all the change in GMS expenditure to the estimate of cost per
QALY based only on the 11 PBCs with outcome elasticities because it would imply that GMS only
contributes to these PBCs. Restricting attention to the 11 PBCs with outcome elasticities but
allocating part of the change in GMS expenditure to them based on their proportional share of
changes in overall expenditure would yield a slightly higher cost per QALY than reported in
Table 30, line (2). It should be noted that including changes in GMS expenditure but not assigning
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health effects to this PBC is likely to overestimate the threshold because any health effects associated
with GMS or PBC 22 social care (see Chapter 4, note o), will not be reflected in the estimated
outcome elasticities of other PBCs unless the effects happen to be correlated with changes in
expenditure in those PBCs.
d. The effects of discounting are modest because (i) the health effects of a change in expenditure are
restricted to 1 year (where no discounting is necessary); (ii) most of the total QALY effect occurs
in that year; (iii) it is only some of the life-year effects (adjusted for quality) of a change in mortality in
that year that occur in future years that need to be discounted; and (iv) these need to be discounted
only over 4.6 years on average (see Tables 191 and 192 in Appendix 3 for discounted values).
e. Which is determined by the estimated expenditure elasticities (the proportionate change in PBC
expenditure due to a change in overall expenditure) and total PBC expenditure (see Chapter 3 and
Analysis of programme budgeting expenditure for 2008/9 and mortality data for 2008/9/10 in
Appendix 2).
f. Which are determined by the outcome elasticities (the proportionate effects on mortality and YLL of
a proportionate change in PBC expenditure, see Chapter 4, Using estimates of the quality-adjusted
life-year burden of disease for details of how these estimates can be applied to measures of QALY
burden in all PBCs).
g. See Chapter 4, Including quality-of-life effects during disease for how PBC level effects can be
allocated to the contributing ICD-10 codes and how measures of QALY burden for each ICD-10 code
can be established.
h. Within PBC 11, chronic lower respiratory diseases (J40–J47) account for 85% of the QALY effects of
a change in PBC expenditure; lung diseases due to external agents (J60–J70), 4%; other diseases
of the upper respiratory tract (J30–J39), 4%; other respiratory diseases principally affecting the
interstitium (J80–J84), 1%; and other diseases of pleura (J90–J94), 1%. The other ICD-10 codes
each contribute less, but together account for 4% of the health effects of a change in PBC
11 expenditure.
i. Within PBC 10, ischaemic heart diseases (I20–I25) accounts for 55% of the QALY effects of a change
in PBC expenditure; cerebrovascular diseases (I60–I69), 21%; other forms of heart disease (I30–I52),
7%; congenital malformations and deformations of the circulatory system (Q20–Q28), 3%; and
diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified (I80–I89), 3%.
The other ICD-10 codes each contribute less but together account for 8% of the health effects of
a change in PBC 10 expenditure.
j. Within PBC 7, episodic and paroxysmal disorders (G40–G47) account for 73% of the QALY effects
of a change in PBC expenditure; extrapyramidal and movement disorders (G20–G26), 8%;
other degenerative diseases of the nervous system (G30–G32), 5%; other disorders of the nervous
system (G90–G99), 3%; and nerve, nerve root and plexus disorders (G50–G59), 2%. The other
ICD-10 codes each contribute less but together account for 9% of the health effects of a change in
PBC 7 expenditure.
k. HES costs only account for 16.8% of total costs in PBC 5 and only explain 5.9% of the variance in
PBC costs across PCTs (see Chapter 4, notes an, au and Chapter 5, note ai), therefore it seems
unlikely that a large proportion of investment and disinvestment in this PBC has been associated with
these ICD-10 codes.
l. Although the published evidence suggests that investment and disinvestment opportunities in this
PBC tend to be much more valuable than the implied cost per QALY, we have little information
on the particular investments and disinvestments that were actually made by PCTs. The review of
local data sources (see Appendix 3, Addendum 2: the role of data on local NHS decisions) revealed
very little routinely collected information about specific investments and disinvestments beyond more
aggregate measures of spending. In common with other PBCs, there will inevitably be inefficient,
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ineffective or even iatrogenic practice (e.g. due to poor diagnosis and inappropriate prescribing).
Insofar as these types of activities are sensitive to changes in PBC expenditure this will tend to
increase the cost per QALY associated with changes in expenditure in this PBC. Whether or not both
the extent of these inefficiencies and their sensitivity to changes in expenditure are sufficient to
increase the cost per QALY above £18,744 is unclear, although it seems unlikely. Note that the
effects of the scale and sensitivity to expenditure of inefficient or even harmful practice in the other
PBCs where outcome equations could be specified are already captured in the estimated
outcome elasticities.
m. In principle, at least, with sufficient panel data which would allow a more complex lag structure and
simultaneous estimation of expenditure and outcome elasticities across all PBCs, it might be possible
to isolate the short run effects of a change in expenditure in one PBC across all the others. In the
absence of such data and so long as adjustments are expected take place quickly relative to the time
horizon of the effects of the new technology on NHS cost and outcomes (i.e. marginal NHS
resources can be reallocated in the medium term), using the overall cost per QALY threshold for
technologies relevant to any PBC is reasonable and more so than other alternative assumptions that
might be made.
n. The health effects of a change in expenditure in a ‘contributory’ PBC will not be reflected in the
estimated health effects of change in expenditure in the ‘recipient’ PBCs unless they happen to be
correlated with changes in expenditure in the ‘recipient’ PBCs, i.e. all changes in expenditure are
assigned to PBCs but all the health effects may not be. This suggests that the health effects are likely
to be underestimated and the overall threshold underestimated.
o. The quite general theoretical framework in Chapter 3 assumes that PCTs maximise some unspecified
welfare function where health (not necessarily QALYs) is one of its arguments (see Chapter 3,
Modelling framework). The type of econometric analysis conducted would remain the same
irrespective of the measure of health or weights that might be place on different types of health
gained or lost. The assumption required is that mortality is related to the ‘health’ argument,
however, ‘health’ might be specified. We make no comment on whether or not QALY maximisation
ought to be the objective of PCTs, nor is that required to estimate a threshold for NICE which is
currently based on cost per (unweighted) QALY.
p. A form of value of information analysis could be applied to these estimates in subsequent research,
ideally capturing some of the other sources of uncertainty. Such analysis has firm foundations in
statistical decision theory and has been applied to health-care decisions. More recently it has been
applied to the decisions faced by NICE when considering whether or not there is sufficient evidence
to support the approval of a new technology.
q. The Monte Carlo simulation is in essence Bayesian, where the standard errors from the frequentist
econometric analysis are used to assign normal prior distributions with means equal to the point
estimates and a standard deviation equal to the estimated standard errors. This is equivalent to a
fully Bayesian analysis with initially uninformative priors which are updated through the analysis of
expenditure and mortality data.
r. Note that the mean of the simulated values is not the mean of the sampled ratios but the ratio of
the mean sampled values for the numerator and denominator. Deterministic and simulated values
are the same for 2006, 2007 and 2008 expenditure data (other than negligible Monte Carlo error
from 1000 samples). Also note that in constructing the cumulative probability density function in
Figure 5 and the histograms of values in Appendix 3 it is important to identify whether sampled
negative values favour a low value for the threshold or an unbounded one (there were no negative
values sampled in the simulation of values for all 23 PBCs).
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s. Positive correlation suggests that a high spend elasticity will be associated with a high outcome
elasticity (i.e. less negative, implying a smaller heath effect of a change in expenditure) resulting in a
higher estimate of the threshold. It also suggests that when spend elasticity is low, outcome elasticity
will also tend to be lower (i.e. more negative, implying a larger health effect of a change in
expenditure) resulting in a lower estimate of the threshold. Although realisations of spend elasticities
higher and lower than the mean estimate are equally likely, higher spend elasticities provide a
greater ‘weight’ associated with higher estimates of the threshold (where outcome elasticity is also
high) when calculating the mean threshold. For these reasons a positive correlation will tend to
increase the mean estimate of the threshold.
t. Only a negative skew in the distribution of the threshold would tend to offset the implications of the
non-linear relationship between NHB and the value of the threshold. However, in this case the mean
estimate is very similar but slightly greater than median values (see Using ratios of quality-adjusted
life-years to years of life lost in Appendix 3) indicating a small positive skew, which reinforces the
implication that the policy threshold should be below the expected or mean value.
u. Rather than solve for this type of ‘certainty equivalent’, a probabilistic analysis of the
cost-effectiveness of a technology which integrated the uncertainty associated with the cost per
QALY threshold as well, would take account of these issues (i.e. the technology would be
cost-effective if it offered the highest expected net benefit when averaged over all Monte Carlo
simulations, including sampling from the distribution of the cost per QALY threshold).
v. Although health benefits can be expressed in terms of consumption (in money) using some consumption
value of the health effects (WTP), NHS costs must be first converted into health forgone, using an
uncertain estimate of the threshold, before these are also expressed in consumption (money terms) using
the same consumption value of health, i.e. the non-linear effect of the threshold remains unavoidable.
Failure to account for the threshold and the implications of its uncertainty would only be reasonable in a
heath-care system where expenditure was not constrained and/or all costs fell on private consumption.
w. There are of course other unquantified sources of structural uncertainty in any statistical model.
In this case the underlying model is based on a production function for health consistent with
Cobb–Douglas, which has firm theoretical foundations and has been widely used in health and
elsewhere. Although it might be possible to test more flexible function forms (also founded in
economic theory) to quantify this other source of structural uncertainty, there are no reasons to
believe that more flexible functional forms would necessarily increase or reduce the estimates of
outcome elasticities.
x. What can be estimated is the health effect over the observed variation in expenditure. This will also
be the ‘true’ marginal effect (tangency at a budget of B1) if health returns to expenditure diminish
at a constant rate (the second derivative is constant) as illustrated in Figure 7. As nothing is ‘truly’
marginal the important question is how the threshold changes with the sign and scale of the
non-marginal budget impact associated with approval of a new technology.
y. Due to the diminishing marginal returns illustrated in Figure 8 (see Impact of investment,
disinvestment and non-marginal effects for further explanation).
z. 2008 expenditure expressed in 2007 NHS prices based on 3.9% NHS inflation from the HCHS
index – see Adjusting the cost of life-year estimates to constant prices in Appendix 2.
aa. See Tables 157 and 184 in Appendix 3 for a summary of outcome and expenditure elasticities and
total expenditure by PBC in 2007 and 2008. Also see Table 180 in Appendix 3 with Table 31 for an
indication of these net effects on the share of health effects and changes in expenditure.
ab. If the growth rate in the nominal threshold between 2007 and 2008 was applied, the current 2012
threshold would be expected to be £10,536.
ac. All relevant documentation is available at NICE.108,109
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ad. Although there was insufficient mortality at PCT level to estimate outcome elasticities for the other
PBCs, the measure of QALY burden in some of these PBCs does include some mortality (based on
ONS data). Therefore, applying a proportionate effect to measures of QALY burden of will include
some mortality and life-year effects although they represent only a small proportion of the total
QALY effects.
ae. The differences in contribution to deaths compared with life-years reflects the distribution of age at
death and the age and gender distribution of the population at risk in the ICD-10 codes that
contribute to each PBC (see Chapter 4, From mortality to life-years and Addendum 1: data sources
in Appendix 3).
af. Information about the age, gender and the incidence of sequelae associated with different diseases
within a PBC are only available for U-codes which can be mapped to groups of three-digit ICD-10
codes. Also allocating PBC level effects to ICD-10 codes was based on the proportion of the total
PBC population within each contributing ICD-10 codes because PBC costs are not available at
ICD-10 code level across PCTs. Although costs from HES data are available at ICD-10 code level they
are only a small component of total PBC costs and contribute very little to the variability in PBC costs
across PCTs especially in those PBCs where mortality effects could not be estimated (also see
Chapter 4, notes ap and av, and Addendum 1: data sources in Appendix 3).
ag. This is implicit in the estimates of outcome elasticities presented in Chapter 3. Although 3 years of
mortality data are used in the analysis of each year of expenditure, these are averaged to an annual
value prior to estimating outcome elasticities, so the estimated outcome elasticities represent the
proportionate effect on mortality in 1 year due to a proportionate change in expenditure. This is
likely to underestimate effects on mortality as expenditure that reduces mortality risk (or reduces the
QALY burden of disease) for an individual in 1 year may well also reduce their risk (reduce QALY
burden) over subsequent years; possibly over the whole of their remaining disease duration.
Expenditure may also prevent disease in future patient populations. Therefore, total health effects
will be underestimated and the cost per life-year or QALY threshold will be overestimated.
ah. The YLG associated with each death averted are based on what would have been their LE taking
account of their age and gender (using life tables for the general population).
ai. It should be recognised that the purpose is to inform an assessment of the threshold for decisions
that have not yet been made (i.e. prediction for decisions not yet made rather than a description of
the past). Therefore, irrespective of the availability of evidence or the sophistication of analytical
methods, the need for assumptions or scientific value judgements can never be avoided but only
better informed.
aj. The nature of prediction to inform decisions, combined with the reality of a forever unobserved
counterfactual makes judgement unavoidable – see note ai.
ak. For example, a more structural approach of estimating an outcome equation jointly with an
expenditure equation, both with appropriately specified lag structures and controlling for
unobserved PCT effects might be possible, although changes to PCT boundaries, recording of PBC
data and the recent formation of Clinical Commissioning Groups (CCGs) makes the time
series problematic.
al. The health effects of previous changes in expenditure in t – n will not be reflected in estimates
of the health effects of changes in expenditure in t unless they happen to be correlated with
changes in expenditure in t. Therefore, excluding a longer lag structure for the health effects
of changes in expenditure in t – n, . . . t, . . . , t+ n is likely to underestimate the effects of changes
in expenditure in t.
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am. These effects will be picked up in the cross-sectional variation, at least partially, so long as there is
some variation in the health effects achieved and scale of simultaneous investment or disinvestment
across PCTs.
an. This would be particularly interesting when reconsidering the subgroup analysis in Impact of
investment, disinvestment and non-marginal effects with panel data.
ao. We have taken account of competing risks or counterfactual deaths (which might appear in any of
the PBCs in our calculation of net YLL – see Chapter 4, Years of life lost and accounting for
counterfactual deaths). The health effects of a change in expenditure in ‘contributory’ PBCs
will not be reflected in the estimated health effects of change in expenditure in the ‘recipient’ PBCs
unless they happen to be correlated with changes in expenditure in the ‘recipient’ PBCs, i.e. all
changes in expenditure are assigned to PBCs but all the health effects may not be. This suggests
that the health effects are likely to be underestimated and the overall threshold underestimated
(see Which programme budget categories matter most? and note p).
ap. The vast majority of hip and knee replacements are for osteoarthritis which is included in PBC 15.
aq. These data have only been collated centrally since April 2012 despite IAPT sites collecting these data
at individual patient encounters for many years. In April 2012, the IAPT data standard was approved
by the NHS Information Standards Board as a nationally mandated data standard. Data is now
collected centrally on a monthly basis from over 200 service locations. The first report on the quality
of IAPT data was published in November 2012 but the quarterly IAPT data reports, which were
scheduled to be released at the same time have not been made available. Although there is a
commitment to make the data set publicly available, the timing and details of what will be available
(summaries or patient-level data and whether it will include the waves of data collected since 2006)
and who might have access (commissioners, service providers or independent researchers) remains
unclear (see www.iapt.nhs.uk and www.hscic.gov.uk/iapt).
ar. Similar difficulties will arise, however, when translating the observed impact of a therapy on QoL,
before and immediately after the intervention, into longer-term effects.
Appendix 1
This is the aim of a value-based pricing approach previously considered by the Department of Health.2
a. In fact, the 2004 NICE Methods Guide5 noted that ‘the threshold will change over time as the
budget for healthcare changes’ (p. 33). However, there is no clear reference to this change in the
2008 Methods Guide.3
Appendix 2
a. This study builds on previous work that was undertaken as part of the Quest for Quality and
Improved Performance, a 5-year initiative of the Health Foundation.
b. Strictly speaking, these local health authorities are PCOs but the vast majority of these are ‘trusts’
and we retain this terminology throughout.
c. In April 2010 two PCTs [East and North Hertfordshire (5P3) and West Hertfordshire (5P4)] merged
to form a single organisation [Hertfordshire PCT (5QV)] so that, since this date, there have been
151 PCTs. At the same time Blackburn and Darwen PCT (5CC) became Blackburn and Darwen
Teaching Care Trust Plus (TAP). In April 2011 Solihull Care Trust (TAM) became a PCT (5QW).
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d. Some commentators have suggested that some of the within programme variation in expenditure
observed across PCTs reflects different accounting conventions or unknown local factors. One way
of reducing the impact of such unobserved heterogeneity is to construct a longitudinal data set with
expenditure and mortality for each PCT for several years. With the availability of several years of data
for both expenditure and mortality, we wanted to estimate a panel data model. However, most of
the instruments employed here are based on the 2001 Census and thus estimation of a panel model
will not be possible until these too become time variant; this should occur later this year with release
of the 2011 Census data at PCT level. The same difficulty arises with the estimation of an
incremental model.
e. This figure ignores intracategory changes (e.g. where an ICD-10 code is reallocated from category 1A
to 1B) and only counts cross-category changes (e.g. where the code is switched from category 1 to
category 2).
f. This expert review also led to the introduction of 40 additional subcategories including 10 subcategories
for the cancer and tumour programme.
g. Expenditure on, for example, community care, A&E, ambulance services and outpatients can be
difficult to attribute a particular PBC. Critical care, rehabilitation and specialised commissioning
across care settings will also be difficult to attribute to a particular programme.
h. This cost adjustment reflects the fact that health economy input prices vary considerably across the
country and, for some inputs, are up to 40% higher in London and the south east of England than
elsewhere. We have used a weighted average of the three MFFs for HCHS, for prescribing, and for
GMS/PMS to adjust the raw expenditure figures in Table 2 for local input prices.74
i. This needs adjustment incorporates the AREA resource allocation formula for HCHS.76
j. The Association of Chartered Certified Accountants (ACCA)/Audit Commission [Association of
Chartered Certified Accountants (ACCA)/Audit Commission. Costing Care Pathways: Understanding
the Cost of the Diabetes Care Pathway. London: ACCA/Audit Commission; 2011] looked at the
reliability of the PB data for the diabetes subgroup within the endocrine and metabolic problems
category. The ACCA/Audit Commission noted that PB data includes inpatient and prescribing
expenditure, which are thought to be relatively reliably allocated to PBCs and to be consistently
costed across PCTs, and outpatient and community service expenditure, which are thought to be
less reliably allocated to PBCs and to be less consistently costed across PCTs. The ACCA/Audit
Commission compared the variation in expenditure for inpatient and prescribing expenditure with
that for total programme budget expenditure and found that the latter was far greater than the
former. However, the interpretation of this result is not straightforward; as the ACCA/Audit
Commission noted, it is difficult to know whether differences in programme budget spend are
attributable to variation in service provision and efficiency, or simply to different approaches to
cost allocation.
k. One exception to this is the mortality rate for the trauma and injuries programme where initially only
SMRs were available.
l. The NHS IC reports mortality rates using deaths pooled over a 3-year period because the relatively
small number of annual deaths in some disease categories might lead to large year-on-year
fluctuations in death rates at PCT level.
m. However, we do experiment with replacing and supplementing this all service measure of need with
more programme-specific measures where these are available (e.g. using the diabetes and epilepsy
prevalence rates).
n. Although need is a function of mortality/morbidity in the resource allocation formula, the relationship
is not sufficiently strong enough for us to be concerned about the endogeneity of the need in any
individual care programme.
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o. When estimating expenditure equations using PB data for 2005/6 for cancer and circulatory disease
we persevere (for continuity with previous studies) with the use of the circulatory disease SYLLR as
the proxy for other programme need in the cancer programme, and we use the cancer SYLLR as the
proxy for other programme need in the circulatory disease programme (see Martin et al.60,63).
p. The IV procedure involves the estimation of the second-stage expenditure equation as specified in
Equation 12 and the estimation of a first-stage expenditure equation associated with Equation 13.
The same variable might have different coefficients in these two equations because the equations
will have different sets of covariates.
q. For the case of a single endogenous regressor and three excluded instruments, Stock and Yogo80
critical values are as follows in terms of the bias of 2SLS relative to bias of OLS: relative bias 5%,
critical value= 13.9; relative bias 10%, critical value= 9.08; relative bias 20%, critical value= 6.46;
relative bias 30%, critical value= 5.39.
r. The OLS version of Ramsey’s81 reset test was invoked using Stata’s -ovtest- command, and the IV
equivalent was invoked using -ivreset-.
s. As all PCTs face the same prescribing costs, the prescribing MFF is 1 for all PCTs.
t. The ‘big four PBCs’ are the cancer, circulatory disease, respiratory problems and gastrointestinal
problems. They are ‘big’ programmes in terms of the number of deaths associated with
each programme.
u. The programme-specific cost per life and life-year estimates presented here will underestimate
the true programme-specific costs because not all PCT expenditure can be allocated to a specific
programme (e.g. all GMS expenditure is allocated to PBC 23 rather than being split between
cancer, circulatory disease, respiratory problems, etc.). However, this more generic expenditure is
incorporated into the calculation of the cost of a life-year when this calculation is undertaken across
all programmes.
v. These are the ‘big four PBCs’ in terms of the number of lives (or life-years) lost.
w. The cost of a life-year for a group of PBCs is calculated by dividing (a) the sum of the change in
spend on the component PBCs by (b) the sum of the change in the number of lives/life-years lost for
the component PBCs.
x. We are grateful to Steve Morris for this suggestion.
y. Instead of estimating programme-specific models we also tried estimating an outcome model using
the all-cause mortality rate and expenditure across all programmes combined but this was not
successful (again, counterintuitive signs were obtained on some variables). We also investigated the
possibility of using an overall measure of health derived from the HSE. Apart from sample size issues
at PCT level (4645 adults in England were interviewed for the 2009 survey), such surveys by
definition only provide information about the health status of the living population and reveal
nothing about the level of mortality.
z. The cost of a life-year for those 13 programmes where there is no health gain is, of
course, undefined.
aa. Note that implied need= unified weighted population/(CARAN MFF× raw population).
ab. Ideally, the test F-statistic should be ≥ 10.
ac. Clearly, some expenditure in year t will have an effect on mortality beyond t + 2 but we have no
mortality data that would allow us to include this in our modelling work. We must assume that, for
expenditure that affects mortality beyond t+ 2, PCTs have reached some sort of equilibrium position
in terms of their expenditure choices and the outcomes secured.108,109
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ad. When re-estimating the all PCT model for ‘high spenders’ and then for ‘low spenders’, no attempt
was made to adjust the estimating equation for any implied model misspecifiaction.
ae. The cost of a life-year estimates presented in Table 74 are not adjusted for the mismatch in the
ICD-10 coverage of the expenditure and mortality data because such an adjustment would not
affect our conclusions.
af. See column (1) of Table 65 for the estimated IV cancer outcome model.
ag. We used a symmetrical distribution about zero because we have no priors about the signs of the
coefficients on the instruments. The use of a uniform distribution is arbitrary but of no significance.
ah. The outcome model for circulatory disease reported in Table 65 (using PB expenditure for 2006/7
and mortality data for 2006/7/8) contains four instruments. The application of the sensitivity analysis
described in this section is considerably easier to implement if only two instruments are present and
re-estimation of the outcome model for circulatory disease without the two least significant
instruments generates very similar results to those obtained with all four instruments (e.g. the
coefficient on expenditure declines marginally from –1.434 to –1.427). Therefore, the sensitivity
analysis reported here uses the outcome model containing only two instruments.
ai. The Kleibergen–Paap F-statistic is very close to the target value of 10 for both the genitourinary and
infectious diseases outcome models.
aj. Expenditure on, for example, community care, A&E, ambulance services and outpatients can be
difficult to attribute to a particular PBC. Critical care, rehabilitation and specialised commissioning
across care settings will also be difficult to attribute to a particular programme.
ak. With the index for 1987/8 set equal to 100, then 2005/6= 240.9, 2006/7= 249.8, 2007/8= 257.0,
and 2008/9= 267.0.87
Appendix 3
a. The calculated mid-points are as follows:
Age range (years) < 1 1–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44
Mid-point 0.5 3.0 7.5 12.5 17.5 22.5 27.5 32.5 37.5 42.5
Age range (years) 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85–89 90+
Mid-point 47.5 52.5 57.5 62.5 67.5 72.5 77.5 82.5 87.5 92.5
b. The YLL available from NHS IC represented all deaths from maternity and all deaths under 28 days
across PBCs. The coverage factor (0.679) adjusts this YLL to represent maternity and all deaths
< 1 year across PBCs. The calculation is described in Appendix 2, Table 37 footnotes.
c. Figures for England, from ONS.152
d. Note that the outcome elasticities are based on PBC mortality that is sensitive to changes in
expenditure (i.e. is avoidable) at the margin so no assumptions about how much of the PBC
mortality is avoidable is required.
e. Although this research was not funded to purchase access to GPRD data we were able to examine a
sample of it which comprised of 22,313,086 rows/patient–ICD-10 events (three digit) representing
4,229,910 patients with data on new diagnosis of diseases observed between 1 January 2006 and
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24 June 2011 (see Addendum 1: data sources). Although GPRD data could, in principle, provide this
type of information the difficulties of reliability, face validity and interpretation of the sample data in
the form available to us meant that it was not directly useful.
f. We are aware that the 2000–2 WHO GBD study and the update which was published in 2008 using
2004 data has itself recently been updated. However, the report and tools were not publically
available at the time this research was conducted.
g. Throughout the analyses in this appendix, mortality, life-years and QALY were not assigned to
procedural ICD-10 codes (i.e. those in ICD-10 chapter Z, Factors influencing health status and contact
with health services). Health effects from increased spending on these ICD-10 codes would either be
non-existent or would be evident in other ICD-10 codes related to the procedure. This means that no
health effects are associated with PBC 22 social care (which only includes procedural ICD-10 codes),
although changes in expenditure on PBC 22 are included. This is likely to overestimate the threshold
because any health effects associated with PBC 22 will not be reflected in the estimated outcome
elasticities of other PBCs unless the effects happen to be correlated with changes in expenditure in
those other PBCs.
h. This is the same as life-years associated with excess deaths, as all observed deaths in this PBC
are excess.
i. It should be noted that including changes in GMS expenditure but not assigning health effects to this
PBC is likely to overestimate the threshold because any health effects associated with GMS will not be
reflected in the estimated outcome elasticities of other PBCs unless the effects happen to be
correlated with changes in expenditure in those PBCs.
j. This information is also used in Including quality-of-life effects during disease.
k. As some of the variation in mortality in the first year that is not sustained to the third year will
nevertheless be sustained for 1 or 2 years, 2 life-years per death averted represents somewhat less
than the minimum, consistent with restricting YLGs to the observed mortality data.
l. The table below reports the cost per QALY threshold using a relative weight based on the size of the
ICD-10 code population to allocate health effects:
Cost per QALY threshold (£)
(1) DALY ratios (2) Adjusted DALY ratios (3) QALY ratios (HODaR and MEPS)
All big four programmes 4400 5100 2340
11 PBCs (with mortality) 8066 9267 4212
All 23 PBCs 9117 10,474 4760
m. In Chapter 4, Adjusting life-years for quality-of-life each life-year gained could be assumed to be lived
in full health, lived in a QoL that reflects age and gender norms of the general population or lived in a
QoL that reflects the original disease state. Applying an estimated proportionate effect on the life-year
burden of disease to measures of QALY burden of disease implies a proportionate improvement in the
QoL with disease applied to any life-year effects. Therefore, basing estimates on measures of QALY
burden provides are more conservative estimate of the QALY effects of changes in mortality than the
best estimate reported in Chapter 4, Adjusting life-years for quality-of-life, which was based on
QoL norms.
n. HES costs are a much smaller proportion of total PBC expenditure for the 11 PBCs where mortality
effects could not be estimated (HES costs account for < 15% of total PBC expenditure) and account
for very little of the variability in PBC costs across PCTs (the contribution that variance in HES costs
makes to variance in PBC expenditure in this group of PBCs is < 8%). Therefore, allocating PBC level
effects to ICD-10 codes based on contribution to variance in HES costs is less appropriate when
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information about QALY burden in this group of PBCs is used to inform the estimate of the
overall threshold.
o. Note that this is the ratio of total change in health to total change in expenditure across these PBCs
(rather than an average ratio) and the contribution that each of these PBCs make to these total
effects on health and expenditure depends on the estimated expenditure as well as the
outcome elasticities.
p. Applying the absolute health effect of expenditure from the 11 PBCs with outcome elasticities implies
different (higher) proportionate effects in the other PBCs.
q. Note that the proportionate difference between the estimates in Table 153 column (3) and columns (1)
and (2) are greater in lines (1) and (2), reflecting the additional health effects from considering the likely
impact of changes in expenditure on QoL during disease. These differences are less marked in line
(3) because the effects in those PBCs where an outcome elasticity can be estimated are extrapolated to
the other PBCs using proportionate effect on QALY burden and measures of QALY burden in these
other PBCs.
r. It would be inappropriate to assign all the change in GMS expenditure to the estimate of cost per
QALY based only on the 11 PBCs with outcome elasticities as it would imply that GMS only
contributes to these PBCs. Restricting attention to the 11 PBCs with outcome elasticities but
allocating part of the change in GMS expenditure to them based on their proportional share of
changes in overall expenditure would yield a slightly higher cost per QALY than reported in
Table 153, line (2). It should be noted that including changes in GMS expenditure but not assigning
health effects to this PBC is likely to overestimate the threshold because any health effects associated
with GMS (or PBC 22 see Chapter 4, notes m and u) will not be reflected in the estimated outcome
elasticities of other PBCs unless the effects happen to be correlated with changes in expenditure in
those PBCs.
s. Which are determined by the estimated expenditure elasticities (the proportionate change in PBC
expenditure due to a change in overall expenditure) and total PBC expenditure (see Chapter 3 and
Analysis of programme budgeting expenditure for 2008/9 and mortality data for 2008/9/10 in
Appendix 2).
t. Which are determined by the outcome elasticities [the proportionate effects on mortality and YLL of
a proportionate change in PBC expenditure (see Including quality-of-life effects during disease for
details of how these estimates can be applied to measures of QALY burden in all PBCs)].
u. See Including quality-of-life effects during disease for how PBC level effects can be allocated to the
contributing ICD-10 codes and how measures of QALY burden for each ICD-10 code can
be established.
v. HES costs only account for 16.8% of total costs in PBC 5 and only explain 5.9% of the variance in
PBC costs across PCTs, therefore it seems unlikely that a large proportion of investment and
disinvestment in this PBC has been associated with these ICD-10 codes.
w. Although the published evidence suggests that investment and disinvestment opportunities in this
PBC tend to be much more valuable than the implied cost per QALY, we have little information on
the particular investments and disinvestments that were actually made by PCTs. The review of local
data sources (see Addendum 2: the role of data on local NHS decisions) revealed very little routinely
collected information about specific investments and disinvestments beyond more aggregate
measures of spending. In common with other PBCs, there will inevitably be inefficient, ineffective or
even iatrogenic practice (e.g. due to poor diagnosis and inappropriate prescribing). Insofar as these
types of activities are sensitive to changes in PBC expenditure this will tend to increase the cost per
QALY associated with changes in expenditure in this PBC. Whether or not both the extent of these
inefficiencies and their sensitivity to changes in expenditure are sufficient to increase the cost per
QALY above £13,876 is unclear, although it seems unlikely. Note that the effects of the scale and
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sensitivity to expenditure of inefficient or even harmful practice in the other PBCs where outcome
equations could be specified are already captured in the estimated outcome elasticities.
x. Professor Craig Currie and Sara Jenkins-Jones.
y. This represents six fewer than the incidence data as in these instances the end dates for the disease
were beyond the end of the data collection period.
z. Mapping algorithms were provided by the NHS Connecting for Health group,
see www.connectingforhealth.nhs.uk/systemsandservices/data/clinicalcoding/crossmap for
more details.
aa. Representing instantaneous, 1 month, 1 year, 5 years and lifelong.
ab. For more information on access to the toolkit see WHO.156
ac. For more information on the surveys and the data they collect see Department of Health.158
ad. This contrast was informed by our clinical representative (Dr Charlotte Haylock, York Teaching
Hospital NHS Foundation Trust, 2012, personal communication).
ae. Estimate by Tim Kendal.
af. This view was informed by our clinical advisors.
ag. Although there was insufficient mortality available at PCT level to estimate outcome elasticities for
the other PBCs, the measure of QALY burden in some of these PBCs does include some mortality
(based on ONS data). Therefore, applying a proportionate effect to measures of QALY burden
disease of will include some mortality and life-year effects although they represent only a small
proportion of the total QALY effects.
ah. Information about the age, gender and the incidence of sequelae associated with different diseases
within a PBC are only available for U-codes which can be mapped to groups of three-digit ICD-10
codes. Also, allocating PBC-level effects to ICD-10 code was based on the proportion of the total
PBC population within each contributing ICD-10 code because PBC costs are not available at ICD-10
code level across PCTs. Although costs from HES data are available at ICD-10 code level, they are
only a small component of total PBC costs and contribute very little to the variability in PBC costs
across PCTs especially in those PBCs where mortality effects could not be estimated (also see
Chapter 4 notes ap and av and Addendum 1: data sources).
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Appendix 1 Systematic review of the literature
on the cost-effectiveness threshold
Systematic review approach
Introduction
The aim of the systematic review was to inform the development of the conceptual framework, as well
as the design, implementation and interpretation of the empirical analyses. Rather than define a set of very
specific questions to answer through the review, the objective was to characterise the existing literature in
terms of the questions addressed and approaches taken. However, it was hoped that insights would be
provided on topics including:
l general conceptualisation of the cost-effectiveness threshold
l how NICE’s cost-effectiveness threshold should be defined, characterised and operationalised
l approaches to estimating cost-effectiveness thresholds in general and the NICE threshold in particular.
In the initial stages of this systematic review it became clear that the ‘traditional’ method of conducting
systematic searches of existing literature on the topic of the cost-effectiveness threshold would be
insufficient to deal with the requirements of this particular study. Here we refer to the ‘traditional’ method
as the practice of finding key terms and medical subject headings (MeSHs) that most accurately capture
the range of literature relevant to the topic, while attempting to include as few irrelevant studies as
possible (making use of programs such as MEDLINE).
The main weaknesses of using such an approach for a systematic review of this topic is that it requires a
pre-existing knowledge of the terms used and topics covered in the current literature. This process has
always required a degree of expertise (and luck) as to the strategy taken, including both knowledge of the
literature to find likely search terms and skill in the construction of the strategies. The implications of
excluding a single key term are potentially equivalent to ignoring vast areas of the literature. In addition,
the traditional approach relies on key terms existing that suitably encapsulate the relevant literature.
Finding common terms used in literature with potential relevance to the cost-effectiveness threshold was
found to be a significant problem as many relevant topics were not specifically aimed at issues relating to
the NICE cost-effectiveness threshold (e.g. the Martin et al. publications57–59 which provide a precursor
to this project). In addition, due to the wide range of coverage of topics such a ‘threshold’ and
‘cost-effective’, any attempts at a systematic review would be either excessively large or result in a clearly
limited snap-shot of the existing literature.
As a result a pragmatic approach was taken to the identification of relevant papers, one of ‘pearl growing’
which can be defined here as the use of existing collections of studies to identify additional relevant
parts of the literature. The approach uses a pool of ‘initial pearls’ to grow the literature both through
references and citations until all relevant papers have been discovered. This approach therefore relies on
the expertise of the authors of the existing literature to populate the pool of studies rather than the
searcher’s potentially limited knowledge.
Although this approach of ‘pearl growing’ was significantly limited by the existing software available
and has a time consuming element, it represents an approach that corrects for many of the failings of
traditional searches for topics that share the characteristics of the cost-effectiveness threshold.
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Systematic review methods
The ‘pearl growing’ method of systematic review can be characterised into five steps for the identification
of relevant papers.
1. Identification and extraction of ‘initial pearls’.
¢ ‘Initial pearls’ were identified through consultation with researchers with experience of the
cost-effectiveness threshold literature. Fourteen initial pearls were identified through this process.
These publications were chosen for their wide-ranging coverage of the topic as well as their
anticipated significance.
2. Extraction of citations and references from ‘initial pearls’.
¢ Citations: Web of Knowledge was selected to perform the citation searches. The reason for this
selection was in part due to expert advice from an information specialist as well as brief and
non-systematic investigations of citation results from a range of alternative software packages.
¢ References: Web of Knowledge was also used for the collection of papers’ references.
¢ Both citations and references were exported into an EndNote library (EndNote X6, Thomson
Reuters, CA, USA) for the purpose of collection and further analysis (exclusion of repeats, title
searching and review of the abstracts).
3. Identification of further ‘pearls’ from cited and referenced papers.
¢ Once citations and references of the ‘initial pearls’ had been collected, they were subjected to a set
of investigations to identify further ‘pearls’.
¢ Papers were excluded based on whether or not the titles or abstracts suggested the paper
contained information on five topics of interest. These topics had been previously identified given
the objectives of the project and from a review of the ‘initial pearls’ and included papers were
classified by whether or not they could inform:
¢ introduction to the cost-effectiveness threshold topic and policy context
¢ discussion and debate around the current value use of the threshold
¢ potential methods suggested to find a suitable threshold value
¢ specific values proposed
¢ the use of individual and societal valuations of health gains to inform the value of the threshold.
4. Repetition of citation and reference searches.
¢ The process was then repeated for the ‘pearls’ identified in step 3.
¢ This process was repeated until no new ‘pearls’ were discovered by additional iterations.
5. Manual search of references.
¢ To ensure as complete a search had been conducted as possible a retrospective manual search of
all of the ‘pearls’ references was conducted. Any potentially relevant references not discovered
previously (most likely due to a mix of user error and limitations with the software used) were
added to the analysis at the relevant step and further pearl growing methods applied to them to
ensure completeness of results.
Systematic review results
The ‘pearl growing’ method of systematic review revealed 76 papers deemed relevant. The results from
each stage of the process are reported in Figure 9. The figure highlights that after four iterations no new
relevant papers were identified by the systematic process.
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
136
Step 1: citation search
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FIGURE 9 Graph showing process results from pearl growing systematic review. (continued)
D
O
I:
1
0
.3
3
1
0
/h
ta
1
9
1
4
0
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
5
V
O
L.
1
9
N
O
.
1
4
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
5
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
C
la
xto
n
et
al.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
1
3
7
Combined steps 3 and 4
relevant papers
Step 5: citation search
(n=456)
Step 6: reference search
(n=598)
Excluded repeats (n=36)
Title search (n=385)
Initial and steps 1–4
pearls (n=22)
Abstract review (n=11)
Relevant step 5 papers
(n=2)
Excluded repeats (n=28)
Title search (n=524)
Initial and steps 1–5
pearls (n=34)
Abstract review (n=7)
Relevant step 6 papers
(n=5)
Combined steps 5
and 6 relevant papers
(n=7)
Step 7: citation search
(n=77)
Step 8: reference search
(n=198)
Excluded repeats (n=0)
Title search (n=70)
Initial and steps 1–6
pearls (n=4)
Abstract review (n=3)
Relevant step 7 papers
(n=0)
Excluded repeats (n=2)
Title search (n=185)
Initial and steps 1–7
pearls (n=10)
Abstract review (n=1)
Relevant step 8 papers 
(n=0)
Combined steps 7
and 8 relevant papers
Relevant papers
(n=76)(n=18)
(n=0)
FIGURE 9 Graph showing process results from pearl growing systematic review. (continued)
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Review of the literature
Introduction and policy context
Due to the broad range of context which the relevant literature covers it is necessary to break down the
literature review into several topics, these will be discussed independently. The 76 papers (see Papers
discovered by the literature review for all of these papers) identified by the systematic review were defined
into three different categories:
1. literature covering the introduction to the cost-effectiveness threshold topic and policy context
2. discussion and debate around the current value use of the threshold
3. potential methods suggested to find a suitable threshold value.
These categories were chosen to reflect the broad range of relevant topics and areas of discussion
covered by the cost-effectiveness threshold literature. It should be noted that the majority of the literature
identified by the literature review fell into the first and last categories, with very few covering multiple
categories sufficiently to be discussed in more than one section. The final category will only be discussed
briefly as it can be seen as a separate, unrelated approach to the threshold required for purposes of
decision-making by NICE.
The majority of papers (34 of the 76 papers discovered) identified in the literature review could be
characterised as introducing the idea of a cost-effectiveness threshold (these consist of the very early
literature pre-dating NICE) or discussing the policy context through the years.1–3,5,7,8,15,33,40,46,47,50,52–55,114–130
This section will characterise the main areas of discussion in the literature and briefly describe the key parts
of the literature development.
Definition of the cost-effectiveness threshold
An important place to start is the consideration of how the literature has defined the cost-effectiveness
threshold. This is important to analyse in the review as not only is it worth ensuring that a good definition has
been presented, but it also allows us to assess whether or not the existing literature uses a definition that is
both consistent and accurate.
One of the earliest definitions of something resembling the modern interpretation of the cost-effectiveness
threshold comes from Weinstein and Zeckhauser.15 Their paper identifies a ‘critical ratio’ between
monetary costs and a measure of health gains. This critical ratio was argued to represent ‘a cut-off point
for allocation’ of an activity in a budget-constrained public sector entity (p. 1).15
A similar, more recent approach to define the threshold is that taken by Towse et al.130 where the author
considered a hypothetical budget-constrained health-care sector, with a perfectly informed decision-maker
who only considers the cost per QALY of health technologies. Assuming perfect information, the
decision-maker is able to rank all of the potential health-care activities based on their cost per QALY.
A decision-maker will implement as many of the relatively low cost per QALY activities as possible until the
budget is used up. Eventually a point will be reached where society is not willing to pay for a further
marginal increase in QALYs and would rather the funding be used on other consumption. The cost per
QALY at which this cut-off occurs can be described as the cost-effectiveness threshold as it represents
the switching point between an activity being funded and not. As the budget is assumed to be fully
responsive, any new technologies with a cost per QALY below this threshold will be funded in the future.
National Institute for Health and Care Excellence and the
cost-effectiveness threshold
The use and valuation of a cost-effectiveness threshold by NICE has been controversial. Williams8
highlighted three events that may be argued to have particularly muddied the water. First, NICE did not
set a threshold value by the government at the time of its inception in 1999. This meant that NICE was
obliged to come up with a de novo estimate fairly rapidly. Through his set of discussions with NICE,
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Williams stated that at the point of inception NICE came up with a value of ‘roughly £30,000 per QALY,
plus or minus £5000 depending on the specific circumstances’ (p. 7)8
The second event which Williams refers to was NICE’s initial resistance to acknowledging that any form of
threshold value existed. Following analyses such as Towse et al.130 and Devlin and Parkin6 investigating
previous NICE decisions and inferring an implicit threshold, NICE began to publish details of its approach to
an ICER threshold. The major step was the 2004 Guide to the Methods of Technological Appraisal5 that
provided these details, although the definition of the £20,000–30,000 threshold range may be considered
loose and open to interpretation. Although the 2004 guide was one of the first official references to the
threshold, Sir Michael Rawlins did state at the 2001 NICE Annual General Meeting that the Institute would
‘need to be very clear in its reasons for supporting technologies with cost-effectiveness ratios higher than
£30,000 per QALY’.130
Williams’ final event is the often quoted £20,000–30,000 threshold range having never been scientifically
justified. Authors such as Rawlins and Culyer38 have argued that there has never been an empirical basis
for the values or any definitive meaning behind the range. They therefore argued that the threshold should
not be the only tool for NICE to draw conclusions about new technologies.
The threshold as a range
The idea of such a threshold range has been part of the literature for some time. Kaplan and Bush125
considered the idea of a less abrupt approach than that suggested by Weinstein and Zeckhauser.17
Kaplan and Bush125 investigated a set of early Medicare adoption decisions and presented broad criteria of
acceptance based on a set of threshold ranges in terms of cost per additional well-year. These were
defined as < $20,000/well-year (cost-effective), $20,000–100,000 (possibly controversial but justifiable),
> $100,000 (questionable when compared with other expenditure). However, the authors noted that a
$100,000 cut-off was not relevant to the policy decisions at the time and that all results would need
significant future investigation. Similarly, Laupacis et al.53 presented five ‘grades of recommendation’
for decisions about technological reimbursement in Canada.
The conclusions of both of these papers can be represented graphically by Figure 10, which is also
described or presented in much of the literature (see Rawlins and Culyer,38 Littlejohn in Towse et al.,130
Increasing cost per QALY (log-scale) 
A
B
0
1
P
ro
b
a
b
il
it
y
 o
f 
re
je
ct
io
n
 o
n
 t
h
e
g
ro
u
n
d
s 
o
f 
co
st
-e
ff
e
ct
iv
e
n
e
ss
FIGURE 10 Probability of rejection with a ‘soft’ cost-effectiveness threshold. A and B represent the two points
of infection.
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McCabe et al.2 and Devlin and Parkin6). This graph represents the probability of rejection of a new
technology as a function of the technology’s ICER. The graph clearly shows two points of inflection
(A and B in Figure 10), these two points represent an interpretation of the lower and upper bounds of a
cost-effectiveness threshold range.
The literature often makes use of the terms ‘soft’ and ‘hard’ when referring to the threshold. The term
‘soft’ is often used in a similar way to the threshold ‘range’ (alternatively Akehurst’s ‘smudge’130). Although
the underlying idea is the same, a ‘soft’ threshold has also been used to refer to a single threshold. For
example, McCabe et al.2 argued that it is both feasible and probably desirable to use a single threshold
rather than a range, as the threshold should represent the point beyond which factors other than
cost-effectiveness are considered. This approach would suggest that all new technologies with an ICER
below the threshold should receive funding (regardless of their impact on other factors such as equity
of health). It is, however, unclear from this paper what the implications are for technologies with an ICER
beyond the single threshold value.
In contrast, a ‘hard’ threshold represents the situation where the ICER valuation is the sole relevant variable
in an adoption decision, as demonstrated in Figure 11.119 It is an important point that if a ‘hard’ threshold
is set, no other factors can be considered in the decision-maker’s consideration of a new technology.
The difference between a ‘hard’ and a ‘soft’ threshold is therefore largely based on whether or not the
ICER reflects all considerations. Assuming the decision-maker is optimising health, a hard threshold should
represent the most effective allocation of a health-care budget, but cannot account for any equity
concerns (such as the severity of the condition, unmet need and orphan diseases) that are not included in
the calculation of the ICER. Authors such as Dolan et al.21 have demonstrated that a ‘hard’ threshold may
not be able to suitably reflect the non-linearity of social or political values of QALYs to factors such as
quality and length-of-life and for those with worse health prospects or dependents.
What does the threshold represent?
Two broad lines of thought have developed on what the threshold represents, social WTP and shadow
pricing.1,2,8,12,16,17 The key difference between the two is the budget that should be considered by those
accepting or rejecting health technologies. The social WTP approach (usually implicitly) assumes that the
budget of the health-care sector is flexible to the value of health gains determined by society. So in this
case it is the value society places on the health benefits (e.g. in QALYs) generated by new health-care
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FIGURE 11 Graph showing a ‘hard’ cost-effectiveness threshold.
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programmes and technologies is estimated first, and then the health-care budget is the sum of society’s
WTP for all treatments. In other words, the threshold is set exogenously with no reference to a
budget constraint.
In contrast, the shadow pricing approach takes the budget as given (at least beyond the control of those
who determine the cost-effectiveness threshold).1,2 The threshold is, therefore, endogenously based on the
services currently provided within the system. When a new programme or technology is accepted into
the system and imposes an additional cost onto the budget, the only way to meet those costs is to remove
or down-scale existing services which will incur opportunity costs in terms of population health. Hence the
threshold represents the ICER of the least cost-effective existing service covered by the budget. In principle,
it is this service which is removed to fund a new programme or technology. In practice, a range of criteria
is likely to be used to identify appropriate services for displacement to make room in the budget for
new interventions.
In the UK, the main source of debate about which of these concepts of the threshold is the correct one
lies in NICE’s remit. Authors such as Culyer et al.1 have discussed NICE’s position as a ‘searcher’ or a
‘setter’ of the threshold. The distinction between these two roles is that a threshold ‘searcher’ does not set
a threshold with the motivation of maximising social welfare under the assumption of a flexible NHS
budget, but instead investigates the threshold value that is appropriate given current NHS activities and the
fixed budget as set down by Parliament.
Much of the literature on this topic is founded in the discussion of the correct constitutional role of NICE,
the potential negative implications of setting a threshold and the feasibility of identifying displaced
activities. In 2007, Culyer et al.1 argued that it is not appropriate for NICE to be characterised as a
threshold setter. The authors argued that the setting of a threshold would effectively imply that NICE sets
the NHS budget. The setting of the NHS budget, they highlight, is the constitutional responsibility of
Parliament, not NICE. Hence the paper argues that NICE should concern themselves with being threshold
‘searchers’, seeking to identify ‘an optimal threshold ICER, at the ruling rate of expenditure, that is
consistent with the aim of the health service to maximise population health’ (p. 4).1
In a similar vein Appleby et al.56 concluded that the threshold used by NICE should be consistent with the
decisions made by local commissioners within the NHS. This is important given that NICE provides little
guidance to the NHS regarding interventions suitable for disinvestment to release the funding necessary to
cover the new technologies it recommends. If the threshold is set too high NICE may well accept new
technologies which are less cost-effective than the services which local commissioners displace to fund
those technologies. Conversely, if the threshold is set too low, NICE is likely to reject services that are
cost-effective relative to existing services delivered from the NHS budget. The authors conclude that, in the
short term, NICE have to act as a threshold ‘searcher’ to ensure continuity in the NHS.
Alternative arguments have been put forward which reject the idea of NICE as a threshold ‘searcher’.
First, some authors (such as Gafni and Birch7,120) have made the case that an implicit threshold has the
potential to lead to spiralling inflation if new cost-effective technologies are funded without sufficient
disinvestment. However, McCabe et al.2 argued that Culyer’s characterisation of the NICE threshold could
overcome this challenge if it were regularly reviewed so as to be flexible over time to changes in the
NHS budget and the productivity of the sector, and if the threshold for new activities with a non-marginal
budget impact was greater than those with a marginal impact. The issue of the inflationary pressure of a
threshold is discussed further below.
Another concern raised about Culyer et al.’s1 characterisation of the NICE threshold is that of Towse.48
They argue that a lack of knowledge of the true opportunity cost of new activities makes us unable to
identify the value of those activities being displaced and, therefore, it is impossible for NICE to ‘search’ for
a threshold relating to activities displaced at the margin. The issue of the difficulty of identifying current
activities at the margin in terms of cost-effectiveness will be dealt with later in this chapter.
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Factors considered by the National Institute for Health and Care Excellence other
than the comparison of the incremental cost-effectiveness ratio and threshold
As was discussed in the section The threshold as a range, the suitable threshold approach is dependent on
the policy context around it, specifically if the comparison of the ICER with the threshold represents the
only relevant piece of information that informs an adoption decision (a ‘hard’ threshold) or if it is simply
one of many factors considered (‘soft’ threshold). In the case of the UK, NICE has openly stated the ICER
of a technology is not the sole consideration of the committee in its adoption decisions.5
Both NICE and a number of other authors have provided overviews of the other factors that are considered
by NICE in the adoption decision, these are provided in Table 35.
Table 35 suggests that the threshold is only one consideration to decision-makers at NICE. However, in
principle, these other types of benefits could be added to health benefits and compared with potential
treatments for displacement which also have wider social benefits. In other words, this wider set of
considerations relating to the benefits of new technologies should arguably also be reflected in
the threshold.a
Multiple thresholds
Similarly, some have argued for using different thresholds for different situations.2,17 The two main cases
for using different thresholds are the size of the budgetary impact, or depending on whether the decision
represents an investment in additional activities or a disinvestment in current activities.
The topic of different thresholds for different budgetary impacts of a proposed technology has received
very little analytical attention from the literature. McCabe et al.2 argue that technologies with a large
budgetary impact should be evaluated against a lower threshold than those with a relatively small impact.
The reason for this is a large budgetary impact will require a greater displacement of current activities
(assuming a fixed overall budget); this may result in displacement of non-marginal activities which may be
associated with a lower ICER than those at the margin.
Several authors have suggested the use of different threshold values depending on whether the
decision represents an investment in additional activities or a disinvestment in current activities.
O’Brien et al.’s 2002 paper131 considers the difference in willingness to accept monetary compensation to
TABLE 35 Table showing factors other than ICER considered by NICE
NICE3,5 Rawlins et al.39 Tappenden et al.40 Devlin and Parkin6
Uncertainty of variables Severity of illness Uncertainty of the ICER Uncertainty of the ICER
Availability of comparators End-of-life treatment Availability of comparators Burden of disease
Clinical priorities
(as set by Secretary of State)
Stakeholder opinion Severity of illness
Clinical need
Innovation
Availability of resources
Population characteristics
(disadvantaged and children)
Innovation
Disease characteristics and
population size
Wider social costs and benefits
Length of benefit
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forgo a health-care programme and WTP for the same benefit and link it to the cost-effectiveness
threshold. This paper came from the perspective of the threshold representing social preferences rather
than the shadow price of a fixed budget constraint and highlights that from a traditional ‘welfarist’
economics standpoint; a greater threshold value for disinvestment may be welfare maximising. Similarly,
both Devlin and Parkin6 and Speight and Reaney132 have suggested a threshold for disinvestment of
currently performed activities could be lower than for new activities, however, neither present any
methodology for calculating the weight of a disinvested activity.
This is in contrast with the view that CEA guides the decisions of health systems with the objective of
maximising some measure of health benefit subject to a budget constraint. Hughes and Ferner50 argued
that differential thresholds with respect to investment and disinvestment would result in suboptimal levels
of population health. This is because a new technology that would improve health may be rejected under
a policy of having different thresholds for investment and disinvestment but not if the threshold values
were the same. The authors argue that this failure to maximise population health represents an avoidable
inefficiency not related to the aim of the health-care sector to maximise health and thus making the case
for a single threshold value for disinvestment and investment. This point can be seen as a further case for
the shadow price approach as opposed to the social WTP perspective as it highlights that, given a fixed
NHS budget, the social WTP approach will not lead to a maximisation of health.
The need for an independent threshold panel
Related to the discussion over the correct role of NICE in determining a suitable cost-effectiveness
threshold for the NHS is the literature on the potential for an independent threshold panel. Such a panel
has been characterised in a similar manner to the Monetary Policy Committee (the setters of the Bank of
England’s interest rate who act independently of the Government of the UK), as an independent
committee responsible for the setting and updating of the cost-effectiveness threshold used by NICE.
The papers covering this topic are consistent in their call for an independent threshold panel, with no
papers identified arguing against it. The main case provided in the literature for an independent setter is
the removal of political influence; Claxton et al.99 argue that political influence may drive the threshold up
as politicians seek to use the threshold as a means to encourage investment by pharmaceutical companies.
Williams8 suggests that NICE is biased in the setting of a threshold, as its political connections mean a
higher threshold makes it more popular with the ‘sellers’ (the author defines sellers as not only the
pharmaceutical industry but health-care professionals and patient groups) by allowing more technologies
to be approved. Similarly, papers by Appleby et al.56 and Raftery133 call for the creation of an independent
threshold setter. The 2008 Health Select Committee14 recommended that a body independent of NICE
should be established to set and review the threshold. However, it is unclear if such a body would also be
independent of political influence or just of the NICE structure.
Arguments against the use of a cost-effectiveness threshold
A number of authors have argued against the use of a threshold. As mentioned earlier authors such as
Gafni and Birch7,120 have suggested that the threshold approach risks leading to spiralling increases in
inflationary pressures on health-care spending, and present an alternative approach based on the use of
league tables of cost-effectiveness. The reason, they argue, is that there is no guarantee that the activities
displaced are less cost-effective than those new technologies imposing costs on the health system
budget. This observation is coupled with the expectation of authors such as Cohen and Looney118 that
pharmaceutical firms will inevitably price their drugs so as to ensure the ICER of their proposed new
technology is sufficiently close to the threshold to ensure adoption and thereby gain maximum producer
surplus. This observation implies that providers such as the NHS may be forced to pay above market costs
of new technologies by revealing their maximum WTP, in the form of the threshold. In addition the point
raised in McCabe et al.2 that the threshold should be adjusted regularly over time to ensure its efficiency
seeks to address both of these arguments.
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Other authors such as Eichler et al.52 have raised and debated the issues around the theoretical base for
the cost-effectiveness threshold, namely the assumption of perfect divisibility of health-care programmes,
constant returns to scale and constant marginal opportunity costs.
Bridges et al.119 argues that a unique threshold value imposes impractical assumptions in the case of the
US health-care sector, and fails to account for supply and demand side variations in the market. As an
alternative the authors propose a series of thresholds that reflect regional, dynamic budgeting and general
methodological differences. They conclude that the case for abandoning a fixed threshold outweighs those
for keeping one in the USA and that any threshold should vary across payer, over time, in the true budget
impact of interventions and in the measurement of the effectiveness of interventions. This argument has
clear links to the argument for shadow pricing of the threshold rather than the social WTP approach, as
the shadow price approach is based on the view that the threshold is determined by budget and current
efficiency which can be seen to differ over time and across payers. The unresolved issue here is the degree
to which different subgroups (e.g. by region or budget) require different threshold values.
Identification of activities under the threshold
An important part of the literature is the discussion around the identification of activities with an ICER
greater than the proposed threshold. The importance of this discussion stems from the requirement of
new activities to displace current activities that are at the margin of what is cost-effective. If it is not
possible to identify these activities separately from others then threshold analysis is methodologically
flawed, as the funding of a new activity may impact on an activity with an ICER above the
proposed threshold.
Most literature on this topic focuses on the importance of identifying activities to be displaced rather than
the process and feasibility of doing so. For example, Hughes and Ferner46 and McCabe et al.2 highlight
the implications of inconsistent displacement on geographic variations in health-care provision and that the
lack of consistency in the displacement process undercuts the use of a single cost-effectiveness threshold
for the evaluation of new technologies. Similarly, Buxton51 suggests that, in order to fully appreciate the
opportunity cost of the implementation of a new technology, we must have a clear knowledge of those
activities displaced at the cost-effectiveness margin.
Few authors have sought to develop methods to identify the activities that should be displaced to free-up
budget for new more cost-effective activities. Elshaug et al.52 outlines a set of criteria for the identification
of existing, potentially non-cost-effective practices which could then be further assessed to determine their
cost-effectiveness using health technology assessment. The criteria suggested include factors such as new
evidence on safety; efficacy or cost-effectiveness; geographic variation that have become apparent since
technology adoption; heterogeneity in the clinical procedure; and technological development.
The current value of the threshold
As it became evident that decision-making bodies such as NICE are using (more or less explicit)
cost-effectiveness thresholds, there has been a significant level of debate over its appropriate
value.6,8,38,39,45,48,51,56,130,134–137 In this section we will present three areas of the debate:
1. the lack of empirical basis to the current value
2. arguments over the value being generally too high or too low
3. if and how the threshold should change over time.
Lack of empirical basis to the current value
Since NICE made it clear that it uses an explicit threshold5 there has been little hiding the lack of evidential
justification behind the £20,000–30,000 range. Indeed the Health Select Committee14 heard (during their
enquiry into NICE in 2008) that the NICE threshold has no basis in hard science. Similarly, Appleby et al.56
noted that ‘the uncomfortable truth is that NICE’s threshold has no basis in either theory or evidence’.
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Similarly, the US value of $50,000 per QALY, which is often cited as the cost-effectiveness threshold
relevant to resource allocation decisions in that country, is often attacked for its lack of empirical
founding.33,45,122,124 Some have suggested that the US figure is rooted in the cost-effectiveness of hospital
renal dialysis,122 although why this makes it suitable for use more generally is unclear.
The threshold changing over time
Another concern of current NICE practice is the apparent lack of change in the threshold value used since
the body’s inception. Many authors have argued that factors such as the NHS budget, price inflation,
technological developments in the NHS and the discount rate applied to economic evaluations35,122,125,126
have all changed since the first use of the cost-effectiveness threshold. As such, the threshold should have
changed to reflect this fact. Braithwaite and Roberts45 sought to demonstrate the impact of budget and
technological growth on the optimal threshold. By creating a computer simulation of the US Medicare
system, the authors were able to demonstrate the impact of these factors. Although there is no doubt in
the literature that the NICE threshold should potentially change over time,a no papers have been identified
which model the impact of any changes on the threshold.
Both Ubel et al.136 and Raftery133 discuss the principles behind the directional change the threshold should
take over time. Ubel et al.136 have argued that the optimal threshold value needs to fall over time assuming
medical innovation continues at roughly its current rate. Raftery133 has noted that, in real terms, the
threshold has been falling since 1999 as, in order to stay constant in real terms, it should have increased
given inflation (up 40% in the time period) and increased NHS spending (up 90%). The authors argue that
this decline in the threshold should have been observed in the value used by NICE in decision-making.
They describe the suggestion of a rise in the threshold being linked to the observed growth of the NHS
budget over the last decade as ‘audacious’.133 It is unclear to what extent the authors disagree with this
interpretation of NHS efficiency as a relevant factor affecting the optimal threshold.
Threshold value generally too high or low
The majority of the debate over the current use of the threshold in the UK (and elsewhere) has been
centred on whether the current value is too low or too high. The papers that will be discussed in this
section focus on the general discussion of necessary directional change in the value rather than the
presentation of a specific value; the latter is discussed in more detail in the following section on
the proposed values of the threshold in the literature.
Vernon et al.137 presented an analysis of the implications of the threshold being above or below its
optimum value in terms of signals to the companies involved in research and development of new medical
products. The authors concluded that if the threshold is set too low (below the economic value of the
health benefit) it will result in research and development investment levels that are too low relative to
their economic value (at the margin). The reason for this lies in a lack of returns to investments for
the pharmaceutical companies. However, in the isolated case of the threshold relevant to the NHS
(a small proportion of the world pharmaceutical market), the impact of changes to the threshold on
the international pharmaceutical market equilibrium is unknown but likely to be small.
Similarly, thresholds set too high (above the economic value of the health benefit) will result in inefficiently
high levels of research and development spending, such that the health-care provider is funding projects
that do not have a sufficient impact on social welfare.
The literature that argued the threshold is too high in the UK can be broadly characterised into three key
papers. Williams8 made the case that, intuitively, the threshold should not be significantly greater than the
gross domestic product (GDP) per capita (roughly £18,000 in the UK in 2004). He made the case that,
although it may be possible to provide a lot of the population with health care when the threshold is
above the GDP per capita, it is not possible to provide health care for much of the population without
imposing great hardship on those expected to foot the bill (the tax payer or government debt).
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Second, Raftery133 argued that, although the UK threshold has been historically too high, it does not need
reducing as the real value has decreased since 1999 due to inflationary pressure and increases in the NHS
budget. He also suggests that recent policies implemented by NICE, such as greater weight being given
to the benefits of treatment accruing to patients at the end of their life, need to be offset by reductions in
the threshold for all other treatments for expenditure to remain within the NHS budget. Finally, Raftery
cites the opportunity cost analysis of trastuzumab (Herceptin®, Roche)114 which showed that more
cost-effective oncology services were being sacrificed to fund trastuzumab in breast cancer. This result
suggests directly that, in some cases at least, the threshold value is too high.
Work by Martin et al.57–59 investigated the cost per life-year saved in a selection of the 23 PBCs used in the
NHS; these results are presented in Table 36. It is important to note that these results are presented as
the cost per YLG rather than the cost per QALY of the least cost-effective current activity. The authors and
others have used these results to argue that the threshold used by NICE may be too high.128 Similarly,
Collier’s47 report of the Health Select Committee suggests that the threshold used by NICE is higher than
that used by PCTs.
In contrast, a range of authors have argued that the current NICE threshold is too low. Both Speight and
Reany132 and Towse48 argued that the inclusion of wider social costs/benefits and full consideration of
social WTP for additional health gains show that the threshold should be significantly larger. Both cite
recent NICE work by Mason et al.29,135 which suggested the threshold should be between £30,000 and
£75,000 per QALY based on attempts to model a WTP-based value of a QALY based on observations of
the value of avoiding a statistical fatality. Similarly, in the USA, Ubel et al.136 have argued that, if inflation
and WTP valuations are taken into account, the relevant threshold in the US should be closer to $200,000
per QALY than the regularly cited $50,000.
Those analyses which conclude the UK and US thresholds should be significantly higher have, at the core
of their argument, the assumption that the respective health-care budget is fully capable of responding
to society’s WTP for additional health gains.
Potential methods for threshold estimation
There are broadly three approaches that can be taken to determine the threshold value:51,56 social WTP,
non-analytical approaches. Such as expert elicitation and shadow pricing of the budget constraint. This
project is concerned with the latter approach to estimating the cost-effectiveness threshold. This is entirely
consistent with the remit of the NHS in general and NICE in particular – they do not set the NHS budget
but have to allocate those finite resources appropriately.
TABLE 36 Table showing cost per YLG results of Martin et al. papers57–59
PBC
Cost per YLG (£)
2005/6 data 2004/5 data
Cancer 13,137 13,931
Circulation problems 8426 7979
Respiratory problems 7397 N/A
Gastrointestinal problems 18,999 N/A
Diabetes 26,453 N/A
N/A, not applicable.
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Papers seeking to elicit social willingness to pay and non-analytical approaches
The majority of the literature that has presented a proposed value for the threshold (in the UK, USA and
elsewhere) has done so using valuation methods based on WTP for an additional health benefit.18–32,34–37
However, other approaches have been suggested. For example, the WHO’s 2002 report138 suggested that
interventions costing less than three times GDP per capita for each DALY averted represent good value
for money.
Lee et al.139 sought to update the US ‘dialysis standard’ often claimed to be the base of the US Medicare
threshold.122 The authors present a valuation of $129,090 per QALY based on current dialysis practice
in the USA. Finally, in an appendix to their edited book, Towse et al.130 provide an interesting set of
results drawn from a set of participants to the associated workshop (the majority of which were health
economists). The participants were asked to anonymously record their view on what threshold NICE should
apply. Eighteen responses were recorded with the average of all responses being £29,000 per QALY.
Papers considering the shadow price of the budget constraint
The systematic review only identified four different papers by three different authors that suitably fell
into the category of shadow pricing of the budget constraint.
Williams8 suggested investigating the cost-effectiveness of NHS interventions that represent the majority
of the budget (he speculated that some 300 interventions accounted for about 90% of the cost incurred by
the NHS). The purpose of this would be to identify current NHS activities that might not be cost-effective.
He acknowledged the implausibility of conducting full technological appraisals on such a large number of
interventions (estimating this would take 10 years, at which point it would be necessary to re-evaluate the
initial appraisals), and thus suggested relying on expert opinion and existing patient data to speed up
the process.
While Williams’ recommendations related to identifying current interventions with a high cost per QALY as
the basis for disinvestment, there is the potential to take this approach further and use it for a method to
determine the cost-effectiveness threshold even down to the level of a local decision-maker. This was
attempted by Appleby et al.49 who conducted a feasibility experiment into the estimation of the
appropriate NHS threshold by examining decision-making in the NHS at a local level. The authors propose
a structured model considering the new technology’s cost per weighted QALY gain in a table of all existing
services. In an attempt to test the feasibility of this model they conducted interviews with senior NHS staff
as well as investigating information on public health to construct a list of health-care services introduced or
discontinued in 2006/7. The authors found that it was feasible to identify decisions and to make the
important step of estimating their cost-effectiveness; however, they noted that any attempts to fully
evaluate sufficient decisions as to estimate a threshold would require a detailed understanding of the
decision structure at a local level as well as a significant number of observations.
The other key papers seeking to develop and implement methods for estimating the NHS threshold were
those of Martin et al.57–59 They aimed to establish a link between health-care spending and health
outcomes in the NHS after having adjusted for the need of the patient population. They made use of data
around the observed mortality at PCT level in the NHS alongside expenditure data on health care across
23 programmes of care based on ICD-10 disease categories. As has been mentioned earlier in this chapter
these papers present the cost per life-year for a range of PBCs; however, the key result of these papers is
that it is possible to make use of existing data to determine such valuations for current NHS interventions.
The authors concluded that although their results are highly limited and do not present a single cost per
QALY estimate for the optimal threshold they can ‘inform the decisions of NICE on whether their current
threshold for accepting new technologies is set at an appropriate level’ (p. 37). These studies are the
precursor of analyses presented in this report, and further details can be found in Appendix 2 and in
Chapter 3 of the main report.
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In the area of the efficient allocation of health care it is also important to note the contribution of the
earlier mathematical papers such as Stinnett and Paltiel16 who outlined mathematical techniques to
approach the problem through the use of a mixed integer programming approach. Although their
approach differs from the interpretation of the threshold as used in this study it represented an important
step in the evaluation of the methodology of seeking to solve the optimisation problem apparent in
health care.
Conclusion
This systematic review of the literature surrounding the cost-effectiveness threshold has highlighted
the significant range and diversity of the literature. Despite the international and mature nature of the
literature there are significant differences in the suggested methods to represent a cost-effectiveness
threshold. The main areas of debate relevant to this report have revolved around the role of NICE as a
‘searcher’ or ‘setter’ of the threshold.1,2 Although some authors have implicitly argued for NICE to fulfil the
role of a threshold ‘setter’ by suggesting methods of elicitation of social WTP valuations of a QALY, death
or life-year,18–32,34–37 the literature of most relevance to this research has sought to consider estimation
methods consistent with its role as a ‘searcher’.56–59
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Appendix 2 The link between NHS spending
and mortality: estimating the cost of a life-year
in Englanda
Prologue
This report presents, in a linear fashion, details of the econometric work undertaken to estimate the link
between NHS spending and mortality. It also presents details of how the econometric work is used to
calculate the cost of a life-year. This report is designed to serve as a reference document in support of the
main project report, which highlights the major findings from the project. As a supporting document this
report provides far more detail than most interested parties will require. Nevertheless, those who seek
more detail than that contained in the main project report may find the material here useful.
Background, model, data, and estimation approach
Introduction
In a recent White Paper the new British Conservative government emphasised the importance of clinical
outcomes. It notes that, in future, success will be measured, not through the achievement of process
targets, such as short waiting times, but against outcomes such as cancer and stroke survival rates.12
Although the NHS budget is ring-fenced against the ongoing public sector deficit reduction programme,
its budget is still likely to be under considerable pressure, and attention is likely to focus on the extent to
which any additional health-care expenditure yields genuine patient benefits in the form of improved
health outcomes.
However, one of the most fundamental yet unresolved issues in health policy is the extent to which
additional health-care expenditure yields patient benefits, in the form of improved health outcomes.
The work of health technology agencies, such as NICE, has greatly improved our understanding at the
micro-level of the costs and benefits of individual therapeutic technologies. However, there remains a
dearth of evidence at the macro-level on the benefits of increased health system expenditure.
Recently a series of studies has taken advantage of the availability of two new data sets to examine the
relationship between NHS expenditure and mortality rates for various disease categories.59,60,62,63 One data
set contains mortality rates for various disease categories at the level of geographically defined local health
authorities, known as PCTs. The other data set presents NHS expenditure by PCT on 23 broad programmes
of care. This data set embraces most items of publicly-funded expenditure, including inpatient, outpatient
and community care, and pharmaceutical prescriptions.
Like previous studies, we employ a model that assumes that each PCT receives an annual financial lump
sum budget from the national ministry and allocates its resources across the 23 programmes of care to
maximize the health benefits associated with that expenditure. Estimation of this model using the
expenditure and mortality data facilitates two related studies: first, a study of how changes in the NHS
budget impact on expenditure in each care programme; and second, a study of the link between
expenditure in a programme and the health outcomes achieved, notably in the form of disease-specific
mortality rates. The latter study also permits the calculation of the cost of an additional life-year for
individual programmes of expenditure.
DOI: 10.3310/hta19140 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 14
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Claxton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
155
The work presented here draws heavily on previous studies. These were constrained in a number of ways
and, in this analysis, we build on and improve these previous studies in four major ways:
¢ First, due to data limitations previous studies related expenditure in time period t to mortality in periods
t, t – 1, and t – 2 combined. In doing this, such studies assumed that PCTs had reached some sort of
equilibrium in the expenditure choices they make and the outcomes they secure. This is probably not
an unreasonable assumption given the relatively slow pace at which both types of variable change but,
with more recent mortality data now available, here we relate expenditure in time period t to mortality
in periods t, t + 1, and t + 2 combined (see Model estimation using 2006/7 expenditure data and
mortality data for 2006/7/8: CARAN need and two market forces factors).
¢ Second, previous studies have tended to focus on a very limited number of care programmes
(e.g. cancer, circulatory disease, gastrointestinal problems and respiratory problems). Here we present
plausible outcome models for a larger number of budgeting categories.
¢ Third, previous estimates of the cost of a life-year have been for individual programmes of care.
Here we present estimates of the cost of a life-year for an enlarged number of programmes and,
importantly, with the aid of assumptions about the productivity of programmes without a meaningful
mortality-based outcome indicator, we extend our individual programme estimates to incorporate
expenditure across all programmes of care.
¢ Finally, although previous results and our current models ‘pass’ the appropriate statistical tests,
we subject our latest results to a substantial sensitivity analysis.
The structure of this report is as follows. Previous studies presents a brief review of previous empirical
studies in this domain, which have often yielded conflicting results. A straightforward theoretical model of
the budgetary problem faced by a PCT manager seeking to allocate limited funds between competing
programmes of care is presented in Theoretical model. The PB and health outcome (mortality) data are
described in NHS programme budgeting in England and Health outcome and other data respectively.
Estimation issues and strategy outlines our estimation methods and some of the issues surrounding them.
In Analysis of programme budgeting expenditure for 2005/6 and mortality data for 2002/3/4 we commence
our empirical work by estimating well-specified econometric models that outline (a) the budgetary expenditure
choices and (b) the health outcomes achieved by PCTs using expenditure data for 2005/6 and mortality data
for 2002/3/4. Analysis of programme budgeting expenditure for 2006/7 presents results using expenditure
data for 2006/7 and mortality data for 2004/5/6. It also presents results using the same expenditure data but
updating the mortality data to 2006/7/8. Several pieces of sensitivity analysis are also included in Analysis of
programme budgeting expenditure for 2006/7, but the major piece of sensitivity analysis – examining the
impact of relaxing the instrument validity restriction – is reported in The sensitivity of the outcome elasticity to
the validity of the instrument exclusion restrictions.
In Analysis of programme budgeting expenditure for 2007/8 and mortality data for 2007/8/9 we
re-estimate our model using updated expenditure and mortality data. In particular, we use the PB
expenditure for 2007/8 and mortality data for 2007/8/9 to re-estimate our outcome and expenditure
equations. In Analysis of programme budgeting expenditure for 2008/9 and mortality data for 2008/9/10
we update the data set again, and this time we employ PB expenditure data for 2008/9 and mortality data for
2008/9/10. We also compare the elasticities and cost of a life-year estimates that we have obtained using
expenditure and mortality data for different years.
Finally, Summary and concluding remarks presents a summary of our findings and some concluding remarks.
Previous studies
There is a large body of literature on the determinants of international variations in health-care spending in
which income levels often play a central role.140 However, whether or not more expenditure generates
better outcomes – for example, in terms of reduced mortality – remains a matter of debate. For example,
Fisher and Welch141 note various ways in which more health care might harm patients and they cite various
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studies supporting their arguments. In a comprehensive review, Nolte and McKee67 discuss many studies
that examine the impact of health care and other explanatory variables on some measure of health-care
outcome. Nolte and McKee67 point out that researchers usually combine a production function approach
with the application of regression analysis. For example, in an early cross-sectional study of 18 developed
countries, Cochrane et al.64 use regression analysis to examine the statistical relationship between mortality
rates on the one hand and per capita GNP and per capita consumption of inputs such as health-care
provision on the other. They find that the indicators of health-care provision were generally not associated
with the outcomes in the form of mortality rates. Thereafter, the failure to identify strong and consistent
relationships between health-care expenditure and health outcomes (after controlling for other factors) has
become a consistent theme in the literature, while, in contrast, socioeconomic factors are often found to
be good determinants of health outcomes.65–67
This failure to detect a significant positive relationship between expenditure and health outcome might
reflect the difficulties associated with any such study rather than the absence of such a relationship.
For example, Gravelle and Backhouse68 examine some of the methodological difficulties associated with
empirical investigation of the determinants of mortality rates. These include simultaneous equation bias
and the associated endogeneity problem (that the level of health-care input might reflect the level of
health outcome achieved in the past), and that a lag may occur between expenditure and outcomes
(studies typically assume that expenditure has an immediate effect on mortality). To avoid the difficulties
imposed by data heterogeneity inherent in international analyses, the study by Cremieux et al.69 examines
the relationship between expenditure and outcomes across 10 Canadian provinces over the 15-year period
1978–92. They find that lower health-care spending is associated with a significant increase in infant
mortality and a decrease in LE.
Although challenging the received empirical wisdom, one difficulty with the Cremieux et al.69 study is that the
estimated regression equation consists of a mixture of potentially endogenous variables (such as the number
of physicians, health spending, alcohol and tobacco consumption, and expenditure on meat and fat) and
exogenous variables (such as income and population density). The authors’ chosen estimation technique
(GLS) does not allow for this endogeneity and consequently the coefficients on the endogenous variables
may be biased.68 Or’s142 study of the determinants of variations in mortality rates across 21 Organisation for
Economic Co-operation and Development countries between 1970 and 1995 may suffer from the same
weakness. She finds that the contribution of the number of doctors to reducing mortality in Organisation for
Economic Co-operation and Development countries is substantial but her estimation technique assumes
that the number of doctors is exogenous to the health system.
Nixon and Ulmann70 provide a detailed review of 16 studies that have examined the relationship between
health-care inputs and health outcomes, using macro-level data. They also undertake their own study using
data for 15 EU countries over the period 1980–95. They employ three health outcome measures – LE at
birth for males and females, and the infant mortality rate – and a dozen or more explanatory variables
including per capita health expenditure; number of physicians (per 10,000 head of population); number of
hospital beds (per 1000 head of population); the average length of stay in hospital; the inpatient admission
rate; alcohol and tobacco consumption; nutritional characteristics; and environmental pollution indicators.
Nixon and Ulmann70 conclude that although health expenditure and the number of physicians have made
a significant contribution to improvements in infant mortality, ‘. . . health care expenditure has made a
relatively marginal contribution to the improvements in LE in the EU countries over the period of the
analysis’. Again, however, the study does not allow for the possibility that some of the explanatory
variables may be endogenous.
Although loosely based on the notion of a health production function, the traditional empirical study
described above has rarely been informed by an explicit theoretical model. This is understandable, as the
processes giving rise to the observed health outcomes are likely to be very complex, and any theoretical
model might become rather unwieldy. However, this absence of a model has usually led to a theoretical
search for measures of health inputs demonstrating a statistically ‘significant’ association with health
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outcomes. In contrast, in this study we inform our empirical modelling with a theoretical framework.
We believe that this may lead to a more convincing and better specified model of health outcomes than
that used in many previous studies, and this model is outlined in the next section.
Theoretical model
Our modelling framework assumes that each PCT i receives an annual financial lump sum budget yi from
the national ministry, and that annual total expenditure cannot exceed this amount. The PCT must then
decide how to allocate its budget across the J programmes of care (J= 23 in this case). For each
programme of care there is a ‘health production function’ fi(.) that indicates the link between local
spending xij on programme j and health outcomes in that programme hij. Health outcomes might be
measured in a variety of ways, but the most obvious is to consider some measure of improvement in LE,
possibly adjusted for QoL, in the form of a QALY.
The nature of the specific health production function confronted by a PCT will depend on two types of
local factors: the clinical needs of the local population relevant to the programme of care (which we
denote nij); and broader local environmental factors zij relevant to delivering the programme of care (such
as input prices, geographical factors, or other uncontrollable influences on outcomes). Both clinical and
environmental factors may be multidimensional in nature. Increased expenditure then yields improvements
in health outcomes, as expressed, for example, in improved local mortality rates, but at a diminishing rate.
That is:
hi j = f j(x i j, ni j, zi j); δf j=δx>0; δ
2f j=δx
2<0: (9)
We assume there is a PCT social welfare function W(.) that embodies health outcomes across the J
programmes of care. Assuming no interaction between programmes of care, each PCT allocates its budget
so as to maximise total welfare, subject to the local budget constraint and the health production function
for each programme of care:
max W (hi1, hi2,…, hi J)
subject to ∑
j
x i j ≤ y i
hi j = f j(x i j, ni j, zi j); j=1,… J:
(10)
It can of course quite plausibly be argued that decision-makers do not discriminate between health
outcomes in different programmes of care, and that W(.) is merely the sum of such outcomes. However,
there is no need for that assumption in our formulation.
Each PCT allocates expenditure across the 23 programmes of care so that the marginal benefit of the last
pound spent in each programme of care is the same. This is represented diagrammatically in Figure 12,
which illustrates the trade-off between just two programmes of care. The top left-hand quadrant indicates
the health production function for programme 1, whereas the bottom right-hand quadrant indicates the
health production function for programme 2, albeit in transposed form. The bottom left-hand quadrant
indicates the budget constraint; the expenditure choice must lie on the budget line. This means that for
each feasible pair of expenditure choices (points on the budget constraint line), a pair of health outcomes
in the two programmes emerges, which is traced out as the health production possibility frontier in the
top-right quadrant. The PCT will choose the point on this frontier that maximizes welfare. In this example,
we have indicated a simple health maximizing approach (the maximum health summing across the two
programmes), leading to optimal health outcomes (H1*, H2*) and expenditure (X1*, X2*).
Solving the constrained maximisation problem yields the result that the optimal level of expenditure in
each category, xij*, is a function of the need for health care in each category (ni1, ni2, . . . , niJ),
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environmental variables affecting the production of health outcomes in each category (zi1, zi2, . . ., ziJ), and
PCT income (yi). Thus:
xi j = g j(ni1, : : : ni J, zi1, : : : zi J, y i); j = 1, : : : , J (11)
Thus, for each programme of care there exists an expenditure equation (see Equation 11) explaining
expenditure choice of PCTs and a health outcome equation (see Equation 9) that models the associated
health outcomes achieved.
Our model is static in the sense that the health production function (see Equation 9) assumes that all
health benefits occur contemporaneously with expenditure. We acknowledge that for some programmes
of care benefits might occur ≥ 1 year after expenditure has occurred. This is particularly likely to be the
case for those programmes aimed at encouraging healthy lifestyles, where some benefits may occur
decades after the actual programme expenditure. For other programmes, such as maternity/reproductive
conditions and neonate conditions, benefits may be largely contemporaneous with expenditure.
Furthermore, we do not model the decision-maker’s time preferences.
For our empirical modelling, however, we are constrained by the data we have available, which are largely
cross-sectional in nature. Owing to data limitations, previous studies have had to relate expenditure in
period t to mortality data in periods t, t – 1, and t – 2 combined so that the mortality data precedes the
expenditure data. This is not ideal. Implicitly previous studies have had to assume that the data represent a
quasi long-run equilibrium position, and that relative expenditure levels and health outcomes within each
PCT have been reasonably stable over a period of time. As we shall see, this appears to be a reasonable
assumption because we obtain similar results when we estimate our models using expenditure for period t
with either mortality data for periods t, t – 1, and t – 2 combined (see Model estimation using 2006/7
expenditure data and mortality data for 2004/5/6: CARAN need and two market forces factors) or with
mortality data for periods t, t + 1, and t + 2 combined (see Health outcome and other data).
Having outlined our model, in the next section we discuss the data sets used to estimate this model.
NHS programme budgeting in England
The English NHS is the archetypal centrally-planned and publicly-funded health-care system. Its revenue
derives almost entirely from national taxation, and access to the system is generally free to the patient.
H2
H1
X2
X1
The budget line
Programme 1
Programme 2
(H1
*,H2
*)
(X1
*,X2
*)
FIGURE 12 Graph showing optimal trade-off between two programmes of care.
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Primary care is an important element of the system, and GPs act as gatekeepers to secondary care and
pharmaceuticals. The system is organised geographically, with responsibility for the local administration of
the NHS devolved to local health authorities known as PCTs.b For the purposes of this study, there were
303 PCTs with an average population of about 160,000 people until October 2006. In October 2006
the 303 PCTs became 152 PCTs. Some PCT boundaries remained unchanged whereas other PCTs were
merged with one or more neighbours to form a new larger PCT. In a few cases the geographic area
covered by an existing PCT was split between two or more new PCTs. These 152 PCTs have an average
population of about 330,000 people.c PCTs are allocated fixed annual budgets by the national ministry,
within which they are expected to meet expenditure on most aspects of health care, including inpatient,
outpatient and community care, primary care and pharmaceutical prescriptions.
The rationale behind the construction of programme budget data
Traditionally, PCTs and their predecessors have reported expenditure on the basis of inputs (e.g. total
expenditure on pay and non-pay items). However, NHS policy-makers have for some time realised that this
approach does not create clinically meaningful financial data or help in the design and evaluation of
programmes of patient care. The Department of Health therefore initiated a ‘Programme Budgeting’
project. This has sought to create an accounting system that is more aligned with the distinct outputs and
health outcomes of the health-care system. Since April 2003, in addition to its conventional accounting
data, each PCT has prepared expenditure data disaggregated according to 23 programmes of health care.
These programmes are defined by reference to the ICD-10 codes at the four-digit level, and most PBCs
reflect ICD-10 chapter headings (e.g. cancer and tumours, circulation problems, renal problems, neonates,
problems associated with the skin, problems associated with vision, problems associated with hearing,
etc.). In some cases, the 23 categories are broken down into further subareas to achieve a closer match
with the various NSFs; for example, the large mental health category is broken down into ‘substance
abuse’, ‘dementia’, and ‘other’.
Programme budgeting seeks to allocate all types of PCT expenditure to the various PBCs, including
secondary care, community care and prescribing. However, the system acknowledges that a medical model
of care may not always be appropriate, and two specific non-clinical groups – ‘healthy individuals’ and
‘social care needs’ – have been created. These are intended to capture the costs of disease-prevention
programmes and the costs of services that support individuals with social rather than health-care needs.
In addition, in some cases it is not possible to assign activity by medical condition, preventative activity,
or social care need and, in these cases, expenditure is assigned to a residual category (PBC 23) entitled
‘other’. The most important element of this residual programme is expenditure on GP services (PBC 23a).
In principle, it should be possible to allocate each GP consultation to a particular care programme.
However, at the moment the available data information systems do not permit such an allocation and so
all primary care expenditure is allocated to this residual programme. The use of this residual category
ensures that all expenditure is assigned to a programme of care.73
The aim of the programme budget classifications is to identify the entire volume of health-care resources
assigned to broad areas of illness according to the primary diagnosis associated with an intervention.
It serves a number of purposes, most notably to assist in the local planning of health care. However, for
this study its crucial merit is that it opens up the possibility of examining the statistical relationship between
local programme spending and the associated disease-specific outcome.
The collection of programme budgeting data
Programme budgeting information is collected centrally by the Department of Health as part of the annual
accounts process. Each PCT is required to submit an annual PB return to the Department which shows
how their total expenditure is allocated across the 23 PBCs.
Various forms of data collection and analysis are required to map PCT expenditure onto acute, community
and other services to the 23 PBCs. From the PCT perspective, however, the construction of each PCT’s
return largely involves collating information provided by other bodies and drawing on other information
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already in the PCT’s own annual accounts. Thus GMS/PMS expenditure, which is already reported in PCT
accounts, relates to direct primary care and is mapped in its entirety to PBC 23a (other: GMS/PMS); general
ophthalmic service expenditure (again from PCT accounts) maps directly to PBC 8 (eye/vision problems);
and general dental service expenditure maps directly to PBC 12 (dental problems). Prescribing and
pharmaceutical services expenditure is allocated to PBCs on the basis of an annual apportionment report
provided by the prescription pricing authority for each PCT as part of the annual accounts process. This
apportionment report allocates each PCT’s annual family health service prescribing expenditure across
the 23 PBCs. The balance of any primary health care purchased by the PCT is allocated/apportioned
across the 23 PBCs on the basis of local records, with any remaining expenditure allocated/apportioned in
line with the distributions already made across the budget categories.
It is the responsibility of all NHS providers – which includes PCTs, NHS trusts, and foundation hospitals – to
allocate admitted patient care expenditure across the PBCs, specific to each PCT that utilises its services.
These allocations are constructed using ‘finished consultant episodes’ (FCEs) (from the mandatory
administrative HES data set returned by each provider) each of which is assigned to a Healthcare Resource
Group (HRG), an English version of Diagnosis-Related Groups. National grouping software automatically
assigns each HRG to 1 of the 23 PBCs and attaches the provider’s average reference cost for the relevant
HRG to each record. For each PCT this information generates a split of inpatient care expenditure by PBC
for each of its secondary health-care providers.
There are numerous difficulties faced when attempting to allocate non-admitted patient care activity
(that is, outpatients, community services, direct access, A&E, etc.) to PBCs. The difficulties are primarily due
to the absence of clear diagnostic codes. The ‘primary reason for care’ (equivalent to a diagnosis code) is
not information that is routinely collected for community patients. Because of this, the approach prescribed
is for service providers to produce a generic allocation analysis/report, for all PCTs making use of their
services, for all non-admitted patient care costs across the 23 PBCs. Once derived, this generic allocation
analysis/report is made available to PCTs at the same time as the unique (PCT-specific) inpatient care
information described above. Unlike the first apportionment report relating to admitted patient care, the
non-admitted patient care apportionment report will not be unique to the PCT, but will represent the
provider’s overall experience. PCTs are expected to use these data to inform the apportionment of their
own spend on non-admitted patient care across the 23 PBCs.
The Department of Health recognises that this approach – the provision of a PCT-specific breakdown of
admitted patient care costs and a generic allocation of all PCTs non-admitted patient care spend by
providers – is likely to generate a crude method for apportioning non-admitted patient care costs.
PCTs and their providers are therefore encouraged to put in place other arrangements that allow a more
sophisticated analysis of non-admitted patient care expenditure. Such arrangements may well rely on an
activity sampling approach.73
Mental health providers may not need to complete and forward detailed admitted and non-admitted
patient care apportionment reports to PCTs. The nature of the services they provide may be such that the
entire spend with them relates exclusively to the mental health programme (PBC 5). Ambulance trusts are
required to provide non-admitted patient care information to those PCTs for whom they provide services.
Where it is not possible to split the activity by PCT, a generic non-admitted patient care report is produced
for all purchasers.73
The Department of Health has been criticised for the rather simplistic way in which it has apportioned
certain costs among categories, and there are obvious issues with the allocation of costs associated
with patients who have multiple disorders. However, the Programme Budgeting project is very much
work-in-progress and the Department is investigating ways to improve the accuracy with which costs are
allocated across programmes (e.g. the Department is investigating the possibility of allocating training
expenditures to specific programmes rather than to the generic medical training programme PBC 23b).d
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Programme budgeting expenditure, 2003/4–2008/9
National (all PCT) expenditure per head and the growth in this expenditure are shown for each PBC for
2003/4–2008/9 in Table 1. Comparable data for each programme budget subcategory are shown in
Table 91 in the Annex. Year-on-year comparisons of expenditure in each group are complicated by the fact
that the algorithms used to allocate activity to PBCs are regularly revised. For example, for 2006/7 two
major changes were made to the methods employed to construct the PB data. First, expert medical
opinion was employed to re-evaluate the existing mapping from inpatient diagnosis codes to PBC. This led
to the reassignment of just over 10% of all diagnosis (ICD-10) codes from one PBC to another.e,f Second,
activity to be costed used the newly introduced version 4 of the HRG software which, among other things,
changed the methodology for calculating non-admitted patient care costs. HRG4 reflected advances in
clinical practice and was designed to generate a much more accurate costing of complex cases. Other
developments, such as the transfer of responsibility for dental funding from local dental boards to PCTs,
also complicate the interpretation of comparisons through time (e.g. per capita dental expenditure by
PCTs increased from £13.55 in 2004/5 to £51.93 in 2006/7).
The expenditure figures for the first year (2003/4) are calculated on a slightly different basis to those
for the other years (2004/5–2008/9). In particular, the figures for 2003/4 are on a ‘net expenditure’ basis
whereas the figures for 2004/5–2008/9 are on an ‘own population’ basis. The ‘own population’ figure
starts with net expenditure, it adds any expenditure funded from sources outside of the NHS, and
then deducts any expenditure on other PCTs’ populations incurred through lead/host commissioning
arrangements. In 2006/7 and across all PBCs, expenditure per head on an own population basis was
2.3% greater than expenditure on a net population basis.
In 2004/5 total PCT expenditure per person was £1200. The category attracting the most expenditure was
the ‘other’ category (PBC 23) with per capita expenditure of almost £158 (13.2%). This category included
primary care expenditure, workforce training expenditure, and a range of other miscellaneous expenditure
items. Of these components, primary care expenditure was by far the largest element at £127 per head.
In 2004/5 there were two other categories with a budget share of over 10%: mental health (PBC 5)
attracted 12.2% of expenditure (£147 per person), and circulation problems (PBC 10) recorded 10.2% of
expenditure (£122 per person). Seven PBCs – cancers and tumours (£76), gastrointestinal problems (£73),
trauma and injuries (£72), musculoskeletal problems (£72), respiratory problems (£63), genitourinary
problems (£62) and maternity and reproductive conditions (£55) – had expenditure shares of between
4.6% and 6.3%. Finally, the 13 remaining PBCs – from hearing problems (£6) to learning disability
(£43) – each account for between 0.5% and 3.6% of total expenditure.
By 2008/9 total PCT expenditure per person had increased to £1531 (up 28% from 2004/5). The residual
‘other’ category (PBC 23) still accounted for the largest share of expenditure (14.9%) with per capita
expenditure of almost £228, of which £145 was accounted for by primary care expenditure. Mental health
(PBC 5) still accounted for just over 12% of expenditure, but the expenditure share recorded by circulation
problems (PBC 10) had fallen from 10.2% to 8.5%. Other categories recording a fall in budget share
of more than one half of one percentage point included the gastrointestinal system (down from 6.1%
to 5.1%), the musculoskeletal system (down from 6% to 5.2%), trauma and injuries (down from 6% to
4.2%) and maternity (down from 4.6% to 3.9%).
Categories recording an increase in budget share of more than one half of one percentage point included
neurological problems (up from 2.9% to 4.4%) and dental problems (up from 1.1% to 4.1%).
Some of these changes will partly reflect revisions to the algorithms used to allocate expenditure to
particular PBCs. For example in 2006/7 expenditure per person on musculoskeletal problems fell by 11%
and expenditure on trauma and injuries fell by 25%. In the same year, expenditure on neurological
problems increased by 35%. This suggests that some types of activity, which were previously allocated to
musculoskeletal problems and/or trauma and injuries, were reallocated to neurological problems.
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Similarly, up to and including 2006/7, expenditure that was not directly attributable to a particular
programme category was apportioned using admitted patient care percentages.g In other words, if x% of
total admitted patient care expenditure was allocated to PBC 1, then x% of all expenditure that was not
directly attributable to a particular programme category was also allocated to PBC 1. With effect from
2007/8, however, NHS organisations were asked to select an appropriate basis for the apportionment of
this non-programme-specific expenditure and that, where no reasonable basis existed, such expenditure
was to be allocated to the ‘other – miscellaneous’ (PBC 23X) category.
These two changes to the algorithm used to allocate expenditure to particular PBCs illustrate that
year-on-year comparisons of expenditure need to be interpreted with care.
Obviously, expenditure per head on any given programme varies from one PCT to another and Table 2
presents some statistics that indicate the degree of variation in expenditure levels across PCTs by PBC.
Columns (2)–(5) of Table 2 present descriptive statistics for PCT expenditure per person by PBC. These
reveal that, for example, PCT per capita expenditure in the cancer programme averaged £96.30 across all
PCTs, with the minimum spend being £62.90 and the maximum being £155.70.
Some PCTs will be spending more than other PCTs simply because they face higher input costs. Columns
(6)–(9) in Table 2 present descriptive statistics for PCT per capita expenditure that has been adjusted for
the unavoidable geographical variation in costs (input prices) faced by PCTs.h However, if anything this
adjustment appears to increase the variation in expenditure across PCTs; for example, the range of per
capita expenditure on cancer increases from between £62.90 and £155.70 (unadjusted) to between
£59.10 and £163.10 (adjusted for local health-care input prices).
Another cause of the variation in expenditure levels will be the fact that the need for health care will vary
from one PCT to another. For example, areas with a relatively large proportion of elderly residents, or PCTs
operating in relatively deprived locations, can be expected to experience relatively high levels of spending.
The Department of Health has a well-developed methodology for estimating the relative health-care needs
of PCTs, which it uses as the basis for allocating health-care funds to PCTs.74 Recent ‘needs’ formulae have
been derived from an adjustment for the demographic profile of the PCT and a series of econometric
analyses of the link between health-care expenditure and other socioeconomic factors at a small area level
within England.74
Columns (10)–(13) in Table 2 present descriptive statistics for PCT per capita expenditure that has been
adjusted for both the unavoidable geographical variation in costs and the local need for health care faced
by PCTs.i For virtually every PBC this adjustment reduces the variation in expenditure across PCTs (e.g. the
standard deviation of PCT per capita expenditure, falls from £19.70 to £15.30 for the cancer programme).
Although this adjustment reduces the variation in expenditure levels across PCTs, this decline is quite
modest and there are still substantial differences in expenditure even after allowing for differences in local
cost and need. For example, expenditure per head in the circulation problems category varies between
£78 and £328 using cost-adjusted expenditure data, but falls between £76 and £327 using cost- and
need-adjusted population data.
This variation in expenditure across PCTs has led some commentators to question the reliability of the PB
data. In a good governance report, the NAO75 sought to ‘ . . . examine the quality, timeliness and suitability
of PB data to support [their] audit of the Department of Health Resource Account and determine whether
the systems and processes in place to provide the data are accurate’. The NAO undertook a survey of
trusts, PCTs and SHAs. The NAO noted that a number of PCTs expressed concern about the accuracy
of data supplied to them by their service providers and noted that this was believed to be because most
trusts did not use or find the data they supply to PCTs of any use to themselves. Overall, the NAO’s main
conclusion was that although the processes for collecting the budgeting data were well defined in most
areas, there remained scope for improvement to the robustness of some of the data (such as the
non-admitted patient care data).
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Appleby et al.76 also considered the issue of data reliability in their study of variations in PCT spending on
cancer services. They noted a rather dramatic variation in spending across PCTs for any given year, and
that a relatively large number of PCTs report relatively large year-on-year changes in cancer expenditure.
However, and as the authors point out, it is difficult to define what might be either an implausible level of
expenditure or an implausibly large change in expenditure. Moreover, the interpretation of a large change
in expenditure is complicated by the fact that the Department of Health makes regular changes
(improvements) to the algorithm used to allocated activity to PBCs (as detailed above).
As a case study of the reliability of the PB data, Appleby et al.76 report the results of West Kent PCT’s use
of an alternative approach to producing the PB data for cancer and tumours. This alternative approach
identified similar levels of expenditure to the traditional method at the aggregate level, but there were
differences between the two approaches at the subprogramme level (that is, for expenditure on specific
cancer sites and in the residual ‘other cancers’ category).
As with any data set, there are likely to be recording and other errors associated with the PB data.
However, there is no evidence on the magnitude of such errors and we have no reason to believe that
such errors are likely to bias our estimates in one particular direction (e.g. we have no reason to believe
that measurement errors are systematically related to other relevant factors such as mortality rates). In this
study, our focus is on whole programme expenditure and thus we avoid the data reliability issues inherent
in any analysis of the subprogramme expenditure data.j Moreover, although we present estimates of the
cost of a life-year for individual programmes, our primary focus is on the cost of a life-year across all
programmes combined. The advantage of this is that the impact of a PCT reporting, for example, too little
expenditure in one category might be offset by reporting too much expenditure in another.
Although we note that the allocation of expenditure might not be consistent across PCTs there is no systematic
evidence that the magnitude of any inconsistency is sufficiently large to cause concern. Accordingly, for each
disease category, the observed variation in expenditure per person – holding constant input prices and the
need for health care – offers the opportunity to examine whether or not PCTs that spend more on health care
achieve a better outcome and, if so, at what cost. Empirical estimates of the strength of this relationship for
both individual and all programmes of care are presented later in this report.
Health outcome and other data
Health outcome data
Most studies of the relationship between expenditure and outcome have used some measure of mortality
as an indicator of the latter. We too employ mortality as our outcome measure for two reasons: first, it is a
relevant (but admittedly not comprehensive) measure of the outcome of health-care expenditure; and
second, it is available for more disease areas than any other outcome measure at PCT level.
Although mortality is available (by PCT) for several disease areas, it is not available for just over a half of all
programmes not least because it is simply not relevant for these programmes (e.g. for learning disabilities,
vision problems, hearing problems, dental problems and skin problems). Moreover, even where a mortality
measure is available, the ICD-10 coverage of the mortality data often falls short of the coverage of the
expenditure data. For some programmes, therefore, we have combined the published mortality rates for
two or more disease areas in an attempt to match the ICD-10 coverage of the mortality data with that of
the expenditure data.
Table 37 shows how we have attempted to marry the mortality data [see Table 37, column (4)] and the
expenditure data [see Table 37, column (2)]. However, and as Table 37 shows, the ICD-10 coverage of
the component mortality rates for some PBCs still falls short that of the expenditure data and the extent
of this shortfall is illustrated by the ratio reported in the final column of Table 37. For example, the cancers
and tumours programme covers all expenditure associated with ICD-10 codes C00–C97 and D00–D49 but
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TABLE 37 Table showing ICD-10 coverage of the expenditure and outcome measures
(1) PBC (2) ICD-10 coverage of PBC
(3) Number of deaths, < 75 years,
2008, England (ONS, VS3)
corresponding to column (2)
ICD-10 codes
(4) ICD-10 coverage of best
match PCT-based mortality
rate(s)
(5) Number of deaths, < 75 years,
2008, England (ONS, VS3)
corresponding to column (4)
ICD-10 codes
(6) Ratio
[column (5)/
column (3)]
1 Infectious diseases (large parts
of A00–B99)
1968 Infectious diseases (A00–B99) 1968 1
2 Cancers and tumours
(C00–C97, D00–D49)
63,076 All cancers (C00–C97) 62,072 0.984
3 Blood disorders (D500–D899) 393 No relevant mortality rate by
PCT available
N/A N/A
4 Endocrine, nutritional and
metabolic problems (E000–E899)
2368 Diabetes (E10–E14) 1501 0.634
5 Mental health (F00–F69, Z55, Z56) N/A No relevant mortality rate available N/A N/A
6 Learning disability (F700–F739,
F780–F849, F88–F90, Q90, Q91)
N/A No relevant mortality rate available N/A N/A
7 Neurological system (G000–G999,
Q000–Q079, R200–R999)
5238 Epilepsy (G40–G41) 713 0.136
8 Eye and vision problems
(H000–H599, Q100–Q159)
N/A No relevant mortality rate available N/A N/A
9 Hearing problems
(H600–H999, Q160–Q179)
N/A No relevant mortality rate available N/A N/A
10 Circulation problems
(I00–I99, Q20–Q28)
39,923 Circulatory diseases (I00–I99) 39,590 0.992
11 Respiratory problems
(A150–A169, A190–A199,
J000–J989, Q300–Q349,
R000–R099)
14,417 Asthma (J45–J46); bronchitis,
emphysema, other COPD (J40–J44);
pneumonia (J12–J18)
11,147 0.773
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TABLE 37 Table showing ICD-10 coverage of the expenditure and outcome measures (continued )
(1) PBC (2) ICD-10 coverage of PBC
(3) Number of deaths, < 75 years,
2008, England (ONS, VS3)
corresponding to column (2)
ICD-10 codes
(4) ICD-10 coverage of best
match PCT-based mortality
rate(s)
(5) Number of deaths, < 75 years,
2008, England (ONS, VS3)
corresponding to column (4)
ICD-10 codes
(6) Ratio
[column (5)/
column (3)]
12 Dental problems (K000–K099) N/A No relevant mortality rate available N/A N/A
13 Gastrointestinal problems
(I840–I859, K091–K929,
Q380–Q459, R100–R198)
10,656 Liver disease (K70, K73–K74);
ulcers (K25–K27)
6082 0.571
14 Skin problems (L000–L999,
Q351–Q379, Q800–Q859)
367 No relevant mortality rate available N/A N/A
15 Musculoskeletal problems
(M00–M99, Q18, Q650–Q799)
933 No relevant mortality rate available N/A N/A
16 Trauma, burns and injuries
(S000–S999, T000–T357,
T79, T90–T98)
5809 Skull, cranial injury (S02, S06, T90);
fracture of thighbone (S72)
1014 0.175
17 Genitourinary problems
(A50–A64, N00–N99,
Q500–Q649, R30–R39, R86–R87)
1565 Chronic renal failure (N18) 269 0.172
18 Maternity and reproductive
problems (N96–N98,
O000–O999, Z300–Z391)
41 No relevant mortality rate available N/A 8.213, but
see note
below
19 Neonate conditions (P000–P299,
P350–P399, P500–P619,
P700–P839, P900–P969)
226 Infant mortality rate per 1000 live
births, aged < 28 days (all
ICD-10 codes)
4345 8.213, but
see note
below
20 Poisoning (Q86, R78,
R82, T360–T888)
N/A No relevant mortality rate available N/A N/A
21 Healthy individuals N/A No relevant mortality rate available N/A N/A
22 Social care needs N/A No relevant mortality rate available N/A N/A
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COPD, chronic obstructive pulmonary disease; N/A, not applicable.
The listed ICD-10 coverage of the PB expenditure data includes the major ICD-10 codes covered.
The ICD-10 coverage of PBC 1 includes large elements of codes A00–B99 but a substantial minority of these codes map to the respiratory (PBC 11) and gastrointestinal (PBC 13)
programmes. We do not have the detailed deaths data to remove them from the total for A00–B99 and then to add them to the respiratory and gastrointestinal programmes. Instead,
we acknowledge that the number of deaths attributed to PBC 1 will be overstated [and that the adjustment ratio in column (6) will be too low], and that the number of deaths attributed
to PBCs 11 and 13 will be understated [and that their adjustment ratios in column (6) will be too high] but this is the best that can be achieved given the available data.
The ICD-10 coverage of the all England mortality data does not always match precisely that of the expenditure data or the PCT-level mortality data; again, we have done the best that can
be achieved given the available data. In particular, the national epilepsy mortality data relates to ICD-10 code G40 (687 deaths) but the PCT-level data relates to G40 and G41 (annual
average over 2007/8/9 is 713 deaths); the national renal failure mortality data relates to ICD-10 codes N17–N19 (415 deaths) but the PCT-level data relates to N18 (annual average over
2007/8/9 is 269 deaths); the national liver disease mortality data relates to ICD-10 code K70–K77 (6020 deaths) but the PCT-level data relates to K70, K73–K74 (annual average over 2007/
8/9 is 5195 deaths); and there is no good ICD-10 code match for femur and skull fracture deaths using national VS3 data (the PCT-level data relates to S72, S02, S06, T90: annual average
over 2007/8/9 is 1014 deaths). For these four cases we use the annual average number of deaths over 2007/8/9 from the PCT-level data as the numerator when calculating the coverage
adjustment factor [column (6)].
The number of deaths in England for those aged < 75 years for the trauma, burns and injuries programme [column (3)] relates to 2004 and is for the secondary cause of death
(Martin et al.63).
The mortality rate for neonate conditions relates to deaths aged < 28 days for all ICD-10 codes but the expenditure data relates only to ‘P’ ICD-10 codes. Hence, the large adjustment factor
of 8.213 because the coverage of the expenditure data is much smaller than that of the mortality data. However, at the very end of the project it became clear that although the number of
deaths data for those aged < 75 years includes those dying at all ages < 75 years (including those at < 1 year), the disease-specific years of life lost totals for those aged < 75 years excludes
those dying at < 1 year of age and actually refers to those dying at ages 1–74 years (the argument is that infant deaths are mostly a result of causes specific to the age and have different
causes to disease-specific deaths later in life). We therefore have two adjustment factors for the maternity and neonates programme: first, an adjustment factor for the number of deaths
derived on the same basis as the adjustment factors for other programmes; and second, an adjustment factor for the YLL that reflects both the YLL in the maternity and neonates
programme, as well as the YLL associated with deaths that would have been attributed to other programmes had the individual died > 1 year of age. [NB The total number of deaths in
England in 2008 of those aged < 1 year is 3184 and if we divide 2193 by (3184 + 41) we obtain the YLL coverage adjustment factor (= 0.679) for maternity and neonates.]
The PCT-level mortality rates are available from the NHS IC website.
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the PCT-based mortality data only relates to ICD-10 codes C00–C97. At the national (all England) level,
figures are available which show that, in 2008, there were 62,072 deaths of those aged under 75 years
from codes C00–C97 and that there were 63,076 deaths from codes C00–C97 and D00–D49 combined.
In other words, the PCT-level mortality data reflects 98.4% of all deaths associated with the expenditure
codes. Initially, we did not adjust our cost of life (year) estimates for this mismatch but, as we will see
in Adjusting the cost of life (year) estimates for the mismatch in the ICD-10 coverage of the expenditure
and the mortality data, an adjustment has been made for this mismatch in the final calculation of the cost
of a life (year) associated with expenditure for 2006/7. The same adjustment has also been applied to the
cost of a life (year) estimates associated with expenditure for 2007/8 and for 2008/9.
Of course, we acknowledge that mortality is a more relevant outcome indicator for some programmes
(e.g. for circulatory problems) than for others (e.g. for epilepsy) and, for this reason, we would expect better
results in some programmes than others. We also acknowledge that this focus on mortality ignores the
impact of expenditure aimed at chronic care and at palliative care. Nevertheless, our focus on mortality is
purely practical: it is both a widely available measure and it is clearly a relevant outcome indicator. Moreover,
the approach adopted here is extendable in principle to other non-mortality-based outcome indicators.
We illustrate such an application in Application of method to other non-mortality-based outcome indicator
where we use EQ-5D utility scores pre and post an operative procedure from the PROMs programme to
generate a non-mortality-based outcome indicator, and we use this indicator to estimate our outcome model.
Previous studies using the PB data have employed two alternative mortality-based outcome indicators: the
under 75 years of age SMR and the under 75 years SYLLR. The SMR gives equal weight to all deaths
irrespective of the age at which they occur but the SYLLR gives greater weight to deaths that occur at
earlier ages.
We employed both the SMR and the SYLLR when undertaking some preliminary sens7itivity analysis
(i.e. in Estimation issues associated with the use of 2006/7 expenditure data when considering, for example,
which measure of need to use), but elsewhere we have focussed solely on a measure of the avoidable YLL.k
This is calculated by summing over ages 1–74 years the number of deaths at each age multiplied by the
number of years of life remaining up to age 75 years. The crude YLL rate is simply the number of YLL divided
by the resident population aged < 75 years. Like conventional mortality rates, the crude YLL rate can be age
standardised to eliminate the effects of differences in population age structures between areas, and this (age)
standardised YLL rate is the health outcome variable generally employed in this study (Lakhani et al., p. 379).77
Descriptive statistics for the SYLLRs employed in this study are shown in Table 38. For example, for all deaths
over the 3-year period from 2006 to 2008, the annual SYLLR across all PCTs for those aged < 75 years
averaged 467 YLL per 10,000 population, but this rate varied considerably across PCTs, ranging between 288
and 749 YLL per 10,000 population. Similarly, large variations in the mortality rate across PCTs are evident
for other disease groups.l
Other variables
We employ an IV estimation technique to estimate our outcome and expenditure equations because
(i) own programme expenditure is likely to be endogenous in the outcome equation and (ii) other
programme need is likely to be endogenous in the own programme expenditure equation.
Instrumental variable estimation is described in Instrumental variable estimation, below, but basically it
involves replacing the endogenous variable in the equation of interest with its predicted value from an OLS
regression which regresses the endogenous variable on a set of IVs. These instruments should be good
predictors of the endogenous variable (i.e. they should be relevant and strong predictors) but should be
appropriately excluded from the equation of interest (i.e. they should be valid instruments).
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TABLE 38 Table showing descriptive statistics for the mortality variables
Variable Observations Mean SD Min. Max.
All causes of death, SYLLR, 2002/3/4 303 489.2 94.2 320.3 889.5
All causes of death, SYLLR, 2004/5/6 152 483.4 83.9 318.1 742.5
All causes of death, SYLLR, 2006/7/8 152 467.3 83.7 287.8 748.9
All causes of death, SYLLR, 2007/8/9 151 457.1 81.8 297.2 731.6
All causes of death, SYLLR, 2008/9/10 151 446.4 78.6 290.8 736.9
Cancer, SYLLR, 2002/3/4 303 161.9 20.8 115.6 263.4
Cancer, SYLLR, 2004/5/6 152 158.4 18.3 103.4 218.8
Cancer, SYLLR, 2006/7/8 152 154.2 19.0 90.5 212.2
Cancer, SYLLR, 2007/8/9 151 151.0 18.5 98.3 201.9
Cancer, SYLLR, 2008/9/10 151 147.9 17.5 100.2 193.9
Circulatory disease, SYLLR, 2002/3/4 303 114.4 31.3 57.7 225.7
Circulatory disease, SYLLR, 2004/5/6 152 108.6 25.2 65.2 177.8
Circulatory disease, SYLLR, 2006/7/8 152 99.0 23.7 54.4 156.7
Circulatory disease, SYLLR, 2007/8/9 151 94.4 22.6 51.4 149.9
Circulatory disease, SYLLR, 2008/9/10 151 91.1 21.7 50.9 154.8
Asthma, SYLLR, 2002/3/4 303 2.7 2.0 0.0 12.2
Asthma, SYLLR, 2004/5/6 152 2.4 1.3 0.1 6.3
Asthma, SYLLR, 2006/7/8 152 2.0 1.1 0.0 5.0
Asthma, SYLLR, 2007/8/9 151 1.9 1.1 0.0 5.7
Asthma, SYLLR, 2008/9/10 151 1.7 1.1 0.0 4.6
Bronchitis, emphysema and other COPD, SYLLR, 2002/3/4 303 12.5 5.7 2.6 35.5
Bronchitis, emphysema and other COPD, SYLLR, 2004/5/6 152 12.0 4.8 3.7 26.1
Bronchitis, emphysema and other COPD, SYLLR, 2006/7/8 152 12.0 4.8 4.0 24.4
Bronchitis, emphysema and other COPD, SYLLR, 2007/8/9 151 11.8 4.7 4.1 24.8
Bronchitis, emphysema and other COPD, SYLLR, 2008/9/10 151 11.6 4.9 4.2 26.6
Pneumonia, SYLLR, 2002/3/4 303 9.1 4.1 1.4 24.6
Pneumonia, SYLLR, 2004/5/6 152 9.7 3.7 3.6 21.9
Pneumonia, SYLLR, 2006/7/8 152 9.7 3.9 3.6 32.4
Pneumonia, SYLLR, 2007/8/9 151 9.8 4.0 3.9 34.4
Pneumonia, SYLLR, 2008/9/10 151 9.3 4.0 2.8 36.1
Tuberculosis, SYLLR, 2002/3/4 N/A
Tuberculosis, SYLLR, 2004/5/6 152 0.8 1.1 0.0 5.2
Tuberculosis, SYLLR, 2006/7/8 152 0.8 1.0 0.0 7.6
Tuberculosis, SYLLR, 2007/8/9 N/A
Tuberculosis, SYLLR, 2008/9/10 N/A
Respiratory problems, SYLLR, 2002/3/4 (excluding TB) 303 24.3 9.7 5.4 64.2
Respiratory problems, SYLLR, 2004/5/6 (including TB) 152 24.9 8.9 9.7 51.7
continued
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TABLE 38 Table showing descriptive statistics for the mortality variables (continued )
Variable Observations Mean SD Min. Max.
Respiratory problems, SYLLR, 2006/7/8 (including TB) 152 24.6 8.5 11.3 56.4
Respiratory problems, SYLLR, 2007/8/9 (excluding TB) 151 23.4 8.1 8.5 57.4
Respiratory problems, SYLLR, 2008/9/10 (excluding TB) 151 22.6 8.5 8.5 65.0
Liver disease, SYLLR, 2002/3/4 303 20.1 10.0 3.6 70.9
Liver disease, SYLLR, 2004/5/6 152 22.9 9.9 8.2 75.0
Liver disease, SYLLR, 2006/7/8 152 23.9 10.8 7.0 81.7
Liver disease, SYLLR, 2007/8/9 151 23.7 10.6 9.4 81.1
Liver disease, SYLLR, 2008/9/10 151 23.5 9.9 8.4 77.4
Gastric, duodenal and peptic ulcers, SYLLR, 2002/3/4 303 2.6 1.6 0.0 10.2
Gastric, duodenal and peptic ulcers, SYLLR, 2004/5/6 152 2.7 1.5 0.1 11.6
Gastric, duodenal and peptic ulcers, SYLLR, 2006/7/8 152 2.4 1.3 0.5 8.5
Gastric, duodenal and peptic ulcers, SYLLR, 2007/8/9 151 2.4 1.3 0.4 7.0
Gastric, duodenal and peptic ulcers, SYLLR, 2008/9/10 151 2.3 1.4 0.4 7.6
Gastrointestinal problems, SYLLR, 2002/3/4 303 22.7 11.0 4.7 77.8
Gastrointestinal problems, SYLLR, 2004/5/6 152 25.6 10.7 9.3 80.3
Gastrointestinal problems, SYLLR, 2006/7/8 152 26.3 11.5 8.1 87.6
Gastrointestinal problems, SYLLR, 2007/8/9 151 26.1 11.1 10.7 86.3
Gastrointestinal problems, SYLLR, 2008/9/10 151 25.8 10.5 9.2 82.5
Infectious diseases, SYLLR, 2002/3/4 303 7.0 4.2 0.1 28.1
Infectious diseases, SYLLR, 2004/5/6 152 8.1 4.3 2.4 24.9
Infectious diseases, SYLLR, 2006/7/8 152 8.3 4.4 0.6 26.1
Infectious diseases, SYLLR, 2007/8/9 151 8.2 4.2 2.1 25.1
Infectious diseases, SYLLR, 2008/9/10 151 7.7 4.0 1.6 22.6
Diabetes, SYLLR, 2002/3/4 303 4.7 2.3 0.0 13.4
Diabetes, SYLLR, 2004/5/6 152 4.5 2.1 1.3 15.3
Diabetes, SYLLR, 2006/7/8 152 4.3 2.0 0.5 14.6
Diabetes, SYLLR, 2007/8/9 151 4.0 1.8 0.3 11.2
Diabetes, SYLLR, 2008/9/10 151 4.0 1.7 0.4 10.0
Epilepsy, SYLLR, 2002/3/4 303 5.2 2.7 0.3 16.1
Epilepsy, SYLLR, 2004/5/6 152 5.3 2.1 0.5 13.1
Epilepsy, SYLLR, 2006/7/8 152 5.1 2.1 0.9 12.7
Epilepsy, SYLLR, 2007/8/9 151 4.9 1.9 1.3 14.5
Epilepsy, SYLLR, 2008/9/10 151 4.8 2.0 1.1 13.7
Renal failure, SYLLR, 2002/3/4 303 0.9 0.9 0.0 6.0
Renal failure, SYLLR, 2004/5/6 152 0.9 0.7 0.0 4.0
Renal failure, SYLLR, 2006/7/8 152 0.8 0.7 0.0 5.5
Renal failure, SYLLR, 2007/8/9 151 0.7 0.6 0.0 4.3
Renal failure, SYLLR, 2008/9/10 151 0.6 0.6 0.0 3.0
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We have a number of potential instruments available, mostly derived from 2001 Population Census.80
In our earlier studies we found that a small subset of these instruments proved sufficient to generate
plausible results and these included:
l the proportion of the population providing unpaid care
l the proportion of households that are one-pensioner households
l the index of multiple deprivation
l the proportion of the population in the white ethnic group.
We also had available a further set of potential instruments and, where our more limited set of instruments
failed to generate plausible results, we extended our instrument search to include this wider set of variables.
This extended set of instruments included:
l the proportion of residents born outside the EU
l the proportion of the population of working age (16–74 years) with a limiting long-term illness (LLT)
l the proportion of the population aged 16–74 years with no qualifications
l the proportion of the population aged 16–74 years who are full-time students
TABLE 38 Table showing descriptive statistics for the mortality variables (continued )
Variable Observations Mean SD Min. Max.
Fracture of femur (S72), SMR, 2002/3/4 (ages 65–84 years) 303 8.9 6.9 0.0 39.3
Fracture of femur (S72), SMR, 2004/5/6 (ages 65–84 years) 152 10.1 6.6 0.0 30.6
Fracture of femur (S72), SMR, 2006/7/8 (ages < 75 years) 152 0.4 0.3 0.0 1.4
Fracture of femur (S72), SYLLR, 2007/8/9 (ages < 75 years) 151 0.3 0.3 0.0 1.7
Fracture of femur (S72), SYLLR, 2008/9/10 (ages < 75 years) 151 0.3 0.3 0.0 2.1
Skull fracture/injury, SMR, 2002/3/4 (ages < 75 years) 303 2.8 1.2 0.4 7.6
Skull fracture/injury, SMR, 2004/5/6 (ages < 75 years) 152 1.9 0.8 0.4 4.4
Skull fracture/injury, SMR, 2006/7/8 (ages < 75 years) 152 1.8 0.7 0.5 4.2
Skull fracture/injury, SYLLR, 2007/8/9 (ages < 75 years) 151 1.7 0.7 0.2 4.2
Skull fracture/injury, SYLLR, 2008/9/10 (ages < 75 years) 151 1.6 0.6 0.1 3.0
Trauma, SMR, 2002/3/4 (weighted average of femur and
skull fractures)
303 4.8 2.4 0.3 15.3
Trauma, SMR, 2004/5/6 (sum of femur and skull fracture rates) 152 12.0 6.8 1.9 32.8
Trauma, SMR, 2006/7/8 (sum of femur and skull fracture rates) 152 2.1 0.8 0.6 4.7
Trauma, SMR, 2007/8/9 (sum of femur and skull fracture rates) 151 2.1 0.8 0.2 4.6
Trauma, SMR, 2008/9/10 (sum of femur and skull fracture rates) 151 1.9 0.8 0.1 4.4
Infant mortality rate, < 28 days per 1000 live births, 2002/3/4 303 3.4 1.3 0.9 7.8
Infant mortality rate, < 28 days per 1000 live births, 2004/5/6 130 3.4 0.9 1.2 6.2
Infant mortality rate, < 28 days per 1000 live births, 2006/7/8 152 3.3 1.0 1.4 6.4
Infant mortality rate, < 28 days per 1000 live births, 2007/8/9 151 3.2 1.0 1.2 6.9
Infant mortality rate, < 28 days per 1000 live births, 2008/9/10 151 3.2 1.0 1.2 6.9
COPD, chronic obstructive pulmonary disease; max., maximum; min., minimum; N/A, not applicable; SD, standard
deviation, TB, tuberculosis.
The SYLLRs are directly age-standardised rates and are expressed as rates per 10,000 European standard population.
Source: NHS IC website.
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l the proportion of households without a car
l the proportion of households that are owner occupied
l the proportion of households that are rented from a local association (LA) or housing association (HA)
l the proportion of households that are rented from private landlords
l the proportion of households that are lone-parent households with dependent children
l the proportion of the population aged 16–74 years who are permanently sick
l the proportion of those aged 16–74 years who are long-term unemployed
l the proportion of those aged 16–74 years in employment who are working in agriculture
l the proportion of those aged 16–74 years in managerial and professional occupations.
Details of the construction of all instruments are shown in Table 92 in the Annex.
Our instruments reflect factors, such as socioeconomic deprivation and the availability of informal care in
the community, which might indirectly impact on mortality rates and/or health-care expenditure levels.
As we shall see, although our instruments ‘pass’ the appropriate statistical tests, some commentators
claim that such tests may have ‘low power’ to detect the presence of invalid instruments. Consequently,
in The sensitivity of the outcome elasticity to the validity of the instrument exclusion restrictions we
examine how sensitive our results are to the presence of invalid instruments.
Table 3 reports descriptive statistics for the socioeconomic and needs variables as available for the
regression analysis of PB expenditure data for 2007/8 and for 2008/9 (these statistics are for the variables
in absolute form). For example, on average, lone-pensioner households comprise 14% of all households,
the ‘white ethnic’ group accounts for 89% of the population, and 10% of the population provide
unpaid care.
In addition to the IVs, Table 3 also report descriptive statistics for various other variables available for the
regression analysis including the of Department of Health’s ‘need for health care’ index (this incorporates
the CARAN formula for HCHS and reflects need across all health-care services), its need for HIV services
index, and its need for maternity services index. The latter two indices are used to either supplement or
replace the all service measure of need when estimating our models. The ‘need for health care’ index
averages about 1 but varies substantially, with some PCTs having a needs index more than 25% below the
national average and others facing a need for health care more than 30% above the national average.
Table 3 also reports descriptive statistics for some disease prevalence rates (e.g. for diabetes and for
epilepsy) and, again, these are used to either supplement or replace the all service measure of need when
estimating our models.
Finally, the MFF index shows that input prices in the most expensive PCT are almost 20% above those in
the least expensive PCT.
Estimation issues and strategy
Introduction
The theoretical framework suggests the specification and estimation of a system of equations, with an
expenditure and health outcome equation for each of the 23 programmes of care. However, this approach
makes infeasible data demands, requiring variables to identify expenditure, need, environmental factors
and health outcomes in each of the 23 programmes of care. Moreover, mortality rates are available
for less than half of the 23 programmes. Rather than estimate a system of equations, we proceed on a
programme-by-programme basis, estimating health outcome and expenditure equations for those
programmes for which mortality data is available.
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In line with the theoretical framework presented in Theoretical model, we specify the following
expenditure (see Equation 12) and health outcome (see Equation 13) models for each of the J programmes
of care (J= 23):
x i = a1þ∑b1 j  nijþdy iþ e1i j = 1, : : : , 23 (12)
hi = a2þb2niþ f x iþ e2i (13)
where:
l xi is the expenditure in PCTi in the selected programme
l nij is the need for care in PCTi in programme j
l yi is the total budget for PCTi
l hi is the health gain in PCTi in the selected programme
l ni is the need for care in PCTi in the selected programme.
Ideally we should employ a programme-specific indicator of the level of need for each care programme but
these are not readily available. When estimating both the outcome and expenditure models we therefore
proxy the own programme health-care need using the ‘needs’ component of the Department of Health’s
resource allocation formula.m This needs element is specifically designed to adjust PCT allocations for local
health-care needs and accordingly, ceteris paribus, we would expect a positive relationship between
expenditure xi and need ni for each programme of care. We would also expect a positive relationship
between need ni and adverse health outcomes hi.
n
The expenditure model includes both the own programme health-care need (which is proxied using the
‘needs’ component of the Department of Health’s resource allocation formula) and the need for health
care in all other programmes. When estimating the expenditure model previous studies have proxied the
need for health care in other (competing) programmes using the mortality rate in those other programmes.
The precise definition of the programmes included in the ‘other programme’ mortality rate has varied a
little, but here all of our preferred results from 2006/7 onwards use the ‘all-cause mortality rate excluding
the mortality rate in the programme of interest’ as the proxy for need in other programmes.o
Instrumental variable estimation
We do not use OLS to estimate Equations 12 and 13 because both are likely to contain an endogenous
regressor. Expenditure in the outcome equation (see Equation 13) and other programme need in the
expenditure equation (see Equation 12) are both likely to be endogenous and, in the presence of an
endogenous regressor, OLS is both a biased and an inconsistent estimator. Instead, we use IV estimation
and implement 2SLS using the -ivreg2- routine in Stata v11. Unlike OLS, IV is a consistent estimator in the
presence of an endogenous regressor and, although in finite samples the IV estimator will be biased, the
belief is that (providing certain assumptions are met) this bias will be less than that associated with OLS.
For the health outcome equation, IV estimation can be viewed as finding variables (instruments) that are
good predictors of programme expenditure but which are appropriately excluded from the equation of
interest (that is, from Equation 13). The assumption is that the instruments and exogenous variables from
the equation of interest impact on the health outcome through their impact on expenditure only, and that
they do not have a direct effect on the outcome.p If, on the other hand, an instrument reflects unobserved
factors that affect both expenditure and mortality directly, then the IV estimator becomes both biased and
inconsistent. Such an instrument is said to be ‘invalid’ because it belongs in the equation of interest in its
own right.
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We have a number of potential instruments available, mostly derived from the 2001 Population Census,80
and these are described in Other variables. In our earlier studies we found that a small subset (four) of
these instruments often proved sufficient to generate plausible results and we commenced our empirical
work with these. If plausible results were not obtainable with some combination of these four instruments,
we employed an extended instrument set. Further details of the identification of suitable instruments for
each model can be found in Re-estimation of poorly performing models with an extended instrument set.
The available instruments reflect factors, such as socioeconomic deprivation and the availability of informal
care in the community, which might indirectly impact on mortality rates and/or health-care expenditure
levels. The set of instruments associated with each estimated equation was selected on both technical and
pragmatic grounds. From a pragmatic point of view, we require a parsimonious set of instruments that
satisfy the necessary technical criteria. These are, first, that they have face validity, that is, that they are
plausible determinants of the endogenous variable being instrumented, and second, that the instruments
are both relevant and valid. The relevance of an instrument set refers to its ability to predict the
endogenous variable of concern, whereas validity refers to the requirement that instruments should be
uncorrelated with the error term in the equation of interest. The set of instruments was modified if,
for example, the Hansen–Sargan test suggested that the set under test was not valid.
Should the instrument set be strong, relevant and valid, 2SLS will produce consistent estimates of the
parameters of the reduced form models. We subject the instrument sets to tests for validity using the
Sargan–Hansen test of overidentifying restrictions. The joint null hypothesis is that the instruments are valid
instruments (i.e. they are uncorrelated with the error term), and that the excluded instruments are correctly
excluded from the estimated equation. A rejection of the null hypothesis casts doubt on the validity of the
instruments. We test for instrument relevance using Shea’s79 partial R2 measure; this reflects the correlation
between the excluded instruments and the endogenous regressor. However, even if valid and relevant,
non-zero but small correlations between the instruments and the endogenous regressors can lead to the
problem of weak instruments. This can be the case even where correlations are shown to be significant at
conventional levels of testing and sample sizes are large.143 The IV estimator becomes a biased estimator if
the instruments are weakly correlated with the endogenous regressors, and the extent of the bias can be
specified relative to the bias of the OLS estimator.
For the case of a single regressor, Staiger and Stock144 suggest applying the criterion that if the first-stage
F-statistic, testing the null hypothesis that the instrument set does not significantly predict the endogenous
regressor, is less than 10 then the instruments can be thought to be weak. Stock and Yogo80 extend these
ideas to the case where there can be multiple endogenous regressors and propose a test for the null
hypothesis that the instruments are weak and provide appropriate critical values. This is an extension of
the Cragg and Donald145 test for instrument relevance. For the case of a single endogenous regressor, the
Cragg–Donald statistic is simply the F-statistic of the test of the hypothesis that the instruments do not enter
the first-stage regression. Stock and Yogo80 provide critical values of the F-statistic (and the Cragg–Donald
statistic for multiple endogenous regressors) that tabulates the ratio of 2SLS bias to the bias of OLS. The
weakness or otherwise of the instruments can then be assessed by the relative bias exceeding a given
threshold (e.g. 2SLS bias exceeding 5% of OLS bias).q
To ensure the robustness of our estimates to arbitrary heteroskedasticity, we estimate our models with
Stata’s -robust- option. The Cragg–Donald statistics are not valid in the presence of heteroskedasticity. We
therefore report the Kleibergen–Paap LM statistic (testing instrument relevance) and the Kleibergen–Paap
F-statistic (testing for weak instruments) which are valid in the presence of heteroskedasticity.
A general test of model specification is provided through the use of Ramsey’s81 reset test for OLS and
an adapted version of the test for IVs.r,81 The tests are more properly thought of as tests of a linearity
assumption in the mean function or a test of functional form restrictions and omitted variables146 and can
be useful as a general check of model specification.
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Finally, we check that the presumed endogenous variable is in fact endogenous using the test proposed
by Durbin.83 If the null hypothesis of exogeneity cannot be rejected, then we also use the OLS estimator.
In addition, although our instruments ‘pass’ the appropriate statistical tests, some commentators claim
that such tests may have ‘low power’ to detect the presence of invalid instruments. Consequently,
in The sensitivity of the outcome elasticity to the validity of the instrument exclusion restrictions we
examine how sensitive our results are to the relaxation of the assumption that the instruments are valid.
Other estimation issues
In this research we build on previous studies that have used the PB data to estimate the outcome and
expenditure models described in Introduction. This previous research was undertaken over a period of
years and a number of changes were made between these studies (these were sometimes forced on the
researchers by, for example, data availability considerations). Here we persevere with the previous
approach used to analyse the 2005/6 PB data,63 but we make some changes to the way in which the
2006/7 (and subsequent) PB data are analysed.
In the next section we start by revisiting the results obtained by Martin et al.63 who used the 2005/6 PB
data. In 2005/6 there were 303 PCTs but a series of mergers reduced this total to 152 in 2006/7. These
mergers exacerbated greatly the difference in size between the PCTs and so from 2006/7 it makes less
sense to give each PCT equal weight in any regression. This is discussed further in Estimation issues
associated with the use of 2006/7 expenditure data when we come to estimate our model using
2006/7 PB data.
Different PCTs face different costs when buying health-care inputs. For example, some health economy
input prices are up to 40% higher in London and the south east of England than elsewhere. In a previous
study,57 we used the MFF index that feeds into the payment by results tariffs for 2007/8 to adjust PB
expenditure in 2006/7 for local input prices.147 This index only reflects costs associated with the purchase
of HCHS services but this was the only index available for the new (post-October 2006) set of PCTs at the
time of that study. Since then, a more comprehensive set of MFF indices for the 152 PCTs has been
published.74 In Estimation issues associated with the use of 2006/7 expenditure data we investigate the use
of alternative weighted averages of the HCHS, prescribing, and GMS/PMS MFF indices with weights
reflecting the national share of expenditure across these three categories (these weights are 76.3%,
12.4% and 11.3% respectively).s For 2005/6, however, we persevere with the MFF employed in the
original Martin et al. study,63 namely the HCHS MFF.148
Estimation of the expenditure equation for any individual programme requires a proxy for the need for
health care across all other programmes. Previous studies of PB expenditure in 2004/5, 2005/6 and
2006/7 have used the circulatory disease mortality rate as a proxy for the need for health care in other
programmes in the cancer expenditure equation, and the cancer mortality rate as the proxy for need in
other programmes in the circulatory disease expenditure equation.59,60,63 As these are both programmes
that attract considerable expenditure and record considerable mortality, it is not implausible that mortality
and expenditure in one of the programmes will impact on expenditure in the other. For other programmes
(e.g. respiratory problems and gastrointestinal problems) Martin et al.59,63 used the all-cause mortality rate
as a proxy for the ‘need in other programmes’ variable when analysing expenditure in both 2005/6 and
2006/7. Here, however, we persevere with the previous approach when using 2005/6 PB data but,
from 2006/7, in all programmes we proxy the need for health care in other (competing) programmes
using the mortality rate in those other programmes (i.e. the all-cause mortality rate minus the own
programme mortality rate).
Finally, one data transformation that has been applied in all previous studies and is applied here too is to
log-transform all variables so that parameter estimates can be interpreted as elasticities. In other words,
a regression coefficient of 0.5 implies that a 1% increase in the regressor is associated with a 0.5%
increase in the dependent variable.
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Empirical results
Analysis of programme budgeting expenditure for 2005/6 and mortality
data for 2002/3/4
This work builds on previous studies. Martin et al.60 reported outcome elasticities for two programmes
(cancer and circulatory disease) using expenditure data for 2004/5 and pooled mortality data for 2002,
2003 and 2004. Martin et al.63 extended their preliminary analysis to include several other programmes
and, in this extension, they used updated expenditure data (for 2005/6). However, the authors found it
difficult to obtain sensible outcome models for some programmes of care. Here we commence our
empirical work with an attempt to obtain plausible outcome models for those programmes that defeated
Martin et al. in their study.63
Construction of an alternative measure of need
Our preferred measure of the need for health care is calculated from the Department of Health’s PB data
set. This data set includes PB expenditure for each care programme as well as the raw population and the
‘unified weighted’ population for each PCT. The unified weighted population incorporates adjustments to
the raw population for both the need for health care as well unavoidable variations in local input costs.
The latter are captured via an index which is known as the MFF. By removing the raw population and MFF
adjustment from the unified weighted population we are left with the implied level of need, and this is the
measure of need that was initially used in the estimation of the model.63
The Department of Health PB measure of need associated with expenditure for 2005/6 incorporates the
AREA resource allocation formula. This has since been replaced with the CARAN formula and recent work
by colleagues at York and the Nuffield Trust has investigated the possibility of constructing a person-based
resource allocation (PBRA) measure of need.149 We therefore decided to investigate the possibility of
applying PBRA methods to the construction of an alternative measure of need.
The construction of all of these measures of need involves two steps. The first step requires the estimation
of the econometric relationship between the previous utilisation of services and the characteristics of the
local areas as existed at the time of the utilisation (e.g. their demographic profile and other indicators of
service need such as socioeconomic measures of deprivation). The second step involves the use of this
relationship to predict future health-care use given predictions about future demographic characteristics
and socioeconomic measures of deprivation.
The major difference between the AREA and CARAN formulae and the PBRA formula is that the former
largely use small area-based indicators of socioeconomic characteristics as indicators of the need for
health care, whereas the latter largely obviates the requirement for these through the extensive use of
individual-based indicators of need. In particular, the PBRA formula employed here is based on an
analysis of inpatient and outpatient cost data for 2007/8 for 10% of the entire population of England.149
As regressors the PBRA utilisation model includes:
(a) 38 age/gender dummies
(b) 150 ICD-10 morbidity markers for each patient reflecting their use of inpatient services in the previous
2 years (that is, in 2005/6 and 2006/7 combined)
(c) four hospital encounter variables for each patient reflecting the intensity of their use of both outpatient
and inpatient services in the previous 2 years (that is, in 2005/6 and 2006/7 combined)
(d) 10 small area-based indicators of either local deprivation or health-care supply characteristics; and
(e) 151 PCT dummies (reflecting variations in health-care supply).
The coefficients from this modelling procedure are applied to patient registration data as at 1 April of the
year for which the measure of need is required. Here we are studying expenditure in 2005/6 and so we
applied the results of the modelling to patient registration data as at 1 April 2005. This requires the
construction of a data set containing the patient registration details of all 50 million patients registered
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with an English practice at this date. To this we added the patient’s age and gender as at 1 April 2005.
We also added each patient’s ICD-10 morbidity markers and their encounter variables for 2003/4 and
2004/5 combined. Each patient’s address [lower super output area (LSOA)] is also added to the data set
and this is used to attach the small number of indicators reflecting the LSOA’s socioeconomic and
health-care supply characteristics.
Given this data set, the calculation of PCT need (given supply) proceeds as follows. First, calculate the
national average supply effect. This is the sum of the products of the national average values of the supply
variables for the population as at 1 April 2005 and the relevant regression coefficients.
Second, ignore supply and calculate PCT need. This involves calculating the PCT average values of the
needs variables by age and gender group for the population as at 1 April 2005. Next, for each PCT,
calculate need by age and gender as the sum of the products of the mean values of the needs variables
and their respective regression coefficients. Then total PCT need is the sum of need in each age/gender
group multiplied by the number of patients in that age/gender group.
Finally, need given supply is calculated as total PCT need plus the number of patients multiplied by the
national average supply effect. PCT need per person is simply total PCT need divided by the PCT
population. Further details of how to use the results of the PBRA modelling to derive PCT weighted needs
indices are presented in Dixon et al.149
Re-estimation of models using a new measure of need
We re-estimated the outcome and expenditure models for the big four programmes as reported by
Martin et al.63 using the new (PBRA-based) measure of need.t In summary, the results for the cancer
programme were acceptable but not quite as good as previously obtained, and the results for circulation
problems, gastrointestinal problems and respiratory problems were poor (e.g. the signs on the expenditure
and need variables in the outcome equation were counterintuitive). These were unanticipated results and
we were curious to know why our alternative measure of need performed less well than the more
established measure.
We undertook a brief comparison of the two measures of need. Figure 13 provides a scatter plot of
the PB and PBRA measures of need. There is a clear positive correlation between the two measures
(correlation coefficient= 0.6146), and the summary statistics in Table 39 suggest that they have
similar ranges.
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FIGURE 13 Graph showing scatter plot of PB measure of need and PBRA measure of need.
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Table 40 reports values for the PB- and PBRA-based measures of need for selected types of PCTs. These
figures suggest that:
l the PBRA measure attributes more need to the least needy areas as defined by the PB measure
[see Table 40, section (a)]
l the PBRA measure attributes more need to the coastal/retirement areas than does the PB measure
[see Table 40, section (b)]; and
l the PBRA measure attributes far less need to inner city areas than does the PB measure [see Table 40,
section (c)].
Although these differences are at first perplexing, they become more understandable when it is noted that
the PB and PBRA measures record the level of need across different baskets of services. The PB measure of
need refers to all health-care activity, that is, HCHS, prescribing and GMS/PMS (primary care), but the
PBRA model only incorporates hospital activity (and it excludes mental health and maternity from this).
The need for hospital-based services is less related to deprivation than are other health-care services.
Hence the PBRA measure of need – because it only relates to hospital services – redistributes need away
from the more deprived PCTs and towards the more affluent ones. Moreover, expenditure on cancer
services is largely hospital based and hence a measure of need based on HCHS spend alone will be
reasonably satisfactory for cancer (as indeed we found). However, such a measure of need will perform
less well for other programmes (e.g. circulatory disease), where more of the expenditure is on prescribing
and/or primary care.
To test these hypotheses we need to compare our PBRA measure of need with a PB measure of need
that only relates to acute services (i.e. that excludes maternity and mental health, and all prescribing and
GMS/PMS). The Department of Health’s measure of need used for the 2005/6 allocations employs the
AREA formula for HCHS. This formula does not permit a separation of acute and maternity need and so
we cannot compare the PBRA measure of need for 2005/6 with the PB measure for 2005/6 for the same
group of specialties (i.e. for acute services excluding maternity and mental health).
However, the CARAN formula, first implemented for the 2009/10 allocations, does distinguish between
acute and maternity. But this formula has only been applied to the new (post-October 2006, n= 152)
PCTs whereas our PBRA-based measure is for the old (pre-October 2006, n= 303) PCTs because we are
modelling PB expenditure in 2005/6. However, not all of the old PCTs were involved in mergers in
October 2006. Thus for about half of all PCTs, we can compare our PBRA-based measure of need for
2005/6 with the CARAN-based measure of need for 2009/10 for the same set of HCHS services
(i.e. for acute services excluding maternity and mental health).
The correlation between PBRA need and CARAN acute services need is much higher (correlation
coefficient= 0.8722) than that between the PBRA and PB need measures. In addition, an inspection of the
values taken by the various need indices (e.g. for acute, maternity, and mental health) for the inner city PCTs
(where the PBRA and PB measures of need diverge the most) supports the hypothesis that it is the different
TABLE 39 Table showing summary statistics for PB- and PBRA-based measures of need
Variable Number of PCTs Mean SD Min. Max.
PB need 295 1.0062 0.1511 0.6883 1.4889
PBRA need 303 1.0146 0.1448 0.6884 1.4554
Max., maximum; min., minimum; SD, standard deviation.
Note that there are only 295 PCTs with a PB-based measure of need because only 295 of the 303 PCTs were used to
estimate our outcome and expenditure models (due to a lack of data for some PCTs).
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TABLE 40 Table showing values for the PB- and PBRA-based measures of need for selected types of PCT
Area PB need PBRA need
(a) Examples of more affluent areas
Wokingham PCT 0.6883 0.7703
Blackwater Valley and Hart PCT 0.7376 0.8395
Bracknell Forest PCT 0.7410 0.8262
Royston, Buntingford and Bishop’s Stortford PCT 0.7426 0.8484
Windsor, Ascot and Maidenhead PCT 0.7460 0.8404
Woking PCT 0.7499 0.8097
Chiltern and South Bucks PCT 0.7515 0.8530
Uttlesford PCT 0.7583 0.8861
North East Oxfordshire PCT 0.7588 0.8372
South Cambridgeshire PCT 0.7619 0.9647
(b) Examples of coastal/retirement areas
Suffolk Coastal PCT 0.9159 1.0815
Western Sussex PCT 0.9613 1.3248
North Somerset PCT 0.9651 1.1746
Poole PCT 0.9860 1.2045
South and East Dorset PCT 1.0079 1.2439
Fylde PCT 1.0304 1.2157
Southport and Formby PCT 1.0657 1.2141
North Norfolk PCT 1.0658 1.3684
Adur, Arun and Worthing PCT 1.0716 1.2641
East Devon PCT 1.0870 1.3325
(c) Examples of inner city areas
Brent PCT 0.9848 0.6991
Lambeth PCT 1.0454 0.7512
Islington PCT 1.1222 0.9014
Southwark PCT 1.1412 0.8163
Newham PCT 1.1746 0.7897
City and Hackney PCT 1.1849 0.8472
Bradford City PCT 1.2131 0.8757
Tower Hamlets PCT 1.2192 0.9299
Heart of Birmingham Teaching PCT 1.2466 0.9052
Central Manchester PCT 1.2965 0.9262
Central Liverpool PCT 1.4065 1.0948
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service coverage of the PBRA and PB measures of need that explains why they are so poorly correlated
(Table 41).
For example, the PB index suggests that per capita need in the Newham PCT is 17% above the national
average, but the PBRA index suggests that it is 21% below the national average. We believe that this
difference is due to the fact that the PB index relates to all services whereas the PBRA index only relates to
acute services. The separate figures for acute, maternity and mental health need from the CARAN formula
confirm this hypothesis: CARAN acute need, like PBRA acute need, is well below the national average,
but maternity and mental health need are well above it.
Re-estimation of poorly performing models with an extended
instrument set
Martin et al.63 found it difficult to obtain sensible outcome models for some programmes of care. As we
were unable to find an improved measure of need, we sought to improve the outcome and expenditure
models reported in Martin et al.63 through the use of an extended set of regressors/instruments.
Martin et al.63 had focussed on the use of four instruments but here we extend the modelling to include
an additional 13 regressors/instruments [born outside EU, LLT, no qualifications, full-time students, no car
households, owner occupiers, privately rented, socially rented, lone parents, permanently sick, long-term
unemployed, work in agriculture, work in professional occupation]. Further details about these variables
can be found in The threshold changing over time and precise details about how they were constructed
can be found in Table 92 in the Annex.
For each PBC, our modelling strategy with these additional regressors/instruments was the same:
(a) First, estimate an IV model using our preferred set of regressors (with need, budget, and other
programme need for the own programme spend model, and with need and spend for the outcome
model) and preferred set of instruments (proportion of households that are lone pensioner households,
per cent of the population providing unpaid care, the IMD2000, and the per cent of the population
in the white ethnic group). Then adjust this set of instruments if necessary (e.g. remove from the
instrument set or add an instrument to the regressor set if the Hansen–Sargan test indicates that this
is appropriate). Estimate an OLS version of the IV model if the theoretically endogenous regressor is
exogenous according to the relevant statistical test.
TABLE 41 Table showing comparing PB, PBRA and CARAN need indexes for selected inner city PCTs
PCT PB need (all services) PBRA need (acute)
CARAN need
Acute Maternity Mental health
City and Hackney PCT 1.1849 0.8472 0.8751 1.6783 1.5340
Tower Hamlets PCT 1.2192 0.9299 0.8451 1.4988 1.6663
Newham PCT 1.1746 0.7897 0.8683 1.8130 1.4486
Haringey PCT 1.0448 0.8347 0.8471 1.4023 1.2886
Brent PCT 0.9848 0.6991 0.8558 1.3420 1.2608
Camden PCT 1.0336 0.8402 0.7667 0.9163 1.3209
Islington PCT 1.1222 0.9014 0.8842 1.1399 1.4516
Lambeth PCT 1.0454 0.7512 0.8111 1.3916 1.3349
Southwark PCT 1.1412 0.8163 0.8445 1.3755 1.3905
Lewisham PCT 1.0402 0.7793 0.8549 1.4253 1.2236
Heart of Birmingham PCT 1.2466 0.9052 0.9078 1.5976 1.5621
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(b) Second, if (a) fails to generate a reasonable model, add the same additional variables to both the
regressor and instrument sets. Then eliminate insignificant regressors (least significant first, but always
retaining, for example, the budget and other need variables in the expenditure model, and own
programme spend in the outcome model). Then eliminate insignificant instruments until a reasonable
model is obtained. Again, estimate an OLS version of the IV model if the theoretically endogenous
regressor is exogenous according to the relevant statistical test.
Instrumental variable estimates of outcome and expenditure models
The above approach generates preferred outcome and expenditure models for each of the programmes
with a mortality-based outcome indicator. Outcome models are shown in Table 42 with expenditure
models in Table 43. The corresponding first-stage regression results can be found in Tables 93 and 94,
respectively, in the Annex.
The first four results in Table 42 show the outcome model for the big four programmes (i.e. for cancer,
circulatory disease, respiratory problems and gastrointestinal problems). In all four programmes the need
variable has a positive and significant effect on mortality, and expenditure has the anticipated negative
effect. The diagnostic statistics reveal that, in all four cases, own programme expenditure is endogenous
and that the instruments are valid. They also suggest that the instruments are relevant and there is no
evidence that the instruments are weak. The Pesaran–Taylor test suggests that there is no evidence of
model misspecification.
The results for the other programmes are similar to but more diverse than those for the big four programmes.
This is to be anticipated because mortality is a much rarer outcome in these programmes than it is in, say,
the cancer programme. Own programme expenditure is not endogenous in the next two programmes
(infectious diseases and neurological problems) and we revert to the use of the OLS estimator. Expenditure
has the anticipated negative effect on mortality in the infectious disease programme, but this is not
statistically significant. The all service measure of need is not relevant for this PBC; instead, we find that a
measure of need associated with HIV is positively associated with mortality, as is a measure of deprivation
(households with no car). Mortality from epilepsy is negatively associated with expenditure in the neurological
programme. The need for health-care variables has a positive and significant effect on mortality.
Expenditure and need have the anticipated effects on mortality in the trauma and injuries programme.
In addition, the provision of unpaid care appears to be associated with an increase in mortality from
fractures. This might be because the availability of care allows the elderly to continue to live in their own
home and that they are more likely to fall and die from a fall at home than they are in alternative
accommodation (such as in a residential home or sheltered housing).
Expenditure has the anticipated negative effect on mortality in the neonates programme where the
generic all service measure of need has been replaced with two more programme-specific indicators of
need (the proportion of births that are low birth weight births, and the proportion of households that are
lone parent households).
The final two results both employ the OLS estimator. Expenditure in the genitourinary programme has a
small negative effect on mortality (from renal problems). The prevalence of one parent households and
non-white residents both seem to be positively associated with mortality.
Finally, expenditure has the anticipated negative effect on mortality in the endocrine problems programme
where the generic all service measure of need has again been replaced with a more programme-specific
indicator of need (the diabetes prevalence rate). Mortality in this programme is also positively associated
with the IMD2000.
The first four results in Table 43 show the expenditure model for the big four programmes (i.e. for cancer,
circulatory disease, respiratory problems and gastrointestinal problems). In all four programmes both the
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TABLE 42 Table showing preferred outcome models using 2005/6 expenditure data and mortality for 2002/3/4
Variable
2005/6 outcome model, instrument spend, unweighted,
second stage
2005/6, outcome model,
spend exogenous,
unweighted, OLS
2005/6, outcome
model, instrument
spend, unweighted,
second stage
2005/6, outcome model,
spend exogenous,
unweighted, OLS
(1) PBC 2
cancer
(2) PBC 10
circulation
(3) PBC 11
respiratory
(4) PBC 13
gastrointestinal
(5) PBC 1
infectious
disease
(6) PBC 7
neurological
(7) PBC 16
trauma
(8) PBC 19
neonates
(9) PBC 17
genitourinary
(10) PBC 4
endocrine
Own programme
spend per head
–0.394*** –1.370*** –1.574*** –2.018*** –0.152 –0.182 –1.332*** –0.237* –0.034 –0.244*
[0.100] [0.156] [0.483] [0.364] [0.117] [0.143] [0.469] [0.127] [0.220] [0.129]
Need per head 0.905*** 2.628*** 4.076*** 4.254*** 1.157*** 1.588***
[0.083] [0.163] [0.562] [0.412] [0.252] [0.445]
Lone pensioner
households
–0.930***
[0.158]
Born outside EU 0.111*
[0.063]
No car households 0.701***
[0.114]
HIV need per head 0.212**
[0.082]
Unpaid carers 1.164***
[0.392]
Low birth weight births 0.919***
[0.223]
Lone parents households 0.549*** 1.035***
[0.121] [0.211]
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Variable
2005/6 outcome model, instrument spend, unweighted,
second stage
2005/6, outcome model,
spend exogenous,
unweighted, OLS
2005/6, outcome
model, instrument
spend, unweighted,
second stage
2005/6, outcome model,
spend exogenous,
unweighted, OLS
(1) PBC 2
cancer
(2) PBC 10
circulation
(3) PBC 11
respiratory
(4) PBC 13
gastrointestinal
(5) PBC 1
infectious
disease
(6) PBC 7
neurological
(7) PBC 16
trauma
(8) PBC 19
neonates
(9) PBC 17
genitourinary
(10) PBC 4
endocrine
White ethic group –1.246***
[0.329]
Population weighted
IMD2000
0.421***
[0.076]
Diabetes prevalence
rate 2004/5
14.236***
[5.195]
Diabetes prevalence
rate squared
2.026***
[0.759]
Constant 4.101*** 1.849*** –2.892** –2.052** 2.654*** 0.917** 0.689 1.621*** 2.188*** 24.258***
[0.248] [0.324] [1.250] [0.916] [0.443] [0.459] [1.462] [0.455] [0.681] [8.859]
Observations 295 295 295 295 295 294 295 294 267 294
R2 0.328 0.068 0.169 0.203
Endogeneity test statistic 29.216 65.024 12.630 39.106 3.542 4.071
Endogeneity p-value 6.47e-08 0 0.000380 4.01e-10 0.0598 0.0436
Hansen–Sargan test statistic 0.786 7.209 1.877 2.468 1.200 5.976
Hansen–Sargan p-value 0.375 0.0655 0.171 0.291 0.273 0.0504
Shea’s partial R2 0.133 0.311 0.0376 0.173 0.112 0.0735
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TABLE 42 Table showing preferred outcome models using 2005/6 expenditure data and mortality for 2002/3/4 (continued )
Variable
2005/6 outcome model, instrument spend, unweighted,
second stage
2005/6, outcome model,
spend exogenous,
unweighted, OLS
2005/6, outcome
model, instrument
spend, unweighted,
second stage
2005/6, outcome model,
spend exogenous,
unweighted, OLS
(1) PBC 2
cancer
(2) PBC 10
circulation
(3) PBC 11
respiratory
(4) PBC 13
gastrointestinal
(5) PBC 1
infectious
disease
(6) PBC 7
neurological
(7) PBC 16
trauma
(8) PBC 19
neonates
(9) PBC 17
genitourinary
(10) PBC 4
endocrine
Kleibergen–Paap LM
test statistic
26.59 42.31 20.56 34.83 26.97 19.04
Kleibergen–Paap p-value 1.68e-06 1.44e-08 3.44e-05 1.32e-07 1.39e-06 0.000268
Kleibergen–Paap F-statistic 16.94 29.51 10.29 23.32 17.76 11.49
Pesaran–Taylor reset statistic 0.0347 0.162 0.0929 2.196 0.756 1.388
Pesaran–Taylor p-value 0.852 0.688 0.761 0.138 0.385 0.239
Ramsey reset F-statistic 2.089 0.665 1.075 1.118
Probability > F 0.102 0.574 0.360 0.342
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
For the endogeneity test the null hypothesis is that the specified endogenous regressors can actually be treated as exogenous.
The instrument validity test is based on the Hansen–Sargan test. The joint null hypothesis is that the instruments are valid instruments, i.e. uncorrelated with the error term, and that the
excluded instruments are correctly excluded from the estimated equation.
Shea’s partial R2 is an indicator of the degree of instrument relevance (i.e. of the correlation between the instruments and the endogenous regressor). It is the value of R2 from a regression
of the endogenous variable on the excluded instruments.
A statistical test of instrument relevance is provided by the Kleibergen–Paap LM test. The null hypothesis is that the instruments are not relevant.
Weak identification arises when the excluded instruments are correlated with the endogenous regressor, but only weakly. Estimators can perform poorly when instruments are weak.
The Kleibergen–Paap F-statistic provides a formal test of weak identification. The null hypothesis is that the instruments are weak.
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TABLE 43 Table showing preferred expenditure models using 2005/6 expenditure data and mortality for 2002/3/4
Variable
2005/6 spend model, instrument other programme
need, unweighted, second stage
2005/6 spend
model, other
programme need
exogenous,
unweighted, OLS
2005/6 spend model,
instrument other
programme need,
unweighted,
second stage
2005/6 spend model, other
programme need exogenous,
unweighted, OLS
2005/6 spend
model, instrument
other programme
need, unweighted,
second stage
(1) PBC 2
cancer
(2) PBC 10
circulation
(3) PBC 11
respiratory
(4) PBC 13
gastrointestinal
(5) PBC 1
infectious
disease
(6) PBC 7
neurological
(7) PBC 16
trauma
(8) PBC 19
neonates
(9) PBC 17
genitourinary
(10) PBC 4
endocrine
(11) PBC 23
GMS/PMS
SYLLR cancer –0.954***
[0.249]
PCT budget
per head
0.968*** 0.682*** 0.849*** 0.772*** 0.742*** 1.111*** 0.627*** 0.388 1.041*** 0.425** 0.926***
[0.191] [0.161] [0.223] [0.166] [0.180] [0.244] [0.173] [0.391] [0.141] [0.175] [0.199]
Need per head 0.703*** 0.885*** 2.226*** 1.115*** 0.773*** 1.720*** 0.570***
[0.248] [0.261] [0.436] [0.230] [0.298] [0.401] [0.207]
White ethnic
group
0.198*** –0.739***
[0.066] [0.181]
Provision of
unpaid care
0.364*** –0.339*
[0.136] [0.190]
SYLLR circulatory
disease
–0.577***
[0.107]
Lone pensioners –0.612*** –0.257**
[0.165] [0.101]
SYLLR all deaths –1.367*** –0.639*** –0.437*** –0.899*** –1.157*** 0.121 0.035 –0.158 –1.003***
[0.328] [0.149] [0.157] [0.182] [0.274] [0.307] [0.099] [0.116] [0.276]
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TABLE 43 Table showing preferred expenditure models using 2005/6 expenditure data and mortality for 2002/3/4 (continued )
Variable
2005/6 spend model, instrument other programme
need, unweighted, second stage
2005/6 spend
model, other
programme need
exogenous,
unweighted, OLS
2005/6 spend model,
instrument other
programme need,
unweighted,
second stage
2005/6 spend model, other
programme need exogenous,
unweighted, OLS
2005/6 spend
model, instrument
other programme
need, unweighted,
second stage
(1) PBC 2
cancer
(2) PBC 10
circulation
(3) PBC 11
respiratory
(4) PBC 13
gastrointestinal
(5) PBC 1
infectious
disease
(6) PBC 7
neurological
(7) PBC 16
trauma
(8) PBC 19
neonates
(9) PBC 17
genitourinary
(10) PBC 4
endocrine
(11) PBC 23
GMS/PMS
Born outside EU 0.069**
[0.029]
Full-time
students
–0.165*** 0.127***
[0.053] [0.031]
No car
households
0.444***
[0.099]
HIV need
per head
0.142***
[0.034]
London boroughs
dummy
0.942***
[0.106]
LA/HA rented
housing
0.377***
[0.126]
No qualifications 0.521***
[0.140]
Private rented
housing
0.102**
[0.041]
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Variable
2005/6 spend model, instrument other programme
need, unweighted, second stage
2005/6 spend
model, other
programme need
exogenous,
unweighted, OLS
2005/6 spend model,
instrument other
programme need,
unweighted,
second stage
2005/6 spend model, other
programme need exogenous,
unweighted, OLS
2005/6 spend
model, instrument
other programme
need, unweighted,
second stage
(1) PBC 2
cancer
(2) PBC 10
circulation
(3) PBC 11
respiratory
(4) PBC 13
gastrointestinal
(5) PBC 1
infectious
disease
(6) PBC 7
neurological
(7) PBC 16
trauma
(8) PBC 19
neonates
(9) PBC 17
genitourinary
(10) PBC 4
endocrine
(11) PBC 23
GMS/PMS
Work in
agriculture
–0.058***
[0.022]
Constant –0.020 3.440*** 4.368** 1.241 –0.969 2.066* 3.631** –4.760** –2.854*** –2.435*** 4.320**
[0.517] [1.111] [1.757] [0.930] [1.037] [1.131] [1.414] [1.920] [0.604] [0.726] [1.703]
Observations 295 295 295 295 295 295 295 295 295 295 295
Endogeneity
test statistic
6.465 12.921 19.325 7.218 13.865 12.690 5.273
Endogeneity
p-value
0.0110 0.000325 1.10e-05 0.00722 0.000196 0.000368 0.0217
Hansen–Sargan
test statistic
0.416 1.925 0.00232 2.441 0.826 3.577 3.213
Hansen–Sargan
p-value
0.519 0.165 0.962 0.118 0.662 0.0586 0.201
Shea’s partial R2 0.450 0.141 0.168 0.416 0.450 0.239 0.290
Kleibergen–Paap
LM test statistic
63.99 31.27 33.11 57.16 64.15 39.80 47.98
Kleibergen–Paap
p-value
0 1.62e-07 6.47e-08 0 0 2.28e-09 2.15e-10
Kleibergen–Paap
F-statistic
109.7 21.74 19.08 98.29 70.14 40.01 43.10
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TABLE 43 Table showing preferred expenditure models using 2005/6 expenditure data and mortality for 2002/3/4 (continued )
Variable
2005/6 spend model, instrument other programme
need, unweighted, second stage
2005/6 spend
model, other
programme need
exogenous,
unweighted, OLS
2005/6 spend model,
instrument other
programme need,
unweighted,
second stage
2005/6 spend model, other
programme need exogenous,
unweighted, OLS
2005/6 spend
model, instrument
other programme
need, unweighted,
second stage
(1) PBC 2
cancer
(2) PBC 10
circulation
(3) PBC 11
respiratory
(4) PBC 13
gastrointestinal
(5) PBC 1
infectious
disease
(6) PBC 7
neurological
(7) PBC 16
trauma
(8) PBC 19
neonates
(9) PBC 17
genitourinary
(10) PBC 4
endocrine
(11) PBC 23
GMS/PMS
Pesaran–Taylor
reset statistic
2.679 0.231 0.848 0.987 0.0184 0.912 0.668
Pesaran–Taylor
p-value
0.102 0.631 0.357 0.320 0.892 0.340 0.414
R2 0.709 0.177 0.399 0.267
Ramsey reset
F-statistic
1.572 0.250 1.358 0.765
Probability > F 0.196 0.861 0.256 0.514
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
For the endogeneity test the null hypothesis is that the specified endogenous regressors can actually be treated as exogenous.
The instrument validity test is based on the Hansen–Sargan test. The joint null hypothesis is that the instruments are valid instruments, i.e. uncorrelated with the error term, and that the
excluded instruments are correctly excluded from the estimated equation.
Shea’s partial R2 is an indicator of the degree of instrument relevance (i.e. of the correlation between the instruments and the endogenous regressor). It is the value of R2 from a regression
of the endogenous variable on the excluded instruments.
A statistical test of instrument relevance is provided by the Kleibergen–Paap LM test. The null hypothesis is that the instruments are not relevant.
Weak identification arises when the excluded instruments are correlated with the endogenous regressor, but only weakly. Estimators can perform poorly when instruments are weak.
The Kleibergen–Paap F-statistic provides a formal test of weak identification. The null hypothesis is that the instruments are weak.
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need and budget variables have a positive and significant effect on own programme expenditure. In
addition, the proxy for need in other programmes is negative and significant in all four cases. In the
circulatory expenditure programme the provision of unpaid care is associated with more expenditure
(patients may buy care in more affluent areas), as is the proportion of residents in the white ethnic group
(there might be some unmet need associated with circulatory problems in the non-white ethnic groups).
The PCT budget variable is positive in all of the remaining seven programmes and this variable is significant
in six of the seven. The proxy for other programme need (SYLLR all deaths) has the anticipated negative
sign in five of the seven programmes and, where it is positive, it is never statistically significant.
The all service proxy for own programme need is positive and significant in three programmes. In the other
four programmes, however, it has been replaced by various other socioeconomic indicators of need (in the
trauma programme, for example, the provision of unpaid care is associated with a reduction in NHS
expenditure and, in the neonates programme, the proportion of residents in the white ethnic group is
negatively associated with expenditure).
The diagnostic statistics reveal that, for all seven IV models, expenditure is endogenous and the instruments
are valid. They also suggest that the instruments are relevant and there is no evidence that the instruments are
weak. The Pesaran–Taylor test suggests that there is no evidence of model misspecification.
Instrumental variable estimates of outcome and expenditure models:
the first-stage equations
For the health outcome equation, IV estimation involves finding variables (instruments) that are good
predictors of programme expenditure but which are appropriately excluded from the equation of interest
(that is, from the outcome equation). The assumption is that the instruments impact on the health
outcome through their impact on expenditure only, and that they do not have a direct effect on the
outcome. If, on the other hand, an instrument reflects unobserved factors that affect both expenditure and
mortality directly, then the IV estimator becomes both biased and inconsistent. Such an instrument is said
to be ‘invalid’ because it belongs in the equation of interest in its own right.
In our outcome model we typically employ two instruments (call these z1 and z2) for expenditure.
IV estimation assumes that these instruments do not belong in the outcome equation. In other words,
IV estimation assumes that the coefficients γ1 and γ2 in the outcome model:
y = α þ β1x þ β2n þ γ1z1 þ γ2z2 þ ε, (14)
are identically zero (where y is mortality, x is expenditure, and n is a measure of the own programme need
for health care and all variables relate to a particular programme of care). Such exclusion restrictions can
be debatable and researchers who employ IV techniques often devote considerable effort towards
convincing the reader that their assumed exclusion restrictions are a good approximation.88,89 These efforts
usually take two forms: first, researchers often offer a strong theoretical economic argument why their
instruments do not belong in the equation of interest; and second, statistical tests for the validity of the
exclusion restrictions (Sargan 2SLS, Hansen J-test generalised method of moments) are routinely reported
as part of the results for any study that employs IV techniques.
It is difficult for us to identify clear theoretical reasons why our instruments (such as the proportion of lone
pensioner households, the provision of unpaid care and an index of multiple deprivation) do not belong in
the equation of interest (that is, that they will not directly affect mortality). Of necessity, therefore, we
must be guided by the available statistical tests for the validity of the exclusion restrictions. However,
although our outcome models ‘pass’ the relevant statistical test, some commentators have argued that the
Sargan–Hansen test may have weak power and may fail to reject the null hypothesis of instrument validity
even when an exclusion restriction is not valid. As we shall see in The sensitivity of the outcome elasticity
DOI: 10.3310/hta19140 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 14
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Claxton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
189
to the validity of the instrument exclusion restrictions, this is likely to be the case when the induced biases
in the estimates of β1 (the coefficient on the endogenous variable) are the same across all instruments.
The Hansen–Sargan J-test statistic will be small when the null hypothesis of valid instruments is correct; but
it will also be small if the biases induced in bβ1 by invalid instruments all coincide (i.e. the instruments all
identify the same wrong parameter).150 In other words, for the Hansen–Sargan J test to have low power
the use of any subset of instruments should generate the same asymptotic bias in bβ1.
Our approach, implemented below, is to identify theoretical reasons why our instruments might belong in
the first-stage expenditure equation but not in the second-stage outcome equation. Even if our arguments
are thought unconvincing, a critic would also have to argue that any subset of our selected instruments
will each induce the same bias in the coefficient on the endogenous variable. This is because it is only in
these circumstances that the Hansen–Sargan test will be unable to reject the null hypothesis of instrument
validity even when an exclusion restriction is not valid.
The first-stage regressions associated with the IV outcome results in Table 42 can be found in Table 93 in
the Annex. A brief summary of the first-stage regressions is provided below.
Cancer programme of care
The instrument set for the cancer programme of care [see column (1) in Table 93] includes the proportion
of households that are lone pensioner households and the proportion of the population providing unpaid
care. These instruments have intuitive appeal. The first-stage regression of cancer expenditure on the
instruments and the need for health care (as an exogenous regressor in the 2SLS model) reveals a positive
and significant coefficient on lone pensioners and a negative but non-significant coefficient on the
proportion of unpaid carers. The proportion of lone pensioners is likely to reflect an additional adjustment
for health-care need specific to an elderly and needy population. The omission of this variable from the
second-stage regression is plausible as the dependent variable relates to mortality under 75 years of age
and some of the lone pensioners will be aged over 75 years, and members of this group are, by definition,
relatively healthy individuals. Unpaid care might act as a substitute for the provision of health-care services
and, in these circumstances, a negative relationship with expenditure is to be expected. There is no
obvious relationship between the provision of unpaid care and mortality.
Circulatory disease programme of care
The two instruments used for cancer were also employed to predict expenditure in the circulatory disease
programme and they were augmented with the addition of the population weighted index of multiple
deprivation (IMD2000). The relevance of the latter variable is theoretically plausible as circulatory disease is
more related to disadvantage than is cancer. In addition, we also employed the proportion of residents in
the white ethnic group as an additional instrument for expenditure, but its coefficient is very small and it is
not statistically significant.
Increased expenditure on circulatory disease in the first-stage regression is associated with a greater
proportion of pensioners living alone and a greater proportion of unpaid carers. The latter may reflect an
increased awareness and compliance with medical intervention, particularly preventative measures,
brought about by carers, but this will not affect our outcome model if the impact of this additional support
is largely on the mortality of those aged > 75 years. Expenditure on circulatory problems is also negatively
associated with the IMD2000. As the IMD incorporates an access to medical services domain, this negative
association might reflect some unmet need which largely affects mortality in those aged > 75 years.
Respiratory problems programme of care
The IMD2000 is negatively associated with expenditure on respiratory problems. As the IMD incorporates
an access to medical services domain, this negative association might reflect some unmet need which
largely affects mortality in those aged > 75 years. The proportion of the population aged 16–74 years that
is permanently sick has a positive association with expenditure but might not affect mortality in those aged
< 75 years if expenditure is largely directed towards managing chronic disease.
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Gastrointestinal problems programme of care
Increased expenditure on gastrointestinal problems in the first-stage regression is positively associated with
the proportion of residents providing unpaid care. This may reflect an increased awareness and compliance
with medical intervention, particularly preventative measures, brought about by carers, but this will not
affect our outcome model if the impact of this additional support is largely on the mortality of those aged
> 75 years.
Trauma, burns and injuries programme of care
Increased expenditure on trauma, burns and injuries in the first-stage regression is positively associated
with the proportion of pensioners living alone. This may reflect longer stays in hospital and an increased
need for community care. However, the proportion of pensioners living alone will have little effect on our
mortality measure if most of this expenditure is associated with patients > 75 years of age.
Neonate programme of care
The percentage of those aged 16–74 years that are long-term unemployed and the proportion of
households that are in social rented housing are both positively associated with expenditure on neonate
care. These are both indicators of socioeconomic deprivation and might be associated with the presence
of larger families (i.e. more children per family). This would affect expenditure per head of population but
not necessarily mortality per 1000 live births. The negative coefficient on the proportion of those aged
16–74 years with no qualifications might reflect the ‘emigration’ of young adults from those areas that are
particularly deprived. This would reduce expenditure per head of population but would have no impact on
the mortality measure.
The first-stage regressions associated with the IV expenditure results in Table 43 can be found in Table 94
in the Annex.
Cancer programme of care
The first-stage equation for the cancer expenditure model includes two instruments – lone pensioners and
unpaid carers – that are excluded as regressors from the second stage of estimation. In this model the
first-stage regression of other programme need (as proxied here by the circulatory disease mortality rate) on
the instrument set generates a negative coefficient on both instruments excluded from the second-stage
regression. A greater proportion of unpaid carers might reflect an increased level of care (and perhaps
increased compliance with care programmes and drug regimes) resulting in a decrease in other programme
deaths. The availability of unpaid care in the community might not have a direct effect on cancer expenditure
if such care supplements rather than substitutes for NHS-funded care. Conditional on need and the total PCT
budget, the negative coefficient on the proportion of lone pensioners may be indicative of the presence of
increased networks of social support. If this additional support reduces other programme mortality but does
not substitute for NHS care, then the lone pensioner variable will not belong in the expenditure equation.
Circulatory disease programme of care
In the circulatory disease expenditure model, the first-stage regression of other programme need (as proxied
here by the cancer mortality rate) on the instrument set results in a negative coefficient on one instrument
(lone pensioners) and a positive coefficient on the other (the IMD2000). As noted above, the negative
coefficient on the proportion of lone pensioners may be indicative of areas with increased networks of
social support. If this additional support does not substitute for NHS care then the lone pensioner variable
will not belong in the expenditure equation. It is plausible that the IMD2000 should have a positive effect
on other programme need but not belong in the expenditure equation if, for example, there is some unmet
need in another (but not the circulatory disease) care programme.
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Respiratory problems programme of care
In the respiratory disease expenditure model, the first-stage regression of other programme need (as proxied
here by the all cause SYLLR) on the instrument set results in a negative coefficient on one instrument
(unpaid care) and a positive coefficient on another (the IMD2000). A greater proportion of unpaid carers
might reflect an increased level of care (and perhaps increased compliance with care programmes and
drug regimes) resulting in a decrease in other programme deaths. The availability of unpaid care might not
have a direct effect on own programme expenditure if such care does not substitute for NHS-funded care.
It is plausible that the IMD2000 should have a positive effect on other programme need but not belong in
the expenditure equation if, for example, there is some unmet need in another (but not the respiratory
disease) care programme.
Gastrointestinal problems programme of care
In the gastrointestinal problems expenditure model, the first-stage regression of other programme need
(as proxied here by the all cause SYLLR) on the instrument set (including need and total budget) results
in a negative coefficient on one instrument (lone pensioners) and a positive coefficient on the other
(IMD2000). As noted above, the negative coefficient on the proportion of lone pensioners may be
indicative of areas with increased networks of social support. If this additional support does not substitute
for NHS care then the lone pensioner variable will not belong in the expenditure equation. It is plausible
that the IMD2000 should have a positive effect on other programme need but not belong in the
expenditure equation if, for example, there is some unmet need in another (but not the gastrointestinal)
care programme.
Neurological problems programme of care
The first-stage equation for the neurological expenditure model includes three instruments – lone
pensioners, unpaid carers and IMD2000 – that are excluded as regressors from the second stage of
estimation. Explanations for the signs on these variables have been outlined above when discussing the
other first-stage regressions.
Trauma and injuries programme of care
The first-stage equation for the trauma expenditure model includes two instruments – lone pensioners
and the IMD2000 – that are excluded as regressors from the second stage of estimation. Explanations
for the signs on these variables have been outlined above when discussing the other first-stage
regressions.
General medical services/primary medical services programme of care
The first-stage equation for the GMS/PMS expenditure model includes three instruments – households with
no car, lone parents and permanently sick – that are excluded as regressors from the second stage of
estimation. All three are plausibly positively associated with other programme need (as proxied here by the
all cause SYLLR) but do not occur as regressors in the second-stage GMS/PMS expenditure model. The
latter includes at least one measure of deprivation – the proportion of people aged 16–74 years without
any qualifications – and the Hansen–Sargan test suggests that the three excluded instruments offer no
additional explanatory power for observed variations in GMS/PMS expenditure.
We appreciate that not everyone will be convinced by our arguments about the validity of our
instruments and so in The sensitivity of the outcome elasticity to the validity of the instrument exclusion
restrictions we undertake a sensitivity analysis that examines the impact of weakening the instrument
exclusion restriction.
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Calculation of the cost of a life and life-year
The preferred models identified in Tables 42 and 43 indicate the responsiveness of mortality to changes in
expenditure, and of own programme expenditure to changes in budget, using expenditure data for
2005/6. Together with information about programme expenditure and mortality, the coefficients on the
own programme expenditure and PCT budget variables listed in Tables 42 and 43 can be used to calculate
the cost of an additional life-year for the 10 programmes for which outcome and expenditure models
are available.u For a relatively small budget change:
the cost of an additional life in a particular programme
= the change in expenditure in that programme=the change in mortality in that programme
= (annual spendexpenditure elasticity)=(annual mortalityoutcome elasticity expenditure elasticity)
and
the cost of an additional life-year in a particular programme
= the change in expenditure in that programme=the change in life-year lost in that programme
= (annual spendexpenditure elasticity)=(annual life-year lostoutcome elasticity
expenditure elasticity).
Table 44 presents the necessary information to calculate the cost of an additional life (or life-year) for each
of these 10 programmes. There is an assumed small (1%) increase in the national budget and it is also
assumed that this increase is applied to each PCT’s budget. The total additional spend in each programme
associated with this injection [see Table 44, column (D)] is determined by the initial level of expenditure in
the programme [see Table 44, column (B)] and the programme’s expenditure elasticity [see Table 44,
column (C)]. In addition, this additional spend, in conjunction with the outcome elasticity (column F) and
the number of deaths in the programme [see Table 44, column (E)], determine the number of lives saved
that is associated with the additional expenditure. If we divide the change in programme expenditure
[see Table 44, column (D)] by the change in the number of lives lost [see Table 44, column (G)] we obtain
the cost per life gained [see Table 44, column (H)].
Alternatively, we can apply the outcome elasticity [see Table 44, column (F)] to the annual number of life-years
lost in the programme [see Table 44, column (E)] to determine the number of life-years saved that is associated
with the additional expenditure. If we divide the change in programme expenditure [see Table 44, column (D)] by
the change in the number of life-years lost [see Table 44, column (J)] we obtain the cost per YLG [see Table 44,
column (K)]. Note that none of these figures are QALY adjusted and that all costs are at current (2005/6) prices.
The cost per life-year associated with the cancer programme is £13,741 and this is almost identical to
that calculated using expenditure data for 2004/5, but with the same mortality data as that employed
here.60 Similarly, the cost per life-year associated with the circulatory disease programme is £8328 and this
is also almost identical to that calculated using expenditure data for 2004/5 but with the same mortality
data as that employed here.60 The cost per life-year for the respiratory programme (£20,601) and for the
gastrointestinal programme (£18,303) are a little larger than these figures but are still of the same order of
magnitude. Taken together, the cost per life-year for these ‘big four PBCs’ is £12,855.
v,w
Table 44 also contains cost per life-year estimates for the six other programmes for which a mortality-based
outcome indicator is available. These cost estimates are much larger than those for the big four
programmes. This is to be expected as mortality is a less relevant outcome indicator for these PBCs
than for the big four programmes. The cost per life-year across all 10 programmes for which a
mortality-based outcome indicator is available is £21,256.
Although we have an estimate of the cost per life-year for 10 programmes, it is unclear how we should
adjust this estimate for the expenditure associated with the other 13 programmes. We attempted to
estimate an outcome and expenditure model for expenditure and mortality in all 13 of these programmes
combined.x However, this was not successful with, for example, counterintuitive signs on some variables.y
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TABLE 44 Table showing cost of life and life-year estimates for 2005/6 for the 10 programmes for which we have outcome and expenditure elasticities
PBC
scenario
(A)
PBC
description
(B)
Spend
(£M)
2005/6
(C)
Spend
elasticity
(D)
(= 0.01 × B ×C)
change in
spend (£M)
(E) Annual
mortality,
< 75 years,
2002/3/4
(F)
Outcome
elasticity
(G)
(= 0.01 × C × E × F)
change in
annual mortality
(H)(=D/G)
cost per life
gained (£)
(I) Total
life-years lost,
<75 years,
2002/3/4
(J)
(= 0.01 × C× F × I/3)
change in annual
life-years lost
(K)
(=D/J)
cost per
YLG (£)
1 Cancer 4094 0.968 39.63 62,259 0.394 237.45 166,897 2,268,541 2884 13,741
2 Circulatory
problems
6112 0.682 41.68 45,504 1.370 425.16 98,042 1,607,171 5005 8328
3 Respiratory
problems
3421 0.849 29.04 11,601 1.574 155.03 187,350 316,506 1410 20,601
4 Gastrointestinal
problems
3998 0.772 30.86 5926 2.018 92.32 334,318 324,735 1686 18,303
5 Big four
programmes
17,625 141.22 125,290 909.96 155,196 4,516,953 10,986 12,855
6 Infectious
diseases
1161 0.742 8.61 2050 0.152 2.31 3,725,931 106,552 40 215,054
7 Endocrine
problems
1832 0.425 7.79 1690 0.244 1.75 4,442,720 60,615 21 371,601
8 Neurological
problems
2019 1.111 22.43 729 0.182 1.47 15,217,293 66,137 45 503,201
9 Genitourinary
problems
3313 1.041 34.49 294 0.034 0.10 331,432,573 10,030 1 29,144,918
10 Trauma
and injuries
3758 0.627 23.56 1037 1.332 8.66 2,720,657 30,000 84 282,132
11 Neonate
conditions
660 0.388 2.56 2123 0.237 1.95 1,311,733 477,675 146 17,490
12 All 10
programmes
30,368 0.792 240.67 133,213 926.22 259,838 5,267,962 11,322 21,256
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Instead, we decided to make some assumptions about the cost per life-year associated with the other
13 programmes. We examined two possibilities. First, we assumed that the other 13 programmes generate
no mortality gain at all. This is clearly unrealistic but it does provide an upper bound for the cost per life-year
across all programmes of care. Table 45 is similar to Table 44 but it incorporates this zero gain assumption for
the 13 other programmes.
z
It shows that the cost per life-year across all 23 programmes – assuming a zero
mortality gain in the 13 programmes without a mortality based indicator – is £56,799.
Second, the zero mortality gain assumption is an extreme one but possibly relevant for the residual
programme (PBC 23) – where about two-thirds of the expenditure is attributable to primary care – if we
assume that any mortality gain associated with primary care expenditure is reflected in mortality rates
associated with other, more disease-specific, programmes (e.g. cancer, circulatory disease, etc.). However,
if we assume a zero mortality gain in PBC 23, what assumption should we make about the mortality gain
associated with the remaining 12 programmes?
One possibility is to assume that the cost per life (year) in the remaining 12 programmes is on average the
same as that associated with the 10 programmes for which a mortality-based outcome indicator is available.
At first this may sound strange as we have already noted that mortality is not regularly associated with these
programmes whereas it is a normal outcome for the 10 programmes for which a mortality-based outcome
indicator is available (and this is of course why mortality data at PCT level is available for these 10 PBCs).
However, if we broaden our interpretation of health gain to include non-mortality effects (such as those on
the QoL), then this assumption – that the cost per life (year) in the remaining 12 programmes is on average
the same as that associated with the 10 programmes for which a mortality-based outcome indicator is
available – becomes far more plausible.
Thus, Table 46 is similar to Table 45 but incorporates (a) a zero gain assumption for the residual (including
primary care) programme (PBC 23); and (b) an average gain assumption for the remaining 12 programmes for
which no mortality-based outcome indicator is available. Table 46 shows that the cost per life-year across all
23 programmes [see Table 46, row (15)] is £24,200. This is, of course, slightly greater than the cost of a
life-year for the 10 programmes for which a mortality-based outcome indicator is available (£21,256) because
a small proportion of expenditure (that on primary care) is assumed to have no health benefit beyond that
captured by the more disease-specific programmes (e.g. in cancer, circulatory disease, etc.).
The costs quoted in Tables 44–46 make no QALY adjustment but such an adjustment would add between
50% and 66% to the costs quoted.100
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TABLE 45 Table showing cost of life and life-year estimates for 2005/6 for all programmes (assumes that 13 PBCs offer no health gain)
PBC
scenario
(A) PBC
description
(B) Spend
(£M) 2005/6
(C)
Spend
elasticity
(D)
(=0.01×B×C)
change in
spend (£M)
(E) Annual
mortality,
<75 years,
2002/3/4
(F)
Outcome
elasticity
(G)
(=0.01×C×E× F)
change in
annual mortality
(H)
(=D/G)
cost per life
gained (£)
(I) Total
life-years lost,
< 75 years,
2002/3/4
(J)
(=0.01×C×F× I/3)
change in annual
life-years lost
(K)
(=D/J)
cost per
YLG (£)
1 Cancer 4094 0.968 39.63 62,259 0.394 237.45 166,897 2,268,541 2884 13,741
2 Circulatory
problems
6112 0.682 41.68 45,504 1.370 425.16 98,042 1,607,171 5005 8328
3 Respiratory
problems
3421 0.849 29.04 11,601 1.574 155.03 187,350 316,506 1410 20,601
4 Gastrointestinal
problems
3998 0.772 30.86 5926 2.018 92.32 334,318 324,735 1686 18,303
5 Big four
programmes
17,625 141.22 125,290 909.96 155,196 4,516,953 10,986 12,855
6 Infectious
diseases
1161 0.742 8.61 2050 0.152 2.31 3,725,931 106,552 40 215,054
7 Endocrine
problems
1832 0.425 7.79 1690 0.244 1.75 4,442,720 60,615 21 371,601
8 Neurological
problems
2019 1.111 22.43 729 0.182 1.47 15,217,293 66,137 45 503,201
9 Genitourinary
problems
3313 1.041 34.49 294 0.034 0.10 331,432,573 10,030 1 29,144,918
10 Trauma
and injuries
3758 0.627 23.56 1037 1.332 8.66 2,720,657 30,000 84 282,132
11 Neonate
conditions
660 0.388 2.56 2123 0.237 1.95 1,311,733 477,675 146 17,490
12 All 10
programmes
30,368 0.792 240.67 133,213 926.22 259,838 5,267,962 11,322 21,256
13 Assume no
health gain
33,942 402.43 0.00 0
14 All 23
programmes
64,310 643.10 926.22 694,330 11,322 56,799
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TABLE 46 Table showing cost of life and life-year estimates for 2005/6 for all programmes (assumes GMS/PMS provides no gain, other PBCs provide average gain)
PBC
scenario
(A) PBC
description
(B) Spend
(£M) 2005/6
(C)
Spend
elasticity
(D)
(=0.01 ×B×C)
change in
spend (£M)
(E) Annual
mortality,
< 75 years,
2002/3/4
(F)
Outcome
elasticity
(G)
(= 0.01×C×E× F)
change in
annual mortality
(H) (=D/G)
cost per life
gained (£)
(I) Total
life-years lost,
<75 years,
2002/3/4
(J)
(=0.01 ×C× F× I/3)
change in annual
life-years lost
(K)
(=D/J)
cost per
YLG (£)
1 Cancer 4094 0.968 39.63 62,259 0.394 237.45 166,897 2,268,541 2884 13,741
2 Circulatory
problems
6112 0.682 41.68 45,504 1.370 425.16 98,042 1,607,171 5005 8328
3 Respiratory
problems
3421 0.849 29.04 11,601 1.574 155.03 187,350 316,506 1410 20,601
4 Gastrointestinal
problems
3998 0.772 30.86 5926 2.018 92.32 334,318 324,735 1686 18,303
5 Big four
programmes
17,625 141.22 125,290 909.96 155,196 4,516,953 10,986 12,855
6 Infectious diseases 1161 0.742 8.61 2050 0.152 2.31 3,725,931 106,552 40 215,054
7 Endocrine problems 1832 0.425 7.79 1690 0.244 1.75 4,442,720 60,615 21 371,601
8 Neurological
problems
2019 1.111 22.43 729 0.182 1.47 15,217,293 66,137 45 503,201
9 Genitourinary
problems
3313 1.041 34.49 294 0.034 0.10 331,432,573 10,030 1 29,144,918
10 Trauma and
injuries
3758 0.627 23.56 1037 1.332 8.66 2,720,657 30,000 84 282,132
11 Neonate
conditions
660 0.388 2.56 2123 0.237 1.95 1,311,733 477,675 146 17,490
12 All 10
programmes
30,368 0.792 240.67 133,213 926.22 259,838 5,267,962 11,322 21,256
13 (a) Assume no
health gain for
GMS/PMS
8449 0.926 78.24 0.00 0
14 (b) Assume
average gain
in the other
12 PBCs
25,493 1.272 324.20 1247.69 259,838 15,252 21,256
15 All 23
programmes
64,310 643.10 2173.90 295,827 26,575 24,200
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Summary and conclusion
In this section we have extended the results reported by Martin et al.63 by obtaining plausible outcome and
expenditure models for all 10 programmes of care with a mortality-based outcome indicator. In addition,
we have, for the first time, calculated the cost of a life-year across the big four programmes combined
(£12,855) and across all 10 programmes (£21,256). Moreover, with the aid of an assumption about the
productivity (health gain) of programmes without a meaningful mortality-based outcome indicator, we have
extended our individual programme estimates to incorporate expenditure across all programmes of care.
If we assume that the other 13 programmes without a mortality-based outcome indicator generate no
health gain then the cost of an additional life-year across all expenditure for 2005/6 is £56,799.
Alternatively, if we assume that any health-care gain associated with primary care expenditure is reflected
in mortality rates associated with other, more disease-specific programmes, and that the health gain
associated with the remaining 12 programmes is, on average, the same as that recorded by the PBCs with
a mortality-based indicator, then the cost per life-year across all expenditure for 2005/6 is £24,200.
This concludes our analysis of the 2005/6 PB data. In the next section we apply our model to the 2006/7 PB data.
Analysis of programme budgeting expenditure for 2006/7
Construction of an alternative measure of need
The analysis of the 2005/6 PB data employed a measure of the need for health care that incorporated the
AREA resource allocation formula for acute services. As was described in Instrumental variable estimation,
we attempted to construct a better measure of need using a recently developed person-based approach.149
However, we were unable to construct a viable alternative PBRA-based measure of need for use with the
PB data for 2005/6 because the PBRA formula only relates to acute services yet the PB data incorporates
elements for acute, maternity, mental health, prescribing and primary care, and we were unable to
separate these component parts.
The construction of an alternative measure of need is, however, possible for use with the 2006/7 PB data.
Spend and mortality data are available for the new (152) PCTs, and the Department of Health’s resource
allocation exposition book for 2009/10 (which employs the CARAN model) provides separate measures of
need for acute, maternity, mental health, prescribing and GMS/PMS services. We can therefore replace the
(CARAN-based) measure of acute need for the 2009/10 allocation with our own PBRA-based measure of
acute need (albeit for 2006/7) to calculate an alternative to the AREA-based measure of need across all
health-care services.
The PBRA model was applied to all patients on practice lists as at 1 April 2006 to generate a PCT-level
measure of acute need (see Construction of an alternative measure of need for a description of this
approach as applied to patients on practice lists as at 1 April 2005). The resulting PBRA measure of acute
need can be compared with the CARAN-based measure of acute need as reported in the Department of
Health’s resource allocation exposition book for 2009/10. The correlation coefficient for these two
measures is 0.8514 and descriptive statistics for the two measures are shown below in Table 47.
The all service measure of need (which is a weighted average of the acute, maternity, mental health,
prescribing and GMS/PMS measures) as reported in the Department of Health’s resource allocation
exposition book for 2009/10 can be recalculated by replacing the CARAN-based acute measure with the
PBRA-based acute measure of need. The correlation coefficient for these two all service measures of need
is 0.9714 and Figure 14 shows a scatter plot of these two measures. Descriptive statistics for these two all
service measures of need along with the (AREA-based) PB measure of need are shown in Table 48.
The correlation coefficients for the three measures are shown in Table 49.
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FIGURE 14 Graph showing scatter plot of all service measures of need: incorporating CARAN- or PBRA-based
measures of acute need.
TABLE 49 Table showing correlation coefficients for alternative measures of all service need
Variable PCTneed_AREA PCTneed_PBRA PCTneed_CARAN
PCTneed_AREA 1
PCTneed_PBRA 0.9583 1
PCTneed_CARAN 0.9839 0.9714 1
TABLE 48 Table showing all service measures of need: incorporating CARAN-, PBRA- or AREA-based measures of
acute need
Variable Observations Mean SD Min. Max.
PCTneed_CARAN 152 1.0240 0.1339 0.7311 1.3479
PCTneed_PBRA 152 1.0242 0.1395 0.7287 1.3769
PCTneed_AREA 152 1.0293 0.1380 0.7165 1.4006
Max., maximum; min., minimum; SD, standard deviation.
TABLE 47 Table showing summary statistics for the CARAN- and PBRA-based measures of acute need
Variable Number of PCTs Mean SD Min. Max.
CARAN_acute need 152 1.0033 0.1113 0.7659 1.2153
PBRA_acute need 152 1.0037 0.1218 0.7606 1.3420
Max., maximum; min., minimum; SD, standard deviation.
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Estimation issues associated with the use of 2006/7 expenditure data
As well as having to select a preferred measure of need from the three available, the estimation of our
model using PB data for 2006/7 requires the resolution of several other issues.
Estimation issue 1: ‘net spend’ or ‘own population’ spend?
The Department of Health reports two sets of PB spend data: the first is on a ‘net spend’ basis and the
second is on an ‘own population’ basis. The ‘own population’ data starts with the ‘net spend’ figure, adds
any expenditure funded from non-NHS sources, and adjusts for expenditure made under PCT lead/host
commissioning arrangements. These adjustments are usually very small. For 2005/6 we used the net spend
data (because only net spend data was produced in the first year and we were hoping to build a panel)
but given the now regular production of own population data this would seem to be the more appropriate
data set to use as, for example, it includes all expenditure irrespective of its funding source.
Estimation issue 2: to weight or not to weight?
Ordinary least squares and IV estimation implicitly gives the same weight to each PCT when estimating our
expenditure and outcome models. With the reorganisation of PCTs in October 2006, the number of such
organisations was reduced from 303 to 152. However, far from making them more similar in terms of size
(as measured by their population), this reorganisation actually increased the disparity in size between the
largest and the smallest PCTs, with the largest PCT now being 14 times the size of the smallest. Unless we
explicitly weight each observation (PCT) by its size, we will be giving the same weight (influence) to PCTs
that are much smaller than other PCTs.
Estimation issue 3: which market forces factors?
This study builds on previous work using PB data. Martin et al.59 report the results of the estimation of our
model using PB data for 2006/7. One essential step in this estimation is the removal of the impact of
unavoidable variations in local costs from the reported measure of the ‘unified weighted’ population. At
the time of the earlier study the authors only had access to a MFF based on HCHS for the new 152 PCTs.
Now, however, a more broadly-based MFF is available, that is, one based on a weighted average of MFFs
for HCHS, prescribing, and GMS/PMS. Should we use a MFF for HCHS only, or one that incorporates
HCHS and prescribing, or one that incorporates HCHS, prescribing and GMS/PMS?
Estimation issue 4: standardised mortality rates or standardised years of life
lost rates, and which proxy for the other programme need variable?
Previous studies have reported results using both SMRs and SYLLRs but the sheer number of models being
estimated requires that we focus on one measure only. Various proxies for other programme need have
been employed in previous studies (see section Other estimation issues for further discussion). In this
subsection we persevere with this variety but consistency demands that we focus in on a preferred proxy
for other programme need.
This study builds on previous work using PB data. Martin et al.59 report the results of the estimation of our
model using PB data for 2006/7. With several alternative measures of need and MFF available, we
undertook a preliminary empirical analysis of the 2006/7 PB data using the outcome and expenditure
models for the big four programmes as reported in Martin et al.59 as our starting point. These models
incorporated the AREA-based measure of need and a MFF based on HCHS only.
We first re-estimated the outcome and expenditure models by replacing the AREA-based measure of need
with one incorporating the PBRA formula. Then we re-estimated these models again with a measure of
need incorporating the CARAN model. The results suggest that (a) for the outcome models, the use of the
PBRA measure of need generates a smaller coefficient on expenditure than does the AREA measure of
need; and (b) that for the spend models, the use of the PBRA measure of need generates a larger
coefficient on PCT budget than does the AREA measure of need. For both the outcome and expenditure
models, the use of the CARAN measure of need generates outcome and expenditure elasticities that lie
between those generated by the AREA and PBRA measures.
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Next, the results reported by Martin et al.59 employ a MFF based on HCHS only to remove unavoidable variations
in local costs from the reported measure of the (unified weighted) need for health-care services. This was the
only MFF available for the new PCTs at the time of that study. Now, however, a more broadly-based MFF is
available (that is, one based on a weighted average of MFFs for HCHS, prescribing, and GMS/PMS).
To examine the consequences of using the CARAN MFF (i.e. a weighted average of the HCHS, prescribing,
and GMS/PMS MFFs), this MFF was used to calculate the implied level of need given the unified weighted
populations for 2006/7 which are reported alongside the PB spend data by the Department of Health.aa
We found that the use of an extended set of MFFs can sometimes affect the coefficient on the variable
of interest.
Models were also estimated using a weighted average of the CARAN MFFs for HCHS and prescribing only.
The latter results were very similar to those using all three of the CARAN MFFs (i.e. a weighted average
of the HCHS, prescribing, and GMS/PMS MFFs).
We also tried re-estimating the outcome and expenditure models from Martin et al.59 using the ‘own
population’ expenditure data rather than the ‘net spend’ data but this adjustment had very little effect on
the results. In addition, the impact of ‘weighting’ each observation by PCT size was usually rather modest.
Because of the sheer number of variations possible, we decided to estimate 13 particular variants of our
model and details of these variants are summarised in Table 50. These variants were estimated for each of
the big four programmes using both the outcome and expenditure equations. The results are presented
in Tables 51–58.
TABLE 50 Table showing variants of the outcome and expenditure models estimated using 2006/7 spend data
Variant
PCTs
weighted? MFF indicator Indicator of need
Mortality
indicator
1 No weights HCHS AREA-based UWP/HCHS MFF SMR
2 No weights HCHS PBRA model applied to patients on list at
1 April 2006
SMR
3 No weights HCHS CARAN model used for allocations in 2009/10 SMR
4 No weights HCHS AREA-based UWP/HCHS MFF SYLLR
5 No weights HCHS PBRA model applied to patients on list at
1 April 2006
SYLLR
6 No weights HCHS CARAN model used for allocations in 2009/10 SYLLR
7 Yes HCHS AREA-based UWP/HCHS MFF SMR
8 No weights HCHS, prescribing
and GMS/PMS
AREA-based UWP/(HCHS, prescribing and
GMS/PMS) MFF
SMR
9 Yes HCHS, prescribing
and GMS/PMS
AREA-based UWP/(HCHS, prescribing and
GMS/PMS) MFF
SMR
10 No weights HCHS and
prescribing
AREA-based UWP/(HCHS and prescribing) MFF SMR
11 Yes HCHS and
prescribing
AREA-based UWP/(HCHS and prescribing) MFF SMR
12 No weights HCHS, prescribing
and GMS
CARAN model used for allocations in 2009/10 SMR
13 Yes HCHS, prescribing
and GMS
CARAN model used for allocations in 2009/10 SMR
UWP, unified weighted population.
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TABLE 51 Table showing cancer spend models with various indicators of MFF and need
Variable
PBC 2 cancer, 2006/7, spend model
(1) Uses
SMR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(3) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR, no
weighting,
second
stage,
iAREA
need,
HCHS MFF
(5) Uses
SYLLR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(6) Uses
SYLLR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
PCT budget
per head
0.353 0.681*** 0.572** 0.388 0.752*** 0.618** 0.326 0.250 0.245 0.246 0.241 0.552** 0.544*
[0.273] [0.235] [0.247] [0.272] [0.238] [0.247] [0.362] [0.284] [0.357] [0.284] [0.357] [0.239] [0.308]
NeedAREA1 1.513*** 1.557*** 1.351***
[0.288] [0.284] [0.367]
Other
programme
need 1
−0.654*** −0.771*** −0.733*** −0.604*** −0.749*** −0.661*** −0.749*** −0.661*** −0.680*** −0.616***
[0.124] [0.125] [0.124] [0.131] [0.152] [0.154] [0.151] [0.154] [0.126] [0.139]
NeedPBRA 1.320*** 1.352***
[0.261] [0.265]
NeedCARAN 1.431*** 1.477*** 1.347*** 1.160***
[0.287] [0.289] [0.246] [0.294]
Other
programme
need 2
−0.649*** −0.773*** −0.728***
[0.119] [0.124] [0.119]
NeedAREA2 1.778*** 1.554***
[0.329] [0.389]
NeedAREA3 1.765*** 1.545***
[0.328] [0.388]
Constant 0.271 0.707 0.569 0.356 0.835 0.665 0.067 5.901*** 5.559** 5.932*** 5.582** 3.430** 3.220
[0.544] [0.551] [0.554] [0.542] [0.567] [0.554] [0.572] [2.062] [2.550] [2.063] [2.550] [1.645] [2.087]
Observations 152 152 152 152 152 152 152 152 152 152 152 152 152
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Variable
PBC 2 cancer, 2006/7, spend model
(1) Uses
SMR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(3) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR, no
weighting,
second
stage,
iAREA
need,
HCHS MFF
(5) Uses
SYLLR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(6) Uses
SYLLR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
Endogeneity
test statistic
13.112 18.683 18.420 13.313 18.736 18.716 11.940 13.098 11.708 13.017 11.504 16.985 13.460
Endogeneity
p-value
0.000293 1.54e-05 1.77e-05 0.000264 1.50e-05 1.52e-05 0.000549 0.000296 0.000622 0.000309 0.000695 3.77e-05 0.000244
Hansen–Sargan
test statistic
0.870 1.139 0.560 0.504 0.748 0.281 1.089 1.730 1.875 1.711 1.857 0.381 0.321
Hansen–Sargan
p-value
0.351 0.286 0.454 0.478 0.387 0.596 0.297 0.188 0.171 0.191 0.173 0.537 0.571
Shea’s partial R2 0.607 0.526 0.586 0.570 0.482 0.548 0.612 0.511 0.537 0.510 0.536 0.572 0.583
Kleibergen–Paap
LM test statistic
40.55 38.73 40.45 40.49 38.17 41.14 38.91 38.41 37.13 38.38 37.11 43.82 41.36
Kleibergen–Paap
p-value
1.57e-09 3.88e-09 1.64e-09 1.61e-09 5.14e-09 1.16e-09 3.55e-09 4.56e-09 8.66e-09 4.63e-09 8.75e-09 3.06e-10 1.05e-09
Kleibergen–Paap
F-statistic
73.17 63.72 68.50 67.14 51.14 60.78 72.14 57.74 61.44 58.09 61.58 68.29 66.96
Pesaran–Taylor
reset statistic
0.233 0.299 0.0271 0.198 0.211 0.00518 0.000324 0.00529 0.0391 0.0345 0.00971 9.41e-07 0.0158
Pesaran–Taylor
p-value
0.629 0.585 0.869 0.656 0.646 0.943 0.986 0.942 0.843 0.853 0.922 0.999 0.900
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
iAREA need 1=AREA unified weighted population/HCHS MFF.
iAREA need 2=AREA unified weighted population/HCHS, prescribing and GMS/PMS MFFs.
iAREA need 3=AREA unified weighted population/HCHS and prescribing MFFs.
Other programme need 1= circulatory disease SMR.
Other programme need 2= circulatory disease SYLLR.
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TABLE 52 Table showing circulatory disease spend models with various indicators of MFF and need
Variable
PBC 10 circulation, 2006/7, spend model
(1) Uses
SMR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(3) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(6) Uses
SYLLR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
Other
programme
need 1
−0.766** −0.736** −0.811** −0.939*** −0.776** −0.927*** −0.781** −0.935*** −0.831** −1.112***
[0.298] [0.299] [0.370] [0.305] [0.315] [0.324] [0.316] [0.326] [0.367] [0.392]
PCT budget
per head
0.861*** 1.162*** 1.035*** 0.836*** 1.191*** 0.998*** 0.719*** 0.832*** 0.661** 0.829*** 0.657** 0.983*** 0.914***
[0.240] [0.218] [0.219] [0.229] [0.220] [0.210] [0.259] [0.242] [0.264] [0.242] [0.264] [0.213] [0.231]
NeedAREA1 0.624* 0.732* 0.967**
[0.355] [0.389] [0.378]
White ethnic
group
0.215*** 0.187** 0.207** 0.232*** 0.199** 0.225** 0.278*** 0.219** 0.284*** 0.219** 0.284*** 0.209** 0.286***
[0.079] [0.080] [0.086] [0.083] [0.083] [0.095] [0.084] [0.085] [0.091] [0.085] [0.091] [0.086] [0.098]
Provision of
unpaid care
0.457** 0.554*** 0.488** 0.437** 0.549*** 0.466* 0.239 0.527*** 0.336 0.528*** 0.335 0.477** 0.200
[0.205] [0.186] [0.227] [0.212] [0.183] [0.247] [0.227] [0.190] [0.210] [0.190] [0.211] [0.227] [0.268]
NeedPBRA 0.250 0.295
[0.275] [0.280]
NeedCARAN 0.480 0.610 0.546 0.925**
[0.401] [0.479] [0.369] [0.399]
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Variable
PBC 10 circulation, 2006/7, spend model
(1) Uses
SMR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(3) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(6) Uses
SYLLR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
Other
programme
need 2
−0.904** −0.871** −0.956*
[0.365] [0.347] [0.491]
NeedAREA2 0.655* 1.020**
[0.383] [0.424]
NeedAREA3 0.652* 1.018**
[0.381] [0.422]
Constant 2.380** 2.377* 2.621* 3.246** 3.244** 3.533* 2.744** 3.763* 5.275** 3.803* 5.337** 2.827 4.028**
[1.212] [1.251] [1.469] [1.572] [1.553] [2.088] [1.222] [2.133] [2.306] [2.143] [2.319] [1.863] [1.995]
Observations 152 152 152 152 152 152 152 152 152 152 152 152 152
Endogeneity
test statistic
8.506 10.727 8.136 6.475 8.793 5.743 9.019 8.939 8.654 9.036 8.745 8.315 9.729
Endogeneity
p-value
0.00354 0.00106 0.00434 0.0109 0.00302 0.0166 0.00267 0.00279 0.00326 0.00265 0.00310 0.00393 0.00181
Hansen–Sargan
test statistic
2.454 0.640 1.841 2.364 0.423 2.166 2.993 1.770 2.225 1.792 2.237 1.777 2.030
Hansen–Sargan
p-value
0.117 0.424 0.175 0.124 0.515 0.141 0.0836 0.183 0.136 0.181 0.135 0.183 0.154
continued
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TABLE 52 Table showing circulatory disease spend models with various indicators of MFF and need (continued )
Variable
PBC 10 circulation, 2006/7, spend model
(1) Uses
SMR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(3) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(6) Uses
SYLLR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
Shea’s partial R2 0.235 0.205 0.184 0.207 0.184 0.148 0.238 0.225 0.230 0.224 0.228 0.183 0.183
Kleibergen–Paap
LM test statistic
22.99 24.15 20.59 21.32 25.01 17.46 26.79 23.47 27.59 23.63 27.59 20.91 24.11
Kleibergen–Paap
p-value
1.02e-05 5.70e-06 3.39e-05 2.35e-05 3.70e-06 0.000161 1.52e-06 8.02e-06 1.02e-06 7.41e-06 1.02e-06 2.88e-05 5.80e-06
Kleibergen–Paap
F-statistic
23.14 22.53 18.64 17.28 20.44 12.62 22.37 21.47 22.07 21.27 21.63 19.10 18.93
Pesaran–Taylor
reset statistic
0.00329 0.156 0.102 0.0384 0.333 0.288 0.0270 0.123 0.152 0.189 0.235 0.0165 0.190
Pesaran–Taylor
p-value
0.954 0.693 0.750 0.845 0.564 0.592 0.869 0.726 0.696 0.664 0.628 0.898 0.663
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
iAREA need 1=AREA unified weighted population/HCHS MFF.
iAREA need 2=AREA unified weighted population/HCHS, prescribing and GMS/PMS MFFs.
iAREA need 3=AREA unified weighted population/HCHS and prescribing MFFs.
Other programme need 1= cancer SMR.
Other programme need 2= cancer SYLLR.
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TABLE 53 Table showing respiratory problems spend models with various indicators of MFF and need
Variable
PBC 11 respiratory, 2006/7, spend model
(1) Uses
SMR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(3) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(6) Uses
SYLLR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
PCT budget
per head
0.781** 0.992*** 0.957*** 1.045*** 1.315*** 1.204*** 0.808** 0.592** 0.591* 0.588** 0.585* 0.865*** 0.958***
[0.318] [0.330] [0.363] [0.370] [0.409] [0.432] [0.334] [0.282] [0.310] [0.283] [0.310] [0.287] [0.329]
NeedAREA1 1.714*** 1.741*** 1.813***
[0.597] [0.497] [0.563]
Lone
pensioner
households
−0.497 −0.243 −0.483 −0.419* −0.240 −0.380 −0.595* −0.078 −0.304 −0.089 −0.320 −0.447 −0.556
[0.346] [0.243] [0.356] [0.252] [0.210] [0.271] [0.346] [0.285] [0.378] [0.286] [0.380] [0.337] [0.344]
Other
programme
need 1
−0.803** −0.602** −0.890** −0.866** −0.391 −0.664 −0.407 −0.687 −0.834* −0.931**
[0.397] [0.294] [0.439] [0.392] [0.364] [0.478] [0.364] [0.481] [0.428] [0.437]
NeedPBRA 1.176*** 1.226***
[0.391] [0.366]
NeedCARAN 1.686*** 1.720*** 1.680*** 1.782***
[0.627] [0.536] [0.609] [0.561]
Other
programme
need 2
−1.109** −0.955** −1.197**
[0.455] [0.406] [0.552]
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TABLE 53 Table showing respiratory problems spend models with various indicators of MFF and need (continued )
Variable
PBC 11 respiratory, 2006/7, spend model
(1) Uses
SMR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(3) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(6) Uses
SYLLR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
NeedAREA2 1.312** 1.770**
[0.667] [0.803]
NeedAREA3 1.325** 1.788**
[0.661] [0.800]
Constant −0.143 −0.649 0.258 2.954 2.293 3.531 −0.046 1.605 2.457 1.686 2.578 1.022 0.595
[1.250] [0.961] [1.415] [2.335] [2.094] [2.856] [1.220] [2.372] [2.547] [2.389] [2.574] [1.980] [2.082]
Observations 152 152 152 152 152 152 152 152 152 152 152 152 152
Endogeneity
test statistic
7.821 8.431 9.089 9.157 10.215 9.242 6.984 4.679 4.326 4.853 4.475 9.016 6.863
Endogeneity
p-value
0.00516 0.00369 0.00257 0.00248 0.00139 0.00236 0.00822 0.0305 0.0375 0.0276 0.0344 0.00268 0.00880
Hansen–Sargan
test statistic
1.655 3.108 0.983 0.214 1.502 0.0135 0.615 4.704 2.922 4.621 2.855 0.866 0.156
Hansen-Sargan
p-value
0.198 0.0779 0.321 0.644 0.220 0.908 0.433 0.0301 0.0874 0.0316 0.0911 0.352 0.693
Shea’s partial R2 0.164 0.211 0.149 0.183 0.203 0.172 0.167 0.161 0.131 0.161 0.131 0.142 0.146
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Variable
PBC 11 respiratory, 2006/7, spend model
(1) Uses
SMR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(3) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(6) Uses
SYLLR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
Kleibergen–Paap
LM test statistic
18.58 21.08 18.17 22.04 17.51 18.27 18.78 20.00 13.94 20.14 13.90 17.12 16.62
Kleibergen–Paap
p-value
9.22e-05 2.64e-05 0.000113 1.64e-05 0.000158 0.000108 8.34e-05 4.55e-05 0.000940 4.23e-05 0.000960 0.000192 0.000246
Kleibergen–Paap
F-statistic
8.163 14.31 7.772 8.729 8.513 6.885 8.383 13.56 7.241 13.77 7.297 7.776 7.220
Pesaran–Taylor
reset statistic
0.238 0.0135 0.141 0.0704 0.0139 0.0164 1.083 2.231 2.206 2.311 2.283 3.699 4.984
Pesaran–Taylor
p-value
0.625 0.907 0.707 0.791 0.906 0.898 0.298 0.135 0.138 0.128 0.131 0.0545 0.0256
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
iAREA need 1=AREA unified weighted population/HCHS MFF.
iAREA need 2=AREA unified weighted population/HCHS, prescribing and GMS/PMS MFFs.
iAREA need 3=AREA unified weighted population/HCHS and prescribing MFFs.
Other programme need 1= SMR for all causes of death amenable to health care (see Martin et al.63).
Other programme need 2= SYLLR for all causes of death.
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TABLE 54 Table showing gastrointestinal problems spend models with various indicators of MFF and need
Variable
PBC 13 gastrointestinal, 2006/7, spend model
(1) Uses
SMR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(3) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(6) Uses
SYLLR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
PCT budget
per head
0.538 0.876** 0.862** 1.058** 1.461*** 1.396*** 0.627* 0.240 0.271 0.237 0.265 0.509* 0.692**
[0.355] [0.371] [0.414] [0.446] [0.513] [0.533] [0.371] [0.301] [0.334] [0.301] [0.334] [0.305] [0.340]
NeedAREA1 2.627*** 2.840*** 2.775***
[0.851] [0.758] [0.755]
Lone
pensioner
households
−0.838* −0.269 −0.740 −0.793** −0.362 −0.736* −1.080** 0.122 −0.262 0.121 −0.270 −0.612 −0.901**
[0.492] [0.347] [0.520] [0.385] [0.314] [0.422] [0.460] [0.290] [0.375] [0.287] [0.374] [0.453] [0.445]
Other
programme
need 1
−1.386** −0.820** −1.416** −1.572*** −0.279 −0.751 −0.281 −0.763 −1.216** −1.510***
[0.566] [0.402] [0.634] [0.520] [0.366] [0.476] [0.363] [0.475] [0.562] [0.552]
NeedPBRA 1.422*** 1.627***
[0.488] [0.478]
NeedCARAN 2.369*** 2.740*** 2.375*** 2.619***
[0.889] [0.839] [0.836] [0.748]
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Variable
PBC 13 gastrointestinal, 2006/7, spend model
(1) Uses
SMR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(3) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(6) Uses
SYLLR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
Other
programme
need 2
−2.093*** −1.524*** −2.250***
[0.663] [0.588] [0.817]
NeedAREA2 1.267* 1.916**
[0.662] [0.794]
NeedAREA3 1.264* 1.920**
[0.650] [0.784]
Constant 2.133 0.486 2.386 8.379** 5.626* 9.374** 2.512 4.107 5.367* 4.129 5.450* 5.180** 4.691**
[1.763] [1.237] [1.998] [3.338] [2.958] [4.164] [1.605] [2.520] [2.774] [2.524] [2.787] [2.437] [2.310]
Observations 152 152 152 152 152 152 152 152 152 152 152 152 152
Endogeneity
test statistic
3.530 1.329 4.118 11.390 5.366 9.900 7.202 0.041 1.085 0.052 1.144 4.849 8.194
Endogeneity
p-value
0.0603 0.249 0.0424 0.000738 0.0205 0.00165 0.00728 0.839 0.298 0.820 0.285 0.0277 0.00420
Hansen–Sargan
test statistic
7.192 9.154 4.655 2.282 6.867 1.169 5.058 12.98 11.45 12.91 11.31 4.276 2.414
Hansen–Sargan
p-value
0.00732 0.00248 0.0310 0.131 0.00878 0.280 0.0245 0.000316 0.000715 0.000327 0.000771 0.0387 0.120
Shea’s partial R2 0.164 0.211 0.149 0.183 0.203 0.172 0.167 0.161 0.131 0.161 0.131 0.142 0.146
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TABLE 54 Table showing gastrointestinal problems spend models with various indicators of MFF and need (continued )
Variable
PBC 13 gastrointestinal, 2006/7, spend model
(1) Uses
SMR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(3) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(6) Uses
SYLLR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
Kleibergen–Paap
LM test statistic
18.58 21.08 18.17 22.04 17.51 18.27 18.78 20.00 13.94 20.14 13.90 17.12 16.62
Kleibergen–Paap
p-value
9.22e-05 2.64e-05 0.000113 1.64e-05 0.000158 0.000108 8.34e-05 4.55e-05 0.000940 4.23e-05 0.000960 0.000192 0.000246
Kleibergen–Paap
F-statistic
8.163 14.31 7.772 8.729 8.513 6.885 8.383 13.56 7.241 13.77 7.297 7.776 7.220
Pesaran–Taylor
reset statistic
0.00544 0.107 0.00251 0.0613 0.0576 0.000667 0.167 1.735 2.598 1.752 2.633 2.450 3.579
Pesaran–Taylor
p-value
0.941 0.743 0.960 0.804 0.810 0.979 0.683 0.188 0.107 0.186 0.105 0.118 0.0585
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
iAREA need 1=AREA unified weighted population/HCHS MFF.
iAREA need 2=AREA unified weighted population/HCHS, prescribing and GMS/PMS MFFs.
iAREA need 3=AREA unified weighted population/HCHS and prescribing MFFs.
Other programme need 1= SMR for all causes of death amenable to health care (see Martin et al.63).
Other programme need 2= SYLLR for all causes of death.
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TABLE 55 Table showing cancer outcome models with various indicators of MFF and need
Variable
PBC 2 cancer, 2006/7, outcome model
(1) Uses
SMR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(3) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(6) Uses
SYLLR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
NeedAREA1 1.142*** 1.048*** 1.121***
[0.161] [0.143] [0.169]
Cancer spend
per head
−0.426*** −0.287*** −0.351*** −0.356*** −0.223*** −0.291*** −0.487*** −0.284*** −0.367*** −0.284*** −0.366*** −0.421*** −0.494***
[0.125] [0.080] [0.098] [0.110] [0.068] [0.082] [0.148] [0.109] [0.133] [0.109] [0.133] [0.126] [0.156]
NeedPBRA 0.972*** 0.881***
[0.104] [0.090]
NeedCARAN 1.087*** 1.005*** 1.126*** 1.112***
[0.130] [0.110] [0.153] [0.167]
NeedAREA2 1.048*** 1.070***
[0.128] [0.143]
NeedAREA3 1.035*** 1.058***
[0.128] [0.142]
Constant 3.689*** 4.049*** 3.884*** 4.139*** 4.482*** 4.309*** 3.536*** 6.012*** 6.375*** 6.009*** 6.373*** 6.614*** 6.938***
[0.318] [0.202] [0.249] [0.278] [0.172] [0.207] [0.372] [0.476] [0.583] [0.476] [0.583] [0.552] [0.684]
Observations 152 152 152 152 152 152 152 152 152 152 152 152 152
Endogeneity
test statistic
18.518 16.063 19.086 15.982 12.454 17.096 18.965 11.026 13.552 10.985 13.490 19.697 19.500
Endogeneity
p-value
1.68e-05 6.13e-05 1.25e-05 6.40e-05 0.000417 3.55e-05 1.33e-05 0.000898 0.000232 0.000918 0.000240 9.07e-06 1.01e-05
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TABLE 55 Table showing cancer outcome models with various indicators of MFF and need (continued )
Variable
PBC 2 cancer, 2006/7, outcome model
(1) Uses
SMR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(3) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(6) Uses
SYLLR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
Hansen–Sargan
test statistic
0.248 0.239 0.0431 0.163 0.161 0.00820 0.192 0.860 0.690 0.857 0.686 0.000632 0.0933
Hansen–Sargan
p-value
0.619 0.625 0.835 0.686 0.688 0.928 0.661 0.354 0.406 0.355 0.407 0.980 0.760
Shea’s partial R2 0.200 0.246 0.226 0.200 0.246 0.226 0.176 0.202 0.167 0.202 0.166 0.169 0.142
Kleibergen–Paap
LM test statistic
18.49 23.43 21.27 18.49 23.43 21.27 16.89 19.40 17.25 19.39 17.20 18.35 15.71
Kleibergen–Paap
p-value
9.66e-05 8.17e-06 2.41e-05 9.66e-05 8.17e-06 2.41e-05 0.000215 6.12e-05 0.000179 6.17e-05 0.000184 0.000104 0.000389
Kleibergen–Paap
F-statistic
19.15 28.08 24.39 19.15 28.08 24.39 15.16 19.90 14.69 19.81 14.58 16.81 12.05
Pesaran–Taylor
reset statistic
2.789 5.422 3.218 3.506 5.986 3.796 3.838 4.129 5.271 4.234 5.259 4.399 5.890
Pesaran–Taylor
p-value
0.0949 0.0199 0.0728 0.0611 0.0144 0.0514 0.0501 0.0422 0.0217 0.0396 0.0218 0.0360 0.0152
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
iAREA need 1=AREA unified weighted population/HCHS MFF.
iAREA need 2=AREA unified weighted population/HCHS, prescribing and GMS/PMS MFFs.
iAREA need 3=AREA unified weighted population/HCHS and prescribing MFFs.
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TABLE 56 Table showing circulatory disease outcome models with various indicators of MFF and need
Variable
PBC 10 circulation, 2006/7, outcome model
(1) Uses
SMR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(3) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(6) Uses
SYLLR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
NeedAREA1 2.442*** 2.657*** 2.554***
[0.239] [0.256] [0.251]
Circulation
spend per head
−1.166*** −0.945*** −1.080*** −1.245*** −0.983*** −1.138*** −1.258*** −0.968*** −1.077*** −0.966*** −1.075*** −1.285*** −1.379***
[0.203] [0.180] [0.195] [0.215] [0.190] [0.205] [0.207] [0.191] [0.194] [0.191] [0.194] [0.243] [0.238]
NeedPBRA 2.104*** 2.262***
[0.208] [0.220]
NeedCARAN 2.394*** 2.587*** 2.508*** 2.624***
[0.242] [0.257] [0.278] [0.282]
NeedAREA2 2.303*** 2.452***
[0.218] [0.233]
NeedAREA3 2.281*** 2.426***
[0.217] [0.231]
Constant 1.971*** 2.456*** 2.165*** 1.983*** 2.555*** 2.222*** 1.771*** 9.078*** 9.596*** 9.073*** 9.584*** 10.605*** 11.050***
[0.429] [0.379] [0.411] [0.454] [0.400] [0.432] [0.438] [0.916] [0.931] [0.914] [0.928] [1.168] [1.145]
Observations 152 152 152 152 152 152 152 152 152 152 152 152 152
Endogeneity
test statistic
32.774 30.750 39.253 38.776 28.130 42.881 28.691 28.410 28.030 28.471 27.939 40.272 38.934
Endogeneity
p-value
1.04e-08 2.94e-08 3.72e-10 4.75e-10 1.13e-07 5.82e-11 8.49e-08 9.82e-08 1.19e-07 9.51e-08 1.25e-07 2.21e-10 4.38e-10
continued
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TABLE 56 Table showing circulatory disease outcome models with various indicators of MFF and need (continued )
Variable
PBC 10 circulation, 2006/7, outcome model
(1) Uses
SMR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(3) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR, no
weighting,
second
stage,
PBRA
need,
HCHS MFF
(6) Uses
SYLLR, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
Hansen–Sargan
test statistic
7.315 11.76 3.706 5.337 12.53 3.288 5.937 10.43 7.965 10.24 7.888 2.449 1.678
Hansen–Sargan
p-value
0.0625 0.00827 0.295 0.149 0.00576 0.349 0.115 0.0153 0.0467 0.0166 0.0484 0.484 0.642
Shea’s partial R2 0.368 0.383 0.376 0.368 0.383 0.376 0.349 0.370 0.346 0.371 0.347 0.305 0.291
Kleibergen–Paap
LM test statistic
29.32 26.93 31.11 29.32 26.93 31.11 32.68 31.06 34.79 31.25 34.98 28.69 31.43
Kleibergen–Paap
p-value
6.73e-06 2.05e-05 2.90e-06 6.73e-06 2.05e-05 2.90e-06 1.39e-06 2.97e-06 5.14e-07 2.72e-06 4.70e-07 9.03e-06 2.50e-06
Kleibergen–Paap
F-statistic
20.24 19.21 20.32 20.24 19.21 20.32 19.89 20.09 19.66 20.15 19.70 15.50 16.33
Pesaran–Taylor
reset statistic
0.0847 0.0884 2.19e-07 0.257 0.0261 0.0107 0.0185 0.0138 0.00282 0.0143 0.00315 2.369 0.196
Pesaran–Taylor
p-value
0.771 0.766 1.000 0.612 0.872 0.918 0.892 0.906 0.958 0.905 0.955 0.124 0.658
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
iAREA need 1=AREA unified weighted population/HCHS MFF.
iAREA need 2=AREA unified weighted population/HCHS, prescribing and GMS/PMS MFFs.
iAREA need 3=AREA unified weighted population/HCHS and prescribing MFFs.
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TABLE 57 Table showing respiratory disease outcome models with various indicators of MFF and need
Variable
PBC 11 respiratory, 2006/7, outcome model
(1) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
PBRA need,
HCHS MFF
(3) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR,
instrument
spend, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR,
instrument
spend, no
weighting,
second
stage,
PBRA need,
HCHS MFF
(6) Uses
SYLLR,
instrument
spend, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
instrument
spend,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
instrument
spend,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR,
instrument
spend, no
weighting
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
instrument
spend,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
instrument
spend,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
NeedAREA1 8.008*** 9.158*** 8.647***
[2.969] [3.298] [3.317]
Respiratory
spend per head
−4.845** −3.364*** −4.149** −5.568** −3.894*** −4.808** −5.182** −3.535** −3.773** −3.536** −3.764** −6.738* −6.640*
[2.147] [1.225] [1.734] [2.388] [1.359] [1.945] [2.352] [1.412] [1.503] [1.400] [1.479] [3.799] [3.464]
NeedPBRA 5.941*** 6.789***
[1.706] [1.887]
NeedCARAN 7.238*** 8.306*** 10.184** 10.352**
[2.492] [2.788] [5.006] [4.635]
NeedAREA2 6.501*** 7.025***
[1.985] [2.176]
NeedAREA3 6.460*** 6.965***
[1.959] [2.130]
Constant −10.277* −6.163* −8.328* −12.218* −7.567** −10.087* −11.234* 17.749*** 18.712*** 17.755*** 18.675*** 31.101** 30.667**
[5.898] [3.355] [4.749] [6.563] [3.723] [5.328] [6.465] [5.877] [6.252] [5.824] [6.151] [15.828] [14.436]
Observations 152 152 152 152 152 152 152 152 152 152 152 152 152
Endogeneity
test statistic
51.569 49.552 54.608 55.731 52.069 58.974 48.137 42.431 44.464 42.671 44.683 57.889 53.094
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TABLE 57 Table showing respiratory disease outcome models with various indicators of MFF and need (continued )
Variable
PBC 11 respiratory, 2006/7, outcome model
(1) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
PBRA need,
HCHS MFF
(3) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR,
instrument
spend, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR,
instrument
spend, no
weighting,
second
stage,
PBRA need,
HCHS MFF
(6) Uses
SYLLR,
instrument
spend, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
instrument
spend,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
instrument
spend,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR,
instrument
spend, no
weighting
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
instrument
spend,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
instrument
spend,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
Endogeneity
p-value
0 0 0 0 0 0 0 7.32e-11 0 6.48e-11 0 0 0
Hansen–Sargan
test statistic
0.302 1.253 0.123 0.305 1.828 0.211 0.179 0.785 0.354 0.700 0.303 0.00383 0.0915
Hansen–Sargan
p-value
0.582 0.263 0.726 0.581 0.176 0.646 0.673 0.376 0.552 0.403 0.582 0.951 0.762
Shea’s partial R2 0.0491 0.0791 0.0593 0.0491 0.0791 0.0593 0.0462 0.0654 0.0624 0.0661 0.0633 0.0235 0.0246
Kleibergen–Paap
LM test statistic
5.660 8.303 7.499 5.660 8.303 7.499 5.437 7.311 6.973 7.461 7.117 3.866 3.772
Kleibergen–Paap
p-value
0.0590 0.0157 0.0235 0.0590 0.0157 0.0235 0.0660 0.0258 0.0306 0.0240 0.0285 0.145 0.152
Kleibergen–Paap
F-statistic
3.344 5.857 4.507 3.344 5.857 4.507 2.959 4.328 3.804 4.402 3.875 2.030 1.859
Pesaran–Taylor
reset statistic
0.791 4.049 0.000560 1.490 5.225 0.00355 0.327 0.0202 0.00861 0.0218 0.0116 3.788 1.716
Pesaran–Taylor
p-value
0.374 0.0442 0.981 0.222 0.0223 0.952 0.568 0.887 0.926 0.883 0.914 0.0516 0.190
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
iAREA need 1=AREA unified weighted population/HCHS MFF.
iAREA need 2=AREA unified weighted population/HCHS, prescribing and GMS/PMS MFFs.
iAREA need 3=AREA unified weighted population/HCHS and prescribing MFFs.
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TABLE 58 Table showing gastrointestinal disease outcome models with various indicators of MFF and need
Variable
PBC 13 gastrointestinal, 2006/7, outcome model
(1) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
PBRA need,
HCHS MFF
(3) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR,
instrument
spend, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR,
instrument
spend, no
weighting,
second
stage,
PBRA need,
HCHS MFF
(6) Uses
SYLLR,
instrument
spend, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
instrument
spend,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
instrument
spend,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
instrument
spend,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
instrument
spend,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
NeedAREA1 3.853*** 3.966*** 3.779***
[0.551] [0.558] [0.499]
Gastrointestinal
spend per head
−1.755*** −1.420*** −1.641*** −1.544*** −1.180*** −1.404*** −1.750*** −1.275*** −1.317*** −1.275*** −1.315*** −2.056*** −2.192***
[0.397] [0.353] [0.427] [0.399] [0.358] [0.429] [0.385] [0.335] [0.326] [0.335] [0.325] [0.589] [0.574]
NeedPBRA 3.342*** 3.413***
[0.486] [0.498]
NeedCARAN 3.794*** 3.887*** 4.140*** 4.250***
[0.612] [0.621] [0.768] [0.710]
NeedAREA2 3.426*** 3.479***
[0.466] [0.419]
NeedAREA3 3.393*** 3.443***
[0.462] [0.415]
Constant −2.155** −1.251 −1.838 −0.954 0.028 −0.566 −2.166** 7.919*** 8.073*** 7.916*** 8.064*** 11.273*** 11.835***
[1.047] [0.928] [1.121] [1.054] [0.943] [1.127] [1.016] [1.431] [1.391] [1.430] [1.387] [2.524] [2.460]
Observations 152 152 152 152 152 152 152 152 152 152 152 152 152
Endogeneity
test statistic
23.347 18.985 25.405 17.048 11.389 17.857 16.834 16.638 11.980 16.689 11.942 25.632 22.341
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TABLE 58 Table showing gastrointestinal disease outcome models with various indicators of MFF and need (continued )
Variable
PBC 13 gastrointestinal, 2006/7, outcome model
(1) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(2) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
PBRA need,
HCHS MFF
(3) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(4) Uses
SYLLR,
instrument
spend, no
weighting,
second
stage,
iAREA
need 1,
HCHS MFF
(5) Uses
SYLLR,
instrument
spend, no
weighting,
second
stage,
PBRA need,
HCHS MFF
(6) Uses
SYLLR,
instrument
spend, no
weighting,
second
stage,
CARAN
need,
HCHS MFF
(7) Uses
SMR,
instrument
spend,
weighted,
second
stage,
iAREA
need 1,
HCHS MFF
(8) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(9) Uses
SMR,
instrument
spend,
weighted,
second
stage,
iAREA
need 2,
CARAN
3 MFFs
(10) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(11) Uses
SMR,
instrument
spend,
weighted,
second
stage,
iAREA
need 3,
CARAN
2 MFFs
(12) Uses
SMR,
instrument
spend, no
weighting,
second
stage,
CARAN
need,
CARAN
3 MFFs
(13) Uses
SMR,
instrument
spend,
weighted,
second
stage,
CARAN
need,
CARAN
3 MFFs
Endogeneity
p-value
1.35e-06 1.32e-05 4.65e-07 3.65e-05 0.000739 2.38e-05 4.08e-05 4.52e-05 0.000538 4.40e-05 0.000549 4.13e-07 2.28e-06
Hansen–Sargan
test statistic
3.067 4.604 1.555 4.936 7.575 2.637 7.476 5.029 8.762 4.907 8.714 1.284 3.554
Hansen–Sargan
p-value
0.216 0.100 0.459 0.0847 0.0227 0.268 0.0238 0.0809 0.0125 0.0860 0.0128 0.526 0.169
Shea’s partial R2 0.193 0.231 0.200 0.193 0.231 0.200 0.191 0.208 0.198 0.208 0.198 0.139 0.135
Kleibergen–Paap
LM test statistic
16.47 17.51 16.32 16.47 17.51 16.32 17.68 17.09 18.26 17.14 18.34 13.39 13.98
Kleibergen–Paap
p-value
0.000910 0.000556 0.000974 0.000910 0.000556 0.000974 0.000511 0.000679 0.000389 0.000661 0.000375 0.00386 0.00293
Kleibergen–Paap
F-statistic
12.12 13.24 10.79 12.12 13.24 10.79 11.96 13.23 12.98 13.24 13.00 7.550 7.248
Pesaran–Taylor
reset statistic
0.233 0.0427 0.0897 1.246 1.121 0.258 0.170 0.0935 0.443 0.0893 0.411 0.00841 0.117
Pesaran–Taylor
p-value
0.629 0.836 0.765 0.264 0.290 0.611 0.680 0.760 0.506 0.765 0.521 0.927 0.732
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
iAREA need 1=AREA unified weighted population/HCHS MFF.
iAREA need 2=AREA unified weighted population/HCHS, prescribing and GMS/PMS MFFs.
iAREA need 3=AREA unified weighted population/HCHS and prescribing MFFs.
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The assimilation of the impact of alternative measures of need, weights and MFFs proved overwhelming.
Instead, we approached the selection of the appropriate need∼weighting∼MFF combination from an
a priori perspective. The AREA-based need formula has been replaced by the CARAN formula for the
purposes of resource allocation and therefore it must be believed to be a better indicator of relative
health-care need. The PBRA approach is relatively new and has not been implemented yet. We therefore
decided to use the CARAN-based measure as our indicator of the level of need.
With some PCTs several times larger than others, it is difficult to justify giving them all the same weighting.
It was therefore decided to weight all of our models by PCT size (where size is measured by the
PCT’s population).
We also decided to use the ‘own population’ expenditure data on the grounds that all NHS expenditure,
irrespective of its funding source, should be included in the analysis (although there is the issue about how
this income is split between PBCs).
Finally, it was decided to focus on the use of the SYLLR as the outcome indicator, and to proxy ‘other
programme need’ in the expenditure equation using the all-cause SYLLR minus the own
programme SYLLR.
Model estimation using 2006/7 expenditure data and mortality data for
2004/5/6: CARAN need and three market forces factors
Initially, acceptable models were obtained by using the CARAN measure of need and adjusting
expenditure for local input prices using a weighted average of the MFFs for all three services (HCHS,
prescribing and GMS/PMS). The outcome and expenditure results for the big four programmes are shown
in Table 59 with the relevant outcome and expenditure elasticities highlighted.
TABLE 59 Table showing outcome and expenditure models for the big four programmes using spend data
(incorporating three MFFs) for 2006/7
Variable
PBC 2 cancer,
2006/7
PBC 10 circulation,
2006/7
PBC 11 respiratory,
2006/7
PBC 13
gastrointestinal,
2006/7
(1) (2) (3) (4) (5) (6) (7) (8)
Regressors Outcome
model
Spend
model
Outcome
model
Spend
model
Outcome
model
Spend
model
Outcome
model
Spend
model
All-cause SYLLR
excluding cancer
−0.952***
[0.179]
Budget per head
(HPG MFF)
0.542** 0.694** 0.712*** 0.650**
[0.242] [0.292] [0.252] [0.289]
Need CARAN 0.958*** 1.765*** 2.830*** 2.185*** 1.764 1.371*** 4.609*** 2.696***
[0.129] [0.286] [0.252] [0.355] [1.192] [0.297] [0.700] [0.679]
Own programme
spend per head
−0.351*** −1.441*** −2.830*** −2.125***
[0.117] [0.219] [0.767] [0.563]
All-cause SYLLR
excluding circulatory
problems
−1.782***
[0.336]
Permanently sick 1.371***
[0.405]
continued
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TABLE 59 Table showing outcome and expenditure models for the big four programmes using spend data
(incorporating three MFFs) for 2006/7 (continued )
Variable
PBC 2 cancer,
2006/7
PBC 10 circulation,
2006/7
PBC 11 respiratory,
2006/7
PBC 13
gastrointestinal,
2006/7
(1) (2) (3) (4) (5) (6) (7) (8)
All-cause SYLLR
excluding respiratory
problems
−0.670**
[0.288]
All-cause SYLLR
excluding
gastrointestinal
problems
−1.856***
[0.612]
Lone pensioner
households
−0.593**
[0.297]
Constant 6.588*** 5.937*** 11.538*** 10.299*** 18.965*** 3.117 12.208*** 9.752***
[0.515] [1.775] [1.050] [2.384] [3.853] [1.976] [2.416] [3.053]
Observations 152 152 152 152 152 152 152 152
Endogeneity
test statistic
14.496 20.274 43.352 25.784 27.923 7.922 21.862 13.531
Endogeneity
p-value
0.000140 6.71e-06 0 3.82e-07 1.26e-07 0.00488 2.93e-06 0.000235
Hansen–Sargan
test statistic
0.208 0.293 1.507 0.542 1.879 0.356 1.006 0.0267
Hansen–Sargan
p-value
0.649 0.588 0.681 0.462 0.170 0.550 0.316 0.870
Shea’s partial R2 0.163 0.445 0.303 0.296 0.0802 0.366 0.142 0.206
Kleibergen–Paap
LM test statistic
16.97 42.38 32.53 32.70 10.51 36.33 15.00 19.07
Kleibergen–Paap
p-value
0.000207 6.28e-10 1.49e-06 7.93e-08 0.00523 1.29e-08 0.000553 7.22e-05
Kleibergen–Paap
F-statistic
12.47 48.32 17.31 25.71 7.482 24.32 11.80 8.660
Pesaran–Taylor
reset statistic
5.471 0.00111 0.0912 0.0183 3.090 1.915 0.267 0.0880
Pesaran–Taylor
p-value
0.0193 0.973 0.763 0.892 0.0788 0.166 0.605 0.767
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
HPG=HCHS, prescribing and GMS/PMS.
Note
All spend figures are on a net population basis and are adjusted for local prices using three MFFs from the Department of
Health’s resource allocation exposition book for 2009/10. All estimated models use 152 PCTs and are weighted by PCT
population. The SYLLR is the mortality indicator. There are several differences between the models estimated here and
those reported in Martin et al.:59 (i) here we use net population spend data (not net spend data); (ii) here we use
three MFFs (not solely the HCHS MFF); and (iii) here we use a consistent definition of the ‘other programme need’
proxy across all programmes (i.e. all-cause SYLLR minus the own programme SYLLR).
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In all four outcome models expenditure has a significant negative effect on mortality and, in three of
these, the all service measure of need has a significant positive effect. In the respiratory outcome model,
where the all service need term is not significant, there is another indicator of need – the proportion of the
population that are permanently sick – and this is both positive and statistically significant. The diagnostic
statistics suggest that, in all four cases, own programme expenditure is endogenous and that the
instruments are valid. They also suggest that the instruments are relevant. There is some evidence that
the instruments are slightly weak in one of the four outcome results (the respiratory model).ab The
Pesaran–Taylor test suggests that there is no evidence of model misspecification.
In all four expenditure models both the need and budget variables have a positive and significant effect
on own programme expenditure. In addition, the proxy for need in other programmes is negative and
significant in all four cases. In the gastrointestinal expenditure programme the prevalence of lone
pensioners households is associated with less NHS expenditure; there might be some unmet need here or
perhaps this is a self-selecting group.
The diagnostic statistics suggest that, for all four expenditure models, the proxy for other programme need
is endogenous and that the instruments are valid. They also suggest that the instruments are relevant
and, with the possible exception of the gastrointestinal expenditure result, there is no evidence that the
instruments are weak. The Pesaran–Taylor test suggests that there is no evidence of model misspecification.
The elasticities shown in Table 59 can be used to calculate the cost of a life-year in each programme and
these calculations – for both these four programmes as well as for the other six programmes with a
mortality-based outcome indicator – are shown in Tables 60 and 61 (the full outcome and expenditure
models for the other six programmes with a mortality-based outcome indicator are not shown here).
Table 60 reveals that the cost of a life-year for the big four programmes combined is £11,298. This is
remarkably close to the figure obtained using expenditure data for 2005/6, an AREA-based measure of
need, and a HCHS MFF (£12,855). The cost of a life-year for all 10 programmes with a mortality-based
measure of need is £21,743, which is even closer to the figure obtained using 2005/6 expenditure data
(£21,256). If we assume a zero gain in the 13 programmes without a mortality-based indicator then the
cost per life-year across all 23 programmes is £66,318 (it is £56,799 for 2005/6 data).
Alternatively, if we assume that PBC 23 generates a zero health gain and that the gain attributable to the
remaining 12 programmes is, on average, the same as that attributable to those with a mortality outcome
measure, then Table 61 shows that the cost of a life-year across all programmes is £25,038 (it is £24,200
for 2005/6 data).
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TABLE 60 Table showing cost of life and life-year estimates using spend data for 2006/7 (three MFFs) and outcome data for 2004/5/6 (assumes zero gain for 13 programmes)
(A) PBC
scenario
(B) PBC
description
(C) Spend
(£M) 2006/7
(D) Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Average
annual mortality,
<75 years,
2004/5/6
(G)
Outcome
elasticity
(H)
(=0.01×D×F×G)
change in
annual mortality
(I) (= E/H)
cost per
life
gained (£)
(J) Total
life-years lost,
<75 years,
2004/5/6
(K)
(=0.01×D×G×J/3)
change in annual
life-years lost
(L) (= E/K)
cost per
YLG (£)
1 Cancer 4122 0.542 22.34 62,259 0.351 118.44 188,625 2,221,530 1409 15,859
2 Circulatory
problems
6161 0.694 42.76 45,504 1.441 455.06 93,959 1,463,912 4880 8762
3 Respiratory
problems
3285 0.712 23.39 11,601 2.83 233.76 100,058 321,264 2158 10,839
4 Gastrointestinal
problems
3700 0.65 24.05 5926 2.125 81.85 293,820 328,853 1514 15,884
5 Big four
programmes
17,268 112.54 125,290 889.12 126,573 4,335,559 9961 11,298
6 Big four
programmes
2005/6
17,625 141.22 125,290 909.96 155,196 4,516,953 10,986 12,855
7 Infectious
diseases
1053 0.725 7.63 2050 0.03 0.45 17,121,951 101604 7 1,036,377
8 Endocrine
problems
1852 0.954 17.67 1690 0.965 15.56 1,135,604 60,615 186 94,985
9 Neurological
problems
2790 0.64 17.86 729 0.1 0.47 38,271,605 68,808 15 1,216,428
10 Genitourinary
problems
3482 0.799 27.82 294 0.074 0.17 160,047,803 11,554 2 12,217,601
11 Trauma
and injuries
2892 0.609 17.61 1037 0.527 3.33 5,291,867 30,000 32 548,767
12 Maternity
and neonates
3574 0.601 21.48 2123 0.036 0.46 46,762,966 484,950 35 614,153
13 Other six
programmes
15,643 110.07 7923 20.43 5,387,190 757,531 277 396,796
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(A) PBC
scenario
(B) PBC
description
(C) Spend
(£M) 2006/7
(D) Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Average
annual mortality,
<75 years,
2004/5/6
(G)
Outcome
elasticity
(H)
(=0.01×D×F×G)
change in
annual mortality
(I) (= E/H)
cost per
life
gained (£)
(J) Total
life-years lost,
<75 years,
2004/5/6
(K)
(=0.01×D×G×J/3)
change in annual
life-years lost
(L) (= E/K)
cost per
YLG (£)
14 Other six
programmes
2005/6
12,743 99.44 7923 16.26 6,115,621 751,009 337 295,074
15 All 10
programmes
32,911 0.676 222.61 133,213 909.55 244,747 5,093,090 10,238 21,743
16 All 10
programmes
2005/6
30,368 0.792 240.67 133,213 926.22 259,838 5,267,962 11,322 21,256
Assume zero health gain in the other 13 programmes
18 Other 13
programmes
34,985 1.304 456.35 0.00 0
19 Other 13
programmes
2005/6
33,942 1.186 402.43 0.00 0
20 All 23
programmes
67,896 678.96 909.55 746,481 10,238 66,318
21 All 23
programmes
2005/6
64,310 643.10 926.22 694,330 11,322 56,799
Note
Italicised text shows estimates reported previously in Table 44.
All 23 programmes spend: 2006/7 £67,896; 2005/6 £64,310.
% change in budget: 2006/7 1.00%; 2005/6 1.00%.
Proportionate change: 2006/7 0.01; 2005/6 0.01.
Change in budget: 2006/7 £678.96; 2005/6 £643.10.
Annual mortality figures reported in cells F5 and F6 ,and F13 and F14 are identical because we do not have mortality data for 2002/3/4.
For 2006/7, the neonate category has been merged with maternity to obtain plausible outcome and expenditure models.
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TABLE 61 Table showing cost of life and life-year estimates using spend data for 2006/7 (three MFFs) and outcome data for 2004/5/6 (assumes some gain in other
13 programmes)
(A) PBC
scenario
(B) PBC
description
(C) Spend
(£M) 2006/7
(D) Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Average
annual mortality,
<75 years,
2004/5/6
(G)
Outcome
elasticity
(H)
(=0.01×D×F×G)
change in
annual mortality
(I) (= E/H)
cost per life
gained (£)
(J) Total
life-years lost,
<75 years,
2004/5/6
(K)
(=0.01×D×G×J/3)
change in annual
life-years lost
(L) (= E/K)
cost per
YLG (£)
1 Cancer 4122 0.542 22.34 62,259 0.351 118.44 188,625 2,221,530 1409 15,859
2 Circulatory
problems
6161 0.694 42.76 45,504 1.441 455.06 93,959 1,463,912 4880 8762
3 Respiratory
problems
3285 0.712 23.39 11,601 2.83 233.76 100,058 321,264 2158 10,839
4 Gastrointestinal
disease
3700 0.65 24.05 5926 2.125 81.85 293,820 328,853 1514 15,884
5 Big four
programmes
17,268 112.54 125,290 889.12 126,573 4,335,559 9961 11,298
6 Big four
programmes
2005/6
17,625 141.22 125,290 909.96 155,196 4,516,953 10,986 12,855
7 Infectious
diseases
1053 0.725 7.63 2050 0.03 0.45 17,121,951 101604 7 1,036,377
8 Endocrine
problems
1852 0.954 17.67 1690 0.965 15.56 1,135,604 60,615 186 94,985
9 Neurological
problems
2790 0.64 17.86 729 0.1 0.47 38,271,605 68,808 15 1,216,428
10 Genitourinary
problems
3482 0.799 27.82 294 0.074 0.17 160,047,803 11,554 2 12,217,601
11 Trauma
and injuries
2892 0.609 17.61 1037 0.527 3.33 5,291,867 30,000 32 548,767
12 Maternity
and neonates
3574 0.601 21.48 2123 0.036 0.46 46,762,966 484,950 35 614,153
13 Other six
programmes
15,643 110.07 7923 20.43 5,387,190 757,531 277 396,796
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(A) PBC
scenario
(B) PBC
description
(C) Spend
(£M) 2006/7
(D) Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Average
annual mortality,
<75 years,
2004/5/6
(G)
Outcome
elasticity
(H)
(=0.01×D×F×G)
change in
annual mortality
(I) (= E/H)
cost per life
gained (£)
(J) Total
life-years lost,
<75 years,
2004/5/6
(K)
(=0.01×D×G×J/3)
change in annual
life-years lost
(L) (= E/K)
cost per
YLG (£)
14 Other six
programmes
2005/6
12,743 99.44 7923 16.26 6,115,621 751,009 337 295,074
15 All 10
programmes
32,911 0.676 222.61 133,213 909.55 244,747 5,093,090 10,238 21,743
16 All 10
programmes
2005/6
30,368 0.792 240.67 133,213 926.22 259,838 5,267,962 11,322 21,256
Assume zero health gain in PBC 23, and gain in 10 PBCs applies to other 12 PBCs
17 PBC 23 10,585 0.844 89.34 0.00 0.00
18 PBC 23 2005/6 8449 0.926 78.24 0.00 0.00
19 Other 12
programmes
24,400 367.01 1499.56 244,747 16,880 21,743
20 Other 12
programmes
2005/6
25,493 324.20 1247.69 259,838 15,252 21,256
21 All 23
programmes
67,896 678.96 2409.11 281,830 27,118 25,038
22 All 23
programmes
2005/6
64,310 643.10 2173.90 295,827 26,575 24,200
Note
Italicised text shows estimates reported previously in Table 44.
All 23 programmes spend: 2006/7 £67,896; 2005/6 £64,310.
% change in budget: 2006/7 1.00%; 2005/6 1.00%.
Proportionate change: 2006/7 0.01; 2005/6 0.01.
Change in budget: 2006/7 £678.96; 2005/6 £643.10.
Annual mortality figures reported in cells F5 and F6 ,and F13 and F14 are identical because we do not have mortality data for 2002/3/4.
For 2006/7, the neonate category has been merged with maternity to obtain plausible outcome and expenditure
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Model estimation using 2006/7 expenditure data and mortality data for
2004/5/6: CARAN need and two market forces factors
Further discussion by the project team noted that the PB data incorporates all PCT expenditure and that, as
there is a separate category for GMS/PMS expenditure (PBC 23a), it seems appropriate that the GMS/PMS
MFF should be applied to this category. However, other categories of expenditure exclude GMS/PMS
expenditure but incorporate both HCHS and prescribing expenditure. It therefore seems appropriate that a
weighted averaged of the HCHS and prescribing MFFs should be applied to these other (non-GMS/PMS)
categories of expenditure.
We therefore re-estimated the outcome and expenditure models for those programmes with a
mortality-based outcome indicator using the CARAN measure of need and adjusting expenditure for local
input prices using the MFFs for HCHS and prescribing services. The outcome and expenditure results for
the big four programmes are shown in Table 62 with the relevant outcome and expenditure elasticities
again highlighted (the first-stage regressions associated with these results can be found in Table 95 in
the Annex).
In all four outcome models expenditure has a significant negative effect on mortality and, in three of
these, the all service measure of need has a significant positive effect. In the respiratory outcome model,
where the all service need term is not significant, there is another indicator of need – the proportion of the
population that are permanently sick – and this is both positive and statistically significant. The all service
measure of need squared is also positive and significant in the cancer outcome equation. The diagnostic
statistics suggest that, in all four cases, own programme expenditure is endogenous and that the
instruments are valid. They also suggest that the instruments are relevant. There is a little evidence that
the instruments are weak in one of the four outcome results, namely the respiratory model. Re-estimation
of the latter model but without the least significant instrument generates a coefficient of −3.507 on
expenditure and the Kleibergen–Paap F-statistic now exceeds 10 (it is 11.799). The Pesaran–Taylor test
suggests that there is no evidence of model misspecification in any of the outcome models.
In all four expenditure models both the need and budget variables have a positive and significant effect on
own programme expenditure. In addition, the proxy for need in other programmes is negative and
significant in all four cases. In the gastrointestinal expenditure programme the prevalence of lone
pensioners households is associated with less NHS expenditure; there might be some unmet need here or
perhaps this is self-selecting group.
The diagnostic statistics suggest that, for all four expenditure models, expenditure is endogenous and
the instruments are valid. They also suggest that the instruments are relevant and, with the possible
exception of the gastrointestinal expenditure result, there is no evidence that the instruments are weak.
Re-estimation of the gastrointestinal expenditure model without the least significant instrument generates
a coefficient of 0.667 on the budget variable and the Kleibergen–Paap F-statistic now exceeds 10
(it is 16.871). The Pesaran–Taylor test suggests that there is no evidence of model misspecification.
APPENDIX 2
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TABLE 62 Table showing outcome and expenditure models for the big four programmes using spend data for 2006/7 (incorporating two MFFs) and mortality data
for 2004/5/6
PBC scenario
PBC 2, cancer, 2006/7 PBC 10, circulation, 2006/7 PBC 11, respiratory, 2006/7 PBC 13, gastrointestinal, 2006/7
(1) Outcome
model
(2) Spend
model
(3) Outcome
model
(4) Spend
model
(5) Outcome
model
(6) Spend
model
(7) Outcome
model
(8) Spend
model
Own programme spend per head −0.337*** −1.447*** −2.839*** −2.137***
[0.104] [0.220] [0.772] [0.569]
Need CARAN per head 0.974*** 1.772*** 2.860*** 2.191*** 1.782 1.375*** 4.657*** 2.697***
[0.110] [0.287] [0.257] [0.355] [1.198] [0.297] [0.716] [0.676]
NeedCARAN per head squared 1.314***
[0.352]
All-cause SYLLR excluding cancer −0.951***
[0.180]
PCT budget per head 0.548** 0.701** 0.718*** 0.655**
[0.242] [0.292] [0.253] [0.289]
All-cause SYLLR excluding circulatory disease −1.778***
[0.336]
Permanently sick aged 16–74 years 1.385***
[0.405]
All-cause SYLLR excluding respiratory problems −0.663**
[0.288]
All-cause SYLLR excluding gastrointestinal problems −1.847***
[0.609]
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TABLE 62 Table showing outcome and expenditure models for the big four programmes using spend data for 2006/7 (incorporating two MFFs) and mortality data
for 2004/5/6 (continued )
PBC scenario
PBC 2, cancer, 2006/7 PBC 10, circulation, 2006/7 PBC 11, respiratory, 2006/7 PBC 13, gastrointestinal, 2006/7
(1) Outcome
model
(2) Spend
model
(3) Outcome
model
(4) Spend
model
(5) Outcome
model
(6) Spend
model
(7) Outcome
model
(8) Spend
model
Lone pensioner households −0.590**
[0.295]
Constant 6.506*** 5.881*** 11.567*** 10.227*** 19.047*** 3.032 12.260*** 9.664***
[0.455] [1.778] [1.058] [2.387] [3.877] [1.977] [2.441] [3.046]
Endogeneity test statistic 15.173 20.248 43.405 25.854 27.876 7.863 21.853 13.607
Endogeneity p-value 9.81e-05 6.80e-06 0 3.68e-07 1.29e-07 0.00505 2.94e-06 0.000225
Hansen–Sargan test statistic 0.00201 0.306 1.440 0.530 1.912 0.344 1.011 0.0294
Hansen–Sargan p-value 0.964 0.580 0.696 0.467 0.167 0.557 0.315 0.864
Shea’s partial R2 0.164 0.445 0.300 0.296 0.0793 0.366 0.140 0.206
Kleibergen–Paap LM test statistic 17.85 42.38 32.37 32.70 10.42 36.33 14.86 19.07
Kleibergen–Paap p-value 0.000133 6.28e-10 1.61e-06 7.93e-08 0.00545 1.29e-08 0.000592 7.22e-05
Kleibergen–Paap F-statistic 13.28 48.32 17.14 25.71 7.390 24.32 11.63 8.660
Pesaran–Taylor reset statistic 0.00226 0.00178 0.0945 0.0215 3.139 1.908 0.266 0.0605
Pesaran–Taylor p-value 0.962 0.966 0.759 0.883 0.0764 0.167 0.606 0.806
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
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The outcome and expenditure elasticities are little changed from those presented in Table 59 and,
like those, these new elasticities can be used to calculate the cost of a life-year in each programme.
These calculations – for both these four programmes as well as for the other six programmes with a
mortality-based outcome indicator – are shown in Tables 63 and 64 (the full outcome and expenditure
models for the other six programmes with a mortality-based outcome indicator are not shown here).
The figures for 2006/7 in Table 63 (which incorporate two MFFs) can be compared with those for 2006/7
in Table 60 (which incorporate three MFFs). Table 63 reveals that the use of a different MFF has little
impact on the cost of a life-year for the big four PBCs (it was £11,298, it is now £10,783) as well as
on the cost of a life-year for all programmes with a mortality outcome measure (it was £21,743, it is
now £20,893).
In addition, Table 64 shows that if we assume that PBC 23 generates a zero health gain and that the gain
attributable to the remaining 12 programmes is, on average, the same as that attributable to those
with a mortality outcome measure, then the cost of a life-year across all programmes is now £23,697
(it was £25,038 for 2006/7 in Table 61).
The figures in Table 64 also reveal that the cost of a life-year in 2006/7 for all programmes (£23,697) is
little changed from the comparable figure for 2005/6 (£24,200).
Model estimation using 2006/7 expenditure data and mortality data for
2006/7/8: CARAN need and two market forces factors
One shortcoming with the models presented above is that they relate expenditure in 2006/7 to mortality in
the same period and in the two previous periods (i.e. in 2004, 2005 and 2006). The difficulty with this is
that one would expect expenditure in year t to affect mortality in year t and possibly subsequent years
(t + 1, t + 2, etc.) but not mortality in previous years (t – 1, t – 2, etc.). However, if we assume that PCTs
have reached some sort of equilibrium in the expenditure choices they make and the outcomes they
secure, so that expenditure levels change relatively little from one year to the next, then mortality over the
3-year period t, t – 1 and t – 2 might be a good proxy for mortality in t, t + 1 and t + 2. Indeed, this is
probably not an unreasonable assumption given the relatively slow pace at which both types of
variable change.
Although this assumption of equilibrium is not an unreasonable one, it is one that ideally we would like to
be able to drop. Fortunately, with the recent availability of more up-to-date mortality data, we have the
opportunity to relate expenditure in 2006 to mortality in the same year and in the two following years
(i.e. in 2006, 2007 and 2008).ac Thus, the models reported in Table 62 were re-estimated replacing the
mortality rate for 2004/5/6 with that for 2006/7/8. The outcome and expenditure results for the big four
programmes are shown in Table 65 with the relevant outcome and expenditure elasticities again
highlighted (the first-stage regressions associated with these results can be found in Table 96 in the
Annex). These elasticities are similar to those presented previously in Table 62 but there are some changes
(e.g. the outcome elasticity in the respiratory outcome equation falls from −2.839 to −2.029).
In all four outcome models expenditure has a significant negative effect on mortality and the all service
measure of need has a significant positive effect. The all service measure of need squared is also positive
and significant in the cancer outcome equation. In the respiratory outcome model, there is an additional
indicator of need – the proportion of the population that are permanently sick – and this is both positive
and statistically significant. The diagnostic statistics suggest that, in all four cases, own programme
expenditure is endogenous and that the instruments are valid. They also suggest that the instruments are
relevant. There is no evidence that the instruments are weak in three of the four outcome results. The
Pesaran–Taylor test suggests that there is no evidence of model misspecification.
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TABLE 63 Table showing cost of life and life-year estimates using spend data for 2006/7 (two MFFs) and outcome data for 2004/06 (assumes zero gain for 13 programmes)
(A)
PBC
scenario (B) PBC description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Average
annual
mortality,
<75 years,
2004/5/6
(G)
Outcome
elasticity
(H)
(=0.01×D×F×G)
change in
annual mortality
(I) (=E/H)
cost per life
gained (£)
(J) Total
life-years lost,
<75 years,
2004/5/6
(K)
(=0.01×D×G× J/3)
change in annual
life-years lost
(L) (=E/K)
cost per
YLG (£)
1 Cancer 4122 0.548 22.59 62,259 0.337 114.98 196,461 2,221,530 1368 16,518
2 Circulatory problems 6161 0.701 43.19 45,504 1.447 461.57 93,569 1,463,912 4950 8725
3 Respiratory problems 3285 0.718 23.59 11,601 3.507 292.12 80,743 321,264 2697 8747
4 Gastrointestinal problems 3700 0.667 24.68 5926 2.137 84.47 292,170 328,853 1562 15,795
5 Big four programmes 17,268 114.04 125,290 953.13 119,650 4,335,559 10,576 10,783
6 Big four programmes 2005/6 17,625 141.22 125,290 909.96 155,196 4,516,953 10,986 12,855
7 Infectious diseases 1053 0.731 7.70 2050 0.03 0.45 17,121,951 101,604 7 1,036,377
8 Endocrine problems 1852 0.966 17.89 1690 0.812 13.26 1,349,579 60,615 158 112,882
9 Neurological problems 2790 0.648 18.08 729 0.098 0.46 39,052,658 68,808 15 1,241,253
10 Genitourinary problems 3482 0.837 29.14 294 0.073 0.18 162,240,239 11,554 2 12,384,965
11 Trauma and injuries 2892 0.617 17.84 1037 0.527 3.37 5,291,867 30,000 33 548,767
12 Maternity and neonates 3574 0.601 21.48 2123 0.035 0.45 48,099,051 484,950 34 631,700
13 Other six programmes 15,643 112.13 7923 18.17 6,172,491 757,531 249 449,706
14 Other six programmes 2005/6 12,743 99.44 7923 16.26 6,115,621 751,009 337 295,074
15 All 10 programmes 32,911 0.687 226.18 133,213 971.30 232,861 5,093,090 10,826 20,893
16 All 10 programmes 2005/6 30,368 0.792 240.67 133,213 926.22 259,838 5,267,962 11,322 21,256
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(A)
PBC
scenario (B) PBC description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Average
annual
mortality,
<75 years,
2004/5/6
(G)
Outcome
elasticity
(H)
(=0.01×D×F×G)
change in
annual mortality
(I) (=E/H)
cost per life
gained (£)
(J) Total
life-years lost,
<75 years,
2004/5/6
(K)
(=0.01×D×G× J/3)
change in annual
life-years lost
(L) (=E/K)
cost per
YLG (£)
Assume zero health gain in the other 13 programmes
18 Other 13 programmes 34,985 1.294 452.78 0.00 0
19 Other 13 programmes 2005/6 33,942 1.186 402.43 0.00 0
20 All 23 programmes 67,896 678.96 971.30 699,024 10,826 62,718
21 All 23 programmes 2005/6 64,310 643.10 926.22 694,330 11,322 56,799
Note
Italicised text shows estimates reported previously in Table 44.
All 23 programmes spend: 2006/7 £67,896; 2005/6 £64,310.
% change in budget: 2006/7 1.00%; 2005/6 1.00%.
Proportionate change: 2006/7 0.01; 2005/6 0.01.
Change in budget: 2006/7 £678.96; 2005/6 £643.10.
Annual mortality figures reported in cells F5 and F6 ,and F13 and F14 are identical because we do not have mortality data for 2002/3/4.
For 2006/7, the neonate category has been merged with maternity to obtain plausible outcome and expenditure models.
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TABLE 64 Table showing cost of life and life-year estimates using spend data for 2006/7 (two MFFs) and outcome data for 2004/06 (assumes some gain in other
13 programmes)
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(= 0.01 × C ×D)
change in
spend (£M)
(F) Average
annual
mortality,
< 75 years,
2004/5/6
(G)
Outcome
elasticity
(H) (= 0.01 ×
D× F ×G)
change in
annual
mortality
(I) (= E/H)
cost per life
gained (£)
(J) Total life-
years lost,
< 75 years,
2004/5/6
(K) (= 0.01 ×
D×G× J/3)
change in
annual
life-years
lost
(L) (= E/K)
cost per
YLG (£)
1 Cancer 4122 0.548 22.59 62,259 0.337 114.98 196,461 2,221,530 1368 16,518
2 Circulatory
problems
6161 0.701 43.19 45,504 1.447 461.57 93,569 1,463,912 4950 8725
3 Respiratory
problems
3285 0.718 23.59 11,601 3.507 292.12 80,743 321,264 2697 8747
4 Gastrointestinal
problems
3700 0.667 24.68 5926 2.137 84.47 292,170 328,853 1562 15,795
5 Big four
programmes
17,268 114.04 125,290 953.13 119,650 4,335,559 10,576 10,783
6 Big four
programmes
2005/6
17,625 141.22 125,290 909.96 155,196 4,516,953 10,986 12,855
7 Infectious
diseases
1053 0.731 7.70 2050 0.03 0.45 17,121,951 101,604 7 1,036,377
8 Endocrine
problems
1852 0.966 17.89 1690 0.812 13.26 1,349,579 60,615 158 112,882
9 Neurological
problems
2790 0.648 18.08 729 0.098 0.46 39,052,658 68,808 15 1,241,253
10 Genitourinary
problems
3482 0.837 29.14 294 0.073 0.18 162,240,239 11,554 2 12,384,965
11 Trauma
and injuries
2892 0.617 17.84 1037 0.527 3.37 5,291,867 30,000 33 548,767
12 Maternity and
neonates
3574 0.601 21.48 2123 0.035 0.45 48,099,051 484,950 34 631,700
13 Other six
programmes
15,643 112..13 7923 18.17 6,172,491 757,531 249 449,706
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(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(= 0.01 × C ×D)
change in
spend (£M)
(F) Average
annual
mortality,
< 75 years,
2004/5/6
(G)
Outcome
elasticity
(H) (= 0.01 ×
D× F ×G)
change in
annual
mortality
(I) (= E/H)
cost per life
gained (£)
(J) Total life-
years lost,
< 75 years,
2004/5/6
(K) (= 0.01 ×
D×G× J/3)
change in
annual
life-years
lost
(L) (= E/K)
cost per
YLG (£)
14 Other six
programmes
2005/6
12,743 99.44 7923 16.26 6,115,621 751,009 337 295,074
15 All 10
programmes
32,911 0.687 226.18 133,213 971.30 232,861 5,093,090 10,826 20,893
16 All 10
programmes
2005/6
30,368 0.792 240.67 133,213 926.22 259,838 5,267,962 11,322 21,256
Assume zero health gain in PBC 23, and gain in 10 PBCs applies to other 12 PBCs
17 PBC 23 10,585 0.759 80.34 0.00 0.00
18 PBC 23 2005/6 8449 0.926 78.24 0.00 0.00
19 Other 12
programmes
24,400 372.44 1,599.42 232,861 17,826 20,893
20 Other 12
programmes
2005/6
25,493 324.20 1,247.69 259,838 15,252 21,256
21 All 23
programmes
67,896 678.96 2,570.72 264,113 28,652 23,697
22 All 23
programmes
2005/6
64,310 643.10 2,173.90 295,827 26,575 24,200
Note
Italicised text shows estimates reported previously in Table 44.
All 23 programmes spend: 2006/7 £67,896; 2005/6 £64,310.
% change in budget: 2006/7 1.00%; 2005/6 1.00%.
Proportionate change: 2006/7 0.01; 2005/6 0.01.
Change in budget: 2006/7 £678.96; 2005/6 £643.10.
Annual mortality figures reported in cells G5 and G6 ,and G13 and G14 are identical because we do not have mortality data for 2002/3/4.
For 2006/7, the neonate category has been merged with maternity to obtain plausible outcome and expenditure models.
D
O
I:
1
0
.3
3
1
0
/h
ta
1
9
1
4
0
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
5
V
O
L.
1
9
N
O
.
1
4
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
5
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
C
la
xto
n
et
al.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
2
3
5
TABLE 65 Table showing outcome and expenditure models for the big four programmes using spend data for 2006/7 (two MFFs) and mortality data for 2006/7/8
Variable
PBC 2 cancer PBC 10 circulation PBC 11 respiratory PBC 13 gastrointestinal
(1)
Outcome
model
(2)
Spend model
(3)
Outcome
model
(4)
Spend model
(5)
Outcome
model
(6)
Spend model
(7)
Outcome
model
(8)
Spend model
Own programme spend per head −0.342*** −1.434*** −2.029*** −1.536***
[0.099] [0.218] [0.636] [0.468]
Need CARAN per head 0.995*** 1.626*** 2.860*** 2.306*** 2.696*** 1.449*** 4.160*** 2.040***
[0.106] [0.343] [0.252] [0.372] [1.044] [0.331] [0.577] [0.378]
Need CARAN per head squared 1.163*** 2.451
[0.348] [1.561]
SYLLR all deaths excluding cancer −0.855***
[0.191]
PCT budget per head 0.465 0.540* 0.679*** 0.446*
[0.300] [0.299] [0.251] [0.263]
SYLLR all deaths excluding
circulatory
−1.666***
[0.295]
Permanently sick 0.759**
[0.367]
SYLLR all deaths excluding
respiratory
−0.672**
[0.305]
SYLLR all deaths excluding
gastrointestinal
−1.206***
[0.314]
Lone pensioner households
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Variable
PBC 2 cancer PBC 10 circulation PBC 11 respiratory PBC 13 gastrointestinal
(1)
Outcome
model
(2)
Spend model
(3)
Outcome
model
(4)
Spend model
(5)
Outcome
model
(6)
Spend model
(7)
Outcome
model
(8)
Spend model
Constant 6.501*** 5.913*** 11.413*** 10.696*** 13.756*** 3.346 9.719*** 8.370***
[0.436] [2.815] [1.046] [2.379] [3.279] [2.075] [2.009] [2.299]
Endogeneity test statistic 13.695 19.421 42.548 24.461 17.687 8.439 16.373 15.211
Endogeneity p-value 0.000215 1.05e-05 6.90e-11 7.58e-07 2.60e-05 0.00367 5.20e-05 9.61e-05
Hansen–Sargan test statistic 0.685 0.021 0.949 1.262 1.462 0.302 2.761 0.0164
Hansen–Sargan p-value 0.408 0.084 0.814 0.261 0.227 0.583 0.0966 0.0898
Shea’s partial R2 0.164 0.445 0.300 0.296 0.0785 0.327 0.140 0.356
Kleibergen–Paap LM test statistic 17.85 41.88 32.37 32.02 10.02 34.98 14.86 35.72
Kleibergen–Paap p-value 0.000133 8.04e-10 1.61e-06 1.11e-07 0.00666 2.54e-08 0.000592 1.75e-08
Kleibergen–Paap F-statistic 13.28 56.69 17.14 31.84 7.022 20.94 11.63 22.40
Pesaran–Taylor reset statistic 0.00537 0.18 0.136 0.00349 0.0120 1.497 1.669 0.007
Pesaran–Taylor p-value 0.942 0.668 0.712 0.953 0.913 0.221 0.196 0.935
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
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However, the Kleibergen–Paap F-statistic for the respiratory disease outcome model is 7.022 and this is
less than the ‘critical’ target of 10.0. This indicates that the instruments may be weak. However, if we
re-estimate this model having dropped the least significant instrument, the coefficient on own programme
expenditure is now −2.622 and this is significant at the 1% level. Moreover, there is now no evidence of
weak instruments (the Kleibergen–Paap F-statistic is 11.025) and it is this coefficient that we use for the
respiratory outcome model in the cost of a life-year calculations below.
In three of the four expenditure models both the need and budget variables have a positive and significant
effect on own programme expenditure. In addition, the proxy for need in other programmes is negative
and significant in all four cases. The diagnostic statistics suggest that, for all four expenditure models,
expenditure is endogenous and the instruments are valid. They also suggest that the instruments are
relevant and there is no evidence that the instruments are weak. The Pesaran–Taylor test suggests that
there is no evidence of model misspecification.
The outcome and expenditure elasticities presented in Table 65 can be used to calculate the cost of a
life-year in each programme. These calculations – for both the big four programmes as well as for the
other six programmes with mortality-based outcome indicators – are shown in Table 66. They show that
the use of a more appropriate measure of mortality (i.e. for 2006/7/8 rather than for 2004/5/6) slightly
increases the cost of a life-year for the big four PBCs (from £10,783 to £12,333) as well as for all 10
programmes with a mortality outcome measure (from £20,893 to £23,780).
In addition, Table 67 shows that if we assume that PBC 23 generates a zero health gain and that the
gain attributable to the remaining 12 programmes is, on average, the same as that attributable to those
with a mortality outcome measure, then the cost of a life-year across all programmes is now £26,876
(it was £23,697 using mortality for 2004/5/6).
APPENDIX 2
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TABLE 66 Table showing cost of life and life-year estimates using spend data for 2006/7 and outcome data for 2006/7/8 (assumes zero health gain for 13 programmes)
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(= 0.01 × C×D)
change in
spend (£M)
(F) Annual
mortality,
< 75 years,
2006/7/8
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(= 0.01 ×D× F ×G)
change in
annual mortality
(I) (= E/H)
cost per life
gained (£)
(J) Total
life-years
lost,
< 75 years,
2006/7/8
(K)
(= 0.01 ×D×G× J/3)
change in annual
life-years lost
(L) (= E/K)
cost per
YLG (£)
1 Cancer 4122 0.465 19.17 61,961 0.342 98.54 194,520 2,207,021 1170 16,383
2 Circulatory
problems
6161 0.540 33.27 41,106 1.434 318.31 104,519 1,361,634 3515 9466
3 Respiratory
problems
3285 0.679 22.31 11,574 2.622 206.06 108,248 324,223 1924 11,593
4 Gastrointestinal
problems
3700 0.446 16.50 6160 1.536 42.20 391,048 345,908 790 20,892
Big four programmes summary
5 Spend 2006
and mortality
2006/7/8
17,268 91.24 120,801 665.10 137,188 4,238,786 7399 12,333
6a Spend 2006
and mortality
2004/5/6
17,268 114.04 125,290 953.13 119,650 4,335,559 10,576 10,783
7b Spend 2005
and mortality
2002/3/4
17,625 141.22 125,290 909.96 155,196 4,516,953 10,986 12,855
8 Infectious
diseases
1053 0.792 8.34 2050 0.047 0.76 10,928,905 106,552 13 630,798
9 Endocrine
problems
1852 0.953 17.65 1542 0.842 12.37 1,426,410 57,672 154 114,416
10 Neurological
problems
2790 0.616 17.19 727 0.112 0.50 34,265,082 66,137 15 1,129,960
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TABLE 66 Table showing cost of life and life-year estimates using spend data for 2006/7 and outcome data for 2006/7/8 (assumes zero health gain for
13 programmes) (continued )
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(= 0.01 × C×D)
change in
spend (£M)
(F) Annual
mortality,
< 75 years,
2006/7/8
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(= 0.01 ×D× F ×G)
change in
annual mortality
(I) (= E/H)
cost per life
gained (£)
(J) Total
life-years
lost,
< 75 years,
2006/7/8
(K)
(= 0.01 ×D×G× J/3)
change in annual
life-years lost
(L) (= E/K)
cost per
YLG (£)
11 Genitourinary
problems
3482 0.912 31.76 294 0.051 0.14 232,226,224 10,030 2 20,421,090
12 Trauma and
injuries
2892 0.358 10.35 1037 0 0.00 N/A 30,000 0 N/A
13 Maternity and
neonates
3574 0.224 8.01 2189 0.482 2.36 3,387,363 492,600 177 45,158
Other six programmes summary
14 Spend 2006
and mortality
2006/7/8
15,643 93.29 7839 16.14 5,780,723 762,991 362 258,046
15a Spend 2006
and mortality
2004/5/6
15,643 112.13 7923 18.17 6,172,491 757,531 249 449,706
16b Spend 2005
and mortality
2002/3/4
12,743 99.44 7923 16.26 6,115,621 751,009 337 295,074
All 10 programmes summary
17 Spend 2006
and mortality
2006/7/8
32,911 0.561 184.53 128,640 681.24 270,881 5,001,777 7760 23,780
18a Spend 2006
and mortality
2004/5/6
32,911 0.687 226.18 133,213 971.30 232,861 5,093,090 10,826 20,893
19b Spend 2005
and mortality
2002/3/4
30,368 0.792 240.67 133,213 926.22 259,838 5,267,962 11,322 21,256
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(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(= 0.01 × C×D)
change in
spend (£M)
(F) Annual
mortality,
< 75 years,
2006/7/8
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(= 0.01 ×D× F ×G)
change in
annual mortality
(I) (= E/H)
cost per life
gained (£)
(J) Total
life-years
lost,
< 75 years,
2006/7/8
(K)
(= 0.01 ×D×G× J/3)
change in annual
life-years lost
(L) (= E/K)
cost per
YLG (£)
Assume zero health gain in the other 13 programmes: other 13 programmes summary
20 Spend 2006
and mortality
2006/7/8
34,985 1.413 494.43 0.00 0
21a Spend 2006
and mortality
2004/5/6
34,985 1.294 452.78 0.00 0
22b Spend 2005
and mortality
2002/3/4
33,942 1.186 402.43 0.00 0
All 23 programmes
23 Spend 2006
and mortality
2006/7/8
67,896 678.96 681.24 996,655 7760 87,494
24a Spend 2006
and mortality
2004/5/6
67,896 678.96 971.30 699,024 10,826 62,718
25b Spend 2005
and mortality
2002/3/4
64,310 643.10 926.22 694,330 11,322 56,799
N/A, not applicable.
a Estimate reported previously in Table 63.
b Estimate reported previously in Table 44.
Note
All 23 programmes spend: 2006/7 £67,896; 2005/6 £64,310.
% change in budget: 2006/7 1.00%; 2005/6 1.00%.
Proportionate change: 2006/7 0.01; 2005/6 0.01.
Change in budget: 2006/7 £678.96; 2005/6 £643.10.
Annual mortality figures reported in cells F6 and F7, and F15 and F16 are identical because we do not have mortality data for 2002/3/4.
We have been unable to obtain a satisfactory outcome model for trauma and injuries and have assumed a zero outcome elasticity.
For expenditure in 2006/7, the neonate category has been merged with maternity to obtain plausible outcome and expenditure models.
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TABLE 67 Table showing cost of life and life-year estimates using spend data for 2006/7 and outcome data for 2006/7/8 (assumes average health gain for
12 other programmes)
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(= 0.01 × C ×D)
change in
spend (£M)
(F) Annual
mortality,
< 75 years,
2006/7/8
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(= 0.01 ×D× F ×G)
change in
annual mortality
(I) (= E/H)
cost per life
gained (£)
(J) Total
life-years
lost,
< 75 years,
2006/7/8
(K)
(= 0.01 ×D×G× J/3)
change in annual
life-years lost
(L) (= E/K)
cost per
YLG (£)
1 Cancer 4122 0.465 19.17 61,961 0.342 98.54 194,520 2,207,021 1170 16,383
2 Circulatory
problems
6161 0.540 33.27 41,106 1.434 318.31 104,519 1,361,634 3515 9466
3 Respiratory
problems
3285 0.679 22.31 11,574 2.622 206.06 108,248 324,223 1924 11,593
4 Gastrointestinal
problems
3700 0.446 16.50 6160 1.536 42.20 391,048 345,908 790 20,892
Big four programmes summary
5 Spend 2006
and mortality
2006/7/8
17,268 91.24 120,801 665.10 137,188 4,238,786 7399 12,333
6a Spend 2006
and mortality
2004/5/6
17,268 114.04 125,290 953.13 119,650 4,335,559 10,576 10,783
7b Spend 2005
and mortality
2002/3/4
17,625 141.22 125,290 909.96 155,196 4,516,953 10,986 12,855
8 Infectious
diseases
1053 0.792 8.34 2050 0.047 0.76 10,928,905 106,552 13 630,798
9 Endocrine
problems
1852 0.953 17.65 1542 0.842 12.37 1,426,410 57,672 154 114,416
10 Neurological
problems
2790 0.616 17.19 727 0.112 0.50 34,265,082 66,137 15 1,129,960
11 Genitourinary
problems
3482 0.912 31.76 294 0.051 0.14 232,226,224 10,030 2 20,421,090
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(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(= 0.01 × C ×D)
change in
spend (£M)
(F) Annual
mortality,
< 75 years,
2006/7/8
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(= 0.01 ×D× F ×G)
change in
annual mortality
(I) (= E/H)
cost per life
gained (£)
(J) Total
life-years
lost,
< 75 years,
2006/7/8
(K)
(= 0.01 ×D×G× J/3)
change in annual
life-years lost
(L) (= E/K)
cost per
YLG (£)
12 Trauma and
injuries
2892 0.358 10.35 1037 0 0.00 N/A 30,000 0 N/A
13 Maternity and
neonates
3574 0.224 8.01 2189 0.482 2.36 3,387,363 492,600 177 45,158
Other six programmes summary
14 Spend 2006
and mortality
2006/7/8
15,643 93.29 7839 16.14 5,780,723 762,991 362 258,046
15a Spend 2006
and mortality
2004/5/6
15,643 112.13 7923 18.17 6,172,491 757,531 249 449,706
16b Spend 2005
and mortality
2002/3/4
12,743 99.44 7923 16.26 6,115,621 751,009 337 295,074
All 10 programmes summary
17 Spend 2006
and mortality
2006/7/8
32,911 0.561 184.53 128,640 681.24 270,881 5,001,777 7760 23,780
18a Spend 2006
and mortality
2004/5/6
32,911 0.687 226.18 133,213 971.30 232,861 5,093,090 10,826 20,893
19b Spend 2005
and mortality
2002/3/4
30,368 0.792 240.67 133,213 926.22 259,838 5,267,962 11,322 21,256
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TABLE 67 Table showing cost of life and life-year estimates using spend data for 2006/7 and outcome data for 2006/7/8 (assumes average health gain for
12 other programmes) (continued )
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(= 0.01 × C ×D)
change in
spend (£M)
(F) Annual
mortality,
< 75 years,
2006/7/8
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(= 0.01 ×D× F ×G)
change in
annual mortality
(I) (= E/H)
cost per life
gained (£)
(J) Total
life-years
lost,
< 75 years,
2006/7/8
(K)
(= 0.01 ×D×G× J/3)
change in annual
life-years lost
(L) (= E/K)
cost per
YLG (£)
Other 13 PBCs? Assume zero health gain in PBC 23 . . .
20 PBC 23: spend
2006 and
mortality
2006/7/8
10,585 0.739 78.22 0.00 0.00
21 PBC 23: spend
2006 and
mortality
2004/5/6
10,585 0.759 80.34 0.00 0.00
22 PBC 23: spend
2005 and
mortality
2002/3/4
8449 0.926 78.24 0.00 0.00
. . . and that the gain in 10 PBCs (see above) applies to the remaining 12 PBCs
23 12 PBCs: spend
2006 and
mortality
2006/7/8
24,400 416.20 1536.48 270,881 17,502 23,780
24a 12 PBCs: spend
2006 and
mortality
2004/5/6
24,400 372.44 1599.42 232,861 17,826 20,893
25b 12 PBCs: spend
2005 and
mortality
2002/3/4
25,493 324.20 1247.69 259,838 15,252 21,256
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(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(= 0.01 × C ×D)
change in
spend (£M)
(F) Annual
mortality,
< 75 years,
2006/7/8
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(= 0.01 ×D× F ×G)
change in
annual mortality
(I) (= E/H)
cost per life
gained (£)
(J) Total
life-years
lost,
< 75 years,
2006/7/8
(K)
(= 0.01 ×D×G× J/3)
change in annual
life-years lost
(L) (= E/K)
cost per
YLG (£)
All 23 programmes
26 23 PBCs: spend
2006 and
mortality
2006/7/8
67,896 678.96 2217.72 306,153 25,262 26,876
27a All 23 PBCs:
spend 2006
and mortality
2004/5/6
67,896 678.96 2570.72 264,113 28,652 23,697
28b All 23 PBCs:
spend 2005
and mortality
2002/3/4
64,310 643.10 2173.90 295,827 26,575 24,200
N/A, not applicable.
a Estimate reported previously in Table 63.
b Estimate reported previously in Table 44.
Note
All 23 programmes spend: 2006/7 £67,896; 2005/6 £64,310.
% change in budget: 2006/7 1.00%; 2005/6 1.00%.
Proportionate change: 2006/7 0.01; 2005/6 0.01.
Change in budget: 2006/7 £678.96; 2005/6 £643.10.
Annual mortality figures reported in cells F5 and F6, and F13 and F14 are identical because we do not have mortality data for 2002/3/4.
For expenditure in 2006/7, the neonate category has been merged with maternity to obtain plausible outcome and expenditure models.
D
O
I:
1
0
.3
3
1
0
/h
ta
1
9
1
4
0
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
5
V
O
L.
1
9
N
O
.
1
4
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
5
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
C
la
xto
n
et
al.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
2
4
5
Adjusting the cost of life (year) estimates for the mismatch in the ICD-10
coverage of the expenditure and the mortality data
The cost of a life (year) estimates presented in Tables 66 and 67 assume a 1% increase in each PCT’s
budget and are calculated as:
the cost of an additional life in a particular programme
¼ the change in expenditure in that programme=the change in mortality in that programme
¼ (annual spend expenditure elasticity)=(annual mortality outcome elasticity expenditure elasticity)
and
the cost of an additional life-year in a particular programme
¼ the change in expenditure in that programme=the change in life-year lost in that programme
¼ (annual spend expenditure elasticity)=(annual mortality outcome elasticity expenditure elasticity)
Thus, an integral part of the calculation of the cost of a life (year) is the annual mortality (life-years lost)
figure associated with a particular programme. Ideally, the ICD-10 coverage of the expenditure data should
coincide with that of the mortality data but, as we know from Table 37, the ICD-10 coverage of the
mortality data typically falls short of that for the expenditure data. Unless we adjust the annual mortality
figure so that its ICD-10 coverage approximates that of the expenditure data, our cost of life (year)
estimates will usually be too large because they will usually underestimate the mortality gain.
Table 68 reproduces Table 66 but incorporates this ICD-10 coverage adjustment [see columns (J) and (O) in
Table 68]. This adjustment reduces the cost of a life-year:
l for the big four programmes from £12,333 to £10,604
l for the 10 programmes with a mortality-based outcome indicator from £23,780 to £19,965
l for all programmes assuming a zero gain for the 13 PBCs without an outcome indicator from £87,494
to £73,457.
Similarly, Table 69 reproduces Table 67 but incorporates this ICD-10 coverage adjustment [see columns (J)
and (O) in Table 69]. If we assume a zero health gain in PBC 23 and an average gain in the other
12 PBCs without a mortality-based outcome indicator, then this adjustment reduces the cost of a life-year
for all programmes from £26,876 to £22,565.
Adjusting the cost of life (year) estimates for Department of Health-funded
expenditure that is not undertaken by primary care trusts
Primary care trust expenditure accounts for a large proportion of Department of Health expenditure but
PCTs do not account for all of the Department of Health’s budget. In 2006/7 the Department of Health’s
gross expenditure totalled £83.5B. Charges raised £3.4B so net expenditure totalled £80.1B. Of this net
expenditure, PCTs accounted for £67.3B (that is, 84%) and various other bodies accounted for the
remaining £12.8B. A breakdown of this gross and net expenditure by major body is shown in Table 70.
The Department of Health has allocated net non-PCT expenditure across the 23 PBCs and the impact of
this allocation on total spend by PBC is shown in Table 71. No geographic breakdown (e.g. by PCT) of this
expenditure is available.
Of the additional £12B of net expenditure, £11.2B (93%) has been allocated to PBC 23. This largely
reflects (a) the allocation of almost all SHA expenditure to either PBC 23B (‘other: SHAs including
workforce development committees’) or PBC 23X (‘other: miscellaneous’); and (b) the allocation of almost
two-thirds of Department of Health expenditure to PBC 23X (‘other: miscellaneous’).
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
246
The remaining £0.8B of additional net expenditure is spread across all PBCs according to various allocation
rules. For example, the majority of expenditure on Special Health Authorities is apportioned across
programme categories on the basis of the PCT and SHA expenditure breakdown. The exception is the NHS
Business Services Authority expenditure which is apportioned on the basis of primary care prescribing
expenditure splits. Although this approach avoids allocating expenditure to the ‘other: miscellaneous’
category, this allocation of expenditure does not necessarily reflect actual expenditure. For example, NHS
Litigation Authority expenditure may not be incurred in the same areas as overall PCT expenditure.34
It is clear that most of the non-PCT expenditure is not specific to any disease area and that, to avoid
putting all of it into a residual category, the Department of Health has identified what are reasonable, but
largely arbitrary, rules to spread what is a relatively small proportion of this non-PCT expenditure across
all PBCs.
The cost of a life (year) estimates presented above are based on the impact of a 1% exogenous change in
total net PCT spend. All of our outcome and expenditure models have been estimated using net PCT
expenditure, and all of our elasticities relate to this expenditure. Implicitly we assume that any budgetary
shock only affects PCT funding and that it leaves non-PCT funding unchanged.
Suppose instead we assume a 1% exogenous change in the Departmental budget. How might this
budgetary shock be split between PCT and non-PCT expenditure? There are two obvious options to
consider. We could assume either (a) that all of this change is applied to PCT budgets and that there is no
change in the non-PCT budget (as we do implicitly at the moment); or (b) that the budgetary shock affects
both PCT and non-PCT budgets.
If the non-PCT budget is wholly unresponsive to the exogenous shock then our cost of a life-year estimates
will be unchanged because this expenditure category attracts none of the budgetary change (although this
expenditure will clearly contribute to a measure of average productivity).
If the non-PCT budget is to some degree responsive to the exogenous shock then it will affect our cost of
a life-year estimates. To calculate the size of this impact we would need to know:
(a) how responsive the non-PCT budget is to a total Departmental budgetary shock
(b) how the responsive part of the non-PCT budget is allocated across PBCs; and
(c) the size of the health effects associated with changes in the non-PCT budget at PBC level.
We have no evidence on how responsive the non-PCT budget is likely to be to a total budgetary shock.
However, from Table 71 and the discussion about the rather arbitrary (but understandable) rules employed
by the Department of Health to allocate non-PCT expenditure to PBCs, it would seem reasonable to
assume that any change in the non-PCT budget should all be allocated to PBC 23. This ‘solves’ the
problem of identifying the health gains associated with this change in the non-PCT budget because, in our
cost of a life-year calculations, we assume that expenditure in this category attracts no health gains.
Thus, although we have no evidence on how responsive the non-PCT budget is likely to be to a total
budgetary shock, we can present two scenarios. In the first scenario, the non-PCT budget is wholly
unresponsive to a budgetary shock and any budgetary change is fully implemented via PCT expenditure.
In this case, there is no impact on the cost of a life-year.
In the second scenario, one might assume that the non-PCT budget is as responsive to Departmental
budgetary changes as is the PCT budget. In this case a 1% change in the Departmental budget is
translated into a 1% change in both the total PCT and total non-PCT budgets, and this will increase the
cost of a life-year by 17.7% for 2006/7, that is, from £22,565 to £26,553. This percentage increase is, of
course, the same figure as total non-PCT expenditure expressed as a percentage of PCT expenditure.
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TABLE 68 Table showing cost of life and life-year estimates using expenditure data for 2006 and outcome data
for 2006/7/8 (assumes zero health gain for 13 programmes) adjusted for the ICD-10 coverage of the expenditure
and outcome data
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F)Annual
mortality,
<75 years,
2006/7/8
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in
annual mortality
(I) (=E/H)
cost per life
gained (£)
1 Cancer 4122 0.465 19.17 61,961 0.342 98.54 194,520
2 Circulatory
problems
6161 0.540 33.27 41,106 1.434 318.31 104,519
3 Respiratory
problems
3285 0.679 22.31 11,574 2.622 206.06 108,248
4 Gastrointestinal
problems
3700 0.446 16.50 6160 1.536 42.20 391,048
Big four programmes summary
5 Spend 2006
and mortality
2006/7/8
17,268 91.24 120,801 665.10 137,188
6 Spend 2006
and mortality
2004/5/6
17,268 114.04 125,290 953.13 119,650
7 Spend 2005
and mortality
2002/3/4
17,625 141.22 125,290 909.96 155,196
8 Infectious
diseases
1053 0.792 8.34 2050 0.047 0.76 10,928,905
9 Endocrine
problems
1852 0.953 17.65 1542 0.842 12.37 1,426,410
10 Neurological
problems
2790 0.616 17.19 727 0.112 0.50 34,265,082
11 Genitourinary
problems
3482 0.912 31.76 294 0.051 0.14 232,226,224
12 Trauma
and injuries
2892 0.358 10.35 1037 0 0.00 N/A
13 Maternity
and neonates
3574 0.224 8.01 2189 0.482 2.36 3,387,363
Other six programmes summary
14 Spend 2006
and mortality
2006/7/8
15,643 93.29 7839 16.14 5,780,723
15 Spend 2006
and mortality
2004/5/6
15,643 112.13 7923 18.17 6,172,491
16 Spend 2005
and mortality
2002/3/4
12,743 99.44 7923 16.26 6,115,621
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(J)
Coverage
of
mortality
data
relative
to
spend
data
(K) (=H/J)
change in
annual
mortality
adjusted
for
coverage
(L) (=E/K)
cost per
life gained
(£)
adjusted
for
coverage
(M) Total
life-years
lost,
<75 years,
2006/7/8
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage
of
mortality
data
relative to
spend
data
(P) (=N/O)
change in
annual
life-years
lost
adjusted
for YLL
(Q) (=E/N)
cost per
YLG (£)
(R) (=E/P)
Cost per
YLG
adjusted
for YLL
coverage
(£)
0.984 100.14 191,407 2,207,021 1170 0.984 1189 16,383 16,121
0.992 320.88 103,683 1,361,634 3515 0.992 3543 9466 9390
0.773 262.57 83,676 324,223 1924 0.773 2489 11,593 8961
0.571 73.90 223,288 345,908 790 0.571 1383 20,892 11,929
761.49 119,823 4,238,786 7399 8604 12,333 10,604
4,335,559 10,576 10,783
4,516,953 10,986 12,855
1.000 0.76 10,928,905 106,552 13 1.000 13 630,798 630,798
0.634 19.52 904,344 57,672 154 0.634 243 114,416 72,539
0.136 3.69 4,660,051 66,137 15 0.136 112 1,129,960 153,675
0.172 0.80 39,942,910 10,030 2 0.172 9 20,421,090 3,512,427
0.175 0.00 N/A 30,000 0 0.175 0 N/A N/A
8.213 0.29 27,820,413 492,600 177 0.679 261 45,158 30,662
25.05 3,724,129 762,991 362 639 258,046 146,108
757,531 249 449,706
751,009 337 295,074
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TABLE 68 Table showing cost of life and life-year estimates using expenditure data for 2006 and outcome data
for 2006/7/8 (assumes zero health gain for 13 programmes) adjusted for the ICD-10 coverage of the expenditure
and outcome data (continued )
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F)Annual
mortality,
<75 years,
2006/7/8
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in
annual mortality
(I) (=E/H)
cost per life
gained (£)
All 10 programmes summary
17 Spend 2006
and mortality
2006/7/8
32,911 0.561 184.53 128,640 681.24 270,881
18 Spend 2006
and mortality
2004/5/6
32,911 0.687 226.18 133,213 971.30 232,861
19 Spend 2005
and mortality
2002/3/4
30,368 0.792 240.67 133,213 926.22 259,838
Assume zero health gain in the other 13 programmes: other 13 programmes summary
20 Spend 2006
and mortality
2006/7/8
34,985 1.413 494.43 0.00
21 Spend 2006
and mortality
2004/5/6
34,985 1.294 452.78 0.00
22 Spend 2005
and mortality
2002/3/4
33,942 1.186 402.43 0.00
All 23 programmes
23 Spend 2006
and mortality
2006/7/8
67,896 678.96 681.24 996,655
24 Spend 2006
and mortality
2004/5/6
67,896 678.96 971.30 699,024
25 Spend 2005
and mortality
2002/3/4
64,310 643.10 926.22 694,330
N/A, not applicable.
Note
All 23 programmes spend: 2006/7 £67,896; 2005/6 £64,310.
% change in budget: 2006/7 1.00%; 2005/6 1.00%.
Proportionate change: 2006/7 0.01; 2005/6 0.01.
Change in budget: 2006/7 £678.96; 2005/6 £643.10.
Annual mortality figures reported in cells F6 and F7, and F15 and F16 are identical because we do not have
mortality data for 2002/3/4.
We have been unable to obtain a satisfactory outcome model for trauma and injuries and have assumed a zero
outcome elasticity.
For expenditure in 2006/7, the neonate category has been merged with maternity to obtain plausible outcome and
expenditure models.
The adjustment for the coverage of the YLL data relative to the spend data uses deaths under age 75 years in
England in 2008.
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(J)
Coverage
of
mortality
data
relative
to
spend
data
(K) (=H/J)
change in
annual
mortality
adjusted
for
coverage
(L) (=E/K)
cost per
life gained
(£)
adjusted
for
coverage
(M) Total
life-years
lost,
<75 years,
2006/7/8
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage
of
mortality
data
relative to
spend
data
(P) (=N/O)
change in
annual
life-years
lost
adjusted
for YLL
(Q) (=E/N)
cost per
YLG (£)
(R) (=E/P)
Cost per
YLG
adjusted
for YLL
coverage
(£)
786.54 234,617 5,001,777 7760 9243 23,780 19,965
5,093,090 10,826 20,893
5,267,962 11,322 21,256
0 0
0
0
786.54 863,228 7760 9243 87,494 73,457
10,826 62,718
11,322 56,799
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TABLE 69 Table showing cost of life and life-year estimates using expenditure data for 2006 and outcome
data for 2006/7/8 (assumes average health gain for 12 other programmes) adjusted for the ICD-10 coverage
of the expenditure and outcome data
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Annual
mortality,
<75 years,
2006/7/8
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in
annual mortality
(I) (=E/H)
cost per life
gained (£)
1 Cancer 4122 0.465 19.17 61,961 0.342 98.54 194,520
2 Circulatory
problems
6161 0.540 33.27 41,106 1.434 318.31 104,519
3 Respiratory
problems
3285 0.679 22.31 11,574 2.622 206.06 108,248
4 Gastrointestinal
problems
3700 0.446 16.50 6160 1.536 42.20 391,048
Big four programmes summary
5 Spend 2006
and mortality
2006/7/8
17,268 91.24 120,801 665.10 137,188
6 Spend 2006
and mortality
2004/5/6
17,268 114.04 125,290 953.13 119,650
7 Spend 2005
and mortality
2002/3/4
17,625 141.22 125,290 909.96 155,196
8 Infectious
diseases
1053 0.792 8.34 2050 0.047 0.76 10,928,905
9 Endocrine
problems
1852 0.953 17.65 1542 0.842 12.37 1,426,410
10 Neurological
problems
2790 0.616 17.19 727 0.112 0.50 34,265,082
11 Genitourinary
problems
3482 0.912 31.76 294 0.051 0.14 232,226,224
12 Trauma
and injuries
2892 0.358 10.35 1037 0 0.00 N/A
13 Maternity
and neonates
3574 0.224 8.01 2189 0.482 2.36 3,387,363
Other six programmes summary
14 Spend 2006
and mortality
2006/7/8
15,643 93.29 7839 16.14 5,780,723
15 Spend 2006
and mortality
2004/5/6
15,643 112.13 7923 18.17 6,172,491
16 Spend 2005
and mortality
2002/3/4
12,743 99.44 7923 16.26 6,115,621
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(J)
Coverage of
mortality
data
relative to
spend data
(K) (=H/J)
change in
annual
mortality
adjusted
for coverage
(L) (=E/K)
cost per life
gained (£)
adjusted
for
coverage
(M) Total
life-years
lost,
<75 years,
2006/7/8
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage of
mortality
data
relative to
spend data
(P) (=N/O)
change in
annual
life-years lost
adjusted
for coverage
(Q) (=E/N)
cost per
YLG (£)
(R) (=E/P)
cost per
YLG
adjusted
for YLL
coverage
(£)
0.984 100.14 191,407 2,207,021 1170 0.984 1189 16,383 16,121
0.992 320.88 103,683 1,361,634 3515 0.992 3543 9466 9390
0.773 262.57 83,676 324,223 1924 0.773 2489 11,593 8961
0.571 73.90 223,288 345,908 790 0.571 1,83 20,892 11,929
761.49 119,823 4,238,786 7399 8604 12,333 10,604
4,335,559 10,576 10,783
4,516,953 10,986 12,855
1.000 0.76 10,928,905 106,552 13 1.000 13 630,798 630,798
0.634 19.52 904,344 57,672 154 0.634 243 114,416 72,539
0.136 3.69 4,660,051 66,137 15 0.136 112 1,129,960 153,675
0.172 0.80 39,942,910 10,030 2 0.172 9 20,421,090 3,512,427
0.175 0.00 N/A 30,000 0 0.175 0 N/A N/A
8.213 0.29 27,820,413 492,600 177 0.679 261 45,158 30,662
25.05 3,724,129 762,991 362 639 258,046 146,108
757,531 249 449,706
751,009 337 295,074
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TABLE 69 Table showing cost of life and life-year estimates using expenditure data for 2006 and outcome
data for 2006/7/8 (assumes average health gain for 12 other programmes) adjusted for the ICD-10 coverage
of the expenditure and outcome data (continued )
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Annual
mortality,
<75 years,
2006/7/8
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in
annual mortality
(I) (=E/H)
cost per life
gained (£)
All 10 programmes summary
17 Spend 2006
and mortality
2006/7/8
32,911 0.561 184.53 128,640 681.24 270,881
18 Spend 2006
and mortality
2004/5/6
32,911 0.687 226.18 133,213 971.30 232,861
19 Spend 2005
and mortality
2002/3/4
30,368 0.792 240.67 133,213 926.22 259,838
Other 13 PBCs? Assume zero health gain in PBC 23 . . .
20 PBC 23 spend
2006 and
mortality
2006/7/8
10,585 0.739 78.22 0.00
21 PBC 23 spend
2006 and
mortality
2004/5/6
10,585 0.759 80.34 0.00
22 PBC 23 spend
2005 and
mortality
2002/3/4
8449 0.926 78.24 0.00
. . . and that the gain in 10 PBCs (see row 17) applies to the remaining 12 PBCs
23 12 PBCs spend
2006 and
mortality
2006/7/8
24,400 416.20 1536.48 270,881
24 12 PBCs spend
2006 and
mortality
2004/5/6
24,400 372.44 1599.42 232,861
25 12 PBCs spend
2005 and
mortality
2002/3/4
25,493 324.20 1247.69 259,838
26 23 PBCs spend
2006 and
mortality
2006/7/8
67,896 678.96 2217.72 306,153
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(J)
Coverage of
mortality
data
relative to
spend data
(K) (=H/J)
change in
annual
mortality
adjusted
for coverage
(L) (=E/K)
cost per life
gained (£)
adjusted
for
coverage
(M) Total
life-years
lost,
<75 years,
2006/7/8
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage of
mortality
data
relative to
spend data
(P) (=N/O)
change in
annual
life-years lost
adjusted
for coverage
(Q) (=E/N)
cost per
YLG (£)
(R) (=E/P)
cost per
YLG
adjusted
for YLL
coverage
(£)
786.54 234,617 5,001,777 7760 9243 23,780 19,965
5,093,090 10,826 20,893
5,267,962 11,322 21,256
0.00 0.00
0.00
0.00
1773.97 234,617 17,502 20,847 23,780 19,965
17,826 20,893
15,252 21,256
2560.50 265,167 25,262 30,090 26,876 22,565
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TABLE 69 Table showing cost of life and life-year estimates using expenditure data for 2006 and outcome
data for 2006/7/8 (assumes average health gain for 12 other programmes) adjusted for the ICD-10 coverage
of the expenditure and outcome data (continued )
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Annual
mortality,
<75 years,
2006/7/8
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in
annual mortality
(I) (=E/H)
cost per life
gained (£)
27 23 PBCs spend
2006 and
mortality
2004/5/6
67,896 678.96 2570.72 264,113
28 23 PBCs spend
2005 and
mortality
2002/3/4
64,310 643.10 2173.90 295,827
N/A, not applicable.
Note
All 23 programmes spend: 2006/7 £67,896; 2005/6 £64,310.
% change in budget: 2006/7 1.00%; 2005/6 1.00%.
Proportionate change: 2006/7 0.01; 2005/6 0.01.
Change in budget: 2006/7 £678.96; 2005/6 £643.10.
Annual mortality figures reported in cells F6 and F7, and F15 and F16 are identical because we do not have
mortality data for 2002/3/4.
We have been unable to obtain a satisfactory outcome model for trauma and injuries and have assumed a zero
outcome elasticity.
For expenditure in 2006/7, the neonate category has been merged with maternity to obtain plausible outcome and
expenditure models.
The adjustment for the coverage of the YLL data relative to the spend data uses deaths under age 75 years in
England in 2008.
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(J)
Coverage of
mortality
data
relative to
spend data
(K) (=H/J)
change in
annual
mortality
adjusted
for coverage
(L) (=E/K)
cost per life
gained (£)
adjusted
for
coverage
(M) Total
life-years
lost,
<75 years,
2006/7/8
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage of
mortality
data
relative to
spend data
(P) (=N/O)
change in
annual
life-years lost
adjusted
for coverage
(Q) (=E/N)
cost per
YLG (£)
(R) (=E/P)
cost per
YLG
adjusted
for YLL
coverage
(£)
28,652 23,697
26,575 24,200
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TABLE 70 Table showing Department of Health-funded expenditure by major bodies, 2006/7
Body Gross spend, £B Income, £B Net spend, £B
PCTs 69.8 2.5 67.3
SHAs 3.8 0.0 3.8
Special Health Authoritiesa 2.8 1.3 1.5
Department of Health own costs (e.g. PSS grants, grants to LAs) 7.1 −0.4 7.5
Total Department of Health 83.5 3.4 80.1
PSS, Personal Social Services.
a This includes, for example, NICE, the NHS Business Services Authority, the Information Centre, the NHS Litigation
Authority, and the National Patient Safety Agency.
TABLE 71 Table showing net PCT and other Department of Health-funded expenditure by PBC, 2006/7
PBC
Net spend, £B, 2006/7
(D) Others’ spend as
% of PCT spend
(A)
All PCTs
(B)
Others
(C) All Department
of Health
1 Infectious diseases 1.1 0.1 1.2 13.3
2 Cancers and tumours 4.1 0.0 4.2 0.8
3 Disorders of blood 0.8 0.1 0.9 12.0
4 Endocrine, nutritional and metabolic issues 1.9 0.1 2.0 5.4
5 Mental health disorders 8.4 0.3 8.7 3.2
6 Problems of learning disability 2.4 −0.1 2.4 −2.5
7 Neurological 2.8 0.0 2.8 1.3
8 Problems of vision 1.4 0.0 1.3 −1.8
9 Problems of hearing 0.3 0.0 0.3 0.5
10 Problems of circulation 6.2 0.2 6.4 4.0
11 Problems of the respiratory system 3.3 0.1 3.3 1.6
12 Dental problems 2.6 −0.2 2.4 −7.0
13 Problems of the gastrointestinal system 3.7 0.0 3.7 −0.5
14 Problems of the skin 1.4 0.0 1.5 2.2
15 Problems of the musculoskeletal system 3.4 0.0 3.4 −0.3
16 Problems due to trauma and injuries 2.9 0.0 2.9 −0.5
17 Problems of the genitourinary system 3.5 0.1 3.6 2.1
18 Maternity and reproductive health 2.9 −0.1 2.8 −2.2
19 Conditions of neonates 0.7 0.1 0.7 10.3
20 Adverse effects and poisoning 0.7 0.0 0.7 −0.8
21 Healthy individuals 1.4 0.0 1.4 0.8
22 Social care needs 1.5 0.0 1.5 0.9
23 Other areas of spend/conditions 10.6 11.2 21.8 106.1
All categories 67.9 12.0 79.9 17.7
Note
The figures in Tables 70 and 71 draw on various sources (e.g. Department of Health resource accounts and PB returns) and
may (a) disagree slightly and (b) create some unusual results (e.g. the aggregate PCT figure for dental problems exceeds the
all England level34).
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This is because all of the additional non-PCT expenditure is allocated to PBC 23 and the assumption is that
all expenditure in this category offers no health gain.
We have no information on how any Departmental budgetary shock is likely to be split between PCT and
non-PCTs budgets. Our cost of a life-year estimates implicitly assume that the non-PCT budget is wholly
unresponsive to any budgetary shock. This is clearly a possibility. Alternatively, one might assume that
the non-PCT budget is as responsive to a Departmental budgetary shock as is the PCT budget. If this was the
case then it would add 17.7% to our cost of a life-year estimate for 2006/7. However, in the absence of any
information about the responsiveness of the non-PCT budget, it is difficult to come to any firm conclusion
about the impact of non-PCT expenditure on our cost of a life-year estimates. We therefore persevere with
the assumption that the non-PCT budget is wholly unresponsive to Departmental budgetary shocks.
Application of method to other non-mortality-based outcome indicators
Not all health-care expenditure will be directed towards the reduction of mortality but it is relatively easy to
envisage how our methods might be applied to other, non-mortality-based, outcome indicators.
To illustrate how our approach might be applied to other such indicators we note that PROMs (health
gain) data for various operations is available from the HES online website. For each PCT this data set
reports the average health gain for those survey respondents who have had a specific operation (e.g. for
hip replacement, for knee replacement, for varicose veins, and for groin hernia) over the survey period.
As a starting point, and to illustrate the principles involved, we focus on hip and knee replacements. As
our outcome indicator for these procedures, we calculate:
½(average health gain per hip operation number of hip operations)
þ (average health gain per knee operation number of knee operations)=total PCT population,
for each PCT (this ignores age standardisation). This health gain measure is broadly comparable
with our usual mortality measure, which is a ‘YLL’ rate per 10,000 of population (again, ignoring
age standardisation).
Ideally the expenditure, number of operations and PROMs data should all relate to the same time period,
but here the PROMs data covers operations undertaken between April 2009 and October 2010 yet the
expenditure and number of operations data relate to 2006/7. Implicitly, we are assuming that the average
gain per operation in 2006/7 is the same as over the PROMs survey period (although this is not particularly
important as we are only illustrating principles here).
Unfortunately, the Department of Health does not report the number of patients undergoing an eligible
operation by commissioner (PCT) so we use the HES data set for 2006/7 to obtain this information.
Eligible hip and knee operations are defined in annex 1 of the Guide to PROMs methodology (on the HES
website)151 and we use these definitions (of eligible operation codes) to obtain a count of eligible hip and
knee FCEs by PCT for 2006/7.
With data for both the average health gain per operation and the number of operations, we are now
in a position to calculate ‘the health gain per head of population’ for hip and knee replacements as
defined above. We can then use this as an outcome indicator for expenditure in the ‘problems of the
musculoskeletal system’ programme (i.e. PBC 15) because the vast majority of hip and knee replacements
are for osteoarthritis and this diagnosis is included in PBC 15.
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Table 72 reports the estimated outcome equation for PBC 15 using the PROMs-based outcome indicator.
The result is intuitively plausible. More expenditure boosts the health gain but, for a given spend, more
need reduces the gain. Of course we should remember that the health gain data relates to operations
undertaken between April 2009 and October 2010 yet the expenditure and number of operations data
(FCEs) relate to 2006/7. However, one might assume that the gain associated with each operation in
2009/10 is the same as the gain associated with each operation in 2006/7.
The diagnostic statistics suggest that expenditure is endogenous and that the instruments are valid.
They also suggest that the instruments are relevant and there is no evidence that the instruments are
weak. The Pesaran–Taylor test suggests that there is no evidence of model misspecification.
This brief example illustrates the principles involved in extending our modelling approach beyond those
programmes with a mortality indicator.
Comparing outcome models for ‘high’ spending and ‘low’ spending
primary care trusts
As we have already noted, not all PCTs spend the same amount in each programme of care. Even after
allowing for differences in local circumstances (such as input prices and need), some PCTs spend more
than others, and it is this variation in expenditure that facilitates the estimation of our outcome and
expenditure models.
TABLE 72 Table showing outcome model for PBC 15, problems of the musculoskeletal system 2006/7
Regressors Coefficient (standard error)
Expenditure per person in PBC 15 1.9068***
(0.4289)
Need CARAN per person –1.6807***
(0.4533)
Constant –6.3486***
(1.794)
Number of PCTs 143
Diagnostic test statistics
Endogeneity test statistic 24.677
Endogeneity p-value 0.0000
Hansen-Sargan test statistic 1.136
Hansen-Sargan p-value 0.2865
Kleibergen–Paap LM test statistic 14.702
Kleibergen–Paap p-value 0.0006
Kleibergen–Paap F-statistic 10.367
Pesaran–Taylor reset statistic 0.03
Pesaran–Taylor p-value 0.8588
*** p< 0.01.
Robust standard errors in brackets.
The dependent variable is the health gain per head of population associated with eligible hip and knee operations
undertaken during 2006/7.
There are only 143 observations and not the usual 152 because, for the other nine PCTs, there are fewer than 30
completed PROMs questionnaires on which to compute the average health gain and, as a result of such a low number of
respondents, these PCTs have been dropped from the sample.
The first-stage regression includes the IMD2007 (coefficient= –0.439, standard error= 0.144) and the proportion of
residents providing unpaid care (coefficient= 0.219, standard error= 0.367).
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Figure 15 illustrates the familiar health gain production function; as expenditure increases so too does
health output but it increases at a diminishing rate. If all PCTs face the same production function
(having controlled for input prices and need), and all PCTs are wholly efficient, then we would expect
those PCTs that spend more (e.g. at point B) to experience a lower outcome elasticity than those that
spend less (e.g. at point A), simply because they are further along the production function and are
experiencing greater diminishing marginal returns.
To test this hypothesis we used the expenditure model for each of the big four programmes to divide the
152 PCTs into two groups: those whose predicted spend is greater than the average predicted spend in
that programme (ceteris paribus), and those whose predicted spend is smaller than the average predicted
spend (ceteris paribus). We then re-estimated our outcome model for each of these two groups of PCTs
and the results of this re-estimation are shown in Table 73.ad
Health gain in programme
A B Health-care spend
in programme
Production function
£GBP
P
o
p
u
la
ti
o
n
 h
e
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lt
h
FIGURE 15 Graph showing health gain production function.
TABLE 73 Table showing re-estimating the 2006/7 outcome model for ‘high’ spending and ‘low’ spending PCTs
IV regression result All PCTs ‘High spend’ PCTs ‘Low spend’ PCTs
Cancer outcome equation
1 Constant 6.500*** 7.132*** 5.352***
2 Need for health care 0.995*** 1.265*** 0.848***
3 Need for health care squared 1.162*** 0.588 0.842
4 Cancer expenditure per person −0.342*** −0.488*** −0.074
Number of observations 152 76 76
Endogeneity test statistic 13.695*** 7.165*** 0.501
Instrument validity: Hansen J statistic 0.685 0.734 1.587
Instrument relevance: Kleibergen–Paap LM statistic 17.847*** 7.102** 13.617***
Weak instrument: Kleibergen–Paap F-statistic 13.279 6.722 7.436
Reset test 0.01 0.68 1.95
Circulatory disease outcome equation
1 Constant 11.413*** 11.254*** 9.356***
2 Need for health care 2.859*** 2.741*** 2.636***
continued
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TABLE 73 Table showing re-estimating the 2006/7 outcome model for ‘high’ spending and ‘low’
spending PCTs (continued )
IV regression result All PCTs ‘High spend’ PCTs ‘Low spend’ PCTs
3 Circulatory expenditure per person −1.434*** −1.403*** −0.995***
Number of observations 152 76 76
Endogeneity test statistic 42.548*** 9.424*** 20.489***
Instrument validity: Hansen J statistic 0.949 4.782 0.366
Instrument relevance: Kleibergen–Paap LM statistic 32.372*** 12.658** 15.123***
Weak instrument: Kleibergen–Paap F-statistic 17.143 6.275 12.421
Reset test 0.14 0 1.29
Respiratory problems outcome equation
1 Constant 17.023*** 22.617** 11.695***
2 Need for health care 2.683** 2.512 3.095**
3 Need for health care squared 3.08 5.537 8.097***
4 Permanently sick 1.031** 1.401 0.844
5 Respiratory expenditure per person −2.622*** −3.697* −1.461*
Number of observations 152 76 76
Endogeneity test statistic 20.860*** 10.254*** 5.380**
Instrument validity: Hansen J statistic N/A N/A N/A
Instrument relevance: Kleibergen–Paap LM statistic 9.091*** 3.591 5.108**
Weak instrument: Kleibergen–Paap F-statistic 11.025 4.568 6.227
Reset test 0 0.08 0.21
Gastrointestinal outcome equation
1 Constant 9.718*** 9.306*** 6.675***
2 Need for health care 4.159*** 5.156*** 3.236***
3 Gastrointestinal spend per person −1.536*** −1.471*** −0.819
Number of observations 152 76 76
Endogeneity test statistic 16.373*** 7.781*** 3.700*
Instrument validity: Hansen J statistic 2.761 1.529 3.824*
Instrument relevance: Kleibergen–Paap LM statistic 14.865*** 10.094*** 7.956**
Weak instrument: Kleibergen–Paap F-statistic 11.629 10.607 7.985
Reset test 1.67 0.15 0.56
* p< 0.1; ** p< 0.05; *** p< 0.01; N/A, not applicable.
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In Table 73 the first column of the IV regression results presents the outcome model for all PCTs; the
second column reports the results for the ‘high spend’ PCTs; and the third column reports the results for
the ‘low spend’ PCTs. For all four programmes, the coefficient on the expenditure variable is larger
(in an absolute sense) for the ‘high spend’ PCTs than for the ‘low spend’ PCTs. This result contradicts our
hypothesis that ‘high spenders’ will have a lower elasticity than ‘low spenders’.
However, if we drop the assumption that all PCTs are equally efficient – so that that some lie within the
frontier defined by the production function – then it is clearly possible for ‘high’ spending PCTs to
experience a larger outcome elasticity than a ‘low’ spending one. In addition, it is rather difficult to defend
the assumption that all PCTs are equally efficient.
We can use the outcome elasticities reported in Table 73 to calculate the cost of a life-year for ‘high’ and
‘low’ spenders in each of the big four programmes. These calculations are shown in Table 74.ae As is to be
anticipated, they reveal that the cost of a life-year is much smaller in ‘high spend’ PCTs than it is in ‘low
spend’ PCTs. For example, the cost of a life-year in the cancer programme is £16,383 across all PCTs, but
for ‘high spenders’ it is much less than this (£11,350) and for ‘low spenders’ it is much greater than this
(£76,620). Presumably ‘high spending’ PCTs are high spenders because the cost of a life-year is relatively
low and additional health gains in a particular programme can be had relatively cheaply. Similarly, ‘low
spending’ PCTs are low spenders because the cost of a life-year is relatively high and additional health
gains are relatively expensive.
Comparing outcome models for over target and under target
primary care trusts
The Department of Health has a well-developed resource allocation formula that determines the size of
each PCTs ‘target’ budget given local conditions (such as population size and the need for health care).
Every few years an improved resource allocation formula is developed and this generates a new ‘target’
budget for each PCT. The new target might be quite different from the old target and the immediate
implementation of the new formula might lead to a large change in the budget for some PCTs. To avoid
the difficulties that sudden large budgetary changes might bring, actual annual financial allocations are
gradually moved towards the latest target budget. This means that in any year some PCTs receive an
actual allocation which is greater than their target allocation, and that others receive an actual allocation
which is less than their target allocation.
To examine whether or not being over or under the target allocation has any impact on the results, we
split the 152 PCTs into two groups: those that received a budget over their target allocation in 2006/7 and
those that received a budget under their target allocation in 2006/7. The outcome elasticities from the
estimation of these models are shown in column (E) of Table 75, and these elasticities are used to calculate
the cost of a life-year for each of these two groups of PCTs for each of the big four programmes [see
column (I) of Table 75].
The results are consistent for each programme: PCTs whose budget is beyond their target allocation record
a smaller outcome elasticity and a larger cost of a life-year than PCTs whose budget is less than their
target allocation. For example, in the cancer programme and across all PCTs the outcome elasticity is
−0.342 and the cost of a life-year is £16,383 (unadjusted for the ICD-10 coverage of the mortality data).
For PCTs with a budget that exceeds their target allocation, the outcome elasticity is smaller (−0.179) and
the cost of a life-year is larger (£32,365) than for all PCTs combined. However, for PCTs with a budget that
falls short of their target allocation, the outcome elasticity is larger (−0.476) and the cost of a life-year is
smaller (£11,502) than for all PCTs combined.
One explanation for this result is that PCTs whose budget is beyond their target allocation are under less
financial pressure than other PCTs, and that one consequence of this is that there is less pressure on them
to behave in the most efficient manner possible. There is some evidence in the literature to support the
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TABLE 74 Table showing calculation of the cost of a life-year for the big four programmes in 2006/7 by type of PCT: ‘high spenders’ and ‘low spenders’
Scenario (A) PBC description
(B) Type
of PCT
(C) Spend
(£M) financial
year 2006/7
(D) 1% of spend
(£M) financial
year 2006/7
(E) Outcome
elasticity
(without
negative sign)
(F) Total
life-years lost,
< 75 years,
2006/7/8
(G) Annual
average
life-years
lost (= F/3)
(H) Change in annual
life-years lost
associated with 1%
increase in
spend (= E ×G)/100
(I) Cost (£) per
YLG (=D/H)
unadjusted for
ICD-10
coverage
Split PCTs according to whether they are ‘high spenders’ (n = 76) or ‘low spenders’ (n = 76)
1 Cancers All 4122 41.22 0.342 2,207,021 735,674 2516 16,383
2 Cancers High spend 2080 20.80 0.488 1,126,580 375,527 1833 11,350
3 Cancers Low spend 2042 20.42 0.074 1,080,442 360,147 267 76,620
4 Circulatory problems All 6161 61.61 1.434 1,361,634 453,878 6509 9466
5 Circulatory problems High spend 3148 31.48 1.403 695,890 231,963 3254 9673
6 Circulatory problems Low spend 3012 30.12 0.995 665,744 221,915 2208 13,641
7 Respiratory problems All 3285 32.85 2.622 324,223 108,074 2834 11,593
8 Respiratory problems High spend 1645 16.45 3.697 174,639 58,213 2152 7644
9 Respiratory problems Low spend 1640 16.4 1.461 149,584 49,861 728 22,513
10 Gastrointestinal
problems
All 37.00 37.00 1.536 345,908 115,303 1771 20,892
11 Gastrointestinal
problems
High spend 1868 18.68 1.471 190,231 63,410 933 20,026
12 Gastrointestinal
problems
Low spend 1832 18.32 0.819 155,676 51,892 425 43,106
Note
‘High spending’ PCTs are those whose predicted spend per person is greater than the average predicted spend per person (ceteris paribus), and ‘low spending’ PCTs are those whose
predicted spend per person is less than the average predicted spend per person (ceteris paribus).
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TABLE 75 Table showing calculation of the cost of a life-year for the big four programmes by type of PCT: over target and under target allocations
Scenario (A) PBC description
(B) Type
of PCT
(C) Spend
(£M) financial
year 2006/7
(D) 1% of spend
(£M) financial
year 2006/7
(E) Outcome
elasticity
(without
negative sign)
(F) Total
life-years lost,
< 75 years,
2006/7/8
(G) Annual
average
life-years
lost (= F/3)
(H) Change in annual
life-years lost
associated with 1%
increase in spend
(= E ×G)/100
(I) Cost (£)
per YLG
(=D/H)
Split PCTs according to whether they are over target allocation (n = 67) or under target allocation (n = 85)
1 Cancers All 4122 41.22 0.342 2,207,021 735,674 2516 16,383
2 Cancers Over target 1733 17.33 0.179 897,403 299,134 535 32,365
3 Cancers Under target 2390 23.90 0.476 1,309,618 436,539 2078 11,502
4 Circulatory problems All 6161 61.61 1.434 1,361,634 453,878 6509 9466
5 Circulatory problems Over target 2587 25.87 1.115 544,326 181,442 2023 12,787
6 Circulatory problems Under target 3574 35.74 1.947 817,308 272,436 5304 6738
7 Respiratory problems All 3285 32.85 2.622 324,223 108,074 2834 11,593
8 Respiratory problems Over target 1357 13.57 2.637 127,810 42,603 1123 12,079
9 Respiratory problems Under target 1928 19.28 2.674 196,413 65,471 1751 11,013
10 Gastrointestinal problems All 3700 37.00 1.536 345,908 115,303 1771 20,892
11 Gastrointestinal problems Over target 1566 15.66 0.569 142,281 47,427 270 58,030
12 Gastrointestinal problems Under target 2134 21.34 1.869 203,626 67,875 1269 16,822
Note that for those over target, the average amount (percentage) is £13.415M (3.6%); for those under target, the average amount (percentage) is £10.575M (2.6%).
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hypothesis that the degree of PCT inefficiency is positively related to the amount by which a PCTs is over
its target allocation.61
If we also re-estimate the expenditure models for both groups of PCTs we can calculate the cost of a
life-year for the big four programmes combined. The relevant expenditure elasticities are shown in
column (D) of Table 76. These expenditure elasticities are far larger for under target PCTs than they are
for over target PCTs. One reason for this might be that the big four programmes are priority (‘hard’)
programmes. Over target PCTs are able to devote sufficient resources to the big four programmes so
that any additional budget is directed towards other (‘softer’) programmes which are less well funded
than the priority programmes. In contrast, under target PCTs are struggling to devote sufficient resources
to the priority programmes so that, when further funding does become available, this is directed towards
the priority programmes.
These expenditure and outcome elasticities in Table 76 can be used to calculate the cost of a life-year for
the big four programmes combined (adjusted for the ICD-10 coverage of the mortality data). This cost is:
l £10,604 for all PCTs combined
l £14,083 for PCTs whose budget is beyond its target allocation
l £8441 for PCTs whose budget falls short of its target allocation.
Again, the cost of a life-year is much smaller for PCTs whose budget falls short of its target allocation.
The correlation between the outcome and expenditure elasticities
To investigate the correlation between the outcome and expenditure elasticities for any given programme,
a random sample (with replacement) of 152 PCTs was drawn from the population of 152 PCTs. In this
random drawing, some of the original observations will appear once, some more than once, and some not
at all. Using this resampled data set, outcome and expenditure models for the selected programme were
estimated (as per Table 65) and the outcome and expenditure elasticities saved. This step was repeated
500 times and the correlation coefficient for the outcome and expenditure elasticities was calculated.
Table 77 shows these correlation coefficients for each of the big four programmes.
Summary and conclusion
In this section we have undertaken several tasks. First, we have identified and resolved several estimation
issues relating to the appropriate measure of need, the appropriate price index to be used to adjust PCT
expenditure for local variations in input prices, and the fact that PCTs vary in size.
Second, we have derived plausible outcome and expenditure models for 10 care programmes using
expenditure data for 2006/7 and mortality data for 2004/5/6. The cost of a life-year across these
10 programmes is £20,893 (it was £21,256 using expenditure data for 2005/6).
Third, we have re-estimated the outcome and expenditure models using the same expenditure data but
replacing the mortality data for 2004/5/6 with data for 2006/7/8. The advantage of this is that it assumes
that the health benefits associated with expenditure occur either in the same period as the expenditure or
in the next two periods. This is an improvement on past practice where data constraints forced researchers
to relate expenditure to the current and two previous periods. This re-estimation increased the cost of a
life-year across all 10 programmes by 14%, from £20,893 to £23,780.
Fourth, we have adjusted the cost of a life-year calculations for the mismatch in the ICD-10 coverage of
the expenditure and mortality data. This reduces the cost of a life-year for 2006/7 for those 10 PBCs with a
mortality indicator from £23,780 to £19,965 (a decrease of 16%).
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Fifth, we have noted that our cost of a life-year estimates are based on the assumption that any
Departmental budgetary change falls entirely on PCTs. Although PCTs account for most of the Department
of Health’s budget, non-PCTs still accounted for 15% of the budget in 2006/7. As we have no information
on how any budgetary change would be split between PCTs and non-PCTs, our estimates implicitly
assume that any Departmental budgetary change falls entirely on PCTs. If, on the other hand, the non-PCT
budget is responsive to changes in the Department’s budget then our cost of a life-year estimates will be
slightly too low [e.g. if the non-PCT budget is as responsive as the PCT budget, then our cost of a life-year
estimate for 2006/7 will be increased by 17.7% (that is, from £22,565 to £26,553)].
We have also illustrated how our modelling framework can be applied to other non-mortality-based
outcome indicators, and the cost of a life-year estimates that are obtained if PCTs are split into different
groups (e.g. those that are under and those that are over their target budget allocations). In the next
section we examine the impact of relaxing the instrument validity restriction on our results.
The sensitivity of the outcome elasticity to the validity of the
instrument exclusion restrictions
Introduction
One of the crucial elements in the calculation of the cost of a life-year for any programme of care is the
coefficient on the expenditure variable in the outcome equation. This coefficient indicates the amount by
which mortality changes following a (small) change in expenditure in that care programme. It is to be
expected that this coefficient will have a negative sign so that as expenditure increases, for example,
mortality will decline. If this coefficient is small (in an absolute sense) then it implies that any change in
expenditure will have little effect on mortality and so the cost of a life-year will be relatively large (ceteris
paribus). Alternatively, if this coefficient is large (in an absolute sense) then any change in expenditure will
have a large effect on mortality and so the cost of a life-year will be relatively small (ceteris paribus).
For this reason it is important that we correctly identify the magnitude of this ‘treatment parameter’.
Our basic outcome model for each programme of care is:
y ¼ αþ β1x þ β2nþ ε, (15)
where y is mortality, x is expenditure, and n is a measure of the need for health care (with all variables
relating to a particular programme of care). We are particularly interested in the size of the coefficient on
expenditure (β1). We do not use OLS to estimate this outcome model because expenditure (x) is
endogenous and, in the presence of an endogenous regressor, OLS will provide both a biased and an
inconsistent estimator of β1. Instead, we use IV techniques. Unlike OLS, IV will provide a consistent
estimator of β1 and, although in finite samples the IV estimator will be biased, the belief is that
(providing certain assumptions are met) this bias will be less than that associated with OLS.
Instrumental variable estimation involves finding variables (instruments) that are good predictors of
expenditure (x), but which are appropriately excluded from the equation of interest (that is, Equation 15).
The assumption is that the instruments impact on mortality (y) through their impact on expenditure (x)
only, and that they do not have a direct effect on mortality (y). If, on the other hand, an instrument reflects
unobserved factors that affect both expenditure and mortality directly, the use of this instrument will lead
to a biased and inconsistent estimate of the coefficient on expenditure. Such an instrument is said to be
‘invalid’ because it belongs in the equation of interest in its own right.
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TABLE 76 Table showing cost of life and life-year estimates using spend data for 2006 and outcome data for
2006/7/8 for the big four PBCs for (i) all PCTs; (ii) PCTs that are over target; and (iii) PCTs that are under target
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2006/7
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Annual
mortality
<75 years,
2006/7/8
(G) Coverage of
mortality data
relative to
spend data
(H) Outcome
elasticity (without
negative sign)
All PCTs together
1 Cancer 4122 0.465 19.17 61,961 0.984 0.342
2 Circulatory
problems
6161 0.540 33.27 41,106 0.992 1.434
3 Respiratory
problems
3285 0.679 22.31 11,574 0.773 2.622
4 Gastrointestinal
problems
3700 0.446 16.50 6160 0.571 1.536
Big four programmes summary
5 Spend 2006
and mortality
2006/7/8
17,268 91.24
For over target PCTs only (n=67)
6 Cancer 1733 0.193 3.34 24,918 0.984 0.179
7 Circulatory
problems
2587 0.150 3.88 16,346 0.992 1.115
8 Respiratory
problems
1357 0.326 4.42 4588 0.773 2.637
9 Gastrointestinal
problems
1566 0.090 1.41 2525 0.571 0.569
Big four programmes summary
10 Spend 2006
and mortality
2006/7/8
7243 13.06
For under target PCTs only (n=85)
11 Cancer 2390 0.785 18.76 37,043 0.984 0.476
12 Circulatory
problems
3574 0.748 26.73 24,760 0.992 1.947
13 Respiratory
problems
1982 1.035 20.51 6986 0.773 2.674
14 Gastrointestinal
problems
2134 0.592 12.63 3602 0.571 1.869
Big four programmes summary
15 Spend 2006
and mortality
2006/7/8
10,080 78.64
Note
All 23 programmes spend: 2006/7 £67,896; 2005/6 £64,310.
% change in budget: 2006/7 1.00%; 2005/6 1.00%.
Proportionate change: 2006/7 0.01; 2005/6 0.01.
Change in budget: 2006/7 £678.96; 2005/6 £643.10.
Note that the adjustment for the coverage of the YLL data relative to the spend data uses deaths under age 75 years in
England in 2008
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(I)
(=0.01×D×F×H/G)
change in annual
mortality, adjusted
for coverage
(J) (=E/I)
cost per life
gained
adjusted for
coverage (£)
(K) Total
life-years
lost,
<75 years,
2006/7/8
(L)
(=0.01×D×H×K/3)
change in annual
life-years lost
(M)
Coverage of
mortality
data
relative to
spend data
(N) (=L/M)
change in
annual
life-years
lost,
adjusted
for coverage
(O)
(=E/L)
cost per
YLG (£)
(P) (=E/N)
cost per
YLG
adjusted
for YLL
coverage (£)
100.14 191,407 2,207,021 1170 0.984 1189 16,383 16,121
320.88 103,683 1,361,634 3515 1.000 3543 9466 9390
266.57 83,676 324,223 1924 0.773 2489 11,593 8961
73.90 223,228 345,908 790 0.650 1383 20,892 11,929
761.49 119,823 7399 8604 12,333 10,604
8.75 382,320 897,403 103 0.984 105 32,365 31,847
27.56 140,806 544,326 303 1.000 303 12,787 12,685
51.02 86,701 127,810 366 0.773 474 12,079 9337
2.26 622,378 142,281 24 0.650 43 58,030 33,135
89.60 145,748 797 927 16,378 14,083
140.67 133,377 1,309,618 1631 0.984 1658 11,502 11,318
363.50 73,544 817,308 3968 1.000 4000 6738 6684
250.12 82,015 196,413 1812 0.773 2344 11,321 8751
69.80 181,000 203,626 751 0.650 1315 16,822 9605
824.09 95,429 8162 9317 9635 8441
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In our outcome models we typically employ two instruments (call these z1 and z2) for expenditure.
IV assumes that these instruments do not belong in the outcome (see Equation 15). In other words,
IV assumes that the coefficients γ1 and γ2 in the outcome model:
y ¼ αþ β1x þ β2nþ γ1z1þ γ2z2ε, (16)
are identically zero. Such exclusion restrictions can be debatable and researchers who employ IV
techniques often devote considerable effort towards convincing the reader that their assumed exclusion
restrictions are a good approximation.88,89 These efforts usually take two forms: first, researchers often
offer a strong theoretical economic argument why their instruments do not belong in the equation
of interest; and, second, statistical tests for the validity of the exclusion restrictions (Sargan 2SLS,
Hansen J-test GMM) are routinely reported as part of the results for any study that employs IV techniques.
It is difficult for us to identify clear theoretical reasons why our instruments (such as the proportion of lone
pensioner households, the provision of unpaid care and an index of multiple deprivation) do not belong in
the equation of interest (that is, that they will not directly affect mortality). Of necessity, therefore, we
must be guided by the available statistical tests for the validity of the exclusion restrictions. However,
although our outcome models ‘pass’ the relevant statistical test, some commentators have argued that the
Sargan/Hansen test may have weak power and may fail to reject the null hypothesis of instrument validity
even when an exclusion restriction is not valid. Given our reliance on this test, it is important that we
examine the circumstances in which this test may have weak power.
The Hansen–Sargan test of overidentifying restrictions: when will it
have low power?
As we have one endogenous variable (expenditure) in our outcome model and more than one instrument
available for health-care expenditure, our estimating equation is said to be ‘overidentified’. With more
instruments than endogenous regressors, there is more than one way of using the instruments to estimate
the parameter β1 on the endogenous variable. The Hansen–Sargan J test of overidentifying restrictions
calculates whether different instruments or different combinations of instruments generate significantly
different values for the coefficient (β1) on the endogenous variable in the equation of interest. If significant
differences are detected then the test will reject the null hypothesis that all instruments are jointly valid.
Of course, the test does not reveal which instrument(s) is(are) invalid; instead, the test uses the fact that
different instruments (or combinations thereof) generate different estimates of β1 to infer that something
is wrong with the set of instruments. Even if all of the instruments are invalid in the sense that they are
all correlated with the error term in the equation of interest (and thus belong in the outcome equation
as regressors), the test can detect this failure if the induced biases in the estimates of β1 differ across
instruments. This ‘vector-of-contrasts’ interpretation of the Hansen–Sargan test makes it clear when the
J test will lack power to reject the null hypothesis when it is false. The J statistic will be small when the null
TABLE 77 Table showing correlation coefficient for the outcome and expenditure elasticities
Programme of care Correlation coefficient between the outcome and expenditure elasticities
Cancers and tumours 0.1542
Circulatory disease 0.1968
Respiratory problems 0.0368
Gastrointestinal problems 0.0611
Note
The estimated elasticities are from unweighted IV regressions because there is no weight option with the bootstrap
command in Stata. However, weighting makes little difference to our IV results. For example, in the cancer outcome model
the coefficient on spend is −0.342 with weighting applied but it is −0.299 without any weighting applied. For the cancer
spend model the coefficient on budget is 0.465 with weighting but 0.520 without weighting.
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hypothesis of valid instruments is correct; but it will also be small if the biases induced in bβ1 by invalid
instruments all coincide (i.e. the instruments all identify the same wrong parameter).150
Most of our estimated models involve the use of two instruments. Kovandic et al.150 point that when there
are only two instruments:
. . . the J test statistic is numerically identical to a Hausman test statistic that contrasts the estimator
using both instruments with an estimator using just one instrument. The intuition [behind this result]
is . . . straightforward: a Hausman test will reject the null hypothesis that the two estimators being
contrasted are both consistent so long as the estimators converge to different values. It is not a
requirement for one of the two estimators to be consistent for the Hausman test (and therefore the
J test) to have power to reject the null.
One implication of this observation is that misspecification, in the conditional mean of the model, need not
necessarily cause the Hansen–Sargan test to fail.
Kovandic et al. point out that these arguments suggest:
‘. . . that the more unrelated the instruments are to each other, the more credible is a failure to reject
the null that the instruments are exogenous, since a failure to reject would require that two unrelated
instruments generate the same asymptotic bias in bβ1
p. 19150
Schaffer argues that:
[d]ifferent sets of instruments are likely to have more or less power depending on where they come
from. If all the instruments are minor variations on the same variable – e.g. they are the same variable
but lagged a few different periods – then they are all likely to identify the same psuedo-parameter.
The critique of low power is going to be fairly convincing here.
Professor Mark Schaffer, Heriot-Watt University, 2011, personal communication
On the other hand, if the instruments are very different and, even better, there are ex ante reasons for
thinking that if they are invalid, they are invalid in ‘different ways’, the J test will have more power.
For example, suppose two instruments are available and it is thought that, if one is invalid, it will bias the
estimated parameter upwards but, if the other instrument is invalid, it will bias the estimated parameter
downwards. If the Hansen–Sargan J test fails to reject in this setting, it is a convincing result
(Professor Mark Schaffer, personal communication).
In this study we typically use any two from three available instruments when estimating our outcome
equations. These three instruments are:
(a) the proportion of households that are lone pensioner households (from the 2001 Census80)
(b) the proportion of residents providing more than 1 hour of unpaid care per week (from the 2001
Census80); and
(c) the IMD2007.
For the Hansen–Sargan J test to have low power the use of any two of these instruments should generate
the same asymptotic bias in bβ1. However, it is far from obvious that this will be the case, particularly given
that our outcome equation already includes a measure of the need for health care.
Nevertheless, we must admit that it is possible that our instruments are correlated with both expenditure
and some unobserved factor which is directly influencing the mortality rate, and that the induced bias in
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bβ1 is the same for both instruments. In the next section we therefore examine the sensitivity of the
estimated outcome elasticity to the validity of the exclusion restrictions.
In summary:
l The Hansen–Sargan J test of overidentifying restrictions calculates whether different instruments or
different combinations of instruments generate significantly different values for the coefficient (β1) on
the endogenous variable in the equation of interest. If significant differences are detected then the test
will reject the null hypothesis that all instruments are jointly valid.
l The J test uses the fact that different instruments (or combinations thereof) generate different
estimates of β1 to infer that something is wrong with the chosen set of instruments.
l Even if all of the instruments are invalid in the sense that they are all correlated with the error term in
the equation of interest, the test can detect this failure if the induced biases in the estimates of β1
differ across instruments.
l This ‘vector-of-contrasts’ interpretation of the Hansen–Sargan test also makes it clear when the J test
will lack power to reject the null hypothesis when it is false. The J statistic will be small when the null
hypothesis of valid instruments is correct; but it will also be small if the biases induced in bβ1 by invalid
instruments all coincide (i.e. the instruments all identify the same wrong parameter).
l Most of our outcome models use two from the following three instruments: lone pensioners, multiple
deprivation and unpaid carers. Thus, our Hansen–Sargan test statistics are likely to have low power if
our selected pair of instruments are both inducing the same bias in bβ1. It is far from obvious that these
instruments will induce the same bias in the coefficient on expenditure.
l However, in case our instruments are imparting the same bias to bβ1, the next section examines the
sensitivity of the estimated outcome elasticity to the validity of the exclusion restrictions.
The value selection problem
Given that the Hansen–Sargan J test might be unable to detect the presence of invalid instruments in
some (rather restrictive) circumstances, several studies have suggested that researchers using IV techniques
should subject the estimated coefficient on the endogenous variable to a sensitivity analysis (e.g. Conley
et al.;88 Small89). Recall that IV estimation involves the assumption that the instruments do not belong in
the equation of interest (i.e. in the outcome equation). In other words, the assumption is that the
coefficients γ1 and γ2 on the instruments z1 and z2 in the outcome model:
y ¼ αþ β1x þ β2nþ γ1z1þ γ2z2þ ε, (17)
are identically zero (where y is mortality, x is expenditure, and n is a measure of the need for health care).
One suggestion is that investigators should relax the assumption that γ1 and γ2 are identically zero and
examine the impact of this relaxation on the estimated value for β1. This proposal, however, raises the
issue of which non-zero values should be imposed on γ1 and γ2.
Proponents of this approach suggest that prior information about the extent of deviations from the exact
exclusion restriction might be drawn from other research studies or from subject matter experts.88,89 In the
present context, however, we have no prior beliefs about the likely values for, or even the signs on, γ1
and γ2.
As a starting point we re-estimated the outcome model for the 2006/7 cancer programme 420 times,
assuming a uniform distribution between −1 and 1 for both γ1 and γ2.af,agTable 78 shows the estimated
coefficients on expenditure (bβ1) in our cancer outcome equation associated with the various pairs of values
imposed on γ1 and γ2. The coefficients in Table 78 indicate that the outcome elasticity is rather sensitive
to the precise values assigned to γ1 and γ2. However, in the absence of any guidance from other research
studies or from subject matter experts, we require a method that will identify a plausible range of values
for both γ1 and γ2, and which we can use as the basis for our sensitivity analysis.
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The identification of values to be imposed on the coefficients on the
excluded instruments
Our outcome equations typically involve two instruments and one endogenous regressor. With this
structure we can re-estimate our outcome model twice, each time including one of the previously excluded
instruments to the equation of interest. In particular, we can estimate:
y ¼ αþ β1x þ β2nþ γ1z1þ ε, (18)
and then
y ¼ αþ β1x þ β2nþ γ2z2þ ε, (19)
with the same set of (included and excluded) instruments (n, z1, and z2) being used to instrument × 1 in
both cases. This provides us with coefficient and variance estimates for γ1 and γ2 and we can sample from
these point estimates and their distributions to examine the impact of different (non-zero) values for γ1
and γ2 on the outcome elasticity (bβ1).
The sampling procedure is straightforward. We sample from these estimates and their distributions by
drawing two random numbers from a standard normal distribution and we form the product of these
numbers and the standard errors associated with our estimates of γ1 and γ2. Our sampled pair of values
of γ1 and γ2 (call these sampled values ~γ1 and ~γ2) are then the sum of these products and the respective
coefficient estimates of γ1 and γ2. Table 79 shows the relevant coefficient and variance estimates for γ1
and γ2 that are used as part of this sampling procedure.
The estimation of Equations 18 and 19 does not generate estimates of γ1 and γ2 as part of the same
model and so the sampling procedure outlined above implicitly assumes a zero covariance between these
estimates. If we want to incorporate a covariance term into the sampling procedure this must be obtained
from elsewhere. In the absence of an obviously better approach, we obtain a covariance term from
the OLS estimation of our outcome model with the previously excluded instruments both included in the
regression equation. Thus we estimate:
y ¼ αþ β1x þ β2nþ γ1z1þ γ2z2 þ ε, (20)
where y, x, n, z1 and z2 have their usual meaning, and where β1 is constrained to be equal to its value
from the IV estimation of Equation 15. The value for the covariance term between the estimates of γ1 and
γ2 for each of the big four programmes is shown in the final column of Table 79.
The sampling procedure from our estimates of γ1 and γ2 with a non-zero covariance is essentially the
same as that outlined above but it incorporates the presence of a covariance term for the estimates of γ1
and γ2. We can illustrate this procedure using data from the cancer outcome model. First, we form the
implied variance-covariance matrix for the estimates of γ1 and γ2:
lone_pensioners IMD2007
lone_pensioners 0.031458 0.004944
IMD2007 0.004944 0.013020
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TABLE 78 Table showing the impact of weakening the exclusion restrictions on the instruments in the
cancer outcome equation
Coefficients on expenditure (bβ1)
Imposed coefficient on IMD variable (γ2)
−1 −0.9 −0.8 −0.7 −0.6 −0.5 −0.4 −0.3
Imposed coefficient on lone
pensioner households variable (γ1)
1.00 −4.47 −4.22 −3.96 −3.71 −3.45 −3.20 −2.95 −2.70
0.90 −4.31 −4.06 −3.80 −3.54 −3.29 −3.04 −2.79 −2.53
0.80 −4.15 −3.90 −3.64 −3.38 −3.13 −2.88 −2.62 −2.37
0.70 −3.99 −3.74 −3.48 −3.22 −2.97 −2.72 −2.46 −2.21
0.60 −3.83 −3.58 −3.32 −3.06 −2.81 −2.55 −2.30 −2.05
0.50 −3.67 −3.41 −3.16 −2.90 −2.65 −2.39 −2.14 −1.89
0.40 −3.51 −3.25 −3.00 −2.74 −2.49 −2.23 −1.98 −1.73
0.30 −3.35 −3.09 −2.84 −2.58 −2.32 −2.07 −1.82 −1.57
0.20 −3.19 −2.93 −2.68 −2.42 −2.16 −1.91 −1.65 −1.40
0.10 −3.03 −2.77 −2.51 −2.26 −2.00 −1.75 −1.49 −1.24
0.00 −2.87 −2.61 −2.35 −2.10 −1.84 −1.58 −1.33 −1.07
−0.10 −2.71 −2.45 −2.19 −1.93 −1.68 −1.42 −1.16 −0.91
−0.20 −2.55 −2.29 −2.03 −1.77 −1.51 −1.26 −1.00 −0.75
−0.30 −2.39 −2.13 −1.87 −1.61 −1.35 −1.10 −0.84 −0.58
−0.40 −2.23 −1.97 −1.71 −1.45 −1.19 −0.93 −0.68 −0.42
−0.50 −2.07 −1.81 −1.55 −1.29 −1.03 −0.78 −0.52 −0.27
−0.60 −1.91 −1.65 −1.39 −1.13 −0.87 −0.62 −0.37 −0.13
−0.70 −1.75 −1.49 −1.23 −0.97 −0.72 −0.47 −0.22 0.01
−0.80 −1.59 −1.33 −1.07 −0.82 −0.57 −0.32 −0.09 0.14
−0.90 −1.43 −1.17 −0.92 −0.67 −0.42 −0.18 0.05 0.27
−1.00 −1.27 −1.02 −0.76 −0.52 −0.27 −0.04 0.18 0.41
Notes: This spreadsheet shows the value of the coefficient on expenditure (bβ1) when estimating the cancer outcome
equation [y×= (y− γ1z1− γ2z2)= α+ β1x+β2n+ ε] using IV estimation having imposed different pairs of values for γ1
and γ2 between −1 and 1. Cells in the top left-hand quadrant contain negative values for the outcome elasticity. The
outcome elasticity associated with our standard IV model (−0.34) is shown in the central square where γ1 and γ2 are,
of course, zero.
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−0.2 −0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
−2.45 −2.20 −1.96 −1.71 −1.47 −1.23 −0.99 −0.75 −0.50 −0.24 0.03 0.30 0.57
−2.29 −2.04 −1.80 −1.55 −1.31 −1.07 −0.83 −0.59 −0.33 −0.07 0.20 0.47 0.74
−2.13 −1.88 −1.64 −1.40 −1.16 −0.92 −0.67 −0.42 −0.16 0.10 0.37 0.65 0.92
−1.96 −1.72 −1.48 −1.24 −1.00 −0.76 −0.51 −0.26 0.01 0.28 0.55 0.82 1.10
−1.80 −1.56 −1.32 −1.08 −0.84 −0.60 −0.35 −0.09 0.18 0.45 0.73 1.00 1.28
−1.64 −1.40 −1.16 −0.92 −0.68 −0.44 −0.18 0.08 0.35 0.63 0.91 1.18 1.45
−1.48 −1.23 −0.99 −0.76 −0.52 −0.27 −0.01 0.26 0.53 0.81 1.09 1.36 1.63
−1.32 −1.07 −0.83 −0.60 −0.35 −0.10 0.16 0.44 0.71 0.99 1.26 1.53 1.80
−1.15 −0.91 −0.67 −0.43 −0.19 0.07 0.34 0.62 0.90 1.17 1.44 1.71 1.97
−0.99 −0.75 −0.51 −0.27 −0.02 0.25 0.52 0.80 1.07 1.34 1.61 1.88 2.14
−0.83 −0.58 −0.34 −0.10 0.15 0.43 0.70 0.98 1.25 1.52 1.78 2.04 2.31
−0.66 −0.42 −0.18 0.07 0.33 0.61 0.88 1.15 1.42 1.68 1.95 2.21 2.47
−0.50 −0.25 −0.01 0.24 0.51 0.79 1.06 1.32 1.59 1.85 2.11 2.37 2.63
−0.33 −0.09 0.15 0.41 0.68 0.95 1.22 1.48 1.75 2.01 2.27 2.53 2.79
−0.17 0.06 0.30 0.57 0.84 1.11 1.38 1.64 1.91 2.17 2.43 2.69 2.95
−0.03 0.20 0.44 0.72 1.00 1.27 1.54 1.80 2.06 2.32 2.58 2.84 3.10
0.10 0.32 0.58 0.87 1.15 1.42 1.69 1.95 2.22 2.48 2.74 3.00 3.26
0.22 0.46 0.73 1.02 1.30 1.57 1.84 2.11 2.37 2.63 2.89 3.16 3.42
0.35 0.60 0.88 1.17 1.45 1.72 1.99 2.26 2.52 2.79 3.05 3.31 3.57
0.50 0.76 1.04 1.32 1.60 1.88 2.15 2.41 2.68 2.94 3.20 3.47 3.73
0.65 0.92 1.20 1.48 1.76 2.03 2.30 2.57 2.83 3.09 3.36 3.62 3.88
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Second, we form the product of a pair of random numbers from the standard normal distribution (r1, r2)
with the Cholesky decomposition matrix from the variance-covariance matrix for the estimates of γ1
and γ2. The latter is given by:
lone_pensioners IMD2007
lone_pensioners 0.177364 0
IMD2007 0.027877 0.110647
Finally, we add this pair of products to the respective coefficient estimates of γ1 and γ2 to obtain our
sampled pair of values of γ1 and γ2 (call these ~γ1 and ~γ2). In other words, for each pair of random
numbers (r1, r2), we calculate the sampled values ~γ1 and ~γ2 where:
h
~γ1
~γ2
i
¼
h
γ^1
γ^2
i
þ
 h
a11 a12
a21 a22
i

h
r1
r2
i 
sampled coefficients Cholesky pair of
values for from decomposition  random
coefficients ¼ IV þ matrix numbers
on excluded regressions from standard
instruments (Equations 19 and 20) normal
above distribution
This sampling procedure is undertaken 1000 times, both with a zero covariance between γ^1 and γ^2, and
again with a non-zero covariance.
These procedures generate two sets of 1000 pairs of values for γ^1 and γ^2 (one set assumes a zero
covariance between γ^1 and γ^2, and the other does not). These sets of values for γ^1 and γ^2 can be used
to examine the sensitivity of the estimated outcome elasticity to alternative non-zero values for the
coefficients on the excluded instruments.
TABLE 79 Table showing various estimates associated with the excluded instruments from the outcome equation
for the big four programmes
Programme Instrument Coefficient
Standard
error Variance Covariance
Cancer z1: lone pensioner households −0.2074942 0.1773647 0.0314582 0.00494454
z2: IMD2007 −0.0827677 0.1141054 0.0130200
Circulatory disease z1: lone pensioner households −0.2606290 0.2441101 0.059590 0.01122591
z2: IMD2007 −0.2105334 0.2879230 0.082900
Respiratory problems z1: long-term unemployment
rate
0.2642582 0.13273061 0.0176174 −0.02136305
z2: LLT rate −1.739808 1.611403 2.5966196
Gastrointestinal
problems
z1: unpaid carers 1.812286 2.347459 5.510564 0.08016639
z2: IMD2007 0.5567431 0.2066839 0.0427822
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Obtaining the outcome elasticities associated with sampled coefficients
on the excluded instruments
For each pair of sampled values of γ1 and γ2 (γ^1 and γ^2), we can use IV techniques to estimate the model:
ynew ¼ y − ~γ1z1 − ~γ2z2 ¼ ∝þ β1x þ β2nþ ∈ (21)
with the usual instrument set (x2, z1 and z2) used to instrument the endogenous variable × 1 (expenditure).
For each pair of sampled values ~γ1 and ~γ2, we obtain a different outcome elasticity (
bβ1) and these different
values can be plotted in a histogram. Such a plot illustrates the uncertainty associated with our point estimate
of the outcome elasticity due to doubts about the validity of our instruments; we call this type of uncertainty
‘level 2’ uncertainty. This ‘level 2’ uncertainty is in addition to what we label ‘level 1’ uncertainty, that is, the
uncertainty about the value of the outcome elasticity assuming the validity of our exclusion restrictions
(remember that our estimated outcome elasticity is only a point estimate and that it has a distribution
attached to it). To illustrate this ‘level 1’ uncertainty, we can sample from the distribution of the point
estimate for the outcome elasticity from our basic IV model (where ~γ1 and ~γ2 are zero in Equation 21) and
plot the sampled values (Figures 16–43).
Plots illustrating the degree of level 1 uncertainty for each of the big four programmes are shown as
Figures 16 (cancer), 23 (circulatory disease), 30 (respiratory problems) and 37 (gastrointestinal problems).
These level 1 uncertainty plots can be compared with plots of bβ1 from the estimation of Equation 21. The
latter plots illustrate the degree of level 2 uncertainty, that is, the uncertainty associated with our point
estimate of the outcome elasticity due to doubts about the validity of the instruments. Figures 17 (cancer),
24 (circulatory disease), 31 (respiratory problems) and 38 (gastrointestinal problems) show plots of the
outcome elasticity (β1 from Equation 21) assuming a zero covariance between γ^1 and γ^2 in Equations 18
and 19. Figures 18 (cancer), 25 (circulatory disease), 32 (respiratory problems) and 39 (gastrointestinal
problems) show plots of the outcome elasticity (bβ1 from Equation 21) assuming a non-zero covariance
between γ^1 and γ^2 in Equations 18 and 19.
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FIGURE 16 Sampling 1000 values from the distribution of the point estimate for the cancer outcome elasticity.
Note: the mean value of these 1000 sampled outcome elasticities is −0.338. The outcome elasticity for cancer
expenditure in the basic IV model is −0.342.
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FIGURE 17 Sensitivity of the outcome elasticity for cancer expenditure to 1000 alternative pairs of coefficients on
the excluded instruments with a zero covariance between these coefficients. Note: the mean value of the 1000
outcome elasticities is –0.209 (mean SE = 0.109). The outcome elasticity for cancer expenditure in the basic IV
model is –0.342 (SE = 0.099). SE, standard error.
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FIGURE 18 Sensitivity of the outcome elasticity for cancer expenditure to 1000 alternative pairs of coefficients on
the excluded instruments with a non-zero covariance between the coefficients. Note: the mean value of the 1000
outcome elasticities is –0.209 (mean SE = 0.105). The outcome elasticity for cancer expenditure in the basic IV
model is –0.342 (SE = 0.099). SE, standard error.
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FIGURE 19 Sampling from the 1000 outcome elasticities for cancer expenditure (that were generated using 1000
alternative pairs of coefficients on the excluded instruments with a zero covariance between these coefficients).
Note: the mean value of these 1000 sampled outcome elasticities is –0.220. The outcome elasticity for cancer
expenditure in the basic IV model is –0.342.
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FIGURE 20 Sampling from the 1000 outcome elasticities for cancer expenditure (that were generated using 1000
alternative pairs of coefficients on the excluded instruments with a non-zero covariance between these
coefficients). Note: the mean value of these 1000 sampled outcome elasticities is –0.218. The outcome elasticity for
cancer expenditure in the basic IV model is –0.342.
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FIGURE 21 Kernel density plots from Figures 16, 17 and 19: illustrating the uncertainty associated with the point
estimate for the cancer outcome. Note: the mean value of the level 1/level 2/level 3 elasticities is –0.338/–0.209/
–0.220. The outcome elasticity for cancer expenditure in the basic IV model is –0.342.
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FIGURE 22 Kernel density plots from Figures 16, 18 and 20: illustrating the uncertainty associated with the point
estimate for the cancer outcome. Note: the mean value of the level 1/level 2/level 3 elasticities is –0.338/–0.209/
–0.218. The outcome elasticity for cancer expenditure in the basic IV model is –0.342.
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FIGURE 23 Sampling 1000 values from the distribution of the point estimate for the circulatory disease outcome
elasticity. Note: the mean value of these 1000 sampled outcome elasticities is –1.418. The outcome elasticity for
circulatory disease expenditure in the comparable IV model is –1.427.
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FIGURE 24 Sensitivity of the outcome elasticity for circulatory disease expenditure to 1000 alternative pairs of
coefficients on the excluded instruments with a zero covariance between these coefficients. Note: the mean value
of the 1000 outcome elasticities is –1.697 (mean SE= 0.269). The outcome elasticity for circulatory expenditure in
the comparable IV model is –1.427 (SE= 0.228). SE, standard error.
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FIGURE 25 Sensitivity of the outcome elasticity for circulatory disease expenditure to 1000 alternative pairs of
coefficients on the excluded instruments with non-zero covariance between the coefficients. Note: the mean value
of the 1000 outcome elasticities is −1.700 (mean SE= 0.269). The outcome elasticity for circulatory expenditure in
the comparable IV model is −1.427 (SE= 0.228). SE, standard error.
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Finally, the point estimates bβ1 from the estimation of Equation 21 also have a standard error and we can
sample from these distributions. These sampled values illustrate what we term ‘level 3’ uncertainty, that is,
the uncertainty associated with the value of the outcome elasticity due to both level 1 (sampling) and
level 2 (instrument invalidity) effects.
Plots illustrating the degree of level 3 uncertainty, assuming a zero covariance between γ^1 and γ^2 in
Equations 18 and 19, are shown as Figures 19 (cancer), 26 (circulatory disease), 33 (respiratory problems)
and 40 (gastrointestinal problems). Plots illustrating the degree of level 3 uncertainty, assuming a non-zero
covariance between γ^1 and γ^2 in Equations 18 and 19, are shown as Figures 20 (cancer), 27 (circulatory
disease), 34 (respiratory problems) and 41 (gastrointestinal problems).
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FIGURE 26 Sampling from the 1000 outcome elasticities for circulatory disease expenditure (that were generated
using 1000 alternative pairs of coefficients on the excluded instruments with a zero covariance between these
coefficients). Note: the mean value of these 1000 sampled outcome elasticities is –1.717. The outcome elasticity for
circulatory expenditure in the comparable IV model is –1.427.
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FIGURE 27 Sampling from the 1000 outcome elasticities for circulatory disease expenditure (that were generated
using 1000 alternative pairs of coefficients on the excluded instruments with a non-zero covariance between these
coefficients). Note: the mean value of these 1000 sampled outcome elasticities is –1.718. The outcome elasticity for
circulatory expenditure in the comparable IV model is –1.427.
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FIGURE 28 Kernel density plots from Figures 23, 24 and 26: illustrating the uncertainty associated with the point
estimate for the circulatory disease outcome elasticity. Note: the mean value of the level 1/level 2/level 3 elasticities
is –1.418/–1.697/–1.717. The outcome elasticity for circulatory disease expenditure in the comparable IV model
is –1.427.
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FIGURE 29 Kernel density plots from Figures 23, 25 and 27: illustrating the uncertainty associated with the point
estimate for the circulatory disease outcome elasticity. Note: the mean value of the level 1/level 2/level 3 elasticities
is –1.418/–1.700/–1.718. The outcome elasticity for circulatory disease expenditure in the comparable IV model
is –1.427.
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FIGURE 30 Sampling 1000 values from the distribution of the point estimate for the respiratory disease outcome
elasticity. Note: The mean value of these 1000 sampled outcome elasticities is –2.004. The outcome elasticity for
respiratory expenditure in the comparable IV model is –2.029.
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FIGURE 31 Sensitivity of the outcome elasticity for respiratory disease expenditure to 1000 alternative pairs of
coefficients on the excluded instruments with a zero covariance between these coefficients. Note: the mean value
of the 1000 outcome elasticities is –1.145 (mean SE= 0.489). The outcome elasticity for respiratory expenditure in
the comparable IV model is –2.029 (SE= 0.636). SE, standard error.
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FIGURE 32 Sensitivity of the outcome elasticity for respiratory disease expenditure to 1000 alternative pairs of
coefficients on the excluded instruments with a non−zero covariance between the coefficients. Note: the mean
value of the 1000 outcome elasticities is –1.149 (mean SE= 0.485). The outcome elasticity for respiratory
expenditure in the comparable IV model is –2.029 (SE= 0.636). SE, standard error.
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FIGURE 33 Sampling from the 1000 outcome elasticities for respiratory disease expenditure (that were generated
using 1000 alternative pairs of coefficients on the excluded instruments with a zero covariance between these
coefficients). Note: the mean value of these 1000 sampled outcome elasticities is −1.146. The outcome elasticity for
respiratory expenditure in the comparable IV model is −2.029.
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Uncertainty and the value of the cancer outcome elasticity
Figure 16 plots 1000 values from the distribution of the point estimate for the cancer outcome elasticity.
The mean value of these sampled values is −0.338 (the outcome elasticity in the basic IV model is −0.342
and its standard error is 0.099) and virtually all of them lie between 0 and −0.6.
The histogram in Figure 17 provides a plot of 1000 point estimates for the cancer outcome elasticity if we
drop the assumption that the coefficients on the excluded instruments are exactly zero (and we also
assume a zero covariance between γ^1 and γ^2 in Equations 18 and 19). The mean value of these 1000
outcome elasticities is −0.209 and this is about one-third lower than the elasticity in the basic IV model
(−0.342). In addition, the mean value of the standard errors associated with these 1000 elasticities (0.109)
is slightly greater than the standard error in the basic IV model (0.099) so that about one-quarter of the
outcome elasticities in Figure 17 take a non-negative value.
The histogram in Figure 18 provides a similar plot to that in Figure 17 but this time we assume a non-zero
covariance between γ^1 and γ^2 in Equations 18 and 19. There is very little difference between the zero
(see Figure 17) and non-zero (see Figure 18) covariance plots, with both the mean elasticity and mean
standard error virtually identical in both plots.
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FIGURE 34 Sampling from the 1000 outcome elasticities for respiratory disease expenditure (that were generated
using 1000 alternative pairs of coefficients on the excluded instruments with a non-zero covariance between these
coefficients). Note: the mean value of these 1000 sampled outcome elasticities is −1.151. The outcome elasticity for
respiratory expenditure in the comparable IV model is −2.029.
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FIGURE 35 Kernel density plots from Figures 30, 31 and 33: illustrating the uncertainty associated with the
point estimate for the respiratory disease outcome elasticity. Note: the mean value of the level 1/level 2/level 3
elasticities is –2.004/–1.145/–1.146. The outcome elasticity for respiratory disease expenditure in the comparable IV
model is –2.029.
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The histograms in Figures 17 and 18 provide plots of the point estimate for the cancer outcome elasticity if
we drop the assumption that the coefficients on the excluded instruments are exactly zero. Each point
estimate also has a standard error and we can sample from these estimates and their distributions to
obtain the histograms shown in Figures 19 and 20. With the exception of a slight lengthening in the tail
on the left hand side, these plots are very similar to the plots in Figures 17 and 18.
Figure 21 reproduces the three kernel density plots shown in Figures 16, 17 and 19 (remember that
Figures 17 and 19 assume a zero covariance between γ^1 and γ^2 in Equations 18 and 19). Together these
plots illustrate the impact of all three levels of uncertainty on our estimate of the cancer outcome elasticity.
It is clear that the uncertainty induced by the instrument validity issue considerably increases the
uncertainty associated with our estimate of the outcome elasticity (compare, for example, the density plot
for level 1 uncertainty with those for both level 2 and level 3 uncertainty).
Figure 22 reproduces the three kernel density plots shown in Figures 16, 18 and 20 (remember that
Figures 18 and 20 assume a non-zero covariance between γ^1 and γ^2 in Equations 18 and 19). As is the
case for Figure 21, these plots illustrate the impact of all three levels of uncertainty on our estimate of the
cancer outcome elasticity and, again, it is clear that it is the uncertainty induced by the instrument validity
issue that considerably increases the uncertainty associated with our estimate of the outcome elasticity.
For example, the standard deviation associated with the level 1 uncertainty density plot is 0.099 but the
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FIGURE 36 Kernel density plots from Figures 30, 32 and 34: illustrating the uncertainty associated with the point
estimate for the respiratory disease outcome elasticity. Note: the mean value of the level 1/level 2/level 3
elasticities is –2.004/–1.149/–1.151. The outcome elasticity for respiratory disease expenditure in the comparable IV
model is –2.029.
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FIGURE 37 Sampling 1000 values from the distribution of the point estimate for the gastrointestinal disease
outcome elasticity. Note: the mean value of these 1000 sampled outcome elasticities is –1.518. The outcome
elasticity for gastrointestinal expenditure in the comparable IV model is –1.536.
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standard deviation for the level 2 (0.338) and level 3 (0.379) uncertainty density plots are both
considerably larger than this.
Uncertainty and the value of the circulatory disease outcome elasticity
Figure 23 plots 1000 values from the distribution of the point estimate for the circulatory disease outcome
elasticity. The mean value of these sampled values is −1.418 and virtually all of these values lie between
−2.0 and −0.75. The outcome elasticity in the comparable IV model is −1.427.ah
The histogram in Figure 24 provides a plot of 1000 point estimates for the circulatory disease outcome
elasticity if we drop the assumption that the coefficients on the excluded instruments are exactly zero
(and we also assume a zero covariance between γ^1 and γ^2 in Equations 18 and 19). The mean value of
these 1000 outcome elasticities is −1.697 and this is about one-fifth larger than the elasticity in the
comparable IV model (−1.427). Similarly, the mean value of the standard errors associated with these
1000 elasticities (0.269) is also about one-fifth larger than the standard error in the comparable basic IV
model (0.228). Virtually all of the point estimates values lie between −4.0 and 0.0, and there are very few
non-negative values.
The histogram in Figure 25 provides a similar plot to that in Figure 24 but this time we assume a non-zero
covariance between γ^1 and γ^2 in Equations 18 and 19. There is very little difference between the zero
(see Figure 24) and non-zero (see Figure 25) covariance plots, with both the mean elasticity and mean
standard error virtually identical in both plots.
The histograms in Figures 24 and 25 provide plots of the point estimate for the circulatory disease
outcome elasticity if we drop the assumption that the coefficients on the excluded instruments are exactly
zero. Each point estimate also has a standard error and we can sample (with replacement) from these
estimates and their distributions to obtain the histograms shown in Figures 26 and 27. With the exception
of a slight lengthening in the tail on the left hand side (as was also observed for the cancer programme),
these plots are very similar to the plots in Figures 24 and 25.
Figure 28 reproduces the three kernel density plots shown in Figures 23, 24 and 26 (remember that
Figures 24 and 26 assume a zero covariance between γ^1 and γ^2 in Equations 18 and 19). Together these
plots illustrate the impact of all three levels of uncertainty on our estimate of the circulatory disease
outcome elasticity. It is clear that the uncertainty induced by the instrument validity issue considerably
increases the uncertainty associated with our estimate of the outcome elasticity (note that the range of
values increases dramatically from the density plot illustrating level 1 uncertainty to that illustrating
level 2 uncertainty).
F
re
q
u
e
n
cy
150
100
50
0
−15 −10 −5 0 5 10
Outcome elasticity for gastrointestinal disease expenditure
FIGURE 38 Sensitivity of the outcome elasticity for gastrointestinal disease expenditure to 1000 alternative pairs of
coefficients on the excluded instruments with a zero covariance between these coefficients. Note: the mean value
of the 1000 outcome elasticities is –2.365 (mean SE= 0.853). The outcome elasticity for gastrointestinal expenditure
in the basic IV model is –1.536 (SE= 0.468). SE, standard error.
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Figure 29 reproduces the three kernel density plots from Figures 23, 25 and 27 (remember that Figures 25
and 27 assume a non-zero covariance between γ^1 and γ^2 in Equations 18 and 19). As is the case for
Figure 28, these plots illustrate the impact of all three levels of uncertainty on our estimate on the
circulatory disease outcome elasticity and, again, it is clear that it is the uncertainty induced by
the instrument validity issue that considerably increases the uncertainty associated with our estimate of
the outcome elasticity. For example, the standard deviation associated with the level 1 uncertainty density
plot is 0.228 but the standard deviation for the level 2 (0.735) and level 3 (0.843) uncertainty density plots
are both considerably larger than this.
Uncertainty and the value of the respiratory disease outcome elasticity
Figure 30 plots 1000 values from the distribution of the point estimate for the respiratory disease
outcome elasticity [see column (5) of Table 65]. The mean value of these sampled values is −2.004 (the
outcome elasticity in the comparable IV model is −2.029) and all of these values lie between −4.0 and 0.
The histogram in Figure 31 provides a plot of 1000 point estimates for the respiratory disease outcome
elasticity if we drop the assumption that the coefficients on the excluded instruments are exactly zero
(and we also assume a zero covariance between γ^1 and γ^2 in Equations 18 and 19). The mean value of
these 1000 outcome elasticities from the respiratory disease outcome model (−1.145) is almost one-half
of the size of the elasticity in the comparable basic IV model (−2.029). And the mean value of the
standard errors associated with these 1000 elasticities (0.489) is about one-quarter less than the standard
error in the comparable basic IV model (0.636).
The histogram in Figure 32 provides a similar plot to that in Figure 31 but this time we assume a non-zero
covariance between γ^1 and γ^2 in Equations 18 and 19. However, there is very little difference between the
zero (see Figure 31) and non-zero (see Figure 32) covariance plots, with both the mean elasticity and mean
standard error virtually identical in these two plots.
The histograms in Figures 31 and 32 provide plots of the point estimate for the respiratory disease
outcome elasticity if we drop the assumption that the coefficients on the excluded instruments are exactly
zero. Each point estimate also has a standard error and we can sample from these estimates and their
distributions to obtain the histograms shown in Figures 33 and 34. With the exception of a slight
lengthening of the tail on the left-hand side, these plots are similar to those in Figures 31 and 32 so the
sampling procedure would appear to have little impact on the distribution of the point elasticities.
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FIGURE 39 Sensitivity of the outcome elasticity for gastrointestinal disease expenditure to 1000 alternative pairs of
coefficients on the excluded instruments with non-zero covariance between the coefficients. Note: the mean value
of the 1000 outcome elasticities is –2.360 (mean SE= 0.839). The outcome elasticity for gastrointestinal expenditure
in the basic IV model is –1.536 (SE= 0.468). SE, standard error.
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Figure 35 reproduces the three kernel density plots shown in Figures 30, 31 and 33 (remember that
Figures 31 and 33 assume a zero covariance between γ^1 and γ^2 in Equations 18 and 19). Together these
plots illustrate the impact of all three levels of uncertainty on our estimate of the respiratory disease
outcome elasticity. It is clear that the uncertainty induced by the instrument validity issue both shifts the
density plot to the right and increases the uncertainty associated with our estimate of the outcome
elasticity (e.g. the range of values increases from −4.0 to 0.0 at level 1 to −5.0 to 2.5 at level 3).
Figure 36 reproduces the three kernel density plots shown in Figures 30, 32 and 34 (remember that
Figures 32 and 34 assume a non-zero covariance between γ^1 and γ^2 in Equations 18 and 19). As is the
case for Figure 35, these plots illustrate the impact of all three levels of uncertainty on our estimate of the
respiratory disease outcome elasticity and, again, it is clear that the uncertainty induced by the instrument
validity issue both shifts the density plot to the right and considerably increases the uncertainty associated
with our estimate of the outcome elasticity. More precisely, the standard deviation associated with the
level 1 uncertainty density plot is 0.636 but the standard deviation for the level 2 (0.919) and level 3
(1.098) uncertainty density plots are both considerably larger than this.
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FIGURE 40 Sampling from the 1000 outcome elasticities for gastrointestinal disease expenditure (that were
generated using 1000 alternative pairs of coefficients on the excluded instruments with a zero covariance between
these coefficients). Note: the mean value of these 1000 sampled outcome elasticities is –2.442. The outcome
elasticity for gastrointestinal expenditure in the comparable IV model is –1.536.
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FIGURE 41 Sampling from the 1000 outcome elasticities for gastrointestinal disease expenditure (that were
generated using 1000 alternative pairs of coefficients on the excluded instruments with a non-zero covariance
between these coefficients). Note: the mean value of these 1000 sampled outcome elasticities is –2.434.
The outcome elasticity for gastrointestinal expenditure in the comparable IV model is –1.536.
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Uncertainty and the value of the gastrointestinal disease outcome elasticity
Figure 37 plots 1000 values from the distribution of the point estimate for the gastrointestinal disease
outcome elasticity [see column (7) of Table 65]. The mean of these sampled values is −1.518 (the outcome
elasticity in the comparable IV model is −1.536) and all of these values lie between −3.0 and 0.0.
The histogram in Figure 38 provides a plot of 1000 point estimates for the gastrointestinal disease
outcome elasticity if we drop the assumption that the coefficients on the excluded instruments are exactly
zero (and we also assume a zero covariance between γ^1 and γ^2 in Equations 18 and 19). The mean value
of these 1000 outcome elasticities (−2.365) is 50% larger than the size of the elasticity in the comparable
IV model (−1.536). And the mean value of the standard errors associated with these 1000 elasticities
(0.853) is about 80% larger than the standard error in the basic IV model (0.468).
The histogram in Figure 39 provides a similar plot to that in Figure 38, but this time we assume a non-zero
covariance between γ^1 and γ^2 in Equations 18 and 19. However, there is very little difference between the
zero (see Figure 38) and non-zero (see Figure 39) covariance plots, with both the mean elasticity and mean
standard error virtually identical in these plots.
The histograms in Figures 38 and 39 provide plots of point estimates for the gastrointestinal disease
outcome elasticity if we drop the assumption that the coefficients on the excluded instruments are exactly
zero. Each point estimate also has a standard error and we can sample from these estimates and their
distributions to obtain the histograms shown in Figures 40 and 41. With the exception of a slight extension
to both tails, these plots are similar to the plots in Figures 38 and 39.
Figure 42 reproduces the three kernel density plots shown in Figures 37, 38 and 40 (remember that
Figures 38 and 40 assume a zero covariance between γ^1 and γ^2 in Equations 18 and 19). These plots
illustrate the impact of all three levels of uncertainty on our estimate of the gastrointestinal disease
outcome elasticity. It is clear that the uncertainty induced by the instrument validity issue both shifts the
density plot to the left slightly and dramatically increases the uncertainty associated with our estimate of
the outcome elasticity (e.g. the range of values increases from −3 to 0 at level 1, from −13 to 9 at level 2,
and then further from −16 to 11 at level 3).
Figure 43 reproduces the three kernel density plots shown in Figures 37, 39 and 41 (remember that
Figures 39 and 41 assume a non-zero covariance between γ^1 and γ^2 in Equations 18 and 19). As is the
case for Figure 42, these plots illustrate the impact of all three levels of uncertainty on our estimate of
the gastrointestinal disease outcome elasticity. And again, it is clear that the uncertainty induced by the
instrument validity issue both shifts the density plot to the left slightly and considerably increases the
uncertainty (range) associated with our estimate of the outcome elasticity. More precisely, the standard
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FIGURE 42 Kernel density plots from Figures 37, 38 and 40: illustrating the uncertainty associated with the point
estimate for the gastrointestinal disease outcome elasticity. Note: the mean value of the level 1/level 2/level 3
elasticities is −1.518/−2.365/−2.442. The outcome elasticity for gastrointestinal expenditure in the comparable IV
model is −1.536.
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deviation associated with the level 1 uncertainty density plot is 0.468 but the standard deviation for the
level 2 (3.658) and level 3 (3.834) uncertainty density plots are both eight times larger than this.
Implications of uncertainty for the estimate of the cost of a life-year
In the previous subsection, we have evaluated the outcome equation elasticities when uncertainty over the
validity of instrument variables is considered (‘level 3’ uncertainty), in contrast to assuming the instruments
are valid (‘level 1’ uncertainty). This analysis showed that including level 3 uncertainty affects the central
value of the outcome elasticities; however, it is difficult to predict its effect on the expectation of the
threshold given the impact of expenditure on mortality appears reduced in some programmes but
increased in others. In Table 80, the mean estimates of the outcome elasticities under level 3 uncertainty
were used to calculate the threshold for the big four programmes of health. The results show that
relaxing the assumption of validity of the instruments has little impact on the expectation of the threshold
for the big four PBCs [the cost per YLG threshold changed from £10,604 (see Table 68) to £11,009
(see Table 80)].
The assumption of validity of instruments is expected to affect significantly the level of uncertainty over
the cost-effectiveness threshold estimate. Illustrations of this source of uncertainty were presented in the
previous section (see Obtaining the outcome elasticities associated with sampled coefficients on the
excluded instruments) using empirical distributions derived from the sampling procedure implemented;
these illustrations represent the uncertainty in the mean estimate for each of the elasticities. To characterise
the effect of levels 1 and 3 uncertainty on the overall threshold we used the sets of simulated elasticities
(one for each of the four programmes of care) to compute a threshold value; in doing so for all simulated
sets, a sample of threshold values was obtained. In this way, uncertainty was propagated from the outcome
elasticities to the threshold estimates, and an empirical distribution describing uncertainty over threshold
estimates obtained. The cumulative density function can be used to display such uncertainty; this plots
the probability (y-axis) of the threshold being below certain values (x-axis) in the simulated sample
(this corresponds to a Bayesian interpretation of uncertainty). Figure 44 plots the cumulative density
curve for the cost per life gained threshold when level 1 and level 3 uncertainty are considered in turn,
and Figure 45 for the cost per YLG threshold.
The probability that the overall threshold is < £7500 per life-year is around 0.2 when uncertainty over the
validity of instruments is considered (level 3), whereas when the instruments are assumed valid (level 1)
this probability is 0. Under level 1 uncertainty, we would be confident that the threshold is < £30,000
(probability of 1), but when considering level 3 uncertainty there is some chance that the threshold is
> £30,000 (probability of 0.2). These plots show that uncertainty on the validity of the instruments
generates significant uncertainty over the threshold value.
0
0.2
0.4
0.6
0.8
kdensity level_1_uncertainty
kdensity level_2_uncertainty
kdensity level_3_uncertainty
−15 −10 −5 0 5 10
Outcome elasticity for gastrointestinal disease expenditure
D
e
n
si
ty
FIGURE 43 Kernel density plots from Figures 37, 39 and 41: illustrating the uncertainty associated with the point
estimate for the gastrointestinal disease outcome elasticity. Note: the mean value of the level 1/level 2/level 3
elasticities is −1.518/−2.360/−2.434. The outcome elasticity for gastrointestinal expenditure in the comparable IV
model is −1.536.
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TABLE 80 Cost of life and life-year estimates for the big four programmes using expenditure data for 2006 and outcome data for 2006/7/8 adjusted for the ICD-10 coverage of
the expenditure and outcome data
PBC description
Spend
(£M)
2006/7
Spend
elasticity
Change
in spend
(£M)
Annual
mortality,
< 75 years,
2006/7/8
Outcome
elasticity
(without
negative
sign)
Coverage
of
mortality
data
relative
to spend
data
Change
in annual
mortality
adjusted
for
coverage
Cost per
life
gained
(£)
adjusted
for
coverage
Total life-
years lost,
< 75 years,
2006/7/8
Coverage of
mortality
data relative
to spend
data
Change
in annual
life-years
lost
adjusted
for YLL
Cost per
YLG (£)
Cost per
YLG
adjusted
for YLL
coverage
(£)
1 Cancer 4122 0.465 19.17 61,961 0.218 0.984 63.90 299,975 2,207,021 0.984 759 16,383 25,265
2 Circulatory
problems
6161 0.540 33.27 41,106 1.718 0.992 384.42 86,544 1,361,634 0.992 4245 9466 7838
3 Respiratory
problems
3285 0.679 22.31 11,574 1.151 0.773 116.99 190,666 324,223 0.773 1092 11,593 20,419
4 Gastrointestinal
problems
3700 0.446 16.50 6160 2.434 0.571 117.11 140,906 345,908 0.571 2192 20,892 7528
5 Spend 2006
and mortality
2006/7/8
17,268 91.24 120,801 682.42 133,707 4,238,786 8288 12,333 11,009
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Summary and conclusion
One of the crucial elements in the calculation of the cost of a life-year for any care programme is the
coefficient on the expenditure variable in the outcome equation. The endogenous nature of expenditure
in our model means that OLS estimation is inappropriate and that instead IV techniques must be used.
The application of these techniques requires the identification of variables that are good predictors of the
endogenous variable (expenditure) but which do not have a direct effect on the dependent
variable (mortality).
It is difficult to provide theoretical arguments why our selected instruments will not affect mortality directly.
Instead, we rely on the widely used Hansen–Sargen test of instrument validity. Although our models ‘pass’
this test, some commentators have argued that this test has weak power and may fail to reject the null
hypothesis of instrument validity even when an exclusion restriction is not valid. Given our reliance on this
test, we noted that this test will only lack power if the biases induced in the coefficient on the endogenous
variable by invalid instruments all coincide (i.e. the instruments all identify the same wrong parameter).
However, it is far from obvious that this will be so in this case, particularly given that our outcome
equation already includes a measure of the need for health care.
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FIGURE 44 Cumulative density plot for the cost per life gained threshold for the big four PBCs (considers
covariance between the coefficients on the excluded instruments). In drawing the cumulative density function,
negative threshold values were dealt with by evaluating whether it was the health component or the cost
component that was negative. For simulations where health change was negative (0% were observed for both
levels 1 and 3), the threshold was left as a negative value. Simulations showing a negative change in spend were
assigned a very high positive threshold value – in these an asymptote is generated in the plot (respectively 0% and
5.6% were observed for levels 1 and 3).
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FIGURE 45 Cumulative density plot for the cost per YLG threshold for the big four PBCs (considers covariance
between the coefficients on the excluded instruments). In drawing the cumulative density function, negative
threshold values were dealt with by evaluating whether it was the health component or the cost component that
was negative. For simulations where health change was negative (0% were observed for both levels 1 and 3), the
threshold was left as a negative value. Simulations showing a negative change in spend were assigned a very high
positive threshold value – in these an asymptote is generated in the plot (respectively 0.04% and 7.7% were
observed for levels 1 and 3).
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Nevertheless, it is possible that our instruments are correlated with both expenditure and some unobserved
factor which is directly influencing the mortality rate, and that the induced bias in bβ1 is the same for
both instruments.
We therefore undertook an extensive sensitivity analysis of the estimated outcome elasticity to the validity
of the exclusion restrictions. In summary, we found that both the central value and distribution of the
outcome elasticity may change if we drop the assumption that the coefficients on the excluded
instruments are identically zero.
This change in the central value of the outcome elasticity reduces the impact of expenditure on mortality in
some programmes (e.g. for cancer the ‘average’ outcome elasticity falls from −0.338 to −0.210, and for
respiratory disease it falls from −2.004 to −1.151). However, in other programmes this change in the
central value increases the impact of expenditure on mortality (e.g. for circulatory disease the ‘average’
outcome elasticity increases from −1.418 to −1.718, and for gastrointestinal problems it increases from
−1.518 to −2.434).
However, in all four programmes the standard deviation associated with the distribution of the value for
the outcome elasticity increased: for cancer it increased from 0.099 to 0.379; for circulatory disease it
increased from 0.228 to 0.843; for respiratory disease it increased from 0.636 to 1.098; and for
gastrointestinal disease it increased from 0.468 to 3.834.
Analysis of programme budgeting expenditure for 2007/8 and
mortality data for 2007/8/9
Outcome and expenditure models were estimated using updated data for expenditure (from 2006/7 to
2007/8) and updated mortality data (from 2006/7/8 to 2007/8/9). Results for the outcome model are
shown in Table 81 and results for the expenditure model are in Table 82. First-stage regressions for these
IV models can be found in Tables 97 and 98 in the Annex.
Outcome models
Some of the outcome models in Table 81 contain just two variables: own programme expenditure and
a measure of the need for health care. The latter is usually the measure of need as employed by the
Department of Health for resource allocation purposes and this incorporates the CARAN formula for acute
services. For the respiratory programme we have added the square of this need measure to improve the
model fit. In other PBCs we found that the all service measure of need performed poorly and we have
replaced or supplemented it with either a more programme-specific measure (e.g. the epilepsy prevalence
rate for neurological mortality) or with a better performing proxy for need (e.g. the percentage of residents
born outside the EU for maternity/neonate mortality).
Two results are reported for three of the big four programmes. One of these two results uses two
instruments and so we report the instrument validity test statistic. We cannot reject the null hypothesis of
instrument validity in all three cases. However, there is some evidence of weak instruments (at least in the
respiratory and gastrointestinal programmes) but, if we drop one instrument and re-estimate the model,
the evidence of instrument weakness disappears (but of course there is no instrument validity test
statistic with this re-estimation). The removal of one instrument has little impact on the coefficient on
expenditure and it is this coefficient from this one instrument model that we use below in our cost of a
life-year calculations.
The first seven results in Table 81 show the outcome model for the big four programmes (i.e. for cancer,
circulatory disease, respiratory problems and gastrointestinal problems). In all four programmes the need
variable has a positive and significant effect on mortality, and expenditure has the anticipated negative
effect. The diagnostic statistics reveal that, in all four PBCs, own programme expenditure is endogenous
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TABLE 81 Table showing outcome models using spend data for 2007/8 (two MFFs) and mortality data for
2007/8/9
Variable
PBC 2, cancer, 2007/8,
outcome model,
instrument spend,
weighted, second stage
PBC 10, circulation, 2007/8, outcome model,
instrument spend, weighted, second stage
PBC 11, respiratory,
2007/8, outcome model,
instrument spend,
weighted, second stage
(1) (2) (3) (4) (5)
Own programme
spend per head
−0.365*** −0.365*** −1.277*** −2.205*** −2.211***
[0.106] [0.107] [0.206] [0.705] [0.739]
Need CARAN
per head
0.984*** 0.985*** 2.818*** 5.119*** 5.113***
[0.108] [0.110] [0.256] [1.052] [1.105]
Need CARAN per
head squared
4.085** 3.982**
[1.721] [1.774]
IMD2007
Diabetes prevalence
rate 2007/8
Epilepsy prevalence
rate 2007/8
Lone parent
households
HIV need per
head squared
HIV need per head
Born outside
the EU
No qualifications
aged 16–74 years
No car households
Full-time students
Constant 6.635*** 6.637*** 10.643*** 12.244*** 12.269***
[0.480] [0.483] [0.996] [2.947] [3.090]
Observations 151 151 151 151 151
Endogeneity
test statistic
17.288 16.323 39.948 21.368 28.333
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PBC 13,
gastrointestinal,
2007/8, outcome
model, instrument
spend, weighted,
second stage
PBC 4,
endocrine,
2007/8,
outcome
model,
instrument
spend,
weighted,
second
stage
PBC 7,
neurological,
2007/8,
outcome
model, other
programme
need
exogenous,
weighted,
OLS
PBC 17,
genitourinary,
2007/8,
outcome
model,
instrument
spend,
weighted,
second stage
PBC 1,
infectious
diseases,
2007/8,
outcome
model,
instrument
spend,
weighted,
second
stage
PBC 18+ 19,
maternity
and
neonates,
2007/8,
outcome
model,
instrument
spend,
weighted,
second stage
PBC 16,
trauma and
injuries,
2007/8,
outcome
model,
instrument
spend,
weighted,
second
stage
(6) (7) (8) (9) (10) (11) (12) (13)
−1.292*** −1.328** −0.566 −0.339** −1.898** −0.546* −0.110 −0.369
[0.497] [0.519] [0.550] [0.144] [0.921] [0.300] [0.139] [0.353]
3.908*** 3.947*** 0.853** 3.029***
[0.633] [0.658] [0.344] [0.717]
0.517*** 0.481***
[0.109] [0.098]
0.820**
[0.359]
0.652***
[0.231]
1.767***
[0.430]
0.143**
[0.064]
0.487***
[0.120]
0.152***
[0.028]
0.990***
[0.115]
−0.658***
[0.221]
0.528***
[0.128]
8.688*** 8.845*** 0.512 3.072*** 12.110** 2.176*** 3.303*** 2.654**
[2.142] [2.237] [1.349] [0.614] [4.852] [0.675] [0.762] [1.346]
151 151 151 151 147 151 151 151
18.871 17.769 1.293 3.916 3.603 0.551 1.375
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TABLE 81 Table showing outcome models using spend data for 2007/8 (two MFFs) and mortality data for
2007/8/9 (continued )
Variable
PBC 2, cancer, 2007/8,
outcome model,
instrument spend,
weighted, second stage
PBC 10, circulation, 2007/8, outcome model,
instrument spend, weighted, second stage
PBC 11, respiratory,
2007/8, outcome model,
instrument spend,
weighted, second stage
(1) (2) (3) (4) (5)
Endogeneity
p-value
3.21e-05 5.34e-05 1.42e-05 3.79e-06 1.02e-07
Hansen–Sargan
test statistic
0.00124 n/a 0.056 n/a 0.163
Hansen-Sargan
p-value
0.972 0.814 0.686
Shea’s partial R2 0.162 0.162 0.323 0.0832 0.0977
Kleibergen–Paap
LM test statistic
19.52 19.44 20.71 8.807 8.840
Kleibergen–Paap
p-value
5.76e-05 1.04e-05 0.0000 0.00300 0.0120
Kleibergen–Paap
F-statistic
14.50 29.13 34.54 12.26 6.533
Pesaran–Taylor/
Ramsey test
statistic
0.00606 0.0115 2.06 2.839 2.850
Pesaran–Taylor/
Ramsey p-value
0.938 0.915 0.1515 0.0920 0.0914
* p< 0.1; ** p< 0.05; *** p< 0.01; n/a, not applicable.
Robust standard errors in brackets.
The addition of unpaid carers as an instrument for the endocrine outcome model generates a Hansen–Sargen test
statistic of 0.372 (p-value 0.5418) and the coefficient on expenditure is −0.423.
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PBC 13,
gastrointestinal,
2007/8, outcome
model, instrument
spend, weighted,
second stage
PBC 4,
endocrine,
2007/8,
outcome
model,
instrument
spend,
weighted,
second
stage
PBC 7,
neurological,
2007/8,
outcome
model, other
programme
need
exogenous,
weighted,
OLS
PBC 17,
genitourinary,
2007/8,
outcome
model,
instrument
spend,
weighted,
second stage
PBC 1,
infectious
diseases,
2007/8,
outcome
model,
instrument
spend,
weighted,
second
stage
PBC 18+ 19,
maternity
and
neonates,
2007/8,
outcome
model,
instrument
spend,
weighted,
second stage
PBC 16,
trauma and
injuries,
2007/8,
outcome
model,
instrument
spend,
weighted,
second
stage
(6) (7) (8) (9) (10) (11) (12) (13)
1.40e-05 2.49e-05 0.255 0.0478 0.0577 0.458 0.241
0.120 n/a n/a 6.710 0.583 0.675 5.001
0.729 0.0349 0.747 0.411 0.0820
0.126 0.112 0.133 0.160 0.104 0.201 0.137
10.76 10.53 20.71 20.01 16.45 30.58 16.82
0.00462 0.00117 5.36e-06 0.000169 0.000917 2.29e-07 0.000770
7.809 14.70 25.56 9.624 9.688 23.31 7.835
0.418 0.106 0.00725 0.469 0.393 2.251 0.00684 0.0128
0.518 0.744 0.932 0.704 0.531 0.134 0.934 0.910
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TABLE 82 Table showing expenditure models using spend data for 2007/8 (two MFFs) and mortality data for
2007/8/9
Variable
(1) PBC 2,
cancer, 2007/8,
spend model,
second stage
(2) PBC 10,
circulation,
2007/8, spend
model,
second stage
(3) PBC 11,
respiratory,
2007/8, spend,
model, second
stage
(4) PBC 13,
gastrointestinal,
2007/8, spend
model, second
stage
(5) PBC 1,
infectious
disease, 2007/8,
spend model,
OLS
All-cause SYLLR
excluding cancer
−1.227***
[0.220]
PCT budget
per head
0.890** 0.293 0.536* 0.622* 1.435***
[0.431] [0.350] [0.298] [0.321] [0.258]
Need CARAN
per head
1.659*** 3.117*** 1.786*** 1.982***
[0.430] [0.535] [0.334] [0.422]
All-cause SYLLR
excluding
circulatory
−2.115***
[0.397]
All-cause SYLLR
excluding
respiratory
−0.781***
[0.236]
Need CARAN per
head squared
1.687***
[0.446]
All-cause SYLLR
excluding
gastrointestinal
−1.279***
[0.333]
HIV need per
head
0.440***
[0.025]
All-cause SYLLR
excluding
infectious diseases
−0.543**
[0.249]
HIV need per
head squared
0.183***
[0.021]
All-cause SYLLR
excluding diabetes
Diabetes prevalence
rate 2007/8
All-cause SYLLR
excluding epilepsy
Epilepsy prevalence
rate 2007/8
All-cause SYLLR
excluding renal
Maternity need
per head
All-cause SYLLR
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
298
(6) PBC 4,
endocrine,
2007/8, spend
model,
second
stage
(7) PBC 7,
neurological,
2007/8, spend
model, second
stage
(8) PBC 17,
genitourinary,
2007/8, spend
model, OLS
(9) PBC 18+19,
maternity and
neonates, 2007/8,
spend model, OLS
(10) PBC 23,
GMS/PMS, etc.,
2007/8, spend
model, second
stage
(11) PBC 16, trauma
and injuries, 2007/8,
spend model,
second stage
0.264 1.036*** 1.004*** 0.514* 0.563 1.686***
[0.206] [0.307] [0.356] [0.264] [0.344] [0.384]
0.925*** 0.029
[0.305] [0.371]
−0.384*
[0.218]
0.332***
[0.123]
−0.259
[0.223]
0.571***
[0.072]
−0.072
[0.168]
0.582***
[0.098]
0.286 −0.169 −0.277
[0.193] [0.290] [0.363]
DOI: 10.3310/hta19140 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 14
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Claxton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
299
TABLE 82 Table showing expenditure models using spend data for 2007/8 (two MFFs) and mortality data for
2007/8/9 (continued )
Variable
(1) PBC 2,
cancer, 2007/8,
spend model,
second stage
(2) PBC 10,
circulation,
2007/8, spend
model,
second stage
(3) PBC 11,
respiratory,
2007/8, spend,
model, second
stage
(4) PBC 13,
gastrointestinal,
2007/8, spend
model, second
stage
(5) PBC 1,
infectious
disease, 2007/8,
spend model,
OLS
Lone
pensioner
households
Population working
in agriculture
Constant 4.973 15.081*** 4.986** 7.488*** −4.212***
[3.047] [3.303] [2.342] [2.786] [1.034]
Observations 151 151 151 151 151
Endogeneity
test statistic
20.985 19.454 11.612 15.477
Endogeneity
p-value
4.63e-06 1.03e-05 0.000655 8.35e-05
Hansen–Sargan
test statistic
0.411 0.003 1.369 0.0201
Hansen–Sargan
p-value
0.522 0.959 0.504 0.887
Shea’s partial R2 0.384 0.253 0.398 0.325
Kleibergen–Paap
LM test statistic
40.04 28.14 39.41 33.23
Kleibergen–Paap
p-value
2.02e-09 7.76e-07 1.42e-08 6.09e-08
Kleibergen–Paap
F-statistic
51.44 29.097 40.69 20.04
Pesaran–Taylor/
Ramsey test statistic
2.262 0.0002 0.0236 0.0341 0.721
Pesaran–Taylor/
Ramsey p-value
0.133 0.988 0.878 0.854 0.541
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
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(6) PBC 4,
endocrine,
2007/8, spend
model,
second
stage
(7) PBC 7,
neurological,
2007/8, spend
model, second
stage
(8) PBC 17,
genitourinary,
2007/8, spend
model, OLS
(9) PBC 18+19,
maternity and
neonates, 2007/8,
spend model, OLS
(10) PBC 23,
GMS/PMS, etc.,
2007/8, spend
model, second
stage
(11) PBC 16, trauma
and injuries, 2007/8,
spend model,
second stage
−0.480***
[0.182]
0.132***
[0.022]
3.555* −1.684 −2.675 −1.222 1.413 −5.960***
[1.817] [1.130] [2.562] [1.388] [1.373] [1.104]
151 151 151 151 151 151
2.846 4.958 0.060 1.769
0.0916 0.0260 0.807 0.183
0.510 2.748 1.091 1.121
0.775 0.0974 0.296 0.571
0.402 0.518 0.416 0.364
40.29 31.53 16.51 27.19
9.26e-09 1.42e-07 0.000260 5.37e-06
37.14 73.21 26.60 32.54
2.351 0.619 1.297 1.018 1.757 0.193
0.125 0.432 0.278 0.387 0.185 0.660
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and that the instruments are valid. They also suggest that the instruments are relevant and there is no
evidence that the instruments are weak in the models with one excluded instrument. The Pesaran–Taylor
test suggests that there is no evidence of model misspecification.
The outcome results for the other programmes [see columns (8)–(13) in Table 81] are similar to but more
diverse than those for the big four programmes. This is to be anticipated because mortality is a much rarer
outcome in these programmes than it is in the big four programmes. Own programme expenditure is not
endogenous in four of these programmes but we retain the IV estimator for three of these four because
this yields more plausible results than the OLS estimator (the results are more plausible in the sense that
the signs on the coefficients are more in line with our prior expectations).
Expenditure has the anticipated negative effect on mortality in the endocrine problems programme but
this is not statistically significant. The all service measure of need is not relevant for this PBC; instead, we
find that the diabetes prevalence rate is positively associated with mortality, as is a measure of deprivation
(the IMD2007).
Mortality from epilepsy is negatively and significantly associated with expenditure in the neurological
programme. Both the all service need for health care and the epilepsy prevalence rate are positively and
significantly associated with mortality in this programme.
Expenditure has a negative and statistically significant effect on mortality (from renal problems) in the
genitourinary problems programme. The prevalence of lone parent households is positively associated
with mortality.
Expenditure has the anticipated negative effect on mortality in the infectious disease programme and this
is statistically significant. The all service measure of need is not relevant for this PBC; instead, we find that
a measure of need associated with HIV is positively associated with mortality, as is a measure of
deprivation (the IMD2007).
Expenditure has the anticipated negative effect on mortality in the maternity and neonates programme,
but the estimated coefficient is not statistically significant. In this PBC the generic all service measure of
need has been replaced with two other indicators of deprivation – the proportion of residents born outside
the EU and the proportion of those aged 16−74 years without any qualifications – and both of these are
positively associated with mortality.
Finally, expenditure and need have the anticipated effects on mortality in the trauma and injuries
programme. In addition, the proportion of households without access to a car is negatively associated with
mortality from fractures (perhaps access to a car facilitates involvement in serious road traffic accidents),
and the proportion of residents that are students is positively associated with mortality from fractures.
The relevant statistical test suggests that expenditure is endogenous in 6 of the 10 programmes but we
have retained the IV estimates for three of the other four programmes because they provide plausible
results. The Hansen–Sargen test suggests that the selected instruments are valid, and the Kleibergen–Paap
LM statistic suggests that they are relevant (i.e. correlated with the endogenous regressor). With the
possible exception of the trauma and injuries programme, the Kleibergen–Paap F-statistic suggests that we
do not have a problem with weak instruments.ai Finally, the Pesaran–Taylor/Ramsey reset test statistics
reveal no evidence of misspecification.
Expenditure models
Most of the expenditure models in Table 82 contain just three variables: the PCT budget, a proxy for the
own programme need for health care, and a proxy for the need for health care in other programmes.
The budget term is positive in all 11 models and it is statistically significant in 8 of these 11 models.
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The usual proxy for the own programme need for health care (i.e. the all service measure of need) is
present in six of the models and it is significant in five of them. Its presence is supplemented with the
addition of its squared value to improve model fit in the respiratory problems programme.
In some programmes (e.g. endocrine, metabolic and nutritional, and neurological), we have replaced
and/or supplemented the all service measure of need with a more programme-specific measure
(e.g. the diabetes prevalence rate and the epilepsy prevalence rate) and these measures of need have the
anticipated positive impact on expenditure.
In addition, in a couple of other programmes we have used alternative proxies for the own programme
need (e.g. with the use of the Department of Health’s measure of maternity need in the maternity and
neonates expenditure equation).
For 8 of the 11 programmes we have used the all-cause mortality rate less the own programme
mortality rate as the proxy for the need for health care in other programmes, and the coefficient on
this term is negative in seven programmes and statistically significant in six of the seven. In three
programmes – maternity and neonates, GMS/PMS, and trauma and injuries programmes – we have used
the all-cause mortality rate as the proxy for the need for health care in other programmes due to
difficulties associated with the measurement of the own programme mortality rate. The coefficient on this
term is not significant in any of the three models.
The relevant statistical test suggests that expenditure is endogenous in 6 of the 11 programmes, but we
have retained the IV estimates for two other programmes (GMS/PMS, and trauma and injuries) because
the IV estimator provides more plausible results. In the other three programmes we report OLS results.
The Hansen–Sargen test suggests that the selected instruments are valid, and the Kleibergen–Paap
LM statistic suggests that they are relevant (i.e. correlated with the endogenous regressor).
The Kleibergen–Paap F-statistic suggests that we do not have a problem with weak instruments.
Finally, the Pesaran–Taylor reset test statistics and the Ramsey reset F-statistics reveal no evidence of
model misspecification.
Calculation of the cost of a life and life-year
Expenditure and outcome elasticities for our preferred models are shown in Table 83 [see columns (D)
and (G)] and these are used to calculate the cost of a life and the cost of a life-year, both for individual
programmes and for all programmes collectively.
Column (L) (see Table 83) reports the cost per life gained and column (R) (see Table 83) reports the
cost per YLG. From the latter we can see that the cost per YLG is £13,830 for the big four programmes
and £28,983 for all 10 programmes with a mortality-based outcome indicator. These represent 30% and
45% increases on the respective costs for the previous year (i.e. using expenditure data for 2006/7
and mortality data for 2006/7/8).
If we assume that the other 13 programmes (all without a mortality-based outcome indicator) offer no
health gain, then the cost per life-year across all PCT expenditure is £82,765. This is up from £73,457
using data for the previous year (an increase of 13%).
In addition, Table 84 shows that if we assume that PBC 23 generates a zero health gain and that the gain
attributable to the remaining 12 programmes is, on average, the same as that attributable to those with a
mortality outcome measure, then the cost of a life-year across all programmes is £31,846 (it was £22,565
using data for the previous year).
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TABLE 83 Table showing cost of life and life-year estimates using spend data for 2007/8 and outcome data
for 2007/8/9 (assumes zero health gain for 13 programmes)
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2007/8
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Annual
mortality,
<75 years,
2007/8/9
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in
annual mortality
(I)
(=E/H) cost per
life gained (£)
1 Cancer 4573 0.890 40.70 61,960 0.365 201.28 202,207
2 Circulatory
problems
6325 0.293 18.53 39,304 1.277 147.06 126,018
3 Respiratory
problems
3431 0.536 18.39 10,764 2.205 127.22 144,557
4 Gastrointestinal
problems
3805 0.622 23.67 6031 1.328 49.82 475,081
Big four programmes summary
5 Spend 2007
and mortality
2007/8/9
18,134 101.29 118,059 525.37 192,795
6 Spend 2006
and mortality
2006/7/8
17,268 91.24 120,801 665.10 137,188
7 Spend 2006
and mortality
2004/5/6
17,268 114.04 125,290 953.13 119,650
8 Spend 2005
and mortality
2002/3/4
17,625 141.22 125,290 909.96 155,196
9 Infectious
diseases
1119 1.436 16.07 1977 0.548 15.56 1,032,863
10 Endocrine
problems
1997 0.264 5.27 1471 0.566 2.20 2,398,551
11 Neurological
problems
3165 1.035 32.76 718 0.339 2.52 13,003,180
12 Genitourinary
problems
3439 1.004 34.53 270 1.855 5.03 6,866,327
13 Trauma and
injuries
2918 1.686 49.20 1013 0.369 6.30 7,806,376
14 Maternity and
neonates
3662 0.514 18.82 2199 0.110 1.24 15,139,113
Other six programmes summary
15 Spend 2007
and mortality
2007/8/9
16,300 156.65 7648 32.85 4,768,699
16 Spend 2006
and mortality
2006/7/8
15,643 93.29 7839 16.14 5,780,723
17 Spend 2006
and mortality
2004/5/6
15,643 112.13 7923 18.17 6,172,491
18 Spend 2005
and mortality
2002/3/4
12,743 99.44 7923 16.26 6,115,621
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(J)
Coverage
of
mortality
data
relative
to spend
data
(K)
(=H/J)
change in
annual
mortality
adjusted
for
coverage
(L)
(=E/K) cost
per life
gained (£)
adjusted
for
coverage
(M) Total
life-years
lost,
<75 years,
2007/09
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage
of
mortality
data
relative
to spend
data
(P) (=N/O)
change in
annual
life-years
lost adjusted
for coverage
(Q)
(=E/N)
cost per
YLG (£)
(R)
(=E/P)
cost per
YLG
adjusted
for
coverage
(£)
0.984 204.55 198,972 2,189,685 2371 0.984 2410 17,165 16,891
0.992 148.25 125,010 1,313,223 1638 0.992 1651 11,315 11,224
0.773 164.58 111,742 315,457 1243 0.773 1608 14,798 11,439
0.571 87.25 271,271 343,355 945 0.571 1656 25,034 14,295
604.62 167,526 4,161,720 6197 7324 16,345 13,830
761.49 119,823 4,238,786 7399 8604 12,333 10,604
4,335,559 10,576 10,783
4,516,953 10,986 12,855
1.000 15.56 1,032,863 106,092 278 1.000 278 57,742 57,742
0.634 3.47 1,520,681 55,492 28 0.634 44 190,745 120,932
0.136 18.52 1,768,432 64,873 76 0.136 558 431,749 58,718
0.172 29.24 1,181,008 8529 53 0.172 308 652,096 112,160
0.175 36.01 1,366,116 21,273 44 0.175 252 1,115,197 195,159
8.213 0.15 124,337,534 489,170 92 0.679 136 204,168 138,630
102.95 1,521,610 745,429 571 1575 274,309 99,428
25.05 3,724,129 762,991 362 639 258,046 146,108
757,531 249 449,706
751,009 337 295,074
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TABLE 83 Table showing cost of life and life-year estimates using spend data for 2007/8 and outcome data
for 2007/8/9 (assumes zero health gain for 13 programmes) (continued )
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2007/8
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Annual
mortality,
<75 years,
2007/8/9
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in
annual mortality
(I)
(=E/H) cost per
life gained (£)
All 10 programmes summary
19 Spend 2007
and mortality
2007/8/9
34,434 257.94 125,707 558.22 462,067
20 Spend 2006
and mortality
2006/7/8
32,911 184.53 128,640 681.24 270,881
21 Spend 2006
and mortality
2004/5/6
32,911 226.18 133,213 971.30 232,861
22 Spend 2005
and mortality
2002/3/4
30,368 240.67 133,213 926.22 259,838
Assume zero health gain in the other 13 programmes: other 13 programmes summary
23 Spend 2007
and mortality
2007/8/9
39,223 478.63 0.00
24 Spend 2006
and mortality
2006/7/8
34,985 494.43 0.00
25 Spend 2006
and mortality
2004/5/6
34,985 452.78 0.00
26 Spend 2005
and mortality
2002/3/4
33,942 402.43 0.00
All 23 programmes
27 Spend 2007
and mortality
2007/8/9
73,657 736.57 558.22 1,319,496
28 Spend 2006
and mortality
2006/7/8
67,896 678.96 681.24 996,655
29 Spend 2006
and mortality
2004/5/6
67,896 678.96 971.30 699,024
30 Spend 2005
and mortality
2002/3/4
64,310 643.10 926.22 694,330
Note
All 23 programmes spend: 2007/8 £73,657; 2006/7 £67,896; 2005/6 £64,310.
% change in budget: 2007/8 1.00%; 2006/7 1.00%; 2005/6 1.00%.
Proportionate change: 2007/8 0.01; 2006/7 0.01; 2005/6 0.01.
Change in budget: 2007/8 £736.57; 2006/7 £678.96; 2005/6 £643.10.
The YLL for maternity and neonates is estimated as [(6456 neonate deaths× 75 years) + (142 maternal deaths× 35 years)].
This totals 489,170 life-years.
The annual mortality figures reported in cells F7 and F8, and F17 and F18 are identical because we do not have
mortality data for 2002/3/4.
For expenditure in 2007/8, the neonate category has been merged with maternity to obtain plausible outcome and
expenditure models.
The adjustment for the coverage of the mortality and YLL data relative to the spend data uses deaths under age 75 years
in England in 2008.
The YLL figure for trauma and injuries has been estimated assuming that each death is on average at age 67 years so that,
on average, 7 years of life are lost per death.
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(J)
Coverage
of
mortality
data
relative
to spend
data
(K)
(=H/J)
change in
annual
mortality
adjusted
for
coverage
(L)
(=E/K) cost
per life
gained (£)
adjusted
for
coverage
(M) Total
life-years
lost,
<75 years,
2007/09
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage
of
mortality
data
relative
to spend
data
(P) (=N/O)
change in
annual
life-years
lost adjusted
for coverage
(Q)
(=E/N)
cost per
YLG (£)
(R)
(=E/P)
cost per
YLG
adjusted
for
coverage
(£)
707.57 364,540 4,907,149 6768 8900 38,110 28,983
786.54 234,617 5,001,777 7760 9243 23,780 19,965
5,093,090 10,826 20,893
5,267,962 11,322 21,256
0.00 0.00 0.00
0.00 0.00
0.00
0.00
707.57 1,040,992 6768 8900 108,829 82,765
786.54 863,228 7760 9243 87,494 73,457
10,826 62,718
11,322 56,799
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TABLE 84 Table showing cost of life and life-year estimates using spend data for 2007/8 and outcome data
for 2007/8/9 (assumes zero health gain for PBC 23 and ‘average’ gain for other 12 programmes)
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2007/8
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Annual
mortality,
<75 years,
2007/8/9
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in annual
mortality
(I) (=E/H)
cost per
life
gained (£)
1 Cancer 4573 0.890 40.70 61,960 0.365 201.28 202,207
2 Circulatory
problems
6325 0.293 18.53 39,304 1.277 147.06 126,018
3 Respiratory
problems
3431 0.536 18.39 10,764 2.205 127.22 144,557
4 Gastrointestinal
problems
3805 0.622 23.67 6031 1.328 49.82 475,081
Big four programmes summary
5 Spend 2007
and mortality
2007/8/9
18,134 101.29 118,059 525.37 192,795
6 Spend 2006
and mortality
2006/7/8
17,268 91.24 120,801 665.10 137,188
7 Spend 2006
and mortality
2004/5/6
17,268 114.04 125,290 953.13 119,650
8 Spend 2005
and mortality
2002/3/4
17,625 141.22 125,290 909.96 155,196
9 Infectious
diseases
1119 1.436 16.07 1977 0.548 15.56 1,032,863
10 Endocrine
problems
1997 0.264 5.27 1471 0.566 2.20 2,398,551
11 Neurological
problems
3165 1.035 32.76 718 0.339 2.52 13,003,180
12 Genitourinary
problems
3439 1.004 34.53 270 1.855 5.03 6,866,327
13 Trauma and
injuries
2918 1.686 49.20 1013 0.369 6.30 7,806,376
14 Maternity and
neonates
3662 0.514 18.82 2199 0.110 1.24 15,139,113
Other six programmes summary
15 Spend 2007
and mortality
2007/8/9
16,300 156.65 7648 32.85 4,768,699
16 Spend 2006
and mortality
2006/7/8
15,643 93.29 7839 16.14 5,780,723
17 Spend 2006
and mortality
2004/5/6
15,643 112.13 7923 18.17 6,172,491
18 Spend 2005
and mortality
2002/3/4
12,743 99.44 7923 16.26 6,115,621
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(J)
Coverage
of
mortality
data
relative
to spend
data
(K) (=H/J)
change in
annual
mortality
adjusted
for
coverage
(L) (=E/K)
cost per life
gained (£)
adjusted
for
coverage
(M)
Total
life-years
lost,
<75 years,
2007/8/9
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage
of
mortality
data
relative
to spend
data
(P) (=N/O)
change in
annual
life-years
lost adjusted
for coverage
(Q)
(=E/N)
cost per
YLG (£)
(R) (=E/P)
cost per
YLG
adjusted
for
coverage
(£)
0.984 204.55 198,972 2,189,685 2371 0.984 2410 17,165 16,891
0.992 148.25 125,010 1,313,223 1638 0.992 1651 11,315 11,224
0.773 164.58 111,742 315,457 1243 0.773 1608 14,798 11,439
0.571 87.25 271,271 343,355 945 0.571 1656 25,034 14,295
604.62 167,526 4,161,720 6197 7324 16,345 13,830
761.49 119,823 4,238,786 7399 8604 12,333 10,604
4,335,559 10,576 10,783
4,516,953 10,986 12,855
1.000 15.56 1,032,863 106,092 278 1.000 278 57,742 57,742
0.634 3.47 1,520,681 55,492 28 0.634 44 190,745 120,932
0.136 18.52 1,768,432 64,873 76 0.136 558 431,749 58,718
0.172 29.24 1,181,008 8529 53 0.172 308 652,096 112,160
0.175 36.01 1,366,116 21,273 44 0.175 252 1,115,197 195,159
8.213 0.15 124,337,534 489,170 92 0.679 136 204,168 138,630
102.95 1,521,610 745,429 571 1575 274,309 99,428
25.05 3,724,129 762,991 362 639 258,046 146,108
757,531 249 449,706
751,009 337 295,074
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TABLE 84 Table showing cost of life and life-year estimates using spend data for 2007/8 and outcome data
for 2007/8/9 (assumes zero health gain for PBC 23 and ‘average’ gain for other 12 programmes) (continued )
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2007/8
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Annual
mortality,
<75 years,
2007/8/9
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in annual
mortality
(I) (=E/H)
cost per
life
gained (£)
All 10 programmes
19 Spend 2007
and mortality
2007/8/9
34,434 257.94 125,707 558.22 462,067
20 Spend 2006
and mortality
2006/7/8
32,911 184.53 128,640 681.24 270,881
21 Spend 2006
and mortality
2004/5/6
32,911 226.18 133,213 971.30 232,861
22 Spend 2005
and mortality
2002/3/4
30,368 240.67 133,213 926.22 259,838
Other 13 PBCs? Assume zero health gain in PBC 23 . . .
23 PBC 23 spend
2007 and
mortality
2007/8/9
11,763 0.563 66.23 0.00
24 PBC 23 spend
2006 and
mortality
2006/7/8
10,585 0.739 78.22 0.00
25 PBC 23 spend
2006 and
mortality
2004/5/6
10,585 0.759 80.34 0.00
26 PBC 23 spend
2005 and
mortality
2002/3/4
8449 0.926 78.24 0.00
. . . and that the gain in 10 PBCs (see row 19) applies to the remaining 12 PBCs
27 12 PBCs spend
2007 and
mortality
2007/8/9
27,460 412.41 892.53 462,067
28 12 PBCs spend
2006 and
mortality
2006/7/8
24,400 416.20 1536.48 270,881
29 12 PBCs spend
2006 and
mortality
2004/5/6
24,400 372.44 1599.42 232,861
30 12 PBCs spend
2005 and
mortality
2002/3/4
25,493 324.20 1247.69 259,838
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(J)
Coverage
of
mortality
data
relative
to spend
data
(K) (=H/J)
change in
annual
mortality
adjusted
for
coverage
(L) (=E/K)
cost per life
gained (£)
adjusted
for
coverage
(M)
Total
life-years
lost,
<75 years,
2007/8/9
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage
of
mortality
data
relative
to spend
data
(P) (=N/O)
change in
annual
life-years
lost adjusted
for coverage
(Q)
(=E/N)
cost per
YLG (£)
(R) (=E/P)
cost per
YLG
adjusted
for
coverage
(£)
707.57 364,540 4,907,149 6768 8900 38,110 28,983
786.54 234,617 5,001,777 7760 9243 23,780 19,965
5,093,090 10,826 20,893
5,267,962 11,322 21,256
0.00 0.00 0.00
0.00 0.00
0.00
0.00
1131.31 364,540 10,821 14,229 38,110 28,983
1773.97 234,617 17,502 20,847 23,780 19,965
17,826 20,893
15,252 21,256
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TABLE 84 Table showing cost of life and life-year estimates using spend data for 2007/8 and outcome data
for 2007/8/9 (assumes zero health gain for PBC 23 and ‘average’ gain for other 12 programmes) (continued )
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2007/8
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Annual
mortality,
<75 years,
2007/8/9
(G)
Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in annual
mortality
(I) (=E/H)
cost per
life
gained (£)
All 23 programmes
31 23 PBCs spend
2007 and
mortality
2007/8/9
73,657 736.57 1450.75 507,717
32 23 PBCs spend
2006 and
mortality
2006/7/8
67,896 678.96 2217.72 306,153
33 23 PBCs spend
2006 and
mortality
2004/5/6
67,896 678.96 2570.72 264,113
34 23 PBCs spend
2005 and
mortality
2002/3/4
64,310 643.10 2173.90 295,827
Note
All 23 programmes spend: 2007/8 £73,657; 2006/7 £67,896; 2005/6 £64,310.
% change in budget: 2007/8 1.00%; 2006/7 1.00%; 2005/6 1.00%.
Proportionate change: 2007/8 0.01; 2006/7 0.01; 2005/6 0.01.
Change in budget: 2007/8 £736.57; 2006/7 £678.96; 2005/6 £643.10.
The annual mortality figures reported in cells F7 and F8, and F17 and F18 are identical because we do not have
mortality data for 2002/3/4.
The coverage of the YLL data relative to the spend data for trauma and injuries is assumed to take a value of 1.0
(that is, the ICD-10 coverage is the same).
For expenditure in 2007/8, the neonate category has been merged with maternity to obtain plausible outcome and
expenditure models.
The adjustment for the coverage of the mortality and YLL data relative to the spend data uses deaths under age
75 years in England in 2008.
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(J)
Coverage
of
mortality
data
relative
to spend
data
(K) (=H/J)
change in
annual
mortality
adjusted
for
coverage
(L) (=E/K)
cost per life
gained (£)
adjusted
for
coverage
(M)
Total
life-years
lost,
<75 years,
2007/8/9
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage
of
mortality
data
relative
to spend
data
(P) (=N/O)
change in
annual
life-years
lost adjusted
for coverage
(Q)
(=E/N)
cost per
YLG (£)
(R) (=E/P)
cost per
YLG
adjusted
for
coverage
(£)
1838.88 400,554 17,590 23,129 41,875 31,846
2560.50 265,167 25,262 30,090 26,876 22,565
28,652 23,697
26,575 24,200
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Summary and conclusion
In this section we have estimated outcome and expenditure models using PB data for 2007/8 and
mortality data for 2007/8/9. The cost of an additional life-year for all 10 programmes with a
mortality-based outcome is £28,983. This is a 45% increase on the cost (£19,965) for the previous year
(i.e. using expenditure data for 2006/7 and mortality data for 2006/7/8). The next section presents outcome
and expenditure models using PB data for 2008/9 and mortality data for 2008/9/10, and it explores the
reasons for the increase in the cost of an additional life-year identified in this section.
Analysis of programme budgeting expenditure for 2008/9 and
mortality data for 2008/9/10
Outcome and expenditure models were estimated using updated data for expenditure (from 2007/8 to
2008/9) and updated mortality data (from 2007/8/9 to 2008/9/10). Results for the outcome model are
shown in Table 85 and results for the expenditure model are in Table 86. First-stage regressions for these
IV models can be found in Tables 99 and 100 in the Annex.
Outcome models
Most of the outcome models in Table 85 contain just two variables: own programme expenditure and a
measure of the need for health care. The latter is usually the measure of need as employed by the
Department of Health for resource allocation purposes and this incorporates the CARAN formula for acute
services. For the respiratory disease programme we have added the square of the need measure to
improve the model fit. In other PBCs (e.g. for the endocrine, metabolic and nutritional programmes),
we found that the all service measure of need performed poorly and we have replaced it with a more
programme-specific measure (e.g. the diabetes prevalence rate) or with a better performing proxy for need
(e.g. the percentage of residents born outside the EU for maternity/neonate mortality).
The relevant statistical test suggests that expenditure is endogenous in 6 of the 10 programmes but we have
retained the IV estimates for the other four because they provide plausible results. The Hansen–Sargen test
suggests that the selected instruments are valid, and the Kleibergen–Paap LM statistic suggests that they are
relevant (i.e. correlated with the endogenous regressor). The Kleibergen–Paap F-statistic suggests that we do
not have a problem with weak instruments (although the F-statistic is marginally less than the conventional
target value of 10 in the genitourinary and infectious disease programmes). Finally, the Pesaran–Taylor reset
test statistics reveal no evidence of misspecification.
Results for the big four programmes are shown in the first five columns of Table 85. Two results are
reported for the gastrointestinal programme. The first of these [see Table 85, column (4)] uses two
instruments and so we report the instrument validity test statistic. However, one of these instruments is
insignificant in the first-stage regression and, if we drop this instrument and re-estimate the model, we
obtain the result in Table 85, column (5) (but of course there is no instrument validity test statistic with this
re-estimation). The removal of one instrument has little impact on the coefficient on expenditure but the
Kleibergen–Paap F-statistic is now much greater than 10.
In all of the big four programmes the need variable has a positive and significant effect on mortality, and
expenditure has the anticipated negative effect. As we have noted before, the outcome results for the
other programmes [see Table 85, columns (6)–(10)] are similar to but more diverse than those for the big
four programmes. This is to be anticipated because mortality is a much rarer outcome in these
programmes than it is in the big four programmes.
Expenditure has the anticipated negative effect on mortality in the endocrine problems programme and
this is statistically significant. The all service measure of need is not relevant for this PBC; instead, we find
that the diabetes prevalence rate is positively associated with mortality, as is a measure of deprivation
(the IMD2007).
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Expenditure has a negative but statistically insignificant impact on mortality from epilepsy in the
neurological programme, and the all service indicator of the need for health care is positively and
significantly associated with mortality in this programme.
Expenditure also has a negative but not statistically significant effect on mortality (from renal problems) in
the genitourinary problems programme. The prevalence of lone parent households is positively associated
with mortality.
Expenditure has the anticipated negative effect on mortality in the infectious disease programme and this
is statistically significant. The all service measure of need is not relevant for this PBC; instead, we find
that a measure of need associated with HIV is positively associated with mortality, as is a measure of
deprivation (the IMD2007).
Expenditure has the anticipated negative effect on mortality in the maternity and neonates programme.
In this PBC the coefficient on the generic all service measure of need is positive but not significant. It has
been supplemented with two other indicators of deprivation – the proportion of residents born outside the
EU and the proportion of those aged 16−74 years without any qualifications – and both of these are
positively associated with mortality.
Finally, we were unable to develop a plausible outcome model for the trauma and injuries programme.
Expenditure models
Most of the expenditure models in Table 86 contain just three variables: the PCT budget, a proxy for the
own programme need for health care, and a proxy for the need for health care in other programmes.
The budget term is positive and statistically significant in 10 of the 11 models.
The usual proxy for the own programme need for health care (i.e. the all service measure of need) is
positive and significant in 5 of the 11 results. In a couple of programmes (respiratory disease and
endocrine problems) we have added the squared value of need to improve the model fit and in both
cases this term is positive and significant.
In some programmes (e.g. endocrine and neurological), we have replaced and/or supplemented the all
service measure of need with a more programme-specific measure (e.g. the diabetes and the epilepsy
prevalence rates) and these usually have a positive and significant impact on expenditure.
In addition, in a couple of programmes we have used alternative proxies for own programme need
(e.g. with the use of the Department of Health’s measure of maternity need in the maternity/neonates
expenditure equation and the use of HIV need in the infectious diseases programme).
For 8 of the 11 programmes we have used the all-cause mortality rate less the own programme
mortality rate as the proxy for the need for health care in other programmes, and the coefficient on
this term is negative in seven programmes and statistically significant in six of the seven. In three
programmes – maternity and neonates, GMS/PMS, and trauma and injuries programmes – we have
used the all-cause mortality rate as the proxy for the need for health care in other programmes due to
difficulties associated with the measurement of the own programme mortality rate. The coefficient on
this term is negative but not significant in these three models.
The relevant statistical test suggests that expenditure is endogenous in 5 of the 11 programmes but we
have retained the IV estimates for two further programmes (endocrine problems, and maternity and
neonates) because the IV estimator provides more plausible results than the OLS estimator. In the other
four programmes we report OLS results.
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TABLE 85 Table showing outcome models using spend data for 2008/9 (two MFFs) and mortality data
for 2008/9/10
Variable
2008/9, outcome model, instrument spend, weighted, second stage
(1) PBC 2,
cancer
(2) PBC 10,
circulation
(3) PBC 11,
respiratory
(4) PBC 13,
gastrointestinal
Own programme spend
per head
−0.307*** −1.319*** −1.808*** −1.287***
[0.084] [0.186] [0.488] [0.478]
Need CARAN 0.954*** 2.840*** 4.811*** 3.907***
[0.095] [0.247] [0.760] [0.625]
Need CARAN2 3.016**
[1.284]
Diabetes prevalence rate
IMD2007
Lone parent households
HIV need per head
HIV need per head squared
Born outside EU
Population with no
qualifications
Constant 6.372*** 10.861*** 10.818*** 8.715***
[0.381] [0.908] [2.111] [2.076]
Observations 151 151 151 151
Endogeneity test statistic 11.547 25.007 30.177 14.839
Endogeneity p-value 0.000679 5.71e-07 3.94e-08 0.000117
Hansen–Sargan
test statistic
0.843 0.801 0.00285 0.101
Hansen–Sargan p-value 0.358 0.371 0.957 0.751
Shea’s partial R2 0.245 0.282 0.176 0.192
Kleibergen–Paap LM test
statistic
23.51 24.85 13.79 13.60
Kleibergen–Paap p-value 7.85e-06 4.02e-06 0.00101 0.00111
Kleibergen–Paap F-statistic 21.14 47.87 15.10 11.93
Pesaran–Taylor
reset statistic
0.416 0.405 0.104 0.483
Pesaran–Taylor p-value 0.519 0.524 0.747 0.487
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
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(5) PBC 13,
gastrointestinal
(6) PBC 4,
endocrine
(7) PBC 7,
neurological
(8) PBC 17,
genitourinary
(9) PBC 1,
infectious disease
(10) PBC 18+ 19, maternity
and neonates
−1.364** −1.170*** −0.417 −1.615 −0.504** −0.125
[0.549] [0.431] [0.473] [1.608] [0.223] [0.188]
3.993*** 1.280** 0.405
[0.700] [0.579] [0.288]
0.903**
[0.371]
0.711*** 0.528***
[0.108] [0.091]
1.820***
[0.659]
0.468***
[0.093]
0.163***
[0.046]
0.169***
[0.031]
0.752***
[0.129]
9.048*** 2.107** 3.233 11.065 1.844*** 3.097***
[2.386] [1.022] [1.987] [8.588] [0.500] [0.949]
151 151 151 148 151 151
11.963 6.209 2.251 0.530 2.952 0.340
0.000543 0.0127 0.133 0.467 0.0858 0.560
0.558 4.446 3.513 4.412 0.225
0.757 0.108 0.0609 0.220 0.635
0.150 0.193 0.155 0.103 0.191 0.263
11.64 25.23 21.85 12.51 20.29 22.02
0.000644 1.38e-05 7.02e-05 0.00192 0.000437 1.65e-05
16.51 13.56 20.13 9.000 9.306 16.92
0.0584 1.211 0.838 1.681 0.0456 0.107
0.809 0.271 0.360 0.195 0.831 0.744
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TABLE 86 Table showing expenditure models using spend data for 2008/9 (two MFFs) and mortality data
for 2008/9/10
Variable
(1) PBC 2,
cancer, 2008/9,
spend model,
instrument
other
programme
need,
weighted,
second stage
(2) PBC 10,
circulatory,
2008/9, spend
model,
instrument
other
programme
need, weighted,
second stage
(3) PBC 11,
respiratory,
2008/9, spend
model,
instrument
other
programme
need, weighted,
second stage
(4) PBC 13,
gastrointestinal,
2008/9, spend
model,
instrument other
programme
need, weighted,
second stage
(5) PBC 1,
infectious
disease,
2008/9, spend
model, other
programme
need
exogenous,
weighted, OLS
All-cause SYLLR
excluding cancer
−1.216***
[0.186]
PCT budget
per head
0.525* 0.648 0.652* 0.456* 1.546***
[0.296] [0.552] [0.337] [0.254] [0.265]
Need CARAN
per head
2.081*** 2.606*** 2.036*** 2.095***
[0.389] [0.623] [0.377] [0.411]
All-cause SYLLR
excluding
circulatory
−1.987***
[0.351]
All-cause SYLLR
excluding
respiratory
−1.081***
[0.264]
Need CARAN
per head
squared
1.336***
[0.501]
All-cause SYLLR
excluding
gastrointestinal
−1.256***
[0.317]
HIV need per
head
0.456***
[0.027]
All-cause SYLLR
excluding
infectious
disease
−0.472**
[0.227]
HIV need per
head squared
0.178***
[0.023]
All-cause SYLLR
excluding
diabetes
Diabetes
prevalence rate
All-cause SYLLR
excluding
epilepsy
Epilepsy
prevalence rate
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(6) PBC 4,
endocrine,
2008/9, spend
model,
instrument
other
programme
need,
weighted,
second stage
(7) PBC 7,
neurological,
2008/9, spend
model,
instrument
other
programme
need, weighted,
second stage
(8) PBC 17,
genitourinary,
2008/9, spend
model, other
programme
need
exogenous,
weighted, OLS
(9) PBC 18+ 19,
maternity and
neonates, 2008/9,
spend model,
instrument other
programme need,
weighted,
second stage
(10) PBC 23a,
GMS/PMS,
2008/9, spend
model, other
programme
need
exogenous,
weighted, OLS
(11) PBC 16,
trauma and
injuries, 2008/9,
spend model,
other
programme
need
exogenous,
weighted, OLS
0.484** 0.980*** 0.697*** 0.975*** 0.494*** 1.344***
[0.240] [0.220] [0.209] [0.303] [0.140] [0.236]
0.553 0.295 0.724**
[0.369] [0.310] [0.334]
1.602***
[0.495]
−0.164
[0.197]
0.439***
[0.112]
−0.257*
[0.153]
0.414***
[0.063]
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TABLE 86 Table showing expenditure models using spend data for 2008/9 (two MFFs) and mortality data
for 2008/9/10 (continued )
Variable
(1) PBC 2,
cancer, 2008/9,
spend model,
instrument
other
programme
need,
weighted,
second stage
(2) PBC 10,
circulatory,
2008/9, spend
model,
instrument
other
programme
need, weighted,
second stage
(3) PBC 11,
respiratory,
2008/9, spend
model,
instrument
other
programme
need, weighted,
second stage
(4) PBC 13,
gastrointestinal,
2008/9, spend
model,
instrument other
programme
need, weighted,
second stage
(5) PBC 1,
infectious
disease,
2008/9, spend
model, other
programme
need
exogenous,
weighted, OLS
Born outside EU
All-cause SYLLR
excluding renal
All-cause SYLLR
Maternity need
per head
Lone
pensioner
households
Permanently sick
aged 16–74 years
Professional
occupations
Working
in agriculture
Constant 7.556*** 11.702*** 6.044** 8.551*** −5.471***
[2.406] [4.445] [2.651] [2.592] [1.096]
Observations 151 151 151 151 151
R2 0.776
Endogeneity
test statistic
17.101 22.697 17.212 12.023
Endogeneity
p-value
3.54e-05 1.90e-06 3.34e-05 0.000525
Hansen–Sargan
test statistic
0.0538 0.332 0.858 0.420
Hansen–Sargan
p-value
0.817 0.565 0.354 0.517
Shea’s partial R2 0.379 0.265 0.389 0.331
Kleibergen–Paap
LM statistic
39.01 29.71 37.32 33.84
Kleibergen–Paap
p-value
3.38e-09 3.54e-07 7.87e-09 4.48e-08
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(6) PBC 4,
endocrine,
2008/9, spend
model,
instrument
other
programme
need,
weighted,
second stage
(7) PBC 7,
neurological,
2008/9, spend
model,
instrument
other
programme
need, weighted,
second stage
(8) PBC 17,
genitourinary,
2008/9, spend
model, other
programme
need
exogenous,
weighted, OLS
(9) PBC 18+ 19,
maternity and
neonates, 2008/9,
spend model,
instrument other
programme need,
weighted,
second stage
(10) PBC 23a,
GMS/PMS,
2008/9, spend
model, other
programme
need
exogenous,
weighted, OLS
(11) PBC 16,
trauma and
injuries, 2008/9,
spend model,
other
programme
need
exogenous,
weighted, OLS
0.039***
[0.014]
−0.029
[0.139]
−0.348 −0.106 −0.269
[0.302] [0.104] [0.195]
0.846***
[0.120]
−0.166**
[0.079]
−0.310***
[0.092]
−0.124*
[0.064]
0.107***
[0.022]
0.488 −1.315 −0.521 −0.696 0.586 −3.605***
[2.282] [1.005] [1.857] [0.800] [1.133] [1.027]
151 151 151 151 150 151
0.497 0.278 0.339
1.803 7.163 3.243
0.179 0.00744 0.0717
0.138 0.594 1.349
0.710 0.441 0.509
0.399 0.500 0.257
38.45 35.08 22.81
4.48e-09 2.41e-08 4.43e-05
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TABLE 86 Table showing expenditure models using spend data for 2008/9 (two MFFs) and mortality data
for 2008/9/10 (continued )
Variable
(1) PBC 2,
cancer, 2008/9,
spend model,
instrument
other
programme
need,
weighted,
second stage
(2) PBC 10,
circulatory,
2008/9, spend
model,
instrument
other
programme
need, weighted,
second stage
(3) PBC 11,
respiratory,
2008/9, spend
model,
instrument
other
programme
need, weighted,
second stage
(4) PBC 13,
gastrointestinal,
2008/9, spend
model,
instrument other
programme
need, weighted,
second stage
(5) PBC 1,
infectious
disease,
2008/9, spend
model, other
programme
need
exogenous,
weighted, OLS
Kleibergen–Paap
F-statistic
39.97 26.93 44.98 20.13
Pesaran–Taylor
reset statistic
1.129 0.0810 0.000203 0.557
Pesaran–Taylor
p-value
0.288 0.776 0.989 0.456
Ramsey reset
F-statistic
1.723
Probability > F 0.165
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
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(6) PBC 4,
endocrine,
2008/9, spend
model,
instrument
other
programme
need,
weighted,
second stage
(7) PBC 7,
neurological,
2008/9, spend
model,
instrument
other
programme
need, weighted,
second stage
(8) PBC 17,
genitourinary,
2008/9, spend
model, other
programme
need
exogenous,
weighted, OLS
(9) PBC 18+ 19,
maternity and
neonates, 2008/9,
spend model,
instrument other
programme need,
weighted,
second stage
(10) PBC 23a,
GMS/PMS,
2008/9, spend
model, other
programme
need
exogenous,
weighted, OLS
(11) PBC 16,
trauma and
injuries, 2008/9,
spend model,
other
programme
need
exogenous,
weighted, OLS
47.20 75.67 16.35
0.354 0.366 0.00412
0.552 0.545 0.949
1.431 0.072 1.044
0.236 0.975 0.375
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The Hansen–Sargen test suggests that the selected instruments are valid, and the Kleibergen–Paap
LM statistic suggests that they are relevant (i.e. correlated with the endogenous regressor).
The Kleibergen–Paap F-statistic suggests that we do not have a problem with weak instruments. Finally,
the Pesaran–Taylor reset test statistics and the Ramsey reset F-statistics reveal no evidence of
model misspecification.
Calculation of the cost of a life and life-year
Expenditure and outcome elasticities for our preferred models are shown in Table 87 [see columns (D) and
(G)] and these are used to calculate the cost of a life and the cost of a life-year, both for individual
programmes and for all programmes collectively.
Again, Table 87, column (L) reports the cost per life gained and column (R) reports the cost per YLG.
From the latter we can see that the cost per YLG has increased slightly compared with that using the
previous expenditure and mortality data set (i.e. for 2007 and 2007/8/9, respectively): it has increased from
£13,830 to £14,650 for the big four programmes and from £28,983 to £30,883 for all 10 programmes
with a mortality-based outcome indicator.
If we assume that the other 13 programmes offer no health gain, then the cost per life-year across all PCT
expenditure has increased from £82,765 in 2007/8 to £84,974 in 2008/9.
In addition, Table 88 shows that if we assume that PBC 23 generates a zero health gain and that the gain
attributable to the remaining 12 programmes is, on average, the same as that attributable to those with a
mortality outcome measure, then the cost of a life-year across all programmes in 2008/9 is £33,333. This is
a 5% increase on the figure (£31,846) for the previous year.
Comparing the cost of life-year estimates associated with different data sets
Table 89 presents expenditure and outcome elasticities for the five combinations of expenditure and
outcome data that have been used to estimate our model. It also reports the corresponding unadjusted
cost of life-year estimates (i.e. estimates that are unadjusted for the mismatch in the ICD-10 coverage of
the expenditure and mortality data). It is clear from Table 89 [see row (13)] that the (unadjusted) cost of a
life-year for the 10 programmes with a mortality-based outcome indicator fluctuated around £22,000 for
the first three sets of estimations [see columns Table 89, (M)–(O)]. However, using the two most recent
sets of expenditure data (i.e. for 2007/8 and then for 2008/9), the figures in the table suggest that this
cost has increased to about £38,000.
What are the proximate causes of this increase? Recall that the cost of a life-year is calculated as:
The change in expenditure associated with a 1% budget increase
The change in the number of life -years lost associated with this increase
For 2006/7 (using mortality data for 2006/7/8) and for the 10 programmes with a mortality-based outcome
indicator, the change in expenditure associated with a 1% budget increase is £184.53M and the change
in the number of life-years lost associated with this increase is 7760 (see Table 67 for the calculation of
these figures). Thus, the cost of a life-year is £23,780 (= £184.53M/7760).
For 2007/8 (using mortality data for 2007/8/9) and for the 10 programmes with a mortality-based outcome
indicator, the change in expenditure associated with a 1% budget increase is £257.94M and the change
in the number of life-years lost associated with this increase is 6768 (see Table 83 in the appendix for the
calculation of these figures). Thus, the cost of a life-year is £38,110 (= £257.94M/6768).
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It is clear that the 60% increase in the cost of a life-year between 2006/7 and 2007/8 is largely attributable
to (a) the 40% increase in the additional expenditure (up from £184.53M to £257.94M) directed towards
these 10 programmes following a 1% budget increase; and (b) the 12% decline in the number of
YLGs associated with this increase in expenditure (down from 7760 to 6768 life-years).
The rise in the share of the budget increase directed towards these programmes can be attributed to
the increase in the implied expenditure elasticity associated with these 10 programmes (up from 0.561
to 0.749). The decrease in the number of YLG appears to be due to (a) an overall reduction in the
(absolute) size of the outcome elasticities; and (b) a shift in the additional expenditure towards
those programmes with a relatively high cost of a life-year. For example, the cost of a life-year for the
‘small six’ programmes is much larger than for the ‘big four PBCs’. However, in 2007/8 the spend elasticity
for the small six increases from 0.561 to 0.961 (71%), whereas the expenditure elasticity for the big four
rises from 0.528 to 0.559 (6%). A similar pattern – of additional expenditure shifting away from the low
cost PBCs – can be seen within the big four programmes. However, it is not clear why such rather
dramatic changes should have taken place.
Table 90 presents cost of life-year estimates (adjusted for the mismatch in the ICD-10 coverage of the
expenditure and mortality data) for various combinations of programmes. These reveal similar increases in
the cost of a life-year between 2006/7 on the one hand and 2007/8 and 2008/9 on the other. The cost of
a life-year increased from £19,965 in 2006/7 to £28,983 in 2007/8 for the 10 programmes with mortality
rate, an increase of 45%; it increased from £22,565 to £31,846 for all programmes if we assume a zero
health gain in PBC 23 and the same gain in the other 12 programmes as in the 10 with a mortality rate
(an increase of 41%).
One reason for this apparent step change in the cost of a life-year might be the adjustment that was made to
the methodology for the collection of the 2007/8 PB data. In previous years, expenditure that was not directly
attributable to a particular programme category was apportioned using admitted patient care percentages.aj
In other words, if x% of total admitted patient care expenditure was allocated to PBC 1, then x% of all
expenditure that was not directly attributable to a particular programme category was also allocated to PBC 1.
With effect from 2007/8, however, NHS organisations were asked to select an appropriate basis for the
apportionment of this non-programme-specific expenditure and that, where no reasonable basis existed, such
expenditure was to be allocated to the ‘other – miscellaneous’ (PBC 23X) category.
The Department of Health estimates that this allocation rule change increased the amount of expenditure
attributed to PBC 23X by £700M. It will also, of course, have reduced expenditure across other
programmes by the same amount in total. However, not all programmes will have been equally affected;
PBCs that are more heavily inpatient based would have ‘lost’ expenditure whereas others, such as learning
disabilities, social care and mental health, will have ‘lost’ considerably less. In addition, not all PCTs will
have been equally affected because each will have employed different apportionment rules for the
non-programme-specific expenditure (Bryn Shorney, personal communication).
Although this allocation rule change has considerably increased the estimated cost of a life-year, we
believe that this rule change has led to a more accurate allocation of expenditure across PBCs, and that
the more recent estimates of the cost of a life-year (for 2007/8 and 2008/9) are more accurate than those
for the earlier years (for 2005/6 and 2006/7).
Adjusting the cost of a life-year estimates to constant prices
The cost of a life-year estimates presented above are all at current prices. To put them on a constant price
basis, we need an index of pay and price inflation for the labour and goods/services purchased by the NHS.
Curtis87 reports a pay and prices index for HCHSs and this implies an inflation rate of 3.7% in 2006/7, 2.9%
in 2007/8 and 3.9% in 2008/9.ak If we assume that similar inflation rates also apply to the purchase of
pharmaceuticals and the provision of primary care (items that are excluded from the HCHS index), then we
can use these figures to put the cost of a life-year estimates on a constant price basis.
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TABLE 87 Table showing cost of life and life-year estimates using spend data for 2008/9 and outcome data
for 2008/9/10 (assumes zero health gain for 13 programmes)
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2008/9
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F)
Annual
mortality,
<75 years,
2008/9/10
(G) Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in
annual mortality
(I) (=E/H)
cost per life
gained (£)
1 Cancer 4843 0.525 25.43 61,899 0.307 99.77 254,855
2 Circulatory
problems
6655 0.648 43.12 38,075 1.319 325.43 132,514
3 Respiratory
problems
3994 0.652 26.04 10,660 1.808 125.66 207,230
4 Gastrointestinal
problems
3989 0.456 18.19 6015 1.364 37.41 486,199
Big four programmes summary
5 Spend 2008
and mortality
2008/9/10
19,481 112.78 116,649 588.27 191,716
6 Spend 2007
and mortality
2007/8/9
18,134 101.29 118,059 525.37 192,795
7 Spend 2006
and mortality
2006/7/8
17,268 91.24 120,801 665.10 137,188
8 Spend 2006
and mortality
2004/5/6
17,268 114.04 125,290 953.13 119,650
9 Spend 2005
and mortality
2002/3/4
17,625 141.22 125,290 909.96 155,196
10 Infectious
diseases
1201 1.545 18.56 1828 0.504 14.23 1,303,576
11 Endocrine
problems
2222 0.484 10.75 1398 1.170 7.92 1,358,473
12 Neurological
problems
3466 0.980 33.97 711 0.417 2.91 11,690,226
13 Genitourinary
problems
3779 0.697 26.34 240 1.615 2.70 9,749,742
14 Trauma and
injuries
3255 1.344 43.75 983 0.000 0.00 N/A
15 Maternity and
neonates
3978 0.975 38.79 2156 0.125 2.63 14,760,668
Other six programmes summary
16 Spend 2008
and mortality
2008/9/10
17,901 172.15 7316 30.39 5,665,475
17 Spend 2007
and mortality
2007/8/9
16,300 156.65 7648 32.85 4,768,699
18 Spend 2006
and mortality
2006/7/8
15,643 93.29 7839 16.14 5,780,723
19 Spend 2006
and mortality
2004/5/6
15,643 112.13 7923 18.17 6,172,491
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(J)
Coverage
of
mortality
data
relative
to spend
data
(K) (=H/J)
change in
annual
mortality
adjusted
for
coverage
(L) (=E/K)
cost per life
gained (£)
adjusted
for
coverage
(M)
Total
life-years
lost,
<75 years,
2008/9/10
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage
of
mortality
data
relative
to spend
data
(P) (=N/O)
change in
annual life-
years lost
adjusted
for
coverage
(Q) (=E/N)
cost per
YLG (£)
(R)
(=E/P)
cost per
YLG
adjusted
for
coverage
(£)
0.984 101.39 250,777 2,170,660 1166 0.984 1185 21,802 21,454
0.992 328.06 131,454 1,285,026 3661 0.992 3691 11,779 11,685
0.773 162.56 160,189 311,034 1222 0.773 1581 21,307 16,470
0.571 65.52 277,620 341,884 709 0.571 1241 25,662 14,653
657.53 171,552 4,108,604 6758 7698 16,688 14,650
604.62 167,526 4,161,720 6197 7324 16,345 13,830
761.49 119,823 4,238,786 7399 8604 12,333 10,604
4,335,559 10,576 10,783
4,516,953 10,986 12,855
1.000 14.23 1,303,576 100,078 260 1.000 260 71,432 71,432
0.634 12.49 861,272 54,779 103 0.634 163 104,008 65,941
0.136 21.36 1,589,871 64,222 87 0.136 643 388,267 52,804
0.172 15.71 1,676,956 8004 30 0.172 175 877,038 150,851
0.175 0.00 N/A 6881 0 0.175 0 N/A N/A
8.213 0.32 121,229,365 479,905 195 0.679 287 198,939 135,080
64.11 2,685,119 713,869 676 1528 254,794 112,674
102.95 1,521,610 745,429 571 1575 274,309 99,428
25.05 3,724,129 762,991 362 639 258,046 146,108
757,531 249 449,706
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TABLE 87 Table showing cost of life and life-year estimates using spend data for 2008/9 and outcome data
for 2008/9/10 (assumes zero health gain for 13 programmes) (continued )
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2008/9
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F)
Annual
mortality,
<75 years,
2008/9/10
(G) Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in
annual mortality
(I) (=E/H)
cost per life
gained (£)
20 Spend 2005
and mortality
2002/3/4
12,743 99.44 7923 16.26 6,115,621
All 10 programmes summary
21 Spend 2008
and mortality
2008/9/10
37,382 284.93 123,965 618.66 460,562
22 Spend 2007
and mortality
2007/8/9
34,434 257.94 125,707 558.22 462,067
23 Spend 2006
and mortality
2006/7/8
32,911 184.53 128,640 681.24 270,881
24 Spend 2006
and mortality
2004/5/6
32,911 226.18 133,213 971.30 232,861
25 Spend 2005
and mortality
2002/3/4
30,368 240.67 133,213 926.22 259,838
Assume zero health gain in the other 13 programmes: other 13 programmes summary
26 Spend 2008
and mortality
2008/9/10
41,016 499.05 0.00
27 Spend 2007
and mortality
2007/8/9
39,223 478.63 0.00
28 Spend 2006
and mortality
2006/7/8
34,985 494.43 0.00
29 Spend 2006
and mortality
2004/5/6
34,985 452.78 0.00
30 Spend 2005
and mortality
2002/3/4
33,942 402.43 0.00
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(J)
Coverage
of
mortality
data
relative
to spend
data
(K) (=H/J)
change in
annual
mortality
adjusted
for
coverage
(L) (=E/K)
cost per life
gained (£)
adjusted
for
coverage
(M)
Total
life-years
lost,
<75 years,
2008/9/10
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage
of
mortality
data
relative
to spend
data
(P) (=N/O)
change in
annual life-
years lost
adjusted
for
coverage
(Q) (=E/N)
cost per
YLG (£)
(R)
(=E/P)
cost per
YLG
adjusted
for
coverage
(£)
751,009 337 295,074
721.64 394,836 4,822,473 7434 9226 38,328 30,883
707.57 364,540 4,907,149 6768 8900 38,110 28,983
786.54 234,617 5,001,777 7760 9243 23,780 19,965
5,093,090 10,826 20,893
5,267,962 11,322 21,256
0.00 0 0
0.00 0 0
0 0
0
0
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TABLE 87 Table showing cost of life and life-year estimates using spend data for 2008/9 and outcome data
for 2008/9/10 (assumes zero health gain for 13 programmes) (continued )
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2008/9
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F)
Annual
mortality,
<75 years,
2008/9/10
(G) Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in
annual mortality
(I) (=E/H)
cost per life
gained (£)
All 23 programmes
31 Spend 2008
and mortality
2008/9/10
78,398 783.98 618.66 1,267,229
32 Spend 2007
and mortality
2007/8/9
73,657 736.57 558.22 1,319,496
33 Spend 2006
and mortality
2006/7/8
67,896 678.96 681.24 996,655
34 Spend 2006
and mortality
2004/5/6
67,896 678.96 971.30 699,024
35 Spend 2005
and mortality
2002/3/4
64,310 643.10 926.22 694,330
N/A, not applicable.
Note
All 23 programmes spend: 2008/9 £78,398; 2007/8 £73,657; 2006/7 £67,896; 2005/6 £64,310.
% change in budget: 2008/9 1.00%; 2007/8 1.00%; 2006/7 1.00%; 2005/6 1.00%.
Proportionate change: 2008/9 0.01; 2007/8 0.01; 2006/7 0.01; 2005/6 0.01.
Change in budget: 2008/9 £783.98; 2007/8 £736.57; 2006/7 £678.96; 2005/6 £643.10.
The annual mortality figures reported in cells F7 and F8, and F17 and F18 are identical because we do not have
mortality data for 2002/3/4.
For expenditure in 2008/9, the neonate category has been merged with maternity to obtain plausible outcome and
expenditure models.
The adjustment for the coverage of the mortality and YLL data relative to the spend data uses deaths under age
75 years in England in 2008.
The YLL figure for trauma and injuries has been estimated assuming that each death is on average at age 67 years
so that, on average, 7 years of life are lost per death.
The YLL for maternity and neonates is estimated as [(6339 neonate deaths× 75 years) + (128 maternal deaths× 35 years)].
This totals 479,905 life-years.
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(J)
Coverage
of
mortality
data
relative
to spend
data
(K) (=H/J)
change in
annual
mortality
adjusted
for
coverage
(L) (=E/K)
cost per life
gained (£)
adjusted
for
coverage
(M)
Total
life-years
lost,
<75 years,
2008/9/10
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage
of
mortality
data
relative
to spend
data
(P) (=N/O)
change in
annual life-
years lost
adjusted
for
coverage
(Q) (=E/N)
cost per
YLG (£)
(R)
(=E/P)
cost per
YLG
adjusted
for
coverage
(£)
721.64 1,086,385 7434 9226 105,460 84,974
707.57 1,040,992 6768 8900 108,829 82,765
786.54 863,228 7760 9243 87,494 73,457
10,826 62,718
11,322 56,799
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TABLE 88 Table showing cost of life and life-year estimates using spend data for 2008/9 and outcome data
for 2008/9/10 (assumes zero health gain for PBC 23 and average gain for other 12 programmes)
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2008/9
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Annual
mortality,
<75 years,
2008/9/10
(G) Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in annual
mortality
(I) (=E/H)
cost per life
gained (£)
1 Cancer 4843 0.525 25.43 61,899 0.307 99.77 254,855
2 Circulatory
problems
6655 0.648 43.12 38,075 1.319 325.43 132,514
3 Respiratory
problems
3994 0.652 26.04 10,660 1.808 125.66 207,230
4 Gastrointestinal
problems
3989 0.456 18.19 6015 1.364 37.41 486,199
Big four programmes summary
5 Spend 2008
and mortality
2008/9/10
19,481 112.78 116,649 588.27 191,716
6 Spend 2007
and mortality
2007/8/9
18,134 101.29 118,059 525.37 192,795
7 Spend 2006
and mortality
2006/7/8
17,268 91.24 120,801 665.10 137,188
8 Spend 2006
and mortality
2004/5/6
17,268 114.04 125,290 953.13 119,650
9 Spend 2005
and mortality
2002/3/4
17,625 141.22 125,290 909.96 155,196
10 Infectious
diseases
1201 1.545 18.56 1828 0.504 14.23 1,303,576
11 Endocrine
problems
2222 0.484 10.75 1398 1.17 7.92 1,358,473
12 Neurological
problems
3466 0.980 33.97 711 0.417 2.91 11,690,226
13 Genitourinary
problems
3779 0.697 26.34 240 1.615 2.70 9,749,742
14 Trauma
and injuries
3255 1.344 43.75 983 0.000 0.00 N/A
15 Maternity
and neonates
3978 0.975 38.79 2156 0.125 2.63 14,760,668
Other six programmes summary
16 Spend 2008
and mortality
2008/9/10
17,901 172.15 7316 30.39 5,665,475
17 Spend 2007
and mortality
2007/8/9
16,300 156.65 7648 32.85 4,768,699
18 Spend 2006
and mortality
2006/7/8
15,643 93.29 7839 16.14 5,780,723
19 Spend 2006
and mortality
2004/5/6
15,643 112.13 7923 18.17 6,172,491
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(J)
Coverage
of
mortality
data
relative
to spend
data
(K) (=H/J)
change in
annual
mortality
adjusted
for
coverage
(L) (=E/K)
cost per life
gained (£)
adjusted
for
coverage
(M)
Total
life-years
lost,
<75 years,
2008/9/10
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage
of
mortality
data
relative
to spend
data
(P) (=N/O)
change in
annual
life-years
lost adjusted
for coverage
(Q)
(=E/N)
cost
per
YLG (£)
(R) (=E/P)
cost per
YLG
adjusted
for
coverage
(£)
0.984 101.39 250,777 2,170,660 1166 0.984 1185 21,802 21,454
0.992 328.06 131,454 1,285,026 3661 0.992 3691 11,779 11,685
0.773 162.56 160,189 311,034 1222 0.773 1581 21,307 16,470
0.571 65.52 277,620 341,884 709 0.571 1241 25,662 14,653
657.53 171,552 4,108,604 6758 7698 16,688 14,650
604.62 167,526 4,161,720 6197 7324 16,345 13,830
761.49 119,823 4,238,786 7399 8604 12,333 10,604
4,335,559 10,576 10,783
4,516,953 10,986 12,855
1.000 14.23 1,303,576 100,078 260 1.000 260 71,432 71,432
0.634 12.49 861,272 54,779 103 0.634 163 104,008 65,941
0.136 21.36 1,589,871 64,222 87 0.136 643 388,267 52,804
0.172 15.71 1,676,956 8004 30 0.172 175 877,038 150,851
0.175 0.00 N/A 6881 0 0.175 0 N/A N/A
8.213 0.32 121,229,365 479,905 195 0.679 287 198,939 135,080
64.11 2,685,119 713,869 676 1528 254,794 112,674
102.95 1,521,610 745,429 571 1575 274,309 99,428
25.05 3,724,129 762,991 362 639 258,046 146,108
757,531 249 449,706
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TABLE 88 Table showing cost of life and life-year estimates using spend data for 2008/9 and outcome data
for 2008/9/10 (assumes zero health gain for PBC 23 and average gain for other 12 programmes) (continued )
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2008/9
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Annual
mortality,
<75 years,
2008/9/10
(G) Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in annual
mortality
(I) (=E/H)
cost per life
gained (£)
20 Spend 2005
and mortality
2002/3/4
12,743 99.44 7923 16.26 6,115,621
All 10 programmes summary
21 Spend 2008
and mortality
2008/9/10
37,382 284.93 123,965 618.66 460,562
22 Spend 2007
and mortality
2007/8/9
34,434 257.94 125,707 558.22 462,067
23 Spend 2006
and mortality
2006/7/8
32,911 184.53 128,640 681.24 270,881
24 Spend 2006
and mortality
2004/5/6
32,911 226.18 133,213 971.30 232,861
25 Spend 2005
and mortality
2002/3/4
30,368 240.67 133,213 926.22 259,838
Other 13 PBCs? Assume zero health gain in PBC 23 . . .
26 PBC 23 spend
2008 and
mortality
2008/9/10
11,663 0.494 57.62 0.00
27 PBC 23 spend
2007 and
mortality
2007/8/9
11,763 0.563 66.23 0.00
28 PBC 23 spend
2006 and
mortality
2006/7/8
10,585 0.739 78.22 0.00
29 PBC 23 spend
2006 and
mortality
2004/5/6
10,585 0.759 80.34 0.00
30 PBC 23 spend
2005 and
mortality
2002/3/4
8449 0.926 78.24 0.00
. . . and that the gain in 10 PBCs (see row 21) applies to the remaining 12 PBCs
31 12 PBCs spend
2008 and
mortality
2008/9/10
29,353 441.43 958.47 460,562
32 12 PBCs spend
2007 and
mortality
2007/8/9
27,460 412.41 892.53 462,067
33 12 PBCs spend
2006 and
mortality
2006/7/8
24,400 416.20 1536.48 270,881
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(J)
Coverage
of
mortality
data
relative
to spend
data
(K) (=H/J)
change in
annual
mortality
adjusted
for
coverage
(L) (=E/K)
cost per life
gained (£)
adjusted
for
coverage
(M)
Total
life-years
lost,
<75 years,
2008/9/10
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage
of
mortality
data
relative
to spend
data
(P) (=N/O)
change in
annual
life-years
lost adjusted
for coverage
(Q)
(=E/N)
cost
per
YLG (£)
(R) (=E/P)
cost per
YLG
adjusted
for
coverage
(£)
751,009 337 295,074
721.64 394,836 4,822,473 7434 9226 38,328 30,883
707.57 364,540 4,907,149 6768 8900 38,110 28,983
786.54 234,617 5,001,777 7760 9243 23,780 19,965
5,093,090 10,826 20,893
5,267,962 11,322 21,256
0.00 0.00 0.00
0.00 0.00 0.00
0.00 0.00
0.00
0.00
1118.02 394,836 11,517 14,294 38,328 30,883
1131.31 364,540 10,821 14,229 38,110 28,983
1773.97 234,617 17,502 20,847 23,780 19,965
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TABLE 88 Table showing cost of life and life-year estimates using spend data for 2008/9 and outcome data
for 2008/9/10 (assumes zero health gain for PBC 23 and average gain for other 12 programmes) (continued )
(A)
PBC
scenario
(B)
PBC
description
(C)
Spend
(£M)
2008/9
(D)
Spend
elasticity
(E)
(=0.01×C×D)
change in
spend (£M)
(F) Annual
mortality,
<75 years,
2008/9/10
(G) Outcome
elasticity
(without
negative
sign)
(H)
(=0.01×D×F×G)
change in annual
mortality
(I) (=E/H)
cost per life
gained (£)
34 12 PBCs spend
2006 and
mortality
2004/5/6
24,400 372.44 1599.42 232,861
35 12 PBCs spend
2005 and
mortality
2002/3/4
25,493 324.20 1247.69 259,838
All 23 programmes
36 23 PBCs spend
2008 and
mortality
2008/9/10
78,398 783.98 1577.13 497,094
37 23 PBCs spend
2007 and
mortality
2007/8/9
73,657 736.57 1450.75 507,717
38 23 PBCs spend
2006 and
mortality
2006/7/8
67,896 678.96 2217.72 306,153
39 23 PBCs spend
2006 and
mortality
2004/5/6
67,896 678.96 2570.72 264,113
40 23 PBCs spend
2005 and
mortality
2002/3/4
64,310 643.10 2173.90 295,827
N/A, not applicable.
Note
All 23 programmes spend: 2008/9 £78,398; 2007/8 £73,657; 2006/7 £67,896; 2005/6 £64,310.
% change in budget: 2008/9 1.00%; 2007/8 1.00%; 2006/7 1.00%; 2005/6 1.00%.
Proportionate change: 2008/9 0.01; 2007/8 0.01; 2006/7 0.01; 2005/6 0.01.
Change in budget: 2008/9 £783.98; 2007/8 £736.57; 2006/7 £678.96; 2005/6 £643.10.
The annual mortality figures reported in cells F7 and F8, and F17 and F18 are identical because we do not have
mortality data for 2002/3/4.
For expenditure in 2008/9, the neonate category has been merged with maternity to obtain plausible outcome and
expenditure models.
For expenditure in 2007/8, the neonate category has been merged with maternity to obtain plausible outcome and
expenditure models.
The adjustment for the coverage of the mortality and YLL data relative to the spend data uses deaths under age
75 years in England in 2008.
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(J)
Coverage
of
mortality
data
relative
to spend
data
(K) (=H/J)
change in
annual
mortality
adjusted
for
coverage
(L) (=E/K)
cost per life
gained (£)
adjusted
for
coverage
(M)
Total
life-years
lost,
<75 years,
2008/9/10
(N)
(=0.01×D×G×M/3)
change in annual
life-years lost
(O)
Coverage
of
mortality
data
relative
to spend
data
(P) (=N/O)
change in
annual
life-years
lost adjusted
for coverage
(Q)
(=E/N)
cost
per
YLG (£)
(R) (=E/P)
cost per
YLG
adjusted
for
coverage
(£)
17,826 20,893
15,252 21,256
1839.66 426,155 18,951 23,520 41,369 33,333
1838.88 400,554 17,590 23,129 41,875 31,846
2560.50 265,167 25,262 30,090 26,876 22,565
28,652 23,697
26,575 24,200
DOI: 10.3310/hta19140 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 14
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Claxton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
337
TABLE 89 Table showing expenditure and outcome elasticities for five combinations of expenditure
and outcome data, and corresponding (unadjusted) cost of life-year estimates
(A) (B) PBC description
Spend elasticities Outcome elasticities
(C) Using
spend for
2005 and
mortality
for
2002/3/4
(D) Using
spend for
2006 and
mortality
for
2004/5/6
(E) Using
spend for
2006 and
mortality
for
2006/7/8
(F) Using
spend for
2007 and
mortality
for
2007/8/9
(G) Using
spend for
2008 and
mortality
for
2008/9/10
(H) Using
spend for
2005 and
mortality
for
2002/3/4
(I) Using
spend for
2006 and
mortality
for
2004/5/6
1 Cancer 0.968 0.548 0.465 0.890 0.525 −0.394 −0.337
2 Circulatory problems 0.682 0.701 0.540 0.293 0.648 –1.370 −1.447
3 Respiratory problems 0.849 0.718 0.679 0.536 0.652 –1.574 −3.507
4 Gastrointestinal
problems
0.772 0.667 0.446 0.622 0.456 –2.018 −2.137
5 All big four PBCs 0.801 0.660 0.528 0.559 0.579 –0.941 −1.083
6 Infectious diseases 0.742 0.731 0.792 1.436 1.545 –0.152 −0.030
7 Endocrine problems 0.425 0.966 0.953 0.264 0.484 –0.244 −0.812
8 Neurological problems 1.111 0.648 0.616 1.035 0.980 –0.182 −0.098
9 Genitourinary problems 1.041 0.837 0.912 1.004 0.697 –0.034 −0.073
10 Trauma and injuries 0.627 0.617 0.358 1.686 1.344 –1.332 −0.527
11 Maternity and neonates 0.388 0.601 0.224 0.514 0.975 –0.237 −0.035
12 All small six PBCs 0.780 0.717 0.596 0.961 0.962 –0.262 −0.122
13 All 10 PBCs with
mortality indicator
0.792 0.687 0.561 0.749 0.762 –0.844 −0.940
14 All 23 PBCs assuming
zero gain in PBCs
without mortality
indicator
N/A N/A N/A N/A N/A N/A N/A
15 GMS/PMS 0.926 0.759 0.739 0.563 0.494 N/A N/A
16 All 23 PBCs
assuming zero gain
in PBC 23 but
average gain in
other PBCs without
a mortality indicator
N/A N/A N/A N/A N/A N/A N/A
N/A, not applicable.
Notes
The spend and outcome elasticities reported for groups of programmes are the implied elasticites calculated from the
totals for the relevant individual programmes [i.e. group spend elasticity= (PBC spend× PBC spend elasticity)/PBC spend,
and group outcome elasticity= (PBC mortality× PBC outcome elasticity)/PBC mortality]. For the purpose of the calculation
of the implied group outcome elasticity, we have used the YLL as the mortality indicator. The implied group elasticities are
directly comparable with the individual programme elasticities as both exclude the impact of the relevant budget elasticities.
The implied group elasticities cannot be used to calculate directly the cost of a life (year) for a group of PBCs. Instead,
the latter should be calculated by summing across the change in spend and the change in mortality for the individual
PBCs within the group.
For each individual programme: the cost of an additional life-year= expenditure elasticity× annual spend/(expenditure
elasticity× outcome elasticity× annual life-years lost).
For a group of programmes: the overall cost of an additional life-year=∑(annual spend× spend elasticity)/(spend
elasticity× outcome elasticity× annual life-years lost).
The results using expenditure for 2006/7 and mortality for 2004/5/6 incorporate MFFs for HCHS and prescribing
(see Tables 63 and 64).
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Cost of an additional life-year (£) (unadjusted for YLL coverage)
(J) Using
spend for
2006 and
mortality
for
2006/7/8
(K) Using
spend for
2007 and
mortality
for
2007/8/9
(L) Using
spend for
2008 and
mortality
for
2008/9/10
(M) Using
spend for
2005 and
mortality
for
2002/3/4
(N) Using
spend for
2006 and
mortality
for
2004/5/6
(O) Using
spend for
2006 and
mortality
for
2006/7/8
(P) Using
spend for
2007 and
mortality
for
2007/8/9
(Q) Using
spend for
2008 and
mortality
for
2008/9/10
−0.342 −0.365 −0.307 13,741 16,518 16,383 17,165 21,802
−1.434 −1.277 −1.319 8328 8725 9466 11,315 11,779
−2.622 −2.205 −1.808 20,601 8747 11,593 14,798 21,307
−1.536 −1.328 −1.364 18,303 15,795 20,892 25,034 25,662
−0.965 −0.872 −0.825 12,855 10,783 12,333 16,345 16,688
−0.047 −0.548 −0.504 215,054 1,036,377 630,798 57,742 71,432
−0.842 −0.566 −1.170 371,601 112,882 114,416 190,745 104,008
−0.112 −0.339 −0.417 503,201 1,241,253 1,129,960 431,749 388,267
−0.051 −1.855 −1.615 29,144,918 12,384,965 20,421,090 652,096 877,038
0.000 −0.369 0.000 282,132 548,767 N/A 1,115,197 N/A
−0.482 −0.110 −0.125 17,490 631,700 45,158 204,168 198,939
−0.392 −0.254 −0.300 295,074 449,706 258,046 274,309 254,794
−0.877 −0.778 −0.747 21,256 20,893 23,780 38,110 38,328
N/A N/A N/A 56,799 62,718 87,494 108,829 105,460
N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A 24,200 23,697 26,876 41,875 41,369
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For example, if we assume that PBC 23 generates a zero health gain and that the gain attributable
to the 12 programmes without a mortality indicator is, on average, the same as that attributable to those
with a mortality outcome measure, then the cost of a life-year across all programmes in 2008/9 is £33,333
at current (2008/9) prices. The cost for 2007/8 is £31,846 at current (2007/8) prices or £33,088 at
constant (2008/9) prices, and the figure for 2006/7 is £22,565 at current (2006/7) prices or £24,125
at constant (2008/9) prices. The conversion of the costs from a current to constant price basis has relatively
little impact because the inflation rate over the relevant period is quite small.
Summary and conclusions
In this section we have estimated outcome and expenditure models using PB data for 2008/9 and mortality
data for 2008/9/10. The cost of an additional life-year for all 10 programmes with a mortality-based
outcome is £30,883. This is similar to the comparable figure (£28,983) for the previous year (i.e. using
expenditure data for 2007/8 and mortality data for 2007/8/9). If we assume that PBC 23 generates a zero
health gain and that the gain attributable to the 12 programmes without a mortality indicator is, on
average, the same as that attributable to those with a mortality outcome measure, then the cost of a
life-year across all programmes in 2008/9 is £33,333 and this, too, is similar to the figure for the previous
year (£31,846).
We have also identified a pay and prices index that can be used to put the estimated costs on a constant
price basis. This index has recorded an annual inflation rate of about 3.5% since 2005/6.
There appears to have been a step change in the cost of an additional life-year. The cost of a life-year
estimates are very similar up to and including 2006/7, and they are very similar for 2007/8 and 2008/9.
However, there is a substantial difference between the figures for 2004/5, 2005/6 and 2006/7 on the one
hand, and for 2007/8 and 2008/9 on the other. The reason for this step change is not obvious but it might
be due to changes in the algorithm used by the Department of Health to allocate non-admitted patient
care activity to budget categories. Although this allocation rule change has considerably increased the
estimated cost of a life-year, we believe that this rule change has led to a more accurate allocation of
TABLE 90 Table showing adjusted cost of life-year estimates for various combinations of programmes
(A) (B) PBC description
Cost per life-year (£) (adjusted for ICD-10 coverage of spend and
mortality data)
(C) 2006/7 (D) 2007/8 (E) 2008/9
1 Cancer 16,121 16,891 21,454
2 Circulatory disease 9390 11,224 11,685
3 Respiratory problems 8961 11,439 16,470
4 Gastrointestinal problems 11,929 14,295 14,653
5 All big four programmes 10,604 13,830 14,650
6 Other six programmes with a mortality rate 146,108 99,428 112,674
7 All 10 PBCs with a mortality rate 19,965 28,983 30,883
(a) if we assume a zero health gain in those PBCs without a mortality rate . . .
8 All 23 programmes 73,457 82,765 84,974
. . . or (b) if we assume a zero gain in PBC 23 and that the average gain from the 10 PBCs with a mortality rate is
applied to the remaining programmes
9 All 23 programmes 22,565 31,846 33,333
Note that the figures for 2006/7 relate to the use of mortality for 2006/7/8 combined.
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expenditure across PBCs, and that the more recent estimates of the cost of a life-year (for 2007/8 and
2008/9) are more accurate than those for the earlier years (for 2005/6 and 2006/7).
Summary and concluding remarks
The findings presented in this report build on four previous studies.59,60,62,63 These studies and the results
presented here draw on the availability of two new data sets to obtain empirical estimates of the
relationship between mortality and expenditure across all English local health authorities.
In this research we have extended the previous studies in several ways. First, we have derived plausible
outcome and expenditure models for a larger number of programmes (n= 10) than previous studies.
The cost of a life-year across all 10 programmes with a mortality-based outcome indicator using
expenditure data for 2006/7 and mortality data for 2004/5/6 is £20,893.
Second, we relate expenditure in time period t to mortality in that period (t) and in the next two periods
(t + 1 and t + 2). In other words, we assume that the health benefits associated with expenditure occur
either in the same period as the expenditure or in the next two periods. This is an improvement on past
practice where data constraints forced researchers to relate expenditure to the current and two previous
periods. When we re-estimated our models having replaced mortality data for 2004/5/6 with that of
2006/7/8, we found that the cost of a life-year across the 10 programmes with a mortality-based outcome
indicator using expenditure data for 2006/7 is £23,780 (up from £20,893, an increase of 14%).
Third, we have noted the mismatch in the ICD-10 coverage of the expenditure and mortality data. If we
adjust the calculation of the cost of a life-year for 2006/7 for this mismatch then the cost of a life-year
across the 10 programmes with a mortality-based outcome indicator declines from £23,780 to £19,965
(a decrease of 16%).
Fourth, previous estimates of the cost of a life-year have been for individual programmes of care. In this
report we have presented estimates of the cost of a life-year for an enlarged number of programmes and,
with the aid of assumptions about the productivity (health gain) of programmes without a meaningful
mortality-based outcome indicator, we have extended our individual programme estimates to incorporate
expenditure across all programmes of care. Thus, for 2006/7 the cost of a life-year for those PBCs with a
mortality-based outcome indicator is £19,965. If we assume that (a) that the health gains associated with
PBC 23, which includes primary care and workforce training expenditure, are reflected in the mortality
rates for disease-specific programmes and (b) that the average health gain across the other programmes
without a mortality-based outcome indicator is the same as that for those PBCs with a mortality-based
outcome indicator, then the cost of life-year across all programmes is £22,565.
Fifth, we have extended our cost of life-year estimates beyond 2006/7. Re-estimation of our model using
budgeting expenditure for 2007/8 generates an all programme cost of a life-year estimate of £31,846, and
re-estimation of our model using budgeting expenditure for 2008/9 generates a similar cost of a life-year
estimate (£33,333). Together, the last two estimates suggest that there has been a step change in the cost
of a life-year, and that this appears to have occurred between 2006/7 and 2007/8. The cost of a life-year
estimates are very similar up to and including 2006/7, and they are very similar for 2007/8 and 2008/9.
However, there is a substantial difference between the figures for 2004/5, 2005/6 and 2006/7 on the one
hand (at about £22,000), and for 2007/8 and 2008/9 on the other (at about £33,000). The reason for this
step change is not obvious but it might be due to changes in the algorithm used by the Department of
Health to allocate non-admitted patient care activity to budget categories. Although this allocation rule
change has considerably increased the estimated cost of a life-year, we believe that this rule change has
led to a more accurate allocation of expenditure across PBCs, and that the more recent estimates of the
cost of a life-year (for 2007/8 and 2008/9) are more accurate than those for the earlier years (for 2005/6
and 2006/7).
DOI: 10.3310/hta19140 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 14
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Claxton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
341
Virtually all of the cost of a life-year estimates presented in this report are at current prices. However,
it is possible to put them on a constant price basis using the HCHSs pay and prices index.87 For 2006/7,
2007/8 and 2008/9 this index recorded an annual rate of inflation of about 3.5% and so the impact of
this constant price adjustment is fairly minimal. For example, if we assume that PBC 23 generates a zero
health gain and that the gain attributable to the 12 programmes without a mortality indicator is, on
average, the same as that attributable to those with a mortality outcome measure, then the cost of a
life-year across all programmes at constant 2008/9 prices is £33,333 for 2008/9, £33,088 for 2007/8, and
£24,125 for 2006/7.
Finally, although previous results and our current models ‘pass’ the appropriate statistical tests and, in
particular, the Hansen–Sargen test for valid instruments, we are aware that this test might be unable to
detect the presence of invalid instruments in some (albeit rather restrictive) circumstances. Responding
to this, several studies have suggested that researchers using IV techniques should subject the estimated
coefficient on the endogenous variable to a sensitivity analysis. We do precisely this for the outcome
equation for each of the big four models. This sensitivity analysis reveals that uncertainty associated with
instrument validity has little effect on our estimate of the cost of a life-year, but it does increase the degree
of uncertainty associated with this estimate.
We recognise that this study has a number of limitations. The cost of an additional life-year estimates for
those programmes with a mortality-based outcome indicator are unadjusted for the QoL during the
additional year; the quoted costs will be an underestimate of the QALY-adjusted cost of a life-year to the
extent that additional life-years are not in perfect health. In previous studies we have noted that a
rudimentary adjustment for this issue using HODaR data increased the cost of a life-year by
about 50–60%.12,100
At the same time, however, the estimated costs will exaggerate the cost of an additional QALY-adjusted
year for those programmes with a mortality-based outcome indicator because they ignore any health
benefits that are not associated with a reduction in mortality. In other words, expenditure that improves
the QoL (e.g. cancer palliative care) but which does not extend the length of life is implicitly given a zero
health gain value.
In addition, the expenditure data relates to expenditure on all patients whereas the mortality data is based
on a LE of 75 years. Thus, implicitly our calculations attribute a zero health gain to all expenditure on those
aged > 75 years. To illustrate the magnitude of the potential health gain ignored by this restriction, note
that in a recent study of costs associated with all inpatient and outpatient activity (excluding mental
health), those aged > 75 years accounted for 25% of all costs in 2007/8.147
Moreover, our cost of a life-year estimates are based on the assumption that any Departmental budgetary
change falls entirely on PCTs. Although PCTs account for most of the Department of Health’s budget,
non-PCTs still accounted for 15% of the budget in 2006/7. As we have no information on how any
budgetary change would be split between PCTs and non-PCTs, we have assumed that that any
Departmental budgetary change falls entirely on PCTs. If the non-PCT budget is responsive to changes in
the Department’s budget then our cost of a life-year estimates will be too low. If the non-PCT budget is as
responsive as the PCT budget, then our cost of a life-year estimate for 2006/7 will be increased by 17.7%
(that is, from £22,565 to £26,553).
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The results presented in this study are all from the estimation of the relationship between expenditure
and mortality using data for a single time period. With the availability of several years of data for both
expenditure and mortality, we wanted to estimate a panel data model because a panel can offer
advantages over a one-period model (e.g. it is better able to handle any unobserved heterogeneity across
PCTs). However, most of the instruments employed here are based on the 2001 Census80 and thus
estimation of a panel model will not be possible until these instruments become time variant; this should
occur later this year with release of the 2011 Census data at PCT level. This is one piece of work that we
intend to pursue in the near future.
Annex
TABLE 91 Table showing national (all PCT) expenditure per head (£) and growth in expenditure (%) by PBC group
and subgroup, 2003/4–2008/9
PBC description
Spend
(£) per
head
2003/4
Spend
(£) per
head
2004/5
Spend
(£) per
head
2005/6
Spend
(£) per
head
2006/7
Spend
(£) per
head
2007/8
Growth
(%)
2007/8
Spend
(£) per
head
2008/9
Growth
(%)
2008/9
1 Infectious
diseases
17.95 20.22 23.61 20.88 22.08 6 23.46 6
1A HIV and AIDS 7.39 8.54 16 10.36 21
1X Infectious
diseases (other)
13.49 13.54 0 13.10 –3
2 Cancers and
tumours
64.95 75.54 83.24 81.67 90.21 10 94.55 5
2A Cancer, head
and neck
2.83 2.65 –6 2.72 3
2B Cancer,
upper GI
4.05 4.38 8 4.73 8
2C Cancer,
lower GI
6.46 6.71 4 7.47 11
2D Cancer, lung 3.89 4.28 10 4.48 5
2E Cancer, skin 1.88 2.05 9 2.05 0
2F Cancer, breast 7.39 8.35 13 9.34 12
2G Cancer,
gynaecological
2.97 2.93 –1 3.05 4
2H Cancer,
urological
7.76 7.84 1 8.17 4
2I Cancer,
haematological
8.40 9.22 10 9.47 3
2X Cancers and
tumours (other)
36.04 41.79 16 43.07 3
3 Disorders of the
blood
14.08 17.00 17.48 16.58 19.44 17 19.50 0
4 Endocrine,
nutritional
and metabolic
28.96 31.86 37.26 36.70 39.39 7 43.38 10
4A Diabetes 17.76 19.44 9 21.73 12
continued
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TABLE 91 Table showing national (all PCT) expenditure per head (£) and growth in expenditure (%) by PBC group
and subgroup, 2003/4–2008/9 (continued )
PBC description
Spend
(£) per
head
2003/4
Spend
(£) per
head
2004/5
Spend
(£) per
head
2005/6
Spend
(£) per
head
2006/7
Spend
(£) per
head
2007/8
Growth
(%)
2007/8
Spend
(£) per
head
2008/9
Growth
(%)
2008/9
4B Endocrine,
nutritional
and metabolic
6.95 7.47 8 7.96 6
4X Other
endocrine,
nutritional,
metabolic
11.99 12.48 4 13.69 10
5 Mental
health disorders
133.31 146.83 158.95 166.53 180.90 9 191.21 6
5A Substance
misuse
13.81 15.76 14 17.81 13
5B Organic mental
disorders
14.24 14.83 4 17.39 17
5C Psychotic
disorders
23.84 31.19 31 33.69 8
5D Child and
adolescent
mental health
12.13 12.15 0 13.33 10
5X Other mental
health disorders
102.51 106.97 4 108.99 2
6 Problems of
learning
disability
37.93 43.37 46.54 48.36 54.20 12 56.11 4
7 Neurological 29.83 35.09 41.06 55.27 62.43 13 67.64 8
7A Chronic pain 19.31 22.12 15 22.79 3
7X Neurological
(other)
35.96 40.31 12 44.85 11
8 Problems of
vision
24.61 27.65 28.24 26.97 30.69 14 32.95 7
9 Problems of
hearing
5.73 6.32 6.27 6.21 8.07 30 8.16 1
10 Problems of
circulation
110.12 122.37 124.28 122.06 124.77 2 129.94 4
10A Coronary heart
disease
38.91 40.32 4 41.20 2
10B Cerebrovascular
disease
16.05 17.30 8 19.35 12
10C Problems of
rhythm
7.22 8.21 14 8.43 3
10X Problems of
circulation
(other)
59.88 58.95 –2 60.96 3
11 Problems of the
respiratory
system
54.60 62.71 69.56 65.07 67.68 4 77.97 15
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TABLE 91 Table showing national (all PCT) expenditure per head (£) and growth in expenditure (%) by PBC group
and subgroup, 2003/4–2008/9 (continued )
PBC description
Spend
(£) per
head
2003/4
Spend
(£) per
head
2004/5
Spend
(£) per
head
2005/6
Spend
(£) per
head
2006/7
Spend
(£) per
head
2007/8
Growth
(%)
2007/8
Spend
(£) per
head
2008/9
Growth
(%)
2008/9
11A Obstructive
airways disease
10.64 10.64 0 12.70 19
11B Asthma 14.04 15.73 12 16.99 8
11X Problems of the
respiratory
system, other
40.40 41.31 2 48.27 17
12 Dental problems 10.78 13.55 24.91 51.93 59.45 14 62.44 5
13 Problems of the
gastrointestinal
system
63.56 73.22 81.30 73.30 75.05 2 77.89 4
13A Upper GI 19.88 19.51 –2 19.89 2
13B Lower GI 20.46 21.92 7 22.63 3
13C Hepatobiliary 11.26 12.23 9 12.90 5
13X Problems of the
gastrointestinal
system, other
21.69 21.39 –1 22.46 5
14 Problems of the
skin
20.98 24.90 26.84 28.31 30.41 7 32.34 6
14A Burns 1.08 1.56 44 1.02 –34
14X Problems of the
skin, other
27.23 28.86 6 31.32 9
15 Problems of the
musculoskeletal
system
61.36 71.72 74.74 66.75 75.91 14 79.68 5
16 Problems due to
trauma and
injuries
62.31 72.13 76.41 57.29 57.56 0 63.54 10
17 Problems of the
genitourinary
system
55.32 62.38 67.38 68.98 67.83 –2 73.78 9
17A Genital tract
problems
19.33 18.80 –3 19.36 3
17B Renal problems 21.54 19.74 –8 22.29 13
17C STDs 4.26 4.71 10 5.43 15
17X Problems of the
genitourinary
system, other
23.85 24.58 3 26.69 9
18 Maternity and
Reproductive
health
52.28 55.04 60.42 57.64 57.09 –1 60.44 6
19 Conditions of
neonates
11.72 13.93 13.42 13.17 15.15 15 17.23 14
continued
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TABLE 91 Table showing national (all PCT) expenditure per head (£) and growth in expenditure (%) by PBC group
and subgroup, 2003/4–2008/9 (continued )
PBC description
Spend
(£) per
head
2003/4
Spend
(£) per
head
2004/5
Spend
(£) per
head
2005/6
Spend
(£) per
head
2006/7
Spend
(£) per
head
2007/8
Growth
(%)
2007/8
Spend
(£) per
head
2008/9
Growth
(%)
2008/9
20 Adverse effects
and poisoning
9.68 12.32 14.25 14.59 15.84 9 18.31 16
20A Unintended
consequences
of treatment
10.54 12.14 15 12.96 7
20B Poisoning 2.13 2.44 15 2.91 19
20C Violence 0.47 0.49 3 1.75 258
20X Adverse effects
and poisoning,
other
1.45 0.77 –47 0.70 –9
21 Healthy
individuals
20.29 22.77 26.18 26.85 31.44 17 35.74 14
21A NSF
prevention
programme
2.30 3.75 63 4.82 29
21B NSF mental
health
prevention
0.17 0.47 176 0.46 –2
21X Healthy
individuals
(other)
24.38 27.22 12 30.46 12
22 Social
care needs
24.81 30.93 33.59 30.29 35.29 17 36.58 4
23 Other 136.94 157.75 171.82 209.70 232.02 11 227.71 –2
23A GMS/PMS 141.42 147.53 4 145.26 –2
23B Training (WDCs) 0.60 0.30 –49 0.24 –21
23X Miscellaneous 67.67 84.19 24 82.20 –2
1 to 23 All PBCs 1052.12 1199.60 1307.76 1345.10 1452.91 8 1530.59 5
AIDS, acquired immunodeficiency syndrome; GI, gastrointestinal; NSF, National Service Framework; STD, sexually
transmitted disease; WDC, Workforce Development Confederation.
Notes
The population figures for 2003/4, 2004/5 and 2005/6 are identical (the total for England is 49,175,998).
The corresponding figure for 2006/7 is 50,476,231, for 2007/8 it is 50,695,989, and for 2008/9 it is 51,220,531.
The spend per head figures are calculated by summing expenditure across all PCTs and dividing by the national population.
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TABLE 92 Table showing set of socioeconomic indicators available as potential instruments in the IV estimation
Indicator
name Short description Long description
BORNEXEU Residents born outside the EU Residents born outside the EU divided by all residents (census cell
definition: KS005008/KS005001)
WHITEEG Population in white ethnic
group
Population in white ethnic group divided by total population
(KS006002 +KS006003 + KS006004)/KS006001
PCWALLTI Population of working age
with illness
Proportion of population of working age with LLT aged 16–74 years
(KS008003/KS09A001)
POPPUCAR Unpaid care providers
in population
Proportion of population providing unpaid care (KS008007/KS008001)
POPPUCA1 Unpaid care (< 20 hours/week)
in population
Proportion of population providing unpaid care for 1–19 hours a week
(KS008008/KS008001)
POPPUCA2 Unpaid care (20–49 hours/
week) in population
Proportion of population providing unpaid care for 20–49 hours per
week (KS008009/KS008001)
POPPUCA3 Unpaid care (> 50 hours/week)
in population
Proportion of population providing unpaid care for > 50 hours a week
(KS008007/KS008001)
NQUAL1674 Proportion aged 16–74 years
with no qualifications
Proportion of population aged 16–74 years with no qualifications
(KS013002/KS013001
FTSTUDEN Proportion aged 16–74 years
full-time students
Proportion of population aged 16–74 years that are full-time students
(KS013008 +KS013009)/KS013001
HHNOCAR Households without a car Proportion of households without a car (KS017002/KS017001)
OWNOCC Owner occupied households Proportion of households that are owner occupied
(KS018002 +KS018003 + KS018004)/KS018001)
LAHARENT Rented social housing Proportion of households that are rented from LA or HA
(KS018005 +KS018006)/KS018001
PRIVRENT Rented private housing Proportion of households that are rented from private landlords
(KS018007/KS018001)
LONEPENH Lone pensioner households Proportion of households that are one pensioner households
(KS020002/KS020001)
LONEPARH Lone parent households Proportion of households that are lone parent households with
dependent children (KS020011/KS020001)
PERMSICK Permanently sick of those
aged 16–74 years
Proportion of population aged 16–74 years that are permanently sick
(KS09A010/KS09A001)
PC74LTUN Long-term unemployed of
those aged 16–74 years
Proportion of those aged 16–74 years that are long-term unemployed
(KS09A015/KS09A001)
WORKAGRI Employed in agriculture Proportion of those aged 16–74 years in employment that are working
agriculture (KS11A002/KS11A001)
PROFOCCU People in professional
occupations
Proportion of those aged 16–74 years in managerial and professional
occupations (KS14A002 +KS14A003 +KS14A004)/KS14A001
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TABLE 93 Table showing first-stage regressions for outcome models associated with 2005/6 expenditure and mortality data for 2002/3/4
Variable
2005/6, outcome model, instrument spend, unweighted, first stage
(1) PBC 2 cancer (2) PBC 10 circulation (3) PBC 11 respiratory (4) PBC 13 gastrointestinal (5) PBC 16 trauma and injuries
(6) PBC
19 neonates
Need per head 0.406*** 1.173*** 1.533*** 0.970*** 0.727**
[0.097] [0.235] [0.401] [0.243] [0.289]
Lone pensioner households 0.593*** 0.229*** −0.118 0.045 0.561***
[0.109] [0.084] [0.112] [0.093] [0.108]
Provision of unpaid care −0.013 0.374*** 0.574*** −0.148
[0.135] [0.115] [0.089] [0.132]
IMD2000 −0.152*** −0.247*** −0.047 −0.016
[0.056] [0.069] [0.060] [0.074]
White ethnic group −0.007
[0.067]
Permanently sick 0.192**
[0.085]
Low birth weight births 0.393
[0.308]
Lone parent households 0.034
[0.209]
No qualifications −0.599***
[0.148]
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TABLE 94 Table showing first-stage regressions for expenditure models associated with 2005/6 expenditure and mortality data for 2002/3/4
Variable
2005/6, spend model, instrument other programme need, unweighted, first stage
(1) PBC
2 cancer
(2) PBC
10 circulation
(3) PBC
11 respiratory
(4) PBC
13 gastrointestinal
(5) PBC
7 neurological
(6) PBC 16 trauma
and injuries
(7) PBC
23 GMS/PMS
No qualifications 0.240***
[0.038]
Lone pensioner
households
−0.686*** −0.244*** −0.234*** −0.266*** −0.234*** −0.234*** −0.129***
[0.067] [0.052] [0.049] [0.049] [0.049] [0.049] [0.038]
Private rented
housing
0.072***
[0.017]
Work in agriculture −0.006
[0.008]
PCT budget
per head
−0.146 −0.003 −0.077 −0.022 −0.077 −0.077 0.043
[0.117] [0.074] [0.070] [0.070] [0.070] [0.070] [0.069]
No car households 0.092**
[0.039]
Lone parent
households
0.171***
[0.035]
Permanently sick 0.125***
[0.027]
Need per head 1.933*** 0.651*** 0.875*** 0.597*** 0.875*** 0.875***
[0.110] [0.157] [0.175] [0.157] [0.175] [0.175]
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Variable
2005/6, spend model, instrument other programme need, unweighted, first stage
(1) PBC
2 cancer
(2) PBC
10 circulation
(3) PBC
11 respiratory
(4) PBC
13 gastrointestinal
(5) PBC
7 neurological
(6) PBC 16 trauma
and injuries
(7) PBC
23 GMS/PMS
White ethnic group 0.197***
[0.038]
Provision of
unpaid care
−0.371*** −0.153** −0.217*** −0.217*** −0.217***
[0.071] [0.065] [0.055] [0.055] [0.055]
IMD2000 0.056* 0.128*** 0.179*** 0.128*** 0.128***
[0.033] [0.038] [0.035] [0.038] [0.038]
Constant 2.562*** 4.103*** 4.851*** 5.114*** 4.851*** 4.851*** 7.361***
[0.159] [0.140] [0.109] [0.082] [0.109] [0.109] [0.139]
Observations 295 295 295 295 295 295 295
R2 0.804 0.680 0.858 0.849 0.858 0.858 0.881
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
These are the first-stage regressions for the IV models reported in Table 43.
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TABLE 95 Table showing first-stage regressions for outcome and expenditure models associated with 2006/7 expenditure and mortality data for 2004/5/6
Variable
(1) PBC 2
cancer, 2006/7,
outcome model,
uses SYLLR,
instrument
spend, weighted,
first stage,
CARAN need,
two MFFs
(2) PBC 2, cancer,
2006/7, spend
model, uses
SYLLR,
instrument other
programme
need, weighted,
first stage,
CARAN need,
two MFFs
(3) PBC 10
circulation,
2006/7, outcome
model, uses
SYLLR,
instrument
spend, weighted,
first stage,
CARAN need,
two MFFs
(4) PBC 10
circulation,
2006/7, spend
model, uses
SYLLR,
instrument other
programme
need, weighted,
first stage,
CARAN need,
two MFFs
(5) PBC 11
respiratory,
2006/7, outcome
model, uses
SYLLR,
instrument
spend, weighted,
first stage,
CARAN need,
two MFFs
(6) PBC 11
respiratory,
2006/7, spend
model, uses
SYLLR, instrument
other programme
need, weighted,
first stage, CARAN
need, two MFFs
(7) PBC 13
gastrointestinal,
2006/7, outcome
model, uses
SYLLR,
instrument
spend, weighted,
first stage,
CARAN need,
two MFFs
(8) PBC 13
gastrointestinal,
2006/7, spend
model, uses
SYLLR, instrument
other programme
need, weighted,
first stage, CARAN
need, two MFFs
Need
CARAN
per head
1.162*** 1.602*** 1.539*** 0.606*** 1.026*** 0.836*** 1.292*** 0.938***
[0.250] [0.126] [0.323] [0.141] [0.368] [0.175] [0.358] [0.167]
Need
CARAN
per head
squared
0.912
[0.666]
Lone
pensioner
households
0.383*** −0.431*** 0.321*** −0.221***
[0.134] [0.073] [0.111] [0.067]
IMD2007 −0.153** −0.247*** 0.117*** 0.104** −0.115 0.107***
[0.074] [0.087] [0.037] [0.043] [0.094] [0.041]
PCT budget
per head
0.120 0.183* 0.077 −0.020
[0.124] [0.094] [0.084] [0.093]
Provision of
unpaid care
−0.410*** 0.097 −0.309*** 0.373* −0.325***
[0.088] [0.197] [0.090] [0.215] [0.078]
White
ethnic group
−0.060
[0.082]
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Variable
(1) PBC 2
cancer, 2006/7,
outcome model,
uses SYLLR,
instrument
spend, weighted,
first stage,
CARAN need,
two MFFs
(2) PBC 2, cancer,
2006/7, spend
model, uses
SYLLR,
instrument other
programme
need, weighted,
first stage,
CARAN need,
two MFFs
(3) PBC 10
circulation,
2006/7, outcome
model, uses
SYLLR,
instrument
spend, weighted,
first stage,
CARAN need,
two MFFs
(4) PBC 10
circulation,
2006/7, spend
model, uses
SYLLR,
instrument other
programme
need, weighted,
first stage,
CARAN need,
two MFFs
(5) PBC 11
respiratory,
2006/7, outcome
model, uses
SYLLR,
instrument
spend, weighted,
first stage,
CARAN need,
two MFFs
(6) PBC 11
respiratory,
2006/7, spend
model, uses
SYLLR, instrument
other programme
need, weighted,
first stage, CARAN
need, two MFFs
(7) PBC 13
gastrointestinal,
2006/7, outcome
model, uses
SYLLR,
instrument
spend, weighted,
first stage,
CARAN need,
two MFFs
(8) PBC 13
gastrointestinal,
2006/7, spend
model, uses
SYLLR, instrument
other programme
need, weighted,
first stage, CARAN
need, two MFFs
Permanently
sick
0.681**
[0.269]
Long-term
unemployed
−0.123***
[0.035]
LLT −0.785*
[0.449]
Constant 5.586*** 3.074*** 6.387*** 3.790*** 3.906*** 4.501*** 5.496*** 5.119***
[0.235] [0.887] [0.363] [0.703] [0.474] [0.595] [0.314] [0.657]
Observations 152 152 152 152 152 152 152 152
R2 0.438 0.846 0.623 0.814 0.623 0.840 0.554 0.827
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
These are the first-stage regressions for the IV models reported in Table 62.
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TABLE 96 Table showing first-stage regressions for outcome and expenditure models associated with 2006/7 expenditure and mortality data for 2006/7/8
Variable
(1) PBC 2
cancer, 2006/7,
outcome
model, SYLLR
2006/7/8,
instrument
spend,
weighted, first
stage, two
MFFs
(2) PBC 2 cancer,
2006/7, spend
model, SYLLR
2006/7/8,
instrument other
programme
need, weighted,
first stage,
two MFFs
(3) PBC 10
circulation,
2006/7,
outcome
model, SYLLR
2006/7/8,
instrument
spend,
weighted, first
stage, two
MFFs
(4) PBC 10
circulation,
2006/7, spend
model, SYLLR
2006/7/8,
instrument other
programme
need, weighted,
first stage,
two MFFs
(5) PBC 11
respiratory,
2006/7,
outcome
model, SYLLR
2006/7/8,
instrument
spend,
weighted, first
stage, two
MFFs
(6) PBC 11
respiratory,
2006/7, spend
model, SYLLR
2006/7/8,
instrument other
programme need,
weighted, first
stage, two MFFs
(7) PBC 13
gastrointestinal,
2006/7, outcome
model, SYLLR
2006/7/8,
instrument
spend,
weighted, first
stage, two MFFs
(8) PBC 13
gastrointestinal,
2006/7, spend
model, SYLLR
2006/7/8,
instrument other
programme need,
weighted, first
stage, two MFFs
Need CARAN
per head
1.162*** 1.574*** 1.539*** 0.791*** 1.061*** 0.909*** 1.292*** 1.059***
[0.250] [0.138] [0.323] [0.157] [0.386] [0.167] [0.358] [0.166]
Need CARAN
per head
squared
0.912 0.455
[0.666] [0.599]
Lone
pensioner
household
0.383*** −0.375*** 0.321*** −0.269*** −0.313***
[0.134] [0.079] [0.111] [0.067] [0.072]
IMD2007 −0.153** −0.247*** 0.097** 0.107*** −0.115 0.066
[0.074] [0.087] [0.039] [0.041] [0.094] [0.040]
PCT budget
per head
0.126 0.128 0.020 0.040
[0.136] [0.101] [0.090] [0.091]
Provision of
unpaid care
−0.386*** 0.097 −0.289*** 0.373* −0.203**
[0.097] [0.197] [0.080] [0.215] [0.088]
White ethnic
group
−0.060
[0.082]
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Variable
(1) PBC 2
cancer, 2006/7,
outcome
model, SYLLR
2006/7/8,
instrument
spend,
weighted, first
stage, two
MFFs
(2) PBC 2 cancer,
2006/7, spend
model, SYLLR
2006/7/8,
instrument other
programme
need, weighted,
first stage,
two MFFs
(3) PBC 10
circulation,
2006/7,
outcome
model, SYLLR
2006/7/8,
instrument
spend,
weighted, first
stage, two
MFFs
(4) PBC 10
circulation,
2006/7, spend
model, SYLLR
2006/7/8,
instrument other
programme
need, weighted,
first stage,
two MFFs
(5) PBC 11
respiratory,
2006/7,
outcome
model, SYLLR
2006/7/8,
instrument
spend,
weighted, first
stage, two
MFFs
(6) PBC 11
respiratory,
2006/7, spend
model, SYLLR
2006/7/8,
instrument other
programme need,
weighted, first
stage, two MFFs
(7) PBC 13
gastrointestinal,
2006/7, outcome
model, SYLLR
2006/7/8,
instrument
spend,
weighted, first
stage, two MFFs
(8) PBC 13
gastrointestinal,
2006/7, spend
model, SYLLR
2006/7/8,
instrument other
programme need,
weighted, first
stage, two MFFs
Permanently
sick
0.677**
[0.272]
Long-term
unemployed
−0.121***
[0.035]
LLT −0.798*
[0.454]
Constant 5.586*** 3.160*** 6.387*** 4.132*** 3.864*** 4.916*** 5.496*** 4.481***
[0.235] [0.963] [0.363] [0.729] [0.493] [0.637] [0.314] [0.654]
Observations 152 152 152 152 152 152 152 152
R2 0.438 0.821 0.623 0.823 0.624 0.831 0.554 0.857
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
These are the first-stage regressions for the IV models reported in Table 65.
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TABLE 97 Table showing first-stage regressions for outcome models associated with 2007/8 expenditure
Variable
(1) PBC 2 cancer,
2007/8,
instrument
spend,
weighted,
first stage
(2) PBC 2 cancer,
2007/8,
instrument
spend,
weighted,
first stage
(3) PBC 10
circulation,
2007/8,
instrument spend,
weighted,
first stage
(4) PBC 11
respiratory,
2007/8,
instrument spend,
weighted,
first stage
(5) PBC 11
respiratory,
2007/8,
instrument spend,
weighted,
first stage
Need CARAN
per head
0.582** 0.545*** 0.724*** 1.251*** 1.196***
[0.284] [0.105] [0.168] [0.094] [0.113]
No car
households
Lone
pensioner
households
0.632*** 0.644*** 0.468*** 0.360*** 0.269***
[0.148] [0.119] [0.100] [0.103] [0.100]
IMD2007 −0.012
[0.088]
Need CARAN
per head
squared
1.332*** 1.338***
[0.428] [0.425]
Provision of
unpaid care
0.441** 0.200
[0.174] [0.160]
Born
outside EU
Diabetes
prevalence
rate 2007/8
Permanently
sick
Lone parent
households
Chronic kidney
disease
prevalence
rate 2007/8
Long-term
unemployed
LLT
HIV need per
head squared
HIV need per
head
Work in
agriculture
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(6) PBC 13
gastrointestinal,
2007/8,
instrument
spend,
weighted,
first stage
(7) PBC 13
gastrointestinal,
2007/8,
instrument
spend,
weighted,
first stage
(8) PBC 4
endocrine,
2007/8,
instrument
spend,
weighted,
first stage
(9) PBC 17
genitourinary,
2007/8,
instrument
spend,
weighted,
first stage
(10) PBC 1
infectious
disease,
2007/8,
instrument
spend,
weighted,
first stage
(11) PBC
18+19
maternity and
neonates,
2007/8,
instrument
spend,
weighted,
first stage
(12) PBC 16
trauma and
injuries,
2007/8,
instrument
spend,
weighted,
first stage
0.999*** 1.047*** 1.111*** 0.856***
[0.105] [0.099] [0.259] [0.282]
0.512* 0.288**
[0.267] [0.137]
0.199
[0.133]
−0.067 0.325
[0.053] [0.224]
−0.054*** −0.067*** 0.004 −0.079**
[0.018] [0.017] [0.041] [0.039]
0.358***
[0.123]
0.307***
[0.061]
0.029
[0.124]
0.123**
[0.061]
0.146**
[0.061]
0.207
[0.134]
0.128***
[0.031]
0.300***
[0.044]
0.152** 0.126***
[0.064] [0.033]
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TABLE 97 Table showing first-stage regressions for outcome models associated with 2007/8 expenditure (continued )
Variable
(1) PBC 2 cancer,
2007/8,
instrument
spend,
weighted,
first stage
(2) PBC 2 cancer,
2007/8,
instrument
spend,
weighted,
first stage
(3) PBC 10
circulation,
2007/8,
instrument spend,
weighted,
first stage
(4) PBC 11
respiratory,
2007/8,
instrument spend,
weighted,
first stage
(5) PBC 11
respiratory,
2007/8,
instrument spend,
weighted,
first stage
Work in
professional
occupation
No
qualifications
Maternity need
per head
Full-
time students
LA/HA
accommodation
Constant 5.759*** 5.747*** 6.754*** 4.886*** 5.172***
[0.252] [0.234] [0.322] [0.201] [0.350]
Observations 151 151 151 151 151
R2 0.369 0.369 0.653 0.659 0.664
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
These are the first-stage regressions for the IV models reported in Table 81.
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
358
(6) PBC 13
gastrointestinal,
2007/8,
instrument
spend,
weighted,
first stage
(7) PBC 13
gastrointestinal,
2007/8,
instrument
spend,
weighted,
first stage
(8) PBC 4
endocrine,
2007/8,
instrument
spend,
weighted,
first stage
(9) PBC 17
genitourinary,
2007/8,
instrument
spend,
weighted,
first stage
(10) PBC 1
infectious
disease,
2007/8,
instrument
spend,
weighted,
first stage
(11) PBC
18+19
maternity and
neonates,
2007/8,
instrument
spend,
weighted,
first stage
(12) PBC 16
trauma and
injuries,
2007/8,
instrument
spend,
weighted,
first stage
0.647***
[0.172]
−0.214
[0.160]
0.647***
[0.159]
0.126
[0.095]
−0.197*
[0.104]
4.531*** 4.104*** 4.224*** 5.269*** 4.226*** 4.004*** 4.766***
[0.281] [0.057] [0.390] [0.209] [1.007] [0.297] [0.339]
151 151 151 147 151 151 151
0.531 0.524 0.436 0.296 0.724 0.407 0.361
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TABLE 98 Table showing first-stage regressions for expenditure models associated with 2007/8 expenditure
Variable
(1) PBC 2 cancer,
2007/8, spend model,
instrument other
programme need,
weighted, first stage
(2) PBC 10 circulation,
2007/8, spend model,
instrument other
programme need,
weighted, first stage
(3) PBC 11 respiratory,
2007/8, spend model,
instrument other
programme need,
weighted, first stage
PCT budget per head
2007/8
0.071 0.066 0.039
[0.137] [0.123] [0.105]
Need CARAN per head 1.613*** 1.201*** 1.050***
[0.149] [0.136] [0.191]
Need CARAN
per head squared
0.343
[0.266]
Lone pensioner
households
−0.357*** −0.220*** −0.261***
[0.067] [0.060] [0.063]
Provision of unpaid care −0.362*** −0.215** −0.156*
[0.094] [0.090] [0.093]
IMD2007 0.070
[0.042]
Diabetes prevalence rate
2007/8
Epilepsy prevalence rate
2007/8
White ethnic group
Work in agriculture
Constant 3.624*** 4.454*** 4.667***
[0.969] [0.848] [0.735]
Observations 151 151 151
R2 0.847 0.828 0.861
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
These are the first-stage regressions for the IV models reported in Table 82.
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(4) PBC 13
gastrointestinal,
2007/8, spend
model, instrument
other programme
need weighted,
first stage
(5) PBC 4
endocrine, 2007/8,
spend model,
instrument other
programme need,
weighted,
first stage
(6) PBC 7
neurological,
2007/8, spend
model, instrument
other programme
need, weighted,
first stage
(7) PBC 23
GMS/PMS, etc.,
2007/8, spend
model, instrument
other programme
need, weighted,
first stage
(8) PBC 16 trauma
and injuries, 2007/8,
spend model,
instrument other
programme need,
weighted, first stage
−0.034 0.057 0.170 0.360** 0.366***
[0.105] [0.121] [0.130] [0.144] [0.136]
0.971*** 1.090*** 1.148***
[0.188] [0.198] [0.137]
−0.274*** −0.444*** −0.255*** −0.229***
[0.063] [0.055] [0.061] [0.072]
−0.296*** −0.181* 0.195**
[0.086] [0.100] [0.092]
0.099** 0.067 0.309*** 0.276***
[0.043] [0.045] [0.043] [0.039]
0.008
[0.069]
0.020
[0.049]
0.221***
[0.060]
0.009
[0.011]
5.298*** 4.496*** 3.974*** 2.054** 2.630***
[0.724] [0.920] [0.954] [0.994] [0.978]
151 151 151 151 151
0.834 0.860 0.839 0.830 0.824
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TABLE 99 Table showing first-stage regressions for outcome models associated with 2008/9 expenditure
Variable
(1) PBC 2 cancer,
2008/9, outcome
model,
instrument
spend, weighted,
first stage
(2) PBC 10
circulation, 2008/9,
outcome model,
instrument spend,
weighted,
first stage
(3) PBC 11
respiratory,
2008/9, outcome
model, instrument
spend, weighted,
first stage
(4) PBC 13
gastrointestinal,
2008/9, outcome
model, instrument
spend, weighted,
first stage
Need CARAN per head 1.122*** 1.274*** 1.228*** 0.989***
[0.198] [0.146] [0.085] [0.088]
Lone pensioner households 0.490*** 0.426*** 0.252** 0.272**
[0.127] [0.090] [0.110] [0.109]
IMD2007 −0.145**
[0.060]
No car households −0.188***
[0.053]
Need CARAN per
head squared
1.071**
[0.426]
Provision of unpaid care 0.339***
[0.117]
Born outside EU −0.042***
[0.016]
Diabetes prevalence rate
2007/8
Permanently sick
Epilepsy prevalence rate
2007/8
Owner occupied
households
Lone parent households
Chronic kidney disease
prevalence rate 2007/8
Long-term unemployed
HIV need per head
HIV need per head squared
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(5) PBC 13
gastrointestinal,
2008/9, outcome
model,
instrument
spend,
weighted,
first stage
(6) PBC 4
endocrine,
2008/9,
outcome
model,
instrument
spend,
weighted,
first stage
(7) PBC 7
neurological,
2008/9,
outcome
model,
instrument
spend,
weighted,
first stage
(8) PBC 17
genitourinary,
2008/9,
outcome
model,
instrument
spend,
weighted,
first stage
(9) PBC 1
infectious
disease, 2008/9,
outcome
model,
instrument
spend,
weighted,
first stage
(10) PBC 18+ 19
maternity and
neonates, 2008/9,
outcome model,
instrument spend,
weighted,
first stage
1.056*** 0.373** 0.659***
[0.087] [0.175] [0.236]
0.287***
[0.109]
−0.082 0.236
[0.091] [0.214]
0.502**
[0.227]
0.539** 1.393***
[0.232] [0.340]
−0.060*** 0.080*** −0.031
[0.015] [0.026] [0.032]
0.167
[0.132]
0.380***
[0.104]
0.486***
[0.121]
−0.235**
[0.113]
0.175** 0.013
[0.080] [0.106]
0.089***
[0.033]
0.148***
[0.045]
0.471***
[0.050]
0.146***
[0.027]
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TABLE 99 Table showing first-stage regressions for outcome models associated with 2008/9 expenditure (continued)
Variable
(1) PBC 2 cancer,
2008/9, outcome
model,
instrument
spend, weighted,
first stage
(2) PBC 10
circulation, 2008/9,
outcome model,
instrument spend,
weighted,
first stage
(3) PBC 11
respiratory,
2008/9, outcome
model, instrument
spend, weighted,
first stage
(4) PBC 13
gastrointestinal,
2008/9, outcome
model, instrument
spend, weighted,
first stage
No qualifications
Work in agriculture
Maternity need per head
Constant 5.937*** 5.435*** 5.610*** 4.752***
[0.221] [0.230] [0.238] [0.236]
Observations 151 151 151 151
R2 0.521 0.612 0.746 0.665
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
Note
These are the first-stage regressions for the IV models reported in Table 85.
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(5) PBC 13
gastrointestinal,
2008/9, outcome
model,
instrument
spend,
weighted,
first stage
(6) PBC 4
endocrine,
2008/9,
outcome
model,
instrument
spend,
weighted,
first stage
(7) PBC 7
neurological,
2008/9,
outcome
model,
instrument
spend,
weighted,
first stage
(8) PBC 17
genitourinary,
2008/9,
outcome
model,
instrument
spend,
weighted,
first stage
(9) PBC 1
infectious
disease, 2008/9,
outcome
model,
instrument
spend,
weighted,
first stage
(10) PBC 18+ 19
maternity and
neonates, 2008/9,
outcome model,
instrument spend,
weighted,
first stage
−0.751*** −0.092
[0.189] [0.113]
0.150***
[0.051]
0.834***
[0.162]
4.167*** 6.379*** 4.808*** 5.363*** 6.010*** 4.171***
[0.048] [0.768] [0.193] [0.121] [1.513] [0.375]
151 151 151 148 151 151
0.648 0.559 0.477 0.378 0.791 0.614
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TABLE 100 Table showing first-stage regressions for expenditure models associated with 2008/9 expenditure
Variable
(1) PBC 2 cancer, 2008/9,
spend model, instrument
other programme need,
weighted, first stage
(2) PBC 10 circulatory,
2008/9, spend model,
instrument other
programme need,
weighted, first stage
(3) PBC 11 respiratory,
2008/9, spend model,
instrument other
programme need,
weighted, first stage
PCT budget per head
2008/9
0.090 0.049 0.020
[0.155] [0.118] [0.113]
Need CARAN per head 1.589*** 1.215*** 1.305***
[0.168] [0.133] [0.129]
Need CARAN per
head squared
0.221
[0.270]
Lone pensioner households –0.371*** –0.209*** –0.286***
[0.071] [0.060] [0.057]
Provision of unpaid care –0.349*** –0.236** –0.266***
[0.105] [0.092] [0.088]
IMD2007
Diabetes prevalence rate
2007/8
Epilepsy prevalence rate
2007/8
Maternity need per head
White ethnic group
Constant 3.457*** 4.528*** 4.687***
[1.131] [0.849] [0.814]
Observations 151 151 151
R2 0.840 0.828 0.854
* p< 0.1; ** p< 0.05; *** p< 0.01.
Robust standard errors in brackets.
These are the first-stage regressions for the IV models reported in Table 86.
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(4) PBC 13
gastrointestinal, 2008/9,
spend model, instrument
other programme need,
weighted, first stage
(5) PBC 4 endocrine,
2008/9, spend model,
instrument other
programme need,
weighted, first stage
(6) PBC 7 neurological,
2008/9, spend model,
instrument other
programme need,
weighted, first stage
(7) PBC 18+ 19 maternity
and neonates, 2008/9, spend
model, instrument other
programme need, weighted,
first stage
–0.115 0.055 0.180 0.452***
[0.106] [0.122] [0.132] [0.128]
1.042*** 1.112*** 1.119***
[0.207] [0.211] [0.141]
–0.256*** –0.453*** –0.106*
[0.062] [0.053] [0.059]
–0.302*** –0.239**
[0.099] [0.119]
0.099** 0.051 0.223***
[0.045] [0.048] [0.044]
0.067
[0.064]
0.036
[0.044]
0.266***
[0.078]
0.292***
[0.065]
5.851*** 4.340*** 3.858*** 1.901**
[0.753] [0.940] [0.979] [0.864]
151 151 151 151
0.830 0.857 0.837 0.843
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Appendix 3 Translating mortality effects into
life-years and quality-adjusted life-years
Introduction
This appendix describes how the results of the econometric work undertaken to estimate the link between
NHS spending and mortality, which was detailed in Appendix 2, can be translated in to effects on life-years
and QALYs. This appendix presents much of the detail of data and analyses that support Chapter 4 of the
main report.
We present three sequential steps of analysis which lead to estimates of the overall cost per QALY
threshold for the NHS:
i. In From mortality to life-years we reconsider how the estimated effects on mortality from the
econometrics work might better translate into life-years by exploring the limitations of mortality data
available at PCT level and the published YLL figures presented in the previous chapter. We explore how
these estimates might be improved using additional data and analysis.
ii. In Adjusting life-years for quality-of-life we consider how these estimates of life-year effects might be
adjusted for the QoL in which they are lived, taking account of the gender and the age at which
life-years are gained or lost as well as the disutility associated with particular diseases.
iii. In Including quality-of-life effects during disease we explore ways to also take account of those effects
on health not directly associated with mortality and life-year effects (i.e. the ‘pure’ QoL effects) to
estimate an overall cost per QALY threshold.
This sequence of analysis is set out and explained based on the analysis of 2006/7 expenditure and
mortality data from 2006 to 2008. At the end of each section, we present a summary which includes a
central ‘best’ estimate as well as extreme lower and upper bounds for the cost per life-year and cost per
QALY threshold. The core assumptions which underpin these three values are common across sections
From mortality to life-years, Adjusting life-years for quality-of-life, Including quality-of-life effects during
disease and Which programme budget categories matter most?. The central or ‘best’ estimate is based
on two assumptions one conservative and the other more optimistic with respect to the health effects
associated with expenditure. The first is that the health effects of changes in 1 year of expenditure are
restricted to 1 year. Analyses in Appendix 2 uses 3 years of mortality data, but these are averaged to an
annual value prior to estimating outcome elasticities. Therefore, the estimated outcome elasticities
represent the proportionate effect on mortality in 1 year due to a proportionate change in expenditure.
This is likely to underestimate effects on mortality as expenditure that reduces mortality risk for an
individual in 1 year may well also reduce their risk over subsequent years; possibly over the whole of
their remaining disease duration. Expenditure may also prevent disease in future patient populations.
Therefore, total health effects will be underestimated and the cost per life-year or QALY threshold will be
overestimated. Although undoubtedly conservative, it may be offset to some extent by the more optimistic
assumption used to translate mortality effects into life-years. In common with YLL figures published by
NHS IC and the WHO GBD study it is assumed that any death averted by expenditure in 1 year will return
the individual to the mortality risk of the general population, i.e. the YLG associated with each death
averted are based on what would have been their LE taking account of their of age and gender (using life
tables for the general population).
The extreme upper and lower bounds for cost per life-year and cost per QALY thresholds are based on
making both assumptions either optimistic (providing the lower bound for the threshold) or conservative
(an upper bound for the threshold). The lower bound is based on assuming that health effects are not
restricted to 1 year but apply to the remaining disease duration for the population at risk during the
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expenditure year (although this still does not account for the effects of expenditure on preventing disease).
The upper bound is based on the combination of assuming that health effects are restricted to 1 year
and that any death averted is only averted for the minimum duration consistent with the mortality data
used to estimate the outcome elasticities in Appendix 2. It is very important to note that the lower and
upper bounds represent extreme values rather than alternative but plausible views that could reasonably
be taken.
The three sequential steps of analysis, which provide a cost per life-year threshold, through a cost per
life-year adjusted for quality to a cost per QALY threshold, are explained and detailed in From mortality
to life-years, Adjusting life-years for quality of life and Including quality of life effects during disease,
using the analysis of 2006 expenditure and mortality data from 2006 to 2008. In Which programme
budget categories matter most?, further analysis using these data highlight which PBCs have the greatest
influence on the overall threshold. An exploration of the impact of the uncertainty over the outcome
and spend elasticities in estimates of the threshold is also presented in How uncertain are the estimates?.
The sequence of analyses is then applied to 2008/9 expenditure and 2008/9/10 mortality data; results of
the cost per QALY threshold for the most recent years of analysis are presented in Re-estimating the
cost per quality-adjusted life-year threshold using 2008 expenditure data. In Re-estimating the cost per
quality-adjusted life-year threshold using 2007 expenditure data we present our best estimate of the
threshold cost per QALY based on the analysis of 2007/8 expenditure and mortality data from 2007
to 2009.
Analysis of 2006/7 expenditure and 2006/7/8 mortality data
From mortality to life-years
In this section we summarise our examination of a number of issues associated with available PCT-based
mortality data and the associated published estimates of YLL. We then examine how, given the limited
information available about the population at risk in each PBC, we might take proper account of the fact
that some of the observed deaths would have occurred anyway (had the same population not been at risk
in the particular PBC) when estimating YLL, i.e. taking account of unobserved counterfactual deaths. This
allows us to estimate the YLL that better reflects the effect of expenditure on the mortality observed in
each PBC, and infer the excess deaths associated with each PBC. Finally, we present the cost per death
averted and cost per life-year which accounts for the issues raised in this section.
Mortality and years of life lost coverage
The mortality data that is available at PCT level does not offer full coverage of all deaths across all the
ICD-10 codes that make up each PBC. Table 101 illustrates, using a few PBCs as examples, the mapping
of three-digit ICD-10 codes to PBCs [see Table 101, column (1)] and the incomplete coverage of these
TABLE 101 Illustrating coverage
PBC
(1) ICD-10 codes covered
by the spend data
(2) ICD-10 codes covered
by the mortality data
(NHS IC)
(3) Coverage of
mortality data relative
to spend data (2008)
1 Infectious diseases Large parts of A00–B99 A00–B99 1.000
2 Cancer C00–C97, D00–D49 C00–C97 0.984
4 Endocrine E000–E899 E10–E14 0.634
10 Circulatory I00–I99, Q20–Q28 I00–I99 0.992
11 Respiratory A150–A169, A190–A199,
J000–J989, Q300–Q349,
R000–R099
J12–J18, J40–J44, J45–J46 0.773
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ICD-10 codes in mortality data [see Table 101, column (2)]. A more detailed account of the extent of
coverage is presented in Table 37 in Appendix 2.
National (English) data are, however, available that cover all deaths associated with all the ICD-10 codes
that make up each PBC. Therefore, it is possible to adjust the incomplete reporting of mortality at PCT
level (see Health outcome data in Appendix 2) before applying the estimated outcome elasticities to
calculate the deaths averted due to expenditure. Applying published estimates of YLL per death to all the
deaths averted using coverage adjustment factors [as illustrated in column (3) of Table 101] provides
the estimate of the cost per life-year reported in Appendix 2. Note that the proportionate effects on
mortality (due to changes in expenditure) are therefore assumed to be similar for mortality that is and is
not recorded at PCT level. This seems more reasonable than assuming no effect of expenditure on
mortality that happens not to be recorded at PCT level.
The published estimates of YLL (NHS IC) used in Chapter 3 only include deaths that occurred before the
age of 75 years (but exclude deaths before age 1 year) and are based on the difference between age
75 years and the age of each death before 75 years. These estimates have the same limited coverage as
PCT-level mortality data, so are not available for all the ICD-10 codes that make up each PBC. Therefore,
applying the available estimates of YLL per death to the estimated number of deaths averted requires an
assumption that the YLL per death is similar for those groups of ICD-10 codes covered and not covered by
the published YLL figures.
This can be examined by using national ONS data to calculate YLL in the same way as NHS IC, but with full
coverage of all the ICD-10 codes that make up each PBC. Although ONS data provides complete coverage
and reports gender, age at death is only reported in 5-year ranges (these data are not available at PCT
level so could not be used when estimating outcome elasticities in Chapter 3). Therefore, using ONS data
to estimate YLL requires taking the mid-pointa of each range as the age of death (i.e. assuming reported
deaths are equally likely over the range in which they are reported). For this reason it is not possible to
precisely recover the published YLL figures using ONS data for those ICD-10 code groupings that can be
precisely matched to the NHS IC coverage. However, the differences are small (ranging from −1% to 2%
as shown in Table 102), suggesting that taking the mid-point of each range as the age of death is a
reasonable approximation.
Published estimates of YLL are available from the NHS IC for PBC 16 (trauma and injuries), but ONS does
not provide the information required to calculate YLL for this PBC. The estimated outcome elasticity for
PBC 16 (trauma and injuries) was zero for 2006 and could not be estimated for 2008 expenditure.
Therefore, this PBC does not contribute any changes in health outcomes, although the changes in this
expenditure are included in subsequent estimates of cost per life-year and QALY thresholds. However, there
was very limited coverage of mortality data recorded at PCT level and the expenditure data for this PBC.
In addition, the mortality data that was available (ICD-10 codes S72, S02, S06 and T90) was less likely to be
TABLE 102 Estimates of YLL for NHS IC and ONS for those ICD-10 code groupings that can be precisely matched to
the NHS IC coverage
PBC (1) YLL<75 (NHS IC)
a (2) YLL<75 (ONS)
b (3) Difference in YLL (%)
1 Infectious diseases 35,517 35,688 0.5
2 Cancer 735,674 744,240 1
4 Endocrine problems 19,224 19,445 1
10 Circulatory 453,878 461,062 2
18+ 19 Maternity and neonates 164,200 163,105 –1
a Does not take into account coverage adjustment.
b Deaths at age < 1 year included in PBC 18 + 19.
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associated with changes expenditure in this PBC and more likely to be associated with changes in
expenditure in others. Consequently, the health effects of changes in expenditure in PBC 16 may be
underestimated. Therefore, this PBC does not contribute any changes in health outcomes due to changes in
expenditure in subsequent estimates of cost per life-year and QALY thresholds.
The differences between estimates of YLL based on ONS and NHS IC data are, however, much more
significant and are reported in Table 103. These reflect differences in the distribution of ages at death
between those groups of ICD-10 codes covered and not covered in the NHS IC figures. For example,
NHS IC figures available at PCT level for PBC 7 (neurological problems) have low coverage of all deaths in
this PBC [0.136 in Table 103, column (1)]. The deaths that are reported in NHS IC are associated with
epilepsy and the YLL [22,046 in Table 103, column (2)] reflects the generally younger age at death in this
group. When adjusted for full coverage [22,046/0.136= 162,100 in Table 103, column (3)], the estimated
YLL is much greater than the YLL based directly on all deaths by age group reported for the PBC in ONS.
This difference in YLL reflects the fact that the deaths in PBC 7 which are not covered by NHS IC figures
tend to be in older age groups so generate fewer YLL.
Using ONS data also allows deaths under the age of 1 year to be appropriately assigned to PBCs via the
ICD-10 code in which they occurred (NHS IC YLL figures exclude deaths under 1 year), rather than
assigning them all to PBC 18 + 19 as in Appendix 2.b This explains the large reduction in YLL for
PBC 18 + 19 (maternity and neonates) as much of the mortality is reassigned to ICD-10 codes which
contribute to other PBCs. As most of the deaths that are reassigned are allocated to PBC 1 (infectious
diseases) the YLL for this PBC increases despite complete reporting of deaths at PCT level and full coverage
by NHS IC figures (Table 104).
Using ONS data to calculate YLL in the same way as the published NHS IC figures, but overcoming some
of the issues associated with the reporting of mortality at PCT level and the coverage of published
estimates of YLL, generates similar estimates of a cost per life-year threshold [see column (2) in Table 106]
to those reported in Appendix 2.
Life expectancy and years of life lost
As noted above, the NHS IC estimates of YLL only include deaths below 75 years and are based on the
difference between age 75 years and the age of each death below 75 years. Implicitly, this treats 75 years
as the appropriate normal LE for males and females for the population at risk in each PBC. However, with
the exception of maternity and neonates, most deaths in PBCs occur above the age of 75 years and
TABLE 103 Estimates of YLL for NHS IC and ONS
PBC
(1) Coverage
of mortality
data relative
to spend data
(2) YLL<75
(NHS IC)
(3) YLL<75
adjusted
(NHS IC)
(4) YLL<75 no
adjustment
needed (ONS)
(5) Difference
from adjusted
NHS IC to
ONS (%)
1 Infectious diseases 1.000 35,517 35,517 40,928 15
2 Cancer 0.984 735,674 747,636 758,804 1
4 Endocrine problems 0.634 19,224 30,322 41,548 37
7 Neurological problems 0.136 22,046 162,100 93,755 –42
10 Circulatory 0.992 453,878 457,538 481,246 5
11 Respiratory 0.773 108,074 139,812 147,465 6
13 Gastrointestinal 0.571 115,303 201,931 177,532 –12
17 Genitourinary 0.172 3343 19,438 17,380 –11
18+ 19 Maternity and neonates 0.679 164,200 241,826 15,409 –94
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LEs are significantly greater than 75 years. Based on 2006–8 data, LE at birth is greater than 75 years
(77.74 years for males and 81.88 years for females).c Given the need to reflect the normal LE for the at risk
population, it is more appropriate to use the age distribution of the general population, and calculate LE
conditional on age averaged over the general population’s age distribution. General population LEs are
estimated to be 80.7 years for males and 84.4 years for females. These LE estimates will always be higher
than LEs at birth.
Based on ONS data, YLL can be recalculated using the above estimates of gender-specific LE for the
general population. When increasing LE two effects occur, both of which tend to increase estimates of
YLL. First, more deaths are included in the YLL calculation (those that occur between age 75 years and LE)
and second, each death previously counted below 75 years will generate 5.7 or 9.4 more YLL for males
and females respectively. The effect on the number of deaths and the YLL for each PBC using the LE of the
general population is reported in Table 106.
The number of deaths counted below LE increases for every PBC except for maternity and neonates
because, as expected, all deaths are below age 75 years in PBC 18 + 19. However, YLL increases for all
PBCs reflecting the additional years otherwise expected to be lived to an older LE. Of course including
more of the deaths observed in each PBC and the greater YLL associated with them will generate more
deaths averted and more YLGs when applying the same proportionate effects from the outcome
elasticities estimated in Appendix 2. Therefore, the cost per death averted and cost per life-year thresholds
are expected to be lower using these figures than those reported in Appendix 2.
TABLE 104 Estimates of YLL for NHS IC and ONS including deaths age < 1 year
PBC (1) YLL<75 (NHS IC) (2) YLL<75 (ONS)
a (3) Difference in YLL (%)
1 Infectious diseases 35,517 40,928 15
2 Cancer 735,674 744,960 1
4 Endocrine 19,224 19,445 1
10 Circulatory 453,878 464,763 2
18+ 19 Maternity and neonates 164,200 15,409b –91
a Deaths age < 1 year included in PBC of death.
b Does not include YLL from deaths < 28 days.
TABLE 105 Summary of cost per death averted and cost per life-year threshold
PBC scenario
Using 75 years as the cut-off (ONS) Using LE as the cut-off (ONS)
(1) Cost per
death averted (£)
(2) Cost per LY
gained (£)
(3) Cost per
death averted (£)
(4) Cost per
YLG (£)
All big four programmes 122,756 10,398 63,426 5487
11 PBCs (with mortality) 240,433 20,031 124,655 10,660
All 23 PBCs (zero health effects for
remaining 12 PBCs)
884,579 73,697 458,620 39,218
All 23 PBCs (non-zero health effects for
remaining 12 PBCs, except GMS)a
271,739 22,639 140,886 12,048
a In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal.
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The impact on the cost per life-year and cost per death averted thresholds is summarised in Table 105.
A detailed breakdown of the changes in spend and YLL across PBCs is presented in Table 107.
A listing of the spend and outcome elasticities used in threshold calculations throughout this section
is in Table 108 [see columns (2) and (5)]. Note that in the analyses in Appendix 2 and sections in this
appendix up to Using ratios of quality-adjusted life-years to years of life lost (corresponding to Chapter 3
and Chapter 4, From mortality to life-years, Adjusting life-years for quality-of-life and Using ratios of
quality-adjusted life-years to years of life lost in main report), expenditure elasticities were not estimated
for the other 11 PBCs where outcome elasticities could not be estimated because the same health effect of
changes in expenditure was assumed, i.e. it did not matter how changes in expenditure were allocated
between them. However, in this section it does matter how the remaining change in expenditure
is allocated.
The cost per death averted (or life saved) threshold should not be overinterpreted because this is of little
direct policy interest as lives are never saved (death is only delayed), and the significance of a death
averted depends critically on how long it is averted and the QoL in which additional years are lived
(see Adjusting life-years for quality-of-life). However, establishing the number of deaths averted which
are associated with net YLL is useful because it enables an assessment of the number of YLGs associated
with each death averted. Table 109 presents the YLL saved for each death averted implied by the
assumptions underlying calculations of the cost per life-year threshold in Table 107. For the 11 PBCs
with a mortality signal, each death averted is assumed to be associated with a gain of 11.7 YLL
[when LE is used, see Table 109, column (2)]. This value is smaller than when using 75 years old as
a cut-off [see Table 109, column (1)] because a higher proportion of deaths closer to the cut-off age
are being considered (i.e. with lower YLL associated).
There are good reasons why YLL figures calculated as the difference between age of death and LE are
likely to be overestimated. This is dealt with in the next section (see Years of life lost and accounting for
counterfactual deaths). In Inferring excess deaths we take account of the fact that some of the deaths
observed in a PBC would have occurred anyway in a similar ‘normal’ population (i.e. the counterfactual
population not at risk through membership of the PBC), so not all observed deaths are ‘excess’ and
generate YLL.
TABLE 106 The difference in YLL by LE
PBC
(1)
Deaths<75
(ONS)
(2)
Deaths<LE
(ONS)
(3) Difference in
deaths due to
increased LE (%)
(4)
YLL<75
(ONS)
(5)
YLL<LE
(ONS)
(6) Difference in
YLL due to
increased LE (%)
1 Infectious
diseases
2050 3710 81 40,928 62,051 52
2 Cancer 62,944 95,212 51 758,804 1,345,013 77
4 Endocrine 2367 4000 69 41,548 65,015 56
7 Neurological 5095 8975 76 93,755 145,526 55
10 Circulatory 41,487 82,098 98 481,246 916,170 90
11 Respiratory 14,000 30,500 118 147,465 310,326 110
13 Gastrointestinal 10,611 15,827 49 177,532 273,303 54
17 Genitourinary 1588 4197 164 17,380 39,098 125
18+ 19 Maternity and
neonates
226 226 0 15,409 17,167 11
LE: male= 80.7 years, female= 84.4 years.
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Years of life lost and accounting for counterfactual deaths
The estimates of YLL based on ONS data overcome many of the limitations of the published NHS IC
figures. However, the YLL reported in Table 106 are calculated in the same way as the NHS IC figures,
by taking the difference between a fixed LE and the age at death for deaths observed below that LE.
Simply taking the difference between a fixed LE and the age at death of deaths that occur below LE and
ignoring those deaths that occur above LE, is only an accurate representation of the YLL if it is reasonable
to assume that no deaths would have otherwise occurred prior to LE (so all ‘normal’ deaths must occur at LE)
and that there are no deaths (survivors) beyond LE in the at risk population (i.e. all deaths below LE are
excess deaths and there are no excess deaths above LE). The estimate of YLL in the previous section may
thus be biased for two reasons: (i) it does not account for the fact that not all deaths observed below LE
are ‘excess’ deaths in the sense that some deaths would have occurred (at the same age) in a similar
population not at risk in the PBC; and (ii) some of the deaths observed above LE may be ‘excess’ deaths
that would not otherwise have occurred at that age (see breakdown of deaths below and above LE
in Table 110).
The overall effect on YLL, and on the cost per life-year, will depend on the number of deaths above and below
LE that are excess. However, it is more likely that deaths below LE are ‘excess’. Estimates of YLL are required
which take account of the ‘counterfactual’ deaths that would have occurred even if the population in the PBC
was not at risk through membership of the ICD-10 codes that make it up, but faced the same mortality risks as
the general population, accounting for the age and gender distribution of the PBC population.
Ideally, with reliable information about the size of the population at risk in each PBC, and its age and
gender distribution, it would be possible to estimate the number of deaths that would be expected
to occur had this population not been at risk, based on mortality data for the general population.
The difference between deaths observed across all ages in the PBC and the deaths expected to have
occurred in this matched ‘normal’ population would provide the number of ‘excess’ deaths by age and
gender. These ‘counterfactual’ deaths will occur in the other PBCs insofar as all deaths are recorded in an
ICD-10 code, taking account of the unavoidable fact that everyone must die of something at some time.
For example, even if all observed cancer mortality was avoidable and could in principle be eliminated with
sufficient expenditure, lives would not be ‘saved’ but deaths delayed and reallocated to other causes.d
The YLL associated with each of these excess deaths is the LE conditional on gender and on surviving to the
age at which the excess death occurred. The total YLL for the at risk population is simply the sum of these YLL
over all excess deaths, which could occur at any age. We do not (and will never) know the counterfactual
expected age of death for each individual patient. However, two perfectly matched populations of individuals,
one at risk and another not at risk in the PBC can be compared in terms of their survival curves (Figure 46).
The area below each survival curve reflects the LE and the area between the two survival curves returns the
YLL. This is equivalent to comparing the average age of death across patients in the population at risk in the
PBC (N patients), with the average age of death in the matched, not at risk, population (for simplicity assumed
to be equally sized). Equation 22 describes the YLL per patient as the difference in the average age of death,
agedeath, observed for each individual, i (out of N individuals), in each population. The YLL for the population is
simply the per patient YLL multiplied by the size of the population N.
YLLper patient ¼ LE
norm−LEPBC ¼
1
N
∑
N
i¼1
agenormdeath, i−
1
N
∑
N
i¼1
agePBCdeath, i
YLL ¼ NYLLper patient
(22)
The difficultly is that routinely available data do not provide any information about the size of the
population at risk or its age and gender distribution (matching criteria). Thus, a matched population cannot
be generated, and the area between the two curves cannot be evaluated. Therefore, it is not possible to
directly estimate excess deaths or compare survival curves. Even if the size of the at risk population is
unknown we can still use information that might be available about its age and gender distribution
(or make reasonable assumptions) to estimate a matched ‘normal’ LE using life tables for the
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TABLE 107 Breakdown of the cost per death averted and cost per life-year thresholds
PBC
Change
in spend
(£M)
Using 75 years as the cut-off (ONS)
Deaths
Change in
death
Cost per
death
averted (£) YLL
2 Cancer 19 62,944 100.10 191,500 758,804
10 Circulatory 33 41,487 321.26 103,560 481,246
11 Respiratory 22 14,000 249.25 89,482 147,465
13 Gastrointestinal 17 10,611 72.69 227,013 177,532
All big four programmes 122,756
1 Infectious diseases 8 2050 0.76 10,936,680 40,928
4 Endocrine 18 2367 18.99 929,559 41,548
7 Neurological 17 5095 3.52 4,889,114 93,755
17 Genitourinary 32 1588 0.74 42,993,075 17,380
16 Trauma and
injuries
10 N/A 0.00 N/A N/A
18+ 19 Maternity and
neonates
8 226 0.24 32,813,038 15,409
First 11 PBCs 240,433
3 Disorders of blood 11 46.57 240,433
5 Mental health 204 849.17 240,433
6 Learning disability 31 128.05 240,433
8 Vision 24 100.54 240,433
9 Hearing 6 26.60 240,433
12 Dental 23 97.72 240,433
14 Skin 11 43.72 240,433
15 Musculoskeletal 15 62.93 240,433
20 Poisoning and
adverse events
4 18.27 240,433
21 Healthy individuals 18 76.27 240,433
22 Social care needs 68 281.19 240,433
23 Other 78 0 N/A
All (23 PBCs) 271,739
N/A, not applicable.
We have been unable to obtain a satisfactory outcome model for trauma and injuries and have assumed a zero
outcome elasticity.
For expenditure in 2006/7, the neonate category has been merged with maternity to obtain plausible outcome and
expenditure models.
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Using LE as the cut-off (ONS)
Change
in YLL
Cost per
YLG (£) Deaths
Change in
deaths
Cost per
death
averted (£) YLL
Change
in YLL
Cost per
YLG (£)
1207 15,885 95,212 151.42 126,599 1,345,013 2139 8962
3727 8928 82,098 635.73 52,333 916,170 7094 4690
2625 8495 30,500 543.00 41,074 310,326 5525 4037
1216 13,568 15,827 108.42 152,198 273,303 1872 8814
10,398 63,426 5487
15 547,796 3710 1.38 6,043,179 62,051 23 361,319
333 52,957 4000 32.10 550,066 65,015 522 33,842
65 265,693 8975 6.19 2,775,491 145,526 100 171,172
8 3,928,251 4197 1.95 16,267,096 39,098 18 1,746,202
0 N/A N/A 0 N/A N/A 0 N/A
17 481,261 226 0.24 32,813,038 17,167 19 431,977
20,031 124,655 10,660
559 20,031 89.83 124,655 1050 10,660
10,193 20,031 1637.87 124,655 19,153 10,660
1537 20,031 246.98 124,655 2888 10,660
1207 20,031 193.92 124,655 2268 10,660
319 20,031 51.30 124,655 600 10,660
1173 20,031 188.48 124,655 2204 10,660
525 20,031 84.34 124,655 986 10,660
755 20,031 121.38 124,655 1419 10,660
219 20,031 35.23 124,655 412 10,660
915 20,031 147.10 124,655 1720 10,660
3375 20,031 542.35 124,655 6342 10,660
N/A N/A N/A
22,639 140,886 12,048
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TABLE 108 Outcome and spend elasticities
PBC
(1) Total spend
2006/7 (£M)
Spend elasticities Change in spend, £M (% share)
(7) Outcome
elasticitiesb
(2)
Unadjusteda
(3) Analysis up to
Chapter 4, Using
ratios of quality-
adjusted life-years
to years of life lost
(and Appendix 3)
(4) Analysis in
Chapter 4, Using
estimates of the
quality-adjusted
life-year burden
of disease
(and Appendix 3)
(5) Analysis up to
Chapter 4, Using
ratios of quality-
adjusted life-years
to years of life lost
(and Appendix 3)
(6) Analysis in
Chapter 4, Using
estimates of the
quality-adjusted
life-year burden
of disease
(and Appendix 3)
2 Cancer 4122 0.465 0.465 0.657 19 (2.8) 27 (4) 0.342
10 Circulatory 6161 0.540 0.540 0.763 33 (4.9) 47 (6.9) 1.434
11 Respiratory 3285 0.679 0.679 0.959 22 (3.3) 32 (4.6) 2.622
13 Gastrointestinal 3700 0.446 0.446 0.630 17 (2.4) 23 (3.4) 1.536
All big four programmes 17,268 91 (13.4) 129 (19)
1 Infectious diseases 1054 0.792 0.792 1.119 8 (1.2) 12 (1.7) 0.047
4 Endocrine 1853 0.953 0.953 1.346 18 (2.6) 25 (3.7) 0.842
7 Neurological 2790 0.616 0.616 0.870 17 (2.5) 24 (3.6) 0.112
17 Genitourinary 3482 0.912 0.912 1.289 32 (4.7) 45 (6.6) 0.051
16 Trauma and injuries 2892 0.358 0.358 0.506 10 (1.5) 15 (2.2) –
18 + 19 Maternity and
neonates
3574 0.224 0.224 0.316 8 (1.2) 11 (1.7) 0.482
First 11 PBCs 32,912 185 (27.2) 261 (38.4)
3 Blood 837 0.700 1.338 0.989 11 (1.6) 8 (1.2) –
5 Mental health 8406 1.271 2.429 1.796 204 (30.1) 151 (22.2) –
6 Learning disability 2441 0.660 1.261 0.933 31 (4.5) 23 (3.4) –
8 Vision 1362 0.929 1.775 1.313 24 (3.6) 18 (2.6) –
9 Hearing 314 1.067 2.039 1.508 6 (0.9) 5 (0.7) –
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PBC
(1) Total spend
2006/7 (£M)
Spend elasticities Change in spend, £M (% share)
(7) Outcome
elasticitiesb
(2)
Unadjusteda
(3) Analysis up to
Chapter 4, Using
ratios of quality-
adjusted life-years
to years of life lost
(and Appendix 3)
(4) Analysis in
Chapter 4, Using
estimates of the
quality-adjusted
life-year burden
of disease
(and Appendix 3)
(5) Analysis up to
Chapter 4, Using
ratios of quality-
adjusted life-years
to years of life lost
(and Appendix 3)
(6) Analysis in
Chapter 4, Using
estimates of the
quality-adjusted
life-year burden
of disease
(and Appendix 3)
12 Dental 2621 0.469 0.896 0.663 23 (3.5) 17 (2.6) –
14 Skin 1429 0.385 0.736 0.544 11 (1.5) 8 (1.1) –
15 Musculoskeletal 3369 0.235 0.449 0.332 15 (2.2) 11 (1.6) –
20 Poisoning and
adverse events
737 0.312 0.596 0.441 4 (0.6) 3 (0.5) –
21 Healthy individuals 1355 0.708 1.353 1.000 18 (2.7) 14 (2.0) –
22 Social care needs 1529 2.314 4.422 3.269 68 (10.0) 50 (7.4) –
23 Other 10,585 0.739 0.739 1.044 78 (11.5) 111 (16.3) –
All 23 PBCs 67,896 679 (100) 679 (100)
a The spend elasticities reflect how a 1% increase in budget is distributed across PBCs; however, in the econometrics, these were estimated separately for each PBC [unadjusted estimates
in column (4)] and because of this, its direct application to spend generates a change in budget bigger than the 1%. An adjustment was thus applied to the remaining 12 PBCs (except
PBC 23 that was left unchanged), by multiplying each by a common factor – the magnitude of the unadjusted spend elasticities is changed but proportionality to the original elasticities
is maintained.
b Without the negative sign.
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TABLE 109 Implied YLL per death averted for each PBC
PBC
(1) Implied YLL per death averted
(< 75 years)
(2) Implied YLL per death
averted (< LE)
2 Cancer 12.1 14.1
10 Circulatory problems 11.6 11.2
11 Respiratory problems 10.5 10.2
13 Gastrointestinal problems 16.7 17.3
All big four programmes 11.8 11.6
1 Infectious diseases 20.0 16.7
4 Endocrine problems 17.6 16.3
7 Neurological problems 18.4 16.2
17 Genitourinary problems 10.9 9.3
16 Trauma and injuries N/A N/A
18+ 19 Maternity and neonates 68.2 76.0
First 11 PBCs 12.0 11.7
N/A, not applicable.
TABLE 110 Number of deaths below and above LE in 2006/7/8, by PBC
PBC
(1)
< LE
2006
(2)
> LE
2006
(3)
< LE
2007
(4)
> LE
2007
(5)
< LE
2008
(6)
> LE
2008
(7) Annual
deaths < LE
(8) Annual
deaths > LE
1 Infectious
diseases
3824 3420 3902 3735 3403 2589 3710 3248
2 Cancer 95,549 34,192 95,331 35,455 94,758 37,144 95,213 35,597
4 Endocrine 4006 2661 3967 2750 4028 2882 4000 2764
7 Neurological 8454 5762 8845 6501 9626 6871 8975 6378
10 Circulatory 84,909 78,369 80,610 78,481 80,779 76,407 82,099 77,752
11 Respiratory 29,925 34,549 29,540 35,060 32,036 35,227 30,500 34,945
13 Gastrointestinal 15,893 8311 15,658 8376 15,930 8274 15,827 8320
17 Genitourinary 4056 6049 4072 6558 4465 6673 4198 6427
18+ 19 Maternity and
neonates
195 0 216 0 267 0 226 0
LE: male= 80.7 years, female= 84.4 years.
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general population – such a LE summarises the area under the counterfactual survival curve
(LEnorm = 1N∑
N
i¼1
agenormdeath, i in Equation 22). Unfortunately, it is not possible to also calculate the LE for the
population at risk in the PBC (or represent the survival curve) without information about the size of the at
risk population – if it was possible, the difference between these life expectancies would approximate the
YLL per patient at risk in a PBC.
Fortunately, we can still recover a consistent estimate of YLL using the normal LE of a matched population
that is not at risk (a summary of the counterfactual average age of death), alongside the death data
available for the PBC population. Equation 23 shows that population YLL can be approximated by
subtracting the age at which each observed death in a PBC has occurred to the normal LE.
YLL = N(LEnorm − 1N ∑
N
i=1
agePBCdeath, i) = ∑
N
i=1
(LEnorm − agePBCdeath, i) (23)
The data on the PBC observed deaths available expresses the ages at which deaths occurred in age groups
(k out of K groups). Following from Equation 23, the population YLL can be evaluated considering the
number of patients dying in each of the age groups, Ndie,k, as depicted in Equation 24. This is equivalent to
comparing survival curves where age is discretised into intervals and the mid-point of the intervals used as
age of death – this is illustrated in Figure 47.
YLL = ∑
K
k=1
(LEnorm − agedeath, k)Ndie, k (24)
The calculations (in Equations 23 and 24) require all observed deaths – both those that occur below and
those that occur above this LE – to be taken into account. Those deaths occurring below LE generate
YLL – compared with the average of a matched population not at risk. However, we must also account
for those deaths that occur at ages above LE. These deaths generate life-years ‘gained’ compared with
the average of a matched population not at risk. Therefore, the appropriate estimate is a net YLL
(i.e. YLL – YLG). In effect, by subtracting YLG from YLL we take account of the fact that not all deaths
below LE are excess deaths but some deaths above LE are. Insofar as deaths above LE have been observed
in a specific PBC, the net YLL estimate will always be lower than the estimate of YLL. Consequently, the
estimates in Years of life lost and accounting for counterfactual deaths overestimate YLL and, hence,
underestimate the cost per life-year threshold.
1
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Matched normal population
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FIGURE 46 Survival curve of a population at risk in a PBC and of a matched ‘normal’ population.
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Using the life expectancy of the general population
Routinely available data provides the age and gender of observed deaths but no information about the
age and gender distribution of the at risk population itself. Using observed age and gender at death
[Table 111, column (3)] as an indication of the distribution of the at risk population will significantly
overestimate the LE of a normal matched population insofar as a disease may be chronic (not all PBC
mortality occurs on entry into the at risk population). If mortality risk increases over the disease duration,
more deaths would be observed in groups that have been prevalent for some time (i.e. are older) than
TABLE 111 Average age (years) and LE (years) for PBCs based on age of the general population
PBC Sex
(1) Average age of
general population
(2) LE of general
population (3) Age at death
(4) LE at age of
death
1 Infectious
diseases
M 38.5 80.7 72.8 87.5
F 40.8 84.4 79.3 91.1
2 Cancer M 38.5 80.7 73.3 86.5
F 40.8 84.4 73.8 88.8
4 Endocrine M 38.5 80.7 72.5 87.1
F 40.8 84.4 77.9 90.6
7 Neurological M 38.5 80.7 72.8 87.2
F 40.8 84.4 77.7 90.5
10 Circulatory M 38.5 80.7 76.4 87.9
F 40.8 84.4 82.7 91.7
11 Respiratory M 38.5 80.7 79.4 89.0
F 40.8 84.4 82.9 91.8
13 Gastrointestinal M 38.5 80.7 68.9 85.7
F 40.8 84.4 77.1 90.1
17 Genitourinary M 38.5 80.7 81.6 90.1
F 40.8 84.4 84.0 92.3
18 + 19 Maternity and
neonates
M 38.5 80.7 1.1 78.3
F 40.8 84.4 11.4 82.7
F, female; M, male.
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FIGURE 47 Area between the survival curves, discretised.
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those that are incident. Older age groups will thus be over-represented in observed deaths compared
with a matched normal population. For these reasons LE and YLL would be overestimated using age at
death as a proxy for the age distribution of the at risk population, and the cost per life-year would
be underestimated.
In the absence of additional external information the net YLL could be based on the LE of the general
population, reflecting its current age and gender distribution. Such net YLL estimates are reported in
Table 112, and illustrate the impact of accounting for counterfactual deaths in the way described above.
The YLL reported in column 5 of Table 112 are calculated the same way and are the same as the figures
previously reported [see column (5) of Table 106]. That is, they do not account for deaths that would have
otherwise occurred below LE or the very many deaths that occur above LE. With the exception of PBC
18 + 19, many deaths occur above the LE of the general population [see column (4) in Table 112] in all
PBCs. As a consequence, there are YLG associated with all other PBCs [see column (6)] so the net YLL in
column (7) are lower than YLL based on the same LE. Therefore, failure to account for counterfactual
deaths would lead to an overestimate of the YLL associated with a PBC and the effects of expenditure on
YLL. The cost per life-year threshold would be underestimated (see Table 115).
However, these figures are only correct insofar as the distribution of age and gender in each PBC is similar
to the general population. For example, if the at risk population tends to be younger the correct LE for the
PBC will be lower. A lower LE will mean that there are less deaths below LE each generating fewer YLL,
and more deaths above LE each generating more YLG. The net YLL will thus tend to be lower. Similarly,
if the at risk population tends to be older than the general population, the correct LE will be higher and
net YLL will also tend to be higher.
This explains the apparent net gain in YLL (negative net YLL) for PBC 17 (genitourinary) where most deaths
occur at ages greater than the LE of the general population so that YLG exceeds YLL. As we are able to
show later (see Table 114), this is because the age distribution in this PBC tends to be older than the
general population (i.e. the LE for a matched normal population should be higher with fewer deaths above
and more below this LE).
TABLE 112 Net YLL using LE of the general population
PBC
(1) LE of
males
(years)
(2) LE of
females
(years)
Average 2006–8
(3)
Deaths
< LE
(4)
Deaths
> LE (5) YLL (6) YLG
(7)
Net YLL
1 Infectious
diseases
80.7 84.4 3710 3248 62,052 18,796 43,256
2 Cancer 80.7 84.4 95,213 35,597 1,345,038 175,350 1,169,689
4 Endocrine 80.7 84.4 4000 2764 65,016 15,864 49,152
7 Neurological 80.7 84.4 8975 6378 145,529 34,621 110,908
10 Circulatory 80.7 84.4 82,099 77,752 916,192 444,694 471,498
11 Respiratory 80.7 84.4 30,500 34,945 310,334 215,829 94,505
13 Gastrointestinal 80.7 84.4 15,827 8320 273,308 45,295 228,012
17 Genitourinary 80.7 84.4 4198 6427 39,099 40,530 –1431
18+ 19 Maternity and
neonates
80.7 84.4 226 0 17,167 0 17,167
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Using additional information about age and gender distribution
It is evident that estimates of YLL require some account to be taken of counterfactual deaths. In the
absence of routinely available information this requires examination of alternative sources of information
which might provide a basis for more credible assumptions about the age and gender distribution of the at
risk population in each PBC than either the distribution of observed deaths or of the general population.e
The WHO GBD study, updated in 2008 using 2004 data (see Addendum 1: data sources for more details)f
provides a range of summary health indicators for the UK, which are, in part, based on estimates of the
incidence and duration of sequelae associated with different types of disease by age and gender.
Therefore, the type of information used by the WHO in the GBD study to generate summary estimates
for the UK can also be used to improve the assumptions required about the age and gender distribution
of the PBC populations. Importantly, at this stage, we do not need to rely on estimates of the absolute
size of the at risk population, but only the relative ‘share’ by age and gender.
Specifically, the information reported by the GBD study (estimates specific to the UK provided in the
National Burden of Disease toolkit) reported the incidence and duration of sequelae associated with
different types of disease by age and gender. As it is possible that a patient may experience more than
one of the types of sequelae reported in the GBD study we use the gender and age distribution of the
sequelae with the highest prevalence, i.e. the minimum estimate of prevalence consistent with these
figures (see Addendum 1: data sources), to evaluate the age and gender distribution within each disease.
Global Burden of Disease classifies diseases by U-codes, which are groups of three-digit ICD-10 codes (see
Addendum 1: data sources for details of how U-codes map to ICD-10 codes).g As we know which ICD-10
codes contribute to each PBC we can map information from U-codes to PBCs via the ICD-10 codes
that contribute to each. The resulting average age and LE for each PBC is reported in columns (1) and
(2) of Table 113 using the information available from the GBD study in combination with life tables for the
general population.
These summary estimates suggest that some of the PBC populations may be on average older than the
general population (e.g. cancer, circulatory and genitourinary) or younger (e.g. maternity and neonates,
infectious diseases and neurological). However, when trying to interpret these summaries it should be noted
that the average age reported in Table 113 is the average over the ages at which sequelae occur within the
ICD-10 codes contributing to the PBC. Therefore, a similar average age can reflect very different age
distributions. Some reflect a markedly bimodal distribution (e.g. PBC 11 respiratory), where there is high
incidence at very young and older ages (Figure 48), or very different age distributions across the type of
diseases that contribute to the PBC. For example, PBC 7 (neurological) includes dementia which accounts
for the vast majority of the PBC population older than 70 years. However, a greater proportion of the
population is in much younger age groups with other conditions, especially migraine (see Addendum 1:
data sources for a detailed description of age and gender distributions in all PBCs). When interpreting these
summary estimates it should also be noted that the reported LEs are not the LEs at the average ages
reported in column (2) (see Table 113), but the average over the life expectancies for each age group within
the contributing ICD-10 codes weighted by the age distribution of the sequelae with maximum prevalence
from GBD U-codes.
The implications for net YLL of using these PBC specific estimates of ‘normal’ LE are reported in Table 114.
As expected, the net YLL for those PBCs with a LE greater than the general population are higher than
those reported in column (7) in Table 112 (e.g. PBC 10 circulatory and PBC 17 genitourinary, which now
has positive net YLL). Similarly, those PBCs with a LE less than the general population have lower net YLL
than reported in column (7) in Table 112 (e.g. PBC 1 infectious diseases and PBC 18 + 19 maternity and
neonates, where the effect of a lower LE is more modest as there are no deaths above either of the
estimates of LE).
The impact on the cost per life-year threshold of the issues discussed in this section is summarised in
columns (3) and (4) of Table 115.
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TABLE 113 Average age and LE for PBCs based on GBD
PBC Sex
(1) Average age of general
population (years)
(2) LE of general
population (years)
(3) Proportion of
males in PBC
(GBD) (%)
(4) Average age
in PBC (GBD) (years)
(5) Normal LE of PBC
population (GBD) (years)
1 Infectious diseases M 38.5 80.7 54.1 28.6 79.6
F 40.8 84.4 45.9 30.2 83.6
2 Cancer M 38.5 80.7 28.0 61.3 83.0
F 40.8 84.4 72.0 52.3 84.7
4 Endocrine M 38.5 80.7 38.4 44.2 81.0
F 40.8 84.4 61.6 50.8 84.7
7 Neurological M 38.5 80.7 28.1 24.8 79.6
F 40.8 84.4 71.9 23.5 83.3
10 Circulatory M 38.5 80.7 51.6 55.4 83.0
F 40.8 84.4 48.4 57.9 86.5
11 Respiratory M 38.5 80.7 48.0 32.1 80.3
F 40.8 84.4 52.0 33.7 84.0
13 Gastrointestinal M 38.5 80.7 42.9 35.8 80.6
F 40.8 84.4 57.1 41.9 84.5
17 Genitourinary M 38.5 80.7 85.9 63.2 83.5
F 40.8 84.4 14.1 47.3 85.6
18 + 19 Maternity and
neonates
M 38.5 80.7 16.3 3.0 78.7
F 40.8 84.4 83.7 24.1 83.1
F, female; M, male.
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FIGURE 48 Distribution of PBC 11 prevalence by age, gender and contributing ICD-10 codes, alongside proportion of prevalent patients in the PBC and contribution to
variance of each ICD-10 code.
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Taking account of counterfactual deaths by calculating net YLL based on the LE of the general population
[see Table 115, column (3)] provides similar estimates to those reported in Appendix 2. Assuming that PBC
populations have the same age and gender distribution as the general population when the, albeit limited,
information that is available suggests otherwise, seems inappropriate. Therefore, our preferred central
estimate of the cost per life-year threshold is reported in column (4) (see Table 115). These are lower than
those based on the general population, reflecting the impact on net YLL of evidence that the population at
risk in some key PBCs (especially PBCs 2 and 10) tend to be older than the general population. A detailed
breakdown of the changes in spend and YLL across PBCs that originate this central estimate are presented
in columns (5)–(7) of Table 116. In Summary of cost per life-year estimates we consider extreme upper and
lower bounds that might be placed on this central estimate.
TABLE 114 Net YLL using LE for each PBC
PBC
(1) LE of
males
(2) LE of
females
Average 2006–8
(7)
Net YLL
Deaths
(5) YLL (6) YLG(3) < LE (4) > LE
1 Infectious
diseases
79.6 83.6 3498 3460 58,686 21,724 36,962
2 Cancer 83.0 84.7 101,203 29,607 1,473,733 126,549 1,347,184
4 Endocrine 81.0 84.7 4068 2696 66,283 15,058 51,225
7 Neurological 79.6 83.3 8370 6983 135,686 41,770 93,917
10 Circulatory 83.0 86.5 96,694 63,157 1,102,020 278,251 823,768
11 Respiratory 80.3 84.0 29,549 35,897 298,343 230,313 68,030
13 Gastrointestinal 80.6 84.5 15,824 8323 273,117 45,414 227,703
17 Genitourinary 83.5 85.6 4969 5655 47,229 29,101 18,127
18+ 19 Maternity and
neonates
78.7 83.1 226 0 16,801 0 16,801
TABLE 115 Summary of cost per life-year threshold
PBC scenario
Using cut-off in estimating YLL
(ONS) (£) Using net YLL estimates (£)
(1) Cut-off
of 75 years
(2) Cut-off of
LE of the general
population
(3) Using LE
of the general
population
(4) Using LE
of the PBC
population (GBD)
All big four programmes 10,398 5487 10,421 8080
11 PBCs (with mortality) 20,031 10,660 19,928 15,628
All 23 PBCs (zero health
effects for remaining 12 PBCs)
73,697 39,218 73,317 57,497
All 23 PBCs (non-zero health
effects for remaining 12 PBCs,
except GMS)a
22,639 12,048 22,523 17,663
a In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal.
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TABLE 116 Life-year threshold using net YLL estimates (non-zero health effects for remaining PBCs except GMS)
PBC
(1) Change in
spend (£M)
Using LE of the general population Using LE of the PBC population
(2) Net YLL
(3) Change in
Net YLL
(4) Cost per
YLG (£) (5) Net YLL
(6) Change in
Net YLL
(7) Cost per
YLG (£)
2 Cancer 19 1,169,689 1860 10,305 1,347,184 2142 8947
10 Circulatory problems 33 471,498 3651 9112 823,768 6379 5216
11 Respiratory problems 22 94,505 1683 13,256 68,030 1211 18,415
13 Gastrointestinal problems 17 228,012 1562 10,564 227,703 1560 10,579
All big four programmes 10,421 8080
1 Infectious diseases 8 43,256 16 518,314 36,962 14 606,574
4 Endocrine problems 18 49,152 394 44,765 51,225 411 42,953
7 Neurological problems 17 110,908 77 224,601 93,917 65 265,235
17 Genitourinary problems 32 –1431 –1 –47,709,995 18,127 8 3,766,371
16 Trauma and injuries 10 N/A 0 N/A N/A 0 N/A
18 + 19 Maternity and neonates 8 17,167 19 431,977 16,801 18 441,387
First 11 PBCs 19,928 15,628
3 Disorders of blood 11 562 19,928 716 15,628
5 Mental health disorders 204 10,245 19,928 13,064 15,628
6 Learning disability 31 1545 19,928 1970 15,628
8 Problems of vision 24 1213 19,928 1547 15,628
9 Problems of hearing 6 321 19,928 409 15,628
12 Dental problems 23 1179 19,928 1503 15,628
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Inferring excess deaths
We have been able to establish a measure of net YLL which takes account of deaths that would have
occurred anyway below a normal LE for the PBC population (i.e. not all deaths observed in a PBC are
excess), and that some deaths observed above this LE would not otherwise have occurred at that age
(i.e. some of these deaths are excess). As explained in Years of life lost and accounting for counterfactual
deaths, net YLL calculated in this way is equivalent to first establishing the number of excess deaths
at each age, then calculating YLL for each excess death (based on the LE conditional on the age at which
each excess death occurred) and then summing these YLL across all excess deaths (i.e. across all ages).
In other words, the estimates of net YLL imply a number of excess deaths required to generate them in
each PBC. Therefore, it is possible to solve for the total number of excess deaths based on the net YLL and
the average YLL per observed death (the average of the sum of the YLL for every observed death where
the YLL for each observed death is the difference between age at death and LE conditional on age of
death). The net YLL divided by the average YLL per death provides the number of excess deaths required,
which on average will generate the estimated net YLL.
In the absence of information about the age distribution of excess deaths, calculations assume that
the average YLL associated with observed and excess deaths are similar. Insofar as excess deaths are
thought likely to generate more YLL than observed deaths the number of excess deaths will tend to be
overestimated. This would tend to underestimate the cost per excess death averted. However, the cost per
life-year estimates remain unchanged and do not require such an assumption.
The implied excess deaths associated with net YLL based on the LE of the PBCs [see Table 114, column (7)]
are reported in Table 117. With the exception of PBC 18 + 19, excess deaths are some proportion of total
observed deaths in each PBC. The proportion of excess deaths differs by PBC reflecting the distribution of
deaths relative to the LE of the PBC. For example, in those PBCs where a large proportion of deaths occur
below LE [see Table 117, columns (3) and (4)], excess deaths tend to be a greater proportion of total
deaths (e.g. PBCs 2, 13 and 10). Where most deaths occur above LE, excess deaths as a proportion of
total deaths tend to be lower (e.g. PBCs 11, 17 and 1). Nevertheless, the impact of the age distribution
of deaths and the age distribution of the at risk population (summarised as LE) on the calculation of excess
deaths is not always obvious as both will affect the numerator (net YLL) as well the denominator (average
YLL per death) in this calculation.
TABLE 117 Excess deaths implied by net YLL
PBC (1) Net YLL
(2) YLL per
observed death
(3) Excess
deaths
(4) Total
deaths
(5) % excess
deaths
1 Infectious diseases 36,962 13.4 2797 6958 40
2 Cancer 1,347,184 14.1 95,715 130,810 73
4 Endocrine 51,225 13.7 3769 6764 56
7 Neurological 93,917 13.7 6909 15,353 45
10 Circulatory 823,768 10.5 79,218 159,851 50
11 Respiratory 68,030 9.2 7386 65,445 11
13 Gastrointestinal 227,703 15.2 15,199 24,147 63
17 Genitourinary 18,127 8.3 2172 10,625 20
18+ 19 Maternity and neonatesa 16,801 73.9 226 226 100
a The number of excess deaths estimated in PBC 18+ 19 was initially estimated to be 230, higher than the number of
total deaths. This is due to the use of approximations (i.e. in the LE, or in using the net YLL), thus, for consistency,
we assumed this to be 100% of the total deaths.
Excess deaths are calculated for each gender by dividing net YLL by the YLL per death [column (5)= column (3)/column (4)].
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Estimates of net YLL and changes in life-years due to expenditure (see Tables 114 and 115) have already
accounted for the fact that not all deaths are excess and do not generate YLL. Nevertheless, solving for the
number of implied excess deaths associated with these net YLL estimates allows a comparison of the cost
per excess and observed PBC death avoided, and an examination of the interpretation that can be placed
of the life-years expected to be gained from an excess or observed death averted.
As only deaths observed in the PBC can be used to estimate the effects of expenditure (excess deaths are not
directly observed as they rely on an unobserved counterfactual population and would occur outside the PBC),
the outcome elasticities can be interpreted as the proportionate change in observed PBC mortality due to a
proportionate change in PBC expenditure. Equally, however, they can also be interpreted as the proportionate
effect on excess death due to a proportionate change in expenditure so can be applied to either total
observed or total excess deaths. Observed PBC mortality that is sensitive to changes in expenditure can be
regarded as ‘avoidable’ and it is only this mortality that contributes to the estimates of outcome elasticities
(not all observed mortality is necessarily avoidable and sensitive to expenditure – such mortality will not
contribute to the estimates). Not all observed mortality is excess when compared with the counterfactual
population, but this is unrelated to the question of how sensitive it is to expenditure (i.e. observed mortality
will be just as sensitive to expenditure whether or not it is regarded as excess). Therefore, the estimated
outcome elasticities can be applied to either observed PBC deaths or excess PBC deaths.
The cost per excess death and the cost per PBC death averted are reported in Table 118, and a detailed
breakdown of changes in spend and excess or total deaths across PBCs is shown in Table 119. The cost
per PBC death averted is, of course, significantly lower than the cost per excess death as excess deaths are
only a proportion of total deaths (see Table 117). Also, the costs per PBC death averted are substantially
lower than those reported in Appendix 2 (see Tables 68 and 69), as these estimates do not restrict the
effects of expenditure to PBC deaths under 75 years of age.
Recall from Appendix 2 that the measure of mortality that is available at PCT level and used to estimate
the outcome elasticities is restricted to deaths under 75 years of age, as are the published estimates of YLL
associated with them (see Mortality and years of life lost). However, to restrict effects only to those aged
under 75 years would imply that there is no excess mortality above 75 years of age or equivalently that
there are no health effects of PBC expenditure above 75 years of age. Rather than assume no effects
of NHS activity in older populations, we apply the effects that can be observed to the whole PBC but
account for deaths that would have otherwise occurred in our estimate of net YLL in Years of life lost and
accounting for counterfactual deaths. Table 120 illustrates the number deaths averted for a 1% change
in budget implicit in the alternative calculations of the cost per death averted threshold.
In many respects, whether or not PBC deaths at older ages are as sensitive to changes in expenditure is
not critical, as any observed deaths that might be averted at older ages are less likely to generate YLGs
because they are more likely to have occurred anyway in that year (i.e. are excess so generate
TABLE 118 Summary of the cost per death averted threshold
PBC scenario
(1) Cost per excess death
averted (£)
(2) Cost per PBC death
averted (£)
All big four programmes 91,129 32,864
11 PBCs (with mortality) 177,692 64,774
All 23 PBCs (zero health effects for remaining 12 PBCs) 653,748 238,310
All 23 PBCs (non-zero health effects for remaining
12 PBCs, except GMS)a
200,829 73,208
a In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal.
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TABLE 119 Breakdown of the cost per death averted threshold
PBC
(1) Change in
spend (£M)
PBC deaths Excess deaths
(2) Total
PBC deaths
(3) Change in
PBC deaths
(4) Cost per
PBC death
averted (£)
(5) Excess
deaths
(6) Change in
excess deaths
(7) Cost per excess
death averted (£)
2 Cancer 19 130,809 208.03 92,147 95,715 152.22 125,934
10 Circulatory problems 33 159,851 1237.82 26,878 79,218 613.43 54,235
11 Respiratory problems 22 65,446 1165.14 19,142 7386 131.49 169,616
13 Gastrointestinal problems 17 24,148 165.42 99,757 15,199 104.12 158,488
All big four programmes 32,864 0 91,129
1 Infectious diseases 8 6958 2.59 3,222,218 2797 1.04 8,014,595
4 Endocrine problems 18 6765 54.28 325,291 3769 30.24 583,830
7 Neurological problems 17 15,353 10.59 1,622,486 6909 4.77 3,605,579
17 Genitourinary problems 32 10,625 4.94 6,425,694 2172 1.01 31,430,287
16 Trauma and injuries 10 N/A 0.00 N/A N/A 0.00 N/A
18 + 19 Maternity and neonates 8 226 0.24 32,813,038 226 0.24 32,813,038
First 11 PBCs 64,774 177,691
3 Disorders of blood 11 172.87 64,774 63.01 177,692
5 Mental health disorders 204 3152.02 64,774 1149.00 177,692
6 Learning disability 31 475.30 64,774 173.26 177,692
8 Problems of vision 24 373.19 64,774 136.04 177,692
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TABLE 120 Illustration of the number of deaths averted for a 1% change in budget
PBC scenario
Using deaths < 75 years
(see Appendix 2, Table 67) Using excess deaths (see Table 118) Using PBC deaths (see Table 118)
(1) Cost per
death
averted (£)
(2) Number of deaths
averted for a 1%
change in budget
(3) Cost per
excess death
averted (£)
(4) Number of excess
deaths averted for a
1% change in budget
(5) Cost per
PBC death
averted (£)
(6) Number of PBC
deaths averted for a 1%
change in budget
All big four programmes 137,188 665 91,129 1001 32,864 2776
11 PBCs (with mortality) 270,881 681 177,692 1039 64,774 2849
All 23 PBCs (zero health effects for
remaining 12 PBCs)
996,655 681 653,748 1039 238,310 2849
All 23 PBCs (non-zero health effects for
remaining 12 PBCs, except GMS)a
306,153 2218 200, 828 3381 73,208 5191
a In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as observed in PBCs for which there was a mortality signal.
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zero YLGs anyway). Therefore, they will have very limited impact on cost per life-year or, subsequently, on
cost per QALY estimates (in Adjusting life-years for quality-of-life and Including quality-of-life effects during
disease). For this reason, it is the cost per life-year rather than cost per death averted, whether excess or
observed, that is of primary interest. The cost per PBC or excess death averted (or life saved) should thus
not be overinterpreted, as lives are never saved (death is only delayed). However, establishing the number
of excess and PBC deaths averted which are associated with net YLL is useful because it enables an
assessment of the number of YLGs associated with each death averted. These are reported for each PBC
in Table 121 and range from 74.3 years per excess death for PBC 18 + 19 maternity and neonates to
8.3 years per excess death for PBC 17 genitourinary. On average, across all 11 PBCs each excess death
averted is associated with 11.4 YLGs.
However, clinicians or the evaluative literature cannot distinguish whether or not an observed death is
excess. What can be observed is if groups of similar patients with and without access to a treatment
survive and for how long. Therefore, it is the life-years associated with each observed death that provides a
context that can be interpreted based on experience and evidence of how effective those interventions
that could be invested or disinvested tend to be. The average life-years expected to be gained associated
with each observed PBC death averted takes account of the fact that some deaths that are avoided in the
PBC are not delayed for very long but quickly occur elsewhere and do not generate YLG (i.e. they were
not excess deaths). The portion of observed deaths that are regarded as excess depend on how time is
discretised. The data available report deaths in annual intervals so in this context ‘quickly’ means within
1 year. If deaths were reported in narrower time intervals then a greater proportion of observed deaths
would be regarded as excess and, in the limit, with continuous time all observed deaths would be excess.
Of course, the average YLL associated with them would be smaller and is approximated by the net YLL per
observed death reported (the effect of approximation is likely to be small but unavoidable as it is due to
deaths being reported in annual intervals).
TABLE 121 Implied YLL per death averted for each PBC
PBC
(1) Implied YLL per excess
death averted
(2) Implied YLL per PBC
death averted
2 Cancer 14.07 10.30
10 Circulatory problems 10.40 5.15
11 Respiratory problems 9.21 1.04
13 Gastrointestinal problems 14.98 9.43
All big four programmes 11.28 4.07
1 Infectious diseases 13.21 5.31
4 Endocrine problems 13.59 7.57
7 Neurological problems 13.59 6.12
17 Genitourinary problems 8.34 1.71
16 Trauma and injuries N/A N/A
18+ 19 Maternity and neonates 74.34 74.34
First 11 PBCs 11.37 4.14
N/A, not applicable.
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The data available report deaths in annual intervals so in this context ‘quickly’ means within 1 year.
If deaths were reported in narrower time intervals then a greater proportion of observed deaths would be
regarded as excess and in the limit with continuous time all observed deaths would be excess. Of course,
the average YLL associated with them would be smaller and is approximated by the net YLLs reported in
Table 12 per observed death (the effects of approximation is likely to be small but unavoidable as it is
due to deaths being reported in annual intervals). These are also reported for each PBC in Table 121 and
range from 74.3 years per observed death for PBC 18 + 19 maternity and neonatesh to 1.0 for PBC 11
respiratory problems, i.e. the YLL per PBC death are much lower for those PBCs where a small proportion
of observed deaths are excess. On average across all 11 PBCs each PBC death averted is associated with
4.1 YLGs.
Summary of cost per life-year estimates
The sequence of analysis set out above has enabled an examination of the impact of the limitations
associated with the incomplete reporting of mortality data at PCT level and incomplete coverage of
published YLL estimates. We have also been able to consider effects above age 75 years while taking
account of the fact that many deaths would have occurred anyway, despite the limited information
available about the population at risk within a PBC. The GBD study does provide some information about
the age and gender distribution of the population at risk in a PBC so offers some improvement over the
other assumptions that would otherwise be required (i.e. that the distribution of age and gender is the
same as the general population or follows the distribution of observed deaths). For this reason, the cost
per life-year threshold in column (4) of Table 115 and repeated in lines (1)–(4) in Table 122 are regarded as
the central or best estimates given the evidence available and the credibility of alternative assumptions that
could be made. As explained in the Introduction, these are based on the conservative assumptions that any
health effects of changes in expenditure are restricted to 1 year, which, to some extent, may be offset by
the more optimistic assumption that any death averted returns the individual to the mortality risk faced
by the general population, matched for age and gender.
It does not seem credible to imagine that NHS expenditure has no health effects in the 12 PBCs which do
not have sufficient mortality reported at PCT level to estimate outcome elasticities – what is implied by the
estimate reported in Table 122, line (3). Therefore, it is the estimates reported in lines (2) and (4) that are
of policy interest. The estimate of £15,628 per life-year [see line (2)] is restricted to the effects of changes
in expenditure in the 11 PBCs where outcome elasticities can be estimated. The threshold of £17,663 per
life-year uses the estimated health effects of expenditure in these PBCs as a surrogate for health effects
in the others, that is assuming that the effects that can be observed will be similar to those that cannot.
However, no health effects are assigned to PBC 23 (GMS) on the basis that any health effects of this
expenditure would be recorded in the other PBCs.
It would be inappropriate to assign all the change in GMS expenditure to the estimate of cost per life-year
based only on the 11 PBCs with outcome elasticities as it would imply that GMS only contributes to these
PBCs. Restricting attention to the 11 PBCs with outcome elasticities but allocating part of the change in
GMS expenditure to them based on their proportional share of changes in overall expenditure would yield
the same cost per life-year as reported in line (4).i
The extreme upper and lower bounds for the cost per life-year thresholds in Table 122 are based on making
the necessary assumptions about duration of health effects and how long a death might be averted optimistic
(providing the lower bound for the threshold) or conservative (an upper bound for the threshold). The lower
bound [see lines (5)–(8)] is based on assuming that health effects are not restricted to 1 year but apply to the
whole of the remaining disease duration of the population at risk in PBCs during the expenditure year.
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Estimates of the average disease durations across the PBCs used in this calculation are depicted in Table 123
[see column (2)].j These were obtained from the GBD study (see Addendum 1: data sources). Although this
lower bound for the threshold combines optimistic assumptions, it is possible, indeed likely, that at least some
expenditure may have effects on the health outcomes of future patients who are not currently part of the
population at risk in a PBC, e.g. investments or disinvestment in prevention will have an impact on populations
that are incident to PBCs in the future. Such effects are not captured in any of the estimates presented in this
chapter so all are conservative with respect to this type of health effect of changes in expenditure.
The upper bound [see lines (9)–(12) in Table 122] is based on the combination of assuming that health
effects are restricted to 1 year for the population currently at risk and that any death averted is only averted
for the minimum duration consistent with the mortality data. The econometrics work used the average of
3 years of mortality (2006–8), so the estimated outcome elasticities are based on differences in mortality
that remain after averaging over 3 years. Therefore, the estimated effects are based on differences in
observed PBC deaths that must have been sustained, on average, for more than a minimum of 2 years.
This is because variation in mortality in the first year of data will only contribute to estimates if differences
are sustained for a minimum of 3 years, variation in mortality in the second year will only contribute if it is
TABLE 122 Summary of the cost per life-year threshold with upper and lower bounds
PBC grouping Cost per life-year threshold
Best estimate
Effect of expenditure on mortality 1 year
YLL per PBC death averted ∼ 4.1
(1) All big four programmes £8080
(2) 11 PBCs (with mortality) £15,628
(3) All 23 PBCs (zero health effects for remaining 12 PBCs) £57,497
(4) All 23 PBCs (non-zero health effects for remaining 12 PBCs, except GMS)a £17,663
Lower bound
Effect of expenditure on mortality Remainder of disease
YLL per PBC death averted ∼ 4.1
(5) All big four programmes £386
(6) 11 PBCs (with mortality) £6106
(7) All 23 PBCs (zero health effects for remaining 12 PBCs) £22,463
(8) All 23 PBCs (non-zero health effects for remaining 12 PBCs, except GMS)a £6901
Upper bound
Effect of expenditure on mortality 1 year
YLL per PBC death averted 2
(9) All big four programmes £16,432
(10) 11 PBCs (with mortality) £32,387
(11) All 23 PBCs (zero health effects for remaining 12 PBCs) £119,155
(12) All 23 PBCs (non-zero health effects for remaining 12 PBCs, except GMS)a £36,604
a In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal.
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sustained for a minimum of 2 years, and in the third year only if sustained for 1 year. If differences in
mortality are similar each year (the 3 years contribute equally to the estimates), then estimated effects must
have been sustained, on average, for a minimum of 2 years.k These estimates can be interpreted as an
upper bound given the data available and therefore the analysis that has been feasible.
Adjusting life-years for quality of life
The central or best estimates of the cost per life-year threshold, which were presented in Table 122
[see lines (2) and (4)], take no account of the health-related QoL in which years of life, expected to be
gained or lost through changes in expenditure, are likely to be lived. Even if attention is restricted to the
direct health consequences of changes in mortality, estimates of the cost per life-year will tend to
overestimate the effects of changes in expenditure (underestimate the threshold) compared with a more
complete measure of health that accounts for the quality in which the years of life are expected to be
lived. In this section we examine the ways in which the life-years reported in From mortality to life-years
can be adjusted for quality, taking account of information that is available about (i) how QoL differs by age
and gender (see From mortality to life-years); and (ii) how the quality of life-years associated with mortality
changes might be affected by the types of diseases that make up each PBC (see Adjusting life-years for
quality of life). Throughout we continue to account for counterfactual deaths in the way described
TABLE 123 Disease duration by PBC (GBD)
PBC
(1) Duration of disease for an
incident patient (years) (GBD)
(2) Remaining duration of disease
for at risk population (years) (GBD)
1 6.21 3.11
2 1.19 0.59
3 1.07 0.53
4 24.83 12.42
5 7.41 3.70
6 3.46 1.73
7 30.91 15.45
8 13.96 6.98
9 16.40 8.20
10 3.21 1.61
11 11.24 5.62
12 0.33 0.17
13 0.27 0.13
14 1.01 0.50
15 9.56 4.78
16 3.74 1.87
17 1.11 0.56
18 0.58 0.29
19 9.71 4.86
20 0.93 0.47
21 1.07 0.53
22 3.74 1.87
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in Years of life lost and accounting for counterfactual deaths, by making the adjustment for quality to
the life-years associated with every observed death, before calculating a quality-adjusted net YLL.
The implications for a cost per QALY threshold that only accounts for the health effects of mortality
changes are presented in Using estimates of the quality-adjusted life-year burden of disease. In Including
quality-of-life effects during disease we explore the ways in which the likely direct effects of expenditure
on QoL (other than through mortality) might also be taken into account.
Quality of life based on the general population
The most commonly used metric of health-related QoL in the UK is EQ-5D,91 which is specified in the NICE
reference case for methods of technology appraisal.153 This metric has five dimensions of quality, each with
three possible levels. Each of these 243 possible health states is valued relative to a score of 1, which
represents full or best imaginable health (the best score across all five dimensions), and a score of 0,
which represents death, based on a representative sample of the UK population.92 Therefore, insofar as the
years of life expected to be gained or lost through changes in expenditure would be lived in this state of
full health, the cost per life-year thresholds reported in Table 122 would also be the cost per QALY
thresholds, albeit ones that only account for the health effects of mortality changes.
However, unsurprisingly, there is good evidence that, on average, the general population is not in this
state of full health. Therefore, the QoL score associated with the health states experienced by the general
population are less than 1, and are expected to decline with age and to differ by gender. These QoL
‘norms’ for the general population by age and gender are illustrated in Figure 49 based on an analysis of
data from the HSE (see Addendum 1: data sources for a description of HSE data and the analysis of QoL
norms illustrated in Figure 49).
These QoL norms can be applied to the YLL associated with all observed deaths in each PBC, taking
account of gender and age at death. The results are reported in columns (4)–(6) of Table 124.
There are two effects of adjusting life-years for quality: (i) since QoL norms are always less than 1 the
adjusted YLL and YLG are always lower than the unadjusted values in Table 124, columns (1) and (2)
(previously reported in Table 106); and (ii) deaths above LE are necessarily at older ages with poorer QoL
norms than those below, so the difference between adjusted and unadjusted values is greater for YLG
than YLL (Table 125 illustrates these effects by showing the implied QoL scores applied to YLL and YLG).
The overall effect of quality adjustment on net YLL is the balance of these two effects, and tends to reduce
the net YLL [compare columns (3) and (6) in Table 124]. The only exception is PBC 11 (respiratory) which
has a large proportion of deaths occurring above the LE of the PBC population (see Table 114).
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FIGURE 49 Quality of life for the general population by age and gender.
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The quality-adjusted net YLL figures in Table 124, column (6) suggest that the health effects of mortality
are lower than when relying only on unadjusted life-years in Years of life lost and accounting for
counterfactual deaths. Therefore, the health effects of changes in expenditure on this more complete
measure of health will also be lower. The implications of these adjustments to a cost per QALY threshold
that only accounts for the direct health effects of mortality are summarised in Table 126, and detailed
in Table 127. As expected, the cost per QALY threshold based on adjusting the YLGs or lost [see Table 126,
column (2)] is higher than a threshold based on unadjusted life-years [see Table 126, column (1), these
results were previously reported in Tables 115 and 122].
Table 128 depicts the judgements over life-years, QoL weights and total QALYs implicit in calculations
of the threshold cost per QALY in Table 126. Specifically, columns (1) and (2) of Table 128 report the
number of life-years associated with each death averted for each PBC; as expected, the values are equal
to those in Table 121 as estimates rely on the net YLL evaluated in Years of life lost and accounting for
counterfactual deaths. In columns (3) and (4), the number of QALYs gained associated with each death
averted are presented. These ranged from 64.46 QALYs gained per PBC death averted for PBCs 18 and 19
(maternity and neonates) to 1.17 QALYs per PBC death averted for PBC 11 (respiratory), see column (4).
TABLE 125 Implied QoL score in the net YLL adjustment for QoL ‘norms’
PBC (1) QoL score for YLL (2) QoL score for YLG
1 Infectious diseases 0.81 0.67
2 Cancer 0.78 0.66
4 Endocrine 0.80 0.66
7 Neurological 0.81 0.68
10 Circulatory 0.77 0.66
11 Respiratory 0.78 0.67
13 Gastrointestinal 0.79 0.67
17 Genitourinary 0.76 0.65
18+ 19 Maternity and neonates 0.87 N/A
N/A, not applicable.
TABLE 124 Net YLL adjusted for QoL ‘norms’
PBC
Unadjusted life-years QALYs
(1) YLL (2) YLG (3) Net YLL (4) YLL (5) YLG (6) Net YLL
1 Infectious diseases 58,686 21,724 36,962 47,481 14,618 32,864
2 Cancer 1,473,733 126,549 1,347,184 1,143,445 84,036 1,059,409
4 Endocrine 66,283 15,058 51,225 52,856 9973 42,883
7 Neurological 135,686 41,770 93,917 109,349 28,262 81,087
10 Circulatory 1,102,020 278,251 823,768 848,046 183,330 664,717
11 Respiratory 298,343 230,313 68,030 231,578 154,743 76,835
13 Gastrointestinal 273,117 45,414 227,703 216,256 30,277 185,979
17 Genitourinary 47,229 29,101 18,127 35,929 18,947 16,982
18+ 19 Maternity and neonates 16,801 0 16,801 14,568 0 14,568
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TABLE 127 A breakdown of the cost per QALY threshold based on population norms
PBC
(1) Change in
spend (£M)
(2) Change
in QALY
(3) Cost per QALY
gained (£)
2 Cancer 19 1685 11,378
10 Circulatory problems 33 5147 6464
11 Respiratory problems 22 1368 16,304
13 Gastrointestinal problems 17 1274 12,952
All big four programmes 9631
1 Infectious diseases 8 12 682,211
4 Endocrine problems 18 344 51,309
7 Neurological problems 17 56 307,201
17 Genitourinary problems 32 8 4,020,316
16 Trauma and injuries 10 0 N/A
18 + 19 Maternity and neonates 8 16 509,044
First 11 PBCs 18,622
3 Disorders of blood 11 601 18,622
5 Mental health disorders 204 10,964 18,622
6 Learning disability 31 1653 18,622
8 Problems of vision 24 1298 18,622
9 Problems of hearing 6 343 18,622
12 Dental problems 23 1262 18,622
14 Skin 11 565 18,622
15 Musculoskeletal system 15 812 18,622
20 Poisoning and adverse effects 4 236 18,622
21 Healthy individuals 18 985 18,622
22 Social care needs 68 3630 18,622
23 Other 78 0 N/A
All 23 PBCs 21,047
N/A, not applicable.
TABLE 126 Summary of cost per QALY threshold based on population norms and mortality effects
PBC grouping
(1) Cost per life-year
threshold (£)
(2) Cost per QALY threshold
(population norms) (£)
All big four programmes 8080 9631
11 PBCs (with mortality) 15,628 18,622
All 23 PBCsa 17,663 21,047
a In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal except GMS.
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In general, these values are expected to be smaller than the unadjusted YLL per PBC death averted in
column (2). The exception is PBC 11 (respiratory) – in this PBC, the number of YLL and YLG are more
similar than in other PBCs [respectively, columns (1) and (2) of Table 124], and given that YLG are
weighted more heavily (with lower QoL scores) than YLL, the netting of adjusted estimates returns a higher
number than the netting of unadjusted estimates. On average, across all 11 PBCs each PBC death averted
is associated with 3.5 QALYs gained.
Adjusting age-related quality-of-life for disease decrements
Adjusting life-years for age- and gender-related QoL norms assumes that any YLG through a change in
expenditure would be lived in a similar QoL to the general population. It is possible, however, that patients
benefiting from reduced mortality may, nevertheless, continue to be affected by the type of diseases that
make up each PBC and experience the QoL associated with the original disease.
The HODaR93 provides over 30,000 observations of EQ-5D measures of QoL by ICD-10 code and the age
and gender of the patients in the sample (see Addendum 1: data sources). Although this is a rich UK data
set, there were a limited number of observations for some of the less common ICD-10 codes. For this
reason HODaR was supplemented with information from the MEPS94 which also provides EQ-5D by ICD
and reports the average age of respondents (see Addendum 1: data sources). These data provided a
means of estimating the QoL associated with each ICD-10 code at the average age of respondents in
the pooled sample (ICD-10 code estimates of the QoL score and age were pooled across data sets by
considering the number of patients from each data set contributing to estimates, i.e. a weighted average).
The QoL associated with each PBC was then expressed as the average of the QoL associated with its
component ICD-10 codes. The average QoL scores across ICD-10 codes which contribute to each PBC and
the average age and gender of respondents were used to calculate a PBC disease-related decrement
(disutility) based on QoL norms from the general population – it is important to note that by expressing the
QoL effects of different diseases as age-related decrements we do not require the HODaR and MEPS
samples to necessarily be representative of the age distribution of the population at risk in the PBCs.
TABLE 128 Implied YLL per excess death averted and implied QoL score per YLL gained, for each PBC
PBC
(1) Implied YLL
per excess
death averted
(2) Implied YLL
per PBC
death averted
(3) Implied QALYs
gained per excess
death averted
(4) Implied QALYs
gained per PBC
death averted
2 Cancer 14.07 10.30 11.07 8.10
10 Circulatory 10.40 5.15 8.39 4.16
11 Respiratory 9.21 1.04 10.40 1.17
13 Gastrointestinal 14.98 9.43 12.24 7.70
All big four programmes 11.28 4.07 9.46 3.41
1 Infectious diseases 13.21 5.31 11.75 4.72
4 Endocrine 13.59 7.57 11.38 6.34
7 Neurological 13.59 6.12 11.74 5.28
17 Genitourinary 8.34 1.71 7.82 1.60
16 Trauma and injuries N/A N/A N/A N/A
18+ 19 Maternity and neonates 74.34 74.34 64.46 64.46
First 11 PBCs 11.37 4.14 9.54 3.48
N/A, not applicable.
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Table 129 summarises the data from HODaR and MEPS and the QoL decrements used in further
calculations of the threshold, namely the number of patients for which QoL scores were available
[see column (1)]; the average age of these patients by gender [see columns (2) and (3)]; the average QoL
scores across PBCs [see column (4)]; the QoL scores for the population norms by gender [see columns (5)
and (6)]; and the calculated disease-related decrements [see columns (7) and (8)].
Figure 50 illustrates the use of the decrement to QoL norms for PBC 1 (infectious disease) across a range
of ages. For PBC 1, the QoL score, evaluated across the component ICD-10 codes, was found to be 0.667
in HODaR and MEPS, at an average age of 54 years for male respondents. As the QoL norms for males
aged 54 years is 0.859, this suggests a decrement associated with membership of PBC 1 of 0.192, which
can then be applied to QoL norms by age as illustrated in Figure 50.
TABLE 129 Quality-of-life scores per PBC from different sources
PBC
HODaR/MEPS
Population norms
Disease-related
decrement compared
with population norms
(1) n
Average age
(4) QoL score
for diseased(2) Male (3) Female (5) Male (6) Female (7) Male (8) Female
1 263 54.0 47.1 0.667 0.859 0.830 0.192 0.163
2 13,324 64.3 59.8 0.692 0.809 0.830 0.117 0.138
3 2464 58.6 58.1 0.656 0.859 0.830 0.203 0.174
4 7128 57.3 56.5 0.701 0.859 0.830 0.157 0.128
5 12,733 47.8 47.9 0.557 0.859 0.830 0.301 0.272
6 301 25.8 25.3 0.671 0.937 0.924 0.266 0.253
7 10,296 55.8 53.8 0.546 0.859 0.830 0.312 0.283
8 11,536 63.8 64.5 0.719 0.809 0.796 0.089 0.077
9 1023 61.7 59.8 0.778 0.809 0.830 0.031 0.051
10 33,854 64.4 64.1 0.629 0.809 0.796 0.179 0.167
11 19,646 48.4 47.2 0.634 0.859 0.830 0.224 0.195
12 1811 40.9 40.0 0.781 0.910 0.894 0.129 0.113
13 23,138 57.3 55.5 0.653 0.859 0.830 0.206 0.177
14 5659 54.8 54.0 0.695 0.859 0.830 0.164 0.134
15 34,590 56.4 56.6 0.578 0.859 0.830 0.280 0.251
16 2652 46.0 58.3 0.652 0.859 0.830 0.207 0.178
17 13,651 57.5 53.0 0.711 0.859 0.830 0.147 0.118
18+ 19 1566 37.8 31.7 0.848 0.910 0.894 0.063 0.047
20 1569 59.1 52.3 0.584 0.859 0.830 0.275 0.246
21 7488 60.6 60.3 0.661 0.809 0.796 0.147 0.135
22 25 78.4 81.4 0.156 0.798 0.636 0.642 0.480
23 1002 62.6 60.8 0.639 0.809 0.796 0.170 0.158
No gender details were available from MEPS so assumed 50 : 50 split of frequency.
Only primary diagnosis is used from HODaR data.
A lower bound of 0 is assumed for disutility for each PBC.
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In principle, it would be possible to estimate disease-related disutility by age rather than assume a fixed
additive decrement. HODaR does provide age for each reported QoL score, but MEPS only provides average
age of respondents in published summaries. However, even with access to ‘raw’ scores and the age and
gender of each, it is very unlikely that there would be sufficient data to estimate age-related decrements in
each of the component ICD-10 codes. It would, however, be possible to assume a proportionate rather
than fixed decrement by age. However, the average age of respondents in the pooled HODaR and MEPS
sample [see columns (2) and (3) of Table 129] tends to be older than the age distribution of the PBC
populations [see columns (3) and (4) of Table 113]. Given that older individuals are expected to have a
lower QoL (norm), relative decrements can overestimate the decrements observed in younger patients.
By applying overestimated decrements, the quality-adjusted net YLL would be underestimated and the cost
per QALY threshold increased compared with the fixed decrement applied here.
Quality-of-life norms adjusted for disease-related decrements can be applied to the YLL associated with
observed deaths in each PBC, taking account of gender and age at death in the same way as From
mortality to life-years. To do so, the ‘PBC decrements’ calculated from HODaR and MEPS were applied to
each observed death and the age at which each life-year was gained or lost (from ONS). The results are
reported in columns (4)–(6) of Table 130. The overall effect of quality adjustment that also applies a
disease-related decrement is to reduce the net YLL to a greater extent than adjustment with population
norms alone [compare column (6) in Table 130 with column (6) in Table 124].
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FIGURE 50 Quality of life for males in PBC 1 (infectious disease) and the general population by age.
TABLE 130 Net YLL adjusted for disease- and age-related QoL
PBC
Unadjusted life-years QALYs
(1) YLL (2) YLG (3) Net YLL (4) YLG (5) YLL (6) Net YLG
1 Infectious diseases 58,686 21,724 36,962 37,055 10,793 26,262
2 Cancer 1,473,733 126,549 1,347,184 955,690 67,930 887,760
4 Endocrine 66,283 15,058 51,225 43,394 7844 35,550
7 Neurological 135,686 41,770 93,917 68,893 15,842 53,050
10 Circulatory 1,102,020 278,251 823,768 656,145 135,241 520,905
11 Respiratory 298,343 230,313 68,030 169,269 106,505 62,764
13 Gastrointestinal 273,117 45,414 227,703 163,593 21,677 141,916
17 Genitourinary 47,229 29,101 18,127 29,749 15,152 14,598
18+ 19 Maternity and neonates 16,801 0 16,801 13,662 0 13,662
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The implied QoL weights (considering the disease-related decrements) for YLL and YLG are shown in
Table 131. Note that, as expected, the weights assume a lower value than in Table 125.
Combining QoL adjustments for both population norms and disease-related decrements assumes that any
YLGs due to a reduction in mortality will be lived in the diseased state until LE (i.e. that all diseases are not
just chronic but disease duration is lifelong). Inevitably, this assumption means that the health effects of
changes in mortality will be reduced. Consequently, the cost per QALY threshold reported in Table 132
[see column (2)] will be higher than adjusting YLGs for population norms in Table 126 [see column (2)].
A detailed breakdown of the cost per QALY threshold based on disease-related disability and mortality
effects is shown is Table 133.
The number of YLGs associated with each death averted [columns (1) and (2) in Table 134] is, again,
consistent with previous estimates (see Tables 121 and 128). The average number of QALYs gained across
all 11 PBCs is 2.8 QALYs per death averted [see column (4) in Table 134]. As expected this value is lower
than in the previous section [see column (4) in Table 128].
TABLE 131 Implied QoL weights in the net YLL adjusted for disease- and age-related QoL
PBC (1) QoL weights for YLL (2) QoL weights for YLG
1 Infectious diseases 0.63 0.50
2 Cancer 0.65 0.54
4 Endocrine 0.65 0.52
7 Neurological 0.51 0.38
10 Circulatory 0.60 0.49
11 Respiratory 0.57 0.46
13 Gastrointestinal 0.60 0.48
17 Genitourinary 0.63 0.52
18+ 19 Maternity and neonates 0.81 N/A
N/A, not applicable.
TABLE 132 Summary of cost per QALY threshold based on disease-related disutility
PBC scenario
(1) Cost per life-year
threshold (£)
(2) Cost per QALY threshold (£)
disease-related disutility
All big four programmes 8080 12,109
11 PBCs (with mortality) 15,628 23,395
All 23 PBCs (zero health effects for remaining 12 PBCs) 57,497 86,072
All 23 PBCs (non-zero health effects for remaining 12 PBCs,
except GMS)a
17,663 26,441
a In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal except GMS.
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TABLE 133 Breakdown of the cost per QALY threshold based on disease-related disutility
PBC
(1) Change in
spend (£M)
(2) Change
in QALY
(3) Cost per QALY
gained (£)
2 Cancer 19 1412 13,578
10 Circulatory problems 33 4034 8248
11 Respiratory problems 22 1117 19,960
13 Gastrointestinal problems 17 972 16,974
All big four programmes 0 12,109
1 Infectious diseases 8 10 853,712
4 Endocrine problems 18 285 61,892
7 Neurological problems 17 37 469,558
17 Genitourinary problems 32 7 4,676,874
16 Trauma and injuries 10 0 N/A
18+ 19 Maternity and neonates 8 15 542,801
First 11 PBCs 0 23,395
3 Disorders of blood 11 479 23,395
5 Mental health disorders 204 8727 23,395
6 Learning disability 31 1316 23,395
8 Problems of vision 24 1033 23,395
9 Problems of hearing 6 273 23,395
12 Dental problems 23 1004 23,395
14 Skin 11 449 23,395
15 Musculoskeletal system 15 647 23,395
20 Poisoning and adverse effects 4 188 23,395
21 Healthy individuals 18 784 23,395
22 Social care needs 68 2890 23,395
23 Other 78 0 N/A
All 23 PBCs 26,441
N/A, not applicable.
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Summary of the cost per quality-adjusted life-year threshold based only on
mortality effects
The analysis to this point is summarised in Table 135. The three estimates of a cost per QALY threshold
are based on assuming that each YLG is either lived in full health [see column (1), equal to the cost per
life-year estimates in Table 122]; lived in a QoL that reflects age and gender norms of the general
population [see column (2)]; or lived in a QoL that reflects the original disease state [see column (3)].
The weights reflecting the quality in which the years of life saved are lived in each of these three estimates
is shown in Table 136.
Assuming that YLGs are lived in full health is not credible and should be regarded as an underestimate of
the threshold given what is known about QoL norms for the general population (see Figure 49). Equally,
assuming that all YLGs are lived in the QoL of the original disease state does not seem credible either, and is
likely to overestimate the threshold as it assumes that all disease is not only chronic but lifelong and all
life-years would be lived in the diseased state until death. The information that is available about disease
duration suggests that many types of disease that comprise the PBCs are not chronic and certainty not
lifelong (see Table 123). Although adjusting YLGs for the QoL of the general population, taking account of
age and gender [see column 2 in Table 135), is likely to underestimate the cost per QALY threshold based
only on mortality effects, it probably represents the ‘best’ of the three alternative estimates available at this
stage of the analysis. The lower and upper bounds are based on combining optimistic and pessimistic
assumptions about the duration of health effects and how long a death might be averted as described in
Summary of cost per life-year estimates.
However, it should be noted that these cost per QALY thresholds only account for the direct health
effects of changes in mortality due to changes in expenditure. Insofar as much, or at least some part, of
NHS activity and expenditure is intended to improve QoL, not just mortality, then these estimates will
underestimate total health effects and overestimate a cost per QALY threshold based on a more complete
TABLE 134 Implied YLL per death averted and implied QoL score per YLL gained, for each PBC
PBC
(1) Implied YLL
per excess
death averted
(2) Implied YLL
per PBC
death averted
(3) Implied QALYs
gained per excess
death averted
(4) Implied QALYs
gained per PBC
death averted
2 Cancer 14.07 10.30 9.28 6.79
10 Circulatory 10.40 5.15 6.58 3.26
11 Respiratory 9.21 1.04 8.50 0.96
13 Gastrointestinal 14.98 9.43 9.34 5.88
All big four programmes 11.28 4.07 7.53 2.71
1 Infectious diseases 13.21 5.31 9.39 3.77
4 Endocrine 13.59 7.57 9.43 5.26
7 Neurological 13.59 6.12 7.68 3.46
17 Genitourinary 8.34 1.71 6.72 1.37
16 Trauma and
injuries
N/A N/A N/A N/A
18+ 19 Maternity and
neonates
74.34 74.34 60.45 60.45
First 11 PBCs 11.37 4.14 7.60 2.77
N/A, not applicable.
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TABLE 136 Implied QoL weight per YLL gained
PBC (1) Full health (2) Population norms (3) Disease-related disutility
2 Cancer 1 0.79 0.66
10 Circulatory 1 0.81 0.63
11 Respiratory 1 1.13 0.92
13 Gastrointestinal 1 0.82 0.62
All big four programmes 1 0.84 0.67
1 Infectious diseases 1 0.89 0.71
4 Endocrine 1 0.84 0.69
7 Neurological 1 0.86 0.56
17 Genitourinary 1 0.94 0.81
16 Trauma and injuries N/A N/A N/A
18+ 19 Maternity and neonates 1 0.87 0.81
First 11 PBC’s 1 0.84 0.67
N/A, not applicable.
TABLE 135 Summary of QALY threshold estimates based only on mortality effects
PBC grouping (1) QoL score= 1 (2) QoL norm (3) QoL diseased
Best estimate
Effect of expenditure on mortality 1 year 1 year 1 year
YLL per death averted ∼ 4.1 YLLa ∼ 4.1 YLLa ∼ 4.1 YLLa
QALYs per death averted ∼ 4.1 QALYs ∼ 3.5 QALYs ∼ 2.8 QALYs
(1) All big four programmes £8080 £9631 £12,109
(2) 11 PBCs (with mortality) £15,628 £18,622 £23,395
(3) All 23 PBCsa £17,663 £21,047 £26,441
Lower bound
Effect of expenditure on mortality Remainder of disease Remainder of disease Remainder of disease
YLL per PBC death averted ∼ 4.1 YLL ∼ 4.1 YLL ∼ 4.1 YLL
QALYs per death averted ∼ 4.1 QALYs ∼ 3.5 QALYs ∼ 2.8 QALYs
(4) All big four programmes £3846 £4252 £5319
(5) 11 PBCs (with mortality) £6106 £6852 £8568
(6) All 23 PBCsa £6901 £7744 £9683
Upper bound
Effect of expenditure on mortality 1 year 1 year 1 year
YLL per PBC death averted 2 YLL 2 YLL 2 YLL
QALYs per death averted 2 QALYs ∼ 1.9 QALYs ∼ 1.5 QALYs
(7) All big four programmes £16,432 £17,456 £21,747
(8) 11 PBCs (with mortality) £32,387 £34,492 £42,967
(9) All 23 PBCsa £36,604 £38,983 £48,561
a In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal except GMS.
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measure of possible health effects. In Including quality-of-life effects during disease we explore the ways in
which the likely effects of expenditure on QoL (other than through mortality) might also be taken
into account.
Including quality-of-life effects during disease
The cost per QALY thresholds presented in Adjusting life-years for quality-of-life only account for the
health (QALY) effects of changes in mortality due to changes in expenditure. It does not seem credible to
suppose that all NHS activity and expenditure only influences mortality with no effect on the QoL while
alive and experiencing a disease. Insofar as changes in NHS expenditure will also affect QoL, as well as
mortality, then total health effects will be underestimated and the thresholds presented in Table 135 will
overestimate the cost per QALY threshold. In this section we explore ways to also take account of those
effects on health not directly associated with mortality and life-year effects (i.e. the ‘pure’ QoL effects) to
estimate an overall cost per QALY threshold.
The routine reporting of QoL outcomes are increasingly available at PCT level (see Addendum 1: data sources
for a description of these data). In principle, the variation in such measures of outcome across PCTs could be
used to estimate outcome elasticities for QoL rather than mortality effects using similar econometric methods
to those described in Appendix 2 (see Application of method to other non-mortality-based outcome
indicators for the results of an exploratory econometric analysis of these data). However, the currently limited
coverage of routine reporting of these outcomes means that it is not feasible to estimate QoL effects across
all the PBCs using these data. Here we explore how estimates of effects of expenditure that can be observed
(i.e. on mortality) can be used to infer the likely effects on what cannot be directly observed (QoL), rather
than making extreme assumptions that are not credible (e.g. assuming that changes in expenditure will have
no effects on QoL outcomes).
In Using ratios of quality-adjusted life-years to years of life lost we use three alternative estimates of the
ratio of QALYs to life-years lost due to different types of disease as a means of inferring the change in QALYs
that is likely to be associated with the estimated change in YLL (i.e. applying the total QALYs lost associated
with each YLL with disease). This is consistent with regarding the estimates of the mortality and life-year
effects as a surrogate for a more complete measure of the health effects of a change in expenditure.
However, these ratios of QALYs lost to life-years lost due to disease in those PBCs where outcome elasticities
could not be estimated cannot inform estimates of the threshold (there are no estimated life-year effects with
which to apply the ratios). Nonetheless, the sources of information on which ratios are based also provide
much of the information required to calculate the QALY burden of disease in these areas, which can be used
to inform estimates of the threshold. Therefore, in Using estimates of the quality-adjusted life-year burden
of disease we use an estimate of the QALY burden of disease, infer a proportionate effect on burden from
the observed effects on life-years, and then apply this proportionate effect to the measures of QALY burden
for all the other PBCs. In this way we can use all the information available about the mortality and QoL
effects of the different types of disease that make up each PBC, including those where mortality-based
outcome elasticities are not available.
Using ratios of quality-adjusted life-years to years of life lost
The ratio of the total QALYs to YLL due to a disease indicates the number of QALYs associated with each
year of life lost. Therefore, any change in YLL is expected to generate a number of QALYs indicated by the
ratio – in this way, the estimated effects on mortality and life-years are interpreted as a surrogate for a more
complete measure of total health effects, which is reasonable. For example, a disease with a ratio > 1
suggests that each year of life lost across the at risk population is associated with more than one QALY
(i.e. there are significantly greater QoL effects while experiencing the disease). Therefore, a change in
expenditure that leads to 1 YLG in this type of disease may generate a greater QALY effect than the same
life-year effects in a disease where this ratio is < 1 (i.e. where most of the effect of disease is on mortality
rather than QoL). Therefore, using these ratios provides a means of accounting for the likely effect on QoL
other than through effects on mortality.
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To understand the differences between the three ratios presented below, it is useful to regard the total
QALYs lost to YLL ratio (R) for a particular disease as the sum of two ratios: (i) the QALYs lost due to
premature death to YLL ratio (Rdeath); and (ii) the QALYs lost during disease (while alive) to YLL ratio (Ralive),
as depicted in Equation 25.
R ¼
QALYs lost
YLL
¼
QALYs lostpremature death
YLL|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
Rdeath
þ
QALYs lostwhile alive
YLL|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
Ralive
(25)
Insofar as YLL would not have been lived in full health, the QoL effects captured in Rdeath are estimated to
be lower than 1. Note that the analyses in Adjusting life-years for quality-of-life already imply a Rdeath ratio
at PBC level. The second component of the ratio, Ralive, represents QALYs lost during disease for the at risk
population as a proportion of the YLL observed in the same population – in diseases for which QoL during
disease is compromised but LE is not changed significantly Ralive may thus assume high values. The ratios do
not represent the balance of QALY gains due to mortality and morbidity in a single patient, but rather in
the population. Where Rdeath is < 1, only when the pure QALY effects offset the less than full QoL of the
YLL is the ratio > 1. Therefore, ratios < 1 are possible even when disease has measurable QoL effects for
those experiencing it.
Disability-adjusted life-year to years of life lost ratios
The WHO GBD study provides UK-specific estimates of the YLD and the YLL due to different types of
disease. Diseases in GBD are classified using U-codes that can then be mapped to ICD-10 codes, as
illustrated in Table 137 (Addendum 1: data sources provides more details on the mapping procedure). GBD
uses DALYs as a measure of the burden of disease. This DALY measure has two components: (i) the YLD,
which evaluates the number of years lived with disability over the durations of disease, and incorporates
weights (between zero and one) to reflect the scale of disability experienced in each year; and (ii) the YLL.
The total DALYs associated with a disease is simply YLL + YLD. Therefore, the DALYs to YLL ratio is
(YLL + YLD)/YLL or equivalently YLL/YLL + YLD/YLL. As the first term (YLL/YLL= Rdeath) must equal 1 and the
second (Ralive= YLD/YLL) must be ≥ 0, a ratio based on DALYs must necessarily be bounded by one.
RDALY ¼
DALYs
YLL
¼
(YLLþ YLD)
YLL
¼ 1|{z}
Rdeath
þ
YLD
YLL|ﬄ{zﬄ}
Ralive
(26)
This is illustrated in Table 138 for the four different diseases (classified by U-codes) introduced in Table 137
which reflect diseases where mortality is the major component (e.g. U016) and where the impact of
disease on the QoL while alive is the major component (e.g. U141).
TABLE 137 Illustration of the mapping between U-code and ICD-10 code
U-code ICD-10 codes
U037 (other infectious diseases) A02, A05, A20–A28, A31, A32, A38, A40–A49, A65–A70, A74–A79, A81,
A82, A83.1–A83.9, A84–A89, A92–A99, B00–B04, B06–B15, B25–B49,
B58–B60, B64, B66–B72, B74.3–B74.9, B75, B82–B89, B92–B99, G04
U016 (tetanus) A33–A35
U061 (mouth and oropharynx cancers) C00–C14
U057 (iron-deficiency anaemia) D50, D64.9
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Note that the estimates of GBD YLL used here are derived using UK data on mortality (relating to the year
2004) by age and gender groups – we assume these data to be from ONS and, thus, consistent with the
data used in this work. However, the calculation of YLL in GBD differs from both the approach adopted by
the NHS IC and the approach adopted here of using net YLL. For each death observed in the data, GBD
evaluates YLL by considering the LE at the age at which the death occurred (and gender).154 This is expected
to overestimate net YLL (which accounts for counterfactual deaths, as detailed in Summary of the cost per
quality-adjusted life-year threshold based only on mortality effects). This will make no difference to the first
term in the QALY ratio (Rdeath) as an overestimate of YLL affects both denominator and numerator of the
ratio. However, the second term (Ralive) is likely to be underestimated. Therefore, the ratios will tend to
underestimate the QALY effects of expenditure and overestimate the cost per QALY threshold. This will be
adjusted for in Using estimates of the quality-adjusted life-year burden of disease, where our preferred
analysis based on burden of disease is presented.
Adjusting disability-adjusted life-years for quality-of-life norms
The use of DALY ratios bounded below by 1 essentially assumes that YLL would have otherwise been lived in
a state of full health. As was discussed in Using ratios of quality-adjusted life-years to years of life lost, this is
not credible given information available about the QoL in the general population (see Figure 49). It would
lead to overestimating the QALYs associated with mortality and life-year effects and underestimating the cost
per QALY threshold. Therefore, it is important to adjust these DALY ratios for the QoL norms by age and
gender in the same way as described in Using ratios of quality-adjusted life-years to years of life lost.
Equation 27 shows how the adjusted ratio is formulated when YLL are adjusted by the QoL in the general
population, un. This is a simplified representation of the adjustment as despite gender and age having been
considered in calculations these are not shown in the notation below.
RDALY ad j ¼
un  YLL
YLL
þ
YLD
YLL
¼ un|{z}
R
death
þ
YLD
YLL|ﬄ{zﬄ}
Ralive
(27)
The effect of this adjustment (within each U-code, see Addendum 1: data sources) is illustrated in Table 139.
Now those types of disease where mortality rather than QoL with the disease is the major component can
have ratios < 1. Indeed, the first term of these ratios (Rdeath) is consistent with (but not equivalent to) the
analysis in Using ratios of quality-adjusted life-years to years of life lost, where the ratio of quality adjusted
net YLL to unadjusted net YLL represents this ratio on average for each PBC.
TABLE 138 Examples of DALY to YLL ratios
U-code DALY ratios (Rdeath+Ralive)
U037 (other infectious diseases) 1.23 (1 + 0.23)
U016 (tetanus) 1.00 (1 + 0)a
U061 (mouth and oropharynx cancers) 1.05 (1 + 0.05)
U141 (spina bifida) 2.34 (1 + 1.34)b
a Given the short disease duration, it is only mortality effects that contribute to the ratio.
b QoL effects during disease contribute significantly to estimates of the ratio.
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Using quality-of-life estimates (based on the Health Outcomes Data
Repository and Medical Expenditure Panel Survey)
The disability weights used in the DALY measure (in Ralive) are not based on the same description of health
states as the EQ-5D measure, nor are the weights based on a representative sample of the UK population
responding to choice-based elicitation questions. EQ-5D based QoL decrements (in relation to age adjusted
QoL norms) associated with different types of disease can be estimated from HODaR and MEPS data for
the groups of ICD-10 codes that make up each U-code. The calculations of the QoL decrements from
HODaR were conducted as previously described in Adjusting age-related quality-of-life for disease
decrements. In summary, the average QoL scores across the ICD-10 codes which contribute to each U-code
(based on the contributing ICD-10 codes, see Table 137 and Addendum 1: data sources for how ICD-10
codes map to U-codes) and the average age and gender of respondents from HODaR and MEPS were used
to calculate a disease decrement for each U-code, based on QoL norms from the general population. Note
that, by expressing the QoL effects of different diseases as age-related decrements (see Figure 50), we do
not require the HODaR and MEPS samples to necessarily be representative of the age distribution of the
population at risk.
The disease-related QoL decrements can then be used to replace the DALY disability weights in Ralive
reported in Tables 138 and 139. This final adjustment is illustrated in Table 140; for example, the evidence
about QoL from HODaR and MEPS suggests that the impact of U037 on QoL is greater than indicated by
DALY disability weights. The QoL effects of U141, although still very significant, are lower than indicated
by DALY disability weights.
By turning what were originally DALY ratios into EQ-5D QALY ratios, we regard the QALY to YLL ratios
rather than DALY or modified DALY ratios as the preferred basis of estimating a cost per QALY threshold.
We consider these estimates to provide a more complete picture of the likely health effects of changes
in expenditure.
U-code quality-adjusted life-year ratios to International Classification of
Disease quality-adjusted life-year ratios
Information about the size and age and gender distribution is only available at U-code level. Therefore
U-code ratios are applied to all the ICD-10 codes that contribute to a particular U-code. Note that, unlike
ICD-10 codes, U-codes do not map directly to PBCs so some ICD-10 codes in different PBCs may belong to
the same U-code and therefore have the same U-code ratio. Some ICD-10 codes are not included in the
TABLE 140 Examples of QALY to YLL ratios (HODaR and MEPS)
U-code QALY ratios (HODaR and MEPS) (Rdeath+Ralive)
U037 (other infectious diseases) 1.37 (0.78 + 0.60)
U016 (tetanus) 0.78 (0.78 + 0)
U061 (mouth and oropharynx cancers) 0.80 (0.78 + 0.02)
U141 (spina bifida) 1.88 (0.85 + 1.03)
TABLE 139 Examples of adjusted DALY to YLL ratios
U-code Adjusted DALY ratios (Rdeath+Ralive)
U037 (other infectious diseases) 1.01 (0.78 + 0.23)
U016 (tetanus) 0.78 (0.78 + 0)
U061 (mouth and oropharynx cancers) 0.83 (0.78 + 0.05)
U141 (spina bifida) 2.18 (0.85 + 1.34)
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U-code classification of disease. Some of these are procedural codes (84 out of 1562) where mortality and
QALY effects were not assigned mortality or QALY effects anyway (any health effects would be evident
in other ICD-10 codes) so it was not necessary to impute ratios for them. Of the others, some were
associated with PBC 16 (186 out of 1562) with a zero outcome elasticity so did not require imputation
either. Imputation based on the median ratio across the ICD-10 codes within the PBC was required for the
remaining (482 out of 1562). Eighty eight of these are not mapped into U-codes – these include three big
categories of ICD-10 codes: symptoms and signs (R00–R69); abnormal clinical and laboratory findings, not
elsewhere classified (R70–R99); and ill-defined and unknown causes of mortality (R95–R99). The remaining
394 were associated with U-codes where the ratio was undefined because the denominator (YLL) was
zero. In both these cases, values were also imputed based on the median ratio across the ICD-10 codes
within the PBC. As the distribution of ratios within a PBC tend to be highly positively skewed, imputation
based on the median is likely to be conservative with respect to health effects and especially in the latter
case where mortality effects appear to be a much less important aspect of the disease.
Table 141 illustrates the variation observed in the ratios (imputed) across ICD-10 codes within the
same PBC.
TABLE 141 Percentiles of the ratio across ICD-10 codes, by PBC
PBC
Percentiles of the adjusted DALY ratios
5% 15% 25% 50% 75% 85% 95%
2 Cancer 0.76 0.76 0.76 0.81 0.85 0.85 0.91
10 Circulatory problems 0.86 0.86 0.86 0.86 0.96 1.00 2.65
11 Respiratory problems 0.22 0.73 1.00 1.67 1.67 1.96 2.67
13 Gastrointestinal problems 0.86 0.96 1.01 1.63 1.63 1.78 2.73
1 Infectious diseases 0.00 0.83 1.01 1.01 1.01 1.01 2.64
4 Endocrine problems 0.77 1.37 1.43 2.97 2.97 2.97 2.97
7 Neurological problems 0.86 1.01 1.01 2.01 2.01 2.01 2.30
17 Genitourinary problems 0.74 0.77 0.77 1.10 1.10 1.10 12.41
18 Maternity 0.00 0.79 0.81 20.39 20.39 20.39 20.39
19 Neonates 1.17 1.17 1.17 1.17 2.29 2.29 2.29
Percentiles of the QALY ratios (HODaR and MEPS)
5% 15% 25% 50% 75% 85% 95%
2 Cancer 0.76 0.76 0.76 0.79 0.80 0.80 0.83
10 Circulatory problems 0.83 0.83 0.83 0.83 0.94 1.01 1.83
11 Respiratory problems 0.73 0.86 1.37 2.09 2.09 2.24 2.80
13 Gastrointestinal problems 0.84 1.01 1.37 1.70 1.70 2.17 7.10
1 Infectious diseases 0.83 1.37 1.37 1.37 1.37 1.37 3.26
4 Endocrine problems 0.77 2.37 2.55 5.12 5.12 5.12 10.15
7 Neurological problems 0.84 0.90 1.37 5.90 5.90 5.90 5.90
17 Genitourinary problems 0.74 0.78 0.78 0.99 0.99 0.99 9.80
18 Maternity 0.81 0.81 0.83 49.30 49.30 49.30 49.30
19 Neonates 0.87 0.87 0.87 0.88 0.88 0.88 0.88
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Allocating effects at programme budget category level to International
Classification of Disease codes
Tables 138–140 illustrate how QALY ratios can be calculated for and differ by U-code. Unsurprisingly,
these ratios differ across the type of diseases that make up each PBC (see Table 141). When using this
information to estimate a cost per QALY threshold the mortality and life-year effects observed at PBC level
must be allocated in some way to the component ICD-10 codes before ratios are applied to life-year
effects and the resulting QALY effects are summed across all the contributing ICD-10 codes.
Alternatively, one could calculate an average of the ratios within a PBC and then apply this ‘average ratio’
to life-year effects at PBC level, rather than calculate QALY effects at ICD-code level by applying the
relevant ratio. This would be inappropriate for two reasons. First, ratios should not be averaged; instead,
the total QALYs lost and YLL should be summed across ICD-10 codes and the ratio of these sums used to
represent a PBC level estimate (i.e. a ratio of averages). Second, even if the appropriate estimate of the
QALY to YLL ratio is calculated at the PBC level, this estimate would assume ICD-10 codes to be equally
representative of the PBC – i.e. that expenditure would be equally likely to affect any of the ICD-10 codes
that compose a particular PBC. This is unlikely to be true not only due to the inherent differences in the
disease described by the ICD-10 coding, but also as ICD-10 codes are likely to differ significantly in what
concerns the size of the at risk population they represent.
It is important to consider explicitly how other information might inform the different ways in which the
effects observed at PBC level might be generated by the distribution of impacts at ICD-10 code level,
i.e. where investment or disinvestment is likely to occur within the PBC and therefore which ICD-10 codes
are likely to contribute most to overall health effects. An important and complementary element to the
econometric analysis of routinely reported information at PBC level, was to investigate this by looking
at local level information available within the NHS. The details of this investigation are reported in
Addendum 2: the role of data on local NHS decisions. The review of local data sources suggested that there
is very little routinely collected data on investment and disinvestment by local NHS organisations beyond the
high-level aggregate data on spending by PBCs which are used in the econometric analysis. Although more
disaggregated data on spending decisions about specific services relevant to particular ICD-10 codes could
in principle be acquired through additional primary research (surveys or freedom of information requests)
this would be costly and with a risk that information acquired in this way may not be complete, consistent
or representative.
In the absence of useful information at a local level, it is possible to assume that a change in PBC
expenditure will be allocated equally (on a per patient basis) across the component ICD-10 codes, i.e. any
investment or disinvestment is equally likely across the population at risk within the PBC. HES (see
Addendum 1: data sources) provides information about the costs associated with each ICD-10 code by
PCT. The variation in per patient costs between PCTs (where total costs allocated to individual ICD-10
codes were divided by the number of patients using services in the PCT) was analysed to establish which
ICD-10 codes contribute most to the variability in HES costs within a PBC, across PCTs. The ICD-10 codes
that contribute most to this variance might be expected to be more likely to have been subject to
differential investment or disinvestment across PCTs. Unfortunately, total PBC costs are not available at
ICD-10 code level across PCTs so could not be used for this purpose. Costs from HES data are only a
component of total PBC costs (41% of total PBC costs for the 11 PBCs where mortality effects can be
estimated) and contribute less to the variability in PBC costs across PCTs (HES contribute only 23% of the
variability for the 11 PBCs where mortality effects can be estimated).
There are differences in relative weight assigned to ICD-10 codes based solely on the size of the population
or its contribution to variance in HES costs. If investment or disinvestment within a PBC tends to focus on
ICD-10 codes representing areas of marginal value the health effects of a change in PBC expenditure may
be overestimated and a cost per QALY threshold underestimated when allocating effects equally across the
population at risk within each PBC. However, weighting ICD-10 codes based on HES data is likely to favour
those ICD-10 codes which represent more severe disease requiring more hospital care. This may over
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represent ICD-10 codes with lower QALY to YLL ratios if mortality effects tend to be a major component of
these types of disease and may be conservative with respect to the health effects of changes in expenditure.
The implications for a cost per QALY threshold that uses the estimated mortality and life-year effects as a
surrogate for a more complete measure of the likely heath effects (i.e. that includes QoL as well as quality
adjusted life-year effects) is summarised in Table 142, and detailed in Table 143. These results use the
contribution to variance in HES costs to ‘weight’ the different ICD-10 codes within a PBC (when allocating
the life-year effects), before applying the QALY ratios associated with each ICD-10 code (see footnote l
reporting results using weights based on the size of the population).
As all the analysis in this section seeks to use the estimated mortality and life-year effects as a surrogate
for a more complete measure of likely health effects, it is the cost per QALY threshold for all 23 PBCs that
is most relevant. As expected, this threshold (£11,638), is lower than a cost per QALY threshold based only
the QALY effects (£21,047 and £26,441 in Table 135 that assumes no effects of NHS expenditure on QoL
itself). This difference gives some indication of the relative importance of QALY effects due to avoidance of
premature death and the QALY effects of avoiding disability during disease. Table 144 reports how the
estimated QALY effects for each PBC can be decomposed into that part associated with QALY effects and
that part associated with ‘pure’ QoL effects. These results appear credible for the first 11 PBCs, where
those for which mortality is the major concern have a much greater share of total QALY effects associated
with avoidance of premature death (e.g. PBCs 2 and 10) compared with those where QoL is the major
concern (e.g. PBC 7).
The ratios of QALYs to YLL due to disease in those PBCs where outcome elasticities could not be estimated
cannot be used to inform estimates of the threshold because there are no estimated life-year effects with
which to apply the ratios. Therefore, as in previous sections, the estimated effect of expenditure on
health for the 11 PBCs with outcome elasticities is applied to the estimated changes in PBC expenditure
for the other 12 PBCs (excluding GMS for the reasons given in Summary of cost per life-year estimates),
i.e. assuming that the health effects that can be observed from a change in expenditure will be similar to
those that cannot. However, the use of QALY ratios also implies that the share of total health effects
between QALY effects and that part associated with ‘pure’ QoL effects are also similar to those PBCs with
estimated outcome elasticities. Summing the different types of health effects across these 11 PBCs
suggests that 50% is due to avoidance of premature death and 50% due to avoidance of disability. This is
clearly not credible when applied to the other PBCs (e.g. mental health, vision and hearing are likely have
a much greater share of total health effects associated with QoL effects and very little associated with
premature mortality).
TABLE 142 Summary of the QALY threshold using ratios
PBC scenario
Cost per QALY threshold (£)
(1) DALY ratios (2) Adjusted DALY ratios (3) QALY ratios (HODaR and MEPS)
All big four programmes 5402 6419 5990
11 PBCs (with mortality) 9958 11,718 10,297
All 23 PBCs 11,254 13,244 11,638a
a Preferred analysis.
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TABLE 143 Breakdown of the QALY threshold using ratios by PBC
PBC
(1) Change in
spend (£M)
Adjusted DALY ratios QALY ratios (HODaR and MEPS)
(2) Change
in QALY
(3) Cost per QALY
gained (£)
(4) Change
in QALY
(5) Cost per QALY
gained (£)
2 Cancer 19 1763 10,871 1699 11,283
10 Circulatory problems 33 7677 4334 6713 4956
11 Respiratory problems 22 2379 9375 3215 6937
13 Gastrointestinal
problems
17 2396 6886 3605 4577
All big four programmes 6419 5990
1 Infectious diseases 8 21 388,430 27 305,724
4 Endocrine problems 18 1077 16,396 2036 8673
7 Neurological
problems
17 296 58,158 342 50,295
17 Genitourinary
problems
32 15 2,158,296 12 2,623,379
16 Trauma and injuries 10 0 N/A 0 N/A
18+ 19 Maternity and
neonates
8 125 64,173 273 29,327
First 11 PBCs 11,718 10,297
3 Disorders of blood 11 956 11,718 1087 10,297
5 Mental health
disorders
204 17,423 11,718 19,828 10,297
6 Learning disability 31 2627 11,718 2990 10,297
8 Problems of vision 24 2063 11,718 2348 10,297
9 Problems of hearing 6 546 11,718 621 10,297
12 Dental problems 23 2005 11,718 2282 10,297
14 Skin 11 897 11,718 1021 10,297
15 Musculoskeletal
system
15 1291 11,718 1469 10,297
20 Poisoning and
adverse effects
4 375 11,718 426 10,297
21 Healthy individuals 18 1565 11,718 1781 10,297
22 Social care needs 68 5769 11,718 6566 10,297
23 Other 78 0 N/A 0 N/A
All 23 PBCs 13,244 11,638
N/A, not applicable.
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TABLE 144 Decomposing estimated QALY effects by PBC
PBC
QALY change
(total)
QALY change
(death)
% QALY gained
Due to avoidance of
premature death
Due to avoidance of
disability while alive
2 Cancer 1699 1641 97 3
10 Circulatory 6713 4856 72 28
11 Respiratory 3215 923 29 71
13 Gastrointestinal 3605 1193 33 67
1 Infectious diseases 27 11 40 60
4 Endocrine 2036 323 16 84
7 Neurological 342 52 15 85
17 Genitourinary 12 6 52 48
16 Trauma and injuries 0 0 N/A N/A
18+ 19 Maternity and
neonates
273 15 6 94
3 Disorders of blood 1087 547 50 50
5 Mental health 19,828 9979 50 50
6 Learning disability 2990 1505 50 50
8 Problems of vision 2348 1181 50 50
9 Problems of hearing 621 313 50 50
12 Dental problems 2282 1148 50 50
14 Skin 1021 514 50 50
15 Musculoskeletal 1469 739 50 50
20 Poisoning and
adverse events
426 215 50 50
21 Healthy individuals 1781 896 50 50
22 Social care needs 6566 3304 50 50
23 Other 0 0 N/A N/A
N/A, not applicable.
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By comparing the change in QALYs in each PBC [that originates cost per QALY threshold estimates,
column (2) in Table 145], with the corresponding change in YLL [see column (6) in Table 116], we can
infer the implied QALY to YLL ratio in each of the PBCs with a mortality signal. These are shown in
Table 145. The QALY to YLL ratio implied by the analysis using QALY ratios for all 11 PBCs with outcome
elasticities is 1.52, which suggests that every life-year is associated with 1.52 QALYs on average across
these PBCs. However, this implied QALY ratio differs across these PBCs, ranging from 0.79 in PBC 2 to
15.05 in PBC 18 + 19 [see column (4) of Table 145]. It should be noted that the implied QALY ratio of
1.33 for the 11 PBCs with outcome elasticities is a ratio of QALYs to unadjusted YLL. The proportion
of total QALY effects due to premature deaths for the same PBCs (50% in Table 144) also implies a
ratio – equal to two. However, this is a ratio of total QALY effects to quality-adjusted YLL. The difference
between these two ratios is the denominator (i.e. quality-adjusted YLL are lower than unadjusted YLL).
The problem is that using QALY to YLL ratios means that much of the information that is available
about the other 12 PBCs cannot be used to inform the estimates of the cost per QALY threshold.
Fortunately, the sources of information on which the ratios are based also provide much of the information
required to calculate the QALY burden of disease in these areas. Using estimates of the quality-adjusted
life-year burden of disease explores how measures of burden can be used to estimate a cost per QALY
threshold that captures the likely effects of a change in expenditure on all aspects of health while using all
the information that is available about all the PBCs.
TABLE 145 Implied QALY to YLL ratios
PBC
Adjusted DALY ratios QALY ratios (HODaR and MEPS)
(1) Implied
QALY
per YLG
(2) Implied
QALY per
excess death
averted
(3) Implied
QALY per
PBC death
averted
(4) Implied
QALY
per YLG
(5) Implied
QALY per
excess death
averted
(6) Implied
QALY per
PBC death
averted
2 Cancer 0.82 11.58 8.48 0.79 11.16 8.17
10 Circulatory
problems
1.20 12.51 6.20 1.05 10.94 5.42
11 Respiratory
problems
1.96 18.09 2.04 2.65 24.45 2.76
13 Gastrointestinal
problems
1.54 23.02 14.49 2.31 34.63 21.80
All big four programmes 1.26 14.20 5.12 1.35 15.21 5.49
1 Infectious
diseases
1.56 20.64 8.30 1.98 26.22 10.54
4 Endocrine
problems
2.62 35.61 19.84 4.95 67.31 37.51
7 Neurological
problems
4.56 61.99 27.90 5.27 71.69 32.26
17 Genitourinary
problems
1.75 14.56 2.98 1.44 11.98 2.45
16 Trauma and
injuries
N/A N/A N/A N/A N/A N/A
18+ 19 Maternity and
neonates
6.88 511.33 511.33 15.05 1118.85 1118.85
First 11 PBCs 1.33 15.16 5.53 1.52 17.26 6.29
N/A, not applicable.
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Using estimates of the quality-adjusted life-year burden of disease
In this section we use estimates of the QALY burden of disease to infer QALY effects in those PBCs where the
mortality effects of changes in expenditure can be observed, and extrapolate the estimated proportionate
effects to those PBCs where the health effects of changes in expenditure cannot be observed. The estimated
proportionate effect of change in expenditure on the life-year burden of disease in the 11 PBCs where
mortality-based outcome elasticities could be estimated are applied to measures of QALY burden in each of
these PBCs (i.e. effects on the mortality burden of disease are used as a surrogate for effects on QALY
burden). The proportionate effect on burden of disease due to the change in expenditure across these PBCs
can then be applied to measures of QALY burden in the other 11 PBCs where mortality effects could not be
estimated (i.e. the observed effects of changes in expenditure on burden of disease is extrapolated to the
other PBCs where health effects cannot be observed). In this way, we can use all the information available
about the mortality and QoL effects of the different types of disease that make up each PBC, particularly
those where mortality-based outcome elasticities are not available. Applying a proportionate effect to
measures of QALY burden of disease is equivalent to assuming that any effects on life-years are lived at QoL
that reflects a proportionate improvement to the QoL with disease.m It also allows QoL effects of changes in
expenditure to be included; also based on proportionate improvement in the QoL with disease.
In Adjusting life-years for quality-of-life, each YLG could be assumed to be lived in full health, lived in a
QoL that reflects age and gender norms of the general population or lived in a QoL that reflects the
original disease state. Applying an estimated proportionate effect on the life-year burden of disease to
measures of QALY burden of disease implies a proportionate improvement in the QoL with disease applied
to any life-year effects. Therefore, basing estimates on measures of QALY burden provides a more
conservative estimate of the QALY effects of changes in mortality than the best estimate reported in
Adjusting life-years for quality-of-life, which was based on QoL norms.
Previously, in sections up to Using ratios of quality-adjusted life-years to years of life lost (corresponding to
Chapter 3 and Chapter 4, From mortality to life-years, Adjusting life-years for quality-of-life and Using ratios
of quality-adjusted life-years to years of life lost of main report), expenditure elasticities were not estimated
for the other 11 PBCs where outcome elasticities could not be estimated because the same health effect
of changes in expenditure was assumed (i.e. it did not matter how changes in expenditure were allocated
between them). Given expenditure elasticities were only estimated for PBC 23 and the 11 PBCs where
outcome elasticities could be estimated, in analyses up to Using ratios of quality-adjusted life-years to years
of life lost the remaining change in total spend was assigned to the other 11 PBCs. As a consequence,
proportionally more of the share of a change in total spend was allocated to these other PBCs in previous
sections [see column (3) of Table 108]. However, in this section it does matter how the remaining change
in expenditure is allocated between the other 11 PBCs as they have different QALY burdens so different
implied health effects of expenditure. Therefore, expenditure elasticities are estimated for all 23 PBCs
[see column (2) of Table 108]. However, it is not possible to estimate expenditure equations for all 23 PBCs
simultaneously, so the 23 independently estimated expenditure elasticities do not account for all of the
change in overall spend (i.e. the sum of changes in PBC expenditure based on the estimated PBC
expenditure elasticities accounts for less than a 1% change in total spend). This remaining change in total
spend is allocated between all 23 PBCs reflecting their relative share of changes in expenditure based on
their estimated expenditure elasticities [see column (4) of Table 108].
The total QALY burden of disease for the population with disease in a particular year includes (i) the
quality-adjusted YLL due to all the disease-related mortality that could occur in this population over their
remaining duration of disease; and (ii) the reduction in QoL while alive also for their remaining disease
duration. These components of burden represent, respectively, the QALYs lost due to premature death
(QALYldeath) and the QALYs lost while alive (QALYlalive) as a consequence of disease.
Burden ¼ QALYIdeath þ QALYIalive (28)
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However, applying the estimated proportionate effects on mortality and life-years to such a measure of
total burden would provide an estimate of the effects of a change in expenditure, not just in 1 year, but in
all the remaining years of disease for the population at risk in that year. Recall from From mortality to
life-years that we have adopted the conservative assumption that changes in expenditure will only have
health effects in 1 year for the population with disease in that year. Therefore, it is not a measure of total
burden that is required, but a measure of the QALY burden of disease during 1 year for the population
with disease (prevalent and incident) in that year. The estimated outcome elasticities can then be
appropriately (and directly) applied to this measure of burden. Of course, it would be possible to solve
for a lower outcome elasticity that could be applied to total burden which would return the required
estimate of total QALY effects restricted to 1 year.
The information from GBD used to derive QALY ratios in Using estimates of the quality-adjusted life-year
burden of disease includes information about the YLL and duration of disease for those incident to a
U-code, i.e. the measure of QALY burden from the information included in the ratios is a measure of the
total burden of the disease but only for the population that is incident (rather than the total population
with disease) in 1 year. Assuming that incidence is stable over the disease duration this is also equivalent to
the QALY burden of disease during 1 year for the population with disease (i.e. those that are incident and
prevalent) in that year. This is valid as long as estimates of the QoL decrement of disease from HODaR and
MEPS are assumed representative of average effects across those earlier (incident) and later (prevalent) in
their disease duration.
However, in moving from ratios to absolute measures of burden it becomes more important to examine
and then adjust for any inconsistency between information about YLL and size of the incident population
from GBD (which is available by U-codes and can be mapped to ICD-10 codes), and the information about
net YLL and observed deaths for each PBC based on ONS data as described in Summary of the cost per
quality-adjusted life-year threshold based only on mortality effects (Table 146).
There are a number of reasons for the potential inconsistencies: (i) GBD is based on earlier years of
mortality data; (ii) the imprecision of mapping from U-codes to PBC via ICD-10 codes; and (iii) the YLL
reported in GBD are based on LE at the age of death (see Adjusting life-years for quality-of-life and
TABLE 146 Comparing deaths and YLL from ONS and GBD
PBC
(1) Excess
deaths
ONS
Deaths YLL
(2) All
deaths
ONS
(3) All
deaths
GBD
(4) Adjustment
factor (deaths)
(5) Net
estimates
ONS
(6) Total
YLL GBD
(7) Adjustment
factor (YLL)
1 Infectious
diseases
2797 6958 1408 4.94 36,962 25,142 1.47
2 Cancer 95,715 130,810 140,124 0.93 1,347,184 1,932,637 0.70
4 Endocrine 3769 6765 7509 0.90 51,225 95,401 0.54
7 Neurological 6909 15,353 12,854 1.19 93,917 164,796 0.57
10 Circulatory 79,218 159,852 178,454 0.90 823,768 1,750,608 0.47
11 Respiratory 7386 65,446 67,441 0.97 68,030 594,529 0.11
13 Gastrointestinal 15,199 24,147 28,329 0.85 227,703 396,829 0.57
17 Genitourinary 2172 10,625 8606 1.23 18,127 77,338 0.23
18+ 19 Maternity
and neonates
226 226 2211 0.10 16,801 149,868 0.11
Total 213,391 420,182 446,936 0.94 2,683,717 5,187,148 0.52
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Including quality-of-life effects during disease) and will overestimate the net YLL. The YLL by U-code,
reported in GBD, that are mapped to ICD-10 codes are adjusted by these proportionate differences
[see column (7) of Table 146] to ensure that the YLL associated with all contributing ICD-10 codes are
consistent with (and do not overestimate) the net YLL for the PBC as a whole. The variation across ICD-10
codes in the adjusted QALY burden associated with mortality gains (for the population with disease in a
particular year) is depicted in column (2) of Table 147.
It is QALY burden per patient with disease in a particular year that is reported in Table 147, including the
median and range across the ICD-10 codes contributing to each PBC. Such measure of burden considers
QoL burden while alive in 1 year and mortality burden for the same time period. Note that mortality effects
of disease in 1 year can lead to the loss of more than 1 life-year, and, for this reason, burden due to
premature death (and consequently overall burden) may assume values bigger than 1. Burden values in
Table 147 reflect variation across ICD-10 codes and should not be misinterpreted as the ‘average’ QALY
burden for the PBC, as this depends on how PBC effects are allocated to ICD-10 codes and the ‘average’
TABLE 147 Variation across ICD-10 codes of the QALY burden of disease for a patient with disease in a
particular year
PBC
Median [5th to 95th percentile]
(1) Burden while alive
(2) Burden due to
premature death (3) Burden
1 Infectious diseases 0.47 [0.00 to 0.82] 0.25 [0.11 to 42.87] 0.72 [0.72 to 42.87]
2 Cancers and tumours 0.09 [0.00 to 0.10] 2.82 [0.51 to 5.11] 2.92 [0.58 to 5.11]
3 Disorders of blood 0.05 [0.05 to 0.07] 0.01 [0.01 to 0.03] 0.06 [0.06 to 0.09]
4 Endocrine 0.10 [0.00 to 0.17] 0.01 [0.01 to 4.82] 0.11 [0.11 to 4.82]
5 Mental health 0.10 [0.07 to 0.22] 0.02 [0.00 to 0.04] 0.12 [0.07 to 0.26]
6 Learning disability 0.10 [0.06 to 0.10] 0.02 [0.00 to 5.34] 0.12 [0.10 to 5.41]
7 Neurological 0.27 [0.00 to 0.37] 0.02 [0.02 to 22.79] 0.29 [0.25 to 22.79]
8 Vision 0.05 [0.00 to 0.06] 0.00 [0.00 to 20.99] 0.05 [0.03 to 20.99]
9 Hearing 0.05 [0.00 to 0.05] 0.00 [0.00 to 20.99] 0.05 [0.00 to 20.99]
10 Circulation 0.09 [0.09 to 0.19] 0.37 [0.06 to 0.39] 0.48 [0.18 to 0.56]
11 Respiratory system 0.14 [0.00 to 0.21] 0.01 [0.00 to 5.17] 0.15 [0.00 to 5.18]
12 Dental 0.03 [0.01 to 0.03] 0.01 [0.00 to 0.01] 0.04 [0.01 to 0.04]
13 Gastrointestinal system 0.10 [0.00 to 0.18] 0.05 [0.00 to 23.67] 0.15 [0.00 to 23.67]
14 Skin 0.06 [0.00 to 0.06] 0.02 [0.02 to 20.99] 0.08 [0.08 to 20.99]
15 Musculoskeletal system 0.10 [0.00 to 0.10] 0.02 [0.00 to 20.99] 0.12 [0.06 to 20.99]
16 Trauma and injury N/A N/A N/A
17 Genitourinary system 0.11 [0.00 to 0.13] 0.04 [0.00 to 8.90] 0.15 [0.05 to 8.90]
18 Maternity 0.01 [0.00 to 0.01] 0.00 [0.00 to 4.68] 0.01 [0.00 to 4.68]
19 Conditions of neonates 0.00 [0.00 to 0.00] 0.03 [0.02 to 0.03] 0.03 [0.02 to 0.03]
20 Poisoning and adverse events 0.03 [0.00 to 0.06] 0.00 [0.00 to 18.63] 0.03 [0.02 to 18.63]
21 Healthy individuals 0.05 [0.05 to 0.05] 0.01 [0.01 to 0.01] 0.06 [0.06 to 0.06]
N/A, not applicable.
Note
QALY burden of disease reflects burden while alive in 1 year and mortality burden in 1 year. Any mortality effects of
disease in 1 year can lead to the loss of more than 1 life-year, and for this reason burden due to premature death may
assume values bigger than 1.
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burden for groups of PBCs depends on how a change in overall expenditure is shared between them
(i.e. the expenditure elasticities estimated for each PBC in Appendix 2).
Due to the earlier years of data and imprecision in mapping from U-codes to ICD-10 codes there might also
be some inconsistency in estimates of the total incidence of disease for a PBC. Insofar as disease-related
mortality risk is stable, the same number of deaths should be observed in GBD and ONS data for the same
at risk population. The PBC deaths recorded in GBD and those observed in ONS data [see columns (2) and
(3) in Table 146] are similar but nonetheless the proportionate difference is used to adjust the scale of QoL
burden while alive based on GBD information (equivalent to adjusting estimates of incidence). Notable
exceptions are PBC 1 and PBC 18 + 19 where the discrepancies are likely to be due to imperfect mapping
from U-code to PBC via ICD-10 codes. Summaries of the ICD-10-specific values of the adjusted burden of
disease while alive are depicted in column (1) of Table 147. Total burden (for the population with disease in
a particular year) is the sum of the two components of burden (Table 148 presents a few examples
for illustration).
The implications for the cost per QALY threshold of using information about the QALY burden of disease
for all PBCs, rather than QALY ratios for those where an outcome elasticity can be estimated, are reported
summarily in Table 149 and in detail in Table 150. The QALY effects of a change in PBC expenditure are
a weighted average of the QALY effects within each of the ICD-10 codes that contribute to the PBC. The
figures reported in column 2 (Table 149) are based on weighing the effects at ICD-code level by the
proportion of the total PBC population within each contributing ICD-10 code, rather than the contribution
to variance in HES costs.n
The cost per QALY threshold for the 11PBCs with outcome elasticities is a little lower using a measure of
QALY burden (£5128) rather than the QALY ratios (£10,297) described in Using ratios of quality-adjusted
life-years to years of life lost. This is in part because the way GBD calculates YLL overestimates net YLL
TABLE 148 Examples of QALY burden of disease for the population with disease in a particular year
U-code QALY burden (QALY lostdeath+QALY lostalive)
U037 (other infectious diseases)a 0.20 (0.09 + 0.11)
U016 (tetanus) 2.73 (2.73 + 0.00)
U061 (mouth and oropharynx cancers) 2.97 (2.87 + 0.10)
U141 (spina bifida) 0.65 (0.18 + 0.46)
a Note that differential adjustments have been made to YLL (affecting QALY lostdeath) and to the incidence (affecting
QALY lostalive), thus implied ratios from these burden estimates may differ from ratios presented in Using ratios
of quality-adjusted life-years to years of life lost.
QALY burden of disease reflects burden while alive in 1 year and mortality burden in 1 year. Any mortality effects of
disease in 1 year can lead to the loss of more than 1 life-year, and for this reason burden due to premature death may
assume values bigger than 1.
TABLE 149 Summary of the cost per QALY threshold
PBC grouping
Cost per QALY gained (£)a
(1) QALY ratios (HODaR and MEPS) (2) QALY burden (HODaR and MEPS)
All big four programmes 5990 3036
11 PBCs (with mortality) 10,297 5128
All 23 PBCs 11,638 10,187a
a Preferred analysis.
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TABLE 150 Breakdown of the cost per QALY threshold
PBC
(1) Change in
spend (£M)
QALY ratios (HODaR and MEPS) QALY burden (HODaR and MEPS)
(2) Change
in QALY
(3) Cost per QALY
gained (£)
(4) Change
in QALY
(5) Cost per QALY
gained (£)
2 Cancer 19 1699 11,283 2121 12,772
10 Circulatory problems 33 6713 4956 8347 5631
11 Respiratory problems 22 3215 6937 28,072 1123
13 Gastrointestinal
problems
17 3605 4577 3922 5944
All big four programmes 5990 3036
1 Infectious diseases 8 27 305,724 74 158,349
4 Endocrine problems 18 2036 8673 6905 3613
7 Neurological
problems
17 342 50,295 1361 17,844
17 Genitourinary
problems
32 12 2,623,379 34 1,320,516
16 Trauma and injuries 10 0 N/A 0 N/A
18+ 19 Maternity and
neonates
8 273 29,327 14 813,578
First 11 PBCs 10,297 5128
3 Disorders of blood 11 1087 10,297 1215 6814
5 Mental
health disorders
204 19,828 10,297 10,878 13,876
6 Learning disability 31 2990 10,297 207 109,806
8 Problems of vision 24 2348 10,297 561 31,858
9 Problems of hearing 6 621 10,297 1168 4047
12 Dental problems 23 2282 10,297 578 30,030
14 Skin 11 1021 10,297 103 75,158
15 Musculoskeletal
system
15 1469 10,297 1005 11,129
20 Poisoning and
adverse effects
4 426 10,297 42 76,909
21 Healthy individuals 18 1781 10,297 40 336,325
22 Social care needs 68 6566 10,297 0 N/A
23 Other 78 0 N/A 0 N/A
All 23 PBCs 11,638 10,187
N/A, not applicable.
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(which accounts for counterfactual deaths, as detailed in Summary of the cost per quality-adjusted life-year
threshold based only on mortality effects). This will make no difference to the first term in the QALY ratio
(Rdeath) used in Using ratios of quality-adjusted life-years to years of life lost as an overestimate of YLL
affects both denominator and numerator of the ratio. However, the second term (Ralive) is likely to be
underestimated. Therefore, the ratios will tend to underestimate the QALY effects of expenditure and
overestimate the cost per QALY threshold (see Table 149). We are able to adjust the GBD-based measure
of QALY burden for this overestimation in calculating the QALY threshold reported in column (2) of
Table 149.
As the purpose of this section is to use the estimated mortality and life-year effects as a surrogate for a
more complete measure of likely health effects, it is the cost per QALY threshold for all 23 PBCs that is of
most relevance. The cost per QALY threshold for all 23 PBCs is based on applying the proportionate effects
on the QALY burden of disease, based on the observed effects of changes in expenditure on mortality in
the 11 PBCs with outcome elasticities,o to the QALY burden of disease in the other PBCs. This generates
a higher cost per QALY threshold (£10,187) than the one based only on the 11 PBCs with outcome
elasticities (£11,638). The reason is that the QALY burden of disease in the other PBCs is, in general,
lower than the QALY burden of disease across those PBCs where outcome elasticities can be estimated
(see Table 147).
Therefore, applying the same proportionate effects to a lower QALY burden generates a smaller
health effect of a change in expenditure.p In essence, the difference between these estimates is that in
column (1) of Table 149 the absolute effect on health associated with an absolute change in expenditure is
extrapolated to the other PBCs, whereas in column (2) of Table 149 it is the relative effect on health of an
absolute change in expenditure that is extrapolated. As we know that QALY burden differs between
(and within) PBCs, and especially between the groups of PBCs with and without estimated outcome
elasticities (see Table 147), it is the values based on QALY burden in column (2) of Table 149 that
are regarded as most credible and represent our central or best estimate.
A detailed breakdown of changes in expenditure and changes in QALYs across all PBCs is shown in
Table 150, where the analysis is based on QALY ratios and on QALY burden of disease. A comparison of
these values suggests that QALY effects for the other PBCs are generally lower and therefore the cost per
QALY for each of these PBCs are in general higher when based on a proportionate effect on QALY
burden. Of course, we have not directly observed QoL effects in these PBCs but inferred them from the
proportionate effects that we can observe. Insofar as investment and disinvestment opportunities in these
PBCs might have been more valuable (offered greater improvement in QoL) than suggested by the implied
PBC thresholds, then overall QALY effects will tend to be underestimated and the cost per QALY
threshold overestimated.
For the reasons discussed in previous sections, we regard all the costs per QALY threshold reported in
column (2) of Table 149 to be on balance conservative with respect to overall health effects of a change in
expenditure. However, the estimate of £10,187 is based on an extrapolation of the proportionate effects
to measures of burden on these PBCs, rather than observations of the direct impact of changes in
expenditure on QoL in these types of disease. This is especially important in PBC 5, mental health
disorders, which accounts for a large proportion of the change in overall expenditure (22%) and where a
review of the evidence suggests that the investment and disinvestment opportunities in this PBC may have
been more valuable than the implied PBC cost per QALY of £13,876 (see Addendum 3: characterisation of
the investment and disinvestment decisions in mental health – depression and schizophrenia). The lower
cost per QALY threshold for the 11 PBCs with outcome elasticities (£5128) might be regarded as more
secure in this respect, but they only account for a proportion (38%) of any change in overall expenditure
(see Table 155).
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Table 151 reports how the estimated QALY effects based on measures of QALY burden for each PBC can
be decomposed into that part associated with life-year effects adjusted for quality and that part associated
with ‘pure’ QoL effects. These results are similar to those reported in Table 144 which were based on QALY
ratios for the 11 PBCs with an estimated outcome elasticity. Those PBCs for which mortality is the major
concern have a much greater share of total QALY effects associated with avoidance of premature death
(e.g. PBCs 2 and 10) compared with those where QoL is the major concern (e.g. PBC 7). The differences
tend to favour QALYs gained though avoidance of disability, which reflects the underestimation of the
effects on ‘pure’ QoL when using QALY ratios based on estimates of YLL from GBD (see the discussion
above). The exceptions are PBC 1 and PBC 18 + 19. The reason is that there are significant adjustments
made based on differences in observed and recorded mortality (to adjust for differences in recording), as
well as differences in YLL due to the GBD method of calculation (see Table 146).
The implied QALY per YLG and death averted are reported in Table 152. As expected, the implied QALY
per PBC death averted across all 11 PBCs with outcome elasticities is higher (12.6 QALYs) than reported in
Using ratios of quality-adjusted life-years to years of life lost (6.3 QALYs) because of the previous bias
against QoL effects.
TABLE 151 Decomposing estimated QALY effects by PBC
PBC
(1) QALY
change (total)
(2) QALY
change (death)
% QALY gained
(3) For premature
death
(4) For disability
while alive
2 Cancer 2121 1968 93 7
10 Circulatory 8347 5727 69 31
11 Respiratory 28,072 1072 4 96
13 Gastrointestinal 3922 1446 37 63
1 Infectious diseases 74 13 18 82
4 Endocrine 6905 380 5 95
7 Neurological 1361 60 4 96
17 Genitourinary 34 8 22 78
16 Trauma and injuries 0 0 N/A N/A
18+ 19 Maternity and neonates 14 10 69 31
3 Disorders of blood 1215 62 5 95
5 Mental health 10,878 949 9 91
6 Learning disability 207 41 20 80
8 Problems of vision 561 22 4 96
9 Problems of hearing 1168 9 1 99
12 Dental problems 578 1 0 100
14 Skin 103 38 37 63
15 Musculoskeletal 1005 50 5 95
20 Poisoning and adverse events 42 7 16 84
21 Healthy individuals 40 6 16 84
22 Social care needs 0 0 N/A N/A
23 Other 0 0 N/A N/A
N/A, not applicable.
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In Using ratios of quality-adjusted life-years to years of life lost, the ratios of QALYs to YLL due to disease in
those PBCs where outcome elasticities could not be estimated could not be used to inform estimates of the
threshold or indicate how any total health effects in these other PBCs are likely to be ‘shared’ between
life-year effects adjusted for quality and that part associated with ‘pure’ QoL effects (see Table 144).
By applying the observed proportionate effects of changes in expenditure to measures of QALY burden of
disease in these other PBCs the likely share of any effects on QALYs between avoidance of premature
mortality and avoidance of disability more closely reflect the nature of these types of diseases (see Table 151).
As expected, a much greater proportion of QALY effects are associated with QoL during the disease
compared with the 11 PBCs where mortality-based outcome elasticities could be estimated. The share of
effects in particular PBCs are also much more credible. For example, in PBC 5 (mental health disorders) the
overwhelming share of QALY effects are associated with QoL itself and for others, such as PBC 12 (dental
problems), PBC 9 (problems of hearing) and PBC 8 (problems of vision), almost all effects are associated with
QoL rather than mortality and life-years. For this, and the other reasons discussed above, the analysis based
on measures of QALY burden are regarded as the best estimate of a cost per QALY ratio that reflects a more
complete picture of the likely health effects of changes in overall expenditure.
Summary of the cost per quality-adjusted life-year threshold
The results of the three sequential steps of analysis described in this appendix are summarised in Table 153.
In From mortality to life-years we explored ways in which the estimated effects on mortality from the
econometrics work in Appendix 2 might be better translated into life-year effects by overcoming some
of the limitations of mortality data available at PCT level and taking account of counterfactual deaths.
The results of this analysis were reported in Table 122 and are repeated in column (1) of Table 153. These
results can be interpreted as cost per QALY thresholds conditional on the assumption that all life-years are
lived in full health and the QoL with disease is zero (equivalent to death).
In Adjusting life-years for quality-of-life we considered how the estimated life-year effects might be
adjusted for the QoL in which they are likely to be lived, taking account of the gender and the age at
which life-years are gained or lost (see Table 135). The results of this analysis are repeated in Table 153,
column (2). Finally, in the current section, we explored ways to also take account of the likely effects of
changes in expenditure on QoL during disease as well as the effects associated with mortality and life-years
TABLE 152 Implied QALY per excess death averted: using burden
PBC (1) QALY per YLG
(2) Implied QALY per excess
death averted
(3) Implied QALY per PBC
death averted
2 Cancer 0.70 9.86 7.21
10 Circulatory problems 0.93 9.63 4.77
11 Respiratory problems 16.40 151.10 17.05
13 Gastrointestinal problems 1.78 26.66 16.78
All big four programmes 2.66 30.02 10.82
1 Infectious diseases 3.83 50.62 20.35
4 Endocrine problems 11.89 161.59 90.04
7 Neurological problems 14.86 202.05 90.92
17 Genitourinary problems 2.85 23.80 4.87
16 Trauma and injuries N/A N/A N/A
18+ 19 Maternity and neonates 0.54 40.33 40.33
First 11 PBCs 3.05 34.65 12.63
N/A, not applicable.
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[see Table 153, column (3)]. These estimates provide our central estimate of a cost per QALY threshold,
because they make best use of available information while the assumptions required, which on
balance are likely conservative with respect to health effects, appear more reasonable than the other
alternatives available.q
The estimate of £5128 per QALY [see Table 153, line (2)] is restricted to the effects of changes in expenditure
in the 11 PBCs where outcome elasticities can be estimated. Although this might be regarded as more
secure, these PBCs only account for a proportion of the change in overall expenditure [approximately 38%,
column (6) in Table 108]. The threshold of £10,187 uses the estimated proportionate effects of expenditure
on the QALY burden of disease in these PBCs as a surrogate for proportionate effects in the others
(i.e. assuming that the effects that can be observed will be similar to those that cannot). As discussed in
Using estimates of the quality-adjusted life-year burden of disease, there are reasons to suspect that this
may underestimate health effects in these PBCs which have most influence on the overall threshold. As in
previous sections, no health effects are assigned to PBC 23 (GMS) on the basis that any health effects of this
expenditure would be recorded in the other PBCs.r Therefore, the best or central estimate of cost per QALY
threshold is £10,187 [see Table 153, column (3), line (3)].
TABLE 153 Summary of cost per QALY threshold estimates
PBC grouping
(1) Chapter 4,
From mortality to
life-years analysis
(2) Chapter 4, Adjusting
life-years for quality-
of-life analysis
(3) Chapter 4, Including
quality-of-life effects
during disease analysis
QoL associated with life extension 1 Norm
QoL during disease 0 0 Based on burden
Best estimate
Effect of expenditure on mortality 1 year 1 year 1 year
YLL per death averted ∼ 4.1 ∼ 4.1 ∼ 4.1
QALYs per death averted ∼ 4.1 ∼ 3.5 ∼ 14.9
(1) All big four programmes £8080 £9631 £3036
(2) 11 PBCs (with mortality) £15,628 £18,622 £5128
(3) All 23 PBCs £17,663 £21,047 £10,187
Lower bound
Effect of expenditure on mortality Remainder of
disease duration
Remainder of
disease duration
Remainder of
disease duration
YLL per death averted ∼ 4.1 ∼ 4.1 ∼ 4.1
QALYs per death averted ∼ 4.1 ∼ 3.5 ∼ 14.9
(4) All big four programmes £3846 £4252 £674
(5) 11 PBCs (with mortality) £6106 £6852 £860
(6) All 23 PBCs £6901 £7744 £1843
Upper bound
Effect of expenditure on mortality 1 year 1 year 1 year
YLL per death averted 2 2 2
QALYs per death averted ∼ 2 ∼ 1.9 ∼ 7.2
(7) All big four programmes £16,432 £17,456 £6292
(8) 11 PBCs (with mortality) £32,387 £34,492 £10,626
(9) All 23 PBCs £36,604 £38,983 £21,111
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This estimate reflects changes in undiscounted QALYs associated with changes in expenditure. Although all
the health effects of a change in expenditure are restricted to 1 year (so no discounting is necessary) some
of the QALY effects of a change in mortality in that year will occur in future years, so in principle should be
discounted. However, discounting these life-year effects, even at the higher rate of 3.5% recommended by
NICE, only increases the cost per QALY threshold to £10,333 (Table 154).
As in previous sections of this chapter, the upper and lower bounds for the cost per QALY thresholds in
Table 153, column (3) are based on making the necessary assumptions about duration of health effects
and how long a death might be averted optimistic (providing the lower bound for the threshold) or
conservative (an upper bound for the threshold). The lower bound [see Table 153, lines (4)–(6)] is based on
assuming that health effects are not restricted to 1 year but apply to the whole of the remaining disease
duration of the population at risk in PBCs during 1 year. Although this combines optimistic assumptions, it
is possible that at least some part of a change in expenditure may prevent disease so will have an impact
on populations that are incident to PBCs in the future. Such effects are not captured in any of the
estimates presented in this chapter so all are conservative with respect to this type of health effects of
expenditure. The upper bound [Table 153, lines (7)–(9)] is based on the combination of assuming that
health effects are restricted to 1 year for the population currently at risk and that any death averted is only
averted for 2 years (see Summary of cost per life-year estimates).
Which programme budget categories matter most?
Which PBCs have the greatest influence on the overall threshold depends, to a large extent, on how a
change in overall expenditure is allocated to the different PBCs [Table 155, column (1)], i.e. those that
account for a greater share of the change in expenditure will tend to have the greater influence.s
However, the overall threshold also depends on the proportionate effect of a change in PBC expenditure
on the QALY burden associated with the PBCt and the scale of the QALY burden (for the population at
risk) associated with the type of diseases that make up each PBC.u These determine the cost per QALY
associated with each PBC [see Table 155, column (4)]. The share, attributable to each PBC, of the total
health effects of a change in overall expenditure [see Table 155, column (2)] is the combined effect of all
of these. The proportionate impact on the overall cost per QALY threshold of a 10% change in PBC health
effects gives an indication of how sensitive the overall threshold is to the estimate of health effects
associated with each PBC [see Table 155, column (3)]
Although the 11 PBCs where outcome elasticities could be estimated only account for 38.4% of the
change in overall expenditure, they account for 76.3% of the overall health effects. Within this group
some PBCs contribute more than others. For example, PBC 11 (respiratory) accounts for a greater share of
total health effects and has a higher elasticity (4.22%) than PBC 10 (circulatory), even though it accounts
TABLE 154 Summary of QALY threshold, discounted
PBC scenario
Best estimate (£)
(1) Undiscounted (2) Discounteda
(1) All big four programmes 3036 3097
(2) 11 PBCs (with mortality) 5128 5218
(3) All 23 PBCsb 10,187 10,333
a Only quality-adjusted net YLL were discounted, and thus QALYs associated with gains in QoL during disease were not.
The discounting factor has been calculated by applying a 3.5% discount rate to each year of life lost in the PBCs – the
estimate of YLL used was the implied YLL per death averted in each PBC [see column (2) of Table 121]. This discounting
factor was applied to net YLL, before applying the outcome elasticity to calculate YLL averted.
b In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal.
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for a greater part of a change in overall expenditure. The reason is that the cost per QALY associated with
changes in expenditure in PBC 11 is lower than PBC 10 and much lower than the overall threshold
(so generates more health effects for the same, or even smaller, change in expenditure). The elasticities in
Table 155, column (3) are instructive (e.g. the elasticity for PBC 11 suggests that even if the health effects
of a change in expenditure in this PBC were overestimated by 30% the overall threshold would only
increase by 12.7% to £11,477). All other PBCs have much less influence in this respect. Nonetheless,
PBC 10 is important compared with others as it does contribute a large share of total health effects and
has one of the highest elasticities (1.25%).
TABLE 155 Impact of each PBC on the overall cost per QALY threshold
PBC
(1) % share of change
in overall expenditure
(2) % share of total
health effects (QALY)
(3) Elasticity of
the thresholda
(4) PBC cost
per QALY (£)
2 Cancer 3.99 3.18 0.32 12,772
10 Circulatory 6.92 12.52 1.25 5631
11 Respiratory 4.64 42.12 4.22 1123
13 Gastrointestinal 3.43 5.89 0.59 5944
1 Infectious diseases 1.74 0.11 0.01 158,349
4 Endocrine 3.67 10.36 1.04 3613
7 Neurological 3.58 2.04 0.20 17,844
17 Genitourinary 6.61 0.05 0.01 1,320,516
16 Trauma and
injuries
2.15 0.00 0.00 N/A
18+ 19 Maternity and
neonates
1.67 0.02 < 0.01 813,578
3 Disorders of blood 1.22 1.82 0.18 6814
5 Mental health 22.23 16.32 1.63 13,876
6 Learning disability 3.35 0.31 0.03 109,806
8 Problems of vision 2.63 0.84 0.08 31,858
9 Problems of
hearing
0.70 1.75 0.18 4047
12 Dental problems 2.56 0.87 0.09 30,030
14 Skin 1.14 0.16 0.02 75,158
15 Musculoskeletal 1.65 1.51 0.15 11,129
20 Poisoning and
adverse events
0.48 0.06 0.01 76,909
21 Healthy individuals 2.00 0.06 0.01 336,325
22 Social care needs 7.36 0.00 0.00 N/A
23 Other 16.28 0.00 0.00 N/A
N/A, not applicable.
a Calculated using the effect on the threshold of a 10% increase (or decrease) in QALY change of the PBC.
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The other 12 PBCs, where outcome elasticities could not be estimated, account for the greater part of a
change in overall expenditure (61.6%) but only 23.7% of the overall health effects (i.e. the cost per QALYs
associated with a change in expenditure in these PBCs are, in general, higher). Of course, we have not
directly observed QoL effects in these PBCs but inferred them from the proportionate effects that we can
observe. Insofar as investment and disinvestment opportunities in these PBCs might have been more
valuable (offered greater improvement in QoL) than suggested by the implied PBC thresholds in Table 155,
column (4), the overall QALY effects will tend to be underestimated and the overall cost per QALY
threshold will be overestimated.
Programme budget category 5 (mental health disorders) accounts for a large proportion of the change in
overall expenditure (22.23%), contributes most to the overall health effects (16.32%) and has the highest
elasticity (1.63%) compared with these other PBCs. The cost per QALY associated with this PBC (£13,876) is
based on an extrapolation of estimated proportionate effects to a population-based measure of QALY burden
in this PBC, rather than observations of the direct impact of changes in expenditure on QoL in the types of
diseases that make up the PBC. Evidence that is available suggests that the investment and disinvestment
opportunities in this PBC may have been more valuable than this implied cost per QALY (see Addendum 3:
characterisation of the investment and disinvestment decisions in mental health – depression and
schizophrenia). A search for evidence about interventions in those ICD-10 codes that contribute most to the
PBC (based on prevalence or the contribution to the variance in PBC costs), suggests that pharmacological,
psychological and social interventions for depression are all more cost-effective (in general much less than
£10,000 per QALY) than the overall threshold, and significantly more valuable than the implied QALY threshold
for this PBC. Based on the contribution that each ICD-10 code makes to variance in HES costs across PCTs,
it is schizophrenia that contributes most.v Although interventions that may have been invested or disinvested
in schizophrenia are, in general, less cost-effective (in general less than £24,000 per QALY) than those available
for depression, they do not appear any less valuable than the implied cost per QALY of this PBC in Table 155.w
How uncertain are the estimates?
There are a number of sources of uncertainty which may contribute to an assessment of how uncertain a
central or best estimate of the cost per QALY threshold might be. There are three reasons why uncertainty
in the estimate of the threshold might be of policy interest: (i) the uncertainty in the parameters that
determine the threshold might influence the mean or expected value of the threshold if they have a
non-linear relationship to the threshold or when they have a multilinear relationship but are correlated
with each other; (ii) the consequences of over- or underestimating the threshold differ so the uncertainty
may have an influence on the extent to which a policy threshold (a single value that can be compared to
the ICER of a new technology) should differ from the mean or expected value of the central or best
estimate; and (iii) in conjunction with other methods of analysis it can indicate the potential value of
gathering more information to improve these estimates in the future. Such analysis, known as value of
information analysis, has firm foundations in statistical decision theory and has been applied to health-care
decisions. A form of these analyses could be applied in subsequent research, ideally capturing some of the
other sources of uncertainty. More recently, it has been applied to the decisions faced by NICE when
considering if there is sufficient evidence to support the approval of a new technology.95 Of course,
hypothesis testing and the traditional rules of inference associated with it, such as statistical significance,
p-values and confidence intervals, have no relevance when making unavoidable decisions about policy
relevant quantities based on information currently available and the best use thereof.96
An assessment of parameter uncertainty
Two sets of parameters are critical to the threshold, the expenditure elasticities estimated for each of the 23
PBCs, and the outcome elasticities estimated for 11 of these. These parameters are estimated with uncertainty,
indicated by the standard errors on the relevant coefficients in the econometric analysis detailed in Appendix 2.
As these statistical models estimate coefficients using normality on the relevant scale, normal distributions can
be assigned to each of these estimated coefficients, each with a mean and standard deviation based on the
results of the econometric analysis. These distributions represent the uncertainty in the mean estimate of each
of the parameters and can be propagated through the various calculations required to estimate the overall cost
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per QALY threshold (i.e. through the sequence of analysis detailed in Adjusting life-years for quality-of-life,
Including quality-of-life effects during disease andWhich programme budget categories matter most?) using
Monte Carlo simulation which randomly samples from the assigned distributions. The use of Monte Carlo
simulation in this context is in essence Bayesian, where the standard errors from the frequentist econometric
analysis are used to assign normal prior distributions with means equal to the point estimates and a standard
deviation equal to the estimated standard errors. This is equivalent to a fully Bayesian analysis with initially
uninformative priors which are updated through the analysis of expenditure and mortality data.
The results of each random sample from the Monte Carlo simulation represent one possible realisation
of the overall threshold, given the uncertainty in estimates of the mean parameter values that determine it.
By repeatedly sampling, a distribution of potential values that the overall threshold might take can be
revealed. The results of this simulation are illustrated in Figure 51 showing a histogram of threshold values,
and in Figure 52 showing the cumulative probability density function for a cost per QALY threshold based
only on the 11 PBCs with estimated outcome elasticities and for all 23 PBCs. It represents the probability
(on the y-axis) that the threshold lies below a particular value.
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FIGURE 51 Distribution of the cost per QALY threshold (all 23 PBCs).
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FIGURE 52 Cumulative probability density function for the cost per QALY threshold.
DOI: 10.3310/hta19140 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 14
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Claxton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
431
It has already been noted that restricting attention only to changes in expenditure in those 11 PBCs where
an outcome elasticity can be estimated results in a much lower estimate of the threshold than considering
all changes in expenditure across all PBCs. This lower estimate of £5144 per QALY is much less uncertain
but these PBCs only account for 38% of a change in overall expenditure, so it is the higher estimate, for
all 23 PBCs, that is of most relevance for policy (see Summary of the cost per quality-adjusted life-year
threshold and Which programme budget categories matter most?). The fact that this estimate is more
uncertain simply reflects the quality and quantity of data currently available. As useful analysis should
endeavour to faithfully characterise uncertainty in policy relevant quantities, rather than select those
quantities or questions for which precise estimates are possible, it is the more uncertain estimate for all
23 PBCs that should be of primary interest. The values that are used to generate Figure 52 are available in
column (2) of Table 156. They indicate that the probability that the overall threshold is < £20,000 per
QALY is 0.97 and the probability that is < £30,000 is 1.00.
TABLE 156 Uncertainty over the QALY threshold
Scenario (1) 11 PBCs (2) All 23 PBCs
Best estimate (deterministic) £5128 £10,187
Mean estimate (from the simulations) £5114 £10,092
Threshold value at the probability of (from the simulations)
2.5% £2956 £6228
5.0% £3237 £6744
50.0% £5250 £10,378
95.0% £8845 £17,061
97.5% £10,068 £20,472
Probability (from the simulations) of the threshold being smaller than
£3000 per QALY 0.03 0.00
£4000 per QALY 0.19 0.00
£5000 per QALY 0.44 0.00
£6000 per QALY 0.66 0.02
£7000 per QALY 0.81 0.07
£8000 per QALY 0.92 0.18
£9000 per QALY 0.96 0.31
£10,000 per QALY 0.97 0.45
£15,000 per QALY 1.00 0.90
£20,000 per QALY 1.00 0.97
£25,000 per QALY 1.00 0.99
£30,000 per QALY 1.00 1.00
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Re-estimating the cost per quality-adjusted life-year threshold
using 2008 expenditure data
The same methods of analysis can be applied to the econometric analysis of the 2008/9 expenditure
and 2008–10 mortality data (see 2008/9 expenditure data and mortality data for 2008/9/10 in Chapter 3 and
Analysis of programme budgeting expenditure for 2008/9 and mortality data for 2008/9/10 in Appendix 2).
The differences between the 2006 analysis reported above and the analysis of expenditure in 2008 reported
below (Table 157) are the (i) total PBC expenditure; (ii) estimated expenditure elasticities; (iii) estimated
outcome elasticities; (iv) observed PBC deaths by age and gender; and (v) LE by age and gender. The other
information about QoL norms (see Adjusting age-related quality-of-life for disease decrements), disease-related
decrements (see Summary of the cost per quality-adjusted life-year threshold based only on mortality effects)
and the information from GBD about incidence (by age and gender) and duration of disease (see Including
quality-of-life effects during disease) remain unchanged between 2006 and 2008.
It should be noted that important improvements were made to the classification and collection of PBC
expenditure data that took place after the 2006 data were collected. Therefore, the differences in
threshold estimates for 2006 and 2008 partly reflect this (see Chapter 3, Comparing the cost of life-year
estimates associated with different data sets and Comparing the cost of life-year estimates associated with
different data sets in Appendix 2) so should not be overinterpreted. The results of the analysis of 2007 and
2008 expenditure are comparable in this respect, providing insights into how the threshold might change
over time and with changes in the overall budget. For the purposes of this methodological research the
2008 expenditure and 2008–10 mortality data were the latest to be analysed.
From mortality to life-years
In this section we summarise the calculation of net YLL, which take account of the fact that some
of the observed deaths would have occurred anyway (had the same population not been at risk in the
particular PBC) when estimating YLL (unobserved counterfactual deaths). In summary, to obtain net YLL, all
observed deaths – both those that occur below and those that occur above LE (Table 158) – are taken into
account. Those deaths occurring below LE generate YLL and those that occur at ages above LE generate
YLG. By subtracting YLG from YLL to generate net YLL we take account of the fact that not all deaths
below LE are excess deaths but some deaths above LE are.
The estimates of net YLL calculated considering estimates of the LE for each PBC are detailed in Table 159.
The impact on the cost per life-year threshold is summarised in column (2) of Table 160, and a detailed
breakdown is shown in Table 161.
DOI: 10.3310/hta19140 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 14
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Claxton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
433
TABLE 157 Outcome and spend elasticities (2008)
PBC
(1) Total spend
2008/9 (£M)
Spend elasticities Change in spend (£M) (% share)
(7) Outcome
elasticitiesa(2) Unadjusted
(3) Analysis up to
Chapter 4, Using ratios
of quality-adjusted
life-years to years of life
lost (and Appendix 3)
(4) Analysis in
Chapter 4, Using
estimates of the
quality-adjusted
life-year burden
of disease
(and Appendix 3)
(5) Analysis up to
Chapter 4, Using ratios
of quality-adjusted
life-years to years of life
lost (and Appendix 3)
(6) Analysis in Chapter 4,
Using estimates of
the quality-adjusted
life-year burden of
disease (and Appendix 3)
2 Cancer 4843 0.525 0.525 0.724 25 (3.2) 35 (4.5) 0.307
10 Circulatory 6655 0.648 0.648 0.894 43 (5.5) 59 (7.6) 1.319
11 Respiratory 3994 0.652 0.652 0.900 26 (3.3) 36 (4.6) 1.808
13 Gastrointestinal 3989 0.456 0.456 0.629 18 (2.3) 25 (3.2) 1.364
All big four programmes 19,481 113 (14.4) 156 (19.8)
1 Infectious
diseases
1201 1.545 1.545 2.132 19 (2.4) 26 (3.3) 0.504
4 Endocrine 2222 0.484 0.484 0.668 11 (1.4) 15 (1.9) 1.170
7 Neurological 3466 0.980 0.980 1.352 34 (4.3) 47 (6) 0.417
17 Genitourinary 3779 0.697 0.697 0.962 26 (3.4) 36 (4.6) 1.615
16 Trauma and
injuries
3255 1.344 1.344 1.854 44 (5.6) 60 (7.7) –
18 + 19 Maternity and
neonates
3978 0.975 0.975 1.345 39 (4.9) 54 (6.8) 0.125
First 11 PBCs 37,382 285 (36.3) 393 (50.1)
3 Disorders of
blood
998 1.171 2.291 1.616 23 (2.9) 16 (2.1) –
5 Mental health 9794 1.036 2.027 1.429 198 (25.3) 140 (17.9) –
6 Learning
disability
2874 0.205 0.401 0.283 12 (1.5) 8 (1) –
8 Vision 1688 0.654 1.279 0.902 22 (2.8) 15 (1.9) –
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PBC
(1) Total spend
2008/9 (£M)
Spend elasticities Change in spend (£M) (% share)
(7) Outcome
elasticitiesa(2) Unadjusted
(3) Analysis up to
Chapter 4, Using ratios
of quality-adjusted
life-years to years of life
lost (and Appendix 3)
(4) Analysis in
Chapter 4, Using
estimates of the
quality-adjusted
life-year burden
of disease
(and Appendix 3)
(5) Analysis up to
Chapter 4, Using ratios
of quality-adjusted
life-years to years of life
lost (and Appendix 3)
(6) Analysis in Chapter 4,
Using estimates of
the quality-adjusted
life-year burden of
disease (and Appendix 3)
9 Hearing 417 1.191 2.330 1.643 10 (1.2) 7 (0.9) –
12 Dental 3198 0.513 1.003 0.708 32 (4.1) 23 (2.9) –
14 Skin 1657 0.674 1.318 0.930 22 (2.8) 15 (2) –
15 Musculoskeletal 4081 0.505 0.988 0.697 40 (5.1) 28 (3.6) –
20 Poisoning and
adverse events
938 0.562 1.099 0.775 10 (1.3) 7 (0.9) –
21 Healthy
individuals
1831 1.097 2.146 1.514 39 (5) 28 (3.5) –
22 Social care
needs
1874 0.911 1.782 1.257 33 (4.3) 24 (3) –
23 Other 11,666 0.494 0.494 0.682 58 (7.4) 80 (10.1) –
All 23 PBCs 78,398 784 (100) 784 (100)
a Without the negative sign.
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TABLE 158 Number of deaths above LE in 2008/9/10, by PBC
PBC
2008 2009 2010
(7) Annual
deaths < LE
(8) Annual
deaths > LE
(1)
< LE
(2)
> LE
(3)
< LE
(4)
> LE
(5)
< LE
(6)
> LE
1 Infectious
diseases
3406 2586 3044 2190 2667 1894 3039 2223
2 Cancer 94,873 37,029 94,276 37,151 94,309 38,198 94,486 37,459
4 Endocrine 4033 2877 3834 2826 3816 2902 3894 2868
7 Neurological 9638 6859 9445 6939 9951 7480 9678 7093
10 Circulatory 80,894 76,292 76,048 73,342 74,035 73,719 76,992 74,451
11 Respiratory 32,083 35,180 29,912 33,304 29,691 33,176 30,562 33,887
13 Gastrointestinal 15,945 8259 15,361 8161 15,595 8372 15,633 8264
17 Genitourinary 4471 6667 4378 6900 4453 7166 4434 6911
18+ 19 Maternity and
neonates
267 0 281 1 247 0 265 0
TABLE 159 Net YLL using LE for each PBC (2008)
PBC
(1) LE of
males
(2) LE of
females
Average 2006–8
(7) Net YLL
Deaths
(5) YLL (6) YLG(3) < LE (4) > LE
1 Infectious
diseases
79.6 83.6 2919 2344 53,926 15,132 38,794
2 Cancer 83.0 84.7 100,487 31,459 1,456,255 134,089 1,322,166
4 Endocrine 81.0 84.7 3945 2818 65,800 15,983 49,817
7 Neurological 79.6 83.3 9112 7659 137,791 47,722 90,069
10 Circulatory 83.0 86.5 89,434 62,009 1,049,459 278,421 771,038
11 Respiratory 80.3 84.0 29,828 34,621 306,838 229,403 77,434
13 Gastrointestinal 80.6 84.5 15,612 8286 271,395 46,141 225,254
17 Genitourinary 83.5 85.6 5058 6287 49,036 32,528 16,508
18+ 19 Maternity and
neonates
78.7 83.1 265 0 19,783 1 19,781
TABLE 160 Summary of cost per life-year threshold (2008)
PBC scenario (1) 2006 (2) 2008
All big four programmes £8080 £10,220
11 PBCs (with mortality) £15,628 £23,360
All 23 PBCs (zero health effects for remaining 12 PBCs) £57,497 £64,275
All 23 PBCs (non-zero health effects for remaining 12 PBCs, except GMS)a £17,663 £25,214
a In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal.
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The estimates of net YLL imply a number of excess deaths required to generate them in each PBC.
The implied excess deaths associated with net YLL are reported in Table 162.
The cost per excess death and the cost per PBC death averted are reported in Table 163, and a detailed
breakdown of changes in spend and excess or total deaths across PBCs is shown in Table 164. The cost
per PBC death averted is, of course, significantly lower than the cost per excess death as excess deaths are
only a proportion of total deaths (see Table 163).
TABLE 161 Breakdown of the cost per life-year threshold (2008)
PBC
(1) Change in
spend (£M)
Using LE of the PBC population
(2) Net YLL
(3) Change in
Net YLL
(4) Cost per
YLG (£)
2 Cancer 25 1,322,166 2131 11,931
10 Circulatory problems 43 771,038 6590 6544
11 Respiratory problems 26 77,434 913 28,528
13 Gastrointestinal problems 18 225,254 1401 12,983
All big four programmes 10,220
1 Infectious diseases 19 38,794 302 61,425
4 Endocrine problems 11 49,817 282 38,122
7 Neurological problems 34 90,069 368 92,282
17 Genitourinary problems 26 16,508 186 141,746
16 Trauma and injuries 44 N/A 0 N/A
18+ 19 Maternity and neonates 39 19,781 24 1,608,817
First 11 PBCs 23,360
3 Disorders of blood 23 979 23,360
5 Mental health disorders 198 8496 23,360
6 Learning disability 12 493 23,360
8 Problems of vision 22 924 23,360
9 Problems of hearing 10 416 23,360
12 Dental problems 32 1374 23,360
14 Skin 22 935 23,360
15 Musculoskeletal system 40 1726 23,360
20 Poisoning and adverse events 10 441 23,360
21 Healthy individuals 39 1682 23,360
22 Social care needs 33 1430 23,360
23 Other 58 0 N/A
All 23 PBCs 25,214
N/A, not applicable.
We have been unable to obtain a satisfactory outcome model for trauma and injuries and have assumed a zero
outcome elasticity.
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TABLE 162 Excess deaths implied by net YLL (2008)
PBC (1) Net YLL
(2) YLL per
observed death
(3)
Excess
deaths
(4)
Total
deaths
(5) % excess
deaths
1 Infectious diseases 38,794 13.4 2934 5262 56
2 Cancer 1,322,166 14.1 93,917 131,945 71
4 Endocrine 49,817 13.7 3663 6762 54
7 Neurological 90,069 13.6 6642 16,771 40
10 Circulatory 771,038 10.5 74,217 151,443 49
11 Respiratory 77,434 9.2 8432 64,449 13
13 Gastrointestinal 225,254 15.2 15,049 23,897 63
17 Genitourinary 16,508 8.3 1978 11,345 17
18+ 19 Maternity and neonates 19,781 74.1 265 265 100
Excess deaths are calculated for each gender by dividing net YLL by the YLL per death [column (3)= column (1)/column(2)].
TABLE 163 Summary of the cost per death averted threshold (2008)
PBC scenario
2006–8 2008–10
(1) Cost per
excess death
averted (£)
(2) Cost per
PBC death
averted (£)
(3) Cost per
excess death
averted (£)
(4) Cost per
PBC death
averted (£)
All big four programmes 91,129 32,864 115,234 46,692
11 PBCs (with mortality) 177,691 64,774 265,784 105,872
All 23 PBCs (zero health effects for remaining
12 PBCs)
653,744 238,310 731,301 291,305
All 23 PBCs (non-zero health effects for remaining
12 PBCs, except GMS)a
200,828 73,208 286,872 114,272
a In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal.
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TABLE 164 Breakdown of the cost per death averted threshold (2008)
PBC
(1) Change
in spend
(£M)
PBC deaths Excess deaths
(2) Total
PBC deaths
(3) Change
in PBC
deaths
(4) Cost per
PBC death
averted (£)
(5) Excess
deaths
(6) Change
in excess
deaths
(7) Cost per
excess death
averted (£)
2 Cancer 25 131,945 212.66 119,559 93,917 151.37 167,969
10 Circulatory
problems
43 151,443 1294.40 33,316 74,217 634.34 67,983
11 Respiratory
problems
26 64,449 759.74 34,276 8432 99.40 261,992
13 Gastrointestinal
problems
18 23,897 148.64 122,379 15,049 93.60 194,332
All big four programmes 46,692 0 115,234
1 Infectious
diseases
19 5262 40.97 452,858 2934 22.84 812,249
4 Endocrine
problems
11 6762 38.29 280,856 3663 20.74 518,533
7 Neurological
problems
34 16,771 68.54 495,603 6642 27.14 1,251,391
17 Genitourinary
problems
26 11,345 127.71 206,253 1978 22.27 1,182,744
16 Trauma and
injuries
44 N/A 0 N/A N/A 0 N/A
18+ 19 Maternity and
neonates
39 265 0.32 120,090,566 265 0.32 120,090,566
First 11 PBCs 105,872 265,784
3 Disorders of
blood
23 215.92 105,872 86.01 265,784
5 Mental health
disorders
198 1874.69 105,872 746.76 265,784
6 Learning
disability
12 108.86 105,872 43.36 265,784
8 Problems of
vision
22 203.97 105,872 81.25 265,784
9 Problems of
hearing
10 91.76 105,872 36.55 265,784
12 Dental problems 32 303.11 105,872 120.74 265,784
14 Skin 22 206.34 105,872 82.19 265,784
15 Musculoskeletal
system
40 380.77 105,872 151.68 265,784
20 Poisoning and
adverse events
10 97.40 105,872 38.80 265,784
21 Healthy
individuals
39 371.11 105,872 147.83 265,784
22 Social care
needs
33 315.43 105,872 125.65 265,784
23 Other 58 0 N/A 0 N/A
All 23 PBCs 114,272 286,872
N/A, not applicable.
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The number of YLGs associated with each excess death averted are reported for each PBC in Table 165
[see column (1)] and range from 74.6 years for PBC 18 + 19 to 8.3 years for PBC 17. On average, across
all 11 PBCs each excess death averted is associated with 11.4 YLGs. The life-years associated with each
observed death are reported for each PBC in Table 165, column (2) and range from 74.6 years in PBC
18 + 19 to 1.2 for PBC 11. On average, across all 11 PBCs each PBC death averted is associated with
4.5 YLGs.
Summary of cost per life-year estimates
The cost per life-year threshold in lines (1)–(4) in Table 166 are regarded as the central or best estimates
given the evidence available and the credibility of the alternative assumption that could be made. As
explained in the Introduction, these are based on the conservative assumption that any health effects of
changes in expenditure are restricted to 1 year, which, to some extent, may be offset by the more
optimistic assumption that any death averted returns the individual to the mortality risk faced by the
general population, matched for age and gender. See How uncertain are the estimates? for guidance in
the interpretation of the upper and lower bound estimates.
Adjusting life-years for quality-of-life
The central or best estimates of the cost per life-year threshold, presented in Table 166 [see lines (2) and
(4)] take no account of the health-related QoL in which years of life, expected to be gained or lost through
changes in expenditure, are likely to be lived. In this section we examine the ways in which the life-years
can be adjusted for quality, taking account of information that is available about (i) how QoL differs by age
and gender, and (ii) how the quality-of-life-years associated with mortality changes might be affected by
the types of diseases that make up each PBC.
TABLE 165 Implied YLL per death averted for each PBC (2008)
PBC
(1) Implied YLL per excess
death averted
(2) Implied YLL per PBC
death averted
2 Cancer 14.1 10.0
10 Circulatory problems 10.4 5.1
11 Respiratory problems 9.2 1.2
13 Gastrointestinal problems 15.0 9.4
All big four programmes 11.3 4.6
1 Infectious diseases 13.2 7.4
4 Endocrine problems 13.6 7.4
7 Neurological problems 13.6 5.4
17 Genitourinary problems 8.3 1.5
16 Trauma and injuries N/A N/A
18+ 19 Maternity and neonates 74.6 74.6
First 11 PBCs 11.4 4.5
N/A, not applicable.
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TABLE 166 Summary of the cost per life-year threshold with upper and lower bounds (2008)
PBC grouping (1) 2006–8 (2) 2008–10
Best estimate
Effect of expenditure on mortality 1 year 1 year
YLL per PBC death averted ∼ 4.1a ∼ 4.5a
(1) All big four programmes £8080 £10,220
(2) 11 PBCs (with mortality) £15,628 £23,360
(3) All 23 PBCs (zero health effects for remaining 12 PBCs) £57,497 £64,275
(4) All 23 PBCs (non-zero health effects for remaining 12 PBCs,
except GMS)b
£17,663 £25,214
Lower bound
Effect of expenditure on mortality Remainder of disease Remainder of disease
YLL per PBC death averted ∼ 4.1a ∼ 4.5a
(5) All big four programmes £3846 £5083
(6) 11 PBCs (with mortality) £6106 £8579
(7) All 23 PBCs (zero health effects for remaining 12 PBCs) £22,463 £23,605
(8) All 23 PBCs (non-zero health effects for remaining 12 PBCs,
except GMS)b
£6901 £9260
Upper bound
Effect of expenditure on mortality 1 year 1 year
YLL per PBC death averted 2 2
(9) All big four programmes £16,432 £23,346
(10) 11 PBCs (with mortality) £32,387 £52,936
(11) All 23 PBCs (zero health effects for remaining 12 PBCs) £119,155 £145,653
(12) All 23 PBCs (non-zero health effects for remaining 12 PBCs,
except GMS)b
£36,604 £57,136
a See Table 165.
b In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal.
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Quality of life based on the general population
Quality-of-life norms (see Figure 49) can be applied to the YLL associated with all observed deaths in each
PBC, taking account of gender and age at death. The results are reported in column (4)–(6) of Table 167.
The implications of the quality adjustment to a cost per QALY threshold that only accounts for the direct
health effects of mortality are summarised in Table 168, and detailed in Table 169.
Table 170 depicts the judgements over life-years, QoL weights and total QALYs implicit in calculations of
the threshold cost per QALY in Table 166.
TABLE 168 Summary of cost per QALY threshold based on population norms and mortality effects (2008)
PBC scenario
2006–8 2008–10
(1) Cost per life-year
threshold (£)
(2) Cost per QALY
threshold (£)
population norms
(3) Cost per life-year
threshold (£)
(4) Cost per QALY
threshold (£)
population norms
All big four
programmes
8080 9631 10,220 12,338
11 PBCs 15,628 18,622 23,360 28,045
All 23 PBCs 17,663 21,047 25,214 30,270
TABLE 167 Net YLL adjusted for QoL ‘norms’ (2008)
PBC
Unadjusted life-years QALYs
(1) YLL (2) YLG (3) Net YLL (4) YLG (5) YLL (6) Net YLG
1 Infectious diseases 53,926 15,132 38,794 43,703 10,187 33,516
2 Cancer 1,456,255 134,089 1,322,166 1,129,191 89,231 1,039,960
4 Endocrine 65,800 15,983 49,817 52,465 10,598 41,867
7 Neurological 137,791 47,722 90,069 110,532 32,262 78,270
10 Circulatory 1,049,459 278,421 771,038 807,893 183,796 624,097
11 Respiratory 306,838 229,403 77,434 237,981 154,300 83,680
13 Gastrointestinal 271,395 46,141 225,254 214,756 30,811 183,945
17 Genitourinary 49,036 32,528 16,508 37,178 21,190 15,989
18+ 19 Maternity and neonates 19,783 1 19,781 17,176 1 17,175
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TABLE 169 A breakdown of the cost per QALY threshold based on population norms (2008)
PBC (1) Change in spend (£M)
YLL using LE of PBC
(2) Change in QALY
(3) Cost per QALY
gained (£)
2 Cancer 25 1676 15,169
10 Circulatory problems 43 5334 8084
11 Respiratory problems 26 986 26,399
13 Gastrointestinal problems 18 1144 15,899
All big four programmes 12,338
1 Infectious diseases 19 261 71,098
4 Endocrine problems 11 237 45,361
7 Neurological problems 34 320 106,193
17 Genitourinary problems 26 180 146,347
16 Trauma and injuries 44 0 N/A
18+ 19 Maternity and neonates 39 21 1,852,926
First 11 PBCs 28,045
3 Disorders of blood 23 815 28,045
5 Mental health disorders 198 7077 28,045
6 Learning disability 12 411 28,045
8 Problems of vision 22 770 28,045
9 Problems of hearing 10 346 28,045
12 Dental problems 32 1144 28,045
14 Skin 22 779 28,045
15 Musculoskeletal system 40 1437 28,045
20 Poisoning and adverse effects 10 368 28,045
21 Healthy individuals 39 1401 28,045
22 Social care needs 33 1191 28,045
23 Other 58 0 N/A
All 23 PBCs 30,270
N/A, not applicable.
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Adjusting age-related quality-of-life for disease decrements
By using age-related QoL disease decrements (exemplified in Figure 50) YLL can be adjusted for QoL of
disease. The results are reported in columns (4)–(6) of Table 171.
The implications of the quality adjustment to a cost per QALY threshold that only accounts for the direct
health effects of mortality are summarised in Table 172, and detailed in Table 173.
Table 174 depicts the judgements over life-years, QoL weights and total QALYs implicit in calculations of
the threshold cost per QALY in Table 172.
TABLE 170 Implied YLL per excess death averted and implied QoL score per YLL gained, for each PBC (2008)
PBC
(1) Implied YLL
per excess
death averted
(2) Implied YLL
per PBC
death averted
(3) Implied QALYs
gained per excess
death averted
(4) Implied QALYs
gained per PBC
death averted
2 Cancer 14.08 10.02 11.07 7.88
10 Circulatory 10.39 5.09 8.41 4.12
11 Respiratory 9.18 1.20 9.92 1.30
13 Gastrointestinal 14.97 9.43 12.22 7.70
All big four programmes 11.28 4.57 9.34 3.78
1 Infectious diseases 13.22 7.37 11.42 6.37
4 Endocrine 13.60 7.37 11.43 6.19
7 Neurological 13.56 5.37 11.78 4.67
17 Genitourinary 8.34 1.46 8.08 1.41
16 Trauma and injuries N/A N/A N/A N/A
18+ 19 Maternity and neonates 74.65 74.65 64.81 64.81
First 11 PBCs 11.38 4.53 9.48 3.78
N/A, not applicable.
TABLE 171 Net YLL adjusted for disease and age-related QoL (2008)
PBC
Unadjusted life-years QALYs
(1) YLL (2) YLG (3) Net YLL (4) YLG (5) YLL (6) Net YLG
1 Infectious diseases 53,926 15,132 38,794 34,108 7524 26,584
2 Cancer 1,456,255 134,089 1,322,166 943,650 72,197 871,452
4 Endocrine 65,800 15,983 49,817 43,063 8334 34,729
7 Neurological 137,791 47,722 90,069 69,520 18,084 51,436
10 Circulatory 1,049,459 278,421 771,038 625,150 135,622 489,527
11 Respiratory 306,838 229,403 77,434 173,953 106,200 67,754
13 Gastrointestinal 271,395 46,141 225,254 162,441 22,060 140,380
17 Genitourinary 49,036 32,528 16,508 30,770 16,949 13,820
18+ 19 Maternity and neonates 19,783 1 19,781 16,100 1 16,099
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TABLE 172 Summary of cost per QALY threshold based on disease- and age-related QoL and mortality effects (2008)
PBC scenario
2006 2008
(1) Cost per
life-year
threshold (£)
(2) Cost per QALY
threshold (£)
disease-related
disutility
(3) Cost per
life-year
threshold (£)
(4) Cost per QALY
threshold (£)
disease-related
disutility
All big four programmes 8080 12,109 10,220 15,534
11 PBCs (with mortality) 15,628 23,395 23,360 35,397
All 23 PBCs (zero health effects
for remaining 12 PBCs)
57,497 86,072 64,275 97,395
All 23 PBCs (non-zero health effects
for remaining 12 PBCs, except GMS)a
17,663 26,441 25,214 38,206
a In PBCs without a mortality signal, health effects were estimated by valuing changes in expenditure at the same rate as
observed in PBCs for which there was a mortality signal, except GMS.
TABLE 173 A breakdown of the cost per QALY threshold based on disease- and age-related QoL and mortality
effects (2008)
PBC
(1) Change in
spend (£M)
YLL using LE of PBC
(2) Change in QALY (3) Cost per QALY gained (£)
2 Cancer 25 1405 18,102
10 Circulatory problems 43 4184 10,307
11 Respiratory problems 26 799 32,604
13 Gastrointestinal problems 18 873 20,833
All big four programmes 15,534
1 Infectious diseases 19 207 89,638
4 Endocrine problems 11 197 54,685
7 Neurological problems 34 210 161,594
17 Genitourinary problems 26 156 169,315
16 Trauma and injuries 44 0 N/A
18+ 19 Maternity and neonates 39 20 1,976,769
First 11 PBCs 35,397
3 Disorders of blood 23 646 35,397
5 Mental health disorders 198 5607 35,397
6 Learning disability 12 326 35,397
8 Problems of vision 22 610 35,397
9 Problems of hearing 10 274 35,397
12 Dental problems 32 907 35,397
14 Skin 22 617 35,397
15 Musculoskeletal system 40 1139 35,397
20 Poisoning and adverse effects 10 291 35,397
21 Healthy individuals 39 1110 35,397
22 Social care needs 33 943 35,397
23 Other 58 0 N/A
All 23 PBCs 38,206
N/A, not applicable.
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Summary of the cost per quality-adjusted life-year threshold based only on
mortality effects
The analysis to this point is summarised in Table 175. The three estimates of a cost per QALY threshold are
based on assuming that each YLG is either lived in full health [see Table 175, column (1)]; lived in a QoL
that reflects age and gender norms of the general population [see Table 175, column (2)]; or lived in a
QoL that reflects the original disease state [see Table 175, column (3)].
Including quality-of-life effects during disease
In this section we explore how estimates of effects of expenditure that can be observed (i.e. on mortality)
can be used to infer the likely effects on what cannot be directly observed (QoL), rather than making
extreme assumptions that are not credible (e.g. assuming that changes in expenditure will have no effects
on QoL outcomes). In Using estimates of the quality-adjusted life-year burden of disease, we described the
use of ratios of QALYs lost to life-years lost due to disease and explored how the use of the QALY burden
of disease is preferable to inform estimates of the threshold. Here we only present the results for the QALY
burden of disease approach.
TABLE 174 Implied YLL per excess death averted and implied QoL score per YLL gained, for each PBC (2008)
PBC
(1) Implied YLL
per excess
death averted
(2) Implied YLL
per PBC
death averted
(3) Implied QALYs
gained per excess
death averted
(4) Implied QALYs
gained per PBC
death averted
2 Cancer 14.08 10.02 9.28 6.60
10 Circulatory 10.39 5.09 6.60 3.23
11 Respiratory 9.18 1.20 8.04 1.05
13 Gastrointestinal 14.97 9.43 9.33 5.87
All big four programmes 11.28 1.80 7.42 3.01
1 Infectious
diseases
13.22 7.37 9.06 5.05
4 Endocrine 13.60 7.37 9.48 5.14
7 Neurological 13.56 5.37 7.74 3.07
17 Genitourinary 8.34 1.46 6.99 1.22
16 Trauma and
injuries
N/A N/A N/A N/A
18+ 19 Maternity and
neonates
74.65 74.65 60.75 60.75
First 11 PBCs 11.38 4.53 6.77 2.99
N/A, not applicable.
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In Table 176, deaths and YLL from ONS (2008–10 mortality data) are compared with those from GBD.
The factors used to adjust GBD information are reported in columns (4) and (7).
The threshold cost per QALY based on burden associated with 1 year of disease derived from GBD are
summarised in Table 177, and detailed in Table 178.
Summary of the cost per quality-adjusted life-year threshold
The results of the three sequential steps of analysis are summarised in Table 179, for this year of analysis.
They include (i) the cost per life-year [see Table 179, column (1)] based on the methods of analysis outlined
in From mortality to life-years; (ii) the cost per life-year adjusted for QoL [see Table 179, column (2)] based
on the methods of analysis outlined in Adjusting life-years for quality-of-life; and (iii) the cost per QALY
[see Table 179, column (3)] based on the methods of analysis outlined in Including quality-of-life effects
during disease. These estimates, in Table 179, column (3), take account of the likely effects of changes in
expenditure on QoL during disease as well as the effects associated with mortality and life-years; making
best use of available information, while the assumptions required appear more reasonable than the other
alternatives available. For this reason these estimates remain our central or best estimates for all the waves
of expenditure and mortality data.
TABLE 175 Summary of QALY threshold estimates based only on mortality effects (2008)
PBC scenario (1) QoL score= 1 (2) QoL norm (3) QoL diseased
Best estimate
Effect of expenditure on mortality 1 year 1 year 1 year
YLL per death averteda ∼ 4.5 ∼ 4.5 ∼ 4.5
QALYs per death averteda ∼ 4.5 ∼ 3.8 ∼ 3.0
(1) All big four programmes £10,220 £12,338 £15,534
(2) 11 PBCs £23,360 £28,045 £35,397
(3) All 23 PBCs £25,214 £30,270 £38,206
Lower bound
Effect of expenditure on mortality Remainder of disease Remainder of disease Remainder of disease
YLL per death averteda ∼ 4.5 ∼ 4.5 ∼ 4.5
QALYs per death averteda ∼ 4.5 ∼ 3.8 ∼ 3.0
(4) All big four programmes £5083 £5811 £7305
(5) 11 PBCs £8579 £9861 £12,720
(6) All 23 PBCs £9260 £10,644 £13,729
Upper bound
Effect of expenditure on mortality 1 year 1 year 1 year
YLL per death averteda 2 2 2
QALYs per death averteda ∼ 2 ∼ 1.8 ∼ 1.4
(7) All big four programmes £23,346 £26,138 £32,797
(8) 11 PBCs £52,936 £59,151 £74,183
(9) All 23 PBCs £57,136 £63,844 £80,069
a See Table 174.
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TABLE 176 Comparing deaths and YLL from ONS and GBD (2008)
PBC
(1) Excess
deaths
ONS
Deaths YLL
(2) All
deaths
ONS
(3) All
deaths
GBD
(4) Adjustment
factor (deaths)
(5) Net
estimates
ONS
(6) Total
YLLGBD
(7) Adjustment
factor (YLL)
1 Infectious
diseases
2934 5262 1408 3.737 38,794 25,142 1.543
2 Cancer 93,917 131,946 140,124 0.942 1,322,166 1,932,637 0.684
4 Endocrine 3663 6762 7509 0.901 49,817 95,401 0.522
7 Neurological 6642 16,771 12,854 1.305 90,069 164,796 0.547
10 Circulatory 74,217 151,443 178,454 0.849 771,038 1,750,608 0.440
11 Respiratory 8432 64,449 67,441 0.956 77,434 594,529 0.130
13 Gastrointestinal 15,049 23,897 28,329 0.844 225,254 396,829 0.568
17 Genitourinary 1978 11,345 8606 1.318 16,508 77,338 0.213
18+ 19 Maternity and
neonates
265 265 2211 0.120 19,781 149,868 0.132
Total 207,097 412,140 446,936 0.92 2,610,861 5,187,148 0.500
TABLE 177 Summary of the cost per QALY threshold (2008)
PBC scenario (1) 2006 (2) 2008
All big four programmes £3036 £4872
11 PBCs (with mortality) £5128 £8308
All 23 PBCs £10,187 £12,936
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TABLE 178 Breakdown of the cost per QALY threshold (2008)
PBC
(1) Change in
spend (£M)
QALY burden (HODaR and MEPS)
(2) Change in
QALY
(3) Cost per QALY
gained (£)
2 Cancer 35 2064 16997
10 Circulatory problems 59 8453 7038
11 Respiratory problems 36 17,981 1998
13 Gastrointestinal problems 25 3441 7293
All big four programmes 4872
1 Infectious diseases 26 1229 20,829
4 Endocrine problems 15 4749 3124
7 Neurological problems 47 8551 5480
17 Genitourinary problems 36 829 43,813
16 Trauma and injuries 60 0 N/A
18+ 19 Maternity and neonates 54 18 2,969,208
First 11 PBCs 8308
3 Disorders of blood 16 1712 9419
5 Mental health disorders 140 7469 18,744
6 Learning disability 8 54 149,883
8 Problems of vision 15 333 45,788
9 Problems of hearing 7 1098 6239
12 Dental problems 23 533 42,472
14 Skin 15 152 101,042
15 Musculoskeletal system 28 1819 15,628
20 Poisoning and adverse effects 7 64 113,546
21 Healthy individuals 28 53 526,771
22 Social care needs 24 N/A
23 Other 80 N/A
All 23 PBCs 12,936
N/A, not applicable.
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Which programme budget categories matter most?
The estimate of £8308 per QALY [see Table 179, line (2)] is restricted to the effects of changes in
expenditure in the 11 PBCs where outcome elasticities can be estimated. However, these PBCs only
account for a proportion of a change in overall expenditure (approximately 50%, Table 180). As was
explained in Including quality-of-life effects during disease the QALY threshold of £12,936 [see Table 179,
column (3), line (3)] uses the estimated proportionate effects of expenditure on the QALY burden of
disease in the 11 PBCs as a surrogate for proportionate effects in the others (i.e. assuming that the effects
that can be observed will be similar to those that cannot), and represents our central or best estimate.
As in previous sections, no health effects are assigned to PBC 23 or 22 (GMS and social care) on the basis
that any health effects of this expenditure would be recorded in the other PBCs. Although this estimate
of £12,936 reflects changes in undiscounted QALYs associated with changes in expenditure, discounting
the QALY effects only increases the cost per QALY threshold to £13,141 (Table 181). The effects of
discounting are modest because (i) the health effects of a change in expenditure are restricted to 1 year
(where no discounting is necessary); (ii) most of the total QALY effects occur in that year; (iii) it is only
some of the life-year effects (adjusted for quality) of a change in mortality in that year that occur in future
years that need to be discounted; and (iv) these need to be discounted only over 4.5 years on average.
TABLE 179 Summary of cost per QALY threshold estimates (2008)
PBC scenario
(1) Chapter 4, From
mortality to
life-years analysis
(2) Chapter 4, Adjusting
life-years for quality of
life analysis
(3) Chapter 4, Including
quality-of-life effects
during disease analysis
QoL associated with life extension 1 Norm
QoL during disease 0 0 Based on burden
Best estimate
Effect of expenditure on mortality 1 year 1 year 1 year
YLL per death averted ∼ 4.5 ∼ 4.5 ∼ 4.5
QALYs per death averted ∼ 4.5 ∼ 3.8 ∼ 15.0
(1) All big four programmes £10,220 £12,338 £4872
(2) 11 PBCs (with mortality) £23,360 £28,045 £8308
(3) All 23 PBCs £25,214 £30,270 £12,936
Lower bound
Effect of expenditure on mortality Remainder of
disease duration
Remainder of
disease duration
Remainder of
disease duration
YLL per death averted ∼ 4.5 ∼ 4.5 ∼ 4.5
QALYs per death averted ∼ 4.5 ∼ 3.8 ∼ 15.0
(4) All big four programmes £5083 £5811 £1194
(5) 11 PBCs (with mortality) £8579 £9861 £1175
(6) All 23 PBCs £9260 £10,644 £2018
Upper bound
Effect of expenditure on mortality 1 year 1 year 1 year
YLL per death averted 2 2 2
QALYs per death averted ∼ 2 ∼ 1.4 ∼ 6.6
(7) All big four programmes £23,346 £26,138 £11,040
(8) 11 PBCs (with mortality) £52,936 £59,151 £18,827
(9) All 23 PBCs £57,136 £63,844 £29,314
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TABLE 180 Impact of each PBC on the overall cost per QALY threshold (2008)
PBC
(1) % share of change
in overall expenditure
(2) % share of total
health effects (QALY)
(3) Elasticity of
the thresholda
(4) PBC cost
per QALY (£)
2 Cancer 4.47 3.41 0.34 16,997
10 Circulatory 7.59 13.95 1.40 7038
11 Respiratory 4.58 29.67 2.97 1998
13 Gastrointestinal 3.20 5.68 0.57 7293
1 Infectious diseases 3.27 2.03 0.20 20,829
4 Endocrine 1.89 7.84 0.78 3124
7 Neurological 5.98 14.11 1.41 5480
17 Genitourinary 4.64 1.37 0.14 43,813
16 Trauma and
injuries
7.70 0.00 0.00 N/A
18+ 19 Maternity and
neonates
6.83 0.03 < 0.01 2,969,208
3 Disorders of blood 2.06 2.82 0.28 9419
5 Mental health 17.86 12.32 1.23 18,744
6 Learning disability 1.04 0.09 0.01 149,883
8 Problems of vision 1.94 0.55 0.05 45,788
9 Problems of
hearing
0.87 1.81 0.18 6239
12 Dental problems 2.89 0.88 0.09 42,472
14 Skin 1.97 0.25 0.03 101,042
15 Musculoskeletal 3.63 3.00 0.30 15,628
20 Poisoning and
adverse events
0.93 0.11 0.01 113,546
21 Healthy individuals 3.53 0.09 0.01 526,771
22 Social care needs 3.00 0.00 0.00 N/A
23 Other 10.14 0.00 0.00 N/A
N/A, not applicable.
a Calculated using the effect on the threshold of a 10% increase (or decrease) in QALY change of the PBC.
TABLE 181 Summary of QALY threshold, discounted (2008)
PBC scenario 2008–10 (£) discounted, best estimate
(1) All big four programmes 4998
(2) 11 PBCs 8467
(3) All 23 PBCs 13,141
Only quality adjusted net YLL were discounted, and thus QALYs associated with gains in QoL during disease were not. The
discounting factor has been calculated by applying a 3.5% discount rate to each year of life lost in the PBCs – the estimate
of YLL used was the implied YLL per death averted in each PBC [in column (2) of Table 165]. This discounting factor was
applied to net YLL before applying the outcome elasticity to calculate YLL averted.
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The upper and lower bounds for the cost per QALY thresholds in column (3) are based on making the
necessary assumptions about duration of health effects and how long a death might be averted optimistic
(providing the lower bound for the threshold) or conservative (an upper bound for the threshold).
The lower bound [see Table 179, lines (4)–(6)] is based on assuming that health effects are not restricted
to 1 year but apply to the whole of the remaining disease duration of the population at risk in PBCs during
1 year. Although this combines optimistic assumptions, it is possible that at least some part of a change in
expenditure may prevent disease so will have an impact on populations that are incident to PBCs in the
future. Such effects are not captured in any of the estimates presented in this report so all are conservative
in this respect. The upper bound [see Table 179, lines (7)–(9)] is based on the combination of assuming
that health effects are restricted to 1 year for the population currently at risk and that any death averted is
only averted for 2 years (see Summary of cost per life-year estimates).
The estimated QALY effects associated with each PBC can be decomposed into that part due to life-year
effects adjusted for quality and that part associated with effects on quality during disease (Table 182).
Those PBCs for which mortality is the major concern have a much greater share of total QALY effects
associated with avoidance of premature death (e.g. PBCs 2 and 10) compared with those where QoL is the
major concern (e.g. PBC 7).
TABLE 182 Decomposing estimated QALY effects by PBC (2008)
PBC
(1) QALY
change (total)
(2) QALY
change (death)
% QALY gained
(3) For premature
death
(4) For disability
while alive
2 Cancer 2064 1912 93 7
10 Circulatory 8453 5778 68 32
11 Respiratory 17,981 789 4 96
13 Gastrointestinal 3441 1268 3 63
1 Infectious diseases 1229 282 23 77
4 Endocrine 4749 254 5 95
7 Neurological 8551 335 4 96
17 Genitourinary 829 162 20 80
16 Trauma and injuries 0 0 N/A N/A
18+ 19 Maternity and neonates 18 12 69 31
3 Disorders of blood 1712 88 5 95
5 Mental health 7469 652 9 91
6 Learning disability 54 11 20 80
8 Problems of vision 333 13 4 96
9 Problems of hearing 1098 8 1 99
12 Dental problems 533 1 0 100
14 Skin 152 56 37 63
15 Musculoskeletal 1819 90 5 95
20 Poisoning and adverse events 64 10 16 84
21 Healthy individuals 53 8 16 84
22 Social care needs 0 0 N/A N/A
23 Other 0 0 N/A N/A
N/A, not applicable.
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How uncertain are the estimates?
In the earlier section How uncertain are the estimates? (pp. 432), the impact of uncertainty over the spend
and outcome elasticities on estimates of the cost per QALY threshold has been illustrated and interpreted
in detail using expenditure data from 2006/7. Here we repeat this analysis using expenditure data from
2008/9 and mortality data from 2008–10 (Table 183). Figure 53 shows the histogram of threshold values
from the Monte Carlo simulation (where each random sample from the simulation represents one possible
realisation of the overall threshold), and Figure 54 shows the cumulative probability density function for a
cost per QALY threshold based on the 11 PBCs with estimated outcome elasticities and for all 23 PBCs.
TABLE 183 Uncertainty over the QALY threshold (2008)
Scenario (1) 11 PBCs (2) All 23 PBCs
Best estimate (deterministic) £8308 £12,936
Mean estimate (from the simulations) £8330 £13,050
Threshold value at the probability of (from the simulations)
2.5% £5176 £8141
5.0% £5438 £8760
50.0% £8346 £13,084
95.0% £17,452 £25,505
97.5% £21,693 £32,173
Probability (from the simulations) of the threshold being smaller than
£5000 per QALY 2% 0%
£6000 per QALY 10% 0%
£7000 per QALY 25% 0%
£8000 per QALY 45% 2%
£9000 per QALY 59% 6%
£10,000 per QALY 71% 13%
£15,000 per QALY 93% 68%
£20,000 per QALY 97% 89%
£25,000 per QALY 98% 95%
£30,000 per QALY 99% 97%
£35,000 per QALY 99% 98%
£40,000 per QALY 99% 99%
£45,000 per QALY 99% 99%
£50,000 per QALY 99% 99%
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FIGURE 53 Histogram of simulation of undiscounted threshold (all 23 PBCs) (2008).
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FIGURE 54 Cumulative probability density function for the cost per QALY threshold (2008).
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Re-estimating the cost per quality-adjusted life-year threshold
using 2007 expenditure data
The same methods of analysis were applied to the econometric analysis of the 2007/8 expenditure and
2007–9 mortality data (see Analysis of programme budgeting expenditure for 2007/8 and mortality data
for 2007/8/9 in Appendix 2). Given the detailed reporting of the methods and interpretation of the
analyses for other expenditure years (see Analysis of 2006/7 expenditure and 2006–8 mortality data and
Re-estimating the cost per quality-adjusted life-year threshold using 2008 expenditure data), we will here
only present the necessary tables of results (Tables 184–192).
TABLE 184 Outcome and spend elasticities (2007)
PBC
(1) Total spend
2007/8 (£)
Spend elasticities
(4) Outcome elasticitiesa(2) Unadjusted (3) Adjusted
2 Cancer 4573 0.890 0.890 0.365
10 Circulatory problems 6325 0.293 0.293 1.277
11 Respiratory problems 3431 0.536 0.536 2.205
13 Gastrointestinal problems 3805 0.622 0.622 1.328
All big four programmes 18,134
1 Infectious diseases 1119 1.436 1.436 0.548
4 Endocrine problems 1997 0.264 0.264 0.566
7 Neurological problems 3165 1.035 1.035 0.339
17 Genitourinary problems 3439 1.004 1.004 1.855
16 Trauma and injuries 2918 1.686 1.686 0.369b
18+ 19 Maternity and neonates 3662 0.514 0.514 0.110
First 11 PBCs 34,434
3 Disorders of blood 986 1.830 2.879 –
5 Mental health disorders 9171 1.145 1.801 –
6 Learning disability 2748 0.440 0.692 –
8 Vision 1556 1.170 1.841 –
9 Hearing 409 1.029 1.619 –
12 Dental problems 3014 0.424 0.667 –
14 Problems of the skin 1542 0.428 0.673 –
15 Musculoskeletal system 3848 0.806 1.268 –
20 Poisoning and adverse
events
803 0.668 1.051 –
21 Healthy individuals 1594 0.986 1.551 –
22 Social care needs 1789 1.852 2.913 –
23 Other 11,763 0.563 0.563 –
All 23 PBCs 73,656
a Without the negative sign.
b Estimated 0.369 but not used in the threshold calculations for consistency with other years of analysis.
DOI: 10.3310/hta19140 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 14
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Claxton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
455
TABLE 185 Number of deaths above LE in 2007/8/9, by PBC
PBC
2007 2008 2009
Annual
deaths < LE
Annual
deaths > LE< LE > LE < LE > LE < LE > LE
1 Infectious diseases 3906 3731 3404 2588 3042 2192 3451 2837
2 Cancer 95,385 35,401 94,814 37,088 94,218 37,209 94,806 36,566
4 Endocrine 3970 2747 4031 2879 3832 2828 3944 2818
7 Neurological 8852 6494 9632 6865 9439 6945 9308 6768
10 Circulatory 80,687 78,404 80,834 76,352 75,993 73,397 79,172 76,051
11 Respiratory 29,571 35,029 32,059 35,204 29,890 33,326 30,507 34,520
13 Gastrointestinal 15,667 8367 15,937 8267 15,354 8168 15,653 8267
17 Genitourinary 4077 6553 4468 6670 4375 6903 4307 6709
18+ 19 Maternity and
neonates
216 0 267 0 281 1 255 0
TABLE 186 Net YLL using LE of the PBC (2007)
PBC
LE of
males
(years)
LE of
females
(years)
Average 2007–9
Net YLL
Deaths
YLL YLG< LE > LE
1 Infectious diseases 79.6 83.6 3280 3008 57,715 19,085 38,629
2 Cancer 83.0 84.7 100,810 30,561 1,464,726 129,810 1,334,916
4 Endocrine 81.0 84.7 4004 2759 66,575 15,386 51,189
7 Neurological 79.6 83.3 8719 7357 135,760 44,925 90,835
10 Circulatory 83.0 86.5 92,729 62,494 1,069,632 276,368 793,264
11 Respiratory 80.3 84.0 29,668 35,359 304,168 230,245 73,922
13 Gastrointestinal 80.6 84.5 15,640 8280 271,092 45,500 225,593
17 Genitourinary 83.5 85.6 5008 6007 47,656 30,931 16,725
18+ 19 Maternity and
neonates
78.7 83.1 255 0 18,844 1 18,843
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TABLE 187 Comparing deaths and YLL from ONS and GBD (2007)
PBC
Excess
deaths
ONS
Deaths YLL
All
deaths
ONS
All
deaths
GBD
Adjustment
factor
(deaths)
Net
estimates
ONS
Total
YLL GBD
Adjustment
factor (YLL)
1 Infectious
diseases
2925 6288 1408 4.47 38,629 25,142 1.54
2 Cancer 94,827 131,372 140,124 0.94 1,334,916 1,932,637 0.69
4 Endocrine 3765 6762 7509 0.90 51,189 95,401 0.54
7 Neurological 6692 16,076 12,854 1.25 90,835 164,796 0.55
10 Circulatory 76,322 155,223 178,454 0.87 793,264 1,750,608 0.45
11 Respiratory 8034 65,027 67,441 0.96 73,922 594,529 0.12
13 Gastrointestinal 15,064 23,920 28,329 0.84 225,593 396,829 0.57
17 Genitourinary 2005 11,016 8606 1.28 16,725 77,338 0.22
18+ 19 Maternity and
neonates
255 255 2211 0.12 18,843 149,868 0.13
Total 209,890 415,939 446,936 0.93 2,643,916 5,187,148 0.51
TABLE 188 Summary of the cost per QALY threshold (2007)
PBC scenario (1) 2006 (2) 2007 (3) 2008
All big four programmes £3036 £4549 £4872
11 PBCs (with mortality) £5128 £8513 £8308
All 23 PBCs £10,187 £13,554 £12,936
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TABLE 189 Breakdown of the cost per QALY threshold (2007)
PBC
(1) Change in
spend (£M)
QALY burden (HODaR and MEPS)
(2) Change in
QALY
(3) Cost per QALY
gained (£)
2 Cancer 51 3820 13,384
10 Circulatory problems 23 3462 6724
11 Respiratory problems 23 16,522 1398
13 Gastrointestinal problems 30 4166 7137
All big four programmes 4549
1 Infectious diseases 20 1300 15,530
4 Endocrine problems 7 1143 5796
7 Neurological problems 41 6421 6409
17 Genitourinary problems 43 1224 35,449
16 Trauma and injuries 62
18+ 19 Maternity and neonates 24 7 3,250,386
First 11 PBCs 8513
3 Disorders of blood 23 2695 8407
5 Mental health disorders 132 8316 15,863
6 Learning disability 15 117 129,512
8 Problems of vision 23 600 38,140
9 Problems of hearing 5 956 5534
12 Dental problems 16 444 36,177
14 Skin 8 98 84,977
15 Musculoskeletal system 39 2926 13,319
20 Poisoning and adverse effects 7 77 87,852
21 Healthy individuals 20 48 414,420
22 Social care needs 42 N/A
23 Other 83 N/A
All 23 PBCs 13,554
N/A, not applicable.
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TABLE 190 Decomposing estimated QALY effects by PBC (2007)
PBC
(1) QALY
change (total)
(2) QALY
change (death)
% QALY gained
(3) For premature
death
(4) For disability
while alive
2 Cancer 3820 3542 93 7
10 Circulatory 3462 2369 68 32
11 Respiratory 16,522 687 4 96
13 Gastrointestinal 4166 1536 37 63
1 Infectious diseases 1300 258 20 80
4 Endocrine 1143 63 5 95
7 Neurological 6421 264 4 96
17 Genitourinary 1224 247 20 80
16 Trauma and injuries 0 0 N/A N/A
18+ 19 Maternity and neonates 7 5 69 31
3 Disorders of blood 2695 139 5 95
5 Mental health 8316 726 9 91
6 Learning disability 117 23 20 80
8 Problems of vision 600 24 4 96
9 Problems of hearing 956 7 1 99
12 Dental problems 444 0 0 100
14 Skin 98 36 37 63
15 Musculoskeletal 2926 145 5 95
20 Poisoning and adverse events 77 12 16 84
21 Healthy individuals 48 7 16 84
22 Social care needs 0 0 N/A N/A
23 Other 0 0 N/A N/A
N/A, not applicable.
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Summary of the cost per quality-adjusted life-year threshold
TABLE 192 Summary of QALY threshold, discounted (2007)
PBC scenario (1) 2007–9
(1) All big four programmes £4690
(2) 11 PBCs £8718
(3) All 23 PBCs £13,801
TABLE 191 Summary of cost per QALY threshold estimates (2007)
PBC scenario Cost per QALY
QoL associated with life extension Based on burden
QoL during disease Based on burden
Best estimate
Effect of expenditure on mortality 1 year
YLL per death averted ∼ 4.8
QALYs per death averted ∼ 16.8
(1) All big four programmes £4549
(2) 11 PBCs (with mortality) £8513
(3) All 23 PBCs £13,554
Lower bound
Effect of expenditure on mortality Remainder of disease duration
YLL per death averted ∼ 4.8
QALYs per death averted ∼ 16.8
(4) All big four programmes £1116
(5) 11 PBCs (with mortality) £1361
(6) All 23 PBCs £2436
Upper bound
Effect of expenditure on mortality: 1 year
YLL per death averted: 2
QALYs per death averted: ∼ 7.0
(7) All big four programmes £10,965
(8) 11 PBCs (with mortality) £20,517
(9) All 23 PBCs £32,670
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Addendum 1: data sources
General Practice Research Database
General Practice Research Database contains over 3 million active patient records drawn from
approximately 400 primary care practices in the UK. The Medicines and Healthcare products Regulatory
Agency manages the data set. The database has clinical and prescription data and can provide information
to support pharmacovigilance (indication, utilisation and risk/benefit profiles of drugs) and formal
pharmacoepidemiological studies, including information on demographics, medical symptoms, therapy
(medicines, vaccines, devices) and treatment outcomes.
As of 29 March 2012 GPRD changed to the CPRD, an expanded data set that represents ‘The All England
Data and Interventional Research Service’. CPRD was approached to provide information on the prevalence
of disease by ICD-10 disease code. A sample set of data was analysed by researchers at Pharmatelligence
x
who were tasked with extracting data on prevalence of each disease state by ICD-10 code.
We were provided with access to data comprising of 22,313,086 rows/patient–ICD10 events (three digit)
y
representing 4,229,910 patients with data on new diagnosis of diseases observed between 1 January 2006
and 24 June 2011. Multiple events per patient are thus possible, and all patients are active in the data set
(i.e. patients had at least one new diagnosis in the period of interest). Newly diagnosed (incident) events
were defined using a wash-in period of 24 months (or from registration to index date if lower than
24 months). The sample contains 1873 unique ICD-10 codes in the data set. Seventy ICD-10 codes
account for 50% of the total number of events, 166 for 75% and 306 for 90%.
Diagnoses are collected in CPRD using Read codes. These were mapped into three-character ICD-10 codes.
Cross-mappings from Read V2 and Read V3 to ICD-10 were used in order to maximize the number of
CPRD Read and ICD-10 codes included (33.2% of Read codes; 99.7% of ICD-10 codes).
z
Unfortunately, due to the short collection period of CPRD it was not possible to directly observe
prevalence only incidence over a period. Attempts were made to elicit a prevalence estimate through
observed incidence data from CPRD coupled with clinical expertise on expected disease duration (provided
by Dr Charlotte Haylock, York Teaching Hospital NHS Foundation Trust). Our approach classified expected
duration for all ICD-10 diseases by three-digit code into one of five duration ‘buckets’.aa However, the
limitations of the data were deemed too extensive to provide sufficient accuracy of estimates to represent a
stronger estimate of prevalence than provided by GBD.
Global Burden of Disease
The WHO GBD project draws on a wide range of data sources to quantify global and regional effects of
diseases, injuries and risk factors on population health. We were provided with access to the beta version
of the WHO’s National Burden of Disease toolkit for the UK which represents a set of metrics on WHO
prior estimates of mortality and burden of disease for WHO member states for 2004 (based on the GBD:
2004 update155).ab
The metrics of interest to our analysis included disease incidence, prevalence, duration and mortality. These
metrics were provided by U-codes which were mapped to ICD-10 codes using direct WHO mapping
algorithms.157 In addition, in many cases each U-code was subdivided by disease sequelae which represent
disease subcategories of each U-code.157 As an individual may be represented in multiple sequelae in a
single U-code to avoid double counting in the event of multiple sequelae in a given U-code our analysis
uses prevalence estimates based on the sequelae with the largest prevalent population.
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Our analysis uses two forms of prevalence data, ‘point prevalence’ and ‘annual prevalence’. ‘Point
prevalence’ represents the instantaneous prevalence of a disease whereas ‘annual prevalence’ represents
the extent of the prevalence population over a given year. To calculate ‘annual prevalence’ incidence of a
disease was multiplied by expected disease duration rounded up to the nearest year.
All data was provided by age, given for both genders in fixed age buckets (either 8 or 19 buckets
depending on the data of interest), as a result it was necessary to assume the relevant population could be
represented by the mid-point of that bucket for the relevant metric.
Health Survey for England
The HSE comprises a series of annual surveys beginning in 1991. This survey is now commissioned and
published by The NHS IC. It is designed to provide regular information on various aspects of the nation’s
health. All surveys have covered the adult population aged 16 years and over living in private households
in England.ac
In order to define the QoL norms for the population of the UK required for the analysis detailed in
Chapter 4, Quality of life based on the general population, data from six Health Surveys for England
(1996, 2003, 2004, 2005, 2006 and 2008) were pooled. Self-reported health status and EQ-5D data were
extracted and used to generate mean health state utility values for the ‘normal’ population.
Surveys are not completed for people age under 16 years; as a result we have assumed that all persons
aged 0–15 years have the same QoL norms as a person aged 16 years. In addition the number of surveys
recorded for persons over 91 years of age is relatively small; as a result all persons aged over 91 years are
assumed to have the same QoL norm as a person aged 91 years. The QoL norms for each age and gender
are shown in Figure 3 in Quality of life based on the general population.
Health Outcomes Data Repository
Health Outcomes Data Repository represents a supplement of routine clinically coded data from the Cardiff
and Vale NHS Hospitals Trust, UK, with survey data covering sociodemographic characteristics, QoL, utility
and resource use information.93 HODaR data were collected for subjects treated at Cardiff and Vale NHS
Hospital from 2002 to 2004. Inpatients were surveyed 6 weeks post-discharge while outpatients are
handed a survey package when they attend. More than 30,000 observations (aged ≥ 18 years) are
available relating to approximately 2000 diagnoses of disease by ICD-10 code.
We used HODaR to estimate health-related QoL by ICD-10 diagnoses codes and age using EQ-5D. If data
on a patient were provided with multiple diagnoses the primary condition was used.
Medical Expenditure Panel Survey
MEPS is a national representative survey of the US civilian non-institutionalised population, collecting
information on health-care utilisation which began in 1996.94 EQ-5D was employed to measure
health-related QoL of the population in years 2000–2. There are about 38,000 adults (aged ≥ 18 years)
completing EQ-5D relating to 700 ICD-10 code diagnoses. MEPS consists of a household component and
an insurance component, both aimed at identifying the medical usage of individuals as well as how they
are funded, their cost, and the scope and breadth of health insurance held and available.
As with HODaR, MEPS allowed us to estimate the health-related QoL by ICD-10 code and age. If data on a
patient was provided with multiple conditions the primary condition was used.
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Hospital Episode Statistics
Hospital Episode Statistics represents a collection of data with details on all admissions to the NHS hospital
in England. It contains admitted patient care data from 1989 onwards, with more than 12 million new
records added each year, and outpatient attendance data from 2003 onwards, with more than 40 million
new records added each year.
Expenditure by ICD-10 codes and PCT was used to estimate the contribution to variance of each PBC. This
was done by calculating the contribution of that ICD-10 code to the variance in expenditure between PCTs
within a PBC (total costs allocated to individual ICD-10 codes were divided by the number of patients
using services in the PCT). For our analysis we make use of HES data on the year 2007/8.
Patient-reported outcome measures
Introduced in 2009, the English NHS PROMs programme routinely collects self-reported health status of
patients receiving surgery for four elective procedures: knee and hip replacement, groin hernia repair,
and varicose vein surgery. Patients are invited to complete a questionnaire prior to surgery, and again
6 (or 3) months after surgery.159 Differences in their self-reported health status are used to explore
differences between provider performance in improving patient health.160 The data that are collected
include both condition-specific questions (the Oxford Hip Score, Oxford Knee Score and the Aberdeen
Varicose Vein score; no condition-specific instrument is available for hernia) as well as the generic
instrument, the EQ-5D (both the EQ-5D profile and the patient’s global assessment of their health,
the EQ-VAS161). All NHS patients receiving these surgical procedures are invited to complete the PROMs
questionnaires – in practice, for a variety of reasons, some patients do not participate, or complete only the
pre-surgery, or the post-surgery, questionnaire – so the data do not cover 100% of patients. However,
good coverage rates have been achieved (e.g. the response rate from hip surgery patients to April 2012 was
78% for the pre-surgery questionnaire, and 81% for the post-surgery questionnaire).162
Patient-level data from the PROMs programme are freely available to download in anonymised form.
Those data can also be linked to further information in the HES database, via requests to the NHS IC.
Standardised reports on the PROMs data, including the average (case-mix adjusted) performance of
providers, is regularly published by the NHS IC, currently on a quarterly basis.
There are plans to extend the PROMs programme in the future, in keeping with the Government’s NHS
Outcomes Framework, and a number of pilot studies have been commissioned by the Department of
Health in order to inform the roll-out to other NHS services. There is currently work under way around the
potential use of PROMs in a wide range of long-term conditions; primary care; cancer survivorship;
cardiovascular services; musculoskeletal; and cosmetic surgery.
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Figures of prevalence distribution within programme budget categories
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FIGURE 55 Distribution of PBC 1 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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personal history and certain conditions influencing health
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FIGURE 56 Distribution of PBC 2 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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FIGURE 57 Distribution of PBC 3 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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FIGURE 58 Distribution of PBC 4 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
ACTH, adrenocorticotrophic hormone; ADH, antidiuretic hormone; FSH, follicle-stimulating hormone; GH, growth hormone; LH, luteinising hormone; PTH, parathyroid
hormone; TSH, thyroid-stimulating hormone. F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female
aged 30–44 years; F60: female aged 45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male
aged 10–14 years; M30, male aged 15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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FIGURE 59 Distribution of PBC 5 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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D Behavioural and emotional disorders with onset usually occuring in childhood and
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E Persons with potential health hazards related to family and personal history and certain
conditions influencing health status (Z80–Z99)
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FIGURE 60 Distribution of PBC 6 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
D
O
I:
1
0
.3
3
1
0
/h
ta
1
9
1
4
0
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
5
V
O
L.
1
9
N
O
.
1
4
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
5
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
C
la
xto
n
et
al.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
4
6
9
Proportion
of patients
Contribution
to variance
Episodic and paroxysmal disorders (G40–G47)
Extrapyramidal and movement disorders (G20–G26)
Other degenerative diseases of the nervous system
(G30–G32)
Other disorders of the nervous system (G90–G99)
Nerve, nerve root and plexus disorders (G50–G59)
Demyelinating diseases of the central nervous
system (G35–G37)
Polyneuropathies and other disorders of the
peripheral nervous system (G60–G64)
Cerebral palsy and other paralytic syndromes
(G80–G83)
Inflammatory diseases of the central nervous
system (G00–G09)
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
Systemic atrophies primarily affecting the
central nervous system (G10–G13)
Diseases of myoneural junction and muscle
(G70–G73)
Viral infections of the central nervous system
(A80–A89)
Other disorders of the ear (H90–H95)
Congenital malformations and deformations
of the nervous system (Q00–Q07)
Viral infections characterised by skin and
mucous membrane lesions (B00–B09)
Other diseases of the urinary system (N30–N39)
Other bacterial diseases (A30–A49)
Other viral diseases (B25–B34)
Helminthiases (B65–B83)
Tuberculosis (A15–A19)
Protozoal diseases (B50–B64)
Symptoms and signs of circulatory and
respiratory systems (R00–R09)
Symptoms and signs of skin and 
subcutaneous tissue (R20–R23)
Symptoms and signs of nervous and 
musculoskeletal systems (R25–R29)
Symptoms and signs of urinary system
(R30–R39)
R
S
T
U
V
W
X
Y
Symptoms and signs of cognition,
perception emotional state and behaviour
(R40–R46)
Symptoms and signs of speech and voice 
(R47–R49)
General symptoms and signs (R50–R69)
Abnormal clinical and laboratory 
findings, not elsewhere classified (R70–R99)
Persons with potential health hazards
related to family and personal history and
certain conditions influencing health status
(Z80–Z99)
Z
AA
AB
AC
AD
5,000,000
4,500,000
4,000,000
3,500,000
3,000,000
2,500,000
2,000,000
1,500,000
1,000,000
500,000
0
M00 M05 M15 M30 M45 M60 M70 M80 F00 F05 F15 F30 F45 F60 F70 F80
AD
Z
V
R
N
J
F
B
AC
Y
U
Q
M
I
E
A
AB
X
T
P
L
H
D
AA
W
S
O
K
G
C
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
M
e
a
s
u
r
e
 
o
f
 
p
r
e
v
a
l
e
n
c
e
 
(
n
o
.
 
o
f
 
p
a
t
i
e
n
t
s
)
FIGURE 61 Distribution of PBC 7 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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FIGURE 62 Distribution of PBC 8 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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FIGURE 63 Distribution of PBC 9 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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FIGURE 64 Distribution of PBC 10 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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FIGURE 65 Distribution of PBC 11 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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A    Diseases of oral cavity, salivary glands and jaws (K00–K14)
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FIGURE 66 Distribution of PBC 12 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
D
O
I:
1
0
.3
3
1
0
/h
ta
1
9
1
4
0
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
5
V
O
L.
1
9
N
O
.
1
4
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
5
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
C
la
xto
n
et
al.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
4
7
5
Intestinal infectious diseases (A00–A09)
Diseases of oesophagus, stomach and
duodenum (K20–K31)
Diseases of appendix (K35–K38)
Other diseases of intestines (K55–K63)
Diseases of liver (K70–K77)
Disorders of gall bladder, biliary tract 
and pancreas (K80–K87)
A
B
C
D
E
F
Non-infective enteritis and colitis 
(K50–K52)
Diseases of peritoneum (K65–K67)
Other diseases of the digestive system
(K90–K93)
Congenital malformations and
deformations of the digestive system
(Q35–Q45)
Helminthiases (B65–B83)
G
H
I
J
K
Diseases of veins, lymphatic vessels
and lymph nodes, not elsewhere
classified (I80–I89)
Viral hepatitis (B15–B19)
Diseases of oral cavity, salivary
glands and jaws (K00–K14)
Certain zoonotic bacterial diseases
(A20–A28)
Other spirochaetal diseases
(A65–A69)
L
M
N
O
P
Arthropod-borne viral fevers and viral
haemorrhagic fevers (A90–A99)
Mycoses (B35–B49)
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Persons with potential health hazards related
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FIGURE 67 Distribution of PBC 13 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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FIGURE 68 Distribution of PBC 14 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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FIGURE 69 Distribution of PBC 15 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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FIGURE 70 Distribution of PBC 17 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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FIGURE 71 Distribution of PBC 18+ 19 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10
code. F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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FIGURE 72 Distribution of PBC 20 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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FIGURE 73 Distribution of PBC 21 prevalence by age, gender and contributing ICD-10 code alongside proportion of patients and contribution to variance of each ICD-10 code.
F00, female aged 0–4 years; F05, female aged 5–9 years; F15, female aged 10–14 years; F30, female aged 15–29 years; F45, female aged 30–44 years; F60: female aged
45–59 years; F70, female aged 60–69 years; F80, female aged ≥ 70 years; M00, male aged 0–4 years; M05, male aged 5–9 years; M15, male aged 10–14 years; M30, male aged
15–29 years; M45, male aged 30–44 years; M60: male aged 45–59 years; M70, male aged 60–69 years; M80, male aged ≥ 70 years.
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Addendum 2: the role of data on local NHS decisions
The role of local data in this study
The aim of this research project, noted in Chapter 1, is to develop and demonstrate methods for threshold
estimation that make best use of routinely available NHS data. The principal focus of that methodological
development, as reflected in the main body of this report, has been the use of econometric methods to
exploit observed variations in spending and health outcomes between PCTs, at the programme budget
level of aggregation.
However, we also aimed to investigate, as a complementary element of the project, the extent to which
there may be other, more disaggregated sources of evidence on investment and disinvestment decisions
made by local NHS organisations which might inform our analysis.
Specifically, we set out to (a) identify and evaluate what data might be routinely available from local NHS
organisations with respect to their decisions to increase or decrease spending on specific services, and
(b) consider if and how such evidence might contribute directly toward the quantitative estimates of the
threshold (e.g. by providing more granular, contextual information on spending decisions that might assist
in the interpretation of model estimates). For example, we wished to explore whether or not there were
any routinely collected data from local NHS organisations that could tell us something about which ICD-10
codes within a given PBC might be the focus of investment and disinvestment.
The work, which was undertaken, was therefore focused on the potential use of local data alongside the
econometric analysis, rather than their potential use as an alternative means of identifying the marginal
cost of a QALY in the NHS.76
Sources of publicly available data on primary care trust investment
and disinvestment
To help us identify possible sources of data on NHS spending decisions, we began by consulting a number
of experts within the NHS, identified for us by our collaborator, Professor David Parkin (Chief Economist at
NHS South East Coast). These included directors of finance, commissioning and public health. Those
discussions helped direct us to a number of initiatives which involved the development of tools or evidence
to inform resource allocation decisions, and helped to identify types and sources of documents published
by PCTs that potentially contained relevant information on spending decisions. We then undertook a
search for publicly available documents, in each case identifying what was available, and assessing its
potential relevance for the purposes of this work outlined above. In evaluating each data source, the key
considerations were:
(a) Whether or not the data were routinely collected: routinely-collected data are preferred, as our
overarching aim is to develop a set of methods to estimate the threshold, which can be readily
updated from data routinely generated by the NHS.
(b) Whether or not the data were in the public domain: published data are preferred to data that can only
be obtained on request, because this would increase the cost and effort required in obtaining data
from all relevant organisations.
(c) Whether or not the data were collected and reported in a systematic and consistent manner that
would facilitate comparisons between PCTs, and with sufficient detail to enable us to link spending
decisions to specific programme budgets or ICD-10 codes. This aspect of the work was undertaken
during 2010.
The following were identified as potential sources of data.
Programme budgeting tools: quadrant analysis – Spend and Outcome Tool
Data are available for 3 years, 2006/7, 2007/8 and 2008/9 under the Spend and Outcome Tool which is
available to download (from Public Health England163). Expenditure data are organised by PBC only, with
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no lower level of disaggregation. The data show, for each PCT, the spend per head this year, the z-score
of that spend, and the PCTs national ranking based on their z-score.
Outcomes data have also been captured, with different outcome measures within each PBC. Again, for
each outcome there is a related z-score and the PCTs national ranking based on that z-score.
The tool enables users to see graphically how one PCT compares with others nationally, by SHA and by
those PCTs similar to it by cluster (e.g. other PCTs in manufacturing towns). The quadrant analysis tool has
the origin as the mean PCT for that PBC, with z-score for both expenditure and outcome equal to zero.
The x-axis shows outcome, and the y-axis expenditure, both by z-score.
Although a useful tool, this source added little to the data already used in the econometric analysis, as it
does not provide any additional information on the allocation of resources within PBCs.
Lists of interventions not normally funded
Most PCTs provide information about interventions not normally funded. However, these were of limited
usefulness because most of the procedures listed are those that might be expected (cosmetic surgery,
tattoo removal, etc.), and are not particularly informative about the marginal cost per QALY in the NHS.
We did not find any information regarding whether or not any previously funded treatments had been
added to these lists.
Special therapeutic and cancer committees
These are regionally based (not PCT or SHA) specialised committees that make decisions regarding
spending on new cancer medicines and other special therapeutic areas. Although such decisions would be
potentially of direct relevance, we were unable to find any public documentation on their processes or
decision outcomes.
Quality, Innovation, Productivity and Prevention published data on efficiency
savings in the NHS
Introduced in 2009, Quality, Innovation, Productivity and Prevention (QIPP) addresses the quality and
productivity challenge faced by the NHS. Developed by NICE, the Cochrane Quality and Productivity topics
identify areas where resources could be significantly reduced or stopped completely without reducing the
quality of NHS care, releasing cash and/or resources to other areas in the NHS. Each Cochrane topic has
been established from systematic reviews undertaken by reviewers at the Cochrane Collaboration.
Every month the Cochrane Collaboration informs NICE as to new or existing Cochrane reviews where they
have found that the existing treatment option(s) is(are) harmful or ineffective and should not be used, or
where evidence is unavailable or insufficient to support widespread use of that treatment in the NHS. NICE
then completes an assessment of a Cochrane topic, to evaluate the efficiency savings that are likely against
the QIPP criteria of likely ease of implementation, impact on productivity, and on the quality of care.
Savings per 100,000 patients are calculated, and then efficiency gains per PCT can be calculated. Once a
topic has been accepted as best practise, users (PCTs) are encourage to submit their experience of
implementing the changes, and the users achieving the best efficiency gains become QIPP examples of
best practise.
The data show which procedures are considered an inefficient use of resources. However, to the extent
these are based on the means of achieving the same or improved outcomes but with lower resources,
they will not be revealing the marginal cost of producing a QALY in the NHS. Furthermore, there is
incomplete information about the extent to which PCTs actually implement these recommendations.
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NHS Right Care
This website (available at Public Health England164), has a section on the NHS Atlas of Variation in Health
care, which seeks to reduce unwarranted variations in health care, defined as ‘. . . variation in the
utilisation of health care services that cannot be explained by variation in patients or patients preferences’,
to increase value and improve quality.
It also provides an Annual Population Value Review (currently third edition) which uses PB and marginal
analysis to deliver QIPP. This provides, among other things, a 10-step, structured approach for PCTs to
follow to establish where investment and disinvestment decisions could be made.
Further, it provides a tool for NHS foundation trusts to improve efficiency via service line management.
Although these tools may be being used by PCTs and foundation trusts, it was not clear to what extent
that was the case, and there is no routine data on their use by NHS organisations or the decisions that
resulted from that.
Health Investment Network: case studies of programme budgeting and
marginal analysis
The NHS network, Health Investment Network, was established to provide the access to the latest
knowledge and tools to help commissioners optimise their investment and disinvestment decisions. It
provides case studies of PCTs which have used PB and marginal analysis to identify efficiency gains. This
includes examples of ‘spend to save’ decisions, for example where an initial investment (e.g. in vascular
checks for men in deprived areas) could be more than outweighed by savings. Such initiatives, although
important, are not useful in identifying the marginal cost per QALY in the NHS. Other case studies identify
‘wish lists’ (areas which PCTs prioritise for additional spending, should budgets expand) and ‘hit lists’
(services that might be reduced, to free up resources for more cost-effective services). These case studies
provide useful selected examples, but do not provide a routine or systematic reporting of such decisions
across all PCTs.
Annual operating plans and strategic commissioning plans
Primary care trusts are required to publish, each year, operating plans and strategic commissioning plans
detailing their planning for the coming year, including information on the way that PCTs have made
decisions concerning resource allocation. As these reports are published annually, we considered that they
constituted the most promising source of data, as they are produced routinely, and cover all PCTs.
Contact details and websites were identified for all 142 PCTs. Strategic commissioning plans were
obtained for an initial 70 of these. These were used to identify any information provided about
programmes of care or specific services where spending was planned to be increased or decreased.
Those data were extracted and recorded into a spreadsheet, along with any relevant contextual
information (e.g. relating to the process by which the decision had been made).
Our review of the data from the first 70 of these showed that there was considerable variation between
the documents in terms of the level of detail and specificity about the services which were the subject
of changes in spending. In many cases, the services were described in terms of broad initiatives which
might have related to multiple programme budgets and ICD-10 codes. There was also variation in,
and occasionally a lack of clarity about, the way in which spending changes were described. For example,
in some cases changes were described in terms of absolute changes in spending, in others as net changes
(once estimates of offsetting savings elsewhere had been taken into account), and in others it was
not stated.
Given those concerns, the data were considered unlikely to be useful to complement the econometric
analysis, and the research team decided not to proceed with further data extraction for the remaining PCTs.
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Conclusions
The context within which this element of the work took place may be relevant to note. Although the NHS
was not subject to the budget cuts imposed on other areas of government activity in response to the
financial crisis, the NHS was required to make substantial productivity improvements within its existing
budgets. This gave rise to a number of initiatives in response to the ‘productivity challenge’ and, generally,
heightened interest in the identification of ways to improve efficiency; potential areas for disinvestment;
and areas for investment which were motivated by ‘spend to save’. This may have made it more likely
that we would observe disinvestment decisions. The NHS was also, during the course of this project,
undergoing a period of restructuring. The transition from PCTs to CCGs, and the disestablishment of
SHAs, may have had an effect on the availability of data and information relating to decision-making.
It may also have broader implications for the availability of data in the future, given the change in
administrative units.
Our review of local data sources suggested that there is very little routinely collected data on investment
and disinvestment by local NHS organisations beyond the high-level aggregate data on spending by PBC
which are used in the econometric analysis. More disaggregated data on spending decisions about specific
services could, of course, be obtained by other means, for example by surveying PCTs, or by requesting
such information from them using a freedom of information request. However, that would impose data
collection costs and would need to be designed carefully to ensure that such efforts yielded complete and
consistent information.
Addendum 3: characterisation of the investment and
disinvestment decisions in mental health – depression
and schizophrenia
Introduction
As has been highlighted in the main body of this project, it was not possible to produce an outcome
equation for PBC 5, mental health problems, because no relevant mortality data was available from the
NHS IC by PCT. Mental health represents a significant incidence and expenditure within the NHS. As a
result, we investigated the direction of bias from the exclusion of mental health problems on our estimate
of the cost-effectiveness threshold. To understand this bias we examined current investment decisions in
mental health. Recent investments in treatments with ICERs above the estimated threshold would suggest
that not including PBC 5 more directly in our calculation may underestimate the threshold, conversely if
recent investment has ICERs below the estimated threshold it would suggest that its exclusion results in an
overestimated threshold. We focussed on depression and schizophrenia because of their high prevalence
and contribution to variance.
Method employed
To evaluate the direction of bias of the exclusion of PBC 5 we followed four steps to make the connection
from the identification of the most significant ICD-10 codes of PBC 5 to considering the cost-effectiveness
of the investment and disinvestment decisions made in the NHS around these disease areas. The strategy
was as follows.
Step 1
l Identify the mental health ICD-10 codes that are most influential and suitable on which to focus
our analysis.
¢ Done from number of patients and contribution to variance calculations using HES.
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Step 2
l Determine the medications or treatments used in the NHS to treat each of the significant ICD-10 codes.
¢ There is likely to be a large crossover in the use of treatments for mental health areas, for example
antipsychotics and cognitive–behavioural therapy (CBT) are both widely used.
¢ We made use of the NHS Choices website coupled with clinical expertise for this identification.
Step 3
l Identify the cost-effectiveness of the current treatments and medications used in the NHS.
¢ This identification will be done from a range of sources including published HTAs, published
guidance, Cost-Effectiveness Analysis Registry (or Tuft’s), NHS EED and MEDLINE searches.
¢ This step relies heavily on the literature published; literature tends to cover historical activities
many of which represent treatments of interest for this analysis. The case could be made that
historical treatments that have not been evaluated have escaped evaluation due to their apparent
cost-effectiveness, and are as such unlikely to be marginal activities.
¢ Further difficulties arose in the identification of the relevant cost-effectiveness figure. Ideally, it
would represent the cost per QALY relative to what would be performed if that activity was no
longer available to the NHS.
Step 4
l Connecting the available literature on the cost-effectiveness to recent investment and disinvestment
decisions made in the NHS.
Results of analysis
Step 1: identification of relevant International Classification of Disease codes
We first rank ICD-10 codes by prevalence and contribution to variance. Prevalence is estimated from
HES data. The contribution to variance is calculated as the variance in expenditure across PCTs for each
ICD-10 code compared with the total variance in expenditure across PCTs for all ICD-10 codes within
PBC 5. The most prevalent ICD-10 code was for mental and behavioural disorders due to use of alcohol
(F10) at 7.48% of all ICD-10 codes within PBC 5 (Table 193). The ICD-10 code with the greatest
contribution to variance was for schizophrenia (F20) with 45.16% (Table 194).
Depression (F32) and (F33) and schizophrenia (F20) have been chosen as the focus of our evaluation as
they represent two of the largest mental health ICD-10 codes in terms of proportion of patients as well as
proportion of variance in expenditure, as shown in Tables 193 and 194. In addition, they represent ICD-10
codes that involve interventions by the NHS that can be more clearly defined (in contrast to, for example,
unspecified dementia and mental and behavioural disorders due to the use of alcohol).ad
Step 2: determination of treatment employed
Table 195 provided an overview of the main treatments for depression and schizophrenia. This list of
treatments was identified using the NHS Choices website165 as well as discussion with our clinical
representative for each of the respective illnesses. This list was used to inform a literature search of
cost-effectiveness publications.
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TABLE 193 Table showing ranking of mental health ICD-10 codes by prevalence from HES
ICD-10 code Description % of mental health prevalence Contribution to variance
F10 Mental and behavioural disorders due
to use of alcohol
27.84 9.70
F20 Schizophrenia 10.01 45.16
F32 Depressive episode 9.96 6.91
F31 Bipolar affective disorder 6.19 6.38
F41 Other anxiety disorders 4.92 0.26
F60 Specific personality disorders 4.33 14.11
F03 Unspecified dementia 3.93 3.29
F01 Vascular dementia 3.32 1.58
G30 Alzheimer‘s disease 3.30 0.84
F33 Recurrent depressive disorder 2.83 3.68
TABLE 194 Table showing ranking of mental health ICD-10 codes by contribution to variance
ICD-10 code Description % of mental health prevalence Contribution to variance
F20 Schizophrenia 10.01 45.16
F60 Specific personality disorders 4.33 14.11
F10 Mental and behavioural disorders due
to use of alcohol
27.84 9.70
F32 Depressive episode 9.96 6.91
F31 Bipolar affective disorder 6.19 6.38
F33 Recurrent depressive disorder 2.83 3.68
F03 Unspecified dementia 3.93 3.29
F01 Vascular dementia 3.32 1.58
G30 Alzheimer‘s disease 3.30 0.84
F41 Other anxiety disorders 4.92 0.26
TABLE 195 Table showing treatments for schizophrenia and depression in the NHS
ICD-10 code Disease Treatment
F20 Schizophrenia 1. Typical antipsychotics
2. Atypical antipsychotics
3. CBT
4. Crisis resolution teams
F32 and F33 Depressive episode and recurrent
depressive episode
1. CBT
2. Interpersonal therapy
3. SSRIs
4. SNRIs
5. TCAs
6. MAOIs
7. Lithium
8. Electroconvulsive therapy
MAOI, monoamine oxidase inhibitor; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake
inhibitor; TCA, tricyclic antidepressant.
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Step 3: evaluation of the relevant cost-effectiveness literature
Using the treatment categories identified in step 2 of this work, a systematic search was conducted to
attempt to identify the range of literature on the cost-effectiveness of current NHS treatment of
schizophrenia and depression. For both illnesses five online databases were searched: the Cost-Effectiveness
Analysis Registry of the Tufts Medical Centre, NHS EED run by the Centre for Reviews and Dissemination at
the University of York, MEDLINE, the NICE online database of Technical Appraisals and Clinical Guidelines, as
well as NIHR’s Health Technology Assessments. All searches were conducted on the 19 October 2011.
The search strategies employed to search for relevant cost-effectiveness literature and details of the results
can be found in the search strategy section at the end of this addendum. For schizophrenia, this approach
identified 61 unique publications, five of which were deemed to be of broad relevance to this analysis.
For depression, 65 publications were discovered, 10 of which were relevant. A paper of relevance to our
analysis of mental health was deemed to be so if it presented cost-effectiveness results (in the form
of a cost per QALY ICER) of a comparison of at least two of the treatments for either schizophrenia or
depression identified in Analysis of 2006/7 expenditure and 2006/7/8 mortality data. These results could be
from a de novo analysis or from a systematic review of the relevant literature.
Table 196 reports the cost-effectiveness results of antipsychotics for schizophrenia as first-line treatments.
The NICE Clinical Guidelines for schizophrenia (CG82)166 demonstrate that the differences in costs and
effects of the first- and second-generation treatments described are very similar with ICERs comparing each
with no treatment ranging from £21,517 to £23,237 per QALY. Comparisons to active treatments result in
ICERs of £5156 to £33,240 per QALY.167,168
The CG82 results are similar to the first-line treatment results from Bagnall et al.,169 shown in Table 197.
The cost-effectiveness of antipsychotics compared with no treatment as second, third or final therapy are
< £20,000 per QALY.
TABLE 196 Table showing cost-effectiveness studies of antipsychotics for schizophrenia
Study Treatment Comparator Cost (£) QALYs
ICER
(£/QALY)
NICE CG82166 Zotepine (Zoleptil®, Movianto)
(second)
No treatment 139,170 6.468 21,517
Paliperidone (Invega®,
Johnson & Johnson) (second)
No treatment 142,173 6.427 22,121
Olanzapine (Zyprexa®, Eli Lilly)
(second)
No treatment 141,212 6.42 21,996
Risperidone (Risperdal®,
Johnson & Johnson) (second)
No treatment 149,112 6.417 23,237
Haloperidol (Haldol®,
McNeil Laboratories) (first)
No treatment 143,406 6.413 22,362
Aripiprazole (Abilify®,
Bristol-Myers Squibb)
(second)
No treatment 145,697 6.400 22,765
Amisulpride (Arnival®,
Sanofi-Aventis) (second)
No treatment 147,920 6.392 23,141
Knapp et al. 2008167 Olanzapine (second) Other antipsychotics 5156
Davies et al. 2008168 Clozapine (Clozaril®,
Novartis) (second)
Other second-generation
antipsychotics
33,240
Aripiprazole then risperidone Risperidone then olanzapine 9440
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Only one study reported the cost-effectiveness of a psychological or social intervention for schizophrenia.
Barton et al.170 conducted a randomised trial to estimate the clinical effectiveness and cost-effectiveness of
social recovery orientated cognitive–behavioural therapy (SRCBT) against case management alone for
people recently diagnosed with psychosis. SRCBT consisted of three stages of social recovery combined
with CBT techniques including vocational case management. SRCBT was found to have an ICER of
£18,844 per QALY compared with case management. However, it is not clear that all forms of CBT are
well represented by this one study or that these results relate well to schizophrenia as this study was for
the use of SRCBT for psychosis disorders in general.
Table 198 reports the cost-effectiveness results of publications identified in the systematic search of drug
treatments for depression in the NHS. As was highlighted in Table 195, a range of drug treatments are
available for depression, broadly falling into five categories: selective serotonin reuptake inhibitors (SSRIs),
serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), monoamine oxidase
inhibitors and lithium.
The NICE guideline CG90 tested the cost-effectiveness of numerous treatments for moderate and severe
depression. It was found that across all the treatments tested the mean QALYs for moderate depression
had a range of 0.053 and severe depression had a range of 0.065. The costs had a range of £408 for
moderate and £396 for severe depression. The results suggest that mirtazapine has the lowest ICER for
both moderate and severe depression. If mirtazapine is not a suitable treatment option than escitalopram
or sertraline is preferred because escitalopram dominates venlafaxine and sertraline dominates the
remaining antidepressants. The ICERs of escitalopram versus sertraline are £32,987 per QALY for moderate
depression and £27,172 per QALY for severe. The authors thus suggest that according to these results
escitalopram should be considered when mirtazapine and sertraline are not suitable. Other ICERs reported
in CG90 can be found in Table 198. CG90 states that the economic evidence had limitations and these
comparisons were considered insufficient to make specific recommendations for treatments.
Incremental cost-effectiveness ratios in other studies range from £2172 to £20,600 per QALY, with TCA
alone being dominated by lofepramine (TCA) in two cases and fluoxetine (SSRI) being dominated by
amitriptyline (TCA).
TABLE 197 Table showing cost-effectiveness studies of antipsychotics for schizophrenia
Bagnall et al. 2003169
Antipsychotic
Line of treatment: ICER (£/QALY)
First Second Third Final
Chlorpromazine (Largactil®, Sanofi-Aventis) (first) 21,989 15,185 15,419 15,303
Haloperidol (first) 24,069 17,177 17,211 17,022
Clozapine (second) 24,500 17,595 17,577 17,402
Olanzapine (second) 25,719 18,869 18,808 18,865
Quetiapine (Seroquel®, AstraZeneca) (second) 26,316 19,090 18,751 19,096
Zotepine (second) 22,769 16,350 16,360 16,400
Risperidone (second) 22,255 15,596 15,599 15,700
Ziprasidone (Geodon®, Pfizer) (second) 21,935 15,192 15,191 15,224
Amisulpride (second) 23,174 15,941 15,945 15,962
Sertindole (Serdolect®, Lundbeck) (atypical) 23,181 16,297 16,308 16,354
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Table 199 provides the results of the combination therapies for moderate and severe depression presented
in CG90171 and Simon et al.177 These studies considered the impact of combined SSRI and CBT compared
with SSRI alone. Both of these studies find combined CBT and antidepressant to have ICERs of < £8000
per QALY.
In addition Table 199 provides results of analyses of computerised CBT compared with treatment as usual
or relaxation. The results generally find CBT and computerised CBT to be highly cost-effective, with the
exception of Behavioral Therapy Steps179 all ICERs are found to be < £18,000 per QALY.
TABLE 198 Table showing cost-effectiveness of drug treatments for depression
Study Treatment Comparator
Incremental
cost
Incremental
QALY (£)
ICER
(£/QALY)
NICE CG90171 Combined SSRI and CBT
(severe depression)
SSRI alone 5558
Duloxetine (Cymbalta®,
Eli Lilly) (SNRI)
SSRI 6300
Duloxetine (SNRI) Mirtazapine
(Avanza®,
Organon) (TCA)
2400
Duloxetine (SNRI) Venlafaxine
(Effexor®, Pfizer)
(SNRI)
Dominates
Escitalopram (Lexapro®,
Forest Laboratories)
(moderate depression)
(SSRI)
Sertraline
(Zoloft®, Pfizer)
(SSRI)
32,987
Escitalopram (severe
depression) (SSRI)
Sertraline (SSRI) 27,172
Lenox-Smith et al. 2009172 Venlafaxine (major
depression) (SNRI)
SSRI 20,600
Fluoxetine (Prozac®,
Eli Lilly) (SSRI)
Amitriptyline
(Elavil®, Densa)
(TCA)
Dominated
Kendrick et al. 2006173 SSRI TCA 2692
TCA Lofepramine
(Gamanil®,
GlaxoSmithKline)
(TCA)
Dominated
SSRI Lofepramine
(TCA)
5686
Hatziandreu et al. 1994174 Sertraline (SSRI) Dothiepin (TCA) 2172
Peveler et al. 2005175 SSRI Lofepramine
(TCA)
0.035 199 5686
TCA Lofepramine
(TCA)
−0.004 93 Dominated
SSRI TCA 0.039 105 2692
Kendrick et al. 2009176 SSRI + standard care Standard care 14,854
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Step 4: connection to investment and disinvestment decisions
In this section we discuss the investment and disinvestment decisions made considering the cost-effectiveness
information in the previous section. If we believe that decision-makers will invest in treatments below their
cost-effectiveness threshold and disinvest in treatments above this threshold then by considering the ICERs of
treatments subject to investment and disinvestment we can create a range for their cost-effectiveness
threshold. This approach and its role in the consideration of a cost-effectiveness threshold has been
previously discussed by Appleby et al.49 With a view of the cost-effectiveness threshold within PBC 5 we
consider how its exclusion from our calculation of the threshold might influence our results.
To identify the broad areas of investment in the disease areas we make use of recent NICE guidance
documents. Although NICE clinical guidance does not definitively represent observed shifts in practice and
are often not well implemented in mental health trusts181 it can help to inform our evaluation. NICE
guidance does not identify areas where disinvestment should occur within a disease; as a result, we have
consulted experts in the respective fields to gain an understanding of any significant recent disinvestment
decisions. For schizophrenia we were provided expert opinion by Professor Tim Kendall (Centre for
Psychological Services Research, University of Sheffield) and for depression by Professor Simon Gilbody
(Health Sciences, University of York).
For both schizophrenia and depression we will briefly discuss the areas of investment and disinvestment in
two care categories: (i) drug treatments, and (ii) psychological and social interventions.
TABLE 199 Table showing cost-effectiveness of psychological and social intervention for depression
Study Treatment Comparator
Incremental
cost (£)
Incremental
QALY
ICER
(£/QALY)
NICE CG90171 Combined SSRI and CBT
(moderate depression)
SSRI alone 7052
Combined SSRI and CBT
(severe depression)
SSRI alone 5558
Simon et al. 2006177 CBT + antidepressants in
severe depression
Fluoxetine 5777
CBT + antidepressants in
moderate depression
Fluoxetine 14,540
Kaltenthaler et al. 2002178 BtB computerised CBT TAU 1209–7692
Kaltenthaler et al. 2006179 BtB TAU 147 0.08 1801
Cope computerised CBT TAU 193 0.03 7139
Overcoming depression
computerised CBT
TAU 64 0.01 5391
FearFighter computerised CBT Relaxation
CBT
138 0.058 2380
Therapist lead CBT Relaxation 194 0.011 17,604
Behavioural therapy steps
computerised CBT
Relaxation 360 −0.01 Dominated
Hollinghurst et al. 2010180 Online computerised CBT TAU 17,173
BtB, Beat the Blues; TAU, treatment as usual.
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Results of step 4 for schizophrenia
Analysis of drug treatment
Antipsychotics used for the treatment of schizophrenia can be broadly identified as first or second
generation (typical and atypical antipsychotics). To a certain extent there is still a debate over the relative
strengths and weaknesses of each,182 and the significance of the adverse events associated with the
second generation may still not be fully understood (such as the impact on new-onset type 2 diabetes183).
However, our clinical experts indicated that clinicians were largely concerned with the adverse effects
associated with the second-generation drugs, and the increasing evidence questioning the relative efficacy,
such as Rosenheck et al.182 who suggests that the first-generation drugs in many cases are just as effective.
Recent NICE guidance leaves the choice of first- or second-generation drugs to the clinician to decide.166
When considering the impact on our estimate of the threshold of the possible shift to first- from
second-generation antipsychotics we must attempt to generalise about the relative cost-effectiveness of
the two. Clearly this is difficult as each generation represents many different drugs. However, from CG82
the costs and benefits of the mainstream antipsychotics are broadly similar Table 196. This would suggest
that a shift away from the second generation back towards the first would have little impact on the overall
threshold as the costs and benefits associated with each are very similar.
Olanzapine came off patent in the third quarter of 2011.184 Olanzapine and similar second-generation
antipsychotics are associated with a cost of around £30M a year,ae clearly the introduction of generics to
the market would significantly reduce this cost and thus increases the cost-effectiveness of these drugs.
Although this shift does not fall within the years of our analysis, it will have a significant impact on the
future value of the cost-effectiveness threshold.
The other significant area of debate, as identified by our clinician, is the role of the antipsychotic clozapine.
It has often been viewed as the most effective antipsychotic drug for schizophrenia, however, the
antipsychotic clozapine has been connected with some severe adverse events (such as myocarditis,185
agranulocytosis186 and central nervous system depression). This has led to the NICE guidelines advising
clozapine only if an array of other antipsychotics has failed.166 Although clozapine is highly clinically
effective it is associated with a higher overall cost (a significant proportion due to the associated adverse
events). As is shown in Table 196, Davies et al.168 show clozapine to have an ICER of £33,240 when
compared with other second-generation antipsychotics. Disinvestment of clozapine suggests that the
threshold is < £33,240 per QALY. However, current investment in other first-line antipsychotics suggests
that the threshold in mental health is > £23,237 per QALY.
Analysis of psychological and social intervention
In this section we discuss all non-drug-related interventions for schizophrenia. The NICE guidelines166 outline
the provision of CBT, arts therapy and family interventions to treat schizophrenia; however, efficacy of these
interventions is disputed187 and little is known about their cost-effectiveness. The systematic review only
yielded one paper that was relevant to our analysis, as is shown in Table 200. The Barton et al.170 study
found that SRCBT had an ICER of < £20,000 per QALY relative to case management. However, as
mentioned previously, this study may not represent all forms of CBT for schizophrenia.
TABLE 200 Table showing cost-effectiveness of psychological/social interventions for schizophrenia
Study Treatment Comparator ICER (£/QALY)
Barton et al. 2009170 SRCBT Case management 18,844
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Our clinical advisors informed us that CBT provision varies significantly across PCTs and therefore
represents an intervention likely to be subject to investment and disinvestment at the margin. The variation
in CBT provision (and indeed other psychosocial/social interventions) is largely a result of the poor support
for its efficacy and significant initial cost.
Other interventions of relevance to this investigation include art therapies and family interventions.
As with CBT there is a significant variation in the provision of family interventions. No information on its
cost-effectiveness was found from our search. Art therapies include music therapy; art therapy; and body
movement or dance therapy. Our clinical advisors have highlighted increasing investigations into arts
therapy, including the ‘Matisse trial’,188 publications around which have shown that art therapy as
adjunctive therapy had little benefit over a comparator activity or treatment as usual.187 No information on
its cost-effectiveness was found from our search.
Early interventions in schizophrenia, which aims to identify and treat early symptoms associated with
schizophrenia, have been a significant area of investment over recent years in the NHS. Although we were
unable to identify any relevant cost-effectiveness literature around early interventions in schizophrenia it is
generally expected that these represent cost-effective interventions over the long term.af
Although the lack of cost-effectiveness literature clearly limits the potential to directly associate these
interventions with the wider cost-effectiveness threshold it is widely accepted that many social
interventions for schizophrenia (specifically around CBT and family interventions) are cost-saving for the
NHS,af as they reduce hospitalisation by reducing emergency hospital access and relapse rates that are high
in schizophrenia representing the majority of related hospitalisations.189
Investment in CBT with an expected ICER of £18,844 per QALY suggests that the threshold for mental
health treatments is above this value.
Results of step 4 for depression
As Table 195 shows, depression is associated with a wider range of treatment than schizophrenia,
specifically a wider range of drug treatments are available. As with the schizophrenia section of this
addendum we will deal with the treatments under the two categories of drug treatments and
psychological/social interventions. Electroconvulsive therapy, which is included in the treatment options
available in the NHS as shown in Table 195, is excluded from this analysis based on expert opinion on the
grounds of it being a very rarely used but extreme treatment that is not likely to be further subject to
substantial investment or disinvestment, so is not relevant for our analysis.
Recent NICE clinical guidance171 highlights a range of key priorities for implementation. As with
schizophrenia there is no guarantee that these are the areas of investment in depression care but it
represents a suitable outline of the areas of interest. Several areas are highlighted:
l early identification and diagnosis
l low intensity psychological interventions (CBT, computerised CBT and group physical activity) for
persistent subthreshold depressive symptoms or mild to moderate depression
l reduced routine use of antidepressants for subthreshold depressive symptoms or mild depression
l combination therapies (antidepressant and psychological) for moderate or severe depression
l extension of therapy (antidepressant and psychological) beyond remission to reduce relapse
l SSRIs are presented as the preferred type of antidepressant due to their equivalent efficacy and
favourable risk–benefit ratio.
These are the areas of investment that our analysis will focus on.
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Analysis of drug treatment
Our clinical advisors reported that the current area of activity in antidepressants is the creation of drugs such
as escitalopram (a SSRI) and venlafaxine (a SNRI) that are relatively similar to generic treatments currently in
the market. As these new drugs are covered by patents they are relatively expensive. Table 198 reports the
results on the cost-effectiveness of these two drugs from NICE CG90171 as well as Lenox-Smith et al.172 In
both reports the drugs are compared with alternative SSRIs in moderate and severe depression. In both
cases the newer SSRIs were approved by NICE with an ICER for escitalopram of £32,987 per QALY and for
venlafaxine of £20,600 per QALY. If mirtazapine and sertraline are not suitable then the ICER of
escitalopram for moderate depression is £5357 per QALY compared with citalopram. Although evidence
was not available on whether or not clinicians were making use of these newer SSRIs, an investment in
them away from alternative SSRIs may represent an increase in the cost-effectiveness threshold due to the
relatively high ICERs reported in the two studies. However, the cost-effectiveness of each depends on what
they displace and ICERs may be lower if the more cost-effective treatments have failed.
Investment decisions in the NHS for antidepressants are likely to represent changes in the type of
antidepressant being prescribed rather than a shift from no treatment to treatment. The majority of trials
discovered by systematic review given in Table 198 show that although the ICER of SSRIs compared with
TCAs is very low,175 this is largely driven by very small gains in QALYs but for a similarly small increase in
cost. As a result any observed investment in SSRIs away from TCAs is likely to lead to a small decrease
in an observed threshold for the NHS.
Analysis of psychological and social intervention
The NICE guidelines reported in CG90 place a lot of focus on the provision of psychological interventions
such as CBT (and computerised CBT) over antipsychotics wherever possible. Table 199 provides the results
of the combination therapies for moderate and severe depression presented in CG90171 and Simon et al.177
These considered the impact of combined SSRI and CBT compared with SSRI alone and concluded that
combined therapies in both populations had ICERs of < £15,000 per QALY. According to our clinicians,
this is an area that is likely to have had significant investment in recent years.
The two HTA reports in Table 199178,179 provide a good analysis of the cost-effectiveness of computerised
CBT compared with treatment as usual. They show that the computerised CBTs investigated have
ICER of < £8000 per QALY relative to TAU. Further analyses investigated different kinds of computerised
CBT and found that compared with relaxation, CBT ICERs ranged from £2380 per QALY to dominated.
Hollinghurst et al.180 report that two CBT interventions compared to TAU had ICERs of £17,173.
As NICE guidelines encourage the use of CBT and our clinical experts believe this has been an area of
increased investment, this review suggests that the threshold in mental health is > £17,173 per QALY.
Conclusion
There is very little accessible data on the investment and disinvestment decisions in specific areas of
mental health and so we relied on the opinions of clinical experts. The NHS IC has some information on
prescriptions of mental health treatments; however, it was not clear for which diseases these treatments
were being used or for which line of therapy. As a result, these data were not included in our analysis as it
was decided they may not represent the investment and disinvestment decisions that we were seeking
to identify.
Most treatments reviewed had an ICER of < £24,000 per QALY. Two treatments had higher ICERs. Clozapine
for the first-line treatment of schizophrenia was found to have an ICER of £33,240 per QALY compared to
other second-generation antipsychotics. NICE’s recommendation to use clozapine only as a last-line treatment
suggests that the threshold is < £33,240 per QALY. Escitalopram for moderate depression has been
recommended by NICE and was reported to have an ICER of £32,987 per QALY compared with seratraline.
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Conclusions on the threshold from this finding are unclear. The cost-effectiveness of escitalopram in the NHS
will depend on its use. If it is used rather than seratraline then the threshold may be over £32,987, but if it is
used as third-line therapy than according to CG90 its use is less costly and more effective than the next
best options.
How well the actual threshold reflects the ICERs reported above depends on how well clinical practice
matches the clinical guidelines (i.e. whether or not the more cost-effective treatments are being used first).
Search strategies
Search strategy for schizophrenia
Cost-Effectiveness Analysis Registry search
Six keywords associated with the entire schizophrenia, schizotypal and delusional disorders. ICD-10
subchapters were searched for in the CEA Registry, these were: schizophrenia, schizotypal, delusional,
psychotic, schizoaffective and psychosis. A search for any of these keywords in the registry yielded
18 different papers at the time of searching, with five of these being deemed suitable for our investigation
(Barton et al.,170 Davies et al.,168 Jarbrink et al.,190 Knapp et al.167 and Davies et al.191).
NHS Economic Evaluation Database search
A single relatively simple search strategy was defined to investigate NHS EED, this was as follows:
((Schizophrenia) AND (cost effectiveness):TI) and Economic evaluation:ZDT and Abstract:ZPS
This result strategy yielded 28 hits, only one of which was both relevant to our search and not discovered
in the CEA Registry search (Rosenheck et al.).182
MEDLINE search
MEDLINE was searched using the strategy:
cost benefit analysis and (schizophrenia or schizotypal personality disorder or delusions) and Great
britain(MeSH)
This strategy yielded 13 hits, none of which were both relevant and had not been previously identified
through the CEA Registry or NHS EED searches.
National Institute for Health and Care Excellence technology appraisals and
clinical guidelines
The NICE online database of published mental health-related technology appraisals and clinical guidelines
(www.nice.org.uk/guidance/index.jsp?action=byTopic&o=7281) was searched for schizophrenia-related
publications. Only one was found to fulfil our criteria for schizophrenia: CG82.192
National Institute for Health Research’s Health Technology Assessments
Finally the NIHR’s database of published HTAs was searched. This activity discovered one additional
relevant publication: HTA 00/20/01 – Bagnall et al.169
Search strategy for depression
Cost-Effectiveness Analysis Registry search
Two keywords were searched on the CEA Registry, they were: depression and depressive. These keywords
yielded 17 papers, five of which were deemed relevant for our purposes (Hollinghurst et al.,180
Lenox-Smith et al.,172 Kendrick et al.,173 Simon et al.177 and Hatzinandreu et al.174).
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NHS Economic Evaluation Database search
A search similar in structure to the search for schizophrenia papers was conducted in the NHS EED:
((depressive OR depression):TI AND (cost-effectiveness):TI) and Economic evaluation:ZDT and Abstract:ZPS)
IN NHSEED
This yielded 43 hits, none of which were both relevant and previously undiscovered by the CEA registry
search. Due to the complete nature of the CEA Registry and NHS EED searches, as well as time constraints
on the systematic review, a MEDLINE search was not conducted as it was decided it would not provide
sufficient added value.
National Institute for Health and Care Excellence technology appraisals and
clinical guidelines
Searching the NICE database of technology appraisals and clinical guidelines yielded one publication
deemed relevant to the analysis: CG90 – depression in adults.193
National Institute for Health Research’s Health Technology Assessments
A search of the NIHR’s online database of published HTAs yielded four relevant publications:
HTA 01/23/01– Kaltenthaler et al.178
HTA 04/01/01– Kaltenthaler et al.179
HTA 96/61/11– Peveler et al.175
HTA 01/70/05 – Kendrick et al.176
Addendum 4: what type of health is forgone by the approval of
a new technology?
The methods of analysis described in this work can identify not only how many QALYs are likely to be
forgone across the NHS as a consequence of approving a technology which imposes incremental costs on
the NHS, it can also indicate where those QALYs are likely to be forgone and how they are made up
[i.e. the additional deaths, life-years lost (unadjusted and adjusted for QoL) and the QoL impacts on those
with disease]. Based on the 2008 central estimate of the cost per QALY threshold, we will exemplify within
this addendum the likely health displaced elsewhere in the NHS as a consequence of approving a
new technology.
The example of ranibizumab for diabetic macular oedema
In 2011, NICE considered whether or not ranibizumab for the treatment of diabetic macular oedema in
patients with central retinal thickness ≥ 400 micrometres should be approved for widespread use in the NHS
(TA237105). Initially, this technology was rejected by NICE on the grounds that, at its current price, it would be
unlikely to be cost-effective. In 2012, however, a rapid review of TA237106 approved ranibizumab if use was
restricted to the most cost-effective subgroup (those with central retinal thickness ≥ 400 micrometres) and
after a PAS for this subgroup of patients was offered (details of the PAS which provides a discount to the
NHS is commercial in confidence). The committee concluded that the most plausible ICER for the subgroup of
people with thicker retinas was likely to be higher than the manufacturer’s estimate (of £13,322 per QALY),
but would be < £25,000 per QALY gained.106
The appraisal and guidance documents106 provide the information required to estimate the additional NHS
costs of treating this subgroup of patients each year. The original manufacturer submission presented an
estimate of the numbers of patients in the NHS eligible to receive ranibizumab, based on its licensed
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indication.107 These estimates are presented in Table 201. In the first year of implementation, up to 44,000
NHS patients would be eligible for treatment with ranibizumab based on its licensed indication. No
consideration is made as to the size of the subpopulation approved for treatment; however, the RESTORE
trial (that informs the submission) found approximately half of the participants in the study to be in this
subpopulation [114 of 217 (52.5%)].105 The subgroup of patients where ranibizumab was ultimately
approved is thus likely to be approximately 23,000 in the first year after approval.
The incremental costs associated with the new treatment (compared with laser monotherapy) in the initial
submission (TA237) were £3506 per patient (Table 202).107 Given estimates reported in the rapid review
are not available (commercial in confidence), we will use this estimate of incremental costs for the
subpopulation of interest. These data suggest that the approval of ranibizumab in this subgroup at the
original appraisal in 2011 (i.e. without a PAS) would impose just over £80M of additional NHS costs for
treating the eligible population each year.
With introduction of the PAS, it is likely that a simple discount on the acquisition price of the new
technology has been approved by the Department of Health.106 Given the scale of the discount is not
available (commercial in confidence), we assumed that this discount would reduce incremental costs by
30% (to £2454 per patient). After such a PAS, the approval of ranibizumab in this subgroup would impose
just £56M (rather than £80M) of additional NHS costs for treating the eligible population in the first year.
What type of health is forgone by approval of a new technology?
Based on the 2008 central estimate of the cost per QALY threshold (£12,936 in Table 30), the approval of
ranibizumab without a PAS would have been likely to displace 6184 QALYs elsewhere in the NHS.
However, the analysis which underpins the threshold estimate can also be used to identify where the
additional NHS cost of £80M are likely to impact and where and what type of health effects are likely to
be forgone. This is illustrated in Table 203.
How the additional NHS cost of £80M will tend to affect spending in each of the 23 PBCs [see Table 203,
column (1)] will be based on the estimated expenditure elasticities and total PBC expenditure (see Table 157).
In calculations of the threshold, the inputs above (expenditure elasticities and total expenditure) allow
TABLE 201 Estimated size of the NHS population eligible for ranibizumab107
Licensed indication 2011 2012 2013 2014 2015
Prevalent cases 43,847 0 0 0 0
Incident cases 0 5481 5481 5481 5481
Total eligible number of patients 43,847 49,328 54,809 60,290 65,771
Subpopulation approved for treatment by NICE
Prevalent cases 23,020 0 0 0 0
Incident cases 0 2878 2878 2878 2878
Total eligible number of patients 23,020 25,897 28,775 31,652 34,530
TABLE 202 Estimated total budget impact of ranibizumab
2011 2012 2013 2014 2015
Total eligible number of patients 23,020 25,897 28,775 31,652 34,530
Total cost, without PAS (£) 80,708,120 90,794,882 100,885,150 110,971,912 121,062,180
Total cost, 30% lower incremental costs (£) 56,495,684 63,556,417 70,619,605 77,680,338 84,743,526
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TABLE 203 Heath forgone across PBCs due to the approval of ranibizumab (£80M budget impact)
PBC
(1) Change in
spend (£M)
(2) Additional
deaths
(3) Life-years
foregone
QALYs foregone
(4) Total QALYs
forgone
(5) Due to
premature death (6) QoL effects
2 Cancer 3.58 30 300 211 195 16
10 Circulatory problems 6.07 182 928 863 590 273
11 Respiratory problems 3.67 107 129 1835 80 1754
13 Gastrointestinal 2.56 21 197 351 129 222
All big four programmes 16 340 1554 3259 995 2265
1 Infectious diseases 2.61 6 43 125 29 97
4 Endocrine problems 1.51 5 40 485 26 459
7 Neurological problems 4.78 10 52 873 34 838
17 Genitourinary problems 3.71 18 26 85 17 68
16 Trauma and injuries 6.16 0 0 0 0 0
18 + 19 Maternity and neonates 5.46 0 3 2 1 1
11 PBCs 40 389 1717 4828 1101 3727
3 Disorders of blood 1.65 3 13 175 9 166
5 Mental health disorders 14.29 23 103 762 67 696
6 Learning disability 0.83 0 2 6 1 4
8 Problems of vision 1.55 0 2 34 1 33
9 Problems of hearing 0.70 0 1 112 1 111
12 Dental problems 2.31 0 0 54 0 54
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TABLE 203 Heath forgone across PBCs due to the approval of ranibizumab (£80M budget impact) (continued )
PBC
(1) Change in
spend (£M)
(2) Additional
deaths
(3) Life-years
foregone
QALYs foregone
(4) Total QALYs
forgone
(5) Due to
premature death (6) QoL effects
14 Skin 1.57 2 9 16 6 10
15 Musculoskeletal system 2.90 3 14 186 9 176
20 Poisoning and adverse events 0.74 0 2 7 1 5
21 Healthy individuals 2.83 0 1 5 1 5
22 Social care needs 2.40 0 0 0 0 0
23 Other 8.11 0 0 0 0 0
All 23 PBCs 80 411 1864 6184 1197 4987
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TABLE 204 Heath forgone across specific PBCs and groups of ICD-10 codes due to the approval of ranibizumab
(£80M budget impact)
Total change in spend
analysed= £80M
(1) Change in
spend (£M)
(2) Life-years
foregone
QALYs foregone
(3) Total
QALYs
forgone
(4) Due to
premature
death (5) QoL effects
Overall 80 1864 6184 1197 4987
PBC specific
PBC 2 (cancer) 3.58 300 211 195 16
Malignant neoplasms, digestive
organs (C15–C26)
81 56 53 3
Malignant neoplasms, respiratory
system and intrathoracic
organs (C30–C39)
69 46 45 1
Malignant neoplasms, breast and
female genital organs (C50–C58)
55 43 35 8
Malignant neoplasms, stated or
presumed to be primary, of
lymphoid, haematopoietic and
related tissue (C81–C96)
27 18 18 1
Malignant neoplasms, human
male genital organs (C60–C63)
17 13 11 1
Other ICD-10 codes in this PBC 51 35 33
PBC 10 (circulatory) 6.07 928 863 590 273
Ischaemic heart diseases (I20–I25) 523 476 334 142
Cerebrovascular diseases
(I60–I69)
190 183 117 66
Other forms of heart disease
(I30–I52)
75 64 48 16
Congenital malformations and
deformations of the circulatory
system (Q20–Q28)
18 43 13 30
Diseases of veins, lymphatic
vessels and lymph nodes, not
elsewhere classified (I80–I89)
36 28 22 5
Other ICD-10 codes in this PBC 87 69 54 15
PBC 11 (respiratory) 3.67 129 1835 80 1754
Chronic lower respiratory
diseases (J40–J47)
57 1568 36 1532
Lung diseases due to external
agents (J60–J70)
8 71 5 66
Other diseases of upper
respiratory tract (J30–J39)
7 65 4 60
Other respiratory diseases
principally affecting the
interstitium (J80–J84)
3 26 2 24
Other diseases of pleura
(J90–J94)
3 26 2 24
Other ICD-10 codes in this PBC 51 79 32 47
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predicting how a 1% change in total spend is distributed by PBC. The same rationale is used here to establish
how the additional NHS cost of £80M will affect each PBC. Hence, changes in spend reported here will be
proportional to changes in spend across PBCs evaluated in calculations of the threshold (as in Table 178).
The estimated outcome elasticities (see Table 157) allow the absolute changes in spend in each PBC
described above to be translated into a change in deaths and life-year effects for the 11 PBCs where mortality
effects could be estimated [see columns (2) and (3) of Table 145]. Applying the estimated proportional effect
on the mortality burden of disease to measures of QALY (including the other PBCs) provides an estimate
of the total QALY effect of the change in spend in each PBC [see Table 203, column (4)].ag The QALY
consequences of changing expenditure by £80M thus reflect PBC estimates of cost per QALY (e.g. for the
cancer PBC, the predicted total health foregone of 211 QALYs was calculated from the change in spend of
£3.58M and reflects the PBC-specific cost per QALY estimate of £16,997 reported for the threshold estimate
in Table 178). In an analogous way, the comparison of life-year and total QALY effects allows the distinction
to be made between QALY effects due the life-year effects of additional deaths and QALY effects due only
to QoL [see Table 203, columns (5) and (6)].
TABLE 204 Heath forgone across specific PBCs and groups of ICD-10 codes due to the approval of ranibizumab
(£80M budget impact) (continued )
Total change in spend
analysed= £80M
(1) Change in
spend (£M)
(2) Life-years
foregone
QALYs foregone
(3) Total
QALYs
forgone
(4) Due to
premature
death (5) QoL effects
PBC 7 (neurological) 4.78 52 873 34 838
Episodic and paroxysmal
disorders (G40–G47)
10 640 7 633
Extrapyramidal and movement
disorders (G20–G26)
10 72 6 66
Other degenerative diseases of
the nervous system (G30–G32)
9 44 5 39
Other disorders of the nervous
system (G90–G99)
2 22 1 21
Nerve, nerve root and plexus
disorders (G50–G59)
2 19 1 18
Other ICD-10 codes in this PBC 19 75 13 62
PBC 5 (mental health) 14.29 103 762 67 696
Mental and behavioural disorders
due to psychoactive substance
use (F10–F19)
39 311 27 283
Mood (affective) disorders
(F30–F39)
2 129 1 128
Organic, including symptomatic,
mental disorders (F00–F09)
34 89 20 69
Neurotic, stress-related and
somatoform disorders (F40–F48)
1 72 1 71
Behavioural syndromes
associated with physiological
disturbances and physical
factors (F50–F59)
3 44 2 42
Other ICD-10 codes in this PBC 24 118 15 103
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The results reported in Table 203 suggests that approval is likely to result in 411 additional deaths [see
Table 203, column (2)] and 1864 life-years [see Table 203, column (3)] forgone, most of which are likely to
occur in circulatory, respiratory and cancer PBCs. However, the impact of approval of this technology on
QALYs forgone due to premature death [see Table 203, column (5)] only accounts for a proportion of the
total QALY effects [see Table 203, column (4)]. Most (4987) are associated with QoL forgone during
disease [see Table 203, column (6)]. These QoL impacts are most likely to occur in respiratory, neurological
and mental health PBCs. The PBC-level effects in Table 203 can also be examined at ICD-10 code level
(Table 204) while recognising the caveats discussed in Chapter 4.ah For example, within the respiratory
PBC, it appears to be chronic lower respiratory diseases (J40–J47) where most additional deaths, life-years
and QoL would be forgone. In the mental health PBC the additional deaths appear to be associated with
disorders due to psychoactive substance use (F10–F19) and mood (affective) disorders (F30–F39).
The impact of a reduction in the price of this technology, either through value-based pricing or the PAS
that was offered during the rapid review, can also be examined in the same way. The PAS was commercial
in confidence, so here we will consider the hypothetical case that a 30% reduction in NHS costs
(incremental costs) would make this technology cost-effective for this subgroup of patients. Such a
discount would be expected to save 1855 QALYs including 126 deaths averted, 559 life-years (359 when
adjusted for quality) and QoL effects during disease equivalent to 1496 QALYs, compared with approval of
the technology at the original list price (Table 205).
TABLE 205 Heath forgone before and after a hypothetical PAS scheme on ranibizumab
PBC description
(1) Change in
spend (£M)
(2) Additional
deaths
(3) Life-years
foregone
QALYs foregone
(4) Total
QALYs
forgone
(5) Due to
premature
death
(6) QoL
effects
Before PAS
All big four
programmes
16 340 1554 3259 995 2265
11 PBCs 40 389 1717 4828 1101 3727
All 23 PBCs 80 421 1864 6184 1197 4987
After PAS
All big four
programmes
11 238 1088 2281 696 1585
11 PBCs 28 272 1202 3380 771 2609
All 23 PBCs 56 295 1305 4329 838 3491
Difference
All big four
programmes
–5 –102 –466 –978 –298 –679
11 PBCs –12 –117 –515 –1448 –330 –1118
All 23 PBCs –24 –126 –559 –1855 –359 –1496
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